Meet in Italy for Life Sciences 2018

Brokerage Event – MIT4LS2018 BE Participants Catalogue 1st October Update 443 Participants

MIT4LS2018 BE Dates to remember 01 Oct 2018*, midnight Deadline for registration *Registrations can be closed earlier depending on the number of participants 19 Sep - 03 Oct 2018, 14:00 Book Face2Face meetings 05 Oct 2018 Release of first version of meeting schedule 10 Oct 2018 11:00 – 18:30 Bilateral face-2-face meetings 11 Oct 2018 09:30 – 18:30 Bilateral face-2-face meetings

een.ec.europa.eu 3C Engineering

Organisation

Country Italy City Roma Street Via Riccardo Pitteri,32 Web http://www.3cengineering.it

Person

Name Fabio Buccolini (3C Engineering Srls) 3C Engineering

Organisation Start up with holistic approach to the IT sector with a vision based on ameliorating the quality of life using technologies. Web platforms, domotics, cybersecurity and App development are the business field of the Start-Up since mid 2018 is also focusing the healthcare sector. In particular for healthcare sector has been developed an IT system (web platform and App) based of Patents Granted and Copyright for CISD able to evaluate Psoriasis and atopic dermatitis increasing the patients quality of life . Areas of Activity

• Bioinformatics, Big data analytics • Medical devices • Consulting services • IT Applications for Health • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine • Software, ICT applications, system integration

Marketplace Opportunities

PRODUCT PSORINO : V-PASI Psoriasis Index PSORINO is an innovative App solution for dermatologists based on a robust new patented technique helpful in the management of treatment plan of PSORIASIS. The patented method and V-PASI Score is very useful in the management of biological therapies, when psoriasis is in complete remission and a customized therapy is required to maintain the remission of the pathology. Finally the App has also the "placebo" effect tools due the autodiagnosis opportunity evaluated by the Dermatologists in a typical telemedicine model. PARTNERSHIP CRO & Cinical Trials The App and its back-end is very useful at R&D level for the evaluation of Pharmaceutical products for

2 / 880 Psoriasis . It is a perfect tool for Clinical Trials able to match data with the PAASI score and V-PASI score considering its micro-measurements. PROJECT COOPERATION H2020 EU Projects focusing CISD and Inflammatory Pathologies The Start-Up is available to evaluate possible partnerships for 2019 applications accordingly with the H2020 Call for Proposals (NO SME Instrument) in the Healthcare sector. INVESTMENT OPPORTUNITY Growth of the ICT infrastructure Teh Start-Up with this new products App PSORINO is available for inverstors (equity)

3 / 880 A Menarini IFR

Organisation

Country Italy City Pomezia Street Via Tito Speri, 10 Web https://www.menarini.it/

Person

Name Claudio Panzarella Head of Biopharmaceuticals Licensing In

Organisation Menarini's delegates will be available for discussions at the workshop "A glance into solution provided by the Menarini Group" that will take place in Oct, 10th at 11,30 am in Didattica B Room. Please come to visit us also at the exposition booth located in the conference center. The Menarini Group is one of Europe’s 15 leading pharmaceutical companies, headquartered in Florence, Italy with global operations powered by more than 17,000 employees generating a turnover of around €4b in 2017. Its rapid international business expansion with more than 100 affiliates and partners, advocates its global reach. Leader in commercial excellence both in Specialist and PCP with an unsurpassed partnering track- record based on generating value and trust. The focus of the privately-owned company is researching, developing, manufacturing and marketing medications of high therapeutic value for patients. It is committed in these key areas: oncology, anti-infectives, pain, respiratory and cardiovascular. Menarini's research activities are carried out throughout its 6 fully-integrated R&D centers in Europe and Singapore in addition to 16 manufacturing plants throughout the globe. The Menarini Group is composed of Pharmaceuticals, Diagnostics and Consumer Health. Areas of Activity

• Biotechnologies (Pharma&Medical • Manufacturing & process engineering Devices) • Pharmaceutics • CMO (Contract Manufacturing Organisation) • CRO (Contract Research Organisation) • Drug screening & delivery

Marketplace Opportunities PARTNERSHIP Collaboration, licensing-in opportunities with Menarini Menarini IFR is looking for potential partnership, collaboration, licensing-in opportunities in pharma, biopharma, diagnostics and consumer health in the key areas: oncology, anti-infectives, pain, respiratory and cardiovascular. Please come to visit us also at the exposition booth located in the conference center. 4 / 880 A.I.S.M.O. Onlus

Organisation

Country Italy City Roma Street Via E.d'Arborea 38 Web www.aismo.it

Person

Name Virginia A. Prof.Cirolla Presidente Nazionale

Organisation The Association AISMO is involved in research, treatment and rehabilitation of patientswith cancer and it is committed in supporting their familiesin the different phases of treatment planning and care. One of its focus is thecancer pain treatment of oncological patients. The association has different branches in Italy, with its headquarter in Rome.http://www.aismo.it Areas of Activity

• Biomaterials • Medical research • Biosensors • Nutraceutics, probiotics, functional food, • Biotechnologies (Pharma&Medical cosmeceutics Devices) • Medical devices • Chemicals & APIs • Diagnostics IVD • Diagnostics - Equipment and accessories

Marketplace Opportunities PRODUCT Nanotechnologies and Oncological Research Drugs development for cancer treatment FUNDING PROGRAMME AND REFERENCE Nanosciences Oncological Diseases Research TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE Universities

5 / 880 A.Menarini Diagnostics

Organisation

Country Italy City Bagno a Ripoli (FI) Street Via Lungo L'Ema, 7 Web http://www.menarini.com

Person

Name Fabrizio Mastrantonio Global Scientific Marketing Affairs Manager

Organisation A.Menarini Diagnostics belongs to the Menarini Pharmaceutical Group which was founded Naples in 1886 and then moved to Florence in 1915. Today it is the leading Italian pharmaceutical company in the world, ranking 16th in Europe (among 5.291 companies) and 38th in the world (among 19.042 companies) IMS World Review 2013). Present in over 130 countries throughout the world, today it counts 16,603 employees and has a 2013 turnover of over € 3,27 billion (US$ 3.7 billion). Menarini Group is the 1st pharmaceutical group in Southern Europe (market share 4.5%) and the first in Italy (market share 8.6%). The A. Menarini Diagnostics Srl was founded in 1976 and began developing and manufacturing its own products in 1982. A Quality Control Department and a Research & Development laboratory have been added since then. A.Menarini Diagnostics has a European-wide corporate organisation. The present structure of Menarini Diagnostics is made up of its Headquarters in Florence and a network of fourteen fully owned affiliates in the following countries: Portugal, Spain, France, UK (Eire), Sweden, Belgium, Netherlands, Germany, Switzerland, Austria, Russia, Italy and Greece. A.Menarini Diagnostics is the biggest Italian company in the In Vitro Diagnostics (IVD) market and the most "internationally oriented" Italian company as far as the number of direct affiliates in Europe is concerned. From July 1997 onwards, A.Menarini Diagnostics has been certified by TÜV in accordance with the ISO 9002 and EN 46002 standard requirements and is currently certified to ISO 9001:2008 and ISO13485:2003standards by TÜV SUD. A.Menarini Diagnostics employs approximately 900 people, 600 of which (approximately 67%) are in the marketing and sales areas while another 125 (almost 14%) are employed in the technical service departments. The turnover for the year 2015 was approximately 250 million Euro (US$ 282 miilion). The strategic areas of A.Menarini Diagnostics are: Diabetes (self testing, POCT and laboratory systems), Clinical Chemistry (laboratory and POCT), Urinalysis &Sediment Analysis, CellPathology&Cytology, Autoimmunity and Molecolar Biology. A.Menarini Diagnostics is strongly and actively engaged in the field of diabetes. Its activities include educational programmes for diabetic patients, advanced systems for the monitoring of diabetes (Glucocard and GlucoMen® systems), the automatic determination of glycated proteins, including glycated haemoglobin, and research which aims at the identification of new devices for the prognosis, the diagnosis and the monitoring of the disease. Since 2001, A.Menarini Diagnostics is involved in the Continuos Glucose Monitoring through the 6 / 880 GlucoDay® / GlucoMen® Day system, a glucose holter which is able to continuously monitor the glucose concentration for a period up to 5 days using the micro-dialysis technology via a subcutaneous microfibre. GlucoDay® has the dimension of a small “walkman” and allows the patient to carry on a normal life style even during the test. The system has been CE-MD marked by the TÜV Product Service notify body. A.Menarini Diagnostics’ main activities are concentrated in Europe where it is ranked 9th in the In-Vitro Diagnostic market. According to “Clinica MedTech 2012 Top 100”, Menarini Diagnostics is ranked at 91st position in the world-wide MedTech market and at the 20th position in the world-wide In-Vitro Diagnostic market, even if mainly present only in Europe. As far as the market shares in the IVD market in some European countries are concerned, A.Menarini Diagnostics is currently ranked the 3rd company in Italy and the 4th in Spain. As far as the "diabetes self testing market" is concerned, Menarini is 1st in Portugal and Spain and 3rd in Benelux and in Italy. Menarini is the market leader in the "Glycated Haemoglobin market" in numerous European countries such as Austria, Greece, Italy, Portugal, Spain and the UK. It is the leader as well as market leader in the "Erithro Sedimentation Rate Market" in Greece, Portugal and Spain. Moreover, Menarini is market leader in Italy in the "automatic systems for Urinalysis" sector and 2nd position in Spain. As far as the highly specialised areas of “auto-immunity” and "Immuno-histo-chemistry" are concerned, Menarini presently holds leading positions in Italy, France, Germany, Spain and in the UK. By carrying out the aforesaid, Menarini Diagnostics is fully aware that it is also acting main interest of all those Partners who have indeed granted Menarini Diagnostics the opportunity of making their products a success. Areas of Activity

• Diagnostics IVD • Medical devices

Marketplace Opportunities PARTNERSHIP Menarini Diagnostics as the reference partner for the success in the In Vitro business in Europe Menarini Diagnostics' network of affiliates companies and an almost 40 year experience in the IVD market could be an interesting partner for the distribution of innovative products in the In Vitro Diagnostic arena, both for self testing and laboratory system. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Menarini Diagnostics is the bigger "distribution" organisation in Europe (excluding the multinational companies that promote their own products) so that Menarini could be considered as the "first option" for jung companies that develop innovative products for the In Vitro testings. Menarini could support its partners also to adapt their products to the needs of the countries, to manage clinical trials and to obtaining regulatory approvals such as CE mark. MARKET APPLICATION Laboratory systems for the In Vitro market with special focus on "Diabetes", "Anatomo Pathology (ImmunoHistochemistry and Cytology)"; AutoImmunity and Pharmacogenomics. In the field of Self Testing : glucose, coagulation, etc. For the Point of Care testing : simple devices for "doctor offices" and Veterinarians

7 / 880 ABzero

Organisation

Country Italy City PIsa Street via Carmignani 6 Web www.abzero.it

Person

Name Giuseppe Tortora Enterpreneur

Organisation ABzero is a start-up that develops innovative medical devices and offers a delivery system for transportation of blood, hemoderivates and organs by means of drones for improving health systems. Areas of Activity

• eHealth, mHealth, telemedicine • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT A drone for life ABzero offers a blood and organ transport service based on flying drones, ensuring delivery in an autonomous and immediate manner and in total safety for the human component, even in case of failure. The transported good is safely stored in a smart capsule, which protects the quality according to the law. The system is based on intuitive, proprietary and effective software, easy to use by the medical staff. INVESTMENT OPPORTUNITY Investment Co-investment with other partners to enable scaling up of the solution REQUEST Pontential customer Hospitals and blood and medical transportation service providers

9 / 880 Accelera Srl

Organisation

Country Italy City Nerviano, Milan Street Viale Pasteur 10 Web www.accelera.org

Person

Name Francesco Sola Key Account Manager

Organisation Accelera, a drug development partner, offering a unique background, built on years as part of global R&D organisations (Pharmacia and Pfizer). We provide services and advice to select the best drug candidates and develop new chemical entities and bio-pharmaceuticals into innovative therapies, running optimised IND enabling studies and managing safety, metabolism, pharmacokinetics and bioanalysis issues through clinical proof of concept up to final registration. With over 25 integrated development programs executed in the last years, we are proud to be working with over 60 sponsors from Europe, North America and Asia. Services: Toxicology and ADME/PK studies in rodent and non-rodent species, including Nonhuman Primates (NHP); IND/CTA enabling packages, including GLP general toxicology, safety pharmacology, genotoxicity, ADME and pharmacokinetics (PK); Bioanalysis and pharmacokinetics for preclinical and clinical studies, including assay development and validation; High-throughput preclinical profiling and PB/PK modelling; PK/PD, and population PK data analysis; Drug disposition packages, including the synthesis of radiolabeled compound and QWBA; Full reprotox package; Preclinical development consultancy and preparation of regulatory documentation; Special expertise in the design and execution of preclinical development programs for different classes of Oncology drugs. Areas of Activity

• Analytical and characterization services • Pharmaceutics • Biotechnologies (Pharma&Medical • Medical devices Devices) • CRO (Contract Research Organisation) • Nutraceutics, probiotics, functional food, cosmeceutics

10 / 880 Marketplace Opportunities SERVICE Preclinical Profiling Accelera provides comprehensive support services and consultancy in the development of small molecules and biologics, through a specialized team of experts in Pharmacology, Preclinical Profiling, Drug Safety, Bioanalysis, PK/PD, Clinical Development and Regulatory. With a flexible business model, Accelera brings unique industry experience to the execution of your Oncology programs. SERVICE Discovery Services:?Oncology Wide array of In Vivo Tumor Models, including xenografts, syngeneic, and Patient derived Xenografts (PDX) Haematological Malignancies and Human Solid Tumors Subcutaneous, Orthotopic, Metastasis, Angiogenesis models Imaging (MRI, Optical) Cell Proliferation Testing Cell Binding & Internalization for ADC characterization PK/PD Modelling SERVICE Cell Therapy CART experience at Accelera Human allogeneic CART cells in immune-deficent mice Efficacy models Pilot studies for cell engraftment, tolerability, surgical implantation GLP cell fate/biodistribution by FACS analysis GLP safety (toxicology) GLP tumorigenicity Pathology and necropsy Immuno-HistoChemistry or qPCR/ddPCR SERVICE Consultancy Expert Solutions for Drug Development Non-Clinical Development strategy Project management and planning Gap analysis, due diligence, trouble-shooting Regulatory consultancy and documentation (IND, CTA, IB, NDA) and interaction with European Regulatory Authorities Non-clinical Safety and Risk Assessment ADME/PK Toxicology Pathology Safety Pharmacology Oncology Drug Development PK/PD Non-clinical Development SERVICE Bioanalysis & PK Preclinical and Clinical Bioanalysis

11 / 880 State-of-the-art LC-MS/MS (incl. API 5500, Orbitrap and 4000 QTRAP) Immunoassay capabilities Fast method development for discovery support Rapid turnaround bioanalysis for Phase I Clinical Studies Validated Software WatsonTM LIMS, PE SCIEX AnalystTM, Spylog® (freezer monitoring) Pharmacokinetic Analysis Integrated design, conduct and reporting of bioanalytical and PK studies Population PK data analysis PK/PD modelling SERVICE Integrated Full ADME packages -Isotope Chemistry Custom synthesis with 14C, 3H, 125I , 35S 50 years experience Chemicals, conjugates, polymers, peptides, biologics -Drug Disposition Mass balance Tissue Distribution by Q-WBA Rodents and large animals -Metabolism Metabolite Profiling by LC-RAD-HRMS. Identification of drug-related material Elemental composition and structural elucidation of metabolites SERVICE Discovery Services In-vitro ADME (Attrition Reducing Technologies) Ad hoc combinations of in vitro assays are used to screen NCEs and design new drug candidates with reduced risk of late attrition Translational Sciences Special effort is devoted to assessing PK/PD correlations in efficacy animal models and predicting clinical outcomes Early assessments of drug-drug interactions are performed to support the development of novel therapies Potential dose-limiting toxic effects (e.g. myelotoxicity) are assessed by in vitro toxicity assays Quantitative non-invasive assays are developed for organ-specific safety biomarkers to be used for preclinical assessment and clinical monitoring of potential toxicities SERVICE Cross Contamination in ?Shared Facilities Accelera Will Provide Expert Assessment for: DERIVATION OF A SAFE THRESHOLD VALUE (PERMITTED DAILY EXPOSURE) through:- hazard identification by reviewing all relevant pharmacological and toxicological data (non-clinical and clinical)- identification of critical effects- determination of the NOAEL for the critical effect- use of uncertainty adjustment factors- extrapolation to different administration routes PREPARATION OF THE “PDE DETERMINATION STRATEGY” DOCUMENT SERVICE Logistic Coordination, Bioanalysis and PK Services for Clinical Study Coordination of samples for Clinical Study Method Development and Validation for 12 / 880 clinical trial Phase I-II-III - Immunogenicity testing (ADA) - Small Molecules and Biologics Biomarkers Rapid turnaround for Phase I Clinical Studies - Protocol preparation, PK data analysis and reporting for: - Bioequivalence - Food effect - Drug-Drug interaction - PK in special population (renal and hepatic impaired patients) - Population PK and PK/PD modelling - PK analysis and statistics performed using validated software system (e.g. Winnonlin, NONMEN, SAS)

13 / 880 ACROSS Global Alliance - represented by MTA

Organisation

Country Singapore City Singapore Street

Person

Name Cristina Morelli Head Quality Management Board

Organisation ACROSS Global is a strategic alliance of clinical research organizations (CRO) extends across the world. Thirteen CRO members across 81 countries provides you with access to 5,000+ study sites and almost endless number of potential clinical trial subjects. ACROSS’ 2,234 employees are fully dedicated to the highest standards of conducting cost-effective clinical trials across the globe. The well-balanced combination of local knowledge, globally experienced professionals and the latest technology allows our clients to conduct faster, cost-effective studies without sacrificing quality. Whether for small or mid-size Pharma and Biotech, the ACROSS Alliance makes global studies seamless. MTA Group is a proud founding member of ACROSS Global. Areas of Activity

• Bioinformatics, Big data analytics • Regulatory affairs, validation • CRO (Contract Research Organisation) • Medical devices • Diagnostics IVD • Pharmaceutics

Marketplace Opportunities SERVICE Innovative and efficient schemes for advancing clinical research practices ACROSS Global is an entirely new business model, providing enhanced and innovative global solutions through highly qualified, knowledgeable local experts. ACROSS Global identifies, analyses and mitigates risks across the entire clinical research spectrum, with an agility and focus to the envy of competitors. We provide value added solutions individually tailored for small and mid-size companies. ACROSS Global’s unique operating model allows our clients the opportunity to select the member 14 / 880 companies and countries of their choice for the conduct of their clinical trial(s) whilst at the same time providing the assurance and confidence that their clinical trial(s) will be managed to the highest possible standards.

15 / 880 Aczon srl

Organisation

Country Italy City Monte San Pietro, Bologna Street via Lavino 265/D Web www.aczonpharma.com

Person

Name Chiara Barattini Product Manager

Organisation ACZON is an Italian biotechnology company founded in 2001. Our team develops, and produces NanoProbes and Silica NanoParticles, and optimises a vast range of conventional reagents for diagnostics, clinical and research applications. Supported by Hydra Group SpA, as well as the world leader in manufacturing optical barcode reader – Datalogic SpA – Aczon has reached a great scientific expertise, combining together chemistry and biotechnology. Our team has developed and optimised – with a high degree of versatility and dynamicity – an array of highly-performing new products (diagnostic/research probes), significantly step forward compared to the state-of-the-art. The core of our activities is the aim to develop and identify new probes for the IVD market and in vivo applications based on our Silica Nanoparticles Technology. In order to provide cutting-edge solutions, in step with the most innovative scientific progress in the field, ACZON has entered into partnerships with several university centres. ACZON is proactively engaged in seeking new collaborations with other centres and facilities, to achieve new research breakthroughs and develop new products for in vitro and in vivo market. The results of our intense research activities at ACZON, in fact, have translated into the production of high-quality products, thanks to the use of state-of-the-art machinery and equipment and the constant supervision of our competent research staff. A further important activity carried out at ACZON is the marketing of our products worldwide – under both the ACZON brand and OEM licences – either directly or through qualified distribution firms, based on a top-of-mind awareness approach, in the diagnostics and research sectors. Areas of Activity

• Analytical and characterization services • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation Devices) • Pharmaceutics • CRO (Contract Research Organisation) • Life sciences related activities • Diagnostics IVD • Project proposals support services • Diagnostics - Imaging equipment and • Medical devices

17 / 880 processing • Drug screening & delivery • Medical research

Marketplace Opportunities PRODUCT Reagents for in vitro diagnostics use AcZon produces and commercializes reagents for immunofluorescence mainly for flow citometry. Thanks to our innovative silica nanoparticles we are able to improve the performance of the current reagents in terms of stability and signal intensity. SERVICE Our know how at your disposal AcZon offers to customers all the know how present in the Company. We can project together with our customers the perfect reagents missing from the catalogues.

18 / 880 Advanced Electronic Biosystem

Organisation

Country Italy City Arce Street Via Stazione snc Web http://www.aebiosystem.com

Person

Name Paolo Marini CEO

Organisation - AEB is an Italian Startup born from the Thermo Medical Sensor Project - The company is based in the province of Frosinone - The company is made up of a group of people with different skills, in the world of electronics and telecommunications systems. Areas of Activity

• Electromedical and medical equipment • IT Applications for Health (non diag) • Medical research • Pharmaceutics • Medical devices

Marketplace Opportunities PRODUCT Thermo Medical - We have made a TEMPERATURE sensor that attaches to the skin simply as a patch - Don’t need Battery, and can be read simply by NFC Phone using an APP - This is the most smaller temperature sensor in the world. The sensor is just 0,8mm thin - We have developed a variant of the sensor for professional use, which uses a thin battery just 1mm, which can log the temperature. Sampling parameters can be configured by user INVESTMENT OPPORTUNITY Thermo Medical - We have made a TEMPERATURE sensor that attaches to the skin simply as a patch - Don’t need Battery, and can be read simply by NFC Phone using an APP - This is the most smaller temperature sensor in the world. The sensor is just 0,8mm thin - We have developed a variant of the sensor for professional use, which uses a thin battery just 1mm, which can log the temperature. Sampling parameters can be configured by user

19 / 880 ADVANTAGE AUSTRIA

Organisation

Country Austria City Vienna Street Wiedner Haupststrasse 63 Web http://www.advantageaustria.org/it/

Person

Name Gregor Postl Commercial Counselor

Organisation ADVANTAGE AUSTRIA Padua is part of the worldwide ADVANTAGE AUSTRIA NETWORK, Austria's official Trade Promotion Organisation (TPO). We offer worldwide support for all Austrian businesses that want to conduct business in Italy and San Marino. Furthermore we offer support for companies or other organizations wishing to obtain goods or services from Austrian companies, to invest in Austria or establish other types of business relationship, ADVANTAGE AUSTRIA should be their first port of call. Our services include: • Sourcing business partners in Austria and creating new business opportunities • Establishing b2b-links and contact facilitation with Austrian exporters • Matchmaking and business partnering • Publications on Austrian products, services and competence • In-depth information about the Austrian market • Investment promotion Areas of Activity

• Other

Marketplace Opportunities SERVICE Consulting and Internationalisation Our services include - beside others - : • Sourcing business partners in Austria and Italy creating new business opportunities • Establishing b2b-links and contact facilitation with Austrian/Italian companies in the Life-Sicience sector • information about the Austrian market PARTNERSHIP Creating partnership with Austrian/Italian companies • Matchmaking and business partnering

20 / 880 AdviQual - Advice for Quality

Organisation

Country Turkey City istanbul Street Mevlana Mah. YıldırımBeyazıt Cad. Ataeli Sitesi Blok:C No:23 Daire:8 Esenyurt Web http://www.adviqual.com

Person

Name Tunca Demirci Medical Device Quality and Regulatory Consultant

Organisation AdviQual is a quality and regulatory consultant dedicated to medical device manufacturers. AdviQual prepares any documents/reports of the technical dossier of a medical product (such as Risk analysis, Clinical evaluation report, Biocompatibility reports, PMS, PMCF plans, process validation reports, Software validation reports etc.) as well as builds the full technical file according to MDR. Besides, our experts set up or improve the manufacturers' Quality Management Systems according to EN ISO 13485:2016 standard. Areas of Activity

• Consulting services • Regulatory affairs, validation • CRO (Contract Research Organisation) • Medical devices • Diagnostics IVD • Electromedical and medical equipment (non diag)

Marketplace Opportunities SERVICE Medical device regulatory consultancy AdviQual prepares/improves any documents/reports of the technical dossier of a medical product (such as Risk analysis, Clinical evaluation report, Biocompatibility reports, PMS, PMCF plans, process validation reports, Software validation reports etc.) as well as builds the full technical file according to MDR. SERVICE

21 / 880 Quality Management System consultancy for medical device manufacturers AdviQual set up from scratch or improve the existing Quality Management Systems according to EN ISO 13485:2016 standard. SERVICE Consultancy in clinical affairs AdviQual writes clinical evaluation reports (CER), PMCF plans/ protocols and organize clinical research for medical devices SERVICE Software and Process Validation AdviQual provides validation services and prepares validation reports for Software that is embedded to a medical device Software that is bought from a 3rd party and used in the design, QMS, ERP, production, traceability etc. processes Production and sterilization processes of medical devices SERVICE Design process consultant AdviQual provides guidance for regulations in the medical device design process. Usability consultancy is another area we give services with our partners SERVICE Registration consultancy of medical devices in Turkey AdviQual provides consultancy for registering medical devices in Turkey. Our large customer database let us to find the right supplier or contract manufacturer in Turkey. PARTNERSHIP Quality and regulatory subjects in medical device sector is our expertise AdviQual has many partners around the world (Canada, Israel, Russia, Italy, France, and the USA) so welcomes any new partnership opportunities. We are open to working with a who resells our services and also providing services of a new partner in Turkey. PROJECT COOPERATION Clinical research for Medical Devices AdviQual is ready to partner with CRO to organize studies/researchs in Turkey

REQUEST Quality and regulatory consultancy for medical device sector We are searching for a partner who can market our services to medical device manufacturers and be a reseller of AdviQual

22 / 880 AFERETICA SRL

Organisation

Country Italy City BOLOGNA Street VIA SPARTACO 10 Web http://www.aferetica.com

Person

Name STEFANO RIMONDI BUSINESS ANGEL

Organisation AFERETICA is an innovative start-up,founded by operators and managers with decades of experience in Dialysis, Intensive Care, Cardiology and Medical Devices in general. We have chosen to stay within the incubator of the Biomedical District of Mirandola, side by side with the Technopole, established with the mission of being the aggregation point of interdisciplinary skills of the territory. Our mission isto contribute to research for development, the realization and diffusion of complete apheresis therapies dedicated to patients’ life and well-being. We would like to be the catalyst for the creation of a network of clinicians, academicians, researchers, industrialists and institutions capable of creating, validating and using apheresis therapies in clinical practice as well as launching their use in new and unexplored clinical areas. AFERETICA may offersrange of innovative products and therapies for: Transplantation SIRS, Sepsis Auto-immune and inflammatory diseases, rare diseases Respiratory diseases (ARDS and COPD) Nephrology. For more detailed information, please visit our website: www.aferetica.com Areas of Activity

• Electromedical and medical equipment (non diag) • Medical devices

Marketplace Opportunities SERVICE System for the conditioning and purification of organs intended for transplantation. System for the conditioning and purification of organs intended for transplantation.

23 / 880 AGAIN LIFE ITALIA S.R.L.

Organisation

Country Italy City SCHIO Street VIA LAGO D'ORTA 1 Web http://www.againlifeitalia.com/en

Person

Name RAFFAELE MIGLIACCIO PRESIDENT

Organisation Again Life Italia (ALI) was born in 2009 from the idea of some researchers and people involved and well inserted in the pharmaceutical world. The main idea has always been to find answers to questions coming from patients with cancer none has been able to give an adequate response to. Again Life Italia now is a Company fully dedicated to control therapies side effects. Our mission is to improve the quality of life of patients suffering from different pathologies, above all those suffering from side effects induced by drugs and by chemo and radiotherapy, because every person deserves to be respected. The Company’s future lies in continuing with Research and Development. We are specialized in biotechnological research and product development with focus in areas such as oncology, ophthalmology, gynecology, dermatology, neurology, diabetology, inflammation, heart disease and others. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PRODUCT ONLIFE® Indicated to control Peripheral Neuropathy induced by Chemotherapy.

24 / 880 Agate Medical Investment

Organisation

Country Israel City Tel-Aviv, Israel Street Web https://www.agate-invest.com/

Person

Name Ariel Moses Managing partner

Organisation Agate Medical investments LP is a group of funds, specialized in providing growth capital to mature Medtech companies. Agate, as one of Israel's leading healthcare investors, has established a leading position in the healthcare VC industry, resulting in quality deal-flow and investor partnerships. Areas of Activity

• Investments • Medical devices • IT Applications for Health

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity for healthcare companies in later stages. Agate Medical investments is a group of funds, specialized in providing growth capital to mature MedTech companies. Agate, as one of Israel's leading healthcare investors, has established a leading position in the healthcare VC industry,resulting in quality deal-flow and investor partnerships. Focus on later stage medical devices and digital health

25 / 880 AirMed PLUS GmbH

Organisation

Country Germany City Bochum Street Harpener Feld 34 Web www.airmedplus.de

Person

Name Birger Nispel CEO

Organisation AirMed PLUS GmbH is a German manufacturer of anti-bedsore systems, located in Bochum, Germany. We offer a complete competitive and good price-performance-relation portfolio of different anti bedsore systems like air-loss systems, alternating systems and static systems as well as complex foam mattresses. Additional own branded products like automatic dispenser for hand-disinfection an liquid soap are completing the portfolio beneath of the companies' newest products, an innovative NON invasive 5-second-eye-tear test for measuring the teat function. Compared to the 'state of the art', competetive test in the marked, the so called "strip meniscometry tests" which are used invasively behind the eye lid and will take 3-5 minutes till the operator will get the result, this test will be used NON invasive (so in opposite to other test not causing pain to the patient!) and will only take 5 seconds. AirMed PLUS has its own R&D department for anti-bedsore-systems and the company as an SME has got national and international distinctions. Our products are used in hospitals (treatment centers, geriatric departments, ICU), home care and elderly and nursery homes. The product range includes high tech devices like "ADS intelligent" as the result of an R&D project with two universities and one industrial Partner, "ADS clinic" and econonic anti bedsore systems like "ADS basic" and "ADS extra". "ADS intelligent" is a total new concept of anti-bedsore systems, it is measuring the rest-mobility of the patient and will actively relocate the area of the highest pressure when patient is not moving. Movement-data will be recorded and can be read out. The "ADS intelligent" is patented and consists of a microprocessor controlled pump and a special designed mattress which fits in each single and brand-independent hospital or ICU bed. Over 20 years esteemed knowledge in high class airloss systems complete the portfolio. AirMed PLUS is looking for dealers in European countries. Areas of Activity

• Medical devices

Marketplace Opportunities PRODUCT 5-seconds NON invasive tear function test We offer an innovative NON invasive 5-second-eye-tear test for measuring the teat function. Compared to the 'state of the art', competetive test in the marked, the so called "strip meniscometry 27 / 880 tests" which are used invasively behind the eye lid and will take 3-5 minutes till the operator will get the result, this test will be used NON invasive (so in opposite to other test not causing pain to the patient!) and will only take 5 seconds. We are looking for wholesaler of eye drops who could use this test in an exclusive way. Also we are looking for wholesaler for eye-doctors, ophthalmologists and optometrists. INNOVATIVE ASPECTS AND MAIN ADVANTAGES only 5 second test time non invasive no pain for the patient MARKET APPLICATION We are looking for wholesaler of eye drops who could use this test in an exclusive way. Also we are looking for wholesaler for eye-doctors, ophthalmologists and optometrists. OEM product is also possible TYPE OF PARTNER SOUGHT Countries wordlwide and within European Union PRODUCT Automatic dispender for desinfection spray and liquids We are looking for dealers for our touchless- automatic dispenser. Due to the risk of infection by pushing and touching manual dispensers by several people per day, the solution of using an automatic dispenser is the only consequent and right one! Saving cost: an automatic dispenser is pumping one time only. Users of manual dispensers are pushing and pumping two, three, four times and waste more liquids than necessary! Fully Automatic / Touch-free: No need to touch any part. Place your hand under the nozzle, infrared sensor will detect your hand and dispense the chemicals (sanitizer or soap) automatically. Suitable for Multiple Solution: the device can be used for disinfectant spray, disinfectant gel, or liquid soap. Level Checking Window: with the transparent window , the user can easy to check the level of liquid without opening the front cover. Dispensing Volume Adjusting: the dispensing volume can be adjusted by user manually. LED lndicator: When the LED indicator is blinking in green, it means the device is operating; when the LED light up in red, it means the battery power is low. Dispenser Volume: the Dispenser Volume can be adjusted manually. Variety of Liquids and Sanitizer sprays: you can use your own different liquids with a normal viscosity and sprays without granulate, you only need to remove the nozzle for hanging from soap to liquid. Safety Switch: when opening the front cover, the safety switch will prevent the machine dispense the liquid. Power Mode(AC/DC available): The machine can be used with 4pcs D-cell batteries or AC power adaptor; 4 brand-new alkaline batteries can operate the machine over 30,000 times continuously (tested with soap). ON/OFF Switch: when the machine will not be used for a long time, the user can turn the switch to OFF to save the power. The machine can be mounted on the wall or stand onto the desk, you can install this unit in any place, especially in hospital, restaurant, kindergarten, factories, public places, train station, airport, autogrill, etc… INNOVATIVE ASPECTS AND MAIN ADVANTAGES touchless, easy, cheap, lot of sites need it, made for 0.5 l and 1.0 l bottles TYPE OF PARTNER SOUGHT This device is easy to sell, easy to explain and has a really fantastic marging for resellers. you can sell your own liquids, there is no need for binding to one supplier. The bottles which come with the dispenser are made for refil systems. We are looking for dealers in each country who are interested into easy going business with good- margin products.

28 / 880 PRODUCT Intelligent anti-bedsore-system "ADS intelligent" - looking for international distributor INNOVATIVE ASPECTS AND MAIN ADVANTAGES First global patented device which measures the patient mobility, reacts on patients non-mobility, records movement data, is undependent from the bed and which mattress‘ can be desinfected by washing in a washing machine. „ADS intelligent“ is the result of an R&D project, which was supported by the German Minstry of Economics and Technology. R&D Partner: RWTH – University of Aachen & University of Witten Herdecke (Department of Nursing Science) MARKET APPLICATION home care, hospitals, nursery homes, private person, dealers (b2b) TYPE OF PARTNER SOUGHT every country PARTNERSHIP Offering distributorship for your homecare products AirMed PLUS GmbH is looking for a bilateral business-relationship. We are offering a distributorship for our high quality anti-bedsore-products, as well as for your own - OEM products. We are looking for products which are already on the market and which show USP's in quality and effectiveness. Products must be able to be sold in German market. For our priority, we are looking for manufacturer of homecare products. Products must have CE label according medical device directive 93/42/EEC and AC 2007/47. Manufaturer should have a European Representative (ER). If no ER is available, discussion about taking over this duty are possible. TYPE OF PARTNER SOUGHT We are looking for a bilateral business-relationship. We are offering a distributorship for our high quality anti-bedsore-products, as well as for your own - OEM products. On the other side, we are looking for interesting devices which could fit into our portfolio. TYPE OF PARTNER SOUGHT Manufacturers of medical devices SERVICE Networking - Find partner und distributors for you in Germany or other Countries Since AirMed PLUS has been founded, the company has built up an international network of several potential partners who are working with various kinds of medical devices. AirMed PLUS can help you to network with these companies if you want to enter special market. We also can assist you for the marketing entry set up as well as in finding sales people and open up a sales structure dedicated to the individual market. SERVICE ISO 13485:2016 lead auditor support Consultants AirMed PLUS can support the company with consultancies of ISO 13485:2016 for new MDR coming up in 2020. Get your quality management and product folder ready for the new demands of new stricter regulations given by new MDR 2020. REQUEST Loocking for distributor partners in all countries for growing market of elderly people We are looking for partners in different countries to enter the market of worldwide growing sector of elderly people. We open for discussion and drive the business very flexible. We also ask "who knows 29 / 880 whom" who could help us to enter into the individual market. Mostly, business works as a bilateral relationship. Let us talk about all possibilities.

30 / 880 Albatross Investment Capital Co.,Ltd

Organisation

Country Korea, Republic Of City Gyeonggi-do Street U-Space2A, 670, Daewangpangyo-ro, Bundang- gu, Seongnam-si Web http://www.albatrossvc.co.kr/

Person

Name Keimin Lee Manager

Organisation Albatross Investment is a corporate venture capital that is established from Sogang University, Plantynet Co., Ltd, KMW.INC, and so on. Our primary goal is to invest primary venture company and we currently manage 6 funds that are worth about 140 billion dollars. Albatross Investment continuously obtained the grade A for six years by the Ministry of SMEs and Startups (MSS). Albatross Investment is an objectively verified venture capital company based on the operation outcome. Areas of Activity

• 3D Printing/addictive manufacturing for • Pharmaceutics biomedical applications • Life sciences related activities • Diagnostics IVD • EPR, Clinical/healthcare management • Drug screening & delivery software • eHealth, mHealth, telemedicine • Vaccines • Electromedical and medical equipment • Laboratory equipment, reagents, software (non diag) • Medical devices • Genetics & Genomics • Investments • Medical research

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity in Pharma & Medical Devices Albatross Investment are interested in the following life sciences areas: - Biotechnologies (Pharma & Medical Devices) - Diagnostics-Imaging equipment and processing - Drug screening & delivery - Genetics &Genomics - Peptides, Proteins & antibodies preparation 31 / 880 - Pharmaceutics - Life sciences related activities - Laboratory equipment - Medical devices Specific sectors of interest: - Biotechnology: Cell culture system, CMO(Contract Manufacturing Organization), etc - Pharmaceutical: Biologics, Antibiotics, Cancer Immunotherapy, CNS(Central Nervous system) therapy, etc. - Digital Healthcare/ Connected Health - Medical Devices, In Vitro Diagnostic, NGS(Next Generation Sequencing), etc. Types of investment: RCPS(Redeemable Convertible Preference Shares), Common Stock, CB(Convertible Bond), BW(Bond with Warrant), etc.

32 / 880 ALFASIGMA spa

Organisation

Country Italy City Bologna Street Web http://www.alfasigma.com/en

Person

Name PIERLUIGI MANGINO Project Manager Officer

Organisation Alfasigma was set-up in 2015 by aggregating Alfa Wassermann and Sigma-tau, 2 Italian leading pharma players who put together their expertise and assets to create a new international key player. Based in Italy (Bologna) with 16 subsidiaries, it employs more than 3,000 people. Thru its R&D, manufacturing capabilities and commercial units, Alfasigma markets prescription and OTC drugs and medical foods. 2017 turnover expected to overcome 1 billion euro; 35% of it is made of 3 internally developed molecules: Sulodexide, L-Carnitin and Rifaximin-α (Normix®, Xifaxan® and others), an innovative intestine-targeted, non-absorbable antibiotic, now available in most countries worldwide, including the USA. Alfasigma is seeking to expand its product portfolio through partnerships and collaborations in the gastroenterology, vascular, orthopedic-rheumatologic and cardio-metabolic areas, with primary focus on the development of new therapeutics for GI and liver diseases. Areas of Activity

• Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics • Medical devices

Marketplace Opportunities PARTNERSHIP Partnerships or collaborations to expand product portfolio in gastroenterology, vascular, orthopedic-rheumatologic, cardio-metabolic areas Alfasigma is very attentive to the continuous evolution of society, studying its changes and monitoring its needs so that it can respond to the requirement for health and prosperity that is the right of every human being. To pursue this aim, Alfasigma specialises in defined therapeutic areas, producing medicines both for prescription and self-medication, other than those resulting from the internal research that has given rise to major patents, both national and international. Gastroenterology is currently the most important sector for the Group, thanks above all to Rifaximin-α, an antibiotic for the cure of disorders of the gastrointestinal tract, intellectual property that was entirely the outcome of Alfasigma

33 / 880 research. It was approved – the first and only antibiotic in the sector of reference – by the FDA for the treatment of travellers’ intestinal disorders in 2004, for the prevention of hepatic encephalopathy in 2010 and for irritable bowel syndrome in 2015. Other products in this therapeutic area are Biochetasi to combat gastric hyperacidity, Limpidex, a proton pump inhibitor, Debridat, an antispasmodic, and Yovis, a probiotic against alterations in the intestinal flora. Vascular Medicine: Alfasigma is also one of the leaders in this therapeutic area due to sulodexide, a heparinoid, and Parnaparin, a heparin used for the prevention of deep vein thrombosis, another product that originated from internal research. Orthopaedics and rheumatology: it is another area of great significance for Alfasigma, with anti- inflammatory medicines like Dicloreum, Tauxib and proprietary medicines like Nicetile for the treatment of mechanical and inflammatory lesions of the peripheral nerve, and the supplements Carnifast Plus, Amedial Plus and Alanerv.

Cardiometabolic: Alfasigma is also active in this field with medicines such as Eskim, Libradin, Goltor and Absorcol.

Moreover, Alfasigma operates in other therapeutic fields such as Bronchopneumology, Diabetology and Nutraceuticals.

34 / 880 AllBioinformatics Org

Organisation

Country Italy City Milan Street Via Marconi 47 Trezzano s/N Web www.allbioinformatics.org

Person

Name Francesco Di Tota Business Developer

Organisation AllBioinformatics Org (AB)was founded in 2012 by a (IBM) spin-off of industrial researchers of the Molecular Biodiversity Laboratory MBLab, to be a network of bioinformatics scientists. We are a multiple disciplines team which aim to join novel industrial maketplace opportunities with current research application every days present.As Bio-ICT medical devices provider our company's strength is to translate a biological content in a Bio-ICT application. We deal from the idea to Bio-ICT solution We work in a place hosting collaborations environment to help our customers for implement, scout, identify, assess feasibility of new business opportunities for an early market positioning of Bio-ICT, IT- Mobile and Gesture technologies applied to Life Sciences, Pharmaceutical and Agrifood marketplace.We are also open to private investment funds as well world-wide research collaborations. Areas of Activity

• Bioinformatics, Big data analytics • IT Applications for Health • Biotechnologies (Pharma&Medical Devices) • Medical research • Medical devices

Marketplace Opportunities SERVICE Bio-ICT solutions and services AllBioinformatics provides professional solution and services across life cycle project in support of our clients in the public and private sectors. We cooperate with highly trained scientists and IT experts to quickly arise additional Bio-ICT values for your industrial research application. AllBioinformatics aim to connect firms to scientific excellence of leading Research Centers with the purpose to build synergy partnerships. We have ongoing projects with public research centers and collaborate intensively with national IT-companies and University. We are open to SMEs, Pharmaceutical farm, Public entities as Technology and Research Institutions as well as University or Government’s labs.

35 / 880 PRODUCT Zero Nicotine: this medical application is a Bio-ICT solution to prevent Nicotine Abuse by Electronic Vapor Devices AllBioinformatics Org in collaboration with a pharmaceutical Sme, physician advisors and a technical partner is developing an innovative medical device to predict over time the human nicotine intake by electronic vaporizer devices. Our system has focused to help smokers patients having heart disease, acute myocardial infarction, congestive heart failure, pneumonia and all the other patients with high nicotine addiction degree (craving symptoms) who is today required a standard nicotine replacement therapy (NRT). Our solution is shaped by a medical device SW Class IIb (Nicotine Profile), Hardware vaporizers under safety condition use and balanced levels of nicotine provided by TPD liquids. A web cloud application is available for personalized forecasting nicotine intake profiles. Nicotine Dependence Tolerance Range - System Model (NDTR-SM) algorithm correlates the old patients nicotine exposure with their nicotine addiction degree. Personalized Nicotine Profiles (NP), which will never exceed of the previous nicotine intake, are individually processed taking into account neurobiological principles of physical nicotine addiction, and psychological factors as well. Zero Nicotine should be also exploited for an extensive commercial application to plan a complete nicotine detoxification program minimizing the adverse events of nicotine withdrawal to prevent tobacco damage. http://0nicotine.com We are seeking for privates or public investor interested in this early stage of application for joint venture, licensing, commercial agreement with technical assistance, dissemination and exploitation of the product in the hospitals, anti-smoking centers and pharmacies.

36 / 880 Altavia Srl

Organisation

Country Italy City Bologna Street Web http://www.altavia.eu/

Person

Name Gualtiero Govoni Senior developer

Organisation Altavia is a software house born in Bologna in 2000. During its growth, it specialized in the development of management systems for electrophysiology and hemodynamics laboratories. Software solutions, used by public and private healthcare organizations in 7 Italian regions, contribute to reducing the costs of the health system, improving the quality of procedures and more generally, increasing their efficiency. Areas of Activity

• Software, ICT applications, system integration • IT Applications for Health

Marketplace Opportunities SERVICE RamWeb RamWeb is an application in web environment for the complete management of hemodynamics, electrophysiology and interventional cardiology. The objective is to assist clinicians and technicians in all diagnostic and interventional phases from patient reception to reporting. The design of this management has always valued the importance of the data collected, allowing the development of both mono and polycentric scientific studies.

37 / 880 Alteredu srl Startup

Organisation

Country Italy City Cosenza Street Piazzetta Meroli Web https://www.alteredu.it/

Person

Name Giacomo Ferlaino Digital Project Manager

Organisation ALTEREDU Srl is an Innovative Start-Up, born from the many years of experience of the founders of the Social Promotion Association "Digital Future", member of the Digital Skills and Jobs Coalition of the European Commission. ALTEREDU offers recognized training courses online, presenting itself as an innovative center of competence enrichment - POLO FORMATIVO - for: - reduce the employment gap between young Italians and Europeans; - to offer courses valid at community level, able to enhance the skills of individuals; - to increase personal skills and professional competitiveness both in Italy and in Europe As an innovative start-up, Alteredu is fully aware of how important research is, in fact, thanks to different experts in the field, it develops new solutions in different fields (first of all the digital one), to be proposed to the current market. Areas of Activity

• Analytical and characterization services • IT Applications for Health • eHealth, mHealth, telemedicine • Life sciences related activities • Other

38 / 880 Alvimedica

Organisation

Country Turkey City Istanbul Street

Person

Name Dilek Uzunok Medical Business Development

Organisation Interventional cardiology products manufacturer Areas of Activity

• Medical devices

39 / 880 Anemocyte S.r.l.

Organisation

Country Italy City Gerenzano Street Via Lepetit, 34 Web www.anemocyte.com

Person

Name Claudio Storini Project Manager

Organisation Anemocyte is a Biotech Manufacturing Organization (BMO); a biotech company active in the field of Cell and Gene Therapies (CGTs) that addresses CGT needs pro-actively offering one stop shop solutions and fostering exciting innovations. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical research biomedical applications • Peptides, proteins & antibodies • Bioinformatics, Big data analytics preparation • Biomaterials • Pharmaceutics • Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Vaccines • CMO (Contract Manufacturing • Medical devices Organisation) • eHealth, mHealth, telemedicine • Genetics & Genomics • Investments • Manufacturing & process engineering

Marketplace Opportunities PARTNERSHIP Looking for real innovation Anemocyte is open to evaluate projects in order to start new partnerships and collaborations for innovation in life science-related fields.

40 / 880 Angel Consulting

Organisation

Country Italy City Milano Street via San Senatore, 14 Web http://www.angelconsulting.eu

Person

Name Matteo Zanotti Russo CEO

Organisation We are a consulting company, specialized in Cosmetics, Medical Devices and Wellness products. We can help companies on new products/processes/technologies on technical/regulatory issues on international rules for compliance, registrations, Technical Files, Product Information Files. Areas of Activity

• Consulting services • Medical devices • Nutraceutics, probiotics, functional food, cosmeceutics • Regulatory affairs, validation

Marketplace Opportunities SERVICE Cosmetics On new cosmetics/cosmetic ingredients we can provide compliance check up, registration, INCI name, CPNP, PIF under EU 1223/2009 and all other regulations worldwide SERVICE Medical Devices We can provide MD validation, approval, registration, assistance to certification and CE mark, Technical File, advertising approvals

41 / 880 Angel Partner Group

Organisation

Country Italy City Roma Street via Marsala 29 H Web www.angelpartnergroup.com

Person

Name Roberto Magnifico President

Organisation Angel Partner Group (APG) is a business angel network founded in 2015. APG is an association of professionals, managers, entrepreneurs and corporate people who believe in entrepreneurship and innovation as drivers of economic growth. The association has among its founding members LVenture Group, one of the leading venture capital operators in Europe, the only one listed on the MTA of the Italian Stock Exchange. We invest in early-stage digital technology startups. Startups must have a team of co-founders, some product and market validation, metrics and some revenues. Pre-money valuations <€5mn. Areas of Activity

• Bioinformatics, Big data analytics • EPR, Clinical/healthcare management • eHealth, mHealth, telemedicine software • Investments • IT Applications for Health • Software, ICT applications, system integration

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment in life sciences digital startups We invest in early-stage digital based technology startups, also in the biomedical sector. Startups must have a team of co-founders, some product and market validation, metrics and some revenues. Pre-money valuations <€5mn.

42 / 880 Angelini S.p.A.

Organisation

Country Italy City Santa Palomba, Pomezia Street P.le della Stazione, snc Web www.angelinipharma.com

Person

Name Gaia Corso Business Development Scientific Liaison

Organisation Angelini is an international groupleader inthe healthcare and wellbeing segmentsin the field of pharmaceutical and consumer products. Founded in Italy at the beginning of the 20th century,Angelini hasnowdirect presencein 20 countries and a worldwide distribution network. In the Pharma field, it does extensive R&D, manufacturing, and marketing of active ingredients, branded medicines, medical products, and food supplements. The Innovation activities are implemented in the RR&D (Research, Regulatory & Development), where the R&D, the Regulatory Affairs, and the Business Development work together to ensure a sustainable Company portfolio with high level of innovation. The RR&D makes strategic partnerships with pre-eminent public and private institutions worldwide under the concept of a dynamic pipeline, where each project can be partially or fully developed in- house or by partners based on the opportunities. In the early development phase, the company is looking for innovative solutions in the healthcare and wellness, to be considered for research collaborations and licensing operations, also in the context of national and international funded projects. The proposals might include novel molecular targets, pharmaceutical products, cosmetics, nutraceutical products, medical devices, drug delivery technologies, and other drug development technological platforms. Presently, the main research programs focus on Pain & Inflammation Disorders, and Nervous System Diseases & Disorders. www.angelinipharma.com Areas of Activity

• Bioinformatics, Big data analytics • Pharmaceutics • Biomaterials • Life sciences related activities • Biotechnologies (Pharma&Medical • Medical devices Devices) • IT Applications for Health • Chemicals & APIs • Drug screening & delivery • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

43 / 880 Marketplace Opportunities REQUEST Business Development Scientific Liaison We are looking for innovative solutions in healthcare and wellness. The proposals might include novel molecular targets, pharmaceutical products in the early development stage (up to clinical Proof of Concept), cosmetics, nutraceutical products, medical devices, drug delivery technologies, and other drug development technological platforms. The proposals can be considered for research collaborations, licensing operations, also in the context of national and international funded projects.

44 / 880 Annalisa Delnevo

Organisation

Country Italy City Sant’Agata Bolognese Street

Person

Name Annalisa Delnevo Onwer

Organisation Innovation and Management Advisor Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Project proposals support services • Consulting services • Medical devices • Electromedical and medical equipment (non diag) • Investments • Packaging & labelling

Marketplace Opportunities SERVICE New Product Development Advisor for new product development - Medical Device SERVICE Innovation & technological due diligence With long experience in R&D, I'm able to provide technical due diligence on new products/ideas

46 / 880 Aptsol srls

Organisation

Country Italy City Novara Street L.go Donegani, 2/3 Web www.aptsol.it

Person

Name Andrea Foglio Bonda Ceo

Organisation APTSol is an Organization specialized in the formulation development of dosage forms or production intermediates. We are specialized in applying innovative technologies to obtain high added-value formulations. We are able to find the right solution to your formulation issue, be it in the pharmaceutical, cosmetic or nutraceutical field. Whether you require a simple emulsion, a nanonized powder, or extremely complex polymeric matrix systems, APTSol will always apply its passion and expertise to obtain high quality products. Our knowledge of processes and formulations, together with the availability of advanced instrumentation, allows us to provide high added-value services that will contribute to the success of your products. The APTSol team is characterized by a strong academic and professional experience in the formulation field, and is able to provide services that range from performing analyses to providing innovative and effective responses to the problems presented by our clients. Areas of Activity

• Medical research • Laboratory equipment, reagents, software • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics • Life sciences related activities

Marketplace Opportunities SERVICE Spray Chilling The spray chilling (or spray congealing) technique involves the atomization of a mixture of molten substances in an environment with a temperature lower than the solidifying temperature of that same material. The sudden temperature drop determines the solidification of the atomized material and the formation of nearly spherical solid micro or nano-particles. There are multiple applications of the spray chilling technology: as an example, the encapsulation of milk enzymes, vitamins or aromas within the food sector. In the pharmaceutical field, the use of lipidic matrix systems, which can also be produced using this technique, allow to determine predictable and stable release performances of active 47 / 880 ingredients, is becoming increasingly frequent. APTSol is equipped with a spray chilling system dedicated to the development of your lipidic formulations. If you are interested in the spray congealing technology, please do not hesitate to contact us.

Our spray congealing technology We have equipped our spray dryer with new features that allow it to turn into an effective spray congealing system for the development of your products.

Product volume: 20 - 300 mL Product temperature: 30 - 150 °C Nozzle diameter: 0,7 - 2,0 mm SERVICE Spray Driyng Spray drying is one of the most widely used methods for the production of a dry material from an aqueous (and/or organic) solution or suspension. Its peculiarity lies in the possibility to obtain powder with a size ranging from 500 μm to a couple of micron, and in some cases to a few hundred nanometers. The liquid material that requires drying is nebulized through a nozzle with an adjusted diameter in a chamber where warm air is circulated at a controlled temperature (from 100 to 220 °C). The drying process is nearly instantaneous because the material, in the form of small nebulized droplets, presents a very wide surface to the drying fluid. Continuous processing, production speed and low operating costs make Spray Drying one of the best processes for the drying of pharmaceutical and food products. Due to APTSol’s considerable expertise in the use of this technology, the Spray Drying process is not only employed just for drying liquid systems, but also for the coating of crystals of hydrophobic active ingredients, for the amorphization of active ingredients, for the microencapsulation of active ingredients and functional substances in polymeric or oligosaccharide vehicles, and for the taste- masking of nutraceutical products. SERVICE Freeze Drying Freeze-drying is today one of the most widely used techniques for the removal of water from food and medicinal products in general. The lyophilized product is a dry powder that can quickly re-gain its appearance and the structural and functional properties of the starting material. One disadvantage of such a technique mainly lies in the employment of resources for its implementation, and in the difficulty to develop an adequate interaction between formulation and process to maintain the product’s desired properties. APTSol advanced equipment for freeze-drying and adequate analytical instrumentation allow the characterization of the achieved products. Moreover, the company’s team can rely on a solid experience in the field of freeze-drying and in the creation of experimental designs. Entrust APTSol for the development of your lyophilized products. Our freeze-drying services Here are some examples of what APTSol can do for your lyophilization projects: - Lab-scale freeze-drying for third party - Processes optimization - Scale up - Formulation development Our freeze-drying technology APTSol is equipped with a lab-scale and pilot freeze-drying unit able to freeze dry liquids and solids in vials, trays or other glass containers. It is ideal to freeze-dry bacteria, proteins, drugs, vitamins, vegetable extracts and food products, and it represents an excellent tool for small-scale research and production purposes.

48 / 880 Condenser capacity: 5 kg Condenser temperature: -85 °C Condenser performance: 4 kg/24 h Unit dimensions: 1267 x 860 x 650 mm Plates number: 3 Plates dimensions: 225 x 300 mm SERVICE Microencapsulation Microencapsulation is a process that allows the delivering of different substances such as active ingredients, vitamins, oils, fragrances and aromas, enzymes, cells or microorganisms in systems of polymeric and/or lipidic nature. There are a number of production techniques available to this purpose, all of which result in the creation of a set of solid particles with a size ranging from 1 to 1000 µm, which are referred to as microcapsules or microspheres according to their structure. Encapsulation has allowed the creation a vast number of products deemed technically impossible for many years. Such ingredients are completely enclosed or absorbed in a coating material which provides additional properties or eliminates unwanted properties from the ingredient. Microencapsulation is a process through which extremely small particles or droplets are surrounded by a coating, or are incorporated in a homogeneous or heterogeneous matrix, to provide small capsules with a number of useful properties. Microencapsulation can provide a physical barrier between the base compound and the other components of the product.

49 / 880 AQUABUDDY srl

Organisation

Country Italy City Budrio Street Via Guizzardi 52 Web http://www.aquabuddy.it/

Person

Name Paolo Monticelli President

Organisation Aquabuddy S.r.l. is a start-up of Pol-Group network, its main goal is improving the life condition of those people who are in a serious conditions such as spinals, obese people, elderlies ecc... A perfect hygiene is a fundamental need, set forth in the Universal Declaration of Human Rights, it should be guaranteed to everyone, especially for those who need constant assistance to perform the basic human needs. Clean up a bedridden person is a difficult and time-consuming operation. Usually it takes several minutes to rise the person, put him on a special stretcher, and transfer him in an accessible bathroom. This common routine requires a great amount of energy and time, so sometimes is preferable a scratch the surface clean up with sponges or wet wipes. This incorrect practice is one of the most common causes of infection spreading among the patients; followed by a massive use of antibacterial and a general reduction of life expectancy. Starting from these preconditions, Pol-Group’s highly specialized staff has developed Aquabuddy-Pro, the first professional device which performs a complete shower directly in the bed within a few minutes, thanks to a waterproof sheet placed under the patient’s body. Aquabuddy-Pro is an electrical medical device that has been implemented in hospitals, elderly homes and nursing homes since 2007. Its unique features can be used even in critical hospital units as burnt and intensive care. Aquabuddy was born in order to bring this new concept from the professional field to the homecare users. Aquabuddy Home has the same features as its twin set Aquabuddy-Pro, it the first portable high technological device that turns the bed in an actual bathtub, by allowing to bathe the person directly in his own bed. Aquabuddy S.r.l. designs and manufactures its own devices in Budrio (Bologna). Areas of Activity

• eHealth, mHealth, telemedicine • Medical devices • IT Applications for Health

Marketplace Opportunities

50 / 880 PARTNERSHIP AQB Sales Partnerships for world-wide exploitment We are looking for international partners/distributors as well as potential investors to enhance our marketing and sales potantialities. PRODUCT Portable Bed-showers We produce portable "bed-showers" to address to the following market segments: - AQB-PRO for Elderly Houses -AQB-PRO for home-care -AQB-CARE for professional care (being at home or in a hospital for specific needs, i.e.burnt...)

51 / 880 Arithmos

Organisation

Country Italy City Verona Street Web https://arithmostech.com/

Person

Name Anna Bottura Business Development Manager

Organisation Arithmos is an innovative IT company with a specific focus on the Life Sciences value chain aiming to increase efficiency in different business areas: Clinical Trials conduct, Pharmacovigilance and Project Management. Arithmos is ISO 9001:2015 certified concerning our Quality Management System and ISO 27001:2014 certified ensuring the compliance of our Information Security Management System. The main proprietary platforms Arithmos has developed are: - SYNClevy: innovative web-based Project and Portfolio Management system created to enhance collaboration among departments; - Argus Blueprint: pre-configured, fully validated pharmacovigilance system to ensure regulatory compliance; - Symphony EDC: user-friendly Electronic Data Capture solution. Arithmos also collaborates to develop solutions in the eHealth sector using big data, IoT and AI.

Areas of Activity

• Bioinformatics, Big data analytics • EPR, Clinical/healthcare management • Biotechnologies (Pharma&Medical software Devices) • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Pharmaceutics • Life sciences related activities

52 / 880 Arithmos

Organisation

Country Italy City Verona Street Via Roveggia 122 Web www.arithmostech.com

Person

Name Emilio Vandelli Managing Director

Organisation Arithmos is an innovative IT company with a specific focus on the Life Sciences value chain aiming to increase efficiency in different business areas: Clinical Trials conduct, Pharmacovigilance and Project Management. Arithmos is ISO 9001:2015 certified concerning our Quality Management System and ISO 27001:2014 certified ensuring the compliance of our Information Security Management System. The main proprietary platforms Arithmos has developed are: - SYNClevy: innovative web-based Project and Portfolio Management system created to enhance collaboration among departments; - Argus Blueprint: pre-configured, fully validated pharmacovigilance system to ensure regulatory compliance; - Symphony EDC: user-friendly Electronic Data Capture solution. Arithmos also collaborates to develop solutions in the eHealth sector using big data, IoT and AI.

Areas of Activity

• Biotechnologies (Pharma&Medical • EPR, Clinical/healthcare management Devices) software • eHealth, mHealth, telemedicine • IT Applications for Health • Pharmaceutics • Life sciences related activities • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT

53 / 880 SYNClevy - The Extended Project &Portfolio Management Platform SYNClevy is an Extended PPM (Project &Portfolio Management) System developed to enhance Clinical Trial monitoring and management. Key advantages: • Makes your process more efficient; • Supports decision making; • monitors P&L management; • creates a collaborative workspace where users can share data and info with other departments. SYNClevy is provided Software as a Service (SaaS). PRODUCT Oracle Argus Blueprint - Pre-Configured and Fully Validated Solution for Pharmacovigilance Argus Blueprint is a pre-configured and fully validated solution for fast deployment of Oracle Argus Safety that allows companies to implement or change pharmacovigilance systems in the most accurate, timely and cost-effective manner. Key advantages: • Pre-valudation and pre-configuration; • Scalability; • Cost-effectiveness; • Fast deployment; • Safety. PRODUCT Symphony EDC - Electronic Data Capture Solution Symphony EDC is a proprietary Software as a Service (Saas) Electronic Data Capture solution designed by an investigator and developed by Arithmos. The goal of Symphony EDC is to accelerate the overall data collection and data management process with an intuitive and powerful tool. Key advantages: • User friendly interface; • Reusable global library forms; • High security level; • Randomization module; • Audit history and electronic signature. PRODUCT Healthentia - eClinical platform that ensures patient retention and data integrity Powered by Arithmos partner, Innovation Sprint, Healthentia is an eClinical platform that responds to two of the biggest challenges in clinical research: patient retention and data integrity. Key Advantages and Differentiators: • Enhanced patient motivation and retention with rich insights and a gamified return on their loyalty; • Reduced cost & time of the study; • Enriched Quality of Clinical trials with richer datasets; • Accuracy in data collection and reduced patients risks with real-time monitor; • Novel communication between patient and Pharma, e.g Chat bot; • Enhanced trial monitoring for the investigator by providing BI analytic tools and functional control panel.

54 / 880 ARTA PEPTIDION Srls

Organisation

Country Italy City Parma Street Via Quasimodo, 11 Web www.artapeptidion.it

Person

Name Antonello Romani Chief Executive Officer

Organisation ARTA PEPTIDION designs and develops custom Bioactive Peptides and Peptidomimetics in the fields of Life Sciences and Technologies for Health. It was established in Parma in 2015, built up on the passion and the expertise of a highly-specialized Team. Arta Peptidion is able to provide feasibility studies as well as concrete scientific solutions to meet the challenges of different business realities operating in the pharmaceutical field – both human and veterinary- and in the food market, especially within antimicrobials and anti-inflammatories. Choosing to work with Arta Peptidion means to choose a team with the same goals as yours : YOUR success is OUR success; YOUR problem is OUR task to find a solution. Our activity consists of two stages. The first one, which may be described as creative, is developed in the headquarters in Parma, where we assess the feasibility of a research, discuss its critical issues and develop Bioactive Peptides and Peptidomimetics employing methods as the “stucture-based de novo peptide/drug design” or the “molecular modelling” in general. In the second stage, our ideas are validated through experimentation conducted by our colleagues of the Department of Life Sciences of Trieste University. For us it is crucial to build an effective relationship with our Clients, following them on the path to success. Our strength is to provide solutions through a pragmatic and efficient approach, determining the technical and economic feasibility of a specific research project. Areas of Activity

• Biomaterials • Pharmaceutics • Biotechnologies (Pharma&Medical Devices) • Peptides, proteins & antibodies preparation

Marketplace Opportunities PRODUCT Novel short and ultrashort Arg-rich antimicrobial lipopeptides for topical formulation The increasing emergence of multidrug-resistant microorganisms represents one of the greatest challenges in the clinical management of infectious diseases, and requires the development of novel antimicrobial agents. To this aim, we de novo designed, by using artificial intelligence approach, a

55 / 880 library ultrashort Arg-rich antimicrobial lipopeptides (USCLs). USCLs exhibited an excellent antimicrobial activity in particular Gram-positive bacteria and fungi, with MIC values below or equal 3.25 µg/mL. Interestingly, no cytotoxic effects were evidenced up to 100 µg/mL in human epidermal model EpiDerm and human keratinocytes HaCaT cell line, thus highlighting a good cell selectivity. These compounds inhibited the growth of S. aureus even at sub MIC concentrations and induced cell membranes permeabilization by producing visible cell surface damages determining a marked reduction of bacterial cell viability. These USCLs could be useful to develop new drugs effective also against slow- or non-growing bacteria, with a limited risk to develop drug resistance, making them very promising antimicrobial and/or antifungal agents useful for many applications.

56 / 880 Assolombarda

Organisation

Country Italy City Milano Street via Pantano 9 Web http://www.assolombarda.it/

Person

Name Felice Lopane Project Manager Life Sciences

Organisation Approximately 6.000 firms located in the Provinces of Milan, Lodi and Monza and Brianza are associated to Assolombarda, which is the largest territorial association of the entire entrepreneurial system in the country. Assolombarda is part of Confindustria (Italian Entrepreneurial Association). The associated firms employ more than 330.000 workers locally and several hundred thousands in the whole country. Foto AssolombardaThe mission of the Association is to protect and represent the enterprises' interests in dealing with the political world, with social and political organizations and with local authorities as well as with trade unions. Assolombarda also provides its associated firms with a great variety of services. Furthermore, assistance, advice and practical handbooks are supplied on several management and strategy aspects. As Assolombarda is an entrepreneurial Association, its principal focus is encouraging the development of the local industry by promoting solidarity and cooperation among its member firms and by fostering and protecting their interests when they have to face problems related to industrial, social, economic or cultural matters. Accordingly, the Association: 1) represents its members’ common interests; 2) permits the comparison between different entrepreneurial realities; 3) supports management of main business functions. Areas of Activity

• Consulting services • Life sciences related activities • Other

Marketplace Opportunities SERVICE Consulting As Assolombarda we offer consulting services to life sciences companies, ranging from labour matters 57 / 880 to policy monitoring and advocacy initiatives to raise the vocie of life sciences companies towards public stakeholders. Moreover, we have a variety of studies and a deep knowledge about the life sciences industry in Italy , its healthcare sector and NHS dynamics. PARTNERSHIP Collaboration As Assolombarda we always seek for institutional partners to create valuable projects and initiatives, especially for life sciences.

58 / 880 Ateknea Solutions

Organisation

Country Malta City Zebbug Street Triq Hal-Dwin Web www.ateknea.com

Person

Name David Micallef management

Organisation Ateknea Solutions is a group of companies with offices in Barcelona, Hungary, Poland and Malta, with over 10 years of experience in the field of EU funding and the development of new products. Ateknea Solutions guides SMEs, by offering advisory services on funding sources, proposal writing, technical support and project management. The company has a team of rover 150 specialised professionals working in project management, proposal writing and the technical execution of innovation projects. Over the years Ateknea has helped numerous SMEs get the required funding to take their innovative prototypes and develop them and bring them into the market. In this event we would like to meet up and discuss funding opportunities with SMEs who have an innovative product in the pipeline. Areas of Activity

• Project proposals support services

Marketplace Opportunities SERVICE Helping SMEs secure funding and providing the necessary support and resources for successful project implementation Accessing funding can be a laborious, time consuming activity and participants can easily get overwhelmed with the huge amount of paperwork that needs to be completed, moreover, when a company comes to execute a project, it is most unlikely that the company has all the required resources and they often need to outsource technical support of some sort. At Ateknea we offer expert services to identify open calls for funding, combined with a tailored approach to idea evaluation, proposal preparation and submission, project implementation and management. The team at Ateknea consists also of engineers with different fields of specialisation. The aim is to offer a comprehensive service, technical input on the project as well as administrative support in executing each project with great success. Ateknea offers its services to clients who are seeking to develop new products and services, however our company does not look to benefit from any IPR generated in the project. https://youtu.be/5bP3qUOlHSQ FUNDING PROGRAMME AND REFERENCE Horizon 2020 SME Instrument Phase 1 and Phase 2 all topics 59 / 880 TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE We are looking for SMEs who demonstrate to have a potential for innovation and who are likely to succeed in the development of new products and services.

60 / 880 Ateknea Solutions

Organisation

Country Malta City Zebbug Street Triq Hal-Dwin Web www.ateknea.com

Person

Name Lorraine Tagliaferro Innovation Manager

Organisation Ateknea Solutions is a group of companies with offices in Barcelona, Hungary, Poland and Malta, with over 10 years of experience in the field of EU funding and the development of new products. Ateknea Solutions guides SMEs, by offering advisory services on funding sources,proposal writing, technical support and project management. The company has a team of rover 150 specialised professionals working inproject management, proposal writing and the technical execution of innovation projects. Over the years Ateknea has helped numerous SMEs get the required funding to take their innovative prototypes and develop them and bring them into the market. In this event we would like to meet up and discuss funding opportunities with SMEs who have an innovative product in the pipeline. Areas of Activity

• Consulting services • Investments

Marketplace Opportunities SERVICE Consultation for EU Funding - H2020 Helping SMEs secure funding and providing the necessary support and resources for successful project implementation

61 / 880 ATLANTIC BONE SCREEN

Organisation

Country France City Saint-Herblain Street 3 rue Aronnax Web www.atlantic-bone-screen.com

Person

Name Elisabeth PORCHER Business Development Manager

Organisation Atlantic Bone Screenis a leading CRO specialized in high-quality preclinical evaluation services / non clinical studies in the field of bone and joint diseases, and more particularly in bone diseases from tumor origin. We provide the following assays : - in-vitro assays and in-vivo assays for drug candidate, nutraceuticals and biomaterials/medical device evaluation,- histology/histopathology services in oncology, neurology, dermatology... - Biomarkers analysis and imaging services Areas of Activity

• Biomaterials • Drug screening & delivery • Biotechnologies (Pharma&Medical Devices) • CRO (Contract Research Organisation)

Marketplace Opportunities SERVICE Preclinical evaluation services Atlantic Bone Screen provides the following services: - in-vitro assays and in-vivo assays for drug candidate, nutraceuticals and biomaterials/medical device evaluation - histology/histopathology services in oncology, neurology, dermatology... - Biomarkers analysis and imaging service Our services are based on: – latest scientific breakthroughs / development of specific preclinical models – personalized experimental protocols thanks to a constantly sustained preclinical platform – working with academic and research centers from the most important pharmaceutical and food

62 / 880 industries as well as biomaterial companies

63 / 880 Atlas Biomed Group

Organisation

Country United Kingdom City London Street Tintagel House, 92 Albert Embankment, Lambeth, London, UK Web https://atlasbiomed.com/uk

Person

Name Sergey Musienko CEO

Organisation Atlas Biomed is a personalised health company, applying the latest genetic technologies to help you navigate towards your potential. To achieve this, Atlas has two tests: the Atlas DNA Test and the Atlas Microbiome Test. Both tests feed into the Atlas platform, which allows you to take control of your health through actionable, personalised recommendations. Areas of Activity

• Genetics & Genomics • Medical research • IT Applications for Health

Marketplace Opportunities PRODUCT DNA and Microbiome Testing The Atlas DNA Test assesses disease risks, carrier status for hereditary conditions, as well as the ability to metabolise nutrients and vitamins. It also considers the athletic component, assessing predispositions to strength and endurance, risk of sports-related injuries and recommended length of training sessions and rest period. Results from this test enable consumers to develop a personalised diet and fitness routine that is based on their unique DNA. The Atlas Microbiome Test analyses bacteria in the gut, detecting the microbes’ ability to synthesise nutrients, protect against disease and even whether your diet contains enough fibre. Results from this test come with extensive food recommendations to change and improve microbiome, boosting general well-being and protection against specific conditions. INVESTMENT OPPORTUNITY Round A Investment We are seeking for a Round A financing which will be used for: UK / EU Sales Expansion to North America 64 / 880 Product promotion Ongoing R&D PARTNERSHIP B2B Partners We are looking for partners to distribute our microbiome tests - fitness clubs, wellness clinics, pharmacies, healthy food stores, etc. PARTNERSHIP Clinics We are looking for clinics who would be our partners for two purposes: 1) Distribution of our DNA and microbiome tests 2) Counselling following DNA or microbiome testing by MDs PARTNERSHIP PR Agency We are looking for an agency responsible for the EU-wide promotion of our DNA and microbiome tests, which would be in charge of media relations and other PR activities.

65 / 880 Aurigon

Organisation

Country Hungary City Dunakeszi Street Pálya utca 2 Web aurigon.eu

Person

Name Tamás Kitka Business Development Manager

Organisation Aurigon, your full-service preclinical CRO, is celebrating 10 years of being Central European Minipig Center. We possess a spacious site for small and large animal testing (rodents, rabbits, dogs, minipig...) including in vitro laboratories close to the city borders of Budapest. We also maintain a well-equipped bioanalytical department in Budapest. We offer full range of preclinical services from development candidate to marketed product with an experience of more than 5600 studies. We offer various types of in vivo and in vitro studies, performed with a variety of test item classes (NCE, NBE, herbal extracts, vaccines, medical devices). These services include, but are not limited to PK/PD, ADME, bioanalytics, toxicology and safety pharmacology in several species from mouse to sheep. Aurigon provides tailor-made services. The studies are performed by highly qualified staff with up to 30 years of experience in purpose-built facilities and with the use of modern equipment and instruments. Our primary goal is to build up long-term partnerships. We intend to achieve this by being involved to our partners’ projects, providing tailor-made designs if possible and acting as a problem-solver partner in their projects keeping their budget, timeline and goals in mind. Areas of Activity

• Analytical and characterization services • Life sciences related activities • Biotechnologies (Pharma&Medical • Surgery technologies and applications Devices) • Vaccines • CRO (Contract Research Organisation) • Medical devices • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities SERVICE

66 / 880 Aurigon - your full-service preclinical CRO Aurigon is a privately-owned contract research institute (headquarter in Germany, R&D facilities in Hungary) offering full range of preclinical services from development candidate to marketed product with an experience of more than 5200 studies. In addition to the services of our GMP and GLP-certified molecular biology lab, we offer various types of in vivo and in vitro studies including, but not limited to PK/PD; ADME, bioanalytics, toxicology and safety pharmacology in several species from mouse to sheep. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Aurigon provides tailor-made pharmacological services. The studies are performed by highly qualified staff with up to 30 years of experience in purpose-built facilities and with the use of modern equipment and instruments. Our primary goal is to build up long-term partnerships. We intend to achieve this by being involved to our partners’ projects, providing tailor-made designs if possible and acting as a problem-solver partner in their projects keeping their budget, timeline and goals in mind. TYPE OF PARTNER SOUGHT Pharmaceutical companies Biotech companies Universities, university spin-offs Nutraceutical companies Medical device companies

67 / 880 AurorA-TT srl

Organisation

Country Italy City Milano Street Via dell'Annunciata 31 Web www.aurora-tt.com

Person

Name Edoardo Negroni Managing Partner

Organisation AurorA-TT is a Technology Transfer Intermediation Company established in 2017 based in Milan, Italy. We identify promising scientific breakthroughs from academia and research centers in Italy and partner with academia, research institutions and biotech companies based globally. We do invest in pre-seed and seed projects to bridge the gap between basic research and industrial drug development with industrial discipline. Successful projects either become assets for the creation of stand-alone companies, partnership with financial investors, biotech and pharma companies, or translate into agreements of varying nature with synergic partners. Areas of Activity

• Biotechnologies (Pharma&Medical • Proteomics, metabolomics, nutrigenomics Devices) • Vaccines • Drug screening & delivery • Investments • Peptides, proteins & antibodies preparation • Pharmaceutics

Marketplace Opportunities REQUEST Looking for investment opportunities Looking for early stage molecules/technologies (drug discovery stage and preclinical) with breakthrough innovation and high market potential in therapeutics (high unmet need, first in class or best in class)

68 / 880 AuXin Surgery

Organisation

Country Belgium City Louvain la Neuve Street Rue Louis De Geer 6

Person

Name Gilles Capart Managing Director

Organisation AuXin Surgery has developed CADISS®, a range of medical devices for a novel method of surgery combining surgery instruments with a drug product which weakens the chemical bonds between tissues, making selective dissection easier without damaging sensitive organs. The proof of principle is supported by clinical trials over more than 900 patients in open, laparoscopic and endoscopic procedures. These devices are being registered as CE Class III Medical Devices in the EU and as Combination Devices in the USA. Commercial launch is scheduled end 2018 in open surgery applications and will be extended in 2020 in minimally invasive surgery applications. The products will be marketed in developed countries that accept CE Mark and FDA registrations. Areas of Activity

• Medical devices

Marketplace Opportunities PRODUCT CADISS System CADISS® is a combination of medical devices for selective dissection in open, laparoscopic and endoscopic surgery, including disposable sources of the active formulation and reusable surgery instruments adapted to several different procedures. INVESTMENT OPPORTUNITY Capital increase AuXin Surgery is proposing investors to participate to a capital increase of 5 Mi€ in several stages with milestones in order to fund the market launch and the development of new applications of of the supply chain.

69 / 880 AV CONSULTING SRL

Organisation

Country Italy City Pesaro Street Via Sirolo 24 Web www.avconsultingitalia.com

Person

Name Michelle Valeri Marketing

Organisation Founded by Gabriele Angelucci and Valter Valenti, AV Consulting isan italian based industrial design and product development agency. We are specialized in market research, product design, mechanical engineering, prototyping and production. It works across a wide array of industries as diverse as medical device, automotive, home applliances, domotic, machinery, lighting to furniture and technology. We make product that look good, adress the need of users and make a substantial impact on the market. We have 3 departments: Strategy & Design Engineering & product development Prototyping & Production Our Partners (in Italy and Asia) have twenty years experience in manufacturing solutions: CAD 3D engineering, FEM analysis rapid prototyping, mould construction for vacuum forming, PUR-RIM, manufacturing, injection moulding, assembly with electronics. First of all to be sure you always make the right choice because you can rely on our counseling during technical and economical evaluation of materials and production techniques. You have the possibility to produce at very competitive costs, because, based on our experience, we know to guide you and find a tailor made solution that fits your requests at one of our approved Asian and Italian production partners. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical facilities furnishings, equipment, biomedical applications goods • Analytical and characterization services • Nutraceutics, probiotics, functional food, • Bioinformatics, Big data analytics cosmeceutics • Biomaterials • Packaging & labelling • Biosensors • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation

70 / 880 Devices) • Pharmaceutics • Chemicals & APIs • Physiotherapy, Orthopaedic technology • CMO (Contract Manufacturing • Proteomics, metabolomics, nutrigenomics Organisation) • Regulatory affairs, validation • Consulting services • Life sciences related activities • CRO (Contract Research Organisation) • Software, ICT applications, system • Diagnostics IVD integration • Diagnostics - Equipment and accessories • EPR, Clinical/healthcare management • Diagnostics - Imaging equipment and software processing • Surgery technologies and applications • Drug screening & delivery • Virtual reality applications • eHealth, mHealth, telemedicine • Other • Electromedical and medical equipment • Laboratory equipment, reagents, software (non diag) • Project proposals support services • Genetics & Genomics • Medical devices • Investments • IT Applications for Health • Manufacturing & process engineering • Medical research

Marketplace Opportunities SERVICE industrial design + product Engineering AV CONSULTING support companies in the assessment of marketing analysis, positioning , concept idea, through to prototype production. A team of marketing staff, product designers, engineers offers companies a tailored service assisting companies NPD requirements meet the needs of the market, the engineering complexities and the aesthetic values without losing sight of user friendly aspects. The team is specialized in industrial and consumer sectors: medical device, electronics, forniture, lighting, aesthetic equipment, machinery. In todays global market, modern and advanced product design is an integral part of the marketing mix, adding value to the products and consolidating companies image. We have twenty years of experience in the design and prototyping and have worked for major corporations in europe. SERVICE Rapid prototyping, Production of plastic components for medical devices injection moulding, thermoforming, composites, polyurethane PROJECT COOPERATION cooperation in Sales, Marketing, Product development AV CONSULTING manages all aspects of design projects through its extensive network of suppliers, from design, mock up, rapid prototyping, and project finalization. AV Consulting support start-up with Marketing services, sales and distribution consultancy in Italy. Each project we take on begins with a kickoff meeting, discussing the project to help determine what exactly it you are looking for. Our design process can then be tailored specifically to your needs and wants. Main topics covered: - Concept design - Usability - Styling - Cost analysis - Product marketing 71 / 880 - Sales and distribution in Italy

72 / 880 AV CONSULTING SRL - Product Design Market development

Organisation

Country Italy City Pesaro Street Via Sirolo 24 Web http:www.avconsulting.it

Person

Name Gabriele Angelucci Founder - Sales & Marketing Manager

Organisation Fondata nel 2007 da Gabriele Angelucci e Valter Valenti, AV Consulting nasce come società di design e progettazione, nel corso degli anni integra competenze specialistiche sia ingegneristiche sia di Marketing, evolvendosi in una struttura in grado di gestire in parziale o completo outsourcing lo sviluppo di progetti per conto di aziende in Italia e all'estero. Grazie ad una propria metodologia collaudata e l'esperienza maturata in ambiti diversi, AV Consulting opera all'interno delle aziende incentivando la generazione di innovazione a vari livelli della catena del valore. Un DNA fatto di dinamicità e flessibilità la rendono particolarmente attraente sia nei confronti di grandi gruppi industriali, piccole e medie imprese, start-up. Tre divisioni integrate Marketing, Design, Production, permettono la gestione in outsourcing di progetti complessi e in diversi settori (industriali e consumer), dispositivi medici, veicoli industriali, automotive, elettrodomestico, macchinari, illuminazione, packaging. Founded in 2007 by Gabriele Angelucci and Valter Valenti, AV Consulting is an italian based agency specialized in new product development. Today AV Consulting applies its "italian design approach" to drive innovation for international brands, sme, start-up. With three integrated departments, Marketing, Design, Prototyping & Production, it works across a wide array of sectors (industrial and consumer) as medical device, transportation, automotive, home applliances, machinery, lighting, packaging. ITALIAN DESIGN DRIVEN INNOVATION E' la metodologia di lavoro finalizzata a stimolare il problem solving e la creatività non solo a livello di Ricerca e Sviluppo ma coinvolge l'intera organizzazione e le strategie con l'obiettivo di ricercare soluzioni alternative per far evolvere il business aziendale. In questo modo riusciamo a creare prodotti dal design italiano, far evolvere quelli esistenti, concettualizzare applicazioni nuove con un notevole impatto sul mercato.

It's our approach for creative problem solving that is not limited to product development but involves the brand identity, strategic services to discorver new alternatives for business and society. We make new product and applications that look good, adress the need of users and make a substantial impact on the market. PRODUCTION MADE IN ITALY 73 / 880 Nel corso di venti anni di attività abbiamo costituito un gruppo di aziende di produzione integrando differenti tecnologie: termoformatura, carbonio e compositi, carpenteria, stampaggio ad iniezione, poliuretano, tecniche di prototipazione rapida. I nostri partner assicurano che i concept prendano forma e sostanza trasformandosi in prodotti di successo partendo da attente analisi di fattibilità tecnica ed economica attraverso un attento processo che dall'idea arriva alla fase di prototipazione e produzione di componenti e prodotti finiti. In twenty years AV Consulting has created a group of manufacturing partners integrating different technologies: thermoforming, composites, injection moulding, poliurethane, rapid prototyping. Our partners ensure that ideas take form and substance and are developed into successful products starting from feasibility analysis to technical and economic evaluation through to speedy prototyping and production. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical facilities furnishings, equipment, biomedical applications goods • Biotechnologies (Pharma&Medical • Packaging & labelling Devices) • Medical devices • Consulting services • Diagnostics - Equipment and accessories • Electromedical and medical equipment (non diag) • Manufacturing & process engineering

Marketplace Opportunities SERVICE Industrial design We support companies and start-up in all phases of product development: - market research - concept design - product engineering - prototyping SERVICE Marketing We support companies and start-up in alla phases of business development: - STRATEGY - benchmarking - web marketing - new corporate identity - new concept idea - restyling product and brand SERVICE PRODUCTION We support companies and start-up in new product develpoment: - Feasibility analysis - Material and Technologues consulting - Rapid prototyping - Tooling - Injection moulding - Thermoforming

74 / 880 - Production of aestetic components - Composites technology - Poliurethane injection - Cost saving SERVICE BUSINESS PLAN Marketing plan for startup and new product development

75 / 880 B.I.Matica sas

Organisation

Country Italy City Quartesana Street via selva 54 Web www.bimatica.biz

Person

Name Ettore Coletti Founder

Organisation B.I.Matica develops Business Intelligence and Datawarehouse systems. It offers turnkey solutions of Management Control, Production Analysis, Budget Analysis ... It develops custom projects for both the data feed part and the Analysis part (navigable dashboards). The data being analyzed can be both management and production processes, imported directly from databases, flat files, excel, machine tools, or other. The technologies used by B.I.Matica are the most used in the market: Oracle, QlikView, SAP Business Objects, Microsoft BI, Pentaho. The Open Source (Linux and Pentaho) solutions allow economic savings, as they do not need software licenses, for an unlimited number of users, and web access in multi-disc mode (PC, Smartphone, Tablet). The products interconnect with any management system. B.I.Matica offers consulting and development on any type of database and data warehouse (Oracle, Sql Server, Postgresql, mysql ..), routine and evolution maintenance of existing solutions. Areas of Activity

• Bioinformatics, Big data analytics • Project proposals support services • Consulting services • IT Applications for Health • Software, ICT applications, system integration • Laboratory equipment, reagents, software

Marketplace Opportunities PRODUCT Management Control Management Control: to monitor and analyze all business activities in time 0 through dashboards and navigable tables up to the maximum detail. The areas are: Sales, Customer Orders, Suppliers, Budget Analysis, Budget, Warehouse Analysis, Production Analysis (waste, machine stops, ...). SERVICE Business Intelligence BIMatica designs, develops and produces Business Intelligence and Datawarehouse systems using all 76 / 880 the technologies on the market: Oracle, QlikView, SAP Business Objects, Microsoft BI, Pentaho ... It offers "Ready to use" Solutions in Management Control , Production Analysis, Budget Analysis ... It provides customizations for both data feeds and Front End processes in order to monitor and analyze processes (production, sales, purchase, etc.). Application processing also allows for analysis (eg what if analysis): for example, predicting the end of a process at the current machine tool speed, sales scenario analysis, what if the parameters vary by x%, ... The analysis dashboards are navigable to the maximum detail and you can generate automatic alerts, by mail, based on events. Datawarehouse, Business Intelligence, Oracle, SAP Business Objects, Power Pivot Microsoft, Pentaho, ETL, Database SQL Server, Database Oracle, Database Postgresql

77 / 880 BADIAMO

Organisation

Country Italy City Bologna Street Via Marco Emilio Lepido 321/2 Web https://www.badiamo.it/

Person

Name Fabio Angelini Operation Mng

Organisation For users who are looking for care, Badiamo.it is a marketplace that provides instant access to freelance caregivers. Unlike traditional care service agencies, badiamo.it provides a combination of real time access to fair prices, comprehensive, transparent individual performances, safe payments and an insured working environment. Areas of Activity

• eHealth, mHealth, telemedicine • Project proposals support services • EPR, Clinical/healthcare management software • Other

Marketplace Opportunities PARTNERSHIP Current and future strategic partner Current partner: - Buyer-supplier: developers and payment providers. Future partnerships focus: - Coopetition: - Local CG agencies. - Residential care centers. - Strategic alliances: insurances. PRODUCT Badiamo.it: Product Description 1. Two sides marketplace: Offer (caregiver) and Demand (care seeker and/or the person receiving care who can coincide with the care seeker); 2. Model: breakdown the tasks, usually delivered by one full time caregiver, into individual services that can therefore be executed by multiple profiles (i.e. Caregivers, nurses, students/non professional caregivers, etc.) with different skillsets to better match the needs; 78 / 880 3. Services: can be executed and booked hourly or daily Other features: a) Registration: via email or Facebook account; b) Online geo-search: interactive google maps and IP tracking o Rating and review module: users can rate and comment service quality (ie. tripadvisor); c) Recommendation system: caregivers can request recommendation to improve credentials via Facebook / Google+ / whatsapp (on mobile); d) Main Social networks share and connect: Facebook connect, Twitter, etc. o Privacy compliant: caregiver details (ie. precise address) not shown o Mobile responsive: fully functional from mobile devices

79 / 880 BAHÇIVAN SAĞLIK AŞ

Organisation

Country Turkey City İstanbul Street perpa tic mrk b11 blok n:1849 Web www.startekticaret.com

Person

Name Hakan BAHÇIVAN Geneal Manager

Organisation medical devices sales company ENT, ICU, ophtalmology, gynecology, neurosurgery Areas of Activity

• Biotechnologies (Pharma&Medical • Surgery technologies and applications Devices) • Medical devices • Diagnostics IVD • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing • Electromedical and medical equipment (non diag)

80 / 880 Bangkok Dusit Medical Service Group

Organisation

Country Thailand City 曼谷(BKK) Street 2 Soi Soonvijai 7, New Petchburi Rd., Bangkok 10310 Web http://www.bdms.co.th

Person

Name Ning Zhou Director - China

Organisation Bangkok Dusit Medical Services (BDMS) is one of the most prestigious hospital networks in the Asia- Pacific region, with 26 hospitals and/or clinical programs out of a total of 45 hospitals across the BDMS network that have been accredited by the Joint Commission International (JCI). We are ranked in the top five private hospital groups globally in terms of Market Capitalization. BDMS offers world-class medical care and treatment to both local and international patients, complemented by the latest medical technology. BDMS also invested and owned a comprehensive portfolio of investments including private hospitals, laboratory, pharmaceutical manufacture, CIT, etc. Areas of Activity

• Bioinformatics, Big data analytics • Medical devices • Biotechnologies (Pharma&Medical Devices) • Diagnostics - Imaging equipment and processing • Physiotherapy, Orthopaedic technology

Marketplace Opportunities PARTNERSHIP Southeast Asia/China Healthcare Market entrance partnership BDMS is one of the largest hospital network in the world, in particular in Southeast Asia. By market cap, BDMS is currently at 2nd of the global largest hospital networks. Apart from operating 45 hospitals in Thailand, Cambodia, Myanmar, etc, BDMS engages investment in healthcare sectors, including but not limited to, Pharmathutical, lab, pharmacy, R&D, CIT, etc. We are open to engage with global partners to discuss market entry opportunities, not only in Southeast Asia, but also in China, which is our key focus market for the following 3-5 years.

81 / 880 BBA Srl

Organisation

Country Italy City Siena Street via Fiorentina, 1 Web https://www.bespokebiotech.com/

Person

Name Riccardo Baccheschi Consultant

Organisation BBA - Bespoke Biotech Advisory is an advisory service for the red biotech sector. BBA provides fully personalized advice and assistance, tailored to suit the needs of its customers. The BBA method adapts to the requirements of start-ups, small product-making companies, companies undergoing renewal, expanding companies and all investors needing industry-specific expertise to make targeted, informed investments. Specialization in the red biotech sector allows identification of expertise in applying biotechnology to the development and production of biopharmaceuticals (research into and production of therapeutic medicines, genetic testing, gene therapy, pharmacogenomics) and in product assessment at the registration or pre-market stage (for example, recombinant drugs, human vaccines, diagnostics, reagents and products for and derived from plasma). Areas of Activity

• Bioinformatics, Big data analytics • Medical devices • Biotechnologies (Pharma&Medical • IT Applications for Health Devices) • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics • Vaccines

Marketplace Opportunities SERVICE Consultancy service in red biotech sector BBA is a strategic consulting company that provides entrepreneurs with expert guidance in key decision areas ranging from go-to-market to international development. By making effective use of the outstanding industry-specific expertise of its partners and their analytical rigor, BBA helps customers make informed strategic decisions and directions. Its array of expertise ensures entrepreneurs can count on specialized support at the most delicate stages of development, including a possible exit strategy. BBA is constantly committed to generating measurable value, especially in the vaccine, diagnostics and services sectors for the biopharmaceutical industry. Entrepreneurs (start-uppers at stage TRL 6/7 or CM 1, 2 or 3, micro-businesses and businesses at stage 83 / 880 CM 4,5 or 6, SMEs started up with expansion and enhancement goals) and Investors, with or without specific knowledge of the industry or segment, seek out BBA’s expertise, vision, guidance and national/ international contacts, all of which are needed to proceed quickly with project development, confidently and informedly. Thanks to its high degree of specialization, BBA engages directly, applying a diversified array of approaches and skills to provide medium-term, tailor-made solutions. It is this expertise, then, that forms the foundations of BBA, ensuring solidity and soundness for partners and customers alike. BBA offers a range of skills to guide those choices that entrepreneurs need to take throughout the product, service or company lifecycle. Each solution is calibrated according to the specific dynamics and needs of the organization and the shareholders’ goals. The main areas of expertise are: Strategy (definition and execution), Marketing and Sales, M&A, Fund Raising

84 / 880 BetaGlue Technologies

Organisation

Country Italy City Milan Street Via San Primo 4

Person

Name Tony Amato Chief Executive Officer

Organisation BetaGlue Technologies is developing a platform for the treatment of several cancers through a beta- emitting glue, which is cleared as a medical device and therefore benefits of a shorter development and registration path. Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Medical devices

85 / 880 Bianco Pharma

Organisation

Country Turkey City Ankara Street Mustafa Kemal Mah. 2133. Sok. No:11/10 Cankaya /Ankara Web http://biancopharma.com.tr/

Person

Name Sema Zati General Coordinator

Organisation Bianco Pharma operates in Ankara, Turkey. It is an young company established by staff with years' of experience in the field of medicine and medical products. Although being young, thanks to founders’ and staff’s efforts, it grows fast and currently has sole distribution of 6 bfrands in Turkey with 30+ staff. Bianco Pharma operates as sole distributor of stereoid free skin care and fingernail care products. Both product families are highly effecitve and has a strong reputation and domestic consumer base. The firm aims to export the products and is open to import innovative products to Turkey. Areas of Activity

• Investments • Medical devices • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics • Other

Marketplace Opportunities PRODUCT Innovative Skincare Solutions (Steroid Free) OTC product family developed for most common skin diseases. It does not include cortisone or streoids, perfectly healthy for use of wide range of people, including children, elderly people, people with disabilities and so on. PARTNERSHIP Partnership for Distribution Innovative health industry products are sought to be imported to Turkey. Our firm has a strong business network and large geographical reach within Turkey covering a population of 60 million. Our staff is experienced in marketing of medicine and medical products. We are open to sole distributor options for innovative product.

86 / 880 PRODUCT Innovative Nail-Care Products (Steroid Free) The OTC products that were developed for nail-related problems that are frequently observed. It does not include cortisone or streoids, therefore healthy for use of wide range of people, including children, elderly people, people with disabilities and so on. REQUEST New Biocidals, Pharmaceuticals, Cosmetics and Medical Devices for Turkey We are looking for new and innovative products looking to enter Turkish market. Products already in market and products ready to enter market would be considered for such cooperation.

87 / 880 Bio-Fab Research

Organisation

Country Italy City Roma Street via mario beltrami 5 Web www.biofabresearch.it

Person

Name Fabio Riccobono CEO

Organisation Bio-Fab srl was founded in November 2005. Our main activity is to produce and develop services with high biotechnological content to offer the necessary support for scientific growth and to improve potential investigation in the fields of medicine, pharmacology and in hospitals. The unit is specialized in genomics, genetics, bioinformatics and biology, and can provide a wide range of services and products to customers toward, University, laboratories research, Hospital and privately owned laboratories, and the Pharmaceutical and Biotechnology Companies. One of our company's strengths is the interaction and collaboration with the customers. We strongly believe that in this way we can offer an high quality service and mostly important is what can differentiates us from the big company. Bio-Fab grows together with the latest technologies and our laboratory are equipped with cutting- edge technology. At present, Bio-Fab is a leader in automatic DNA sequencing and the production and manipulation of DNA/RNA in Italy. Areas of Activity

• Analytical and characterization services • Nutraceutics, probiotics, functional food, • Bioinformatics, Big data analytics cosmeceutics • Biotechnologies (Pharma&Medical • Peptides, proteins & antibodies Devices) preparation • CMO (Contract Manufacturing • Pharmaceutics Organisation) • Proteomics, metabolomics, nutrigenomics • Consulting services • Other • CRO (Contract Research Organisation) • Genetics & Genomics • Medical research

Marketplace Opportunities PRODUCT Next Generation Sequencing. Leading provider of solution for biological

89 / 880 research Bio-fab is a core facility that integrates all the equipment and expertise needed for covering a broad range of applications and research areas. Our lab is certified ISO-9001:2008 and are staffed by qualified and skilled researchers and technicians who offer to the customer the benefit of experience, as well as valuable technical support. The lab is equipped with sequencer from Illumina and Applied Biosystems. Our goal is to interact and share knowledge with researcher community coming from different field with the aim of improving our service and develop new tools. We can also offer in house service to ensure quality and speed of response. We are specialized in using automatic and high-tech machinery and we can hire staff dedicated to the development of joint activities . Our Service: -Next Generation Sequencing (NGS) -DNA Sequencing -Genotyping -DNA/RNA oligonucleotide synthesis -Gene/Peptide synthesis -Cloning and Mutagenesis -Life science products The use of cutting-edge technologies and solid technical skills allow the Bio - Fab to ensure quality and speed of response. Often a research project requires the use of multiple services at the same time and only rarely they are available in institutional settings , hospitals or pharmaceutical . Moreover, the costs of reagents and instrumentation are very high for individual users. Bio – Fab, offering a wide range of different services has the ability to significantly reduce the costs and response times . SERVICE Metagenomics and small genome Through 16S / 18S sequencing applications, metagenomics shotgun, small genomes (bacteria, viruses, megaplasmids etc.) targeted resequencing (amplicons, plasmids, custom panels) we can today: • characterize and preserve animal and plant genetic resources, • certify and constrains the traceability of productions, • make sensory and / or food contaminants and allergen analyzes, • to obtain genetic improvement of animal and plant species, • make phytosanitary diagnoses and agrometeorological forecasts for precision agriculture. • Identify bacteria responsible for food deterioration • follow and monitor the food packaging and storage process • monitor strains • know the origin of the products • create new food products Possibility to characterize many microorganisms directly from environmental samples Metagenomics allow replacing the long laboratory procedures of traditional methods with a faster and cheaper process, and is also effective in identifying pathogens that are usually difficult to diagnose. SERVICE Bioinformatics services Many researchers are comfortable with NGS technology, but encounter difficulties with the bioinformatics part to complete the job, making NGS a less attractive option like primary sequence platform. However, once established and optimized bioinformatics procedures the bottle neck is removed. Our goal is to develop software and graphical interfaces dedicated and adapted to the needs of researchers but also of structures that work in healthcare, environment and nutrition fields.

90 / 880 The result of NGS optimized tools will make the potential of this technology accessible to non-experts by achieving the profitable technology transfer between research and business. BIO-FAB offers a wide range of bioinformatics solutions, primarily in the area of Next Generation Sequencing (NGS) data analysis and big data visualization. We provide consultancy and support to define the optimal project setup. The data generated is carefully processed and analyzed by our bioinformatics unit Our aim is to offer state-of-the-art analysis which guarantee our customers to receive high-quality results and provide clear answers to their research questions. The result of NGS optimized tools will make the potential of this technology accessible to non-experts by achieving the profitable technology transfer between research and business.

91 / 880 Biocompatibility Innovation

Organisation

Country Italy City Padova Street Via Enrico Petrella 4 Web http://www.bioinnovation.it

Person

Name Filippo Naso Scientific Director

Organisation BioCompatibility Innovation (BCI) operates in the biomedical and biotechnology fields and has focused on developing and producing biomimetic and completely biocompatible materials for the manufacture of implantable medical devices (MDI). BCI has developed two industrial processes, protected by intellectual property, in order to create a unique business subject, rich in skills and know-how. BCI has developed a method, currently unrivaled, for doubling the useful life of MDIs, manufactured with tissues of animal origin, such as pericardium from various mammal species. Now, such animal tissues in represent the "gold standard" for the production of organic MDI and are widely used by multinationals and by manufacturing companies in the sector. In particular, BCI has made its efforts in the field of bioprosthetic heart valves substitutes (BHVs). Specifically, the developed methods are suitable for the inactivation of a particular antigenic epitope called alpha-Gal responsible for the onset of degenerative immuno-mediated/dystrophic phenomena that affect the behavior of commercially available implantable MDIs, limiting their life and obliging both surgeons to a repetitive replacement of the bioprosthesis and patients to an even burdensome surgery. Areas of Activity

• Biomaterials • Medical devices • Biotechnologies (Pharma&Medical Devices) • Medical research • Life sciences related activities

Marketplace Opportunities PRODUCT FACTA, an innovative process to extend commercial bioprosthetic heart valves lifespan. Heart valve disease is one of the main causes of morbidity and mortality worldwide. Mechanical (MHVs) and Bioprosthetic (BHVs) Heart Valves are the most used for heart valve replacement. However, 92 / 880 the former have problems related to their thrombogenicity, the latter durability issues that limit their use. Recently an alarming correlation between the presence of the alpha-Gal epitope and a premature BHVs degeneracy was reported. BCI Srl developed and patented FACTA: an innovative and highly biocompatible treatment for the stable and safe inactivation of more than 90% of the alpha- Gal epitopes present in the animal tissues constituting the current BHVs. FACTA is compatible with current manufacturing lines. It can be applied to tissues before the delicate phases of BHVs sterilization and packaging, thus not involving a critical treatment on the finished product rather a simple intermediate processing phase (according to the FDA guidelines 2014) allowing significant cost and time savings. https://www.youtube.com/watch?v=WQiErzLQ3vc FACTA Advantages: Currently chemical treatments of BHVs manufacturers have: limited biocompatibility; immune response activation; high propensity to calcification and limited duration. Moreover, they are not recommended in young patients and entail high costs for hospitals and health facilities due to frequently new operations. The FACTA technology allows: high biocompatibility degree; low thrombogenicity; resistance to degradation phenomena; resistance to calcification and increase in duration. It is also potentially suitable for young patients and reduces costs for hospitals and health facilities avoiding new operations. The reliability and efficacy of FACTA have been validated by extensive in-vitro investigations that confirm: 1) a significant decrease in calcification propensity (over 85% of calcium deposits less than untreated samples); 2) a better resistance of the treated tissue to degenerative/degradation phenomena mediated by enzymes and oxidative stress; 3) no alteration of the hydrodynamic and biomechanical features of the BHVs ensuring the maintenance of the correct compliance and valve competence. INVESTMENT OPPORTUNITY Growth potential of the FACTA project FACTA (patented innovative process to extend commercial bioprosthetic heart valves lifespan) procedure allows BCI to actively enter the market by proposing itself as an industrial partner in the BHV (heart valves substitute) processing flow. For a company, investing in the FACTA project means producing innovative BHVs with characteristics that make them an unique product, limiting the erosion of the market price over time.

Furthermore, compared to competing manufacturers, new market shares will be acquired and expanded to sectors such as young patients. Moreover, BHVs treated with FACTA are also preferable to healthcare facilities and hospitals, as they would guarantee savings in the costs of re-intervention and subsequent management of the patient. BCI intends to obtain animal tissues supplies from various slaughterhouses in Europe suitable/authorized for the sale of animal tissues intended for the manufacture of BHVs, select such tissues, apply the FACTA treatment, store and preserve treated tissues and finally transport them from the BCI manufacturing site to the various BHV manufacturers globally. Growth Potential: In 2019/2020, BCI will carry out a second preclinical trial to confirm the in-vivo inactivation of the alpha-Gal molecule in small animal model (January- July). The estimated cost is about €2.7 M, for: a) existing technical and business personnel effort; b) obtaining the certifications necessary to start the production of semifinished products (GMP); c) designing the new laboratory; d) classifying the slaughterhouses in Europe able to supply the starting material necessary for the production of semi-finished products; e) participating in events, fairs, congresses and meetings with investors; f) purchasing of machinery to start production of semi-finished products. In 2020, BCI aims to start the commercialization of FACTA treated animal tissues. The estimated cost is about €700 k and the expected turnover is about €1.2 M aiming to sell 5.000 FACTA treated animal tissues to 1 big customer (BHVs manufacturer) and reaching the 2,3% of the global market.

93 / 880 In 2021, BCI aims to expand sales of FACTA treated animal tissues. The estimated cost is about €1 M and the expected turnover is about €3.6 M aiming to sell 15.000 FACTA treated animal tissues to 2 big customers (BHVs manufacturers) and reaching the 6,7% of the global market. In 2022, BCI aims to expand sales of FACTA treated animal tissues. The estimated cost is about €1.7 M and the expected turnover is about 12 M€ aiming to sell 50.000 FACTA treated animal tissues to 4 big customers (BHVs manufacturers) and reaching the 22,1% of the global market. Considering the total investment required, is estimated in 5 years (2019-2023) a NPV of over €8.5M and an IRR of 58%. SERVICE Animal Tissue Biocompatibility Evaluation for clinical pourposes Up to date, animal tissues can be considered the "Gold Standard" between the starting material for the manufacture of bioprosthetic substitutes in the clinical field. However, the presence of antigenic molecules of the species of origin cause, in the medium term, the activation of inflammatory and immune-mediated processes that lead to the degeneration of such bioprosthesis (bioprosthetic heart valves, pericardial patches, ligament and tendon). The alpha-Gal epitope is considered the main pro- degenerative factor responsible for the onset of rejection reactions and early calcification. Biocompatibility Innovation boasts many years of experience in the field of Tissue Engineering and Regenerative Medicine, especially in the cardiovascular field. To date, BCI has developed the only test publicly available (patented) capable of quantifying the number of this antigenic molecule in a tissue and evaluating its distribution. The quantification of the alpha-Gal, before and after a specific treatment, is able to provide important indications about the effectiveness in ensuring good tissue biocompatibility for future clinical uses.

94 / 880 Biogazelle nv

Organisation

Country Belgium City Zwijnaarde Street TECHNOLOGIEPARK 3 Web www.biogazelle.com

Person

Name Amparo Cuéllar Account manager

Organisation Biogazelle, specialized in liquid biopsies and non-coding RNA, supports scientists in the development of diagnostics and therapeutics by offering innovative solutions in a qualified environment. Biogazelle offers expert genomic and transcriptomic services performed in an ISO17025 accredited and GCLP-compliant laboratory to support research, clinical trials and precision medicine. www.biogazelle.com Areas of Activity

• Bioinformatics, Big data analytics • Genetics & Genomics • CRO (Contract Research Organisation) • Diagnostics IVD

Marketplace Opportunities SERVICE Diagnostic services Biogazelle offers diagnostic services on a project basis (e.g. analysis of clinical trial samples) or in a partnership with diagnostic companies missing this specific lab component. https://www.biogazelle.com/expertise/diagnostic-services SERVICE Clinical trials Biogazelle is an specialty lab for genomic and transcriptomic analysis in clinical trials. ISO17025 accredited and GCLP-compliant, assure that generated data are robust and comply with data integrity and data security regulations. We offer either off-the-shelf panels and assays as well as customized test development; are highly experienced in analysis of liquid biopsies and fixed tissues and widely recognized as the expert in gene expression analysis and digital PCR. https://www.biogazelle.com/expertise/clinical-trials SERVICE

95 / 880 Data analysis Biogazelle offers comprehensive analysis of your data, using advanced analysis methods, tailored to your needs. These analyses will accelerate your research, turning data into knowledge. Our data analysis services include, among others: - RNA sequencing data processing and QC - mutation and fusion gene identification - pathway analysis - biomarker development - non-coding RNA function prediction - qPCR data analysis - digital PCR data analysis https://www.biogazelle.com/expertise/data-analysis SERVICE Antisense Oligonucleotide (ASO) screening Biogazelle has extensive experience with various antisense technologies to modulate RNA expression. Through four unique modules, we provide expertise to support your antisense oligonucleotide (ASO) drug development pipeline. Our step-based approach includes: - in vitro ASO efficacy screening - ASO specificity analysis - understanding mode of action - development of a companion diagnostic test Find more details here: https://www.biogazelle.com/services/antisense-screening SERVICE RNA sequencing Biogazelle offers a myriad of RNA sequencing services, using tailored sequencing workflow depending on each project needs and with optimized workflows for FFPE and specially for liquid biopsies (plasma, serum, CSF, urine, ...) and minimal input requirements (100 ng RNA, 200 µl body fluid). We provide an A-to-Z approach, from sample preparation to sequencing and downstream data analysis. Find more info on our RNA seq workflows here: https://www.biogazelle.com/services/rna-sequencing; https://www.biogazelle.com/expertise/liquid-biopsies SERVICE Gene expression - Quantitative PCR In our laboratories, we have processed tens of thousands of clinical samples, including various types of body fluids and FFPE material using qPCR for quantification of both protein coding messenger RNAs and non-coding microRNAs and long non-coding RNAs. Biogazelle’s founders prof. dr. Jo Vandesompele and dr. Jan Hellemans have published landmark papers in the field of qPCR based gene expression analysis, being cited more than 20,000 times. https://www.biogazelle.com/services/qpcr https://www.biogazelle.com/services/gene-expression-analysis SERVICE Digital PCR Biogazelle is at the forefront of dPCR-based research, as it was one of the first European laboratories that had access to the technology in 2012. Biogazelle’s co-founders dr. Jan Hellemans and prof. dr. Jo Vandesomple are co-author on the digital MIQE guidelines. Biogazelle is also serving as a reference laboratory for Bio-Rad’s QX200 Digital Droplet PCR system in Europe. Biogazelle has performed various dPCR projects both in research and clinical trial settings, including:

96 / 880 - mutation detection and copy number analysis on cell-free DNA and DNA extracted from FFPE tissue for cancer diagnostics and monitoring of patient response to treatment - splice variant quantification - quantification of reference materials used in GMO analysis - gene copy number quantification to determine the stability of transgenic cells or organisms - Cell therapy biodistribution various additional customized dPCR-based applications More info? - https://www.biogazelle.com/services/digital-pcr SERVICE Test development Biogazelle can assist in the different phases of biomarker development, be it based on biomarker discovery or prior knowledge of a gene, e.g. insights in the mode of action of a candidate drug, in the disease mechanism or in the molecular subgroups of patients. Our test development services range from biomarker signature identification to thorough analytical and clinical validation, and from IUO to CE-IVD level and testing in clinical trials. https://www.biogazelle.com/expertise/biomarker-test-development SERVICE Biomarker discovery The use of biomarkers is the cornerstone of effective precision medicine. RNA forms an excellent source of biomarkers to enable early disease detection, assessment of prognosis, monitoring patient response to therapy or selecting the right treatment for the right patient. Biogazelle has broad experience in the design and implementation of RNA biomarker discovery studies. Through the combination of RNA sequencing and advanced model building, our biomarker development platform aims at establishing a complex biomarker integrating gene expression measurements and clinical parameters. Such a complex biomarker generally outperforms single biomarkers for classification purposes. Learn more here: https://www.biogazelle.com/expertise/biomarker-discovery

97 / 880 Bioindustry Park Silvano Fumero

Organisation

Country Italy City Colleretto Giacosa (TO) Street Via Ribes, 5 Web http://www.bioindustrypark.eu

Person

Name Fabrizio Conicella General manager

Organisation Bioindustry Park Silvano Fumero (http://www.bioindustrypark.eu/) is a science and technology park located in Canavese, near Turin in the north of Italy. The Park promotes and develops research in Life Sciences, hosting companies of the chemical, pharmaceutical, diagnostic, bioengineering and information science fields. It has acted as system integrator for the development of Life Sciences in Piemonte since its creation in 1998. bioPmed (http://www.biopmed.eu) is the new Italian innovation cluster dedicated to bio and medical technologies created thanks to the intervention of Regione Piemonte. It gathers about 80 companies, research centres and three academic institutions (Università di Torino, Università del Piemonte Orientale and Politecnico di Torino), who signed an agreement to create, build, support and animate the local cluster. The initiative is led by Bioindustry Park Silvano Fumero, the local science & technology park founded in 1998 which, since its creation worked as system integrator for the development of Life Sciences in the region. In coherence with the European Union recommendations, bioPmed works to stimulate innovative activity by promoting intensive interactions, sharing of facilities and exchange of knowledge and expertise and by contributing effectively to technology transfer, networking and information dissemination among the undertakings in the cluster. Areas of Activity

• Biotechnologies (Pharma&Medical • Project proposals support services Devices) • Medical devices • Diagnostics - Imaging equipment and • IT Applications for Health processing • eHealth, mHealth, telemedicine • Medical research • Pharmaceutics • Life sciences related activities

Marketplace Opportunities SERVICE

98 / 880 TT support service platform Bioindustry Park is willing to complement Technology Transfer activities through focused support in technology evaluation pre-patent filing and business development support activities post patent filing. In such way operates in synergies with TTOs and research institutions. SERVICE Accelleration support platform Bioindustry Park is offering a company acceleration service platform conceived to support start-ups and spin-off in exploiting their potential. Business modeling, business plan revamping, strategy identification and implementation, innovation management support, networking with investors and business development advice are among services that are offered by Bioindustry Park SERVICE Physical place for Your growth Bioindustry Park is offering flexible solution for the settlement of offices, labs and pilot plants in a innovative and growing ecosystem positioned at international level. PARTNERSHIP bioPmed cluster partnership opportunities bioPmed is the life sciences and health ecosystem of Piemonte region. Networked at international level involves around 80 different companies and research organization to develop R&D projects, to share services focused on internationalization and innovation management. It is open to collaboration and project building and in activities that include the exchange of practices and the development of common initiatives.

99 / 880 Biomech Innovations

Organisation

Country Switzerland City Nidau (BE) Street Aarbergstrasse, 5 Web https://biomech-innovations.com/

Person

Name Stefano Brianza CEO

Organisation At Biomech Innovations we combine solid expertise in medical devices technology with unsurpassable passion for applied science and for marketing groundbreaking devices. Following professional project management and design quality principles we are proud to efficiently and effectively execute our project. Biomech Innovations aims at becoming a high potential company in the next four years. We want to scale up our business stepwise developing and introducing in different markets our disruptive medical devices. Areas of Activity

• Medical research • Medical devices

Marketplace Opportunities INVESTMENT OPPORTUNITY The new generation of trauma devices. The consequences for patients and healthcare expenditure are catastrophic when complications in treating bone fractures occur. Complicated cases require additional surgeries and treatments that often lead to a permanent functional disability and psychosocial morbidity. Today, complicated cases represent about 10% of all cases but account for about 65% of total trauma care cost. The information we have available suggest that the in the coming years the cost of trauma cases will not be sustainable for any healthcare payer. This creates an interesting opportunity for the development and marketing of more efficacious medical devices. In fact, we know that the population of developed countries is continuously aging and that aging is directly correlated with the incidence of fractures and the risk of complications. Thus we can soon expect: 1) a massive increase in the number of fractures to treat, 2) an exponential increase in the number of complications and 3) a dramatic increase in cost dedicated to fractures treatment. Promoting fracture healing at the first surgery in all trauma patients is a preventive action having the potential to dampen this not sustainable increase in costs for fracture treatment. We have optimized the form and function of the most sold trauma device: the screw. It is compatible with state of the art 100 / 880 surgical techniques and devices. It is scalable and ready to be marketed in 2019.

It works and surgeons like it. During the first stage of our project we have been able to achieve: - Consistent development under our quality system. - Notified body contracted and regulatory path defined. - ISO 13485 manufacturers contracted and controlled manufacturing of high quality prototypes. - 90% of verification and validation campaign has been successfully closed including cleaning and sterilization, biocompatibility, aging and packaging testing. - Preclinical investigation. The submission for the technical file is planned for Q4, 2018. Three scientific publications are on the pipeline aiming at creating awareness among surgeons all around the world. Biomech Innovations is looking for competent investors to complete the second stage of the project. There we plan to 1) get CE mark 2) perform a clinical investigation, 3) establish distribution and sell the device 4) validate and upscale the manufacturing processes.

101 / 880 Biomed Systems Limited

Organisation

Country United Kingdom City Luton Street 724 CAPABILITY GREEN Web https://biobanking.software/

Person

Name Kristina Grabusic CEO & Founder

Organisation Biomed Systems Ltd. is an IT company specialized for development of innovative software solutions for biomedical research. Our software solutions encompass management of: 1) storage facilities and stored material in biomedical research 2) reagents, biospecimens and biobanking 3) knowledge base 4) e-ordering 5) e-diary All software solutions include controlled online data access making them ideal platform for both independent and collaborative research projects in biomedicine and biotechnology. Areas of Activity

• Bioinformatics, Big data analytics • Laboratory equipment, reagents, software • Life sciences related activities • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT LABA - Laboratory Assistant and Biobanking Application We have developed innovative software for management of storage facilities and stored material in biomedical research including biobanking. Our software includes: •creation of virtual storage facilities •localisation and quantification of stored material •creation of precise and clearly structured repository of stored material •e-ordering •management of knowledge base and logistics •e-diary

102 / 880 Biomed Systems Limited

Organisation

Country United Kingdom City Luton Street 724 CAPABILITY GREEN Web https://biobanking.software/

Person

Name Tomislav Zafred Head of IT

Organisation Biomed Systems Ltd. is an IT company specialized for development of innovative software solutions for biomedical research. Our software solutions encompass management of: 1) storage facilities and stored material in biomedical research 2) reagents, biospecimens and biobanking 3) knowledge base 4) e-ordering 5) e-diary All software solutions include controlled online data access making them ideal platform for both independent and collaborative research projects in biomedicine and biotechnology. Areas of Activity

• CMO (Contract Manufacturing • Project proposals support services Organisation) • Life sciences related activities • Software, ICT applications, system integration • Laboratory equipment, reagents, software

Marketplace Opportunities PRODUCT LABA - Laboratory Assistant and Biobanking Application LABA is innovative software for management of storage facilities and stored material in biomedical research including biobanking. Our software includes: •creation of virtual storage facilities •localisation and quantification of stored material •creation of precise and clearly structured repository of stored material •e-ordering •management of knowledge base and logistics 103 / 880 •e-diary

104 / 880 Bioridis

Organisation

Country Italy City Bologna Street Via A. Rubbiani, 5 Web http://www.bioridis.com

Person

Name Andrea Tortori CEO

Organisation Bioridis is a biotech start-up company, founded in Bologna in the 2016. Bioridis aims to research, development, production and marketing of new chemical reagents for the biomedical R&D and molecular diagnostics applications. The Bioridis company arises from the need of reduce costs and increase productivity in R&D in the field of biomedical and molecular diagnostics as highlighted from the World Health Organization's (WHO) and EU. In particular in R&D and clinical laboratories, the total costs and production efficiency depend greatly on the characteristics and potential of the reagents used in the analyses and testing. Bioridis's objectives are the development, production and marketing of products for applications in biomedical R&D and molecular diagnostics that have, compared to the products presently available on the market, a greater sensitivity, a reduction in the time of proposed protocols, easier to use, which for our customers means an increase in productivity and a reduction in costs. Bioridis wants to provide the market with consumables (reagents) for biomedical applications in molecular and cellular biology and offer a custom made design and production of its products upon customer request, which may include both the R&D and the production; a service not presently available on the market.The Bioridis products arise from the team's experience. The initial idea arose from this experience and a first scientific analysis. To date we have to create prototypes and make patent applications. Looking for biomedical laboratories to test our products we have had positive feedback for our products and proposals to enter upon projects that are they are developing. Areas of Activity

• Diagnostics IVD • Laboratory equipment, reagents, software • Diagnostics - Equipment and accessories • Genetics & Genomics • Life sciences related activities

Marketplace Opportunities SERVICE

105 / 880 Custom made synthesis Bioridis offers a service custom made for the design and / or production of nucleic acid probe PNA based (peptide nucleic acid). We can design the best probes on customer needs based on our ten years experience, collaborations and the ability to test internally; We have synthesis systems that allow the conjugation of different molecules (e.g. peptides, fluorochromes, ...) to better adapt to the analytical systems desired by the customer We can synthesize client design probes We don’t have a tariff defined to better accommodate the needs of the customer and evaluate together the best quality/price to offer, based on the services required PRODUCT Ev Power Marker Products (patent peding) are kits based on innovative molecular probes specifically designed to allow high-throughput analysis of miRNA. Bioridis developed an optimized, easy, reliable operating procedure that allows these probes to hybridize target nucleic acids more rapidly, with higher affinity and specificity, compared to other probes. Their biological stability allows unique investigations in biological fluid and living cells. What makes BIORIDIS’ assay stand out from the competition are following properties: a) easy-of-use, eliminates critical steps; b) high-throughput analysis, cost and time reduction over 40%; c) increased rate of profitable results; d) reliability, high-affinity and specificity; e) high biological and chemical stability; f) Improve miRNA studies. Product is designed to be used on easily available equipment, largely disseminated in laboratories. INVESTMENT OPPORTUNITY BIORIDIS equity BIORIDIS is looking for funds for the launch of its products on the market PARTNERSHIP Distribution We are looking for companies interested in the distribution of our product

106 / 880 Bioside

Organisation

Country Italy City Lodi Street Cascina codazza Web BIOSIDE.IT

Person

Name Michela Savoldi Boles CTO

Organisation Bioside is an innovative start-up operating in the field of Biotechnology. It was founded in 2014 by a group of highly motivated people to innovate the field of food and environment analysis and it is located at Parco Tecnologico Padano . The strong partnership with food and agricultural companies has been the driving pulse behind the foundation of Bioside. The knowledge of the current and future problems has resulted in finding new and economically attractive approaches to these problems, both in production and in quality control. Furthermore Bioside maintains flexibility to respond to industrial concerns quickly and efficiently, meanwhile realizes a quality policy and safeguard of the Italian products. The mission of Bioside is the scientific research in the field of genetics, molecular biology and microbiology, the development and validation of new methods, the new applications and diagnostic, analytical and preparative technologies in safety and quality assurance of food production. Among the technologies developed Bioside focuses on development, production and marketing of real-time PCR-based rapid detection technologies with innovative solutions from sample processing to the analysis of the data. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Diagnostics IVD • Genetics & Genomics • Manufacturing & process engineering

Marketplace Opportunities PROJECT COOPERATION Agribusiness and environmental diagnostic revolution, developing a new platform for a new fully automated workflow, from the sampling to the data analysis Bioside is a SME involved in innovative research activities in the field of biomaterials, bioprocess, biotechnology and microbiology with a special attention to molecolar biology. We have developed a production process that allows us to maintain stable different molecular biology protocols at room temperatures.

107 / 880 We have also developed and produced different molecular biology kits for the detection of pathogens, unwanted microbiological agents, unwanted species. We want to make a new project that allows us to use our innovative diagnostic solutions directly at the point of need. Analyzing global interview, for industries there are some important attributes for evaluating a diagnostic method or instrument, sensitivity/specificity is the most important attribute but time-to- results is the third, followed by ease-of-use/automation in fifth place. Clearly companies want quick results but only after they are assured that the diagnostic they are using provides accurate results. Now it is possible to provide accurate results but time to result is too high and there is not enough ease of use / automation. The ability to The best solution as detection method must conjugate better sensitivity and speed. Now the diagnosis, specially in agri-business field, provides a classical scheme as follow: - sampling - sending samples to an authorized laboratory (from a few hours to a few days) - performing analysis (molecular biology method few hours, microbiology method from 5 to 10 days) - outcomes result (a few days) - performance management (e.g. taking corrective action in case of non-compliance). In this workflow, time to result is very long so it isn’t possible make necessary actions at appropriate times and this could affect animal and human health. The aim of the project is the implementation of a innovative automatized system of analysis. The system consists of a robotic sampler of fluid, a mechanic DNA extraction and purification from the sample in conjunction with a portable real time PCR instrument. Data analysis is performed in cloud in compliance with the relevant standards. All parts of the instrument work together in automated mode. If Nucleic acid isolation, qPCR preparation and qPCR detection will be automated, the molecular method could be relatively inexpensive and suitable for real time routine analysis on field. The technologies of this project, nucleic acid-based assays, could revolutionized the detection methodology for microbial pathogens in foods and environmental. In addition, the implicated nanotechnology provides a unique approach to pathogen detection. The improvement of this methods could also help the dissemination and implementation of PCR based methods in food supply chain. FUNDING PROGRAMME AND REFERENCE Horizon 2020 TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE We are looking for partners in the following roles: - R&D partner focused in microbiology, molecolar biology and biotechnological engineer; - Technology partner

108 / 880 Biosphere srl

Organisation

Country Italy City Bertinoro Street Via Cellaimo 3456 Web http://www.biospheresrl.com

Person

Name Marco Pistocchi Chief Operating Officer

Organisation Biosphere is an Italian SME founded in 1999 operating in industrial biotechnology, whose core business is the development of fermentation processes for recombinant protein and metabolites expression in bacteria, yeasts and fungi. Following the growing request of biocatalysts in the manufacturing of APIs, Biosphere has developed a strong expertise in process development and manufacturing of customized enzymes applied in several industrial processes. Areas of Activity

• CMO (Contract Manufacturing Organisation) • CRO (Contract Research Organisation)

Marketplace Opportunities SERVICE Fermentation Process Development and Scale-up Biosphere offers R&D services for the development and scale-up of biotechnological process. The service includes fermentation and downstream process development and optimization, to increase production yields and reduce production costs and environmental impact. Biosphere also provides a qualified Contract Manufacturing service in non-GMP environment, for the production of microbial biomass, enzymes and metabolites. The fermentation facilities include fermenters of various size, from laboratory scale (1 and 15 litres) to pilot (150 litres) and pre-industrial scale (1.500 litres) and downstream equipment for biomass separation, cell disruption and tangential flow micro- and ultra-filtration. Chemical and microbiological laboratories provide analytical support for the quality control of raw materials and final products. PARTNERSHIP Looking for collaboration in EU projects We are interested to explore potential collaborations in the context of EU projects in the Biotech sector. We offer our expertise in development and scale-up of fermentation processes, from laboratory to pilot 109 / 880 and pre-industrial scale.

110 / 880 Biotecnomed S.C.aR.L.

Organisation

Country Italy City Catanzaro Street viale Europa, Germaneto Web http://www.biotecnomed.it

Person

Name Basilio Vescio R&D Manager

Organisation Biotecnomed is a LL consortium of public research institutions and small, medium and big enterprises. Born in 2011, it manages the Innovation Pole of Health Technologies and Life Sciences, established with funds from POR FESR Calabria 2007-2013 and from the “Human Health and Biotechnologies” High Technology District, financed by the National Operational Programme on “Research and Competitivity” 2007-2013. With 19 laboratories and 48 associated enterprises, Biotecnomed is a highly specialized organization in the fields of Biotechnology and Human Health, providing advanced services and facilities for research centers and enterprises. Areas of Activity

• 3D Printing/addictive manufacturing for • Proteomics, metabolomics, nutrigenomics biomedical applications • Life sciences related activities • Biomaterials • Other • Biosensors • Laboratory equipment, reagents, software • Biotechnologies (Pharma&Medical • Medical devices Devices) • IT Applications for Health • Consulting services • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE

111 / 880 Research and Development Concept, design and Prototyping, Experimental trials, development and validation of innovative solutions and products for biomedical applications and life sciences. - Design and technological development: development of new products or innovative solutions with the support of our professionals - Research services: tests, assisted experiments and laboratory tests for research activities - Measurement and validation of results: feasibility studies of prototypes, reliability tests of finished products and stress tests on materials - ICT solutions and decision engineering: mobile and distributed software and platforms for managing health services, from workflow management to home care telemonitoring - Research projects: tutorig & partnering in EU, National and regional R&D projects SERVICE Intellectual Property Specialized services for the protection of marks, patents, models, drawings, etc...: All-around support, from the idea and concept to the market. - Search for prior art, Trademarks and Patents: check if your idea is original and if your brand can be protected - Analysis of patent scenarios: updated on technological developments through patent monitoring, to support companies in planning new products and processes and identifying emerging technologies. - Legal status of intellectual property: discover new market opportunities from technical solutions subject to expired patents to be used freely. - Competition monitoring: check competitors' strategies thanks to a survey on issued patents and new applications filed by competitors. - Brands and patents: protect and enhance your ideas. SERVICE RESEARCH SERVICES Laboratory tests and analyses for advanced diagnostics, regenerative medicine, neuromotor rehabilitation and nutraceutics. Physiopathology of movements - Walk Analysis - Postural analysis - Lower limb function and walking - Upper limb and hand function - Study of the Central Nervous System and of the Autonomic System - Study of Peripheral Nervous System and muscular activity - Study of neuropsychological and attitudinal parameters - Physical and psychoattitudinal tests for working categories Dental bioengineering and biomaterials - Experimentation and application of diagnostic and therapeutic protocols aimed at regenerative medicine -Treatment of tissues with bio-scaffolds functionalized to diagnose pathological and degenerative processes in the oral and maxillofacial region - Test on biomaterials - Supply of ceramic, metallic or polymeric materials - Sintering of zirconium oxide elements - 3D CNC milling of zirconium oxide, titanium, polymethacrylate, polyamide, resins - Realization of 3D anatomical models in plaster or resin - 5-axis 3D scanner with laser technology - 3D renderings from virtual simulations - Screw-retained prosthetics

112 / 880 - Design, modeling and construction of special odonto-prosthetic structures - Chromatic tooth mapping - Tensile strength tests or deformations - Vikers hardness test - Cyclic fatigue test, abrasion wear Materials tests - Tension tests - Flexural tests - Hardness test - Fatigue tests - Propagation tests Electronic and mechanical measurements - Reliability studies of electronic devices exposed to radiation - Wafer and electric measurements - Mechanical Measurements - Dimensional Check Proteomics and Mass Spectrometry - Identification, characterization and analysis of proteins - Determination of the molecular weight of synthetic peptides - Determination of the molecular weight of recombinant proteins Nutraceuticals and functional foods - Characterization of the composition of complex biological samples, with research and identification of particular components Neuroimaging 3T-MRI examinations PET+3T-MRI examinations Microbiology - Sequences of microbial genomes: high-throughput analysis of microbial genomes - Complex microbial populations: microbiome and microbiota Molecular oncology and Functional Genomics - Extraction of DNA from blood, tissues, biological fluids, single cells - Extraction of RNA from blood, tissues, biological fluids, single cells - DNA extraction from FFPE - RNA extraction from FFPE - Quality control (QC) of nucleic acids - Library preparation from Whole Genome gDNA - Library preparation from Esoma Illumina gDNA - Library preparation from gDNA Esoma ION-Torrent - Seq Whole Genome (1 sample) 10X deep - Whole Genome Seq (up to 5 samples) 20X deep - Exome 20X (MiSeq up to 3 samples) - Exome 100X (Hiseq 4-9 samples) - Exome 20X (up to 3 samples on Ion-Proton) - Preparation of miRNA libraries - Preparation of Total RNA libraries - Preparation of Total RNA libraries - Quality control (QC) of libraries - miRNAseq - Total RNA gene expression (Paired End) - Total RNA gene expression / variant annotation (Paired End) - Total RNA gene expression / variant annotation (up to 2 samples) - Preparation of cRNA - Primary bioinformatics analysis (QC and FastaQ up to 10 samples)

113 / 880 SERVICE Events and Training Training courses, conferences, Master courses, workshops, contests, informational and promotional events in the biotech and medtech areas. - Training and updating: you can report the topic of your interest through the form on our website - Organization and partnership: proposed as a partner to organize events in the biotech area in Calabria; strategic, organizational and communication support - Promotion: promote your innovative product or service in the biotech sector, you will have strategic, organizational and communication support SERVICE HOSTING Rooms and offices, facilities and business development services for professionals and companies. Basic services and facilities included in the hosting offer: - Secretarial services, reception and correspondence management - Electrical, telephone and internet facilities - Heating and cooling - Audiovisual installations and equipment - Supervision and maintenance of common areas - Cleaning of the premises - Car parking - Use of the meeting room, upon reservation, up to a maximum of 5 accesses / year - Condominium fees Advanced Services on request: - Legal, administrative, fiscal, financial, labor consultancy - Patent and technology transfer consultancy - Monitoring of regional, national and European calls - Administrative management of projects - Networking activities - Training activities in the following areas: legal, administrative, labor, financial, patent - Web space within the Innovation Pole website - Research enhancement services - Use of the meeting room equipped with multimedia systems (over 5 accesses) - Press office and communication activities - Dedicated telematic network, aimed at specific business activities (ie ICT companies, call centers and telemarketing services) Contact Biotecnomed for: - Positioning your company in a strategic area: located in the new Management Area of Catanzaro, near the Regional Citadel and the Magna Græcia University - Developing new opportunities of collaboration and business: work in contact with professionals and companies in the biotech sector and exploit the potential of networking - Take advantage of the technological potential of laboratories: exploiting the technological potential of bio-mechanical and bio-electronics laboratories and of the maker-space - Save on time management and administration: work in an office where the secretariat and other facilities are managed and guaranteed. SERVICE Maker Space Digital fabrication: a dedicated space for companies, professionals and researchers developing new biomedical products and prototypes. - Realize your ideas: make together with our tutors the prototype of a new idea in a professional way - Resolve a technical problem: find a low-cost solution to your specific need, thanks to digital

114 / 880 fabrication - Find out if your idea is functional: test your idea by experimenting with new products and new materials - Increase your know-how: increase your applied knowledge in the scientific and medical fields - Acquire and develop new ideas: share and implement experiences and ideas in a professional, heterogeneous and stimulating environment

115 / 880 BIOTEM

Organisation

Country France City Apprieu Street Web http://www.biotem-antibody.com/

Person

Name Georgia ALAIMO Sales & Business Developer

Organisation Expert in immunotechnologies for more than 35 years, BIOTEM provides fully customized and high added value services for the development of antibodies and immunoassays. Today, thanks to its extensive know-how and a large panel of exclusive technologies, BIOTEM proposes contracts with guaranteed results (> 96% success rate). All services are available as 100% fee for service (No claims, no royalties, and no follow-up rights) and are qualified ISO 9001 / ISO 13485. Service offer: Custom Antibody Development (Hybridoma and Phage Display Technology) - Therapeutic antibodies (human and veterinary applications) Diverse and exclusive technologies depending on project specification - Rabbit monoclonal antibodies: Highest affinity antibodies / Optimal for small molecule detection / Novel epitope recognition - Murine monoclonal antibodies: Exclusive technologies for low immunogenic targets / small quantity of antigens / short deadlines - Polyclonal antibodies: Custom & standard immunization protocols Custom Immunoassays Development: Lateral flow & ELISA (low detection limit / Any matrix & analyte)

Additional services: Antibody characterization & modification (hybridoma sequencing, affinity determination, etc.) - Antibody production (in vitro & in vivo systems, Recombinant antibody platform) etc. Areas of Activity

• Biotechnologies (Pharma&Medical • Other Devices) • Medical devices • CRO (Contract Research Organisation) • Diagnostics IVD • Drug screening & delivery • Peptides, proteins & antibodies

116 / 880 preparation

Marketplace Opportunities SERVICE Antibody Development - 100% Royalty Free - Custom development for your R&D, Diagnostic and Therapeutic Programmes 35 years expertise in immunotechnologies. Exclusive Technologies & Guaranted Results! - Hybridoma Technology - Phage Display Technology - Recombinant antibody production - Antibody characterization

117 / 880 Biotron Diagnostics USA

Organisation

Country United States City Hemet Street 615 N Palm Ave Web www.biotrondiagnostics.com

Person

Name George Gagneja President/Chairman

Organisation Biotron Diagnostics Inc., formerly known as Nuclear Diagnostics Inc., and Sterling Biochemical Inc., has a history of over 30 years in successfully developing, designing, producing, selling and marketing a complete line of diagnostics reagents and kits for use in Hospitals, Medical Laboratories, Research Institutions and the Health Care and Pharmaceutical Industries. Its strength stems from a foundation of knowledge and experience in product development with a commitment to quality and cost effectiveness in the biotechnology field. Biotron Diagnostics Inc.’s products are developed, designed and produced with unique formulations using state-of the-art technology. All in-vitro diagnostics reagents and kits are produced using GMP rules and regulations of the United States Food and Drug Administration. Products are marketed in, and legally exported from, the USA.

We are very proud of our high quality FDA approved product lines, particularly “Research Chemistries” & Immunochemistries, which are currently being sold to institutions such as: CDC, NIH, Prestigious Universities, Research Centers, Cancer Research Institutions, and other Government and Prestigious Private Hospitals. Biotron Diagnostics has been certified as a US Government Supply Administration Federal Vendor. Products are competitively priced. Biotron Diagnostics’ main Mission is to produce and distribute USA Made and FDA approved IVD Kits and Reagents globally. OEM, Private Label, Bulk Reagents/Components, CRO and Technology Transfer Services are available. Presently Biotron Diagnostics Inc. has three international branches (India, China, and Latin America) and a worldwide distribution network. Biotron Diagnostics has a reputation for high quality, performance and innovation. Biotron continues to provide high quality standard IVD Kits and Reagents while meeting the changing needs of the IVD industry. The company’s main objective is to continue to maintain high quality standards using the latest inventions, discoveries and technologies to develop its products. The strength of the company stems from knowledge and experience in high quality product development provided by Ph.D. Chemists, Biologists and Medical Doctors.

Sharan D. Dominguez M.DAnita J GagnejaDr. George Gagneja Rudy DominguezJim Kemp Vice President COO President/Chairman Director Sales Director Areas of Activity

118 / 880 • Diagnostics IVD • Medical devices

Marketplace Opportunities PRODUCT Molecular Diagnostics (Genomics) and Immunofluorescent Assays Technology Transfer/ Sale/Licence ------Molecular Diagnostics Research Kits (HPV. Fifteen high-risk types Kits both in multiplex and genotyping formats, Chlamydia Trachomatis, Clostridium Difficile, Coxiella Burnetii, Neisseria Gonorrhoeae, Yesinia Pestis, Bacillus Anthracis, Francisella Tularensis, Haemophilus, Legionella, Listeria, Salmonella, Staph and Trichomonas Vaginalis), ------Immunofluorescent Assays . Infectious Diseases —Chagas, Toxplasmosis, Hidatidosis, Syphilis, Triquinosis, Chlamydia trachomatis, Autoimmune Diseases- Anti-DNA, ANAHEp-2, AMA, ASMA, APCA, ANA, LMK, EMAIgA0 Plasma Proteins RID- human proteins, Combo Immunoglobulins PRODUCT IVD Diagnostics - (Kits and Reagents) Complete line of medical technology Biotron Diagnostics develops, produces, provides OEM services and distributes high quality and low cost in vitro diagnostics kits and reagents for: - Clinical Chemistry (Routine and Research chemistries - similar to Sigma and ultra-sensitive Sickle Cell Kits & Controls) - Immunochemistry (ELISA/CLIA) - Urinalysis, Serology, Fertility (Pregnancy and Male Sperm) - Coagulation, Blood Banking - Rapid Diagnostics, Drug Screening, Biomarkers (Tumor Markers and Cardiac Tests) - Infectious Diseases Rapid Tests (Export only) - Bulk Clinical Chemistry & Coagulation Reagents for Instruments, Calibrators, Controls & Standards, Diabetes (Dr. G Glucosemeter & Test Strips) - Hematology (Buffers & Reagents), Microbiology (Media, Stains and Reagents) - Histology and Cytology (Buffers & Reagents) - Veterinary test kits and Petnostics and Molecular Diagnostics (Genomics) Innovated Gene Testing Assays for Cancer and Infectious Diseases. Most Popular & Best Seller Popular Products include advanced Sickle Cell Kit and Sickle Cell Controls (Sensitivity correlates with Hemoglobin Electrophoresis), Biotin-streptavidin Technology based ELISA Kits, Most advanced UroFast Urine Reagent Test Strips, Dr.G Gluccisemeter, Research Chemistries, Infectious Disease Rapid Tests for Export, and Temperature Stable Culture Media (up to 60'C) Our Newest Products now includes: - ultra-sensitive tests for Feltility (Pregnancy and Male Fertility) - Dr. G Glucosemeters ( Dr. G Smaft 1, Dr.G Smart 2 , Dr.G Smart 3) - Serology (Rubella, SLE, ANA, RPR, FOB, Staph A, Strep A, Febrile Antibodies Kits: febrile Kit, Widal Kit 400 , Widal Kit 800, Rose Bengal Kit, Dri.Dot Kits and H Pylori) - Highly Sensitive Infectious Disease Rapid Tests (Strips & Cards) for Export only (CE Mark ,WHO) for Hepatitis, Human Immunodeficiency Virus 1+2, Treponema Pallidum, Neisseria Gonorrhoeae, Helicobacter Pylori, Malaria, Cholerae Vibrio Antigen (Ogawa/Inaba), Yesinia Pestis, Plague, Tuberculosis, Adenovirus, Rotavirus, A Streptococcus, Chlamydia Trachomatis, Procalcitonin test, Salmonella Typhi, Chagas, Zika Virus, and Precise Biomarkers (CEA, FOB, AFP, PSA, Fatty Acid, Troponin I, CK-MB, Myoglobin, Creactive Protein) - Molecular Diagnostics Research Kits (HPV. Fifteen high-risk types Kits both in multiplex and genotyping formats, Chlamydia Trachomatis, Clostridium Difficile, Coxiella Burnetii, Neisseria Gonorrhoeae, Yesinia Pestis, Bacillus Anthracis, Francisella Tularensis, Haemophilus, Legionella, Listeria, Salmonella, Staphylococcus and Trichomonas Vaginalis) 119 / 880 - Immunofluorescent Assays (infectious Diseases -Chagas, Toxplasmosis, Hidatidosis, Syphilis, Triquinosis, Chlamydia trachomatis, Autoimmune Diseases- Anti-DNA, ANAHEp-2, AMA, ASMA, APCA, ANA, LMK, EMAIgAO) and plasma proteins RID- human proteins, Combo Immunoglobulins (IgA, IgG, IgM, IgD, Complement C-3 and C-4 and others and Bio-Defense related test assays are researched, developed, formulated and produced) PARTNERSHIP Joint Venture Partner IVD field in Europe INVESTMENT OPPORTUNITY Joint Venture/Turn Key Projects Biotron will provide know how /technology transfer as a 50% partnership REQUEST European IVD Companies should contact directly

120 / 880 BiT256 srl

Organisation

Country Italy City Roma Street via Nemi, 8, Scala C, piano 2, int. 5 Web https://dojunction.online

Person

Name fabio guglietta CEO

Organisation The JUNCTION™ ecosystem has as its main purpose to link, through a communication generated by the consumers interaction with the product, Companies and Consumers. This communication, that is regardless of the actors in the distribution chain, allows Consumers to know the origin of the product, its storytelling, its traceability and allows the Company to enhance Customer Retention, control of the supply chain and its markets. Areas of Activity

• Software, ICT applications, system integration

121 / 880 Bluegreen Strategy srl

Organisation

Country Italy City Forlì Street Corso G. Mazzini 132 Web www.bluegreenstrategy.com

Person

Name Paolo Paganelli CEO

Organisation Bluegreen Strategy srl (Italy) is a consulting company specialised in innovation financing. Bluegreen helps startup and innovative companies to finance the development and commercialization of their products, applying to European Commission and national programs, equity crowdfunding platforms and private equity funds. Bluegreen brings an in-depth knowledge of business models and business planning tools applied in several sectors, gained through many years of experience in projects carried out for leading companies and in the frame of EU research and innovation programmes. Areas of Activity

• Consulting services • Investments • Project proposals support services

Marketplace Opportunities SERVICE Funding opportunities for Startups and Innovative Companies Do you need funds for your new product or service? We help you to apply to European Commission funding programs and equity crowdfunding platforms.

122 / 880 Braimage

Organisation

Country Italy City Bologna Street

Person

Name Vittorio Grieco R&D

Organisation Braimage is developing a software aimed to improve the diagnostic workup of dementia. It's a data integration platform, equipped with artificial intelligence algorithms, that simplifies and strengthens the diagnosis. Areas of Activity

• Bioinformatics, Big data analytics • Software, ICT applications, system • Diagnostics - Imaging equipment and integration processing • IT Applications for Health • eHealth, mHealth, telemedicine • Medical research

Marketplace Opportunities PRODUCT Dementia diagnosis made simple To date, dementia represents the fourth most common disease worldwide, with a huge social and economic impact. This term refers to a group of chronic diseases of the central nervous system (such as Alzheimer's) that afflict about one million people in Italy and more than 50 million people worldwide. According to the World Alzheimer Reports, to date, the average time to reach a final diagnosis of dementia is about 2 years, which is clearly quite a long time, that causes several problems in terms of patients‘ quality of life, management and expenditures (about 70.000€/year/patient of direct and indirect costs). This delay is mainly due to two different problems. On one hand, there is a lack of interacting between the various physicians involved (such as Geriatrician, Radiologist, Nuclear Medicine Physician and so on), because they often work in different hospitals, sometimes even in different cities. On the other hand, there is complexity of the disease itself, due to the multiple overlapping clinical patterns. An early and precise diagnosis of the type of dementia is essential to allow the implementation of either clinical or non-clinical interventions, the sooner the better. Here it comes Braimage. Braimage is a software that solves both problems at the same time. It is an integrated medical record, where every physician can manage the information of a patient and interact with each other easily. Moreover, it is equipped with artificial intelligence algorithms, that will

123 / 880 independently analyze all the recorded data and, on the base of a reference database and on the experience that the program itself will develop over time, it will be able to suggest a possible diagnosis. In this way, Braimage will help doctors to diagnose dementia faster and more accurately, significantly improving patient's quality of life and lowering expenditures.

124 / 880 Braimage

Organisation

Country Italy City Bologna Street Via Giampietro Zanotti 17 Web https://braimage.it

Person

Name Antonella Matti Founder

Organisation Braimage is developing a software aimed to improve the diagnostic workup of dementia. It's a data integration platform, equipped with artificial intelligence algorithms, that simplifies and strengthens the diagnosis. Areas of Activity

• Bioinformatics, Big data analytics • EPR, Clinical/healthcare management • Diagnostics - Imaging equipment and software processing • IT Applications for Health • eHealth, mHealth, telemedicine • Life sciences related activities • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT Diagnosis made simple To date, dementia represents the fourth most common disease worldwide, with a huge social and economic impact. This term refers to a group of chronic diseases of the central nervous system (such as Alzheimer's) that afflict about one million people in Italy and more than 50 million people worldwide. According to the World Alzheimer Reports, to date, the average time to reach a final diagnosis of dementia is about 2 years, which is clearly quite a long time, that causes several problems in terms of patients‘ quality of life, management and expenditures (about 70.000€/year/patient of direct and indirect costs). This delay is mainly due to two different problems. On one hand, there is a lack of interacting between the various physicians involved (such as Geriatrician, Radiologist, Nuclear Medicine Physician and so 125 / 880 on), because they often work in different hospitals, sometimes even in different cities. On the other hand, there is complexity of the disease itself, due to the multiple overlapping clinical patterns. An early and precise diagnosis of the type of dementia is essential to allow the implementation of either clinical or non-clinical interventions, the sooner the better. Here it comes Braimage. Braimage is a software that solves both problems at the same time. It is an integrated medical record, where every physician can manage the information of a patient and interact with each other easily. Moreover, it is equipped with artificial intelligence algorithms, that will independently analyze all the recorded data and, on the base of a reference database and on the experience that the program itself will develop over time, it will be able to suggest a possible diagnosis. In this way, Braimage will help doctors to diagnose dementia faster and more accurately, significantly improving patient's quality of life and lowering expenditures. INVESTMENT OPPORTUNITY Braimage: investment in the Future To date, dementia represents one of the most disabling and complex diseases worldwide, with a huge social and economic impact. This term refers to a series of chronic neurodegenerative diseases (of which the best known is Alzheimer’s Disease), characterized by a progressive cognitive deterioration, with consequent loss of autonomy: it afflicts 50 million patients worldwide (of which 10 million in Europe) and, with the progressive aging of the population, these numbers will increase over time. Braimage is developing a software aimed to improve the diagnostic workup of dementia. It's a data integration platform, equipped with artificial intelligence algorithms, that simplifies and strengthens the diagnosis. Thanks to Braimage, it will be possible to reach a diagnosis faster and to early implement the correct therapy, with the result of slowing down the progression of the disease, increasing patients' quality of life and reducing health expenditures. We are looking for a seed investment to reach our goals faster.

126 / 880 Brain Control

Organisation

Country Italy City Siena Street Via Cesare Maccari, 1 Web www.braincontrol.com

Person

Name Francesco Landolfi VP Sales and Marketing

Organisation Developed innovative medical device Brain Control leveraging Brain Computer Interface technology. Our device provides communication capabilities to patients with severe neurological diseases (ALS, multiple sclerosis, muscular dystrophies, ischemic or traumatic injury, tethraplegic patients: about 3.7 million people worldwide suffer from severe communication and mobility disabilities due to those conditions). Based on a proprietary Brain-Computer Interfaces (BCI) technology, Braincontrol interprets the electric map that corresponds with certain brain activity and allows patients to control a communicator, domotic devices (lights, doors, windows, alarms, temperature, bed position, etc.), and other assistive technologies. Braincontrol fills a technological void for patients who are cognitively aware, but completely unable to move or communicate, a state called “locked-in”, and meets many of the unmet needs for patients in less advanced states who are currently using or cannot use eye-tracking systems. Braincontrol is commercially available, including a sentence finder and a yes/no/don’t know selector. The interface uses scanning to move between available options and utilizes just one movement-related thought to select the desired choice. The pre-defined sentences in the sentence finder are completely customizable, including the addition of images, audio feedback and the creation of sub-menus. Braincontrol is also highly portable, consisting only of a tablet PC and a wireless EEG headset. Future versions will implement advanced communication and entertainment (virtual keyboard, text-to- speech, web browsing, interaction via SMS, social networks, e-mail, web radio), home automation (lighting, alarms, temperature, etc.) and robotics (humanoid robots and exoskeletons). Braincontrol is certified as class I CE medical device and is not intended for the diagnosis, therapy, monitoring or treatment of any disease, injury or handicap. Braincontrol has received several awards, including first place in the EU eHealth Competition and the Marzotto Prize for new Social and Cultural Enterprises. Areas of Activity

• Diagnostics - Equipment and accessories • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health

127 / 880 • Electromedical and medical equipment (non diag) • Medical research • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT BRAINCONTROL medical device - Mind power for assistive technologies Braincontrol is a breakthrough technology that could help around 3.7 million of people worldwide, affected by Amyotrophic Lateral Sclerosis, Multiple Sclerosis, ischemic or traumatic injuries or other disabilities, to overcome their severe physical and communicative disabilities, interacting and communicating at levels unimaginable until a few years ago. The system will give those patients the opportunity to control devices with their minds. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Braincontrol is a brain-computer interface (BCI) technology that give disabled people the power to control objects with their thoughts. There are several competitive advantages including being usable by people who can’t use currently available technologies and being portable and usable in more environments. Braincontrol is non-invasive, thanks to commercial available wireless EEG headsets and is innovative for its structure and the functionality offered. It is also aggressively priced, making it more accessible than competing products, despite being a cutting edge innovation. Braincontrol works like a “mental joystick”, using thoughts related to movement, such as forward, back, left, right, etc. These thoughts create unique patterns of electrical activity in our brain that can be identified. Braincontrol then uses the thoughts of movement to control devices such as a communicator, domotic devices (lights, doors, windows, alarms, temperature, bed position, etc.), wheelchairs, and other assistive technologies. Braincontrol is highly portable, consisting only of a tablet PC and a wireless EEG headset. CURRENT STAGE OF DEVELOPMENT: Braincontrol includes a sentence finder and a yes/no/don’t know selector. The interface uses scanning to move between available options and utilizes just one movement-related thought to select the desired choice. The pre-defined sentences in the sentence finder are completely customizable, including the addition of images, audio feedback and the creation of sub-menus. This version is designed for patients who are locked-in or in advanced stages of ALS and meets many of the unmet needs for patients in less advanced states who are currently using or cannot use eye-tracking systems. Advanced communication and entertainment ((virtual keyboard, text-to-speech, web browsing, interaction via SMS, social networks, email, web-radio) home automation (lights, alarms, temperature, etc.) and the control of a wheelchair are currently under advanced development. MARKET APPLICATION People suffering from pathologies such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, tetraplegia, various kinds of muscular dystrophies, ischemic or traumatic injuries retaining their intellectual abilities. TYPE OF PARTNER SOUGHT Commercial partners. Research and development cooperation in the field of assistive technologies. PARTNERSHIP Brain Control We have developed a quite innovative and unique technological platform in the Augmentative and Alternative Comunnication field aimed at allowing neurological patients (ALS, multiple sclerosis, stroke, etc) in condition of Locked-in stage to communicate and interact with external world. 128 / 880 We look for partnerships both in the area of Distribution/Go to market and R&D/Product development .

129 / 880 Braincontrol

Organisation

Country Italy City Siena Street VIALE MACCARI, 1, VAT 01293870521 Web http://www.braincontrol.com

Person

Name PASQUALE FEDELE CEO

Organisation BrainControl is a framework based on Artificial Intelligence for human-machine interaction through biofeedbacks. Its first application was addressed as BCI-based augmentative and alternative communication (AAC), a sort“mental joystick”, allowing to overcome severe physical and communicative disabilities. “BrainControl BCI AAC” fills a technological void for patients who are cognitively aware, but completely unable to move or communicate, a state called “locked-in”, and meets many of the unmet needs for patients in less advanced states who are currently using or cannot use eye-tracking systems. Future versions will include advanced functionalities of communication, entertainment, home automation and robotic. Working prototypes of a virtual keyboard, home automation, wheelchair control and of a humanoid robot control with multiple modes of interaction have already been developed. Areas of Activity

• Bioinformatics, Big data analytics • Medical devices • Biosensors • IT Applications for Health • Biotechnologies (Pharma&Medical Devices) • eHealth, mHealth, telemedicine

Marketplace Opportunities PARTNERSHIP Partnerships for scaleup We are looking for partnerships both in the area of Distribution/Go to market and R&D PRODUCT Braincontrol BrainControl is a platform based on Artificial Intelligence for human-machine interaction through biofeedbacks. Its first application was addressed as BCI-based augmentative and alternative communication (AAC), a sort “mental joystick”, allowing to overcome severe 130 / 880 physical and communicative disabilities. “BrainControl BCI AAC” fills a technological void for patients who are cognitively aware, but completely unable to move or communicate, a state called “locked-in”, and meets many of the unmet needs for patients in less advanced states who are currently using or cannot use eye-tracking systems. Future versions will include advanced functionalities of communication, entertainment, home automation and robotic. Working prototypes of a virtual keyboard, home automation, wheelchair control and of a humanoid robot control with multiple modes of interaction have already been developed.

131 / 880 Brussel Photonics, Vrije Universiteit Brussel

Organisation

Country Belgium City Brussels Street Pleinlaan 2 Web http://www.actphast.eu

Person

Name Nathalie Debaes ACTPHAST central contact point

Organisation Brussel Photonics is coordinating the European project ACTPHAST4.0, a unique one-stop-shop solution for supporting photonics innovation in European companies, especially adapted to the needs of small- and medium-sized enterprises. Areas of Activity

• Analytical and characterization services • Manufacturing & process engineering • Biotechnologies (Pharma&Medical • Packaging & labelling Devices) • Virtual reality applications • CRO (Contract Research Organisation) • Other • Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine

Marketplace Opportunities SERVICE Support to innovate your product or production with photonics ACTPHAST 4.0 is supporting photonics innovation projects with companies all across Europe in all application domains where photonics is a key enabling technology, e.g. Communications, Manufacturing, Lighting, Displays, Energy, Environment, Transport, Medical Devices & Life Sciences, Security, Sensors, Consumer Goods, Food Processing, and many more. ACTPHAST4.0 is specifically designed to remove the major innovation roadblocks for companies, especially SMEs, by providing support which is: Lower cost – 75%- 100% subsidy for SMEs Lower risk – we do the matching between your business need and the best experts & technologies Less admin – we do the paperwork for you Faster results – we complete projects within 6-9 months

132 / 880 C&P Engineering

Organisation

Country Italy City Scandicci Street Via dei Pratoni 16, Scandicci Web http://www.cep-eng.it

Person

Name Alessandro Fiani Sales & Marketing Manager

Organisation Services proposed by C&P encompass all technical problems typical of the operativity of a production unit, from building structures and utilities to process lines, of finished products andA.P.I ( Active Pharmaceutical Ingredients); in brief, C&P operations' areas are: Pharma Engineering · Pharmaceutical Design ( from Basic to Executive design)· Planning and construction assistance· Qualification and Validation· Maintenance management Construction · Process integrated systems· Controlled contamination environment· Service and special plants· Machinery and accessories for the control of environmental contamination Energy&Facility · Energy use optimization· Contractual energy management· Facility Management Projects· Waste optimizzation and management Areas of Activity

• Biotechnologies (Pharma&Medical • Software, ICT applications, system Devices) integration • Chemicals & APIs • Other • Consulting services • Laboratory equipment, reagents, software • Manufacturing & process engineering • Project proposals support services • Nutraceutics, probiotics, functional food, • Medical devices cosmeceutics • Packaging & labelling • Pharmaceutics • Regulatory affairs, validation

Marketplace Opportunities SERVICE C&P Engineering - Facility Design & turnkey construction for Pharma &

133 / 880 Biotech INNOVATIVE ASPECTS AND MAIN ADVANTAGES C&P Engineering is tightly linked with PharmaD&S ( regulatory affairs, process & quality services for pharmaceuticals). The upmentioned connection allows C&P engineering to offer a state-of-the-art support to overcome challenges faced by pharmaceutical production plant versus continuos quality requirements requested by national and oversea MoH. MARKET APPLICATION Pharmaceutical, API, Medical devices production plants

134 / 880 Calculus System SARL

Organisation

Country Congo, The Democratic Republic Of The City Kinshasa Street 44, av démocratie, Gombe Web http://calculus-system.net/

Person

Name Alpha Mukadi Kazadi CEO

Organisation Calculus System partnership support local businesses in the IT delivery to the staff level, the routine use of the computer and computer maintenance. The culture of computer technology is not developed and there is often lack of equipment necessary. How to transform organizations to incorporate ICT as workplaces specialization, regulation of time, the ability to exchange ideas and knowledge to exploded with digital networks. Areas of Activity

• Consulting services • IT Applications for Health • Software, ICT applications, system integration • EPR, Clinical/healthcare management software

Marketplace Opportunities PRODUCT Hostoo Hostoo is a centralized and computerized platform for end-to-end medical resource management. This platform offers 3 essential modules to know: • Management of the medical facility: this module allows the management of the medical establishment by automating the customer journey, billing, inventory management and specialized services; • Statistical and Epidemiological: Thanks to the centralization of data, this module allows a real-time interpretation of statistics to make forecasts and preventions on epidemiological situations; • An Expert System: an artificial intelligence that is continually enriched by medical field specialists to enable patients to interact with an AI through a mobile and / or web interface to guide diagnoses according to the patient's symptoms. A secure payment gateway will be integrated into the platform to facilitate the acceptance of bank cards and electronic wallets (E Wallet). Management module of the medical facility 135 / 880 Several features are deployed in this module to facilitate the management of a medical center. These features are: 1. Management of the patient path: the patient's journey from reception to the application of medical procedures is automated. End-to-end automation. 2. Drug Inventory Management and Medical Consumables: Inputs and outputs of drugs and medical consumables are managed automatically. And control points are implemented. This results in better management and efficient use. 3. Billing and Cash Management: billing of medicines and medical procedures is automated. An electronic cash register will be implemented to allow traceability of cash balances and disbursements. As a result, there is better cash flow management. This function has the role of giving financial visibility to the Congolese State in order to improve decision-making. 4. Subscription and mutuality management: this feature allows you to manage patients belonging to mutual societies and / or having medical insurance. These features facilitate the administrative management of medical centers and health zones. Statistical and Epidemiological Statistics: A dashboard to display statistics based on predefined queries in the system to allow the administrator to have visibility on Health Zones at the local and national level. Epidemiological: According to statistics, this feature allows to have a medical interpretation and orientation. Expert System An artificial intelligence implemented to facilitate an interaction with the collected data in order to make predictions and medical orientations. An Android client interface will be implemented to allow the patient to make an online consultation and to have a medical orientation that will be confirmed in the nearest medical center. PRODUCT ToonaCRM ToonaERP is a management application for SMEs to steer them towards good governance of their business. It is part of the candle of social innovation. the app based on a local and private cloud that is gradually expanding. Our goal is to give these small and medium business, tools simple and easy to use at low prices.

136 / 880 Camlin Italy Srl

Organisation

Country Italy City Pisa Street Via Matteucci 34/B Web https://www.camlingroup.com/

Person

Name Francesca Sernissi Clinical and Business Developer

Organisation Camlin operates with the vision of bringing revolutionary products to life for a wide range of industries, including the healthcare sector. At Camlin we believe in high quality engineering and design, allowing us to develop market leading products and services. In short, we love creating value for our customers by solving difficult problems. As of today, the Camlin operation spans over 20 countries across the globe. Camlin is strongly committed to R&D. The research group consists of several teams with a wide variety of skill sets, from physicists and chemical engineers to machine learning software developers and biomedical engineers. The team is engaged in the design and development of innovative products, rapid prototyping and continuous problem solving in our core business of Power and Rail as well as in new sectors such as Healthcare, Security and beyond. Healthcare Research Our Healthcare research team applies advanced machine learning and microfabrication technologies to the design of innovative products and solutions for the Healthcare industry. We work in partnership with internationally recognized research centres, such the Institute of Neuroscience and IMEM (Institute of Materials for Electronics and Magnetism) of the INRC (Italian National Research Council), with whom we operate joint research laboratories. Our team consists of experts in biomedical engineering, machine learning, computer science, electronics, physics, material science and telecommunications, complemented by CNR’s neuroscientists and material scientists. We also collaborate with global industrial, academic and clinical partners across several projects. Current projects include: Brain Computer Interfaces, Decision Support Systems for surgical epilepsy treatment and neurorehabilitation. Camlin Italy HQ is in Parma, with also an healthcare branch office in Pisa. Areas of Activity

• Bioinformatics, Big data analytics • Medical devices • Biosensors • IT Applications for Health • eHealth, mHealth, telemedicine • Physiotherapy, Orthopaedic technology

137 / 880 • Surgery technologies and applications

Marketplace Opportunities PARTNERSHIP EPILEPSY TREATMENT - Decision support system to easily characterise the spiking activity in sEEG recordings A fraction of pharmacologically intractable epileptic patients require treatment by resective surgery. A positive outcome of the procedure and the absence of adverse effects strongly depend on the correct and specific identification of the epileptic network, i.e. of the area(s) of the brain that are involved in the generation and propagation of the seizure. In collaboration with CNR’s Institute of Neuroscience we are developing a tool to support the clinician in the identification of the epileptic network, based on the automatic identification, analysis and statistical characterization of interictal epileptiform discharges in long intracranial recordings. PARTNERSHIP ARC-Intellicare platform for home-based rehabilitation ARC-Intellicare is a machine learning (ML)-based wireless platform designed to work at patient’s home in post-acute phase after stroke. ARC can address the specific rehabilitation needs of each patient, by allowing therapists to personalize rehabilitation routines, providing continuous monitoring and performance feedbacks during both the exercises program and ADLs. Main components are: wearable inertial sensors for upper, lower limb and postural monitoring, a tablet and a SW platform, with a simple and straightforward UI. The solution has been developed within the MAGIC Pre-Commercial Procurement. During MAGIC phase 2, Camlin has released ARC first prototype of software and hardware components, and designed the field research protocol for its clinical validation.

138 / 880 CARBON LINE COMPOSITES SAS DI ROSSI GIULIANO & C.

Organisation

Country Italy City Ravenna Street Via Giuseppe Stefano Bondi, 3/A Web http://www.carbonlinecomposites.com

Person

Name Guido Rossi Head of Technical Department

Organisation We are specialized in the research, design, development, manufacture and supply of broad range of components, parts, accessories in advanced composite materials with polymeric matrix for nuclear medicine, industrial, design, renewable energy. Areas of Activity

• Medical facilities furnishings, equipment, • Medical devices goods • Packaging & labelling • Other

Marketplace Opportunities PRODUCT Protections shielding ionizing radiation We realize custom protections. We make custom-made protections for equipment and objects of all types and shapes. Our devices guarantee greater safety for operators, lower weight of the devices, greater resistance to chemical agents and impermeable to water. With complete isolation of the shielding material from contact with people and the environment. We provide technical advice, design and product customization. We make prototypes, pre-series, small and medium production series. PRODUCT Containers for electronic components We make containers for electronic components shielding, or not, radio frequencies. Completely insulating against liquids, vapors and powders. Also for new generation batteries. We provide technical advice, design and product customization. We make prototypes, pre-series, small and medium production series.

139 / 880 PRODUCT Casings We make custom-made casings of all types and shapes, including shielding ionizing radiation for any type of equipment or machinery. We provide technical advice, design and product customization. We make prototypes, pre-series, small and medium production series. SERVICE Technical advice, design and product customization We provide development support for objects and components to be produced with advanced composite matrices

140 / 880 CART-Tech B.V.

Organisation

Country Netherlands City Utrecht Street Padualaan 8 Web htttp://cart-tech.com

Person

Name Paul Leufkens CEO

Organisation CART-Tech is developing a medical software device that supports the cardiologist with easy to use image guided placement of cardiac pacemaker leads (electrodes). The product, CARTBox, will substantially decrease the number of incorrect lead placements and will be of great benefit to patients, cardiologists, pacemaker manufacturers and healthcare payers. Clinical proof-of-concept has been achieved, the product has received CE mark and is now being introduced in the first leading clinics. As a next step, the company is seeking finances to complete product development and to speed-up the introduction into the market, supported by additional clinical studies in several EU countries. Areas of Activity

• Medical devices

Marketplace Opportunities INVESTMENT OPPORTUNITY CARTBox CART-Tech is developing a medical software device that supports the cardiologist with easy to use image guided placement of cardiac pacemaker leads (electrodes). The product, CARTBox, will substantially decrease the number of incorrect lead placements and will be of great benefit to patients, cardiologists, pacemaker manufacturers and healthcare payers. Clinical proof-of-concept has been achieved, the product has received CE mark and is now being introduced in the first leading clinics. As a next step, the company is seeking finances to complete product development and to speed-up the introduction into the market, supported by additional clinical studies in several EU countries.

141 / 880 CASA DI CURA DEL POLICLINICO

Organisation

Country Italy City Milano Street VIA DEZZA 48 Web http://www.ccppdezza.it/

Person

Name Massimo Caprino Chief Innovation Officer

Organisation Casa di Cura del Policlinico (CCP) is a fully integrated multi-specialty clinical centre aiming at providing both inpatient and outpatient services mainly directed to neurological patients. The Centre is a Department of Neurorehabilitation Sciences, accredited by the Italian National Health System, and economically supported by Regione Lombardia. The Scientific Director, Dr Massimo Corbo, neurologist raised the clinical interest in Neurodegenerative Diseases at CCP, focusing on dementia disorders. As supervisor, he is involved in coordinating and monitoring researcher’s activities; he manages stakeholders’ and research network The Centre draws together the expertise of a large team of specialists, e aimed to cover needs of patients with neurological disorders, including clinicians (neurologists, physiatrists, pulmonologists, cardiologists, phoniatrists), psychologists, biologist, bioengineer, motor and occupational therapists, speech therapist, dieticians, and clinical nurse specialists. Research is mainly dedicated to the Neurological Sciences, the Neurorehabilitation Sciences and to Quality of Life. CCP is partner in national and international consortiums for innovative research, both clinical and technological, applied to neurorehabilitation and frailty conditions in aging. The active collaboration in European projects during the last years led CCP achieve national and community funding, e.g. PhDITalent Program (Fondazione CRUI), Ricerca Finalizzata (Italian Health Ministry), MSCA (H2020), Health Demographic Change and Wellbeing (H2020) and AAL Program The organization is improving ICT enabled projects with industrial partners in order to extend the range of services aimed to an effective continuity of care. Research activities are pursuing in the direction of personalized rehabilitation programs. AAL and cognitive technologies, like body and environmental sensors, cameras, mobile apps (e.g. serious gaming), brain computer interface and even robotics will support this process in monitoring behavioural profiles and physical activities in aging. Virtual Coaching System for rehabilitation in elderly is one of the focus in international research (https://vcare-project.eu/) CCP is providing an ideal setting for promoting translational research in Neuroregenerative Diseases in order to facilitate the rapid transfer of research knowledge to the clinical environment 142 / 880 CCP is collecting biological samples from neurological patients who belong to the structure, thanks to the activation of the internal BioBank. This choice is in line with the efforts of the international scientific community aiming at identifying the genetic and biochemical markers of neurological diseases. It can thus provide a further significant contribution to medical research in the interest of its own assisted and of all the patients suffering neurological disorders The effort is not limited to the clinical expression, but also based on biomolecular and morpho- functional characterization, linked to neuro imaging studies, with attention to the characterization of neurological diseases, on the neuro-degenerative and stroke side. CCP enabled the collection of biological samples from patients with various diseases, such as ALS, PD, peripheral neuropathies, multiple sclerosis, cerebral stroke and AD , banking plasma, PBMCs, serum, DNA and blood The Centre is actively involved in a clinical and preclinical research program into neurodegenerative diseases, including biomarker analysis and genetic studies as well as innovative new therapies for affected patients. Research efforts include biomarker analysis and genetic studies, as the application of innovative new therapies in neurodegenerative patients. It is a national recognized neurological Centre for pharmacological trials and for patients with neurodegenerative diseases and different brain-lesions It is a member of the Presidium of the Lombardy Regional Network for Rare Diseases. The Centre is actively collaborating with the EIP-AHA, a pilot initiative launched by the EC to foster innovation in the field of active and healthy ageing. CCP became member of the Action Group A2 “Personalized health management and prevention of falls” https://ec.europa.eu/eip/ageing/ commitments-tracker/a2/preventing-secondary-injurious-falls_en Backgrounds' studies dealing with: -Impact of specific cognitive disabilities on the motor and functional short term and long- term recovery of post-acute stroke -brain and cognitive dynamics of multiple-object processing in normal aging, MCI and AD -virtual reality in the rehabilitation of upper limbs’ movement disorders -effects on short-term and long-term recovery of different cognitive impairments on elderly patients after hip fracture -improvement of episodic memory in elderly individuals with MCI through non-invasive electrical stimulation (tDCS), on the basis of MRI exams and in relation to some of their genes associated with memory. Areas of Activity

• Analytical and characterization services • Proteomics, metabolomics, nutrigenomics • Bioinformatics, Big data analytics • EPR, Clinical/healthcare management • Biotechnologies (Pharma&Medical software Devices) • Virtual reality applications • eHealth, mHealth, telemedicine • Medical devices • Genetics & Genomics • IT Applications for Health • Peptides, proteins & antibodies preparation • Pharmaceutics

Marketplace Opportunities PARTNERSHIP Rehabilitation technology pilot assessment

CCP could provide conditions and facilities where clinical investigations of medical devices could be performed. The pilot could be guested in the Neurorehabilitation Sciences Department, where patients are rehabilitated for a period of 2/6 months. In the basement of this structure are located equipment and spaces useful for:

143 / 880 • cognitive and functional rehabilitation • house environment simulation • movement tracking Within this infrastructure, a pilot with neurological patients can be set up, potentially extending it to a clinical study, following a shared clinical protocol, approved by an ethical committee. Project use cases can be extended also at home in a logic of continuity of care. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Different and various are the activities that can be performed, which constitute interesting backgrounds to proposal participation, as the studies dealing with: • Impact of specific cognitive disabilities (i.e. aphasia, executive function deficits, neglect, and memory loss) on the motor and functional short term and long-term recovery of post-acute stroke patients • brain and cognitive dynamics of multiple- object processing in normal aging, MCI and Alzheimer disease • virtual reality in the rehabilitation of upper limbs’ movement disorders” • effects on short-term and long-term recovery of different cognitive impairments on elderly patients after hip fracture” • VHP multi-scale computer modelling with clinical application in the neurological domain • AAL solutions based on open platforms MARKET APPLICATION Market application refers to the enhancement of TRL, from TRL 4 (Component/subsystem validation in laboratory environment) to TRL 7 (system prototype demonstration in operational environment). Test could include a Health Technology Assessment or a clinical validation. TYPE OF PARTNER SOUGHT Innovative SMEs willing to certificate their products, in order to show scientific evidences of their solutions. Facilities to access to the Italian market could be added according to a specific exploitation plan, to be drafted taking in case the relationship facilities that CCP could provide, through the access to the national Life Science Cluster and to the neurological rehabilitation network. PARTNERSHIP Neurological biological profiling enabled by internal Biobank CCP is strongly interested and active in the study of neurodegeneration with the absolute need to identify the genetic and biological markers (biomarkers) for the neurological diseases treated into the clinic. In light of the foregoing and its mission of translational and clinical research, CCP is collecting biological samples related to the diseases suffered the people who belong to the structure in order to provide a further significant contribution to medical research in the interest of its assisted and, by far, of all the patients suffering from neurological disorders. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The Innovative aspects we can express are the following: • Promote basic scientific research for the detection of etiopathogenetic mechanisms related to specific diseases; • Promote the collection of samples belonging to individuals / populations with peculiar characteristics for which it can be assumed a particular genetic predisposition or susceptibility to environmental factors to a greater risk to certain diseases; • Make available for clinical pharmacology (pharmacogenetics to farmacoproteomica) samples for the study of nucleotide and amino acid sequence variants associated with different responses to drug therapy; • Offer a service to biomedical research for the development of research lines intra and inter- institutional national and international. MARKET APPLICATION Among the scenarios with high clinical impact in which the biomarker would be particularly useful in characterizing the expression of disease, we are left to put an early diagnosis and / or pre- symptomatic, to follow the progression of the disease and to determine the prognosis. The purpose is to identify new predictive biomarkers, Diagnostic and / or Prognostic, potentially transferable in the

144 / 880 clinical field, not only in the field of laboratory diagnostics, but also for innovative treatments such as the "targeted therapy"; TYPE OF PARTNER SOUGHT Universities and Research Centres aiming to design & test novel more personalized interventions & patient-centred therapies for neurological chronic diseases. Clinical centres networking to extend cohorts in neurological diseases and integrating their own biobanks. Companies providing services for analysing genomic data. REQUEST Voice, speech and communication enabling technologies

SOLUTION OR EXPERTISE SOUGHT We are looking for research organization or enabling technologies to enhance: • screening tools for swallowing disorders • evaluation protocol for bulbar functions in ALS patients • use of AAC and assistive technologies for people with speech/communication disorders • evaluation protocol for motor speech disorders • use of tDCS for rehabilitation of language disorders in patients with aphasia TYPE OF PARTNER SOUGHT Research organization willing to perform multicentre clinical studies. Innovative companies willing to test innovation in real environment.

145 / 880 Cassovia Life Sciences

Organisation

Country Slovakia City Kysucké Nové Mesto Street Litovelská 670/27 Web http://cassovialifesciences.eu

Person

Name Norbert BOMBA managing director

Organisation Cassovia Life Sciences is a not-for-profit association of scientific and research institutes, innovative industry participants, SME-s related to medical and life-sciences research and innovation. CLS functions as a central connecting point for multiple research facilities in the proximal region of Kosice and within the cross-border region of Slovakia, Hungary and Ukraine. CLS builds international stakeholder network, promotes the competencies and capacities of its members, organizes conferences, seminars, workshops and disseminate achievements of its members internationally. Areas of Activity

• Biotechnologies (Pharma&Medical • Project proposals support services Devices) • Nutraceutics, probiotics, functional food, cosmeceutics • Proteomics, metabolomics, nutrigenomics • Life sciences related activities

Marketplace Opportunities SERVICE CLS Capacities CLS is a competence and resource hub that connects complementary scientific and research facilities of academia and innovative industry in order to exploit the potential of joint efforts and collaboration. CLS offers following equipment with free capacity for collaboration: - TWINSHIME (simulator of the human intestinal microbial ecology) - germ-free pig and mouse models, gnotobiotic animals, diet-induced atherosclerosis model, chemical- induced colorectal cancer model - Real-time PCR system, RX Daytona clinical chemistry analyzer, Xcelligence, 2D PAGE DIGE-SDS electrophoresis, nano LC-MS system, Q-TOF Ultima electrospray MS/MS, MALDI TOF/TOF Bruker Ultraflextreme, MALDI Imaging Bruker ImagePrep, spotter Bruker Proteineer fc II, GC-MS quadrupole system, software Bruker Compass 1.3 for FLEX series, PDQuest, Bio-Rad imaging instruments, 146 / 880 ProteomeWorks spot cutter, Protein Prospector, MASCOT, Proteomics, METLIN, Agilent Mass Profiller, NIST – AMDIS, NIST-MS-Search, Fiehn MS Search and Wiley’s NIST/EPA/NIH 2011 - Group of Companies “Agro-Food Platforms” currently united 170 organisations – National Leaders in different fields of KBBE including modern-equipped JSO Certified Diagnostic Labs; Technology Transfer Companies; Research Institutes of NASU and Universities, SMEs and Big Industrial Companies. All relevant to the KBBE profile research equipment and expertise are available to carry out morphological, cytological, gene, microbiological, immunological, biochemical, biophysics, mathematic, statistical studies among all 3 countries. Collaboration is highly required for the promotion of implementation in practice already developed, pilot tested innovative technologies and proposed products. PARTNERSHIP CLS competences for partnerships, collaborations, projects development CLS functions as a central connecting point for multiple research facilities in the promixal region of Kosice and within the cross-border region of Slovakia, Hungary, Ukraine and offers these competencies and experience for collaboration: - Experimental studies in biomedical research (genomics, proteomics and metabolomics), immunology, microbiology, molecular biology - in vitro models, in vivo models of atherosclerosis and cancerogenesis, germ-free and gnotobiotic animal models - in vitro simulations of the human gut - proteomics platform including analysis of complex protein mixtures, the comparison of proteomes from cell/tissue/organism, identification and quantification of proteins - metabolomics workflow including discovery and targeted metabolomics with profiling and identification of metabolites with spectral library and database searching - genomics platform with qualitative and quantitative analysis of nucleic acids up to genome wide gene expression, genotyping and gene dose analysis - In each chosen call – pre-formed Consortium that includes few SMEs and S&T - Innovative and Certified idea as scientific background specific to the targeted task of each separate call - Newly proposed innovative functional (food) products and nano-smart-biomaterials - Techniques and Models (in vitro, in situ, cell, animal models, clinical trial etc.) - Bench of unique patented practical methodologies and personal professional skills - Internal and External networks, sustainable partnerships, WP and tasks Leaders

147 / 880 Cathay Venture Inc

Organisation

Country Taiwan City Taipei City Street Web https://www.cathayholdings.com/holdings/ cathayventure

Person

Name Kate Chen Assistant Manager

Organisation Cathay Venture is a 100 % subsidiary of Cathay Financial Holdings, therefore we are a evergreen fund with size about USD 100M. As for our investment scope, we focus on early stage company equity investment worldwide. As a financially driven investor, we seek to participate in Series A to C rounds and our typical investments range from USD 1 to 5 million and our investment process timeline is about 1-2 month. We consider broadly across the healthcare field, including new drugs, medical devices, diagnostics, and healthcare IT. We prefer products that have achieved prototype and clinical proof-of- concept. Areas of Activity

• Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity As a financially driven investor, we seek to participate in Series A to C rounds and our typical investments range from USD 1 to 5 million and our investment process timeline is about 1-2 month. We consider broadly across the healthcare field, including new drugs, medical devices, diagnostics, and healthcare IT. We prefer products that have achieved prototype and clinical proof-of-concept.

148 / 880 Cba Informatica

Organisation

Country Italy City Rovereto Street Viale Trento, 56 Web https://www.cba.it/home

Person

Name Sara Turrini Customer Care & PM

Organisation CBA Group is a software house based in the beautiful region of Trentino, North-East of Italy. Since 1975 CBA Group has been leading innovation in the health and social care sector by providing comprehensive and cutting-edge technology solutions for hospital, care homes for the elderly, day care facility and housing for the disabled, rehabilitation centers. We design and develop integrated, complete and easy-to-use programs that allow social care providers to efficiently manage every single department of their organisation: HR, payroll, administration, billing, medication management, electronic health record, reporting. We also offer training courses, consulting and support to more than 1,400 customers across the country. Our focus is on helping social care providers enhance the care they deliver to people and therefore the quality of their life. Our numbers: 130 employees 12,700 installed softwares 1,410 clients 139,000 assisted guests PROJECT http://www.cba.it/collegamenti http://www.cba.it/-/minerva Areas of Activity

• Consulting services • IT Applications for Health • Software, ICT applications, system integration • Other • Project proposals support services

Marketplace Opportunities SERVICE

149 / 880 CONSULTING CBA aims to support cultural and methodological change within social and health structures and support all those who daily are called to produce quality results in the Welfare sector. CBA uses the experience and skills of internal professionals and the collaboration of external partners with the aim of providing effective and quality training. The training is organized both in residential mode (classroom courses, workshops, conferences) and in FAD (distance learning). PRODUCT SIPCARplus

SIPCARplus® is a platform composed of over 50 modules divided into seven areas: Personnel, Administration, Organizational Instruments, Guests, Health and Social Services Briefcase, and Territorial Services.

150 / 880 CBM - Centro di Biomedicina Molecolare - Smart Health Cluster of Friuli Venezia Giulia

Organisation

Country Italy City Trieste Street Strada Statale 14, Km 163,5 - Località Basovizza Web www.cbm.fvg.it

Person

Name Laura Cerni PhD - Cluster Manager

Organisation The CBM, acknowledged by Regional Law 26/2005 and identified as an Innovation District in Regional Law 3 of 02/20/2015, seeks to develop the potential of the Smart Health Cluster in the Italian region of Friuli Venezia Giulia (FVG). It focuses on the following sectors: Biomedicine, Biotechnology, e-Health, and Ambient Assisted Living (AAL). CBM, in charge of the Smart Health area in the Smart Specialization Strategy (S3) of FVG, plays a leading role in building relationships among all the actors in this field—enterprises, universities, research institutions, research hospitals, start-up incubators, finance institutions, education and technology transfer parks, and policy makers—with the goal of promoting business innovation and social and economic growth. The FVG health sector is characterized by important cross-sectoral activities and competences featuring a broad array of industry interdependencies and research activities. The Cluster consists of 120 companies; 14 research bodies (public and private), universities, and research institutions operating in the life science field; 4 science and technology parks; and 1 public organization providing services to senior citizens, particularly those who are disabled. As a member of the National Technological Cluster ALISEI (Advanced Life Sciences in Italy), CBM is the regional reference and technological coordinator of life sciences at the national, European, and international level. Thanks to the geographical location of FVG, CBM can be proactive in creating contacts with other clusters, industries, and research institutes located in neighboring states, such as Austria, Slovenia, Croatia, and the other Balkan regions, to promote and develop synergies and cooperation. In addition, CBM offers Genetic services by Next Generation Sequencing. Areas of Activity

• Bioinformatics, Big data analytics • Genetics & Genomics • Biomaterials • Medical research

151 / 880 • Biosensors • Nutraceutics, probiotics, functional food, • Biotechnologies (Pharma&Medical cosmeceutics Devices) • Pharmaceutics • Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • IT Applications for Health • Diagnostics - Imaging equipment and processing • Drug screening & delivery • eHealth, mHealth, telemedicine

Marketplace Opportunities PARTNERSHIP Partnership agreement between regional Clusters for improving collaborative networks The Cluster Smart health of Friuli Venezia Giulia organisation is interested in activating partnership agreement with other european Cluster organisations, focused on Biomedical, Biotechnological and e- health sectors, with particular attention to create the right condition for an operating network between its companies and research institutes and those of Central and Eastern Europe and Balkan regions.

152 / 880 CellDynamics Srl

Organisation

Country Italy City Imola Street via Villa Clelia 62/D Web www.celldynamics.it

Person

Name Luca Sereni CEO

Organisation CellDynamics is a young start up developing a new technology and a new line of products called CellViewer. We develop a novel device able to join time lapse microscopy, cell culture in suspension or floating condition and automatic management of the all parameters of the culturing conditions, media, temperature, atmosphere, ... We are opening novel application fields and improving considerably productivity in laboratory analysis on cells cultures. Areas of Activity

• Biomaterials • Drug screening & delivery • Biotechnologies (Pharma&Medical • Laboratory equipment, reagents, software Devices) • Diagnostics IVD • Diagnostics - Imaging equipment and processing

Marketplace Opportunities

PARTNERSHIP Manufacturing capabilities At present stage we are looking for organizations with good manufacturing capabilities in order to take charge of the manufacturing of part or whole of our device. We are manufacturing the first products that we are preparing in this period, but we want to maintain in house development and prototyping capabilities while we are looking for manufacturing capabilities in some external partners. We have developed the blue print and the whole project of our device. At the same time, and in a different partnership, we are looking for manufacturing capabilities in microfluidics for the microchip or consumable of our device: this could be a second axe of strategic partnership. SOLUTION OR EXPERTISE SOUGHT For the device the competences sought are: optics, microfluidics, electronics, mechanics and testing facilities. For the chip: microfluidics, material engineering, biocompatibility. TYPE OF PARTNER SOUGHT 153 / 880 Enterprise with former experiences on in vitro diagnostics manufacturing. Preferred European origin of the company. INVESTMENT OPPORTUNITY Funding We are interested in getting in contact with financial organization (Venture Capital, Corporate with industrial interests in the same business area) in in order to share future funding needs for the development of the start-up. PRODUCT Time lapse microscopy videos for cells or spheroids CellDynamics' technology allows to culture in a microenvironment, in a small testing chamber, a culture of single cells or a 3D model of cells i floating conditions. During the culture, thanks to our proprietary solution, we can manage the position of the floating partile (cell or spheroid) and we can have time lapse microscopy on the experiment. We can record the video and we can also allow customers to see the live imaging of the experiment. INNOVATIVE ASPECTS AND MAIN ADVANTAGES This solution enables users in creating easily videos of their biological experiments. At the same time this solution allows biologists to develop testing conditions coherent for ste cell studies, due to the fact that floating conditions help the stem behavior on cells. MARKET APPLICATION Our system allows also easy culture media change: this feature and the previous characteristics allow the study of 3D cellular systems in complex protocol where we can easily change the culture media. Simulation of drug actions or bacteria effects or different agents effects will be quite easy to realize. This experiments can be developed in a contest where the optic analysis will be performed in bright field or dark field but also in fluorescence. TYPE OF PARTNER SOUGHT We address to research teams in biology, biotechnology and bio-medicine that want to create video documents in order to explain in a more effective way the phenomena that they are studying in their research program. research laboratories of pharma industries can also benefit of this technique. REQUEST Commercial competences According to our future commercial activity we are looking for integrating in our present competences further marketing and sales skills in order to boost our action SOLUTION OR EXPERTISE SOUGHT We are looking for agents or sale persons with a specific experience in sales of devices addressed to research laboratories in Biology, Biotechnology, Bio-Med and Medicine with a consolidated knowledge of major institutions and companies present on the Italian and/or European market. Experience in microscopy could be preferred.

154 / 880 Cellply

Organisation

Country Italy City Bologna Street Via Massarenti 61 Web www.cellply.com

Person

Name Massimo Bocchi CEO

Organisation Cellply is a medtech company focused on the development of cell-based analytical systems aiming at predictingthe efficacy of anticancer drugs on a patient-by-patient basis. Weaim at changing the way patient stratification is performed by providing information currently missing in the clinical setting to match the right drug with the right patient through personalized and individualized drug response profiles. Our approach is to test the in-vitro activity of candidatedrugs on fresh tumor specimens with a highly- innovative platform suitable for being installed in the hospital setting. We hold 6 patents on the core microfluidic technology used in the platform, with 3 patents currently granted in EU, US and China. Clinical testing has recently started in the field of leukemias and we successfully predicted the outcome of the therapy in more than 90% of the cases. Cellply technology supports drug developers by enabling drug testing on human samples prior to clinical development and by optimizing patient stratification during clinical trials. Since 2014 the company has raisedmore than€3m funding from business angels and VCs. Cellply is currently seeking new investors for a SeriesA financing round, to support product development and clinical validation and make the platform ready for the market. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Diagnostics IVD • Diagnostics - Equipment and accessories

Marketplace Opportunities PRODUCT Drug testing on human samples Cellply aims at changing the way patient stratification is performed by providing information currently missing in the clinical setting to match the right drug with the right patient through individualized drug response profiles. We have developed an innovative platform allowing to test the efficacy of anticancer drugs on fresh tumor biopies. The plaform is suitable for being used in diagnostic labs. Clinical testing on leukemia patients reported a best-in-class 90% accuracy in predicting the response of the patient to the treatment. 155 / 880 We hold 6 patents (3 granted) on a proprietary microfluidic technology and methods for automated sample processing, drug testing and data analysis. Cellply is interested in partnering with oncology institutes to expand its clinical validation activities and with pharmaceutical companies to support new drug development, drug repurposing and biomarker development.

156 / 880 CellPly

Organisation

Country Italy City Bologna Street Web https://cellply.com

Person

Name Laura Rocchi Head of biology

Organisation Cellply is a biomedical company focused on the development of near-patient diagnostic systems aiming at defining anticancer drug response profiles on ex-vivo patient samples through the analysis of the biological response. Leveraging on a patented microfluidic technology, highly-integrated cell processing and analysis methods are supported and drug testing in the clinical setting is enabled with a high degree of automation and standardization. Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Diagnostics IVD • Medical devices

157 / 880 CellPly srl

Organisation

Country Italy City Bologna Street via Massarenti 61 Web https://cellply.com/

Person

Name Andrea FAENZA CTO

Organisation CellPly s.r.l. develops a diagnostic tool for clinicians and researchers to personalize cancer treatment. Its tool enables users to analyze small ex-vivo samples and rare cells immediately after obtaining them from patients and preserving microenvironment conditions to provide information about tumor cell sensitivity to drugs and in-vivo status of single immune cells that are located close to tumor cells. The company’s solution also helps oncologists in selecting the best treatment options, scientists in studying cell response to therapy, and pharmaceutical companies in increasing drug efficacy and rescuing drugs. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Diagnostics IVD • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing

158 / 880 Centro Cardiologico Monzino

Organisation

Country Italy City Milan Street Via Carlo Parea 4

Person

Name Elisa Gambini Researcher

Organisation The Monzino is a clinical research hospital that is highly specialised in the heart and its vessels. Founded in 1981, it is part of the IEO-Monzino group: two centres of excellence in the management of major pathologies of the Western world, which reinvest all their profits in research and innovation. Monzino is the first hospital in Europe exclusively devoted to Cardiac care, with advanced therapies and innovative technologies. Areas of Activity

• Medical research • Life sciences related activities • IT Applications for Health

Marketplace Opportunities INVESTMENT OPPORTUNITY Cell Therapy for Cardiovascular Diseases Continual technical improvements in mechanical coronary revascularization have produced as a paradoxical effect a growing number of patients with advanced coronary artery disease, who are considered no longer suitable for state-of-the-art cures and experience refractory angina (RA) despite best medical management. Given the lack of effective options, regenerative therapies by means of cell administration into the heart exerting a potent angiogenic effect represents a particularly attractive approach for the treatment of these patients. The invention, named CPCPlus, is an Advanced Therapy Medicinal Product (ATMP) specifically conceived to exert a potent angiogenic effect to the ischemic myocardium. CPCPlus consists of 1) a proprietary method for cardiac-derived cell manufacturing and 2) a proprietary human cardiac-derived progenitor cell product. In particular, the manufacturing process consists of an innovative fully GMP-compliant high-efficient and cost-effective scalable method to isolate human cardiac progenitor cells (hCPC) both in autologous and allogenic settings. The cell product is a cardiac progenitor with high potency for therapeutic angiogenesis and possesses high immunomodulatory capacity.

159 / 880 Centro cardiologico Monzino

Organisation

Country Italy City Milano Street Via C. Parea, 4 Web www.cardiologicomonzino.it

Person

Name Maurizio Pesce Group Leader

Organisation Centro Cardiologico Monzino is a Private Reasearch and Care Institution (IRCCS) uniquely specialized on Cardiovascular Diseases; Translational Research in Cardiovascular Diseases. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical research biomedical applications • Biomaterials • Biotechnologies (Pharma&Medical Devices)

Marketplace Opportunities PARTNERSHIP H2020 initiative on cardiac regeneration I am looking for industrial Partners / SMEs to cooperate in a new H2020 project focused onto cardiac regeneration INVESTMENT OPPORTUNITY Living pericardium material for heart valve surgical reconstruction We are looking for seed-money Investors to boost a technology to manufacture living aortic vlave tissue employable for surgical reconstruction of the aortic valve. This method has a possibility to be used as a novel 'personalized' medicine approach in valve therapy. PARTNERSHIP Cooperation on cardiac valve materials We have patented and published new materials (Acrylates) which may be employed for valve scaffold engineering. We are looking for Partners interested in R&D collaboration and manufacturing (3D Printing, microtextile technologies) to realize cardiac valve 'smart' scaffolds. SERVICE Expertise in cardiovascular tissue engineering We have developed cell/tissue engineering know-how in cardiovascular medicine research areas

160 / 880 (cadiac repair/regeneration; valve/vascular diseases). We offer support to implementation of R&D projects in this field.

161 / 880 Centro di Riferimento Oncologico di Aviano

Organisation

Country Italy City Aviano Street Via F.Gallini, 2 Web http://www.cro.sanita.fvg.it/it/index.html

Person

Name Marco Sollitto Knowledge Transfer Manager

Organisation The Centro di Riferimento Oncologico (IRCCS CRO Aviano) - National Cancer Institute is an Italian public institute committed to pursue excellence in all aspects of clinical oncology and management of health services. CRO is also an excellence in translational and clinical research activity, which is based on five research lines: 1- Tumor genetics and biology, 2- Tumor epidemiology and prevention; 3- Hematologic neoplasias. Translational and clinical research; 4- Solid tumors. Translational research to better diagnosis and treatment; 5- Infectious agents associated tumors. Clinical research is based on mono- and multidisciplinary therapeutic protocols, both promoting and participating to Phase I-II mono- and multicentre clinical trials. Areas of Activity

• 3D Printing/addictive manufacturing for • Peptides, proteins & antibodies biomedical applications preparation • Bioinformatics, Big data analytics • Pharmaceutics • Biosensors • Proteomics, metabolomics, nutrigenomics • Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Laboratory equipment, reagents, software • Diagnostics - Imaging equipment and • Medical devices processing • IT Applications for Health • Drug screening & delivery • eHealth, mHealth, telemedicine • Genetics & Genomics • Medical research

Marketplace Opportunities PRODUCT

163 / 880 Apparatus for rapid evaluation of thrombo-hemolytic risk It is a patented micro-fluidic device that perform real-time volumetric analysis of coagulation formation of a blood sample in laminar flux conditions. The device is based on the analysis of impedentiometric variations that occurs during clot formation. The tool is an integrated device with limited size, possibly made of disposable materials and exploitable for Point-of-Care usage. It is designed for rapid evaluation of thrombo-hemolytic risk to prevent and reduce ischemic and hemorrhagic risks due to congenital causes or external factors such as prolonged therapy with anticoagulant drugs; it can be used for both diagnosis and follow-up. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Real-time evaluation of the clotting process, without relevant interferences in the coagulation process in flux conditions. It does not require optical devices for the analysis, therefore limiting both costs and size of the device and make it usable for Point-of-Care applications. MARKET APPLICATION Medical device is the reference market. There is an increasingly request of technologies for near patient testing and estimates shows a market value of about $ 300 mln for Point-of-Care device for coagulation analysis. Our solution targets operators in the diagnostic stream, producers and providers of medical device and medical service providers. TYPE OF PARTNER SOUGHT We have an achieved Italian patent and a PCT priority and we have realized prototypes of the components; we are looking for partners and/or investors to proceed with industrial verification. PRODUCT Epigenetic Markers of Melanoma Prognosis The use of genomic DNA methylation status as epigenetic marker for independent prognosis of stage IIIC melanoma patients. Melanoma of skin across Europe, for both sexes, has an incidence rate of 13,0/ 100000, with an increasing trend and a mortality rate of 2,2/100000. There is an increasingly need for markers of cutaneous melanoma able to identify patients with increased risk of bad prognosis from patients with good prognosis, in order to provide the high risk group with differentiated therapeutic approaches and follow up and concomitantly avoiding side effects deriving from the unnecessary exposure to drug for the low risk group. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The methylation markers we have identified are able to independently define prognosis of melanoma patients within the same sub-stage of disease (IIIC). This prognostic value is maintained by methylation signatures composed of a limited set of genes (e.g., 17) and even by single selected genes. Other advantages comprises far superior stability of DNA methylation markers in clinical samples as compared to RNA-based markers, the technology robustness (NGS based) and the applicability to different types of biological samples, including archival FFPE tissues. MARKET APPLICATION The reference sector for our technology has been identified in “cancer/tumor profiling”, including diagnostics, prognostic and research technologies, which will globally grow to nearly €57.5 billions by 2021 at a CAGR of 19% from 2016 to 2021. The Europe CAGR growth will be of about 17%. TYPE OF PARTNER SOUGHT Support for validation process and scale up PARTNERSHIP Innovation in Nanotechnology The Experimental and Clinic Pharmacology Division (SOC-FSC) of CRO Aviano performs translational research to advance therapeutic efficacy and developing new tools for drug monitoring. Nanotechnology allows the manipulation of matter at the atomic and molecular level and has the potential to revolutionize healthcare by providing new platforms for tumour diagnostics, prognostics and treatment. The need for improved tumour markers enabling early diagnosis, as well as new insight into pathogenesis addressing for potential new treatments, is straightforward. In fact, prognostic

164 / 880 information relative to cancer disease is expected to allow the definition of effective and personalized treatment of patients. A Nanotechnology laboratory is currently under development within the Experimental and Clinical Pharmacology Division of CRO Aviano. > A pivotal aim of this multidisciplinary team is the development of a point-of-care testing device (PoCT) for cancer patients to (i) sensitively measure in real-time the concentrations of circulating biomarkers, currently used in the clinical practice and to (ii) perform therapeutic drug monitoring (TDM). > Another important field of activity concern the development of nano-drugs with improved specificity for cancer cells. - ADVANTAGES- > Basic and Translational research in the fields of molecular and cellular biology, animal modelling, bio-analytical, pharmacogenetics, proteomics, and nanotechnology involving expertise in molecular physics, physical chemistry and surface functionalization and nanomanipulation; all these proficiency thanks to a multidisciplinary team of highly trained researchers in chemistry, physics and biology. > Our research on Nanotechnology for clinical applications has so far attracted grants from public funds, both Regional and European, and also from private agencies. - COLLABORATION OFFER - Collaborations are offered to partners aimed to: -Identifying and incubating novel technological approaches for cancer diagnostics, prognotics and chemotherapeutic treatment. -Joint applications for industry-oriented grants focused on nanotechnology applications to oncology. PARTNERSHIP Metabolic signature of peripheral blood enables breast cancer screening in young women What is it about? 1 in 8 women in the EU-28 will develop breast cancer before the age of 85. An average of 20% of breast cancer cases in Europe occur in women when they are younger than 50 years old. Current screening programs of breast cancer rely mainly on X-ray scan (mammography). What needs covers? Mammography is not effective on dense breast tissue, typical, but not exclusive, of young women. For this reason, screening programs prescribe mammography on women older than 50 years, with alternative techniques (US, MRI) being only partially effective for younger women. What advantages? Breast cancer screening provided by a metabolic signature in the peripheral blood of young women will increase sensitivity and specificity of current screening programs with minimal invasivity. In addition, it will decrease time for analysis, cost and operator bias compared to currently used ultrasound (operator-dependent) and MRI (complex and time-consuming). Which is the reference market? Breast cancer is the 2nd most common cancer among the women in the world. Breast Cancer Screening Market (Mammography, MRI & Ultrasound) will be approximately US$ 8 Billion in Europe, and US$ 20 billion worldwide by the end of the year 2022.

165 / 880 Centro Servizi Rieducatore Sportivo srl

Organisation

Country Italy City Castenaso Street via Nasica 41/2 Web www.rieducatoresportivo.it

Person

Name Nicola D'Adamo Direttore Generale

Organisation RS Sport educator and Services Center is an innovative start-up born in the 2015, currently formed by nine people, and we collaborate with 30 experts in different fields, in this contest the undersigned Nicola D’adamo has the 54% value of the society. RS boastes 10 years of experience and very strong know how about the welfare of industry and big companies. Our goal is the welfare market and especially we would be a service center to improve the life quality. Sure the enthusiasm, concreteness and the continuous progress are the key words of our company. Areas of Activity

• Consulting services • IT Applications for Health • Life sciences related activities • Software, ICT applications, system integration • Project proposals support services

Marketplace Opportunities PRODUCT RS Planet One "Planet One" consists of an offer for all the companies, sports clubs and schools. We are able to identify a critical issues, the level of health and efficiency of the community examined and provides the tools necessary for a general improvement, this thank a web platform, we developed, a simple app for your smartphone. Our appstores the data on individual person or groups of people, employees, in order to analyse the Energy Story and to create a database for us and for people to visit the app and see the improvment thank to our approach. The reserved area of the RS® application is guided from an "Health Coach RS", a graduate operator in Motor Sciences and specialized in RS® Higher Education. The Health Coach RS represents, a constant reference point and a guide from which to draw important resources for a general improvement /

166 / 880 growth of the people. All data, according to the laws of privacy, are used solely for the purpose of offering useful tools for a general improvement of individual and collective well-being. The results of the test of the team's basal middle energy and other important data, monthly, are sent to the managers / administrators of the companies, giving them the possibility to use them for strategic purposes. PRODUCT RS APP Our "RS APP" consists of a simple application for smarphone and tablet that, through several elements and in particular to answers given to a specific tests based on scientific litterature and OMS principles, develops a quantifiable result relative to the "vital energies" of the person. "energy is life" and for man it results to be a decisive variable for the proper functions of the organism andfor the maintenance of its health. "RS APP" was born with the objective of providing the value that identify the quantity / quality (percentage) of life energy the test results gives an important index about health, and mental / physical performance. app iter is based on 1) evaluation o the starting point of the basal energy of the person; 2 ) prevention, it transmits a numerical value correlated to the state of health; 3 ) information and awareness to the person. 4 )comprension of certain dynamics linked toa correct life style; 5 )new stimulus to undertake a healthy change in lifestyle. SERVICE RS Centro Servizi Sports Re-educator" works on the real causes of a disorder, helping the person to find new stimulus thanks to a Global Approach CONSIDERING the Mind and the Body of a single person: tone and posture are 2 body hinges that we consider for and healthy state. RS Offers More Solutions: the most important is the presence of an health coach for every person requestes PARTNERSHIP Lenders We are looking for lenders who allow us to invest in the marketing area and in the research and development area of our online digital services. INVESTMENT OPPORTUNITY we look for lenders We live in a society that is multi-informed by the media but is not used to thinking about the inevitable differences between one individual and another, as well as the consequent and different solutions. Sport re-educator is working on these aspects and wants to become a Leader in the Prevention /Health sector. Past Traumas are responsable of our future. The solution to the malaise is often called awareness, is based on sound information and needs balanced actions, aimed at the causes ". Re-educator Sportivo, through a global vision of the individual, plans and manages tailor-made interventions aimed at a Conscious Control of basic vital energies. 86% of diseases and the incidence of mortality in the industrialized countries of this era are mainly attributed to bad habits. Again according to statistical data, we are in the full crisis of the 21st century and the perception of this fact influences negatively markets and people, influencing productivity, well being and health. Even for this reason, even more than in the past, people develop discomfort and undertake incorrect lifestyle that, over time, will turn into Cardiopathies, Strokes, Tumors, Obesity, Rachialgia and other diseases. These disorders are often the consequence of inflammatory processes that become chronic, partly because of a prevention plan that is probably not the real solution to a particular problem. On the basis of this premise, we develop our project to build a portal that can offer an innovative 167 / 880 multidisciplinary service. WE HAVE MATURED GREAT EXPERIENCE on the healthy topic, disorders, prevention and sure on welfare.

168 / 880 Chemifarma

Organisation

Country Italy City Forli' Street Don Eugenio Servadei Web www.chemifarma.it

Person

Name Riccardo Romagnoli President

Organisation Chemifarma S.p.A. is an Italy based VETERINARY pharmaceutical company, with an extended experience in Research Development and Production of veterinary drugs and nutritional supplements Thanks to its strongly integrateded team Chemifarma can supply to its customers high quality standards services, including process R&D, analytical method development, scale-up, validation and commercial scale production. Chemifarma manufacturing capabilities cover many finished dosage forms, including solid, liquid and microencapsulated forms. Chemifarma’s headquarter is located in a strategic position:less than 30 km from Ravenna sea port and less than1 km from the A14 motorway exit. It stretches over a total of 13,500 square meters almost 6300 of wich are covered. Areas of Activity

• Manufacturing & process engineering • Other • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics • Regulatory affairs, validation

Marketplace Opportunities PRODUCT Producers or Researchers of innovative API in the field of nutraceutic and/or pharmaceutical products, suitable for the Veterinary sector Chemifarma is looking for Producers or Researchers of innovative API in the field of nutraceutic and/or pharmaceutical products suitable for the Veterinary sector

169 / 880 SERVICE VETERINARY Contract Manufacturing WHAT WE OFFER: VETERINARY Contract Manufacturing, Pharmaceutical Development services and Stability Test Services Production of oral-solids (soluble powders, premixes for feed), oral liquids (drops, syrups) in several packaging forms, and micro-encapsulated for nutritional supplements. The projects are carefully evaluated together with the customer and analyzed in accordance with the state of the art of regulatory requirements and the value is established for each project step, by granting competitive prices referred to the World veterinary market. PARTNERSHIP Pharma research cooperation suitable for Veterinary Pharma products We are looking for new development in the area of Veterinary Pharma products wich can upscale or improve some product's feature like: better bioavailability, better stability, Long Acting effect, etc.

170 / 880 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd

Organisation

Country China City Shenzhen Street Web https://www.999.com.cn/

Person

Name Jieming Bai Head, Global M&A, Business Development

Organisation China Resources Group is one of the largest conglomerate based in Hong Kong, covering natural resources, infrastructure, commerce and finance sectors, and ranking 86th in Global Fortune 500 in 2017. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR999) is tier 1 Business Unit of China Resources Group.It is founded in 1985, Shenzhen, is a large state-owned listed company with pharmaceutic business in self-diagnosis (OTC and Customer Healthcare) and prescription medicines. Total employees exceed 13,000. Areas of Activity

• Chemicals & APIs • Nutraceutics, probiotics, functional food, • CMO (Contract Manufacturing cosmeceutics Organisation) • Pharmaceutics • CRO (Contract Research Organisation) • Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment and partnership opportunities in pharma China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceutical products. It began to earn its reputation by its leading brands and productions in OTC and Traditional Chinese Medicine, and has expanded the pipeline in most key therapeutic fields by M&A and global cooperation, now owning 22 GMP manufacture bases nationwide, 2 GSP sales centers, 1 international trading company in Hong Kong, and 3 R&D platforms. The main sector of interest for investment is the pharmaceutical industry, considering various investment operations depending on the opportunity (Strategic investment, acquisition, strategic alliance, etc.) 171 / 880 PARTNERSHIP Partnership for developing business in China China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR999) is interested in OTC and prescription drug business in China, and hopes to establish a strategic cooperation on drug registration, sales promotion, R&D, manufacture, and jointly explore the Chinese market. CR999 is confident to be the qualified partner for the following reasons: - Top 1 brand in OTC and TCM areas. The distribution channels covers more than 4000 Grade II and III hospitals, and 30,000 pharmacies nationwide. - Sophisticated marketing ability: professional marketing teams for each major field, and over 10 year relationship with most of national and regional KOLs. - Cooperation Experience: Profound experience in collaboration with cross-boarder partners as well as strong capacities of operating global brands in China.

172 / 880 China Sinopharm International Corporation

Organisation

Country China City Beijing Street

Person

Name Wen Yang Business Manager

Organisation China Sinopharm International Corporation is the wholly-owned subsidiary of Sinopharm. The company shoulders Sinopharm’s strategic mission of developing international pharmaceutical business, and medical and healthcare industry. The main business covers international pharmaceutical trade, overseas pharmaceutical investment, international medical cooperation, and medical and health services. Areas of Activity

• Chemicals & APIs • Nutraceutics, probiotics, functional food, • CMO (Contract Manufacturing cosmeceutics Organisation) • Pharmaceutics • CRO (Contract Research Organisation) • Genetics & Genomics • Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Overseas investments Sinopharm International has been simultaneously developing international trade and overseas investment, and vigorously engaged in the resource optimization of world pharmaceutical, medical and health market. On behalf of Sinopharm, Sinopharm International formed 7 joint ventures with a number of multinational pharmaceutical companies, established close partnerships with more than 100 world famous pharmaceutical companies, medical equipment suppliers and healthcare product manufacturers, and introduced advanced technologies, equipment and quality products into China. “Pharmaceutical business loop” is led by overseas pharmaceutical business, covering project investment, engineering and construction, API supply, pharmaceutical factory operation, etc. “Medical business loop” is headed by overseas medical infrastructure projects, engaging in engineering design, construction, equipment support, professional training, facility maintenance, hospital management and medicine distribution, etc. PARTNERSHIP

173 / 880 Partnerships in pharma/medical sector Sinopharm International develops medical and healthcare related business in both domestic and overseas markets. The company is Sinopharm’s unified medical and healthcare business platform. In China, Sinopharm International has established a 3-tier medical system: national healthcare group, regional hospital management company and local medical institutions, and operate at an industrial level by building centralized medicine and medical equipment procurement center, discipline construction center and operation maintenance center. In the world, Sinopharm International has carried out more than 100 programs between the Chinese government and governments of over 70 countries in foreign aid medical equipment, material supply and medical technological cooperation, receiving great appreciation from local governments and people.

174 / 880 Chino.io - Data Security Platform for Digital Health Innovators

Organisation

Country Italy City Rovereto Street Via S. G. Bosco 27 Web www.chino.io

Person

Name Jovan Stevovic CEO

Organisation Chino.io helps digital health companies toensure compliance with EU/GDPR and US/HIPAA data protection laws by offering them a secure API and Database as a Service. With Chino.io service companies caneasily secure their data and users,ensurecompliance with data protection laws, and reduce drastically development costs andtime to market. Chino.io is a multi-awarded companyborn in 2014. Chino.io won the 1st prize at theEITDigital Challenge on Cyber Security & Privacy and it has been awarded with the Seal of Excellencee by the EU Commission. Currently Chino.io delivers its services to 30+ small and large companies and 13 hospitals in10EU states, and it works also with companies such as BT and TIM on cybersecurity innovation projects. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Regulatory affairs, validation • Software, ICT applications, system integration • EPR, Clinical/healthcare management software

Marketplace Opportunities SERVICE Secure API and Database for health data in compliance with EU/GDPR, national and US/HIPAA regulations Chino.io offers to app developers secure API and Database as a Service to to ensure compliance with EU/GDPR, national and US/HIPAA regulations. With Chino.io services developers can save up to 300K Euro in application development and 1 year of time, ensuring the possibility to deliver their apps globally without legal barriers. Chino.io is FREE for development and it provides startup-friendly pricing plans. 175 / 880 INNOVATIVE ASPECTS AND MAIN ADVANTAGES Chino.io is the only service in the EU that: - offers a secure, reliable, scalable and ready to use backend and database as a Service - helps companies to ensurw compliance with EU, Member States and US/HIPAA data protection laws - reduces drastically development costs and time to market - helps reducing the risks for sensitive data management (criminal law liability). MARKET APPLICATION Any health application or service that stores and manages health data in cloud environments. TYPE OF PARTNER SOUGHT We offer: - our API and Database services - collaborations with software development agencies and consultants on improving each others' offers

176 / 880 Ciaotech/Gruppo PNO

Organisation

Country Italy City Milano Street via Pacini 11 Web http://www.pnoconsultants.it/

Person

Name Marina Dora Tavano Grants & Networking Assistant

Organisation PNO Group (operating in Italy under the CiaoTech brand name) is a private company specialised in Innovation Management and Open Innovation, providing support services to private and public organisations (SMEs and Les, Universities and Research Centers) in Product and Process Innovation, Technology Transfer, IT solutions and support for research and development projects. Headquartered in Italy (Rome, Milan, Bologna and Naples), CiaoTech is made up of a pool of professional engineers with consolidated experience in international working environments. CiaoTech team has strong involvement in R&D and technology transfer activities conducted with highly qualified EU Companies and Research Centres. CiaoTech core business is to support SMEs, industries, Public Administration and research organizations in the definition and implementation of their innovation strategies, through the development of EU and national collaborative R&D projects, the exploitation and dissemination of advanced technologies, the setting up of international technology transfer and open innovation networks and knowledge sharing communities. Thanks to its broad experience in submitting H2020 and other EU funding Programmes applications, CiaoTech improves your chances of success with a complete support in the project proposal preparation and in the project management and compliance. Areas of Activity

• 3D Printing/addictive manufacturing for • Electromedical and medical equipment biomedical applications (non diag) • Analytical and characterization services • Genetics & Genomics • Bioinformatics, Big data analytics • Investments • Biomaterials • Manufacturing & process engineering • Biosensors • Medical research • Biotechnologies (Pharma&Medical • Nutraceutics, probiotics, functional food, Devices) cosmeceutics • Chemicals & APIs • Software, ICT applications, system • Consulting services integration • Diagnostics - Equipment and accessories • Project proposals support services • Diagnostics - Imaging equipment and • Medical devices processing • IT Applications for Health • Drug screening & delivery • eHealth, mHealth, telemedicine

177 / 880 Marketplace Opportunities PROJECT COOPERATION Innovation Management, R&D projects, access to national and European funding opportunities CiaoTech improves your chances of success with a complete support in the project proposal preparation, allowing your resources to focus on the project concept and main technical standpoints, and leaving to our experienced consultants the task of preparing a sound funding proposal. We are looking for valuable and innovative ideas in the fields of Research, Innovation and Technological Development to get funding for your projects. SERVICE H2020, R&D projects, access to national and European funding opportunities, Open Innovation and Innovation Management CiaoTech improves your chances of success with a complete support in the project proposal preparation, allowing your resources to focus on the project concept and main technical standpoints, and leaving to our experienced consultants the task of preparing a sound funding proposal. We are looking for valuable and innovative ideas in the fields of Research, Innovation and Technological Development to get funding for your projects. PARTNERSHIP Innovation Management, R&D projects, access to national and European funding opportunities CiaoTech improves your chances of success with a complete support in the project proposal preparation, allowing your resources to focus on the project concept and main technical standpoints, and leaving to our experienced consultants the task of preparing a sound funding proposal. We are looking for valuable and innovative ideas in the fields of Research, Innovation and Technological Development to get funding for your projects.

178 / 880 CitareTx Investment Partners

Organisation

Country United States City Houston Street 1120 NASA Parkway Suite 600 Web http://www.citaretx.com

Person

Name Jeffery Sheldon CEO, General Partner & Managing Director

Organisation CitareTx Investment Partners is a venture development, investment, and start-up management company concentrated on promising new medical devices. Our investment activities are primarily focused on Class II medical devices for which the United States Food and Drug Administration pre- market notification process (i.e. 510(k)) can be utilized as the means to obtain regulatory clearance and begin commercial sale of product. Areas of Activity

• 3D Printing/addictive manufacturing for • Surgery technologies and applications biomedical applications • Medical devices • Diagnostics IVD • Diagnostics - Equipment and accessories • Electromedical and medical equipment (non diag) • Medical research

Marketplace Opportunities REQUEST Class II Medical Device Investment Opportunities Seeking investment opportunities for Class II Medical Devices that have an FDA 510(k) regulatory pathway. SERVICE Contract Product Development Services We provide contract product development and commercialization services.

179 / 880 Citoxlab group

Organisation

Country France City Evreux Street Web https://www.citoxlab.com/en/

Person

Name Gianpaolo Fogliatto Business Development Manager

Organisation With nine facilities located in France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), the US (Kansas-City), Denmark (Copenhagen) and Hungary (Veszprém, Budapest, Szeged), Citoxlab Group offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies worldwide. Citoxlab carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers. Citoxlab and Atlanbio also offer both preclinical and clinical bioanalysis and biomarker services. AccelLAB provides efficacy and safety studies in medical devices (cardiology, ENT, orthopedics, and regenerative medicine). With Solvo Biotechnology joining the Group, products and services in the field of transporters and DDI are now available. Today, Citoxlab has 1,300 employees working at nine sites with state-of-the-art facilities. Areas of Activity

• CRO (Contract Research Organisation)

Marketplace Opportunities

SERVICE Toxicology and Safety Pharmacology With more than 40 years of experience, Citoxlab provides toxicology and safety pharmacology services to the pharmaceutical, biotechnology, chemical, agrochemical, cosmetics, food and medical devices industries. Our studies meet the highest standards, we invest continually in new equipment to offer you the latest technologies, and our facilities are custom built for efficiency and to ensure animal wellbeing SERVICE ADME/PK ADME is the evaluation of absorption, distribution, metabolism and excretion properties of compounds and their metabolites. We can help you develop ADME testing strategies spanning early stage development, preclinical toxicity and through your clinical trials.

180 / 880 SERVICE Immunology and Biomarkers Citoxlab can help you from early stage development, during your preclinical studies and right through your clinical trials. Several sites in the Citoxlab group offer immunology services and provide industry- leading expertise in the conduct of immunotoxicology evaluations. We offer validated, reproducible methods and robust study data which meet GLP standards and comply with European and international regulations. Our competence and reactivity, allied with state‑of-the-art equipment, enable us to respond promptly. SERVICE Biodistribution for Cell and Gene Theraphy Gene and cell therapy products are at the forefront of modern medicine, and Citoxlab has helped its partners in the preclinical development of many viral, plasmid or cell-based drug products. For each product, detailed biodistribution data are required by regulatory authorities. We combine our extensive experience in toxicology with our expertise in genomics, to offer you advice and robust biodistribution studies which meet the expectations of current authority guidelines. We can use diverse matrices from the whole panel of animal models and development states to investigate a wide range of compounds (vaccines, cells, plasmids, viruses, etc.). With a suitably qualified detection system (qPCR) and genomics-specific necropsy procedures, we are able to detect as little as five copies of gene or cell DNA in any tissue or fluid in any species. Together with our expertise in other areas, such reprotox, we are able to offer complete investigations covering integration, expression, persistence and shedding. SERVICE Preclinical and clinical genomics Leading-edge data analysis technologies enable us to offer you far-reaching studies spanning the constantly evolving field of genomics and miRNA investigation. Whether you are developing a protein, nucleic acid or cell-based therapeutic, Citoxlab can provide full support, from toxicology species justification, through assay development, to final report submission. Quantitative gene expression for biomarker analysis Biodistribution and genomic integration analysis (nucleic acid therapeutics) Whole genome vaccine candidate screening Cell surface antigen identification Disease marker formation with proteome / transcriptome analysis Gene expression profiling Data mining (for integration of adverse effects and risk factors) Bioinformatics (biological function/structure of genes for protein coding in DNA sequences) Metabolic pathway in silico screening

181 / 880 CLINICAL ACCELERATOR

Organisation

Country United Kingdom City London Street Web http://www.clinicalaccelerator.com

Person

Name Nikolai Nikitin DIRECTOR

Organisation Our goal is to accelerate the drug development programs of our biotech clients through early entry into the clinic and fast implementation of clinical studies on economical budgets. We accelerate the entry into the clinic for our customers by mitigating the costly and time-consuming preparation of extensive clinical trial applications. We have options for simple and efficient regulatory approvals in our region of operation (Central and Eastern Europe) which allow the sponsors of our clinical trials to start their clinical projects sooner and with less expense. We accelerate implementation of our clinical trials by ensuring fast and efficient patient enrolment. This is achieved thanks to a combination of good conditions for clinical trials in our region of operation and our dedicated system of patient enrolment and retention support. As specialists in effective and timely patient recruitment, we commit to achieving patient enrolment targets within compact timelines. We accelerate clinical studies of any complexity, including projects in rare patient populations, and routinely rescue stalled projects. Clinical Accelerator helps our clients from North America, Europe and Asia to achieve significant financial savings by slashing start-up costs, controlling the timelines of clinical studies and minimizing the number of investigative sites used for our projects. Areas of Activity

• Biotechnologies (Pharma&Medical • Regulatory affairs, validation Devices) • Life sciences related activities • Consulting services • Vaccines • CRO (Contract Research Organisation) • Medical devices • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities SERVICE

182 / 880 Clinical trial services Clinical trials (Phase I to IV), design and implementation, primarily for international biopharma, biotech and medtech companies. Full range of CRO services. A network of physicians and a patient enrolment organization. Focus on fast and effective patient enrolment. Ensuring compact timelines for clinical studies. Difficult and rescue clinical trials. All main therapeutic areas including rare diseases. Cost- effective clinical trial solutions. Optional risk sharing

183 / 880 ClinOpsHub

Organisation

Country Italy City Mesagne (BR) Street Via Biscosi 8

Person

Name Stefano Lagravinese CEO and Founder

Organisation ClinOpsHub is a companyfully dedicated to Clinical Research training courses and consulting. Since the beginningthe company trained more than 600 people in the Clinical Research field and had 5 pharmaceutical and 2 hospitals as a client. CRAsecrets.com is the brand of the italian community born in 2008 fully dedicated to Clinical Research Professionals in italy. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • CRO (Contract Research Organisation) • Medical research • Pharmaceutics

Marketplace Opportunities PRODUCT Monitoring Clinical Trials Site Selection, Submission to Ethical Committees and Management of Clinical Trials. PRODUCT Clinical Research Academy An online school fully dedicated to Clinical Research. At least 20 webinars each year. A community of professionals willing to improve their skills.

184 / 880 Close to Business

Organisation

Country Italy City Milano Street Web http://www.closetb.com/

Person

Name Valeria Ferrara Attorney

Organisation Close to Business is a targeted consultancy practice, focused on providing legal services to the Life Sciences and Healthcare industries. We offer a highly efficient, flexible and unique service: high-quality legal advice coordinated across a number of jurisdictions to give clients a single, cost effective, consistent and tailored service across the region. Areas of Activity

• CMO (Contract Manufacturing • Life sciences related activities Organisation) • Consulting services • CRO (Contract Research Organisation) • Pharmaceutics

Marketplace Opportunities

SERVICE Legal Counsel - Life Science ClosetoBusiness provides multiple legal services for pharma companies. We will be able to support you in - Drafting and negotiating contracts in connection with pharma business(distribution agreements, supply and manufacturing contracts, license agreements etc) or Research and Development areas (Clinical trial agreements, CRO contracts, partnership agreements) - M&A transactions - Market access and lobbying support throught accreditated itaian agencies; - Due diligence; REFERENCE Having worked as in house General Counsel for many years for a US pharmaceutical company, I have a developed strong knowledge of the pharma business and an ability to negotiate with different partners either in Europe or Middle East. 185 / 880 TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE international partner in Europe and Middle East. Networking with other consultancy companies.

186 / 880 Clust-ER Health (Emilia-Romagna)

Organisation

Country Italy City Bologna Street Web health.clust-er.it

Person

Name Sauro Vicini Cluster Manager

Organisation The Emilia-Romagna’s Clust-ER Health & Wellbeing aims to bring together companies, universities, research centers and regional stakeholders along with the Emilia-Romagna’s S3 Strategy. The Clust-ER Health aims to forge synergies and set up coordinated and stable networks with public-private agglomerations operating in the same sectors at European and International level. The Clust-ER Health covers 4 different Value Chains in the health & life sciences sector: • New Generation Medtech and Prothesics • Regenerative and Restorative Medicine • Pharmaceutical and Omics Sciences • Inclusive Services and Usable Technologies for Healty Living and Active Aging Clust-ER Health objectives are: • Support the development of new diagnostic, therapeutic devices and new drugs maximizing efficacy and improving patient’s quality of life. • Support innovation in industrial processes introducing biofabrication and industrial modernization (4.0) and reducing the time to market of innovative technologies whose cost / effectiveness ratio has been proven. • Promote competitiveness of medical devices companies that are already excellence in the regional industrial sector. • Promote people's health and well-being through healthy and conscious lifestyles. • Increase efficiency and public/private healthcare integration, focusing on de-hospitalization, patient- centric care pathways and individual’s autonomy. • Ensure a continuous industrial innovation, through shared projects between companies, research laboratories, healthcare systems, in order to improve their competitiveness. Areas of Activity

• 3D Printing/addictive manufacturing for • Nutraceutics, probiotics, functional food, biomedical applications cosmeceutics • Bioinformatics, Big data analytics • Pharmaceutics • Biotechnologies (Pharma&Medical • Life sciences related activities

187 / 880 Devices) • Medical devices • Diagnostics - Equipment and accessories • IT Applications for Health • eHealth, mHealth, telemedicine • Genetics & Genomics • Medical research

Marketplace Opportunities PARTNERSHIP Collaboration among Clusters We are a Cluster interested in European and international collaboration for the development of R&D Projects, and collaboration between companies and research organization.

188 / 880 CNR NANO, Istituto di Nanoscienze

Organisation

Country Italy City Modena Street Via G. Campi 213/A Web http://www.nano.cnr.it

Person

Name Giorgia Brancolini researcher

Organisation L'Istituto Nanoscienze è costituito da due centri, NEST-Pisa e S3-Modena. Le attività di ricerca dell'istituto includono - la sintesi e la fabbricazione di nanostrutture e nanodispositivi, - lo studio sperimentale e computazionale-teorico delle loro proprietà e funzionalità e delle loro interfacce, - la loro integrazione in sistemi funzionali complessi. Le conoscenze acquisite vengono utilizzate per elaborare applicazioni multidisciplinari in diversi campi, in particolare energia, nano (bio) tecnologie e nano-medicina. L'Istituto contribuisce anche alla comunicazione e all'educazione nelle nanoscienze. La principale peculiarità dell'Istituto è la presenza di un numero elevato di infrastrutture di ricerca ad alto livello tecnologico e la presenza di una massa critica di attività di ricerca nell'ambito del programma Horizon 2020.

Areas of Activity

• Biomaterials • Project proposals support services • Biosensors • Medical devices • Drug screening & delivery • IT Applications for Health • Medical research • Software, ICT applications, system integration

189 / 880 CNR-IFAC

Organisation

Country Italy City Sesto Fiorentino Street Via Madonna del Piano 10 Web http://bnlab.ifac.cnr.it/

Person

Name Francesca Rossi Researcher

Organisation Francesca Rossi is part of the BioPhotonics and Nanomedicine Lab (BPNLab) at the Institute of Applied Physics (IFAC-CNR) of the CNR in Florence. Our research activities focus on: - preclinical and clinical studies on the use of laser and other optoelectronics devices for minimally invasive surgery (e.g. in ophthalmology, microvascular surgery and dermatology) - development and applications of plasmonic nanoparticles for theranostics - microscopy analysis (e.g. fluorescence, Raman, - multiphoton and photoacoustic) on molecules of biological and medical interest - plasmon-enhanced spectroscopies and sensing (SERS, TERS) - agri-food photonics and biosensing Areas of Activity

• Biomaterials • Laboratory equipment, reagents, software • Biotechnologies (Pharma&Medical • Medical devices Devices) • IT Applications for Health • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing • Life sciences related activities • Surgery technologies and applications

Marketplace Opportunities SERVICE Empowering Photonics through Regional Innovation Strategies in Europe I am the italian scientific coordinator of the H2020 European project EPRISE. EPRISE supports SMEs working in the Photonics Industry to overcome market barriers. Photonics has been selected by the European Commission as one of the key enabling technologies to furthering development in four key market area: medical technologies, pharmaceuticals, agriculture and food. EPRISE has brought nine leading European photonics organisations together to support SMEs working in the photonics industry to overcome the market barriers. Find out more about the EPRISE project. 190 / 880 The project will deliver a series of European roadshow events for the photonics industry, with the aim of providing SMEs with solutions on how to overcome the market barriers and boost collaboration via pre-arranged B2B meetings. PARTNERSHIP BioPhotonics and Nanomedicine Lab - BPNLab As BioPhotonics and Nanomedicine Lab we are interested in partnership with companies and academia about R&D project collaboration in the field of biophotonics. We actively participate in European projcets. We have expertise in laser technology, plasmonic nanoparticles for theranostics, multiphoton and photoacoustic microscopy, plasmon-enhanced spectroscopies and sensing, biosensing. Some examples of projects we are involved in/carried out follow: Nanomedicine: - Laser-assisted nanomedicine for tumor theranostics - Light-sensitive implantable devices for "on demand“ drug release Biophotonic therapy: - Laser-assisted repair of biological tissues - LED technologies for photocoagulation of abrasions and wound healing Biophotonic diagnostics: - Advanced methods in laser biomedical imaging - Nanospectroscopy - Fluorescence wide-field and confocal microscopy localization of polyphenols in plant tissues - Mapping winegrape phenolic maturity by using a fluorescence optical sensor INVESTMENT OPPORTUNITY Laser Assisted Robotic Surgery of the anterior Eye Segment We buid up a prototype as a result of a EU project. The goal was to develop a proof of concept of a robotic platform dedicated to Laser assisted Keratoplasty (cornea transplantation), with the objective to substitute the laser tip currently handled by the ophthalmic surgeon. The solution proposed offers a tool capable to safely assure the “welding” (i.e. an immediate suturing without needle and stitches) of the cornea in a way not possible with other techniques. The system is fully controlled by the surgeon with an on line control of the trajectory of the laser and the temperature of welding, critical to have a safe success of the entire surgical intervention. The system is composed by a robotic arm able to position the end-effector over the eye of the patient. The three microstep motors are able to move the laser along the trajectory. Two cameras, one dedicated to the general vision and the other one devoted to the control of the temperature, together with the general control system based on a visual servoing continuously adjust the trajectory.

191 / 880 CNT Lab srl

Organisation

Country Italy City Fidenza (Parma) Street via Aldo Gramizzi 6 Web http://www.cnt-lab.com/

Person

Name Bruno Cantarelli Director

Organisation Our activity is an emanation of CNT Group with the aim of producing nanometal colloid and antimicrobial formulation.Our competence and experience are at the Group’s service to satisfy every clients’ needs of antimicrobial applications to their industrial sector researching new technological solutions compatible with their buisness.Our laboratory realizes materials for active packaging (bacteriostatic action), surface coatings ( additives for paintings and coating for every kind of surfaces), agricolture (active adjuvants to preserve every kind of crops), pharma and cosmetics; on veterinary and animal husbandry (disinfectants, antiseptic cleaners, veterinary medical devices)We are also specialized in finding solutions for every kind of application of these materials. La nostra attività è emanazione CNT Group per la produzione di nanometalli colloidali e loro formulati antimicrobici.La nostra professionalità ed esperienza è messa al servizio del Gruppo per cercare di soddisfare ogni esigenza sul mercato circa le matrici attive da utilizzare in ogni settore industriale.Il nostro laboratorio realizza le seguenti tipologie di matrici: per imballaggi alimentari (azione batteriostatica); per superfici (antifouling per navi; idropitture antibatteriche e antimuffa; coating per ogni tipo di superfici); per agricoltura (preservanti batteriostatici; antimuffa); per la farmacia (gel, creme, liquidi e emulsioni antibatteriche e batteriostatiche); per la detergenza (antisettico); per la cosmetica (coformulanti antimicrobici); per la veterinaria e la zootecnia (sanificanti, detergenti antisettici, dispositivi medici veterinari)Siamo inoltre specializzati nelle soluzioni tecnologiche sulle varie applicazioni circa le matrici elaborate. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PARTNERSHIP

192 / 880 Nutraceutics for humana and animals We are looking for industrial partners for the production of new line of nutraceuticals for animals.

193 / 880 CNT-Agro srl

Organisation

Country Italy City Fidenza PR Street Via Cardano 32 Web http://www.cnt-agro.com/

Person

Name NATALIA CANTARELLI Director Assistant

Organisation The company, in partnership with CNT LAB, produces products for animal husbandry. Help against mastitis and dermatitis in dairy cows. Sanitation of the environments with alternative methods. The company produces special fertilizers. Areas of Activity

• Other • Medical devices

Marketplace Opportunities PRODUCT Mastercow spray Lavender to reduce the problem of mastitis in dairy cows. PRODUCT Mastercow podalis spray Lavender to reduce the problem of dermatitis in cows PROJECT COOPERATION Salus Thermae (project) We are looking for industrial partners to produce new line of cosmetics for pets. The distribution project at pharmacists is ready. The brand is ready. The sales network is present. Our sales partner: Salus Cutis Italia srl

194 / 880 CO BIK

Organisation

Country Slovenia City Ajdovscina Street Tovarniska cesta 26 Web www.cobik.si

Person

Name Matjaz Peterka CEO

Organisation Centre of excellence for biosensors, instrumentation and process control - COBIK is a non for profit organization established to facilitate innovation and hi-tech entrepreneurship. COBIK’s activities are organized in scientific, education, and investment platform. CO BIK has a strong expertise in the field of biotechnology with the emphasis on biochemical engineering, microbial ecology, bacteriophages, aptamer and sensors technologies. CO BIK’s Managerial-Entrepreneurial Skills Development for Researchers (MBSDr) is an international, highly-intense, training programme targeted at (1) researchers employed by public research institutions and (2) R&D managers employed in high-tech companies. The main aim of the MBSDr program is to develop the managerial and entrepreneurial skills of R&D professionals as individuals, and consequently improve the functioning of their teams and organizations. CO BIK’s COINVEST is a platform where startups from Europe and global venture investors connect and grow together. COINVEST aims to develop a lively innovative ecosystem to help prospective startups obtain necessary assets: capital, access to market, soft skills. COINVEST provides investment readiness training for promising startups and connects them to investors. It organizes successful events for fostering global-minded tech entrepreneurship and investments, such as tech investment conferences and startup cafes. Areas of Activity

• Biosensors • Vaccines • Biotechnologies (Pharma&Medical Devices) • CRO (Contract Research Organisation) • Peptides, proteins & antibodies preparation

Marketplace Opportunities SERVICE Bioprocess development Production and analytics of proteins, nucleic acids, and viruses are complex and require constant 195 / 880 improvements to ensure safe, economic, and regulatory-compliant production. COBIK has substantial expertise in developing upstream and downstream processes for biomolecules and viruses. COBIK team is offering process development for proteins, plasmid DNA, live and inactivated viral vaccines, and virus-like particles. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The main contribution of COBIK is design of technical superior and economic production process that can be scaled up and transferred to GMP facility. In addition LBABio has a capacity to produce smaller amounts of bio-molecules and viruses needed for toxicological and animal trials. MARKET APPLICATION Biomolecules/viruses/ vaccines developing companies. TYPE OF PARTNER SOUGHT (1) Life science/biotech start up companies having process development and manufacturing capacities (2) Large biotech and bio-pharma companies needing troubleshooting services PRODUCT PresSense Nanoparticle characterization is a bottleneck in large biomolecules process development and manufacturing, because conventional methods do not match the data accuracy required for efficient process optimization and method validation. COBIK is developing sensor for nanoparticle analysis. Devise will be applicable in production processes of viral vaccines, viral vectors where fast, accurate, and reliable in-process methods are needed.

196 / 880 Cocomint S.r.l.

Organisation

Country Italy City COLOGNE Street VIA BRESCIA 71

Person

Name Vito Traversa Entrepreneur

Organisation Cocomint S.r.l. was created in June 2017 by Dr. Vito Traversa, nutritionist specialized in physiopathology, kinesiologist and rehabilitation therapist. After many years of experience in the field of nutrition and sport, the founder decided to develop aliments for metabolic disorders, sport, health & well-being as well as next-generation electronic devices for personal use. Areas of Activity

• 3D Printing/addictive manufacturing for biomedical applications • Diagnostics - Equipment and accessories • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PARTNERSHIP Looking for partners interested in further developing an innovative 3D printer

Cocomint is developing a 3D printer with innovative build area, extruder, internal system and modularity. In the medical field, the device could be used for the creation of plastic and polycarbonate prosthetic prototypes. The 3D printer is in a growth and establishment phase. Therefore Cocomint is looking for partners interested in a cooperation during the final development stage, before the patenting and the start of commercialization. PARTNERSHIP Looking for partners interested in further developing (and financing) a monitoring device for physiological parameters

Cocomint is developing an electromedical device aimed at monitoring physiological parameters. After

197 / 880 applying the apparatus on the tissue, it provides values which could be used to evaluate the physical and organic well-being or stress of an individual, in relation to the food consumed or excessive motor activity and much more. The electromedical device automatically downloads the data on the smartphone and makes them available via an app. Within the project “La nutrizione tisanoceutica” (for more details see the product profile), the apparatus is able to support the individual react better to nutrition and physical activity. The electromedical device is in a growth and establishment phase. Therefore Cocomint is looking for partners interested in a cooperation during the final development stage, before the patenting and the start of commercialization. PRODUCT Looking for distributors of aliments for metabolic disorders, sport, health & well-being

Cocomint produces artisanal food aimed at maintaining health and well-being. The founder Dr. Vito Traversa has developed some aliments for those people suffering from metabolic disorders (overweight, diabetes, food intolerances, hypertension, pregnant women, etc.), working in various sport sectors or simply willing to preserve their health and well-being. Raw materials that have scientific feedback, are rich of active ingredients and interact with the DNA (modifying the genomic response) are used to develop these products, which to this day fall under the scope of pastry (cookies, snacks, cupcakes, chocolates, etc.), pasta, beverages and herbal teas in general. Cocomint presents itself on the market with a series of innovative products, different from the usual concept of the bio and non-bio product. Cocomint is looking for partners interested in distributing their new products (registered under the trademark "La nutrizione tisanoceutica").

198 / 880 Collabobeat

Organisation

Country Italy City Fermo Street Via Campania 9 Web http://www.collabobeat.com

Person

Name Floriano Bonfigli Founder & CEO

Organisation Imagine WhatsApp for doctors and patients, in Oncology. In particular, we provide: 1. a proprietary asynchronous messaging technology 2. promoting patient engagement in Oncology, 3. that can be integrated into your Hospital Information System. Areas of Activity

• Bioinformatics, Big data analytics • IT Applications for Health • eHealth, mHealth, telemedicine • Software, ICT applications, system integration • EPR, Clinical/healthcare management software

Marketplace Opportunities PARTNERSHIP Clinical Trials We aim to transform our technology into a digital therapy (DTx), so we are open to discuss partnership leading to experiments and eventually scientific papers.

199 / 880 COMECER SPA

Organisation

Country Italy City Castel Bolognese Street Via Maestri del Lavoro, 90 Web htttp://www.comecer.com

Person

Name Marco Fadda R&D Specialist

Organisation Comecer is a confirmed leader in isolation technology for pharmaceutical, biotech, chemical, and food industry applications. Its portfolio covers various standard products, but also high-quality customised solutions thanks to specific expertise acquired over the years. Continuous technological updating and the particular client requirements contribute to ensuring operator safety and product sterility. Its containment solutions range from isolators that handle highly active principles or excipients to multi-stage isolators for chemical synthesis or laboratory operations. Its asepsis offerings include isolators designed for sterility tests and formulation of sterile drugs, isolators or RABs integrated into filling lines, and dedicated solutions for Regenerative Medicine applications, including the innovative FlexyCult incubation system for Advanced Therapy labs. Comecer products are known and used in hospitals, universities, research centers, pharmaceutical companies and large industrial groups worldwide. More information can be found at www.comecer.com Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Chemicals & APIs • Manufacturing & process engineering • Medical facilities furnishings, equipment, goods

Marketplace Opportunities PRODUCT Isolators (Glove Boxes) for sterile pharma and biological applications Isolators are segregated environments which guarantee sterile environments where different applications can be carried on. In particular their use is suitable for the production of pharmaceutical sterile drugs. Furthermore, COMECER has developed and patented a specific product line dedicated to 200 / 880 Cell Culture, making possible the production of Regenerative Medicine products, avoiding use of expensive and cumbersome cleanrooms

201 / 880 Comftech S.r.l.

Organisation

Country Italy City Monza Street Via Castello 9 Web www.comftech.com

Person

Name Lara Alessia Moltani Amministratore

Organisation ComfTech s.r.l. – Comfortable Technology (www.comftech.com) is an innovative SMEdeveloping and producing sensorized textiles for biosignal monitoring with optimized shape and fit. Its systems are the outcome of the integration of synergic know-how: Biomedical Technologies, in particular for the unobtrusive measurement of physiological parameters, Textiles, with Designer specialized for egarments, Ergonomics and Design for usability, wearability, comfort, and user- friendliness of the system. Company ISO 13485 Areas of Activity

• eHealth, mHealth, telemedicine • Other • Medical devices

Marketplace Opportunities PRODUCT Smart garments and textile electrodes for wearable non invasive monitoring systems Comftech develops monitoring systems for physiological signals based on smart garments embedding textile sensors ( patented) The company produces two systems for newborn monitoring ( CE MEd class IIB) and is open to collaborations for new projects and products INNOVATIVE ASPECTS AND MAIN ADVANTAGES Smart garments can be considered the best platform for embedding sensors in case of continuous monitoring. They are easy to dress and undress, sensors are immediately in the right position, users find them comfortable. Comftech textile sensors, originally developed for NICU, can be embedded in different garments, so they can provide reliable data in many situations. MARKET APPLICATION Markets where comfortable, non-invasive, reliable and continuous monitoring is advisable: elderly monitoring ,corporate (stress and sleep), emergency

202 / 880 Compliance srl

Organisation

Country Italy City Firenze Street Via Vittorio Emanuele II, 16, 16 Web https://www.hu-care.com

Person

Name Giacomo Sebregondi Project manager

Organisation Compliance is a startup developing technological and digital solutions to support clinical trials. Compliance developed Hucare, a specific software to improve and monitor patient adherence during each clinical trial, integrating all the people involved in the trial, patient, caregivers, clinicians. Areas of Activity

• Software, ICT applications, system integration • EPR, Clinical/healthcare management software • IT Applications for Health

Marketplace Opportunities PRODUCT HuCare Trial A specific software made to improve and guide patient compliance during each clinical study. It helps and streamlines the work of researchers by standardizing communications with patients, monitoring the process of the therapies and evaluating their adherence and effects.

203 / 880 Connected Health Now A.p.S.

Organisation

Country Italy City MILANO Street Piazzale Giovanni dalle Bande Nere, 9 Web http://www.ConnectedHealthNow.com

Person

Name Bruno Conte President

Organisation Connected Health Now is a non-profit network, an international competence center to foster and empower the research, aggregation, connection of innovative technologies and methodologies in the future of health. IoT, sensoring, AI, M2M, blockchain, wearable, etc. are just few of the ways we will live health in the future, where all citizens, patients, MDs, hospitals will share together informations. Our aim is to concentrate all efforts around several aspects of digital health, eHealth, mHealth, web people health, patient online communities, to for the largest connected community, borderless like the human being should be. Connected Health Now: Driving the digital transformation of Health Areas of Activity

• 3D Printing/addictive manufacturing for • Nutraceutics, probiotics, functional food, biomedical applications cosmeceutics • Analytical and characterization services • Packaging & labelling • Bioinformatics, Big data analytics • Peptides, proteins & antibodies • Biomaterials preparation • Biosensors • Pharmaceutics • Biotechnologies (Pharma&Medical • Physiotherapy, Orthopaedic technology Devices) • Proteomics, metabolomics, nutrigenomics • Chemicals & APIs • Regulatory affairs, validation • CMO (Contract Manufacturing • Life sciences related activities Organisation) • Software, ICT applications, system • Consulting services integration • CRO (Contract Research Organisation) • EPR, Clinical/healthcare management • Diagnostics IVD software • Diagnostics - Equipment and accessories • Surgery technologies and applications • Diagnostics - Imaging equipment and • Vaccines

204 / 880 processing • Virtual reality applications • Drug screening & delivery • Other • eHealth, mHealth, telemedicine • Laboratory equipment, reagents, software • Electromedical and medical equipment • Project proposals support services (non diag) • Medical devices • Genetics & Genomics • IT Applications for Health • Investments • Manufacturing & process engineering • Medical research • Medical facilities furnishings, equipment, goods

Marketplace Opportunities SERVICE Connections Our main mission is "connecting dots": our scope is to bring territories, including operators, hospitals, clinics, MDs, nurses, research centers, universities, companies, startups, to bring together ideas and to foster innovation at any level, scale it and produce products and services for massive transformation of health using new paradigm and technologies. We started in Milano, but are already connected with the largest institutions worldwide. PARTNERSHIP Let's connect ! We are open ! Our aim is to aggregate to scale. Our touch base will be MIND Milano Innovaton District, where Expo2015 was held, an innovative district where Human Technopole is becoming one of the largest research center worldwide for life sciences. Would you be part of our network? Let's talk PROJECT COOPERATION We may help a lot... Our network is hungry for innovation and we have the top of the researchers for funds and project management in every country of Europe (for now...) and aiming to connect with rest of world. Just ask, we may help you

205 / 880 COOSS Marche

Organisation

Country Italy City Ancona Street Via Saffi 4 Web www.cooss.it

Person

Name Francesca Scocchera EU Projects Area Manager

Organisation COOSS is a health and care services provider. It is a private company (social enterprise) established in 1979; it manages social residential and daily facilities (institutions, sheltered apartments, etc.) as well as home care and assistance intervention to people in need, mostly elderly and disabled people, together with other groups in need of care (minors, migrants, mental illness, etc.). COOSS provides services to about 9.000 users per years (40% are elderly and 40% are disabled). It has a Department of Research and Training experienced in EU Research Projects (Framework Programme - 5th, 6th and 7th; AAL JP; Horizon2020), representing COOSS as End User Organisation (Impact Organisation) and mainly acting in activities like: - end users needs and requirements analysis; - accessibility and usability studies; - pilot and validation; - legal and ethical issues; - business model and exploitation of ICT solution. Areas of Activity

• Analytical and characterization services • IT Applications for Health • eHealth, mHealth, telemedicine • Nutraceutics, probiotics, functional food, cosmeceutics • Project proposals support services

Marketplace Opportunities SERVICE Health social care services provider COOSS as main provider of health social care services in the region Marche is able to engage and implement large-scale pilots and field test of many different ICT-based solutions devoted to the care and wellbeing of older adults and persons with mental and physical disabilities and diseases. The pilot activities that COOSS can implement can be summarized in two different Scenarios: Scenario 1 – Diffused Experimentation: test of solutions within home environments. It is a testing 207 / 880 activity with final users in different social, health and economic conditions and contexts, with the remote support by Call Center. Scenario 2 – Targeted Experimentation: test of solutions within sheltered and protected housing solutions and accommodations, in environments monitored H24 by professional care operators and nurses. In both scenarios COOSS act with mediators between the technological innovation provided by the test and the final users. PROJECT COOPERATION Research and Training Department On 1993, COOSS established its internal Department of Research and Training. The Department designs, develops and manages EU-funded project and training courses within the health, care and social fields of interest. Since 1993 the Department has been working on the social needs of population by inquiry, analysis, development and testing of innovative solutions, through projects co-funded by European, national and regional funds. Within twenty-five years of experience in European projects, it has promoted and joined thematic, structural and cross-border programs, it has developed and strengthened important networks and partnerships both at local, as well as at international level. The Department is composed by experts in economics, psychology and welfare, as well as by technical and communication consultants; they have a qualified background in users’ needs and requirements analysis, testing of innovative solutions and management of multidisciplinary processes. It has joined a significant number of projects, both as coordinator and/or partner, within the main European programs. It can join EU consortia covering several roles and carrying on different kind of actions and activities, according to past experience and acquired know-how: 1) Skills in Research and validation: scenario definition; users’ needs and requirements analysis; impact analysis; definition of functional/non-functional specifications; pilot tests of validation and experimentation; development of ethical codes and protocols; users’ feedback analysis and evaluation. 2) Skills in Business Model design: active participation to forum and fairs; presentation of papers and articles; market research; business model pilot phase; social innovation start-up (AiCare).

208 / 880 Corion Biotech srl

Organisation

Country Italy City Torino Street via Quarello 15/a Web www.corionbiotech.com

Person

Name Carlo Cavallero CEO

Organisation Corion Biotech project originates from over 2 decades of translational research in the fields of human placenta physio-pathology and Preeclampsia by the University of Turin team leaded by Tullia Todros and Alessandro Rolfo, President and CSO of the company. The team, committed to find innovative solutions for severe pregnancy-related disorders, characterized a specific population of Placental Mesenchymal Stromal Cells (hPDMSCs) that possess unique therapeutic abilities beneficial for Preeclampsia and that are able to produce a wide range of human proteins. The most recent outcome of this research is an innovative process to culture placental cells in order to produce human natural proteins. These proteins provide several advantages vs the recombinant DNA molecules currently available on the market. Indeed, Corion Biotech harnesses the natural protein expression abilities of hPDMSCs to produce high quality human proteins. We call these products “Human Natural Proteins”. This process was patented in 2011. Moreover, Corion Biotech technology allowed us to develop in-vitro the therapeutic abilities of hPDMSCs, thus producing a natural molecular cocktails characterized by a potent in-vitro anti- inflammatory action on the preeclamptic placental tissue. We call our treatment strategy “cell therapy without cells”. We conducted an extensive study with our CBChMF11as "proof of concept" using a Preeclampsiaanimal model well recognized by the scientific community. Theoutcomes exceed our best expectations and have been recently. presentedin medical congress Now the project is mature for the next step, a full scale preclinical study to be conducted using a GMP produced cocktail of proteins. For this study we need to follow the regular authorization path for biodrugs. COMPETENCES: the team skills have been sufficient for the project so far, havinga robust backgroundinbiotechnology and in clinical practices. We hired a consultant firm with a specific expertise in pharma regulation and authorization. INNOVATIVE ASPECTS/MAIN ADVANTAGES/BENEFITS: Our approach offers a unique opportunity to treat Preeclampsia, severe human pregnancy-related syndrome affecting over 5% of all pregnancies, thus being the main cause of fetal and maternal mortality and morbidity worldwide. Importantly, Preeclampsia accounts for serious long-term sequelae for both mother and child as neurologic and cardiovascular disorders, diabetes and metabolic syndrome. 209 / 880 Preeclampsia therapy has a major social-economical impactas itprovides substantial savings for the Public Health System during pregnancy as well as for the rest of mother and child life. Our innovative theraputic approach with CB-ChMF-11 has been tested succesfully on animals with the symptoms of this syndome, nevertheless it is expected to beeffective also for the prevention of the syndrome. CB-CHMF-12 induces a rapid encapsulation of the tumor with a dramatic reduction ofmethastasys. After thistreatmentthe constrained tumor can be easily and safely treated with traditional surgery. INTELLECTUAL PROPERTY RIGHTS (IPR): Patent for Preeclampsia treatment granted in EU and pending in USA, Japan, Canada. Patent for Epitelial Tumors Treatment granted in Italy, USA and Japan; pending in: EU, Canada, China, Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Pharmaceutics

Marketplace Opportunities PARTNERSHIP Partnership for preclinical study We are looking for partnership to develop preclinical study in GMP facilities

210 / 880 Covance

Organisation

Country Italy City Rome Street Viale Luca Gaurico 11

Person

Name David Di Marcantonio Senior Business Development Director

Organisation Covance is the drug development business of LabCorp, the world’s leading health care diagnostics company. Together Covance and LabCorp bring clients innovative drug development solutions with unique breadth and depth of capabilities. We generate more safety and efficacy data to support drug approvals than any other company in the world, having completed nearly 200 IND/CTA submissions in the last 5 years alone. We’d like to highlight the following solutions to attendees of Meet in Italy for Life Sciences: Covance MarketPlace: Gain crucial visibility for your molecule during the early phases of development and find the right partner with the desire and resources to help you realize your molecule’s potential. Early Phase Development Solutions: Bridge your journey across key development milestones from the only provider that has the global infrastructure and industry-leading nonclinical, regulatory, clinical and medical expertise and capabilities. Commercial Market Access: We’ll help you transform market data into actionable insights, reveal opportunities to better build product value, improve access, reimbursement and deliver insight, control and predictability to the new realities of contract management. Experts will be on hand at this year’s meeting to discuss how our solutions can help you succeed. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • CRO (Contract Research Organisation) • Drug screening & delivery

Marketplace Opportunities SERVICE Drug Development Services and partnering solutions Covance offers services in any phase of the drug development process, from Lead Optimisation to Market Access. Furthermore we can help emerging biotechs in finding partnerships for their programs. Through our Covance MarketPlace platform, which helps emerging biotechs to showcase their molecule to our Large Pharma clients SUMMARY PRODUCTS/SERVICES/TECHNOLOGIES: We are market leaders in pre-clinical and clinical development, central laboratory, bioanalysis, and

211 / 880 market access areas of drug development, bringing you unmatched expertise, scale, geographic coverage (or footprint) and scientific depth. PARTNERING STRATEGY: Covance MarketPlace is a unique solution to one of the most significant and urgent challenges for an emerging biopharmaceutical company – standing out amid a crowded field of companies trying to sell or license their compound. Covance MarketPlace, provides the right connection and helps you showcase your molecule and company to Covance strategic partners: Enhance your visibility to companies seeking new development candidates Obtain development support from an experienced partner to address your molecule’s unique challenges Advance your development package through our insightful guidance Align your molecule with the Covance reputation for superior quality Stand out from the field: Exclusive network places your candidate in line of sight of interested parties Tailored search capabilities put focus on your molecule’s strategic attributes Direct communication from interested parties accelerates strategic discussions Proven data reliability increases confidence in the quality of your product and its potential To learn more, visit www.covance.com/marketplace CLIENT PORTFOLIO: Covance actively works with more than 500 emerging biopharmaceutical companies globally and has managed more than 1800 unique molecules. At Covance, we’re committed to a client-centric approach when working with emerging biopharmaceutical companies: Team members experienced working with biotechs Therapeutically focused team Program details (timelines & cost estimates) suitable for submission to investors/partners Committed team will stay engaged from proposal to study execution Flexible processes & pricing structures to address needs of biotechs We also work with most of the world’s large and mid-size pharmaceutical companies, many of which we have strategic relationships with, including Eli Lilly, Sanofi and Bayer, among others.

212 / 880 Cozily S.r.l.

Organisation

Country Italy City Milano Street Web https://www.cozily.it

Person

Name Filippo Scarabelli Founder & CEO

Organisation Cozily is an App that delivers affordable, anonymous and secure chat therapy services. It connects willing users to specialists with expertise in life coaching and degrees in human behavior. The welcome is free for 2 days. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health

Marketplace Opportunities INVESTMENT OPPORTUNITY Seeking for a Seed Investment Cozily is looking for a seed investment in order to boost marketing campaigns and hire the necessary resources. PRODUCT Cozily App for iOS & Android Text-therapy is available downloading the Apps on the main stores! PARTNERSHIP Interest in Partnerships Cozily in interested in partnerships that can help its expansion on the italian territory.

213 / 880 CROS NT

Organisation

Country Italy City Verona Street Via Germania 2 Web www.crosnt.com

Person

Name Dario Spiller Account Manager

Organisation CROS NT is a global, data-driven Contract Research Organization (CRO). Founded in 1992 CROS NT enhances clinical trial outcomes and optimizes vendor oversight with data-driven services and solutions. We offer a center of excellence for clinical trial data with a full service capability. Services include clinical data management, biostatistics programming and analysis, medical writing, regulatory consultancy and study startup and management. These services are supported by industry-leading as well as proprietary technologies including data visualization and data integrity, clinical analytics, EDC, eCOA, IVR, eHealth and data anonymization. Areas of Activity

• Bioinformatics, Big data analytics • Other • Biotechnologies (Pharma&Medical • Medical devices Devices) • IT Applications for Health • CRO (Contract Research Organisation) • Pharmaceutics • Life sciences related activities

Marketplace Opportunities PRODUCT DataX - Data Anonymization Tool “The Data Anonymization Tool for Clinical Trials” DataX is a leading Data Anonymization Tool with data-driven support - Providing up to Level 3 data protection with macro tool - Add-on support from industry-leading data experts in biostatistics, data management and medical writing - Support with SDTM and ADaM datasets as CDISC Gold Member - Risk Analysis / Gap Analysis with data experts and technology experts SERVICE

214 / 880 Biostatistics & Programming CROS NT’s biostatistics team has a range of experience, from the planning and design of a trial, to reporting and regulatory submission guidance. It is generally agreed that the best time to involve a biostatistician in a clinical study is at its inception. This allows the biostatistician to support with common biostatistics challenges in clinical research: understanding the study design and making suggestions on hypothesis testing and analysis. - Study Design - Sample Size Calculation - Protocol Writing & Review - Statistical Analysis Plans - Meta Analyses - Integrated Summaries of Safety & Efficacy - Filing & Reporting with Regulatory Authorities Our statistical programming team works closely with the Statistical Methodology Team maintaining a highly qualified group of SAS programmers expert in CDISC standards. CROS NT provides customized programming solutions to meet the unique needs of clients. We have a long history of developing and advancing SAS coding tools for programming reports. These tools allow us to create customized RTF output. The most recent extensions have proven very useful for generating patient profiles. Our staff continues to develop the company’s reporting tools to increase our efficiency. CROS NT is a CDISC Gold Member. SERVICE Clinical Data Management CROS NT’s clinical data management team has extensive knowledge in the management of data generated in Phases I-IV and medical device trials. The team is expert in various data collection, reporting and visualization systems. - CRF Design & Review - Database Design and Validation - Data Management Plan - Data Cleaning - Medical Coding - Data Entry - Study Management and Quality Control - Risk Management Metrics to facilitate Risk-Based Monitoring CROS NT is equally capable of performing data management activities with eCRF or paper CRF. Our Data Management consultants can also provide guidance on the selection of an EDC system based on your study requirements and budget. Our Data Managers have wide-ranging skills covering DATATRAK, Medidata Rave, Oracle InForm, Oracle RDC, Mednet and Symphony EDC. PRODUCT CROScheck™ CROScheck combines leading statistical methodology with an easy-to-follow E6(R2) compliant workflow. It leverages information from Statisticians and Data Managers for the benefit of CRAs by identifying the key risk indicators, pinpointing where to focus monitoring effort, and providing a mechanism to track corrective actions. It offers Sponsors of clinical trials an independent oversight of data coming from sites. Through Centralized Statistical Intelligence, sponsors have complete oversight of the quality of data coming from sites. Its technology uses Principal Component Analysis, assigns a risk score per site, and highlights erroneous data and potential misconduct.

215 / 880 CSEM

Organisation

Country Switzerland City Landquart Street Bahnhofstrasse 1 Web www.csem.ch

Person

Name Samantha Paoletti Business Development Manager

Organisation CSEM is a private Swiss research and technology organization (rTO) with the mission to develop microtechnologies and transfer them to the industrial sector, thereby reinforcing the sector’s competitive advantage. Our customers operate in established markets such as medtech, industrial control (including the machine tools industry), watch-making and aerospace, as well as in emerging markets such as cleantech (including energy production and management) and environmental monitoring (in transportation or agriculture). Under contract to the Swiss Confederation, CSEM develops innovative technology platforms through four strategic programs – microsystems, systems, ultra-low-power integrated systems and surface engineering – corresponding to domains in which it has acquired over the years a national and international reputation. By expanding its knowledge and adapting it to the needs of industry, new products are brought to market and new ventures are created. Approximately 400 people with industrial backgrounds, mostly top level engineers and holders of PhDs, dedicate their passion to this mission. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Medical devices • Diagnostics IVD • Diagnostics - Equipment and accessories • eHealth, mHealth, telemedicine

Marketplace Opportunities SERVICE Biotech-Pharma service: toxicology, pharmacology, diagnostics and assays services The majority of today’s innovative medicines—whether manufactured using biotechnological approaches or via chemical synthesis, as are traditional small-molecule medicines—and many diagnostic products are only available thanks to the application of modern biotechnology in their development and/or manufacturing processes. 216 / 880 CSEM has become increasingly active in the domain of biotech and the life sciences. We use our miniaturization, integration, and microengineering expertise to develop new devices, with a focus on components, tools, and systems for toxicology and pharmacology, and on diagnostics and assays. The toxicological testing of chemicals and cosmetics and the efficacy tests used in the development of new pharmaceuticals all require in vitro, 3-D microenvironments that correspond closely to living tissues. CSEM is developing more authentic, physiologically relevant microenvironments, including co- culture systems, structured surfaces, connected cultures, mechanical stimulation of bone and muscle cells, and cell culture supports. We’re also developing new analytical tools to study the function of living cells and understand how they are affected by toxins. We’re looking closely at the development of microfluidics devices that can finely control fluids in both time and space. Such control enables the precise production of biocompatible tools such as microbeads for cell culture in bioreactors and can be adjusted to handle various polymers and address a variety of needs. Besides being able to mimic certain biological functions, we also need to be able to monitor biological parameters on different scales. Electrochemical sensors can be adapted to fit these requirements. Reliable handling and pre-treatment of samples and reagents is a key requirement in applications such as drug development, diagnostics, and food and water quality monitoring. The trend toward smaller volumes and highly integrated sample pre-treatment calls for new approaches to dealing with the highly precise dosing of liquids and the integration of elements for filtration or the concentration of analytes. SERVICE Development of healthcare monitoring (wearable) devices The ongoing digital revolution and efficient, pioneering medical-device technologies offer patients and doctors new solutions that increase the standard of care and reduce costs. Thanks to CSEM’s industrial heritage—particularly from the watchmaking and microtechnology industries—we have acquired decades of knowledge in the areas of precision mechanics, sensors, and electronics. CSEM’s medical- device technology research activities are paving the way for a new era of digital, personalized healthcare in domains such as sensors, implants, hearing aids, diagnostic tools, and laboratory instruments. The current focus on prevention, public health, patient empowerment, and out-of-hospital care is transforming the entire healthcare sector. More and more people have started using wearables to track their physical activity, sleep patterns, and calorie consumption, and the trend is toward digital, personalized healthcare. Our research activities on multi-signal ambulatory monitoring are driving global innovations and helping open up new applications in the fields of telemedicine, rehabilitation and home care—in particular for the elderly, and sport, as well as in health promotion and security. Our innovative technologies allow patients to be inconspicuously monitored as they go about their daily business, including when working or sleeping. And systems that offer more comprehensive information will also open the way to a whole range of clinical and physiological studies in real conditions. Finally, our technologies will give doctors, insurers, and rescue teams more information related to occupational medicine, including on how the body reacts to working in harsh environments. Compared to even state-of-the-art medical monitoring systems, CSEM’s sensor technologies simultaneously offer better ergonomics, higher information content, lower cost, higher autonomy, and better signal quality. Our solutions allow comprehensive measurement of physiological signals during daily activities—including while sleeping—and are thus ideal, for example, for outpatients who suffer from pathologies such as lung or heart diseases. They are also excellent for managing comorbidities, because the same sensors can simultaneously measure biopotential (e.g., ECG or EMG), impedance (e.g., EIT, respiration, GSR, hydration, or fat), skin temperature and heat flux, SpO2, sound (e.g., coughing, wheezing, or snoring), and kinetics (e.g., physical activity and activity classification). CSEM‘s innovative tools for managing pathologies have the potential not only to reduce costs, but also to improve the lives of patients and their caregivers. CSEM has successfully transferred these and other technologies to industry in the fields of portable

217 / 880 human vital sign monitoring systems, point-of-care systems for multi-parameter biochemical monitoring or miniaturized sensing, processing, packaging, and wireless communication technologies to serve the needs of a non-invasive and mobile healthcare service.

218 / 880 Cyanagen

Organisation

Country Italy City Bologna Street Web http://www.cyanagen.com

Person

Name Manuela Vargiolu Bio-Applications Dept Manager

Organisation Cyanagen Srl is a biotech company located in Bologna, dedicated to research, development and production of reagents for molecular biology since 2003. Currently Cyanagen is one of the leading companies in the field of reagents for Western blotting and ELISA. The main product lines are focused on chemiluminescence and fluorescent dyes for biological analysis, genomics, proteomics and chemical sensors. Our products are based on Cyanagen internationally patented technologies and achieve outstanding performance in terms of sensitivity and stability. These products are also available as OEM. Furthermore, Cyanagen offers: •Customized research and development programs in the diagnostics and bioanalytical fields; •Chemical synthesis according to client’s specifications; •National and international collaborations for applications to research calls. Areas of Activity

• Peptides, proteins & antibodies preparation • Laboratory equipment, reagents, software

Marketplace Opportunities SERVICE Design and synthesis of new dyes for biological applications and immunoassays The company is highly experienced in the design and sinthesis of organic dyes as sensors for biological applications and immunoassays. A full range from 400 nm to 800 nm is available in the Cyanagen's portfolio of products. Furthermore, the company offers the service of customized design and synthesis of new dyes based on the client's specifics. The in-depht collaboration between chemical and biological teams allows for a 360-degree point of view of new technologies in the field of diagnostics and molecular biology. Among the full range spectra of dyes, the NIR dyes represent a very interesting and promising class. 219 / 880 These dyes offer different advantages including minimal interfering absorption and fluorescence from biological samples, reduced scattering and enhanced tissue penetration depth. Due to these aspects, they are being more often the choice dyes for applications in biomedical, materials and related fields. The use of NIR dyes in immunoassays allows a fast, reproducible and quantitative detection of the analyte. Furthermore, their use in POCT (Point of Care Test) could afford a high quality and cost affordable test with a huge and fast potential market penetration.

220 / 880 DAIMON Team - Consiglio Nazionale delle Ricerche

Organisation

Country Italy City Bologna Street

Person

Name Francesco Mercuri Senior Researcher

Organisation Health, advanced manufacturing, environment, energy. These words describe some of the grand challenges for the next future. We believe that new simulation and virtualization technologies, from large-scale computing to artificial intelligence, have the potential to unravel the complexity posed by these global challenges. The activity of the DAIMON R&D Team is focused on the development, implementation and application of advanced simulation environments for the predictive modelling of complex systems. We rely on a variety of methodologies, including multi-scale concepts, integrating different simulation techniques. Our approach is particularly relevant in fields of application where the properties of a system at a smaller scale impact strongly on the behavior at a macro-scale, as for example in nanotechnology. Areas of Activity

• 3D Printing/addictive manufacturing for • Software, ICT applications, system biomedical applications integration • Bioinformatics, Big data analytics • Virtual reality applications • Biomaterials • Other • Biosensors • Laboratory equipment, reagents, software • Biotechnologies (Pharma&Medical • Project proposals support services Devices) • Medical devices • Consulting services • IT Applications for Health • CRO (Contract Research Organisation) • Manufacturing & process engineering • Life sciences related activities

Marketplace Opportunities PRODUCT Modelling of materials, processes and devices Advanced modelling sw/hw infrastructure for the simulation of complex systems in application fields

222 / 880 ranging from manufacturing to health and energy SERVICE Modelling of materials, processes and devices Advanced platform and modelling environment for the multi-scale simulation of complex systems in several application fields, including manufacturing, energy, healthcare, etc. PARTNERSHIP Multi-scale modelling Our expertise in the multi-scale simulation of complex systems, focusing on materials, processes and devices, enables the development of predictive models in several fields of both basic and applied research PROJECT COOPERATION Multi-scale modelling of materials, processes and devices We are always interested in possible new collaborations. We already take part in several collaborative projects, at the national and international level. Our expertise in the multi-scale simulation of complex systems, focusing on materials, processes and devices, enables the development of predictive models in several fields of both basic and applied research.

223 / 880 DataRiver Srl

Organisation

Country Italy City Modena Street Via Emilia Est 985 interno 2 Web www.datariver.it

Person

Name Marco Silvio Monari Business Development and Sales and Marketing Area

Organisation DataRiver is a Contract Research Organization founded in 2009 asa Spin-Off of the University of Modena and Reggio Emilia. DataRiver offers software solutions for clinical trials design and development, pathology registry management, elaboration of clinical data surveys and statistics compliant with sensitive data security and confidentiality requirements, including the development of mobile Apps for physical data capture and management on mobile and wearable devices, that are able to interface and exchange information with clinical data management systems. DataRiver provides innovative services and consultancy in the field of Clinical Data Management, Data Integration, Business Intelligence and Semantic Web. DataRiver was awarded for the 2016-2017 edition of the Italian Award for Digital Innovation in Healthcare with the project "My Smart Age with HIV", an innovative mobile and IoMT platform designed and developed in collaboration with the Metabolic Clinic of the University of Modena and Reggio Emilia. The company is accredited as Research and Innovation Structure of the High Technology Network of the Emilia Romagna Region and is a member of the executive committee of the Regional Clust-ER Steering Committee on "Health and Wellbeing Industries" involving Universities, Research Laboratories and Pharmaceutical Companies. Areas of Activity

• Bioinformatics, Big data analytics • Software, ICT applications, system • CRO (Contract Research Organisation) integration • eHealth, mHealth, telemedicine • EPR, Clinical/healthcare management • Medical research software • Nutraceutics, probiotics, functional food, • Medical devices cosmeceutics • IT Applications for Health • Pharmaceutics

Marketplace Opportunities PRODUCT

224 / 880 MyHealth: an innovative mobile platform for patient’s empowerment MyHealth Platform is an innovative Web and smartphone App designed and developed to extend the traditional healthcare infrastructure, providing patient monitoring and support outside the hospitals. MyHealth is able to integrate in a single platform data collected from wearable devices, questionnaire collected through a smartphone App and data stored in Electronic Health Records (EHR). It allows the analysis of the collected data, and provide real-time insights of patient’s health status. Health coaches can monitor the patient’s care path and establish a direct communication channel through an integrated secure chat system. Physicians are enabled with a continuous patient monitoring system to measure the response to illness and the life quality improvement. Patients have an up to date insight of their health conditions and a constant support via a direct communication with the health coaches. MyHealth Platform have been successfully applied to international clinical trials and in several therapeutics area: Oncology, Cardiology, Infectious diseases, Neurology and Endocrinology. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The MyHealth Platform is designed to extend the traditional healthcare, ensuring many advantages in patient monitoring and empowerment: • Collection of patient’s data from multiple and heterogenous devices • Continuous patient monitoring, leveraging data from wearable and mobile devices • Integration, analysis and real-time insights of the collected data • Health coach support to establish a direct communication channel with patients through an integrated secure chat system • Patient’s empowerment and quality of life improvement, through statistics on health status and progress indicators and tips for a better lifestyle displayed directly on user’s smartphone MARKET APPLICATION Healthcare My Health platform can be used for patient monitoring and empowerment in several therapeutics area, especially in Oncology, Cardiology, Infectious diseases, Neurology and Endocrinology. Stakeholders are: Pharma, CRO, Research Institution, Hospital TYPE OF PARTNER SOUGHT Research institution for coooperation in m-health research projects sponsored by pharmaceutical industries and public institutions PRODUCT My Health Platform The Internet of Medical Things (IoMT) Platform "MyHealth" allows a unified and complete view of patient information, integrating the data collected through: - wearable devices wear by patients for collecting physical activity data - medical devices for the collection of physiological parameters - App for managing patient questionnaires via smartphone - Database for the collection of clinical data and software for eCRF

225 / 880 Day One

Organisation

Country Italy City Roma Street Viale dell'Oceano Atlantico, 18 Web http://www.day-one.biz/

Person

Name Francesca Petrucci Innovation Manager

Organisation Day One is an Open Innovation Lab for researchers and high tech startups. We work together with innovators coming from all European Universities and Research Centers. Areas of Activity

• 3D Printing/addictive manufacturing for • Manufacturing & process engineering biomedical applications • Medical research • Analytical and characterization services • Nutraceutics, probiotics, functional food, • Bioinformatics, Big data analytics cosmeceutics • Biomaterials • Packaging & labelling • Biosensors • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation Devices) • Pharmaceutics • Chemicals & APIs • Physiotherapy, Orthopaedic technology • CMO (Contract Manufacturing • Proteomics, metabolomics, nutrigenomics Organisation) • Life sciences related activities • CRO (Contract Research Organisation) • Software, ICT applications, system • Diagnostics IVD integration • Diagnostics - Equipment and accessories • Surgery technologies and applications • Diagnostics - Imaging equipment and • Vaccines processing • Other • Drug screening & delivery • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Electromedical and medical equipment (non diag) • Genetics & Genomics • Investments

Marketplace Opportunities SERVICE

226 / 880 We team up with researchers and startuppers to develop and commercialise disruptive products We support high tech start-ups who are in need of funding to complete their product development and go-to-market strategy. We operate with several private and public funding sources (mostly Venture Capital firms and Horizon 2020 funds).

227 / 880 DE.TEC.TOR. SRL

Organisation

Country Italy City Torino Street Web http://www.detector-group.com

Person

Name Giuseppe Pitta' President & CEO

Organisation Resulting from years of research experience in particle physics, our company was founded in 2009, as a Turin University spin-off company, with the aim of industrializing detectors for particle-therapy, an advanced radiation technique for inoperable and radio-resistant tumours. We are specialized in the design and manufacturing of high-performance medical devices, for the monitoring and verification of therapeutic particle beams both during patient treatment and daily quality control of the particle accelerator. During these years we had the opportunity to carry out various research projects, enhancing our scientific, engineering and management expertises. Nowadays we offer particle physics solutions for different applications (medical devices, agrifood, enviroment, childcare industry, cultural heritage, automotive industry) to help our Customers improving their manufacturing processes and clinical procedures. Areas of Activity

• Medical devices

228 / 880 Denosens Biotechnology Drug Chemistry R&D LTD.

Organisation

Country Turkey City izmir Street teknopark ege 172/70H Bornova

Person

Name Z. Onur Uygun, MSc. CEO

Organisation Denosens is a start up that develops point of care diagnostic devices. Areas of Activity

• 3D Printing/addictive manufacturing for • Diagnostics IVD biomedical applications • Medical devices • Analytical and characterization services • Biosensors • Biotechnologies (Pharma&Medical Devices)

229 / 880 Dept. of Neurorehabilitation Sciences, casa di Cure del Policlinico (CCP)

Organisation

Country Italy City Milano Street Via G. Dezza, 48 Web https://www.ccoodezza.it

Person

Name Valentina Brunati Research Project Officer

Organisation Casa di Cura del Policlinico (CCP) is a fully integrated multi-specialty clinical centre aiming at providing both inpatient and outpatient services mainly directed to neurological patients. The Centre is a Department of Neurorehabilitation Sciences, accredited by the Italian National Health System, and economically supported by Regione Lombardia. The Scientific Director, Dr Massimo Corbo, neurologist raised the clinical interest in Neurodegenerative Diseases at CCP, focusing on dementia disorders. As supervisor, he is involved in coordinating and monitoring researcher’s activities; he manages stakeholders’ and research network The Centre draws together the expertise of a large team of specialists, e aimed to cover needs of patients with neurological disorders, including clinicians (neurologists, physiatrists, pulmonologists, cardiologists, phoniatrists), psychologists, biologist, bioengineer, motor and occupational therapists, speech therapist, dieticians, and clinical nurse specialists. Research is mainly dedicated to the Neurological Sciences, the Neurorehabilitation Sciences and to Quality of Life. CCP is partner in national and international consortiums for innovative research, both clinical and technological, applied to neurorehabilitation and frailty conditions in aging. The active collaboration in European projects during the last years led CCP achieve national and community funding, e.g. PhDITalent Program (Fondazione CRUI), Ricerca Finalizzata (Italian Health Ministry), MSCA (H2020), Health Demographic Change and Wellbeing (H2020) and AAL Program The organization is improving ICT enabled projects with industrial partners in order to extend the range of services aimed to an effective continuity of care. Research activities are pursuing in the direction of personalized rehabilitation programs. AAL and cognitive technologies, like body and environmental sensors, cameras, mobile apps (e.g. serious gaming), brain computer interface and even robotics will support this process in monitoring behavioural profiles and physical activities in aging. Virtual Coaching System for rehabilitation in elderly is one of the focus in international research (https://vcare-project.eu/) 230 / 880 CCP is providing an ideal setting for promoting translational research in Neuroregenerative Diseases in order to facilitate the rapid transfer of research knowledge to the clinical environment CCP is collecting biological samples from neurological patients who belong to the structure, thanks to the activation of the internal BioBank. This choice is in line with the efforts of the international scientific community aiming at identifying the genetic and biochemical markers of neurological diseases. It can thus provide a further significant contribution to medical research in the interest of its own assisted and of all the patients suffering neurological disorders The effort is not limited to the clinical expression, but also based on biomolecular and morpho- functional characterization, linked to neuro imaging studies, with attention to the characterization of neurological diseases, on the neuro-degenerative and stroke side. CCP enabled the collection of biological samples from patients with various diseases, such as ALS, PD, peripheral neuropathies, multiple sclerosis, cerebral stroke and AD , banking plasma, PBMCs, serum, DNA and blood The Centre is actively involved in a clinical and preclinical research program into neurodegenerative diseases, including biomarker analysis and genetic studies as well as innovative new therapies for affected patients. Research efforts include biomarker analysis and genetic studies, as the application of innovative new therapies in neurodegenerative patients. It is a national recognized neurological Centre for pharmacological trials and for patients with neurodegenerative diseases and different brain-lesions It is a member of the Presidium of the Lombardy Regional Network for Rare Diseases. The Centre is actively collaborating with the EIP-AHA, a pilot initiative launched by the EC to foster innovation in the field of active and healthy ageing. CCP became member of the Action Group A2 “Personalized health management and prevention of falls” https://ec.europa.eu/eip/ageing/ commitments-tracker/a2/preventing-secondary-injurious-falls_en Backgrounds' studies dealing with: -Impact of specific cognitive disabilities on the motor and functional short term and long- term recovery of post-acute stroke -brain and cognitive dynamics of multiple-object processing in normal aging, MCI and AD -virtual reality in the rehabilitation of upper limbs’ movement disorders -effects on short-term and long-term recovery of different cognitive impairments on elderly patients after hip fracture -improvement of episodic memory in elderly individuals with MCI through non-invasive electrical stimulation (tDCS), on the basis of MRI exams and in relation to some of their genes associated with memory Areas of Activity

• Medical research • IT Applications for Health • Life sciences related activities • Virtual reality applications • Medical devices

Marketplace Opportunities PARTNERSHIP Rehabilitation technology assessment for market access- User requirements analysis and clinical trials The main objective of our clinical interventions pertains to the rehabilitation of patients with different types of brain-lesions, for instance those lesions due to acute events such as cerebral stroke or traumatic brain injury. Stroke rehabilitation may include some or all of the following activities: strengthening motor skills, mobility training, range of motion therapy, neuropsychological evaluation and cognitive rehabilitation, therapy for language and communication disorders, electrical stimulation, and virtual reality. Rehabilitation programs also address to subjects requiring high complexity assistance.

231 / 880 CCP could provide conditions and facilities where clinical investigations of medical devices could be performed, in terms of multidisciplinary competencies, equipment, wide spaces and laboratories. The pilot could be guested in the Neurorehabilitation Sciences Department in order to clinically validate rehab technologies for personalized and innovative therapies. In the clinic we offer high intensity rehabilitation programmes for a period between 2 and 6 months, post-acute. In the basement of this structure are located equipment and spaces dedicated to the rehabilitation activities: -rehabilitation Technogym - house/ living environment simulation - warm swimming pool for hydrokinesistherapy -Occupational Therapy laboratory, including a complete housing setting Moreover, the Centre refers to internal Radiology (including CT scan and MRI) and Laboratory services for biological analysis. Within this infrastructure will be set up a Living Lab that will support the rehab activities. Project use cases will be extended also to the home activities that represent an extension of actual services. FUNDING PROGRAMME AND REFERENCE Different and various are the actual research activities, which constitute interesting backgrounds to proposal participation, as the studies dealing with: - Impact of specific cognitive disabilities (i.e. aphasia, executive function deficits, neglect, and memory loss) on the motor and functional short term and long-term recovery of post-acute stroke patients - brain and cognitive dynamics of multiple- object processing in normal aging, MCI and Alzheimer disease - virtual reality in the rehabilitation of upper limbs’ movement disorders” - effects on short-term and long-term recovery of different cognitive impairments on elderly patients after hip fracture” - VHP multi-scale computer modelling with clinical application in the neurological domain - AAL solutions based on open platforms - Biobanking analytical tools TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE Innovative SMEs, Research Centres, Universities, willing to perform a multicenter clinical trial, in order to show scientific evidences of their solutions. Facilities to access to the Italian market could be added according to a specific exploitation plan, to be drafted taking in case the relationship facilities that CCP could provide, through the access to the national Life Science Cluster and to the neurological rehabilitation network. PARTNERSHIP Neurological biological profiling enabled by internal Biobank CCP is strongly interested and active in the study of neurodegeneration with the absolute need to identify the genetic and biological markers (biomarkers) for the neurological diseases treated into the clinic. In light of the foregoing and its mission of translational and clinical research, CCP is collecting biological samples related to the diseases suffered the people who belong to the structure in order to provide a further significant contribution to medical research in the interest of its assisted and, by far, of all the patients suffering from neurological disorders. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The Innovative aspects we can express are the following: • Promote basic scientific research for the detection of etiopathogenetic mechanisms related to specific diseases; • Promote the collection of samples belonging to individuals / populations with peculiar characteristics for which it can be assumed a particular genetic predisposition or susceptibility to environmental factors to a greater risk to certain diseases; • Make available for clinical pharmacology (pharmacogenetics to farmacoproteomica) samples for the study of nucleotide and amino acid sequence variants associated with different responses to drug

232 / 880 therapy; • Offer a service to biomedical research for the development of research lines intra and inter- institutional national and international. MARKET APPLICATION Among the scenarios with high clinical impact in which the biomarker would be particularly useful in characterizing the expression of disease, we are left to put an early diagnosis and / or pre- symptomatic, to follow the progression of the disease and to determine the prognosis. The purpose is to identify new predictive biomarkers, Diagnostic and / or Prognostic, potentially transferable in the clinical field, not only in the field of laboratory diagnostics, but also for innovative treatments such as the "targeted therapy". TYPE OF PARTNER SOUGHT Universities and Research Centres aiming to design & test novel more personalized interventions & patient-centred therapies for neurological chronic diseases. Clinical centres networking to extend cohorts in neurological diseases and integrating their own biobanks. Companies providing services for analysing genomic data.

233 / 880 Dermolex Ltd.

Organisation

Country Hungary City Budapest Street Pf. 41. Web http://www.dermolex.hu/en

Person

Name Péter Joó managing director

Organisation Dermolex Ltd. has a special anti-decubitus skin regenerating gel which provides effective care for permanently bedridden patients independent of age and is a useful help in both hospital and home care. We are looking for distributors both in and out of Europe. Dermolex skin regenerating gel is simple, cheap and wounds can be avoided with a few minutes of treatment for less than EUR 1 cost a day. The brand is on the Hungarian market supported by pharmacy-focused wholesale partners, home care providers and webshops.The product complies with Regulation (EC) No 1223/2009 on cosmetic products. Areas of Activity

• Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PRODUCT Dermolex skin regenerating gel The aging of the society is a growing problem worldwide therefore caring for immobilized, elderly family members has become an everyday task for the families. However not only the elderly people are concerned but who can suffer an unexpected accident or become bedridden for an extended period of time, therefore dermolex gel can help with preventing the symptoms of decubitus regardless of their age group. Dermolex skin regenerating gel was studied and evaluated by the Department of Dermatology and Allergology of the Medical and Pharmaceutical Centre of the Faculty of Medicine, Szeged University. The investigators concluded that dermolex gel was a useful complement to the therapy of bedsore (decubitus ulcer).

234 / 880 DI.V.A.L. TOSCANA S.R.L.

Organisation

Country Italy City SESTO FIORENTINO (FI) Street VIA MADONNA DEL PIANO 6 Web www.divalsrl.com

Person

Name Matteo Stefanini Associate

Organisation DI.V.A.L. TOSCANA is a contract research organization (CRO), based in Florence, Italy, offering a wide range of preclinical servicesfor early drug discovery andpreclinical developmentin Oncology and other human diseases. In addition to well-established research services, our highly-qualifiedscientific team can designspecific study setups for testing new drug candidates, in orderto make our customers' drug development processfaster and more predictive at affordable prices. With over twentyyears of experienceinantibody production services, we are the right partner for tailor- made solutionsto researchprojects of any size.Focused on our customers' needs, we ensurean intensive collaboration for tailored solutions. - Preclinical in-vitro and in-vivo services: We adopt an integrated approach for thesafety pharmacology assessment ofcancerdiseases,ranging fromin vitrocell culture assays toin vivomodels. We provide a wide range of services, fully customizable, following our customer needs.A broad range ofin vitroservicesfor screening,efficacy evaluation and preliminary assessement of safety of new drugs and formulations. A key area of our expertise is represented by in vitro electrophysiology studies (Cardiac Safetyand High throughput automated Patch Clamp). Custom-tailored assay services can be designed by using ourcomprehensive experience in the field of cancer. We have a long term experience with in vivostudies, starting fromthe most common animalmodels, e.g. subcutaneous, intravenous and orthotopictobioluminescenceand fluorescence read-out modelsfor testing the efficacy of novel therapeutic agents on primary tumors in animals. In addition to oncological models, custom-tailored study protocolscovering a wide range of diseasescan be designed. - Dynamic optical imaging system We provide the opportunity to perform longitudinal studies of the same animal, minimizing experimental variability and number of animals per study. 235 / 880 ThePhotonIMAGER™is a modular system for the non-invasive detection, localization and quantification of dynamic optical signal from live animals. A unique photon counting technology makes it extremely sensitive from the very start of image acquisition and enables the unparalleled kinetic recording of dynamic processes without the need for setting acquisition time, or pixel binning prior to imaging. DI.V.A.L. TOSCANAoffers different kinds of imaging analysis, so you can adapt your choice to your needs. - Antibody production Our research antibodies andcustom antibody developmentservices help scientists andlab techniciansto optimize their research experiencewith reducedcosts. Ourexperienced staffcanassistyou with any aspect of your custom antibody developmentproject. YOUR ADVANTAGES: • tailor made services; customized to our customers’ needs • responsive, timely and professional delivery of results including presentation & interpretation • state-of-the-art technology, methods and equipment • experienced and knowledgeable staff Areas of Activity

• Biomaterials • Nutraceutics, probiotics, functional food, • Biosensors cosmeceutics • Biotechnologies (Pharma&Medical • Peptides, proteins & antibodies Devices) preparation • Consulting services • Pharmaceutics • CRO (Contract Research Organisation) • Proteomics, metabolomics, nutrigenomics • Diagnostics - Imaging equipment and • Life sciences related activities processing • Project proposals support services • Drug screening & delivery • Medical devices • Genetics & Genomics • Medical research

Marketplace Opportunities SERVICE Preclinical service and cardiac safety assessment A broad range of in vitro services for screening, efficacy evaluation and preliminary assessement of safety of new drugs and formulations; a key area of our expertise is represented by in vitro electrophysiology studies (Cardiac Safety and High throughput automated Patch Clamp). - Cardiac Safety-hERG test - in vitro toxicology - Immunology - Molecular biology - Drug delivery - Genotoxicity - Cellular assay services - Biochemistry We also have a long term experience with in vivo studies, starting from the most common animal models, e.g. subcutaneous, intravenous and orthotopic to bioluminescence and fluorescence read-out models for testing the efficacy of novel therapeutic agents on primary tumors in animals. In addition to oncological models, custom-tailored study protocols covering a wide range of diseases can be designed. - Toxicology - Animal models - Custom models/services

236 / 880 - in vivo laboratory support PRODUCT Engineered antibody and customized nanoparticles - We can produce polyclonal/monoclonal customized antibodies and we can develop engineered antibodies following your research needs. - DI.V.A.L. TOSCANA is able to develop tools against difficult antigenic targets such as: low expression proteins/non-protein antigens/phosphorylation sites/low antigenic potential molecules - Thanks to the strong partnership with Colorobbia S.p.A., our company can produce engineered/ functionalized nanoparticles in order to satisfy any customer need. - DI.V.A.L. Toscana patented ion channel transporters antibodies are commercially available PROJECT COOPERATION Constantly engaged in research opportunities DI.V.A.L. Toscana has many years of experience as partner in national/international research projects, such as: IPERNANO(IT); DESIRE (EU); RAPIDPHARMA (EU); OMITERC (IT); PAIN-NET (EU). We are glad to offer our experience (as PMI or external subcontractor) participating as a partner in research/translational projects. INVESTMENT OPPORTUNITY GLP qualification of cardiac safety preclinical tests for pharmaceutical companies A key area of our expertise is represented by in vitro electrophysiology studies (hERG test and High throughput automated Patch Clamp). Since the cardiac safety studies are mandatory in the preclinical studies for a new drug development, our years of experience in this field could be a great opportunity for creating a GLP compliant services for the cardiac safety assessment. Considering the lack of this kind of services in Italy, we are searching for potential investors who can create with us a national service provider, in order to limit the cost of this tests.

237 / 880 Diamond Biofund

Organisation

Country Taiwan City Taipei Street Web http://www.diamondbiofund.com/en/

Person

Name Yen Chen Huang VP

Organisation Diamond BioFund is the largest fund dedicated to biotechnology innovation, managing assets worth over 260 million USD. We are also the first evergreen fund in Taiwan, assisting our venture partners to grow continuously. With renowned shareholders including a Fortune 500 enterprise and major financial holding companies in Taiwan, Diamond BioFund is led by an experienced management team with professionals from various backgrounds such as biotech, financial services and academia, supporting our venture partners with practical knowledge in development and management. Driven by innovation excellence and operation efficiency, Diamond BioFund is committed to become the leading biotech venture fund in Taiwan and the global community. Areas of Activity

• Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity in healthcare, biotech, medical devices, pharma Diamond BioFund currently focuses on healthcare and biotech related industry, including new drugs development, medical devices, health supplements, diagnostics, healthcare retailing channels, and innovative healthcare services. Our investment targets early stage innovative technology with global cutting edge impact. Leveraging the boom in China's healthcare market, we also target valuable assets in the Greater China region.

238 / 880 Dianax Srl

Organisation

Country Italy City MILAN Street Viale Ortles 22-4 Web https://www.dianax.eu

Person

Name Andrea Zanella CEO

Organisation Dianax is making point of need testing a reality. Our revolutionary ‘lab-on-a-chip’* puts diagnostics in the palm of your hand - literally - by working in synergy with your smartphone, taking diagnostics straight to the POINT OF NEED for the first time ever. Patients and physicians can KNOW NOW. •Patients NEED easy ways to monitor their health ‘on the go’, empowering them to be a custodian of their own health, which in turn has been shown to improve health outcomes •Physicians NEED fast, reliable and accurate results of blood tests to determine the best course of action •Payors NEED affordable diagnostics, supporting wider shift towards decentralization, value-based healthcare and personalized care Time is now. dianax is at the cutting-edge of mobile diagnostic transformation. Rapid detection, informed decision-making will optimize treatment and improve patient outcomes. Whether screening, diagnosis and management of chronic diseases, such as diabetes or anemia, or detecting bacterial respiratory infections to prevent overuse or misuse of antibiotics it’s concerned, dianax aims to provide fast, reliable and affordable diagnostics at the point of need – anytime, anywhere, for anyone. That’s because when it comes to people’s health we understand that to KNOW NOW really does matter Areas of Activity

• Biomaterials • Proteomics, metabolomics, nutrigenomics • Biosensors • Medical devices • Diagnostics IVD • Peptides, proteins & antibodies preparation

Marketplace Opportunities PRODUCT

239 / 880 Glycated Homoglobin - HbA1c Point of Need Rapid Testing System. Glycated Hemoglobin A1c measurement system with Lab-on-Chip disposable device connected through an electronic reader to a Smartphone or Tablet or Personal Computer and dedicated Application for screening, diagnosing and therapy monitoring Diabetic Patients. It should give the IVD test result in 5 minutes and send the outcome though cloud at the GP's office or Hospital. PARTNERSHIP Glycated Homoglobin - HbA1c Point of Need Rapid Testing System. We are looking for partnering with IVD Manufacturer and Service Providers to distribute our Glycated Hemoglobin measurement at Point of Need mobile device connected through Cloud INVESTMENT OPPORTUNITY Glycated Hemoglobin A1c - Point of Need Rapid Testing for Diabetes Screening, Diagnosing and Monitoring We are developing a new breakthrough device - Glycated Hemoglobin A1c measurement system with Lab-on-Chip disposable device connected through an electronic reader to a Smartphone or Tablet or Personal Computer and dedicated Application for screening, diagnosing and therapy monitoring Diabetic Patients. It should give the IVD test result in 5 minutes and send the outcome though cloud at the GP's office or Hospital. - Business Opportunity of €280M in 2017 expected to grow to €600M in 2023.

240 / 880 Diatheva Sol group

Organisation

Country Italy City Pesaro -Fano Street Web https://www.diatheva.com/

Person

Name Cosimo Lenti business development manager

Organisation DIATHEVA is an Italian biotechnology company founded in 2002 with the aim to bring research into industrial products by cooperating with firms, public and private research institutions. DIATHEVA focuses on development, production and marketing of new and innovative products for diagnostic, research and therapeutic applications mainly in the field of Cancer and Microbial Infection. Since its foundation DIATHEVA has heavily invested in R&D activities and the company has applied with success to many funded European and national research projects enlarging its collaborative and commercial network and acquiring an updated know-how. In 2012 Diatheva become part of SOL GROUP, the most innovative provider of gases in the industrial and medical sectors DIATHEVA applies on a diversified range of activities, from the development, manufacturing and marketing of innovative diagnostic kits and reagents to the providing of contract research and manufacturing services. Most of the products realized by DIATHEVA are unique on the market and they are applicable in clinical and industrial sectors. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Consulting services • CRO (Contract Research Organisation) • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Process development and cGMP protein production services Diatheva hold a GMP production facility, authorized by AIFA, to produce and release of biological APIs for pre-clinical and clinical applications with a special emphasis on new immunogens, enzymes and antibody fragments. 241 / 880 The company has the experience, expertise, capacity, and flexibility to serve as strategic partner for drug development and manufacturing needs. SERVICE Immunological and Molecular Tests Development Diatheva offers highly specialized services for research & development of customised tests. Thanks to a tough and long-lasting experience in molecular and immunological diagnostics, we are able to quickly develop kits, protocols and reagents on several platforms. Whether you require the complerte outsourced service or just an initial feasibility analysis, Diatheva can provide customised development. We have over 15 years of experience developping immunological and molecular assays for use in a variety of settings. A dedicated team of scientists works exclusively on your project to ensure rapid progress. PRODUCT PBRT Molecular diagnostic kit and reagents Diatheva produces and commercializes molecular diagnostics kits and reagents. Diatheva has industrialized the PCR Based Replicon Typing (PBRT) kit, a method for the study of antimicrobial resistance through the monitoring of plasmids disseminating antibiotic resistance genes in gram-negative bacteria. Other molecular assay are for pathogens detection from various matrices. A recent assay developed by Diatheva is a Real-time PCR method for the detection and quantification of Legionella spp. in water sample according to ISO/TS 12869. Diatheva has an exclusive licence for the industrialization and commercialization of PBRT method. The kit is unique on the market and represents a valid tool to test a wide panel of bacterial strains in a very short time and to follow the dissemination of resistance determinants allowing the description of antimicrobial resistance diffusion. The Diatheva method allows for the detection and quantification of Legionella spp. in clear water samples in 4 hours using real-time PCR technologies, MARKET APPLICATION PBRT kit customers are distributed in three distinct area of interest: veterinary, human and food. Some example of actual customers are microbiologists, epidemiologists and clinicians working in Institute and department for Infectious Diseases, Institute of Veterinary Bacteriology or animal health, Institute of Public health and more. Water testing - Legionella- Public and private laboratory testing of water samples PRODUCT ELISA kits for the diagnosis of microbial infections Diatheva produces and commercializes immunological diagnostics kits and reagents. The main product lines are dedicated to diagnosis, control and prevention of animal and human microbial infections. The ListeriaTest is an ELISA assay for the rapid detection of anti-Listeriolysin O (LLO) antibodies in human serum and plasma. The immunoenzymatic assay is CE-IVD marked and can be used as an aid for the diagnosis of listeriosis, a foodborne infection caused by a bacterium called Listeria monocytogenes. The Salmonella abortus ovis ELISA test allows for the detection of anti-Salmonella abortus ovis IgG in sheep serum and plasma for the diagnosis of abortive salmonellosis infection and evaluation of antibody response to vaccination. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Listeria test and the Salmonella abortus ovis ELISA test are unique on the market. Both assays have been widely validated ensuring high specificity and sensitivity. Moreover, Diatheva is able to guarantees a great device reproducibility lot-to-lot. MARKET APPLICATION 242 / 880 Listeria Test-Clinical Laboratories, both private and public. Salmonella abortus ovis ELISA test- Veterinary analysis laboratories /OIE Reference laboratories TYPE OF PARTNER SOUGHT Diatheva is interested in finding new distribution partners around the world. PRODUCT HIV-1 DNA Test - Molecular test for the detection and quantification of HIV-1 DNA Diatheva has developed the HIV-1 DNA Quantitative kit (MBK0086), a real-time PCR assay for the quantification of HIV-1 DNA in human blood. The kit can be used to study the HIV-1 reservoir in infected patients. The evaluation of this marker can help clinicians to choose the best therapeutic strategies and to control the progression of infection. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The kit provides and accurate quantification of HIV-1 DNA using a ready to use amplification mix with a technology that neutralizes a broad spectrum of PCR inhibitors. The presence of an Internal Control in the amplification mix allows to detect PCR inhibitors in the samples and to garantee the accuracy of DNA quantification.

243 / 880 Distretto Toscano Scienze della Vita - Tuscany Life Sciences Cluster

Organisation

Country Italy City Siena Street Web http://www.scienzedellavita.it

Person

Name Francesco Mazzini Cluster manager

Organisation The Tuscany Life Science Cluster mission is to create, mantain and keep growing a productive enviroment in terms of innovation and business opportunity for all the players of the regional life sciences sector. To this purpose, its actions aims to: • facilitate networking activities, animation, monitoring, stimulation of collaboration and the creation of partnerships • facilitate technology transfer and exploitation of research results; • stimulate and support the creation of innovative start-ups; • support the creation of a marketplace of ideas; • simplify the access to regional infrastructure, facilities and expertises for local and extra-regional players • support internationalization processes; • dialogue with institutions, at every level, to trasmit the needs of companies within the political and economic development of the sector; The Cluster gather together all the main regionale stakeholders (more than 190 companies operating in the life science field, as well as all the regional universities and research centers), and it is managed by Fondazione Toscana Life Sciences Areas of Activity

• 3D Printing/addictive manufacturing for • Medical research biomedical applications • Nutraceutics, probiotics, functional food, • Biotechnologies (Pharma&Medical cosmeceutics Devices) • Pharmaceutics • Diagnostics IVD • Life sciences related activities • Diagnostics - Equipment and accessories • Vaccines • Diagnostics - Imaging equipment and • Medical devices processing • IT Applications for Health • Drug screening & delivery

244 / 880 • eHealth, mHealth, telemedicine • Electromedical and medical equipment (non diag) • Genetics & Genomics • Investments

Marketplace Opportunities SERVICE Partnering facilitator The Tuscany Life Sciences Cluster aggregates the most important regional companies and all the research centers of the life sciences sector. It thus represents the reference portal to access the technology and business opportunities that Tuscany can offer in the life sciences field The Cluster in pills : 194 companies affiliated over 300 operating in the life sciences field in Tuscany 3 Univesities, 3 School of Excellence, 15 CNR Research Institutes Regional office for technology transfer and exploitation of biomedical research Enterprise incubators and accelerators regional network Strong relationship with institutional agencies

245 / 880 DNE - Ecological Niche Diet

Organisation

Country Italy City Torino Street corso Palestro 7 Web https://www.dietanicchiaecologica.com

Person

Name Lorenzo Bracco Medical Doctor, Specialist in Physiatry, Psychotherapist

Organisation www.ecologicalnichediet.com (www.dietanicchiaecologica.com) is a project conceived by Lorenzo Bracco, Medical Doctor, Specialist in Physiatry, Psychotherapist (founder and scientific director) and Dario Voltolini, journalist and writer (press officer). The result involves diet, namely nutrition and lifestyle, wellness, health, medicine, psychology, and trauma therapy, from a perspective that considers gender and individuality. It uses an educational and participatory model widely described by Dr. Bracco in his books for predictive and preventive medicine. Areas of Activity

• Consulting services • Proteomics, metabolomics, nutrigenomics • CRO (Contract Research Organisation) • Life sciences related activities • Genetics & Genomics • Vaccines • Investments • Other • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics • Physiotherapy, Orthopaedic technology

Marketplace Opportunities PROJECT COOPERATION We are looking for industrial partners for a new way of producing vaccines, that is patent pending Among all the parameters for production of vaccines, there is a parameter that has not been taken into consideration. The idea is that vaccine production should consider also this parameter. But this idea, being the subject of patent filing, will be unveiled according to the time and arrangements to be agreed. 246 / 880 PROJECT COOPERATION Looking for Partner for scientific research on the correlation of different blood types (0,A,B,AB) between mother/daughter and Anorexia of the Female Adolescent We are looking for a Scientific Partner (e.g., a Research Institute) and/or a Sponsor Investor for this scientific research. An example of preventive and predictive medicine is the new theory by Dr. Bracco on Anorexia of the Female Adolescent formulated in his book "ANOREXIA. The Real Causes: Blood Types and Trauma". This specific type of anorexia begins within a limited period of time after menarche and is characterized by weight loss and loss of the menstrual cycle for more than three months. In short, according to Bracco, in addition to the psychological causes of the girl and existential ones of the family, this type of anorexia requires a specific biological condition: "A different blood type between mother and daughter (0, A, B, AB) + traumatic contact of blood between the two during pregnancy and/or birth". This biological condition is necessary but not sufficient (conditio sine qua non) for the onset of Anorexia of the Female Adolescent. When this theory is confirmed, it will allow all physicians to make an early diagnosis of anorexia. In fact, the "group at risk of anorexia" to be monitored is reduced to a small percentage of adolescent girls: only those with a blood type different from that of the mother. Because the late diagnosis is the main cause of death, this new perspective will save many lives, avoid much suffering for girls and their families and also reduce the consequences (for example, osteoporosis). Dr. Bracco is very confident that a scientific research will confirm his theory, because during 25 years of medical profession he has collected more than a hundred cases of Anorexia of the Female Adolescent that confirm his theory. This scientific research consists of checking the blood type of the mother and the daughter, who suffers from Anorexia of the Female Adolescent, and checking the blood type of the control group of mother and daughter, who does not suffer from eating disorders. Compared with many other scientific researches, this one can be considered low-cost. With little money, a Scientific Partner (e.g., a Research Institute) and/or a Sponsor Investor can participate in a potentially significant research.

247 / 880 DocFaber srl

Organisation

Country Italy City Bologna Street Web https://www.docfaber.com/

Person

Name Fabrizio Malipiero Founder and Ceo docFaber srl

Organisation We promote healthy lifestyle through nutrition education web app, virtual tracking and online diet coaching. We do business of Mediterranean eating culture. Right food combinations, meal distribution, Made in Italy recipes, personalized diets programs, meal shopping lists, online coaching are some of our web services. Areas of Activity

• Software, ICT applications, system integration • IT Applications for Health

Marketplace Opportunities PRODUCT DocFaber - Software and web app for nutrition education We promote healthy lifestyle through nutrition education web app, virtual tracking and online diet coaching. We do business of Mediterranean eating culture. Right food combinations, meal distribution, Made in Italy recipes, personalized diets programs, meal shopping lists, online coaching are some of our web services. SERVICE DocFaber - Online Nutritionist Food Health Italian Education which processes weekly diets and personalized menus. DocFaber improve the people's relationship with food. DocFaberbBring the figure of the nutritionist "Outside the clinic", thorugh ONLINE messaging and REMOTE coaching. PARTNERSHIP Commercial and marketing partnership We are looking for commercial and marketing partnership with companies interested on business and 248 / 880 culture of healthy eating, Mediterranean culture of well being. PROJECT COOPERATION DocFaber abroad diffusion with customized services We are interested on spreading our project all around the world. Our algorithm and software can be customized according to a specific business and the type of final user and customer. INVESTMENT OPPORTUNITY Marketing Investment Investment on Google Adwords, advertising, Re-marketing and all the tools necessary to multiply the number of accounts exponentially. INVESTMENT OPPORTUNITY Tech implementations Usability improvement, chat-ad-on development, target selection, community, link with app shopping list or food delivery online managing, menus modification - single food selection / exclusion, server upgrade for download management over 40,000 users.

249 / 880 Don Carlo Gnocchi Foundation IRCCS

Organisation

Country Italy City Firenze Street Web https://www.dongnocchi.it/

Person

Name Federica Vannetti Reseaercher at Don Gnocchi Foundation

Organisation The mission of the don Carlo Gnocchi Foundation is to assist and take care of persons with disabilities. The Foundation provides in 9 regions rehabilitation services in hospital or at home. Areas of Activity

• 3D Printing/addictive manufacturing for • Virtual reality applications biomedical applications • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Medical research • Physiotherapy, Orthopaedic technology • Software, ICT applications, system integration

Marketplace Opportunities PARTNERSHIP GOAL project Home-based rehabilitation for mild cognitive impariment GOAL (http://goaltoscana.cbim.it/index.php/home)

250 / 880 Dottikon Exclusive Synthesis AG

Organisation

Country Switzerland City Dottikon Street Web https://dottikon.com/

Person

Name Mario Marcia Buisiness Development Manager

Organisation DOTTIKON EXCLUSIVE SYNTHESIS AG is the specialist for hazardous reactions and the strategic development and manufacturing partner of the world's leading chemical and pharmaceutical companies. Areas of Activity

• Analytical and characterization services • Manufacturing & process engineering • Chemicals & APIs • Pharmaceutics • CMO (Contract Manufacturing Organisation) • CRO (Contract Research Organisation)

Marketplace Opportunities PARTNERSHIP Interested in out-sourcing opportunities I am interested in meeting biotech and bio-phramaceutical companinies and know more about their out-sourcing needs (R&D and manufacturing activities)

251 / 880 DU IT

Organisation

Country Italy City Florence Street Web https://www.duitfor.com/

Person

Name Elena Bellini architect, PhD, co-founder, R&D coordinator

Organisation DU IT is a new way to design for users by innovative technologies. DU IT mission is to improve people's quality of life by healing environments and psychological comfort. The vision is the integration of design, psychology and technology to find innovative solutions for living with cognitive disabilities. DU IT design sensory therapeutic environments and assistive technologies for cognitive, behavioural and psychological diseases. It aims at developping people's abilities and their inclusion in the society. The team is composed by two architects: Lorenzo Romualdi, co-founder, CEO and Elena Bellini, co- founder, PhD, R&D coordinator; two psychologists: Ugo Romualdi, coordinator of psychological area for dementia and mental disabilities and Francesco Bicchi, psychotherapist in sensory environments; an advanced computer developer, Andrea Campinoti, a sensory garden consultant, Donato Sabato and two other architects involved in design, Paola De Vita, and research, Alessia Macchi. Elena Bellini and Alessia Macchi are also involved in different researches at the Department of Architecture – University of Florence, establishing a partnership in the field of health and social care. DU IT won a funding call by the Technological Incubator of Florence to start and develop the company, that was founded at the end of 2015. One of DU IT most important projects is an autism-friendly sensory waiting room for the Emergency Department of Careggi Hospital in Florence, inaugurated in July 2016, as the first multisensory environment in hospital in Italy and one of the few examples in Europe. DU IT is also participating in the European Project MinD-Designing for People with Dementia promoted by the University of Wolverhampton. Areas of Activity

• Life sciences related activities • IT Applications for Health • Software, ICT applications, system integration • Virtual reality applications • Other

252 / 880 Marketplace Opportunities PRODUCT Duit POD Duit POD is a sensory nest where people can take their time and take care of their-selves during an individual moment of relax, play and leisure. It aims at reducing stress and improving people’s wellbeing. Sensory environments were first designed for people with cognitive disabilities, to regulate the contest for their particular sensory sensibility. This project represents a development of this sensory therapy through a software that make it flexible for different users. It is particularly addressed to business men/women that work hard, present a high level of stress and need to increase productivity, concentration and creativity. It is also useful during working travel and it can be installed in airports, railway station, waiting rooms, or hotel chains. Duit POD represents a secure and calming environment where it is possible to interact with a technological system to change and adapt the environment its-self. There are four base-case scenarios - relax, energy, balance and dream - that integrate some sensory stimulations: coloured lights, video, music, tactile vibrations and aromas. Anyway, it can also be customised for different locations and users: personalised design, finishes and colours, multiple scenarios, etc. People can lie down inside Duit POD and choose one or more scenarios, depending on their mood. An acoustic curtain takes each one out off the contest. The sensory experience starts when the user press one button and can last all the time the person needs to get relaxed. Stress can be considered one of the biggest challenges in our contemporary society and it represents a nagging issue for each person in every situation of its life. It deals also with a lot of related problems, such as depression, fatigue, overworking, gastrointestinal and cardiovascular diseases, etc. Stress is a state of mental, emotional or physical tension resulting from negative effects of the environment. Changing the environment, we're going to tranform these negative effects in positive sensory stimulations. In this way, Duit POD wants to be a new solution for well-being and health. Disease causes also expenses in health and loss of working days. It is estimated that the 41% of workers are stressed, 40 millions of people in Europe and only 9 millions in Italy, for a waste of money of about 2 billions of euro each year in Europe. PARTNERSHIP Expanding collaborations in designing for health and social care We are willing to promote synergistic strategies (research projects, joint applications for EU grants, etc.) with companies, public institutions or stakeholders who intend to make use of our expertise in the field of health and social care design. INVESTMENT OPPORTUNITY Looking for investors to scale up validated product Our Duit POD product reached market validation this year, we are now on investors search to promote market seeding and international market penetration, in order to boost marketing campaigns and hire the necessary resources. PROJECT COOPERATION Duit POD product evolution We are searching for industrial partner/distributor to cooperate on Duit POD product evolution towards international market distribution. PROJECT COOPERATION Design for Dementia: application of VR in sensory environment DU IT is looking forward to collaborating with research groups or industrial partners who has strong research/project capacity on Dementia and Alzheimer’s disease (AD) or on Virtual Reality devices for healthcare.

253 / 880 PROJECT COOPERATION Design for ASD: how sensory environment can support the quality of sleeps We are highly interested in collaborating and partnering with researchers, universities, laboratories and other companies interested in the same field of investigations. We strongly aim an integration with neuroscience expertise. We are open to cross-border R&D projects. PROJECT COOPERATION R&D project on sensory environment supporting birth spaces We are looking for industrial partners to develop a prototype of a specific sensory forniture/device for birth rooms. Research project already ongoing, involving public healthcare authority in Tuscany.

254 / 880 eHealthTech srl

Organisation

Country Italy City Calenzano (FI) Street Via delle Cantine 27 Web www.ehealthtech.eu

Person

Name Renato Calamai Administrator

Organisation eHealthTech is a micro-enterprise in the Healthcare IT area, started up in 2004 within the Florence Technological Incubator. eHealthTech carries out research and development for the consulting, design and implementation of innovative technology solutions for the exchange, sharing and integration of clinical and administrative information among health information systems, based on the Health Level Seven International (HL7) standards for interoperability of health information technology, and the interoperability framework Integrating the Healthcare Enterprise (IHE). Collaboration Since 2006 eHealthTech is member of HL7 Italia, the Italian affiliate organization of HL7 International, and participates in the V3 Domain Work Groups to localize the standards according to the national or regional requirements, such as Patient Administration domain – Person and Patient Topic, Implementation Guide for CDA Rel.2 – e-Prescription and Patient Summary, Object Identifier (OID) Registry, White paper - Social welfare and health services, and EHR-System Functional Model, Release 2.0. It also participated in some HL7 International Conference, Working Group Meetings, and E-learning course. Areas of Activity

• Bioinformatics, Big data analytics • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Genetics & Genomics • Software, ICT applications, system integration • EPR, Clinical/healthcare management software

Marketplace Opportunities SERVICE Healthcare IT Solutions to enable interoperability based on HL7 standard and IHE framework Consulting, design and development of IT solutions for integration between healthcare systems in

255 / 880 administrative and clinical domains, according to the international standards for interoperability of Health IT and national/regional specifications. - Patient Administration for management of demographic information - Electronic Prescription (e-Prescription) - Patient Summary for General Practitioners - Laboratory Information Systems in clinical laboratories - Radiology Information Systems in medical imaging departments - Operating Room management systems - Chronic Care Model and Long Term Care services - Electronic Health Record (EHR) - Personal Health Record (PHR) - Mobile Health - Clinical Genomics for Personalized Medicine TECHNICAL SPECIFICATIONS: - HL7 v2 and HL7v3 messaging - Clinical Document Architecture (CDA R2) - Fast Health Interoperable Resources (FHIR) - EHR-System Functional Model - PHR-System Functional Model - IHE Profiles on FHIR TYPE OF PARTNER SOUGHT Private and Public Healthcare Providers Health IT Vendors Producers of Diagnostic Medical Systems and Medical Devices PARTNERSHIP H2020 - Health IT - Clinical Genomics Looking for industrial partners and university/research centres in H2020 projects - SME Instrument - in the area of ICT Solutions for Health, Well Being and Ageing Well, in particolar for applications in the field of Clinical Genomics. TYPE AND ROLE OF PARTNER SOUGHT Industrial partners (SMEs) University e Research centres

256 / 880 EIT Health

Organisation

Country Italy City Napoli Street Web https://www.eithealth.eu

Person

Name Chiara Maiorino Education Manager, Regional Manager South Europe

Organisation EIT HEALTH - Together for healthy lives in Europe EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business – for the benefit of citizens. Areas of Activity

• Investments • Project proposals support services • Life sciences related activities • Other

Marketplace Opportunities PARTNERSHIP Looking for Investors to join our EIT Health network EIT Health works with the main aim to support exploitation of innovative technologies and knowledge in favor of society and citizen. We also work to trigger business creation, to foster entrepreneurship and foster business development within the health sector. We are searching for investors interested to join our network and invest in the best-in-class European Startups. SERVICE Mentoring for Startups EIT Health Accelerator is a business creation programme, set up to support the best and brightest health industry entrepreneurs. To tackle the future challenges of European healthcare, EIT Health Accelerator creates a favourable environment for innovation, providing skills and services to get promising business ideas into the market. The Accelerator pillar of EIT Health provides support to healthcare entrepreneurs at every stage of the process. We incubate idea, we validate concepts, we scale businesses. SERVICE

257 / 880 Education opportunities for talents, entrepreneurs, executive&professional, citizen EIT Health Campus, the education programme of EIT Health, provides up-to-date knowledge, skills and attitudes to help turn the brightest learners into healthcare leaders and entrepreneurs, who will shape the future of Europe’s health. Campus educational offerings are intended to increase industry knowledge and deliver novel skills, as we seek to inject an entrepreneurial approach into European healthcare education. We are building a unique European talent pool in healthcare by connecting our learners to the EIT Health network – one of the strongest healthcare communities worldwide, composed of research- intensive companies, elite universities and innovative health and care providers. Working together, the learners and our partners can pursue EIT Health’s mission of encouraging innovation and entrepreneurship to bring about healthcare improvement for the benefit of the European citizen. EIT Health Campus uses a host of activities, divided into five different activity lines, to build a creative healthcare workforce that is conducive to innovation and entrepreneurship, and to improve healthcare knowledge. Read more about the Campus Activities below.

258 / 880 Elysium

Organisation

Country Italy City Roma Street Web http://elysium.tech

Person

Name Ahmed Abdel Rahman CEO

Organisation Elysium provide a decentralized platform based on Blockchain technology for sharing secure and certified health data between Patients, Doctors and Healthcare facilities. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Software, ICT applications, system integration • EPR, Clinical/healthcare management software • Other

Marketplace Opportunities PRODUCT Blockchain in Healthcare - Elysium Elysium is the secure bridge that easily allows existing EHR to safely and compliancy exchange health data and legally allows access to aggregated and anonymized health data, as well as adherence to the therapy. PATIENT Take the ownership of personal health data. Uploading, downloading and sharing certified health data to easily control treatments and adherence of therapy effectiveness. PHYSICIAN Store and update certified portable patient health data in a secured and shared folder for a real-time care. Is also provided with an AI support to avoid errors, lose time and waste money. HEALTH FACILITY Easily provide patient health information to ER doctors and be the bridge between other hospitals and 259 / 880 labs to share health data with any EHR system in EU countries full compliant with GDPR.

260 / 880 Embassy of France in Italy - Trade and Investment Agency

Organisation

Country Italy City Milano Street Corso Magenta, 63 Web www.businessfrance.fr

Person

Name Alberto FRESCURA Senior Trade Advisor

Organisation Business France is the national agency supporting the international development of the French economy Responsible for fostering export growth by French businesses, as well as promoting andfacilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program.Founded on January 1, 2015 through a merger between UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. For the healthcare: In particular in the life sciences sector, Business France in Italy concretely helps Frenchpharmaceutical, CRO, biotech and medial companies to develop business in Italy. We dofacilitate R&D partnerships, distribution agreements and subsidiaries creations. On the other side, we attract Italian investements in France with a free and qualified help from the detection of the project till the realization of it. From 2014, Business France Italie animates an executive club called CLUB SANTE ITALIE gathering 40 of the French subsidiaries of the healthcare sector in Italy: Sanofi, Biomérieux, Ipsen, Stago, Nutricia, just to give some examples. What we do in general : Offering complimentary services to foreign investors and all businesses operating in France to foster international development, exports, and inward investment, by detecting leads and welcoming and supporting enterprise. Supporting decision-making by expanding businesses and foreign investors to attract inward investment projects to France, by drafting and disseminating useful material to inform decisions and organizing all necessary training to ensure project completion. Contributing to the formulation and implementation of nationwide and regional government policy to further international business development in key sectors, and to enhance France’s attractiveness to inward investment. Running and expanding the VIE international internship program. Organizing and overseeing all work to extend international cooperation within the realm of its remit, and participating, where appropriate. Monitoring France’s international business image and attractiveness as an investment location. 261 / 880 Suggesting and implementing strategies to promote France and its regions, businesses and talent, and informing channels of influence in the international business world. Designing, developing and disseminating all relevant communication material to meet its objectives, and adapting them to different targets in France and throughout the world. Aiding government in analyzing and formulating policy within the realm of its remit concerning the international development of the French economy. Carrying out all relevant assignments entrusted to it by the government ministries to which it reports on a permanent or temporary basis. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical research Devices) • Nutraceutics, probiotics, functional food, • CMO (Contract Manufacturing cosmeceutics Organisation) • Packaging & labelling • CRO (Contract Research Organisation) • Pharmaceutics • Diagnostics IVD • Regulatory affairs, validation • Diagnostics - Equipment and accessories • Life sciences related activities • Diagnostics - Imaging equipment and • Medical devices processing • Drug screening & delivery • eHealth, mHealth, telemedicine • Genetics & Genomics • Investments

Marketplace Opportunities PARTNERSHIP PARTNERSHIP WITH FRECH COMPANIES We are always looking for opportunities and partnerships in Italy with life sciences French companies. Medical devices and pharmaceutical R&D are the main fields of interest for: - CRO - licensing (in and out) products - R&D collaborations SERVICE OPPORTUNITIES IN FRANCE - START UP AND INVESTEMENTS France is the one of the most important and active countries in Europe for the great Start up environnement (ex. STATION F in Paris, the major start up hub in Europe) and the high level of R&D. We do help Italian start up to set up in France in this brilliant environnement and we do help Italian investors in investing in France.

262 / 880 EMC Innovation Lab S.r.l.

Organisation

Country Italy City Rimini Street Web http://www.emcinnovation.it

Person

Name Paolo Rossini Head of RD&I

Organisation For SMEs and public administrations, who must increasingly comply with new pressing environmental regulations and needs, EMC Innovation Lab is a consulting firm that provides expert support for environmental issues, design and engineering and innovation. Unlike traditional engineering companies or research bodies, our integrated approach combines Life Cycle Analysis with Big Data analysis, ecodesign, environmental certifications and green chemistry, waste and byproduct valorisation, Circular Economy. Areas of Activity

• Consulting services • Project proposals support services

Marketplace Opportunities PRODUCT Environmental Consulting - Software for monitoring flows (Big Data sector) - Product and process environmental certifications - Life cycle assessment - Product / process sustainability indexes (eg. Carbon and Water Footprint) - Life Cycle Costing Analysis - Waste management plans - Technical writing PRODUCT Design and Environmental Engineering - Management and valorisation of waste / by-products in a circular economy perspective - Environmental and economic feasibility studies - Implementation of processes according to the fundamental principles of green chemistry and engineering PRODUCT

263 / 880 Innovation - Ecodesign and efficient use of resources - Big data management & circular economy - National and international research and innovation projects

264 / 880 EMODIAL SRL

Organisation

Country Italy City Ferrara Street Via Finati 4a

Person

Name Federico Pecorari CEO

Organisation Emodial srl, founded in 1982, is specialised in supplying medical devices used in the dialysis trade and developing, to support dialysis operations, a complete range of products. The company products range: - Tampons, plasters and fistulas compression bandages. - Engage/disengage kits for hemodialysis, catheterism and peritoneal dialysis. - Devices for fistula needles disposal. Areas of Activity

• Biomaterials • Medical devices • Medical facilities furnishings, equipment, goods • Other

Marketplace Opportunities PARTNERSHIP commercial and R&D partnership Emodial is looking for cooperation opportunities mainly in the fields of medical devices for the prevention and cure of infections incurred during a vascular access.

265 / 880 Emotec SrL

Organisation

Country Italy City Medolla Street Via Maestri del lavoro 5 Web http://www.emotec.it/

Person

Name Guido Bergamini Chief Marketing Officer.

Organisation EMOTEC Ltd. of Medolla (MO) is a biomedical company certificated UNI EN ISO 9001-2008/UNI CEI EN ISO 13485:2016 and since 1983 has been researching, projecting, producing and marketing medical devices in sterile and disposable versions. Emotec is capable to develop and produce medical devices OEM, personalized, i.e. as per specific requests of the Client either for national or international market. Among the numerous Customers acquired and consolidated, the company counts big multinational Companies as well. Areas of Activity

• Medical devices

Marketplace Opportunities PRODUCT Production of medical devices We are able to produce sterile medical devices in class 2A with CE certification. We are authorized for secondary packaging of pharmaceutical products SERVICE Assembly of medical device. Assembly in a cleanroom of medical components and packaging of pharmaceutical products. PRODUCT Blood filtrations we are developing new devices for blood purification in hematology, the study involves the application of physical and dynamic filtration and separation systems. We have a patent filed and we are in an advanced study phase. We are looking for investors who believe in our project and are available to collaborate in its development. PROJECT COOPERATION

266 / 880 Blood depuration we are developing new devices for blood purification in hematology, the study involves the application of physical and dynamic filtration and separation systems. We have a patent filed and we are in an advanced study phase. We are looking for investors who believe in our project and are available to collaborate in its development. PRODUCT New device for safe compounding of antiblastic dangerous drugs We have patent and produce a new medical device that combining the mixing, adminisìtration of chemiterapich drug in total absence of accidental contamination of the environment operators.

267 / 880 Endostart srl

Organisation

Country Italy City Certaldo Street Via delle Regioni 265 Web https://www.endorail.com

Person

Name Alessandro Tozzi CEO

Organisation Endostart is a startup founded on May 2018 with the aim of developing an innovative system for making colonoscopy easy, fast and painless. The team has skills in medical device development, marketing, finance and clinical research. Endostart has been recently funded with 700kEuro and is going to close the first round of financing to develop the product, carry out the first clinical trial and get CE Mark within the end of 2019. Areas of Activity

• Diagnostics - Equipment and accessories • Medical devices

Marketplace Opportunities INVESTMENT OPPORTUNITY Device for Colonoscopy Colonoscopy is one of the most performed medical procedures worldwide, accounting for about 15M for USA. It is a difficult exam that requires a long training curve and results incomplete in about 10-15% of the total examinations with important healthcare consequences. Endorail System is a simple accessory for colonoscopes allowing easy, fast and safe colon inspection. It works as an endoscopic magnetic anchor able to guide the endoscope. It is introduced, upon need, through the tool channel of the colonoscope during the procedure if it becomes challenging, upon physician's decision, without the need to pre-mount it or interfere with the normal examination process. Endostart is going to close the first round of financing for developing the product and getting the CE Mark within the end of 2019. REQUEST Investement Request Endostart is closing the first round of financing. We are looking for investors for the development of a new medical device for colonoscopy. The aim is to get CE Mark within the end of 2019.

268 / 880 EOS S.r.l.

Organisation

Country Italy City Milano Street viale Ortles 22/4 Web www.eosinstruments.com

Person

Name Tiziano Sanvito Sole Administrator

Organisation EOS S.r.l. (Effective Optical Systems) is a startup company devoted to the development of new solutions for the characterization and design of micro and nanoparticles in biological, industrial and environmental complex fluids. Implementing strategies for particle analysis in complex fluids via light scattering, EOS provides CLASSIZER™ ONE v0.8 platform for the multiparameter analysis via the novel key-enabling SPES (Single Particle Extinction and Scattering) patented technology and specific algorithms. More reliable and meaningful information are provided, boosting R&D - QC processes, during lab scale design and industrial production of particles. CLASSIZER™ ONE v0.8 classifies single particles: discriminates particles in heterogeneous samples; enables advanced product formulation by monitoring the particle stability and behavior in real complex fluids (aggregation, degradation, wetting); boosts QC operations measuring even in presence of impurities, synthesis residues, bubbles and immiscible liquid droplets (typically no filtration or purification is required). CLASSIZER™ ONE v0.8 will be a powerful tool for product R&D and QC in life science, pharmaceuticals, cosmetics, agrochemicals, food, inks, pigments, lubricants, abrasives and environmental sciences. Several prototypes have been developed, some awards had been won and several scientific papers have been published. EOS Srl has been recently received funding for the CLASSIZER project from the European Union’s Horizon 2020 research and innovation SME Instrument Phase 1 programme under grant agreement No. 781906. The headquarters of EOS are presently located at the Business Accelerator Infrastructure “Fondazione Filarete”, Milano (Italy). Areas of Activity

• Analytical and characterization services • Nutraceutics, probiotics, functional food, • CRO (Contract Research Organisation) cosmeceutics • Diagnostics IVD • Pharmaceutics • Drug screening & delivery • Life sciences related activities • Investments • Laboratory equipment, reagents, software • Manufacturing & process engineering

269 / 880 • Medical facilities furnishings, equipment, goods

Marketplace Opportunities PRODUCT CLASSIZER™ ONE EOS completed the beta production design of CLASSIZER™ ONE particle analyser for the characterization of micro and nanoparticles. Based on patented Single Particle Extinction and Scattering (SPES) key-enabling technology and dedicated data analysis algorithms, it provides more reliable and meaningful information, boosting R&D - QC processes, during lab scale design and industrial production of particles. ▪ CLASSIZER™ ONE provides more independent parameters for each single measured particle, allowing to: i) distinguish particles of different composition, ii) determine actual size distributions, iii) retrieve information about shape/aspect ratio, iv) control stability/wettability, v) monitor the presence of and characterize aggregates and vi) characterize the contaminants and process scraps in fluids. ▪ CLASSIZER™ ONE distinguishes particles and components of complex biological, industrial or environmental fluids, including plasma, blood, etc. It opens new opportunities, such as i) the characterization of particles in the real media where they are supposed to operate, ii) the possibility to measure them despite the presence of synthesis residues allowing a quality control without intermediate steps as purification/filtration/etc, and iii) the detection and data rejection from results of possible gas bubbles or droplets of other immiscible fluids. ▪ CLASSIZER™ ONE analysis can be performed in-line so to i) adjust processes parameters in real-time on the base of particles characteristics, ii) reduce process time and iii) increase synthesis yield. Size sensibility depends mainly on particles composition and structure: e.g. spheres of 75nm for gold, 100nm for oxide and 200nm for polymer, up to few tens of microns in diameter. Numerical particle concentration is typically 10^4 – 10^7 ptc/mL. Few minutes are needed for standard measurement. SERVICE Analysis of micro and nanoparticles in complex fluids EOS developed a patented enabling technology for the characterization of micro and nanoparticles in in heterogeneous biologival, industrial and environmental fluids. SPES (Single Particle Extinction and Scattering) boosts R&D and Quality Controls in life sciences, pharmaceuticals, cosmetics, food and beverages, inks and pigments, agrochemicals, lubricants and abrasives, environmental sciences. It provides multiparameter analysis at single-particle level, paving the way for advanced product formulation by monitoring the particle stability and behavior in real complex fluids (aggregation, degradation, wetting); boosts QC operations measuring even in presence of impurities, synthesis residues, bubbles and immiscible liquid droplets (typically no filtration or purification is required). EOS application specialists are available for every customer that requires a third part characterization of micro and nanoparticles samples in both simple and complex fluids (biological, industrial and environmental). EOS is available to provide dedicated sample preparation protocols and analyses of your samples. ▪ CLASSIZER™ ONE provides more independent parameters for each single measured particle, allowing to: i) distinguish particles of different composition, ii) determine actual size distributions, iii) retrieve information about shape/aspect ratio, iv) control stability/wettability, v) monitor the presence of and characterize aggregates and vi) characterize the contaminants and process scraps in fluids. ▪ CLASSIZER™ ONE distinguishes particles and components of complex biological, industrial or environmental fluids, including plasma, blood, etc. It opens new opportunities, such as i) the characterization of particles in the real media where they are supposed to operate, ii) the possibility to measure them despite the presence of synthesis residues allowing a quality control without intermediate steps as purification/filtration/etc, and iii) the detection and data rejection from results of possible gas bubbles or droplets of other immiscible fluids. 270 / 880 ▪ CLASSIZER™ ONE analysis can be performed in-line so to i) adjust processes parameters in real-time on the base of particles characteristics, ii) reduce process time and iii) increase synthesis yield. Size sensibility depends mainly on particles composition and structure: e.g. spheres of 75nm for gold, 100nm for oxide and 200nm for polymer, up to few tens of microns in diameter. Numerical particle concentration is typically 10^4 – 10^7 ptc/mL. Few minutes are needed for standard measurement. PARTNERSHIP Design products based on particles, emulsions, microcapsules, powders, ... Implementing strategies for particle analysis in complex fluids via light scattering, EOS provides CLASSIZER™ ONE v0.8 platform for the multiparameter analysis via the novel key-enabling SPES (Single Particle Extinction and Scattering) patented technology. CLASSIZER™ ONE v0.8 classifies single particles: discriminates particles in heterogeneous samples; enables advanced product formulation by monitoring the particle stability and behavior in real complex fluids (aggregation, degradation, wetting); boosts QC operations measuring even in presence of impurities, synthesis residues, bubbles and immiscible liquid droplets (typically no filtration or purification is required). EOS S.r.l. is available as partner and/or as CRO in EU/local funded projects to support the development and design of products based on micro and nanoparticles. CLASSIZER™ ONE v0.8 will be a powerful tool for product R&D and QC in life science, pharmaceuticals, cosmetics, agrochemicals, food, inks, pigments, lubricants, abrasives and environmental sciences.

271 / 880 Ephoran Multi Imaging Solution

Organisation

Country Italy City Colleretto Giacosa Street Via Ribes 5 Web http://www.ephoran-mis.com

Person

Name Cesare Ciani Marketing Manager

Organisation Ephoran Multi Imaging Solutions is a Contract Research Organization offering a complete solution toolset for non-invasive in vivo preclinical imaging services. Such expertise are focused to study, develop, and promote the application of imaging technologies in pre-clinical phase drug research. Our pre-clinical in vivo imaging systems offer solution for quantitation, deep tissue targeting, such as lung, heart, liver, kidney, GI, and brain in order to monitor and quantify in real time biological targets and pathways, giving a deeper understanding of the biology underlying disease mechanism and therapeutic response. Our facility is equipped with a 1, 3, ad 7T MRI imagers, hybrid PET/SPECT/CT and SPECT/PET imagers, ultrasound equipment coupled to Photoacustic imaging system, bioluminescence, and fluorescence imaging instruments, along with radiochemistry and radiotherapy capabilities. For situation where one modality will not answer all your biological questions Ephoran is capable of combining functional and anatomical data using a multimodal imaging system (PET/SPECT/CT system). The in-house availability of a cyclotron for industrial production of clinical and preclinical tracers, such as 99-Tc, 18-F, 68-Ga, Y-90, and Lu-177, provides both PET/SPECT agents for custom labeling of candidate molecules for translational studies. Ephoran also helps you prioritize the candidates in your pipeline by providing in vivo targeting and biodistribution data. This crucial data is best generated early in the decision-making process in order to select the candidates most likely to be successful in clinical studies.

Areas of Activity

• Consulting services • CRO (Contract Research Organisation) • Diagnostics - Imaging equipment and processing

Marketplace Opportunities SERVICE Imaging techniques for Pre clinical drug development EPHORAN Multi Imaging Solutions provides a complete toolset of imaging techniques to study, develop, and promote the application of imaging technologies in in-vivo pre-clinical drug research and development. Ephoran can provide preclinical imaging services covering all imaging techniques: MRI, PET, CT, SPECT, 272 / 880 US, Optical Imaging, and Photoacustic imaging, to ensure a link between the preclinical and clinical studies. Services are offered to biotech and pharma industries in Europe or worldwide, to prioritize the candidates in their pipeline by providing in vivo targeting and biodistribution data. Our pre-clinical in vivo imaging systems offer solution for quantitation, deep tissue targeting, such as lung, heart, liver, kidney, GI, and brain in order to monitor and quantify in real time biological targets and pathways, giving a deeper understanding of the biology underlying disease mechanism and therapeutic response. Furthermore Ephoran provides a great variety of in vivo testing services including subcutaneous tumor models (xenograft tumor models), orthotopic tumor models, apoptosis, inflammation, CNS, hematoma, and others. Innovative aspects and main advantages: • Perform pharmacology serial/longitudinal imaging animal studies, reducing the overall number of animals used in the experiments; • de-risk subsequent costly development programs such as optimisation, manufacturing, toxicology and clinical trials; • utilize resources better by focusing on ideal candidates only; • reduce timelines to first-in-human studies; • confirm target selection and mechanism of action in vivo.

273 / 880 Era Endoscopy S.r.l.

Organisation

Country Italy City Peccioli Street Via Boccioni 1 Web http://www.endotics.com

Person

Name Giuliano Gorini CEO

Organisation Era Endoscopy S.r.l. is a medical device company focused on the discovery, development and commercialization of innovative medical devices with excellent performance (in terms of safety and painlessness).The company was established by a group of researchers with long and well proven experience in the field of robotic endoscopy, with the intent of starting a new era in practical endoscopy and, in particular, in colonoscopy.The company was founded, and is run, by the researchers involved from the start in the first project for a self-propelling colonoscope aimed at being the safest and most comfortable/painless medical probe. On the basis of approximately 10 years of research activity the company is now promoting its first ground-breaking medical system: the Endotics® System, the revolutionary endoscopic system with an entirely disposable self-propelling robotic colonoscope. The Endotics® System is a painless system that makes CRC screening well accepted by the patient, making easier colonoscopy procedures for physicians and providingide a cost-effective technology for the healthcare system. Areas of Activity

• Medical devices

Marketplace Opportunities PRODUCT Endotics System - Innovative endoscopic system The Endotics® System was first conceived by observing Geometer moths, as robotics often draws inspiration from animal; plant kinematics and dynamics. Matching patients’ expectations (avoiding pain, infection & perforation risks) and physicians’ requirements (preventing work-related injuries), the Endotics® probe propels itself in the colon by mimicking the movements of the inchworm. This particular locomotion allows the probe to adapt itself to the dynamic curves and bends of the colon; this self-conformation feature minimises the unnatural deformation of the colon inherent in conventional colonoscopy. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The distal end of the probe can be actively steered in any direction (more than 180° along each axis) to 274 / 880 facilitate the negotiation of bends and curves within the colon. The steering mechanism together with the incorporated high resolution CMOS camera & cold lighting allow for optimal frontal and rear endoscopic views. The design of the robot aims to offer a disposable, totally pneumatically driven, very soft and flexible device. A sophisticated electro-pneumatic system - run by the dedicated Endotics® manager software - directs the probe according to the user’s commands. PAINLESS The Endotics® System can make pain-free colonoscopies a reality - without resorting to sedation. The system is highly flexible; the probe advances like a caterpillar without deforming the colon or causing intestinal loops or stress to the mesenteries, and employing only the minimal amount of forced air required for diagnosis. SAFE The Endotics® system is safe: the novel self-propelled probe prevents perforation risks related to pushing actions. The sterile and disposable probe guarantees zero cross-infection risks. The joystick driving system allows physicians to assume a safer posture USER-FRIENDLY The Endotics® System probe is a disposable ready-to-use device, with a plug-in workstation connection. The revolutionary self-locomotion mechanism, together with the innovative joystick-based driving system, allows easy inspection of the entire colon wall. The learning curve is fast, & the system can be operated from a comfortable sitting position. Thanks to its innovative & easy-to-use driving system, competence is rapidly acquired. COST-EFFECTIVE The Endotics® System offers a one-to-one procedure (unassisted as sedation or barrage technique are not required). Endotics® probes eliminate costs related to perforation, cross-contamination, work related injuries, sterilization & sedation, with the plus of increasing patient turnover. The easy-to-use driving system allows a fast learning curve. MARKET APPLICATION Colonscopy TYPE OF PARTNER SOUGHT Distributor of medical products, Technical parthership, Healthcare operators, Hospitals, Private clinics, Gastroenterologists INVESTMENT OPPORTUNITY MKT & Platform we evaluate new funding to expand sales in the US and develop our ecosystem

275 / 880 Esetron Smart Robotechnologies

Organisation

Country Turkey City Ankara Street Esetron Smart Robotechnologies Gül 86 Toplu işyerleri Kooperatifi 1/97 Ostim/ANKARA Web http://www.esetron.com/

Person

Name Ishak ELMAS General Manager

Organisation Esetron aims to integrate robots in our daily lives to make life easier. Esetron develops innovative projects in 3 main areas: robotics, smart cities and medical systems. Six medical test systems under our brand MOD-DENTAL are among Esetron’s top selling products. Esetron also offers technical support in electronics, mechatronics, control and software development. The medical devices that we produce are dental products, especially for testing and monitoring for dental operations/ methods/products/solutions. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical facilities furnishings, equipment, Devices) goods • CMO (Contract Manufacturing • Medical devices Organisation) • CRO (Contract Research Organisation) • eHealth, mHealth, telemedicine

Marketplace Opportunities PRODUCT Micro Tensile-Shear Device It is a high quality micro tension -shear device with high precision. Technical Features: Position calculation with high precision (0.5 um) Force calculation with high precision (800 Hz. data read speed) Advanced Software Easy-to-use user interface Loading Limit: 500 N Load Data Acquisition Speed: 800 Hz Position Resolution: 0.1 Micron

276 / 880 Load Cell Sensivity: <0.05 PRODUCT Occusal Loading Device This device can do thermal cycling and loading at the same time. Chewing is simulated by backward- forward movement. Depending on the model, 4 to 10 teeth can be tested on the device. Chewing Simulator MOY-101 recreates the jaw pressures on teeth. For a more realistic recreation, the tray which holds the teeth moves in 2 axis. This device can do thermal cycling and loading at the same time. Chewing is simulated by backward-forward movement. Depending on the model, 4 to 10 teeth can be tested on the device. MOY-101 recreates the jaw pressures on teeth. For a more realistic recreation, the tray which holds the teeth moves in 2 axis. Technical Features MOY-101 is capable of doing thermal and loading tests at the same time. It can also simulate jaw movement by backward-forward motion. The temperatures of water in the tanks are +5° and +55°. The temperatures can be arranged between 1°-15° and 40°-80°. You can set chewing motion on the computer. The chewing motion can be upward-downward (z axis) or backward-forward (x axis). During X axis movement, pressure on z axis is kept stable. Force on z axis is 500N. Measurement sensitivity is 0.1N. Sensors are highly sensitive with 0, 05% tolerance. The force and the movement applied during the experiment will be saved and can be followed from the computer. Special Features It is ergonomic, easy to use and it takes minimal space. Made and designed in Turkey. PRODUCT Toothbrush Simulator This device is designed to test effect of brushing on erosion of teeth and tooth fillings. The brushing motion recreates real life effects of tooth brushing on the teeth tested. The brushes make a backward- forward motion at a pre-set pressure on the teeth. The cycle of the test can also be set by the user. Special Features Bulky devices which are designed for chemistry/mechanical tests are used for many dentistry tests. Our toothbrush simulator is specially designed for your needs. It is ergonomic and easy to use. Made and designed in Turkey

PRODUCT Thermal Cycler Thermal cycling is one of the most used test protocols for testing dental equipment. The aim of this protocol is to recreate long term clinical conditions restorative materials are kept in. With this device, you can give tooth pieces a cold and hot bath to age them. You can control the temperature of the tanks, waiting duration in each tank, and the number of cycles from the screen on the device. Technical Features The device has a 15cm*15cm*15cm basket to place the teeth in. The size of the device is 70*70*40cm, which makes it the smallest Thermal Cycler in the literature. It has two tanks which contain water at +5° and +55°. The temperature of the water can be arranged between 1°-15° and 40°-80° in the tanks. The basket moves from one water tank to the other. The frequency and number of the cycle can be controlled by the control panel on the device. The device is light and easy to carry. 277 / 880 It has 2000W heating power and 750W cooling power. Special Features Our Thermal Cycler is the smallest one produced for dentistry tests in the literature. It takes minimal space in your laboratory. It can connect to your computer, save your work in case of electric cuts and enables you to control the position of the basket. PRODUCT Loading Device Our Loading Device MIN-100 is specially designed for dentistry studies for pulling, pushing and breaking tests. The device conducts pressure tests by pulling or pushing. It connects to your computer and enables you to check experiment data on computer screen. Technical Features: It is easy to use and takes minimal space. Measurement sensitivity is 0.1N. Sensors are highly sensitive with 0,05% tolerance. It has an LCD panel to control system settings. The settings can also be controlled by a computer. It comes with special pulling and pushing equipment. Test results can be followed from the LCD screen or the computer connected to the device. Special Features: Bulky devices which are designed for chemistry/mechanical tests are used for many dentistry tests. MIN-100 is specially designed for your needs. It is ergonomic and easy to use. PRODUCT Clinical Physiodispenser It is a combined device consisted of FT-70 Android operating system and touch-operated tablet. It is possible to choose type of use from the embedded options and can be adjusted for planned operation. It can be adjusted during the operation easily and offers 10 options for saving different settings. The products supports 4 languages: English, France, Russian and Azerbaijani. Physiodispencer consists of 5 parts: User name, velocity, serum flow rate, torc and handpiece rate. Serum flow rate and torc can be controlled automatically or manually. Physiodispencer pedal is wireless. Buttons for changing serum flow rate, increasing torc and controlling the reciprocating motion of the handpiece and changing users options are exist on the wireless pedals. Besides physiodispencer, the device offers an extra menu for endodontical treatment. In addition to physiodispencer menu, patient information, applied treatments, appointment are added. Patent Information: Consist of name of patient, operation date and time, tooth and ranges in the mounth of the patient. Applied Treatments: Other treatments can be added if there is any. Provides options for giving appointment dates to the patient and makes notifications in the date of appointments of patients. Can send e-mails via pressing only one button to the patients later or when they are abroad.

278 / 880 EU-Japan Centre for Industrial Cooperation

Organisation

Country Japan City Tokyo Street Shirokane-Takanawa Station bldg 4F Web www.eu-japan.eu

Person

Name Alessandro Perna Information services

Organisation The EU-Japan Centre provides free support services to European Union companies and clusters interested in starting and/or expanding their activities with/in Japan. The support services are as follow: Cluster/companies missions to Japan (including a biotech mission in October 2019 & a nanotech one in January 2019) Manufacturing and business trainings Help and Information Desk Logistical support Established in 1987, the EU-Japan Centre for Industrial Cooperation is a unique venture between the European Commission and the Japanese Government. It aims at promoting all forms of industrial, trade and investment cooperation between the EU and Japan and at improving EU and Japanese companies’ competitiveness and cooperation by facilitating exchanges of experience and know-how between EU and Japanese businesses. The EU-Japan Centre is also member of the Enterprise Europe Network, providing with free EEN services in cooperation with EU EEN partnering organisations. Areas of Activity

• Other

Marketplace Opportunities SERVICE TRAINING IN JAPAN ON JAPANESE BUSINESS CULTURE The 2-week Get Ready for Japan programme offers EU companies the unique opportunity to experience and understand both the cultural and economic elements which define and explain Japan's business and technological achievements. The programme provides EU businessmen with a

279 / 880 professional Japan-related expertise. It also includes tailored B2B meetings. https://www.eu-japan.eu/ events/get-ready-for-japan-training-programme SERVICE PRACTICAL INFORMATION ON JAPAN In addition to this website displaying practical information on Japan, several support activities are also organised such as webinars, e-learning sessions and, experts’ publications, all dedicated to providing practical business information on Japan to EU companies. More details: http://www.EUbusinessinJapan.eu SERVICE INFODESK ABOUT JAPAN Any query about Japan? The Centre’s team will be pleased to find the answer for you or redirect you to the most relevant organisation. SERVICE ENTERPRISE EUROPE NETWORK - Japan Representative The Centre is member of Enterprise Europe Network and operates in Japan with the following services: - Promotion of EU Small and Medium Enterprises profiles among our Japan-based Network - Facilitate partnering process More info on http://www.een-japan.eu SERVICE INTERNSHIP PROGRAMME - Vulcanus in Europe Opportunity for EU-based companies to host a Japanese trainee. Every year, the EU-Japan Centre invites EU companies and research centres to host Japanese trainees for an 8-month internship in the EU from August to March of the following year. The trainees come from leading Japanese universities and are students in engineering or other scientific/high-tech fields. More info at: http://www.eu-japan.eu/events/vulcanus-europe-training-programme-japanese-students SERVICE BIOTECH AND NANOTECH MISSIONS TO JAPAN These missions target Clusters and SMEs in the biotech and nanotech sectors. The mission combines 3 days as exhibitors in a targeted trade fair with B2B opportunities plus 1 extra day with a partnering event for the biotech mission. http://www.eu-japan.eu/events/biotech-cluster-sme-mission https://www.eu-japan.eu/events/nanotech-cluster-sme-mission SERVICE World class manufacturing missions in Japan or in the EU To improve the competitiveness of a company: to make a product or provide a service in a quicker, better and cheaper way. oWCM, 1 week mission in Japan The 5-day World Class Manufacturing training mission (WCM) provides an in-depth analysis of Japanese manufacturing methodology and is aimed exclusively at EU Executives and Managers with knowledge of WCM and an engineering background. http://www.eu-japan.eu/events/world-class-manufacturing oLean in Europe, 2 days in the EU A benchmark mission to visit EU companies that are former participants to our WCM mission in Japan and that agreed to share their Lean experience and how they implemented what they learn in Japan in their manufacturing plant. http://www.eu-japan.eu/lean-europe-driving-competitiveness

280 / 880 EuCRF European Centre for Research & Financing

Organisation

Country Israel City Binyamina Street 2 Hamarva Street Web www.eu-crf.net

Person

Name Zohar Ben-Asher Head of Corporate Strategy & Innovation

Organisation EuCRF - European Centre for Research & Financing is a research, strategic planning & project management organisation (SME), concentrating on internationally funded R&D projects; on devising and implementing academic, scientific & developmental strategies and on research in such areas as social & management sciences, gender, educational planning, finance and strategic development. Typically, we work with both management and scientists on developing and implementing R&D internationally-funded projects so they meet, as best as can be, the expectations of the review process. In academic and research organisations, we work with the institution on academic & scientific strategies and performance assessment, offering assistance in developing methodological evaluation, co-ordination & management of proposed scientific & research projects and assistance in the preparation of proposals. We also contribute, as partners in R&D projects, to the RTD effort of planned projects as well as to the dissemination & exploitation (& commercialisation) efforts of the results of such projects. Our research expertise encompass the domains of social, financial, management & legal sciences, including cost-benefit & SWOT analyses and project budgeting, as well as gender issues, humanities & ethics, trade, marketing & business strategy and development. We also have in-house expertise pertaining to water & waste management and industrial planning. At the stage of the proposal preparation, we monitor and correct the work of the scientists on the sections dealing with of scientific & technological excellence and impact, so as to make them as suitable as possible to the expectations of the review process. We actually contribute to the writing the entries for sections pertaining to management and implementation, dissemination, exploitation & commercialisation and we prepare (together with the scientists) the risk analysis. Apart from working on the proposal, in projects in which we participate, we are normally responsible for the project management (and co-ordination if this is needed), the dissemination, exploitation & commercialisation and the work package devoted to socio-economic impact & implications (which has now become almost “required” in publicly funded projects). In collaborative projects, we shall also help you in the construction of the consortium so it is balanced to requirements and expectations in terms of geographical and professional distribution. EuCRF has been involved in setting research & development strategies and devising funding policies aimed at the increase of external funding to academic and industrial organisations in the UK, Denmark, Slovenia and more, where EuCRF and its teams have played crucial role. EuCRF and its 281 / 880 teams have been involved in the preparation, research work and management of numerous FP and other internationally funded projects, including NEWS, Coll-Plexity, PreGenesys, MoCaSin, HELM, HotZyme, TrainBioDiverse, BluePharmTrain and more. We have worked closely with numerous organisations & institutions, including universities, large industrial organisations, SMEs and others, such as University of Copenhagen, Buckingham University, Sigma Aldrich, Novozymes, Unilever, Montana State University, MictoDish, S.N. Winogradsky Institute of Microbiology of the Russian Academy of Sciences, the Italian Consiglio Nazionale Delle Ricerche, Universitaet Duisburg-Essen and many more. References and testimonials pertaining to EuCRF and its capabilities can be obtained from members of both management and developmental staff in all the organisations we have worked with, e.g., Dr. Esben Findt (University of Copenhagen), Dr. Roland Wohlgemuth (Sigma Aldrich), Dr. Zalan Szabo (MicroDish), Dr. Tanja Botić (University of Ljubljana) and more. Contact details of these persons are available upon request. I shall be happy to discuss with you further the possibilities of co-operation. You can contact me directly to my e-mail address: [email protected] or to my cellular phone: +972-54-6848845 or at my Skype: Zohar-BA. Areas of Activity

• Analytical and characterization services • Medical research • Bioinformatics, Big data analytics • Nutraceutics, probiotics, functional food, • Biomaterials cosmeceutics • Biosensors • Proteomics, metabolomics, nutrigenomics • Biotechnologies (Pharma&Medical • Regulatory affairs, validation Devices) • Life sciences related activities • Consulting services • Other • eHealth, mHealth, telemedicine • Project proposals support services • Genetics & Genomics • Investments

Marketplace Opportunities SERVICE R&D Projects' preparation & management -

282 / 880 Euronda spa

Organisation

Country Italy City sandrigo Street via chizzalunga,1 Web http://www.euronda.com

Person

Name idelbo tardelli Process technology and disposable product development manager

Organisation Manufacturer of disposable items and small equipment in the dental field and specific for hygiene and sterilization Areas of Activity

• Electromedical and medical equipment (non diag) • Medical devices

Marketplace Opportunities REQUEST electron accelerators Developing electron accelerators to sterilize and also suitable for small and medium-sized companies PROJECT COOPERATION electron accelerators Developing electron accelerators to sterilize and also suitable for small and medium-sized companies

283 / 880 Euronext

Organisation

Country Italy City Milano Street Corso Italia, 1 Web http://www.euronext.com/en

Person

Name Giovanni Vecchio Director - Italy Representative

Organisation Largest european stock exchange managing Paris, Amsterdam, Dublin, Lisbon and Brussels stock exchange. 1300 listed issuer, around 3.8bn market cap and first tech stock exchange in Europe with more than 350 tech SMEs listed and 94 lifescience company accessin an international investor pool and superior liqiodity. Areas of Activity

• Investments

Marketplace Opportunities SERVICE Accessing international investors through an IPO More than 1000 international investor from around the world focused on lifescience investing in our 94 listed lifescience issuers on our pan-european markets.

284 / 880 Exosomics Siena S.p.A.

Organisation

Country Italy City Siena Street Strada del Petriccio e Belriguardo, 35 Web www.exosomics.eu

Person

Name Andrea D'Ambrogio Head of Business Development

Organisation Exosomics is an innovative diagnostic company specialized in cancer screening and liquid biopsy. We develop screening tests and molecular diagnostics solutions to detect cancer early, when it can still be cured, based on the use of circulating exosomes and microvesicles as a source of biomarkers. We have a long-standing expertise and unique intellectual property related to the isolation and selective enrichment of tumor-originated extracellular vesicles (EVs) and exosomes from complex biofluids. To this purpose we develop and continuously implement our core line of proprietary reagents, kits and stand-alone solutions for cancer screening and liquid biopsy. This product line focuses on pre- analytical sample preparation and it is suitable for research use and clinical diagnostics. Our sample type- and purpose-tailored exosomes/EVs isolation and pre-analytical tools provide solutions that shorten the translation of biomarker discovery and clinical research data into diagnostic assays. Our state-of-art pre-analytical solutions include: - Sample collection and stabilization - Selective EV/exosome Enrichment solutions with tunable selectivity for distinct EV types - Ready-to-use EV-RNA and DNA extraction kits Areas of Activity

• CRO (Contract Research Organisation) • Medical research • Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • Investments

Marketplace Opportunities PRODUCT SoRTEV™ EV-RNA Low Volume 24rxn From plasma to RNA. Input from 0.5 to 2ml of plasma. This kit allows the purification of tumorderived RNA from tumor-derived exosomes. Enables the next generation of diagnostic assays based on the analysis of RNA. PRODUCT

286 / 880 SeleCTEV™ EV-DNA Low Volume 24rxn From plasma to DNA. Input from 0.5 to 2ml of plasma. This kit allows the purification of both circulating free DNA (cfDNA) and tumor-derived exosome DNA. SERVICE STANDARD EV ISOLATION AND CHARACTERIZATION State-of-art methods for EV isolation, quantification and characterization are available, in line with international guidelines and standards. SERVICE END-TO-END COMPANION DIAGNOSTIC SERVICES PARTNER TO PHARMACEUTICAL COMPANIES Exosomics exploits the proprietary EV specific reagents and finely tuned protocols to empower state- of-art analytical technologies and to build-up innovative blood and urine-based tests that can help advancing your efforts to bring effective precision medicine therapies to the market. Noninvasive and highly sensitive tests support high enrollment and more efficient patient stratification for more efficient clinical studies and trials. INVESTMENT OPPORTUNITY A Series Funding; Capital Seeking: € 5 M Company Stage: Commercial Launch Market Potential: € 80 BL 2018 Target Revenue: € 350K 2024 Target Revenue: € 35 ML High Growth Rate after 2024

287 / 880 Exosomics Siena SpA

Organisation

Country Italy City Siena Street Strada del Petriccio e Belrigurdo 35 Web http://www.exosomics.eu

Person

Name Antonio Chiesi CEO

Organisation Exosomics is an innovative diagnostic company specialized in cancer screening and liquid biopsy. We develop screening tests and molecular diagnostics solutions to detect cancer early, when it can still be cured, based on the use of circulating exosomes and microvesicles as a source of biomarkers. We have a long-standing expertise and unique intellectual property related to the isolation and selective enrichment of tumor-originated extracellular vesicles (EVs) and exosomes from complex biofluids. To this purpose we develop and continuously implement our core line of proprietary reagents, kits and stand-alone solutions for cancer screening and liquid biopsy. This product line focuses on pre- analytical sample preparation and it is suitable for research use and clinical diagnostics. Our sample type- and purpose-tailored exosomes/EVs isolation and pre-analytical tools provide solutions that shorten the translation of biomarker discovery and clinical research data into diagnostic assays. Our state-of-art pre-analytical solutions include: - Sample collection and stabilization - Selective EV/exosome Enrichment solutions with tunable selectivity for distinct EV types - Ready-to-use EV-RNA and DNA extraction kits Areas of Activity

• CRO (Contract Research Organisation) • Life sciences related activities • Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • Medical research

Marketplace Opportunities REQUEST Series A financing round We are looking for a 5 ml euro series A financing round INVESTMENT OPPORTUNITY Series A financing round we have launche a series A financing round for 5 ml euro open to external investors 288 / 880 PARTNERSHIP Solutions for Liquid Biopsy We are looking for development and/or commercial partners for our solutions for exosome based liquid biopsy enabling next generation DNA and/or RNA molecular diagnostics PRODUCT SoRTEV and SeleCTEV kits SoRTEV™ Enrichment kit allows the selective purification of tumor-derived RNA from tumor-enriched extracellular vesicles and exosomes from biofluids. The isolation is based on immuno-affinity binding to beads coated with Exosomics proprietary antibodies against exosome surface antigens. SeleCTEV™ DNA Enrichment Kits SeleCTEV™ Enrichment kit allows the selective purification of tumor-derived DNA from tumor-enriched extracellular vesicles and exosomes from biofluids. The isolation is based on Exosomics proprietary peptide affinity method. SERVICE END-TO-END COMPANION DIAGNOSTIC SERVICES PARTNER TO PHARMACEUTICAL COMPANIES Exosomics exploits the proprietary EV specific reagents and finely tuned protocols to empower state- of-art analytical technologies and to build-up innovative blood and urine-based tests that can help advancing your efforts to bring effective precision medicine therapies to the market. Noninvasive and highly sensitive tests support high enrollment and more efficient patient stratification for more efficient clinical studies and trials. Exosomics offers following spectrum of companion diagnostic services: Non-invasive specimen collection and accommodation of low sample volumes (0.5-2 ml of plasma, 5-10 ml of urine sample). SOPs for sample harvesting and storage, friendly to ship, low sample handling Flexibility and collaborative project scheme – tailored to the client and market needs Feasibility and Concept Study Qualitative and Quantitative detection of biomarker of interest Custom Companion Diagnostics Development including: Biomarker assay (immunoassays and molecular Dx assays) development and analytical validation Prototype kit development Clinical validation support Strict Quality Control System Expert Project Management for timely support and delivery according to Milestones GCP/ISO Compliance Commercialization of kits to global markets

289 / 880 Fastenica s.r.l.

Organisation

Country Italy City Pontedera Street Viale Rinaldo Piaggio, 32 Web http://www.fastenica.it/

Person

Name Fabio Leoni President and CEO

Organisation FASTENICA s.r.l. is a product company spin-off of Scuola Superiore Sant’Anna established in 2008. The company mission is devoted to both industrial and market exploitation of technical and scientific results achieved by his shareholders during their engagement in several local, regional and European projects. The basis of our business model is inspired by our vision about how an efficient technology transfer between Research and Industries must be carried out. FASTENICA’s business development is based on our multidisciplinary knowledge and competencies which locates our company at the center of relations between product makers, research and fund raising activities, technological providers and real market expectations. This approach enable us to be able to put on the market innovative and attractive mechatronic, robotic products and services in order to generate profits in a sustainable and long-term way for our company and our clients. Areas of Activity

• Manufacturing & process engineering • Surgery technologies and applications • Medical devices

Marketplace Opportunities PRODUCT LA-ROSES – Laser Assisted Robotic Surgery of the anterior Eye Segment The objective of LA-ROSES is the development of a teleoperated robotic consolle for laser assisted suturing of corneal wounds in keratoplasty (cornea transplantation). The robotic platform, which will be developed in the framework of the European Project ECHORD++ (http://echord.eu) will be useful in several ophthalmic surgical applications replacing the stitches inserted inside the eye for suturing. Examples of applications are: the laser welding of full-thickness corneal transplantation, surgery in the anterior lamellar, in endothelial transplantation, congenital cataract surgery and, more generally, for the closure of corneal incisions. One of the main advantages, thanks to the reduction of the inflammatory reaction, of such laser robotic platform will be the reduction of the post-surgical recovering time. Laser welding also allows the suturing of the cornea endothelium which is impossible to seal using other surgical techniques. 290 / 880 Fen Technology

Organisation

Country United Kingdom City Cambridge Street Web https://www.fentechnology.co.uk/

Person

Name Francesco Di Martino Innovation Process Manager

Organisation Fen Technology Ltd is a Cambridge (UK) based company. We offer innovative electronics software & hardware development services as well as easy access to many new technologies. Our primary activity is new product development; however we also have a good track record of helping clients identify their products' technological "next step" based on our broad experience of applying innovations, in electronics sensing, control & monitoring techniques, to existing products. Our skills include: • Hardware development • Software development • FPGA design • Embedded firmware • PC Lab • Web & Mobile App design • GUI design Some of our capability areas include: • Biosensors and microfluidic sample handling systems • End to End IoT technology • Scientific instrument design • Control, sensing and power units for Scanning Electron Microscopes, Electron Beam Micro- Fabrication units and Mass spectrometers • Ultrasonic flow sensors for liquid & gaseous systems; modelling, simulation & design • Image analysers including hardware accelerated morphological processors • Automated robotic laboratory slide manipulation, sensing and control • Cross platform mobile & web software apps • High-speed image inspection systems for pharmaceuticals and industrial materials • Portable civil / military medical vital signs monitor & communications hub See the marketplace profile for more details. Fen do not retain or seek to retain IP in product designs carried out for it’s customers. If you ever have need of additional design capacity or engineering experience in areas not currently covered by your own design team, we would be grateful for the opportunity to discuss with you how we might support those requirements.

291 / 880 Areas of Activity

• 3D Printing/addictive manufacturing for • Software, ICT applications, system biomedical applications integration • Bioinformatics, Big data analytics • EPR, Clinical/healthcare management • CMO (Contract Manufacturing software Organisation) • Virtual reality applications • Diagnostics - Equipment and accessories • Medical devices • Diagnostics - Imaging equipment and • IT Applications for Health processing • eHealth, mHealth, telemedicine • Electromedical and medical equipment (non diag) • Manufacturing & process engineering

Marketplace Opportunities SERVICE Electronic Design Services for life sciences and other sectors Innovative Hardware and Software solutions designed by experienced development engineers. Since its foundation Fen has completed some 400 development projects for around 100 clients covering a diverse range of technology areas and market sectors. We offer a comprehensive service, supporting clients from concept through to vendor selection, mass production and production test. Fen's engineers have experience of the different challenges faced by high volume consumer, low volume instrumentation and most other variations of product in between. Our capability areas include: • Biosensors and microfluidic sample handling systems • Cross platform mobile & web software apps • Scientific instrument design • Control, sensing and power units for Scanning Electron Microscopes, Electron Beam Micro- Fabrication units and Mass spectrometers • Ultrasonic flow sensors for liquid & gaseous systems; modelling, simulation & design • Portable civil / military medical vital signs monitor & communications hub • Image analysers including hardware accelerated morphological processors • Automated robotic laboratory slide manipulation, sensing and control • End to End IoT technology. Bespoke hardware & software design, wireless comm’s (2G/3G4G/ZigBee/ Bluetooth/BLE/Dect ULE/WiFi/Lora/NB-IoT/Cat-M1,) mobile software apps, web pages, data compression (lightweight OTA protocols), cloud / secure server side software (web application frameworks), database design both SQL and NoSQL, telemetry, tracking in multi-country scenarios, connected homes. • High-reliability, environmentally robust, analogue and digital logging products • Precision video & telemetry data sync • IR line scanners, cameras and thermography instrumentation • Embedded control and monitoring solutions for fuel cell • Road Toll Vehicle Tagging system • High-speed image inspection systems for pharmaceuticals and industrial materials • Gas detection • Environmental sensors & monitoring systems • Acoustic correlation fault detections systems • GNSS/Cellular sub-min tracking tags, telemetry & remote diagnostics systems • GUI development • Printer electronics hardware & software design for inkjet / thermal / laser printers. We have developed innovative low-power, customisable waveform, inkjet print head driver technology IP which is now 292 / 880 available. • Exceptionally high-quality audio amplifiers • Processing of multiple professional audio streams • Streaming and server-based audio systems • Oil well-head / pipeline laminar fluid flow sensors

293 / 880 FESTO SPA

Organisation

Country Italy City Assago (MI) Street Via E Fermi, 36 Web https://www.festo.com/medlab/en/cms/blog.htm

Person

Name Loris Scalzo Sales Engineer

Organisation Festo’s LifeTech division offers innovative solutions for medical technology and laboratory automation. Festo supports systems and equipment manufacturers by combining top quality with maximum efficiency in components and custom-specific solutions. Areas of Activity

• Diagnostics - Equipment and accessories • Laboratory equipment, reagents, software • Packaging & labelling • Life sciences related activities • Other

Marketplace Opportunities PRODUCT Liquid Handling Modular Dosing System with dispense head VTOE Dosing with one to eight liquid channels, different fluids and dosing volumes – the modular dosing system VTOE is compact, flexible and extremely precise

PRODUCT Proportional valves with piezo technology Proportional valves with piezo technology are suitable for a huge variety of applications in medical technology. Thanks to their compact design and low power consumption, they are ideal for installation in battery-operated devices.

294 / 880 FitoAmico Italia s.r.l.

Organisation

Country Italy City CESENA Street piazzale dell'Autostrada, 36

Person

Name Davide Alessandri Project Manager

Organisation Our project deals with the research, control and formulation of foods and ingredients that can bring healthy benefit to people and in particular to people of the Third Age In particular, we select, test and formulate products and ingredients that respect eco-sustainability and have a significant added value Areas of Activity

• Consulting services • Medical devices • Investments • Nutraceutics, probiotics, functional food, cosmeceutics • Proteomics, metabolomics, nutrigenomics

Marketplace Opportunities PRODUCT Selection of new nutraceutical and cosmeceutical products and ingredients We are looking for new products and ingredients, nutraceuticals and cosmeceuticals for inclusion in our selections for senior citizens. The countries of destination of the products and ingredients will be those European and Swiss

295 / 880 Flowmetric Europe S.p.A.

Organisation

Country Italy City Lodi Street Via Albert Einstein Web www.flowmetric-europe.com

Person

Name Stefano Di Giovine COO & Director Business Development

Organisation FlowMetric Europe S.p.A. (FME), is a provider of polychromatic florescence flow cytometry and cell sorting (FACS) services. We serve partners in multiple fields including biotechnology, small and large cap pharmaceuticals, hospitals, academic institutions and Agri-Food companies. Established in July 2014 at the Parco Tecnologico Padano (Lodi) provides state-of-the-art flow cytometry techniques that combine proprietary assays with advanced analytics to support all stages of drug development including pre-clinical, non-clinical and clinical development, testing of bio-actives compounds and to support product claims. FACS represents a fast and reliable method for characterizing and isolating certain cell subpopulations based on fluorescent labeling, and can be applied to a great variety of organisms and cell types, including prokaryotic as well as eukaryotic cells. About The FlowMetric Family of Companies The FlowMetric Family of Companies consist of FlowMetric, Inc and two additional companies, FlowMetric Europe, S.p.A. and FlowMetric Diagnostics, Inc. FlowMetric, Inc. and FlowMetric Europe, S.p.A., founded in 2010 and 2014 respectively, are FACS service contract research organizations (CROs), focused on providing polychromatic flow cytometry and cell sorting services to bio-pharma and drug discovery companies. FlowMetric Diagnostics, Inc., founded in 2014, utilizes a flow cytometry-based platform to analyze cell-mediated immune responses. The company’s proprietary assays can be readily adapted for infection screening and immune response evaluation through highly sensitive biomarker analysis. The FlowMetric family of companies are committed to providing independent, unbiased, comprehensive and precise results delivered with an uncompromising commitment to quality. Areas of Activity

• Analytical and characterization services • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation Devices) • Pharmaceutics • CRO (Contract Research Organisation) • Life sciences related activities • Diagnostics IVD • Vaccines • Drug screening & delivery • Medical research

296 / 880 • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Fluorescence Activated Cell Sorting Fluorescence activated cell sorting (FACS) is routinely used in pharmaceutical and biotechnology companies to isolate cells. Typically, the cells in suspension are “tagged” with fluorescent antibodies. This tag allows for pertinent cells to be identified and isolated into a liquid medium for further analysis. The biological applications for cell sorting include: - Protein Engineering & Development - Screening of peptide libraries for binding - Selecting antibody mutants - Screening for enzymatic activity - Screening for over-producing cells - Cell Engineering - Disease Identification/Characterization - Isolating cells to characterize them based on multiple modalities - Nucleic acid - Protein expression - Cellular function With cell sorting At FME, we guide partners to achieve their biological goals, whether it is isolation of rare or abundant eukaryotic cell types. SERVICE Pre-Clinical Flow Cytometry Services Flow Cytometry is a technology that is used in all aspects of pre-clinical development ranging from target selection and validation, to mechanism of action identification. Using cells in suspension, either from cell lines or from peripheral blood, we will quantitate the response on a per-cell basis. This is especially valuable in a setting where there are multiple phenotypes in the cell suspension and the biological response is different in each subset. This is possible with cells from multiple species including, but not limited to, human, non-human primates, rodents, and canine. The possible applications for pre-clinical development include: - Understanding the mechanism of action of compounds. - Understanding the response of cells to external stimuli (Virus, drug, and other entities). - Developing potential biomarkers for diagnostic use to support diagnosis of specific disease conditions or personalized medicine options. - Identification of ways to separate patients within a heterogeneous disease such as cancer into different categories so that treatment can be personalized leading to improved response rates. - FlowMetric routinely performs pre-clinical assays using flow cytometry to answer the above questions. Some examples are: - Cell cycle analysis – Identification of cellular division stages. - Cell proliferation – Identification and enumeration of cellular proliferation levels. - Cell viability – Identification and numeration of dead (necrotic) and dying (apoptotic) cells. - Cell phenotyping – Identification and enumeration of different types of cells in heterogeneous mixture. - Cell signaling – Identification and enumeration of messaging within and between cell. - Intracellular Cytokine Secretion (ICS) – Identification and enumeration of cells that are secreting factors (cytokines)

297 / 880 SERVICE Clinical Flow Cytometry Services Flow cytometry is routinely used in clinical laboratories for the diagnosis, prognosis and monitoring of disease. This leads to familiarity within the physician and nurse practitioner community on the use and collection of blood and other fluids for flow cytometry. Some of the common applications include: - Detection of minimal residual disease (MRD) - Stem cell enumeration - Solid organ transplantation - T-cell cross match - Postoperative monitoring - Autoantibody detection - HIV infection status - Primary and secondary immunodeficiency - Paroxysmal nocturnal hemoglobinuria (PNH) diagnosis - Red Blood cell, reticulocyte and plate deficiencies SERVICE Custom Monoclonal Antibody Production & Screening Services FME uses proven and tested methodologies for generating your next monoclonal antibody. As a one stop source for both your hybridoma production and screening needs using your in-house/vendor generated tissue, FlowMetric can perform any, and all of the following phases in our GxP laboratories: SERVICE Agri-Food Services Flow cytometry is a powerful technology with a wide variety of applications in Agri-Food sector including: - Analysis of Ploidy Level - Check of ploidy level of starting material for tissue culture. - Check for purity of seed. - Screen for haploids and diploids from anther, microspore and ovary cultures. - Screen for diploids after genetic transformation. - Screen for triploids, e.g. production of hybrid seed. - Screen for tetraploids, e.g. spontaneously caused by endomitosis or artificially caused by chemical treatment or after radiation treatment. - Analysis of Endopolyploidy - Detection of chimaeras after artificial polyploidisation. - Analysis of endopolyploidy in plants or plant parts. - Cell Cycle Analysis or the measure of polyploidy - Determination of percentages of cells in different stages of cell cycle (G1, S, G2/M phase of the mitosis). - Determination of the percentage of cells in the different ploidy levels of polyploid plants. - Determination of small differences in DNA amount For aneuploids. - For interspecific hybrids (only if the difference of the nuclear DNA amount between the parents can be measured). - Search for polyploidy as a result of apomixes. - Determination of Nuclear Genome Size - Detection of differences between genotypes.

298 / 880 Fondazione E. Amaldi

Organisation

Country Italy City Rome Street

Person

Name Costantino Del Gaudio Head of Bioengineering Department

Organisation Fondazione E. Amaldi (E. Amaldi Foundation) has been established by the Italian Space Agency and the Research Consortium Hypatia in 2017 with the mission to foster, support and develop scientific research oriented to technology transfer. For this aim, Fondazione E. Amaldi promotes the dissemination of the technological know-how within national and international research centres of excellence, concurs to define the national strategic industrial plan, encourages the reliable translation of the collected results, especially by SMEs, and improves the patent application process. Fondazione E. Amaldi aims to establish the Key Enabling Technologies Laboratories (KET Labs) to support the R&D activity of SMEs and bridge the gap with large enterprises in order to define a common working unit. This will be accomplished by setting up tailored research laboratories and rapid prototyping centres, and offering specific facilities and management consulting for education, technical tutoring and grant application. Areas of Activity

• 3D Printing/addictive manufacturing for • Life sciences related activities biomedical applications • Project proposals support services • Biomaterials • Consulting services • Investments • Medical research

Marketplace Opportunities SERVICE Clustering The main activities are focused to: •Support interdisciplinary approaches and manage complexity introduced by new technologies either at economic and social level;

299 / 880 •Elaborate original solutions combining multiple technological inputs; •Cooperate with universities to plan strategic activity towards business outputs; •Manage research laboratories to optimize their targets; •Make results available within national and international networks to enhance a cooperative model. PARTNERSHIP Cooperation for research projects Fondazione E. Amaldi is available to start a partnership for national and European research project proposal, offering both scientific expertise on additive manufacturing and materials characterization, and management skills.

300 / 880 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Organisation

Country Italy City Milano Street Via Francesco Sforza 28 Web https://www.policlinico.mi.it/

Person

Name Laura Spinardi TTO manager

Organisation The Fondazione IRCCS "Ca' Granda Ospedale Maggiore Policlinico" is a leading Italian medical research institute committed to healthcare and translational medicine. The Ospedale Maggiore of Milan – Magna Domus Hospitalis or Cà Granda - was funded in 1456 by the Duke of Milan Francesco Sforza. The mission of the Foundation is to pursue excellence in the domain of translational research in biomedicine and in the organization and management of health services.The scientific traslational research programmes are focused on: - Rare diseases and Emergency medical care. - Regenerative medicine and transplantation. Major expertise are also in the study of pathophysiology of: acute and chronic respiratory disease, autoimmune diseases and immunotheraphy, bleeding and thrombotic diseases, clinical hypertension and cardiovascular diseases, metabolic and digestive diseases, neurological diseases.The Fondazione combines the hospital service and the scientific research with university education. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Laboratory equipment, reagents, software • Diagnostics - Imaging equipment and • Medical devices processing • eHealth, mHealth, telemedicine • Genetics & Genomics • Medical research • Proteomics, metabolomics, nutrigenomics

Marketplace Opportunities

301 / 880 PARTNERSHIP Method for determining inhomogeneity in lung tissue It represents an advancement in the treatment of patients undergoing mechanical ventilation allowing: a quantification of the lung damage related to mechanical ventilation; a selection of the patients who needs alternative treatment techniques. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The method is undergoing a validation study to optimize a software for the determination of pressure multipliers within the lung parenchima on CT scan images. The identification of patients for whom mechanical ventilation is dangerous and need ExtraCorporeal Membrane Oxygenation (ECMO) support will allow prompt patient referall to ECMO centers avoiding prolonged mechanical ventilation with increased odds of unfavorable outcome. CURRENT STAGE OF DEVELOPMENT: Development phase – laboratory tested. Patent granted in Europe. MARKET APPLICATION Diagnostic and Clinic. TYPE OF PARTNER SOUGHT Industry for co-development and implementation of the existing system and distribution PARTNERSHIP Neuron Specific Proteins for the treatment of nephropathies Podocytes are highly differentiated cells with a crucial role in the glomerular fitration barrier. Alteration in the podocyte funcion may lead to proteinuria and disorders of the kidney (nephropathy). INNOVATIVE ASPECTS AND MAIN ADVANTAGES We identfy that glomeruli express many neuron-specific and especially synapse-specific protein similarities, including neurotransmitter receptors. Moreover, modulation of the activity of these synapse-specific proteins results in modulation of podocyte funcion. Use of neuron specific proteins in the manifacture of a medicament for the use in the treatment of nephopaties. Nanodelivery of the medicament will be preferred. Proof of concept on human primary cells and animal models. Patent granted in Europe and USA. MARKET APPLICATION By nephopathies , we include all disorders characterized by alteration of the glomerular cells. TYPE OF PARTNER SOUGHT Industrial partners & research institutes for clinical trials and co-development .

302 / 880 Fondazione Unimi

Organisation

Country Italy City Milano Street viale Ortles 22/4 Web http://www.fondazionefilarete.com/it/index.html

Person

Name Margherita Chierici Business Devlopment

Organisation The University of Milan, founded in 1924, is one of the major universities in Lombardy and it is the unique Italian university member of the LERU network. From 2017 the University of Milan has started the process of creation of a new operational structure for knowledge transfer in the form of a University Foundation with governance autonomy, strategic flexibility and financial independence. The UniMi Foundation was established In June 2018 and it manages all the activities related to Intellectual Property, from ideas disclosure to patent licensing and commercialization, and to University’s spin off creation, including incubation activities. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Life sciences related activities • Genetics & Genomics • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PARTNERSHIP Treatment for Parkinson's disease Parkinson's disease is a neurodegenerative disease whose typical motor symptoms result from the death of the substantia nigra cells. Currently the treatment of these symptoms occurs by pharmacological and surgical means. The researchers have identified a molecule whose administration leads to a reduction of the motor symptoms typical of Parkinson's disease (data obtained in vivo), and which could also bring positive results in the treatment of other neurodegenerative diseases such as Alzheimer's and Multiple Sclerosis or in reducing the symptoms related to the aging process. The chemical structure of this molecule (oligosaccharide) has no critical factors on the toxicity profile and is able to pass the blood-brain barrier remaining unchanged

303 / 880 PARTNERSHIP Antiseptic Molecule Domiphen bromide is a molecule with antiseptic activity, active both on Gram positive bacteria and on Gram negative bacteria, used as a preservative in pharmaceutical and cosmetic formulations and in some commonly used hygiene products (for example toothpastes or mouthwashes). This compound tends to degrade over time, losing the stated dosage. The new synthesized compound has a greater stability over time, maintaining its concentration unaltered. In addition, in vitro tests performed showed a comparable antiseptic activity if not greater than commonly used domiphen bromide. PARTNERSHIP Antiinflammatory molecules The tanshinones molecules represent a class of natural quinone products, derived from traditional Chinese medicine, and known for their therapeutic properties (for example, protective activity on cardio- and cerebrovascular system, anti-cancer, antioxidant and neuro-protective). The researchers have identified a preparation pathway for analogous molecules that show similar biological properties but which can be - given the flexibility of the synthetic pathways - easily modifiable to better orient the activity towards a specific therapeutic area or molecular target, and to be improve their stability and bioavailability (unlike natural tanshinones).

304 / 880 Freia Farmaceutici Srl

Organisation

Country Italy City Milano Street Web www.freiafarmaceutici.it

Person

Name Alessandro Cavalieri CEO

Organisation We are an indipendent Italian pharmaceutical company established in 2009, committed to research, develop, manufacture and commercialize pharmaceutical products and active ingredients originated from plants, particularly Canapa Sativa. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Nutraceutics, probiotics, functional food, cosmeceutics • Proteomics, metabolomics, nutrigenomics

Marketplace Opportunities PRODUCT Dermatological line Topic products (medical devices class IIa) for oncologic patients (radio- chemio-therapy), for dermatitis and post-surgical patients.

PRODUCT Gynecologic line Gynecologic products (medical devices class IIa and nutritional supplements) toimprove women quality of life, taking care of pregnancy and nursing needs, symptoms of menopause, preventing osteoporosis and offering an innovative therapy for lichen and vaginal dryness.

305 / 880 Fusion farm SRL

Organisation

Country Italy City Viterbo Street Via G. Marconi 17 Web http://www.fusionfarm.it

Person

Name Grazia Tocchi Co-Owner

Organisation Fusion Farm devices, plans and products new muscle skeletal, neurological, gastrointestinal nutraceuticals on the base of grounded scientific literature in according with regulations in force. The plant contract manufacturing is certified organic, ISO 9001;2008, GMP. Fusion Farm is committed in research and innovation and it is holder of Italian and PCT patent application . We invest in clinical studies and we are able to deliver “turnkey”, tailor made and effective nutraceuticals using our know-how and patent innovation. Fusion Farm proposes nutraceuticals for wide application fields: osteoporosis, osteopenia, fibromyalgia, sarcopenia, intestinal disorders. Desired cooperation type: licensing agreement to introduce, in new markets effective nutraceuticals . Fusion Farm is available for licensing-out agreement concerning: patent, know-how and trade mark. Areas of Activity

• Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PRODUCT Patented Nutraceuticals Our patent concerns protection of tight junctions and intestinal villus architecture by damage induced by stress, aging, chemical agents, alcohol ect. Applications are wide because scientists consider intestinal barrier disruption as the developing key for allergic, autoimmune, and metabolic diseases. In fact the intestinal mucosa is charged with task of maintaining the balance between the absorption of nutrients and ions, the secretion of fluids, and the protection from microorganisms, toxins, and dietary antigens present in the lumen. The epithelial cells are held together by tight junctions, adherens junctions and desmosomes. The lack of intestinal barrier modulated by tight junctions, increases intestinal permeability, that has been shown to play a crucial role in the pathogenesis of Celiac and Inflammatory bowel disease, Multiple sclerosis, Obesity, Polycystic ovary syndrome, Heart diseases, Neurological disorders, Systemic infectious diseases, Non-celiac gluten sensitivity, Intestinal diseases. Our patent formulation Sitrophin (EU Trade Mark): 1) it is composed by natural substances, useful to protect intestinal barrier 306 / 880 2)it is supported by in-vitro studies (clinical study in the works ) 3)it can be used even in combination with minerals, vitamins, proteins and many others active components 4)it is new in the marked 5) it is active in small amounts and suitable for tablets, capsules, granules Others nutraceuticals now available concern: - Bone health 1) Complete of all nutrients for bone health 2) Comfortable tablets 3) Bioavailable Calcium source 4) High gastrointestinal tolerance 5) clinical study under going 6) patent -Fibromyalgia 1) studied for : fibro fog, pain, depression, fatigue, gastrointestinal disorders 2) supported by scientific literature 3) clinical study in the works 4) patent 5) flavoured granulate formulation - Sarcopenia 1) new approach to sarcopenia 2) flavoured granulate formulation 3) supported by scientific literature 4) clinical study in the works 5) patent SERVICE Nutraceuticals We are able to deliver “turnkey”, tailor made and effective nutraceuticals using our know-how and patent innovation. PARTNERSHIP Type and Role of Partner Sought Nutraceutical or Pharmaceutical companies active in muscle skeletal, gastrointestinal, neurological fields and equipped with a force sales of representatives visiting rheumatologists, physiatrists, endocrinologists, neurologists or gastroenterologists. The partner should be interested to licensing-in agreement for nutraceuticals. License agreement concerning: patent, know-how, trade marks-

307 / 880 FUTURE FIT ENGINEERING

Organisation

Country Spain City SANT CUGAT DEL VALLES Street CALLE PAU CASALS 35-41 ESC B BAJOS 1º Web http://www.futurefitengineering.com

Person

Name Andrea de Luca CEO

Organisation Founded by Andrea de Luca Future Fit is an engineering development company located in Barcelona (Spain) that helps companies bring to the market new and better products from the point of view of aesthetics, manufacturability and functionality. To achieve this, we follow the project from the initial concept, helping customers to define the list of requirements, through the conceptual and mechanical design, to reach the industrialization phase. "Design for simplicity" is our motto. We tried to apply it to achieve high value added products as well as simple for functionality and manufacturing processes. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical devices biomedical applications • Consulting services • Manufacturing & process engineering

Marketplace Opportunities SERVICE Product development We offer these services: -Industrial design -Mechanical Engineering -Prototype -Industrialization For more details, please visit the web site: http://www.futurefitengineering.com/ PRODUCT Product development of medical devices You don't have to care about any of these steps: Product specification Conceptual development Mechanical engineering and Cad and Fea development 308 / 880 Machine design Functional prototype Engineering documentation

309 / 880 GEM FOR LAB

Organisation

Country Italy City Colleretto Giacosa Street Via Ribes, 5 Web http://www.gemforlab.com

Person

Name SIMONE CANESTRI Marketing and Development Manager

Organisation GEM FORLAB gives continuity to the experience of ABLE Biosciences as a global provider of scientific technology and services to the life science industry. It delivers solutions to companies of all size and shapes. GEM FORLAB performs its activities by means of three technology areas: • Cell and Molecular Biology & Immunoassay • Mass Spectrometry & Proteomics • Organic Chemistry The chemistry unit provides all essential components for early drug discovery such as synthesis of chemical intermediates, process impurities, reference compounds, drug metabolites, and pro-drugs; lead generation and optimization; bioconjugate chemistry; targeted molecules for MRI and others molecular imaging techniques. ABLE Biosciences is a GLP certified Test Facility for small and large molecules quantitative analysis in biological matrices by means of mass spectrometry, immunometric assays and qPCR and it is included in OsSC register of private laboratories qualified to perform analysis on samples derived from drug clinical trials (phase I-II-III) in compliance with GCP. Areas of Activity

• Analytical and characterization services • Pharmaceutics • Biotechnologies (Pharma&Medical • Proteomics, metabolomics, nutrigenomics Devices) • Regulatory affairs, validation • Chemicals & APIs • Life sciences related activities • CRO (Contract Research Organisation) • Vaccines • Diagnostics IVD • Medical devices • Drug screening & delivery • Genetics & Genomics • Nutraceutics, probiotics, functional food, cosmeceutics

310 / 880 Marketplace Opportunities SERVICE In vitro Target Validation – Signal pathway investigation GEM FORLAB can support discovery phases as in vitro Target Validation or signal pathway investigation by means of the integration of techniques like stable or transient cell transfection, Protein/protein interaction, Antagonist competition, Cell uptake, ICC/IHC/IF, Phosphoproteomics, Gene expression. SERVICE Biomarker discovery and detection Thanks to the gathered experience GEM FORLAB can support Biomarker discovery and detection Proteome analysis through, as instance, Gene expression analysis, Quantitative detection method set up and application (immunoenzymatic assys, mass spectrometry, real time PCR). SERVICE Protein identification and characterization MALDI imaging of endogenous or exogenous unlabeled compounds (small molecules and proteins) (case study). Peptide mass fingerprinting by protease digestion (proteins are digested with trypsin and the resulting peptides are analyzed by LC-MS/MS). Protein mapping (processing with multiple enzymes, identification reported for individual enzymes). Proteome and phospho-proteome qualitative and semi-quantitative analysis by 2-DE followed by image analysis. Phosphorylation and glycosylation sites determination through MS/MS (from a high purity sample). Protein/proteome profiling (qualitative profile of a complex sample). ImmunoPrecipitation-profiling (ID of immunoprecipitated or co-immunoprecipitated proteins; these experiments can be used to profile the protein content of a sample). SERVICE Pharmacokinetics/ADME Pharmacokinetics Biodistribution (case study; case study) CYPs Inhibition/Induction Cytotoxicity Drug Solubility In-vitro Intrinsic Clearance Membrane Permeability Metabolic Stability Protein Binding GLP Compliance SERVICE Bioanalytical Method Development and Validation Quantitative analysis of proteins in complex matrices (method setup and validation, analysis) using immunoenzymatic assays. Quantitative analysis of nucleic acids (case study, case study) in complex matrices (method setup and validation, analysis) using Real time PCR. LC-MS/MS for quantitative analysis of small molecules and peptides (case study) (method setup and validation, analysis) using SRM or MRM mode. PK/TK and Biomarkers analyses, if required by regulatory authorities, can be performed according to GLP and relevant ICH, EMEA, and FDA guidelines and routinely audited by our Quality Assurance

311 / 880 Group. SERVICE Pharmacokinetics/Pharmacodynamic on human clinical samples Anti-drug antibodies Anti Host Cell antibodies (case study) Biomarkers Circulating proteins (e.g.,cytokines, chemokines and additional auto-antibodies) Gene Expression GCP compliance SERVICE Bioanalytical Method Development and Validation for human samples analysis Quantitative analysis of proteins in human samples (case study) (method setup and validation, analysis) using immunoenzymatic assays. Quantitative analysis of nucleic acids in human samples (method setup and validation, analysis) using Real time PCR. LC-MS/MS for quantitative analysis of small molecules and peptides in human samples (method setup and validation, analysis) using SRM or MRM mode. PK/TK and Biomarkers analyses, if required by regulatory authorities, can be performed according to GCLP and relevant ICH, EMEA, and FDA guidelines and routinely audited by our Quality Assurance Group. SERVICE In vitro diagnostics GEM FORLAB can give support to validation of IVD equipment and reagents Different matrices: human whole blood, plasma, CSF, urine and nasal swab, stool and fecal swab Different steps: extraction, amplification and result interpretation. As regards assays, an analytical performance evaluation is executed; the method efficiency, linearity, accuracy, precision, repeatability, reproducibility and sensitivity is analyzed. Several human samples from different donors are then analyzed and data compared with results obtained with reference method; this way their negativity/positivity is confirmed to assess the assay specificity and sensitivity. SERVICE Quality Control Contamination detection from Mycoplasma, bacteria, viruses (case study), production processes (nucleic acids, nucleases, endotoxins). Qualitative analysis of low and high molecular weight compounds for purity/identity/homogeneity verification by mass spectrometry or HPLC-UV. PARTNERSHIP Test Facility for in vivo study phase GEM FORLAB would like to widen its offer and conduct also the in vivo phase of a non-clinical study; GLP Compliance

312 / 880 Gemma SRL

Organisation

Country Italy City Lodi Street Corso Roma 118

Person

Name Giuseppe Augello Researcher

Organisation A company which want to develop a system to monitor patient with heart and pulmonary disease both in hospital and in home setting with appropriate werable devices. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • IT Applications for Health • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine

Marketplace Opportunities PRODUCT Device to monitor patient status while at home or in the hospital A glove to monitor cardiac status with blood pressure, O2 and ECG. Able to transmit patient data trough telephone patient. PARTNERSHIP Find a company able to product our glove We search for a partner able to product and commercialize our glove. REQUEST Find a partnership to product and commercialize our product We are a startup which idealized a glove to monitor patient cardiac condition. We search for a partner to product and commercialize our device.

313 / 880 Genovax

Organisation

Country Italy City Colleretto Giacosa Street Via Ribes, 5 Web www.genovax.it

Person

Name DOMENICO CRISCUOLO President

Organisation Genovax is a spin-off of the University of Genova and was founded in 2008 as part of the portfolio of start-up companies that were funded and are managed by Eporgen Venture (www.eporgen.com). Genovax is developing its products up to pre-clinical (GX101) or clinical (GX301) proof-of-concept and will subsequently seek a suitable partner for out-licensing. At present Genovax has a pipeline of 2 active projects: GX 101 (lupus) Proof-of-concept in animal models of SLE of the efficacy of gene vaccination with a vector containing the gene coding for the pCons “consensus” peptide. GX 301 (prostate and other cancers) Phase I study in kidney and prostate cancer patients subjected to active immunization with telomerase-derived peptides. This project was sold to an Italian pharma company, and has now completed a Phase II clinical study. Both projects are covered by international patents.

Areas of Activity

• Biotechnologies (Pharma&Medical • Vaccines Devices) • Medical research • Life sciences related activities

Marketplace Opportunities REQUEST Looking for a partner to develop the first gene therapy for SLE Genovax has published data showing that the GX101 has significant activity in the lupus mice model: it improves the proteinuria of the treted mice, and significantly prolong survival. Genovax has a clear development plan, discussed and agreed with Italian regulatirs in a pre-IND meeting: we are looking for a partner to support the development costs up to a proof of concept study. 314 / 880 Gentras Srl

Organisation

Country Italy City Prato Street Via degli Abatoni 11/6 Web www.gentraslabs.com

Person

Name Valentina Cesati AD

Organisation Profile. Gentras is a private company founded in 2010 thanks to the creativity and know-how of three experts in the field of DNA analysis. Human genome sequencing has led to an explosion for the genetic characterization of each individual, both for susceptibility to diseases and for other useful traits. Today we can "read" within the genome of each of us, letting us understand better our uniqueness and how we can use it to live better. Core technology Cheap and affordable DNA genotyping: the same technical approach for countless applications. Gentras has its strength in continuous learning, developing and marketing services/ products with high technological content based on the analysis of DNA. The vision and creativity combined with specific skills make Gentras a unique company in this field, capable of providing innovative solutions for genetic characterization. Vision Making genetic information EASILY ACCESSIBLE to everybody. Mission Gentras, across a wide range of products and services, develops and provides innovative solutions to RESPOND WITH SIMPLE and EFFECTIVE answers to the increasingly frequent requests for typing on genetic basis. Gentras has different Business Units: - Forensics: DNA-based individual identification (ie paternity tests, forensics test, kit Truecode for autosampling for informative paternity test) - Wellness&Well-Being, over-the-counter products (skin ageing risk, efficiency&metabolism - vitamin d and folate, obesity predisposition, efficiency of caffeine metabolism, lactose intolerancecode, xeliac test) - Dental, microbiological test: typing and quantification of periodontal bacteria - Genetic test: interrogation of the IL-1 gene cluster - Veterinary: Molecular sexing, Avian pathologies, Equine and Canine Pedigree Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities

315 / 880 Devices) • Genetics & Genomics • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PARTNERSHIP Matching with product developers in the field of wellness (nutritional, probiotics, supplements) We are looking for companies developing wellness-related product to be matched with our already available and in progress genetic tests. SOLUTION OR EXPERTISE SOUGHT Italian or international companies with the ability to produce and commercialize custom welness- related products. PARTNERSHIP Developing custom genetic tests We offer to develop personalizing genetic tests based on DNA polymorphisms to be coupled with specific supplement products. We are specialized in wellness-related and veterinary applications, following rigorous scientific guidelines. TYPE OF PARTNER SOUGHT Producers of nutraceuticals, food, probiotics, Italian of international. The task is designing products oriented to the specific genetic blueprint of the clients. PRODUCT Innovative DNA genetic tests Gentras has its strength in continuous learning, developing and marketing services/ products with high technological content based on the analysis of DNA. The vision and creativity combined with specific skills, make Gentras a unique company in this field, capable of providing innovative solutions for genetic characterization of each individual. The same technical approach is used for countless applications TECHNICAL SPECIFICATIONS: Innovative typing or susceptibility tests based on DNA analysis with non-invasive sampling, with Real time PCR and HRM analysis methods TESTS: Gentras provides genetic tests in the following areas: 1) Forensics: Genetic typing (ie paternity tests, forensics test, kit Truecode for autosampling for informative paternity test) 2) Wellness and well-being: - skin aging risk - efficiency & metabolism vitd and folate - obesity predisposition - efficiency of caffeine metabolism - lactose intolerance - xeliac 3) Dental, susceptibility combined test for parodontal pathology: - microbiological test: typing and quantification of periodontal bacteria (multi-shot mode) - genetic test interrogation of the IL-1 gene cluster 4) Veterinary: - molecular avian sexing 316 / 880 - avian pathologies - horse, bovine and canine pedigree MARKET APPLICATION Forensic field Pharma channel Private and public laboratory channel Dental specialistic channel Dermatologic, gastroeneterologic, pediatric, nutritional channel Veterinary channel TYPE OF PARTNER SOUGHT Commercial partnership

317 / 880 Giotto Biotech Srl

Organisation

Country Italy City Sesto Fiorentino (Firenze) Street Madonna del Piano, 6 Web www.giottobiotech.com

Person

Name Laura Bassani Marketing

Organisation Giotto Biotech Srl is a biotech company, spin-off of the University of Florence. Giotto Biotech Srl offers an extensive catalog of proteins produced through expression inE. coli,and a custom production service is available. All our proteins can be uniformly and selectively labeled with stable isotopes, typically 13C, 15N and 2H. Additionally we can provide ready-to-use NMR reference proteins for solution and solid-state NMR in a broad range of molecular weights. Giotto Biotech offers a custom production service for the synthesis of glyco-derivatives (GPI building blocks, Glc/Gal-Pam3CysSer, Glc/Gal-KLH) and a large variety of glyco-amino acids. Our experts have an extensive experience in the synthesis of a wide variety of Gc/MS standards for environmental analysis. Finally, Giotto Biotech is presently carrying on lines of research and development in different areas: Advances in protein production techniques and the production of novel proteins Progress in NMR-based metabolomics Exploration of new routes for organic synthesis with special attention to environmentally-friendly processes Structural biology by NMR and advances in information technologies Studies of the use of algae as cell factories and development of new methods for their exploitation In the above areas we are presently part of various and different EC, MIUR and Tuscany Region research projects. Areas of Activity

• Peptides, proteins & antibodies preparation • Proteomics, metabolomics, nutrigenomics

Marketplace Opportunities PRODUCT Custom production of recombinant proteins and organic compounds We specialize in proteins and organic compounds custom production service. 318 / 880 Our experts provide you with a detailed feasibility study feasibility study that will be accompanied by precise projections of delivery times. We can also offer a multiple-step production that will allow you to evaluate our results step-by-step, as well as the possibility of success of the following step. All our proteins can be selectively and uniformly labeled with stable isotopes, typically 13C, 15N, and 2H. All our organic compounds can be labelled in specific position with stable isotopes, typically 13C and 2H. Upon request we are open to signing a non-disclosure agreement in order to protect our clients' confidential information or the materials that are shared with us. SERVICE NMR-based metabolomics service Our experts can provide you with metabolomics services thanks to access to top-of-the-line instrumentation (including a fully robotized 600 MHz NMR machine for high volumes, a 600 MHz HR- MAS, and an 850 MHz solid-state machine for metabolomics on tissue extracts). Some examples of the fields of application: - Biomedical: metabolomic profiling of biological fluids (breath condensate, expectorate, sweat, urine, blood, serum), disease fingerprinting - Pharmaceutical: prediction of drug toxicity, analysis of mechanism of action and side effects - Agro-food: analyses of food products (fruits, vegetables, dairy products, olive oil, meat and fish, etc.) - Probiotic: metabolomics of probiotic products for their characterization PRODUCT Synthesis of process and degradation impurities of Active Pharmaceutical Ingedients and drug formulations Our laboratory can help Pharma companies in the identification and synthesis of API impurities detected by the customer in raw materials or drug formulations. Our experts analyze the sample (HPLC, MS, high field NMR), identify the structure, and provide you with the target impurity as a standard for its precise quantification. In case you need bigger quantities for activity and toxicity assessment, we can scale up the production to the tens of grams. PRODUCT PAA (peroxyacetic acid) Detectors - Fast and immediate instruments for determination of peroxyacetic acid (PAA) dedicated to health and safety professionals Also known as peroxyacetic acid or PAA (CAS No. 79-21-0), this chemical is being increasingly used as a chemical disinfectant in healthcare, agro-food companies and other industries. The use of PAA is growing as an alternative traditional sterilants. Potential hazards for the workers: •corrosive and on contact can severely irritate and burn the skin and eyes. • Inhalation of the vapor can irritate the note and throat, cause coughing and/or shortness of breath. •exposure can cause a pulmonary edema with severe shortness of breath (medical emergency) and may affect liver and kidneys. Giotto Biotech developed a low cost, fast and easy-to-use device to detect and to identify a over the limit PAA presence in the environment.

319 / 880 GOVISYSTEM

Organisation

Country Spain City Barcelona Street Pelai, 12 Pral. M Web https://govisystem.org/

Person

Name Xavier Prat Business Development

Organisation We are a recent startup with a powerful patented solution against nosocomial infections. We are looking for funds in order to install our solution in several hospitals in United States. Areas of Activity

• Investments • Software, ICT applications, system integration • Medical devices

Marketplace Opportunities PRODUCT Govisystem: Disinfection control for the hands of doctors and nurses Since 1980, awareness training has been used as main strategy to improve hand hygiene compliance. For decades compliance levels have been less than 50% world-wide. This historically stable non- compliance levels tell us that things won´t get any better. Whenever there is a serious consequence for protocol non-compliance, a control mechanism is needed to detect and warn non-complying individuals to slowly create the habit of compliance. Govisystem™ consists of patented, intelligent dispenser system that does not give the option of undetected non-compliance to employees. Each dispenser unit reads the fingerprint of the very hand placed in it to obtain sanitizer gel, identifies the employee doing so and transmits their hygiene moments in real time. Through this system, supervisors can sit in their office and know in real time which employee obtained gel, at which dispenser location (which patient room), at what moment, how many times and at what intervals, given the clinical task assigned PARTNERSHIP Looking for international partners to spread our patented system worldwide We are looking for partners for endorsement and funding our solution. 7-10% of all hospitalized patients and 30% of intensive care patients are infected by the contaminated 320 / 880 hands of doctors and nurses. Our Govisystem dispenser unit reads the fingerprint of the very hand placed in it to obtain sanitizer gel, identifies the employee doing so and transmits their hygiene moments in real time. Through this system, supervisors can sit in their office and know in real time which employee obtained gel, at which dispenser location (which patient room), at what moment, how many times and at what intervals, given the clinical task assigned. INVESTMENT OPPORTUNITY We need funds for our startup in order to install our solution worldwide Every year in US about 100,000 people dies because of nosocomial infections with a cost around 6,5 billions. The WHO 5 moments protocol is accomplish under 50% because hospitals do not have the right tool. Govisystem is the solution to control and monitoring: Because systemic problems need systemic solutions ! There are other solutions but using our body (our patent) is the easiest and reliable way to do it. This is a social an a profitable project.

321 / 880 Grammelot

Organisation

Country Italy City Milano Street via Copernico 38 Web www.grammelot.eu

Person

Name Fabrizio Sillano Business Development Manager

Organisation Grammelot is an innovative start-up with the aim of spreading e-learning solutions in various sectors such as health care, business and education. Grammelot has been found in 2016 from the merger of two different companies with twenty years of presence in the international e-learning market. Inject interactive approach into rehabilitation strategies in health sectors is our mission. Areas of Activity

• eHealth, mHealth, telemedicine • Software, ICT applications, system integration • IT Applications for Health

Marketplace Opportunities SERVICE Quiddis Quiddis is our online service for cognitive disease rehabilitation to allow therapists to easily create customized interactive content and exercises for their patients, and assign them also on mobile apps. Patients are able to play content and perform assigned tasks also at home on consumer mobile devices, and therapists can track their progress and tune the exercises based on each patient needs.

322 / 880 Greater Geneva Bern area

Organisation

Country Switzerland City Losanna Street World Trade Center – Av. de Gratta Paille 2 Web http://www.ggba-switzerland.ch/

Person

Name Lorenzo Bessone Direttore Italia

Organisation The Greater Geneva Bern area (GGBa) is the investment promotion agency for Western Switzerland, bringing together the cantons of Bern, Fribourg, Vaud, Neuchâtel, Geneva and Valais. Its mission is to provide support to foreign companies allowing them to get established quickly and develop their activities in the region. Since its creation in 2010, the GGBa, in cooperation with the cantonal economic promotion agencies, has guided over 400 companies from around the world in launching their activities in Western Switzerland. Areas of Activity

• 3D Printing/addictive manufacturing for • Packaging & labelling biomedical applications • Peptides, proteins & antibodies • Analytical and characterization services preparation • Bioinformatics, Big data analytics • Pharmaceutics • Biomaterials • Physiotherapy, Orthopaedic technology • Biosensors • Proteomics, metabolomics, nutrigenomics • Biotechnologies (Pharma&Medical • Regulatory affairs, validation Devices) • Life sciences related activities • Chemicals & APIs • Software, ICT applications, system • Diagnostics IVD integration • Diagnostics - Equipment and accessories • EPR, Clinical/healthcare management • Diagnostics - Imaging equipment and software processing • Surgery technologies and applications • Drug screening & delivery • Vaccines • eHealth, mHealth, telemedicine • Virtual reality applications • Electromedical and medical equipment • Laboratory equipment, reagents, software (non diag) • Project proposals support services • Genetics & Genomics • Medical devices • Investments • IT Applications for Health • Manufacturing & process engineering • Medical research

323 / 880 • Medical facilities furnishings, equipment, goods • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Support for Internationalization Through our Investment Agency, entrepreneurs in life sciences looking to establish a company in Western Switzerland can have our free of charge support to set up their business for a fast business implementation.

324 / 880 GreenBone ortho Srl

Organisation

Country Italy City Faenza Street Via ALbert Einstein 8 Web http://www.greenbone.it

Person

Name Lorenzo Pradella Co-Founder & CEO

Organisation GreenBone Ortho is transforming the treatment landscape for large bone defects. Patients with large bone defects caused by trauma, unhealed fractures, infection or cancer have limited treatment options. There is a high social and economic cost as patients often undergo multiple surgeries with long recovery times, and limb amputations are not uncommon. GreenBone is the highly innovative bone graft such patients need, suitable for the treatment of non-loaded and load-bearing large bone damage. Engineered to reflect bone in its anatomy, morphology, physiology and composition, the GreenBone rattan wood-derived scaffold is a calcium phosphate biomimetic material with very high mechanical strength and high porosity endowed with unique capacity to regenerate large portions of bone. Our manufacturing process transforms the wood to bone-like chemical composition while—crucially— preserving its architecture. New functional bone formation from GreenBone has been demonstrated in large animals. Devoid of risks in terms of morbidity and infections, GreenBone is a European class III and a US FDA 510(k) medical device with a short path to market. After the completion of two European clinical studies in patients with non-loaded and load-bearing long bone defects (>3 cm), GreenBone is expected to reach the market in 2020-21, with forecasted European and US peak sales of >$500 million. By improving bone healing, enhancing quality of life, preventing future amputations, and reducing healthcare and social costs, GreenBone is set to have tremendous impact on patients and society. Areas of Activity

• Biomaterials • Medical devices • Biotechnologies (Pharma&Medical Devices) • Physiotherapy, Orthopaedic technology

Marketplace Opportunities PRODUCT

325 / 880 GreenBone new generation bone substitute commercialisation GreenBone Ortho srl is focused on new generation bone regenerative product development and first market introduction. We are approaching first in man clinical development in trauma patient. We are interest to identify strategic partners for commercial exploitation. SOLUTION OR EXPERTISE SOUGHT Strong commercial presence and penetration in orthopaedic and trauma market segment. Expertise in bone substitute development, regenerative medicine and material science. TYPE OF PARTNER SOUGHT National and international market leaders in orthopaedic and trauma commercial segments. Corporation and strategic corporate venture.

326 / 880 GtGsolutions

Organisation

Country Italy City Milano Street Via Durando 39

Person

Name Graziano Tassan Gurle Amministratore Delegato

Organisation GtGprivatecare.it is the first market place for the private health care companies; here purchasers and vendors can meet each other and buy/sell any kind of product or service needed for the health care facility. Each vendor has its own shop in the marketplace; it can present products, special offers, campaign, new products, services provided, information and any kind of marketing information. GtGprivatecare.it offer to the vendors a very intensive market activity plan to reach more than 10.000 Italian private health care facilities (Private Hospitals, Nursing Homes, Diagnostic centers and clinic, path laboratories, and so on. The access to the market place is free for the facilities and for any health care operator while only registered facilities can see the prices and buy the products/Services GtGprivatecare.itis a service provided by GtGsolutions s.r.l. Areas of Activity

• Other

Marketplace Opportunities SERVICE Service towards private health care companies First italian market place focused on private health care organisations (Private hospitals, Nursing Homes, clinics, laboratories, diagnostic centers, etc) that offers a ready solution for e-commerce supported by a very intensive market activity plan that reaches every week more than 10.000 potentiaal customers. Vendor can sell directly or through their existing sales organisation keeping a completa ownership of the final customers/users. GtGprivatecare.it is not a dealer or a distributor. Looking for vendors interested to reach in a very efficient way more than 10.000 small/medium size health care facilities through a marketplace Looking for companies interested to reach Health Care providers to present/sell their product/service

329 / 880 Health Sciences University Tepecik Training and Research Hospital

Organisation

Country Turkey City Izmir Street Gaziler Street Web https://tepecikeah.saglik.gov.tr/

Person

Name Hüseyin Hakan Sakaoglu R&D and Project Director

Organisation Located in Izmir, Tepecik Training and Research Hospital opened as a Social Insurance institution with a 500-bed capacity in 1971. It was granted the identity of a Training and Research Hospital, specializing in internal medicine and surgery; five years later. Presently, Tepecik Training and Research Hospital occupies an outdoor area of 40.000 m2 and an indoor space of 57,000 m2, serving up to 2 million patients with 1030 beds, handling 422,000 emergency admissions and 68.000 trauma cases, and performing a total of nearly 58 thousand(5,192 Group A surgery, 1,056 Group E surgery)surgical procedures (2017 figures) per year via the workforce of 3.000 health staff. Provides 20,150 intensive care hospitalization services within the scope of 194 beds. In 2016 there was 9,751 births (17% of Izmir, 8% Aegean Region) Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Surgery technologies and applications • Laboratory equipment, reagents, software • Medical devices

330 / 880 HemoCue Srl

Organisation

Country Italy City ROMA Street Via Giovanni Battista Tiepolo 21 Web www.hemocue.com

Person

Name Tommaso Gabriele Bruno Sole Administrator

Organisation Distributor State -of -the art-medical and biomedical products to the Italian Medical Community dates back to 1985.The founder Tommaso Bruno is a MD with more 20 years of Sales and Marketing Experience.The company is specialized in the field of blood banks,diagnostics and laboratories,general surgery,critical care.As a result we have managed to achieve a very high degree of specialization in those fields.From 1993,we follow a direct sales force composed of college trained men and women who concentrate their efforts on just two leading product lines with extremely positive results.We provide national coverage with over 20 sales people in the field including direct agents and independent agents.All these people have extensive experience and good rapport with our clients and are backed up with a high scientific degree staff,which now includes a general manager,product specialist,a customer service department,regulatory affairs,and quality assurance people.We also have seervice facilities to maintain the electronic and electro medical equipment we distribute. Areas of Activity

• Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • Laboratory equipment, reagents, software

Marketplace Opportunities PRODUCT Offer of distribution of state-of-art medical and biomedical products Company specialized in blood banks,diagnostics and laboratories,general surgery,critical care. INNOVATIVE ASPECTS AND MAIN ADVANTAGES High quality lines and distribution directly to blood banks,hospital and clinics. MARKET APPLICATION 800 Public Hospitals,300 Private Hospitals,150.000MDs. TYPE OF PARTNER SOUGHT Our mission is to improve the quality of cares in the country and we provide scientific studies,meetings and research.

331 / 880 REQUEST State -of-art medical and biomedical products Distributor to The Italian Medical Community,specialized in the field of blood banks,diagnostics and laboratories,general surgery critical care. SOLUTION OR EXPERTISE SOUGHT From 1993,we follow a direct sales force composed of college trained men and women who concentrate their efforts on hust two leading products lines with extremely positive results. TYPE OF PARTNER SOUGHT People having extensive experience and good rapport with clients and backed up with high scientific degree to improve the quality of cares in the country and to reflect the aim of our Company:Quality and Service.

332 / 880 HiFuture S.r.l.

Organisation

Country Italy City Cologno Monzese (MI) Street Via Torquato Tasso, 1 Web http://www.hifuture.eu

Person

Name Vincenzo Gagliardi BDM, Sales Manager

Organisation Founded in 2013 as innovative start-up by people with a strong background in embedded systems design, now HiFuture is an Italian engineering company that thanks to deep technological skills and strong knowledge of market needs, can provide tailored solutions to Customers who need to integrate electronic in their systems. Integrity, flexibility, reliability and transparency are the values by which HiFuture supports his Customers. Areas of Activity

• Consulting services • Project proposals support services • Diagnostics - Imaging equipment and • Medical devices processing • Electromedical and medical equipment (non diag) • Software, ICT applications, system integration

Marketplace Opportunities SERVICE Electronic Systems Design Services We provide engineering solutions for innovative electronic systems design. Strong competences in Hardware, FPGA, Firmware and Software design, as well as in market's norms like IEC 62304, allow us to provide support both at technological and methodological level. Our references reside in many different areas like oncology, hemodialysis, laparoscopy, diagnostic devices, just to list some of them. PARTNERSHIP Medical partners for R&D projects We are looking for medical partners for R&D cooperation in innovative projects.

333 / 880 HIT

Organisation

Country Italy City 38010 Street Maso Barco, n°34 Web https://www.trentinoinnovation.eu/en/home/

Person

Name Veronica BARCHETTI Market and Business Analyst

Organisation HIT is a consortium and non-lucrative company that promotes the results of research and innovation in the Trentino system in order to support the development of the local economy. Areas of Activity

• Genetics & Genomics • IT Applications for Health • Pharmaceutics • Software, ICT applications, system integration

334 / 880 Hospitex International srl

Organisation

Country Italy City Calenzano Street via Baldanzese 37 Web http://www.cytofast.com

Person

Name Francesco Trisolini BDO

Organisation Hospitex International develops and commercialize innovative solutions for the IVD market with a special focus on new technologies such as Molecular Biology and particulalry Liquid Based Cytology. As a supplier of advanced, reliable and affordable diagnostic equipment, it has gained global recognition for its high quality laboratory solutions including instruments, reagents and consumables, suitable for human and veterinary medicine. A team of quality control managers monitor every step of the production process, ensuring accurate development and realization of the final product. Our company standards allow us to fulfill customer requirements by offering innovative technology, convenience, cost effectiveness and flexibility. Our mission is to make diagnostics instruments that help to detect diseases. Our strategy is to create value for all our stakeholders by accelerating the flow of innovative, new cutting-edge equipments and testing kits that provide improved outcomes for laboratories throughout the world. Most of the products we sell today were discovered or developed by our own scientists and our success depends to great extent on our ability to continue to discover, develop and bring to market innovative new diagnostic equipments. We manufacture and distribute our products through facilities in Italy and our products are sold in approximately 40 countries. Our objective is to become a leader player in the field of Liquid Based Cytology through innovative technologies and durable partnerships. Areas of Activity

• Diagnostics IVD • Diagnostics - Equipment and accessories • Medical devices

Marketplace Opportunities PRODUCT

338 / 880 CYTOfast system Liquid-based cytology (LBC) involves making a suspension of cells from the sample, in a preservative solution, and this is used to produce a monolayer of cells on a slide. Different LBC methods use different technical solutions to achieve this kind of result. The principle on which CYTOfast system is based is a nephelometric reading that determinates the cellular concentration of a cytological sample; in accordance with this determination, a certain quantity of sample is laid on the slide by cytocentrifugation, in order to get standardized slides always containing the same number of cellular elements. CYTOfast is a suitable method for all kinds of cytological sample, as cervico-vaginalis samples, urine, FNA samples, washing, brushings etc… A residual part of sample is always guaranteed for further investigations, after the preparation of the first slide. Auxiliary solutions to be used as pre-treatment are also available, in order to obtain always adequate slides also in case of excessively dirt, mucoid and/or hemorrhagic samples. CYTOfast foresees all the common advantages that have been brought by the introduction of LBC methods in pathological anatomy laboratories. Furthermore, thanks to its alternative methodology, it provides peculiar features and advantages that make it unique and the most valid alternative to other widespread methods. INVESTMENT OPPORTUNITY Development of an innovative automatic system for Liquid Based Cytology investigations The cytology analysis market (namely the examination of the slide where cells of the tissues to be analysed are adherent) it is strongly addressing to the use of the liquid phase, i.e. a preservative liquid enabling a better sample conservation, a more effective processing and a possible availability of a sample for complementary investigations (e.g. FISH or molecular biology). Hospitex International has acquired very specific skills in this sector and has the intention to finalize the development of an automatic system able to process slides starting from vials containing the sample preserved in the liquid. The identified technology is based on two mains technology aspects, to date unique in the market: the numerical standardization of the sample and the monolayer on slides obtained by centrifugation. Hospitex International gathers within it a group of high qualified professionals with pluriannual experience in the IVD sector. The project, in its development, is expecting further recruitment of human resources such as customer service, product specialist e regulatory. On the side the key persons implicated in the project development and in the subsequent marketing of products. The development of an automatic system for liquid-based monolayer cytological slides represents a great opportunity. The technology decision of contemplating a numerical standardization of the sample and a cellular concentration via centrifugation allows important competitive advantages in terms of quality, cost, user friendliness. The reference market presents a stable and constant growth. The weak number of players allows a high visibility on the market. The initial investment seems to be rather small and allows a return on investment lower than 3 years. The plan of development of the new automatic cytology processor has been successfully launched. Hospitex International aims to become a leader player in the field of Liquid Based Cytology through innovative technologies and durable partnerships. Venture Capitalists in this phase of startup will be evaluated. PARTNERSHIP Looking for collaboration in EU project partnerships We are interested in any collaboration in the context of EU projects in the Health and ICT areas. We

339 / 880 offer our deep expertise in development, marketing and regulatory matters of medical devices for the IVD and diagnostics sectors

340 / 880 Houston First Corporation

Organisation

Country United States City Houston Street 701 Avenidas de las Americas, Suite 200, Houston Texas, 77010

Person

Name John Kajander Consultant Healthcare and Life Sciences

Organisation Houston First works with US and international groups and organizations to develop economic ties with the city of Houston, which is America's 4th largest city and home of the Texas Medical Center: The largest medical center in the world. Areas of Activity

• Consulting services • Other

341 / 880 Hovione Capital

Organisation

Country Portugal City Lisboa Street Estrada do Paco do Lumiar, Edificio R Web http://www.hovionecapital.com

Person

Name Goncalo Andrade General manager

Organisation seed and early stage venture capital company, specializing in investing in european based medical device, medical technology and digital health projects and startups. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • EPR, Clinical/healthcare management • eHealth, mHealth, telemedicine software • Genetics & Genomics • Medical devices • Investments • IT Applications for Health • Medical research • Physiotherapy, Orthopaedic technology • Proteomics, metabolomics, nutrigenomics

Marketplace Opportunities PROJECT COOPERATION Co-investement Looking for early stage medical device, medical technology projects to invest in. INVESTMENT OPPORTUNITY Looking for investment opportunities Seed and early stage opportunities in the medical device, medical technology space, European wide. PARTNERSHIP Co-investment partnership Interested in identifying co-investment and co-development opportunities. REQUEST

342 / 880 Medical device and medical technology investment opportunities Seed and early stage investment opportunities in medical device and medical technologies across Europe.

343 / 880 HUMANA BIOSCIENCES

Organisation

Country France City Labege Street Prologue Biotech, 516 Rue Pierre et Marie Curie Web http://humana-biosciences.com

Person

Name Stefano Palea Chief Executive Officer

Organisation Humana Biosciences was incorporated on September 2017. Stefano Palea is the founder and the Chief Executive Officer. Dr. Palea has more than 25 years of experience in preclinical Research, in both big pharma (GSK, Sanofi) and Preclinical CROs. Humana Biosciences is a preclinical Contract Research Organization specialized on Translational research in Respiratory, Gastrointestinal and Urinary Therapeutic Areas. The Company services include RNA purification and PCR arrays on on-demand pathological human tissues (fresh, frozen or formalin-fixed, paraffin-embedded) obtained in full compliance with international Ethical Guidelines. Humana Biosciences also performs pharmacological studies on human and animal isolated tissues for lead compound validation as well as the evaluation of the efficacy of drug candidates in experimental animal models for the pathologies of interest, in particular using transgenic mice. Finally, Humana Biosciences provides, in collaboration with an Italian company, consultancy on Drug Repositioning, by using a proprietary Bioinformatics platform to identify potential off-targets and evaluate therapeutic switching opportunities. Humana Biosciences’ headquarter is located in Prologue Biotech, an Incubator dedicated to Biotechnology companies in Labège, France. Areas of Activity

• CRO (Contract Research Organisation)

Marketplace Opportunities SERVICE In vitro studies on human cells and tissues from patients The Company services include RNA purification and PCR arrays on on-demand pathological human tissues (fresh, frozen or formalin-fixed, paraffin-embedded) obtained in full compliance with international Ethical Guidelines. Humana Biosciences also performs pharmacological studies on human isolated tissues for lead compound validation, in particular studies on myogenic and neurogenic smooth muscle contractions. PARTNERSHIP

344 / 880 Partnership with companies offering supply of human tissues For our needs in preclinical research models, we are looking for companies offering access to fresh , frozen or FFPE human tissues from patients as well as controls. PARTNERSHIP Partnership for EU projects We are interested in partnership with SME, Research institutes and Universities for H2020 future calls in the area of drug discovery for Respiratory, Gastrointestinal and Urinary Therapeutic Areas. SERVICE In vivo studies on experimental animal models We offer in vivo models to evaluate the efficacy of drug candidates in experimental animal models for chronic Respiratory, Gastrointestinal and Urinary pathologies, in particular using transgenic rats and mice. Our services include: - Metabolic cages for accurate separation of urine and feces - Imaging (TEP, MRI, SPECT, Ultra-High Frequency) - Genotyping & Transgenesis (mice, zebrafish) - Genome Editing (CRISPR/Cas9). Our Animal house is certified SPF & SOPF and the experimental platform is certified ISO 9001:2008.

345 / 880 Hyperion Med

Organisation

Country Italy City Cascina Street Via Tosco Romagnola 191 Web http://www.hyperionmed.eu

Person

Name Macchia Enzo President

Organisation Hyperion Med S.r.l. is an innovative startup born from the idea of five partners (two electronic engineers, a medical doctor specialised in dentistry, a medical doctor universitary professor, a researcher in physical science). Its aim is to research, study, develop, design and manufacture personalised biophotonic applicators and devices for tissue treatments. Specifically on this matter a patent application had been submitted. The main application of these devices are in biophotomodulation, photodynamic therapy, photo-stimulation, antibacaterial, anti-inflammatory, antifungal treatments, decontamination, antipain procedures, physical therapy, etc.... They are principally devoted to human medicine and treatments, but applications in veterinary medicine are passibile as well. The use of such photo-medical devices could bring numerous advantages because it would allow to treat diseases with large social impact and considerable health costs more effectively. It also will limit the use of drugs and antibiotics and thus reduce the possibility of occurrence of microbial resistance against them. Areas of Activity

• Electromedical and medical equipment (non diag) • Other • Medical devices

Marketplace Opportunities INVESTMENT OPPORTUNITY Looking for investment in developing new, advanced, personalized skin lesion treatment device The advanced personalised applicator and device allow to treat skin lesions with light irradiations. In particular a personalised photo-active knee-socks for antiseptic / regenerative therapy of lower limb skin ulcers, and a personalised photo-active insole for the antiseptic / regenerative therapy of the diabetic foot, both built on multispectral images of the patient's limb or foot are proposed. These devices are patent pending (application submission date: 24/05/2018) INVESTMENT OPPORTUNITY

346 / 880 Looking for investments in developing new, advanced, photo-medical devices for specific patients, with the possibility of personalisation Hyperion Med S.r.l. intends to develop an entire range of photo-medical devices to meet various needs, ranging from the disinfection of everyday objects to the personalised therapy of specific diseases. They will be new concept phototherapy devices, personalised, meaning both that they can be adapted to the anatomy of the part to be treated of individual patients both that the therapy, established by the competent physician, will be execute by each patient, even at home, simplifying the access to the treatments and their repetition improving the effectiveness and the duration of the effects. Those devices shall allow the treatment of pathologies of vast social impact through photodynamic, bio-inductive, antibacterial, antiviral, antifungal, painkiller and regenerative, without side effects and without the use of drugs and antibiotics. In this way it can be effectively accomplished to the indications of OMS and UE in reduction of antibiotics use and prevention of bacterial resistance against antibiotics. These devices are patent pending (application submission date: 24/05/2018) INVESTMENT OPPORTUNITY Looking for investments in developing photoelectronic devices for general customers for hygienisation of everyday objects Photoelectronic devices intended for general customers to store and disinfect commonly used objects, such as: 1. photo-active toothbrush holder 2. photo-active mobile bite / prosthesis holder 3. photo- active pacifier holder 4. photo-active teat / bottle holder The market target of those devices are families, especially if with infants and young children, nursery schools, elderly with mobile prostheses, children and teenagers in orthodontic therapy, bite carriers for masticatory dysfunctions (e.g. bruxism), implant holders, contacts and cohabitants of patients with proven chronic oral infectious diseases (e.g. periodontitis), to prevent and reduce cross-infections. INVESTMENT OPPORTUNITY Looking for investment in developing new, advanced, personalized bite for odontoiatric and oral pathologies treatment The personalised photoactive bite allows the antiseptic therapy of periodontal and peri-implantal disease. It is realised on the dental impression of the individual patient. This device is patent pending (application submission submission date: 24/05/2018)

347 / 880 IBD srl

Organisation

Country Italy City Forli Street corso mazzini n 132 Web https://www.ibdsrl.com/

Person

Name Corrado Ghidini CEO

Organisation IBD is a start-up was born in 2014, our goal is to make homecare dialysis affordable for many patients,thanks a small machine simple and easy to use. Areas of Activity

• Medical devices

Marketplace Opportunities PRODUCT Dial-IT Dial-IT is a new portable system for home hemodialysis, designed and developed entirely in Italy. It is a compact and lightweight device (size 40x38x32cm, weight 15Kg) conceived to offer an affordable HHD as alternative to in-center treatment. It is easy to install and it does not require neither bulky equipment neither structural changes of the house. The device consists of an innovative hydraulic circuit integrated with innovative sensors and actuators. It integrates connnectivity features in order to perform assisted tele-dialysis and enabling the de- hospitalisation of the therapy. PARTNERSHIP Production of Dial-IT Partnership for contract manufacturing of medical device.

348 / 880 Iconsulting SpA

Organisation

Country Italy City Casalecchio di Reno Street Via Bazzanese 32/7 Web https://www.iconsulting.biz/

Person

Name Vasil Tabaku Senior Manager

Organisation Iconsulting is a Business Analytics and Big Data specialized company which implements complex end- to-end data architectures which bring disruptive change to clients to make their businesses run faster. As with regard to healthcare industry Iconsulting have implemented various vertical solutions to support policy makers optimize patient-based services on territory. Areas of Activity

• Bioinformatics, Big data analytics • IT Applications for Health • Consulting services • Software, ICT applications, system integration

Marketplace Opportunities SERVICE Healthcare Analytical Data Platforms Iconsulting have designed and implemented various complex data platforms (Enterprise Data Warehouse, Data Lake, Data Hub, ...) for private and public healthcare companies. We have a deep knowledge on healthcare processes and data, technology and advisory. This kind of service would enable the organisation to have a sigle robust data platform to enable all kind of vertical analytical applications. We use privacy-by-design principles and proprietary successful methodology to follow the companies in all the data lifecycle. SERVICE Healthcare Analytics Solution for Policy Makers Iconsulting has created a Location Analytics Solution which helps policy makers better govern healthcare services on territory. The solution contains different modules with specific analytical capabilities: - hospital and alike structures attractiveness: Understand how a given medical structure is performing on patients based on specialties, DRG, location, patient attributes, etc; Detailed BI Dashboards that describe in detail the activity of the medical structure through main KPIs (hospitalization duration, 349 / 880 complications, etc); Innovative front-end for healthcare policy-makers that can interact directly with a map to select parameters and view results - service levels provided to a dynamic community of patients: Understand health service levels offered to a community of patients selected dynamically through filters or directly from the map; Detailed simple and complex KPIs on volumes, offer, standardized indexes, etc; Drill-down on territory to dynamically select patients and view KPIs weighted on their territory. - dynamically identify service bottlenecks and simulate impact of health service reorganization on patiens and structures - optimize health service coverage and new service distribution by machine learning algorithms

350 / 880 iDelivery i.s.r.l.

Organisation

Country Italy City Reggio Calabria Street Via Eremo al Santuario 75/a - Italy Web http://www.idelivery.it

Person

Name Angelo Marra CEO

Organisation iDelivery is an innovative company operating in the field of nanotechnology for pharmaceutical,cosmetic and nutraceutical applications. The company activities and service revolve on three mainareas: Advanced Nanotech analysisConsultancy services on nanotechnology & nano delivery system development/testingNew product development The company has currently in pipeline a product (IP licensed): - Lenipsor+: An highly effective and cost efficient care to curepsoriasis plaque Furthermore the Company has a consolidated experience in development complex R&D project in the field ofnanotech for Pharma & Cosmetic applicaiton. Other product: - Bulbixin (www.bulbixin.com): anInnovative, versatile biocompatible nanocarrier, developed with a simple and unexpensive technology presenting high affinity and selectivity to pilosebaceous unit

Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Life sciences related activities • Consulting services • Other • Drug screening & delivery • Medical devices • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics • Peptides, proteins & antibodies preparation

Marketplace Opportunities PARTNERSHIP

351 / 880 Investment / License out. Lenipsor+ Innovative treatment for Psoriasis Plaque Our target is to commercialize an efficient and cost effective care for psoriasis disorder which can delivery to final customer the following advantages: - Increased efficacy of care; - Reduce cost treatment for cycle of care; - Short time regression of psoriatic plaque (one week); - Last longing results for cycle of care (10 months); - Absence of contraindication or side effect; iDelivery i.s.r.l. developed Lenipsor+ an effective low cost topical care for psoriasis plaque that increase, efficiency and efficacy of care. The product active is a plant phytocomplex, the product is covered by IP rights and was extensively tested. Lenipsor+ demonstrated impressive results. SOLUTION OR EXPERTISE SOUGHT Currently we are looking for: - License Agreement - Investment/ Financing - Sale/Distribution Channel TYPE OF PARTNER SOUGHT Financial Support, License agreement, Sale Distribution agreement PRODUCT Investment / License out. Lenipsor+ Innovative treatment for Psoriasis Plaque Our target is to commercialize an efficient and cost effective care for psoriasis disorder which can delivery to final customer the following advantages: - Increased efficacy of care; - Reduce cost treatment for cycle of care; - Short time regression of psoriatic plaque (one week); - Last longing results for cycle of care (10 months); - Absence of contraindication or side effect; Idelivery i.s.r.l. developed Lenipsor+ an effective low cost topical care for psoriasis plaque that increase efficiency and efficacy of care. The product active is a plant phytocomplex, the product is covered by IP rights and was extensively tested. Lenipsor+ demonstrated impressive results. SOLUTION OR EXPERTISE SOUGHT Currently we are looking for: - License Agreement - Investment/ Financing - Sale/Distribution Channel TYPE OF PARTNER SOUGHT Financial Support, License agreement, Sale Distribution agreement

352 / 880 imaginary srl

Organisation

Country Italy City Milano Street via Mauro Macchi 50 Web www.i-maginary.it

Person

Name Lucia Pannese CEO

Organisation Milan based imaginary are one of the longest established and most respected European Serious Games companies (SME). Since its formation in 2004, imaginary has built an enviable reputation for its multi-disciplinary specialisation in the rapidly growing serious games and gamification market place. The key strengths of its multi-disciplinary team are creativity and innovation backed by solid technical competence and an understanding of the commercial potential of serious games and gamification in its 3 main chosen development areas – eHealth, Smart Cities and training where the transformational impact of these technologies and applications is now widely acknowledged. Competencies cover the design, typically carried out through participatory design methods with the target group, and development of enabling technologies and data visualisation, specifically simulation systems, Serious Games, gamified processes, virtual immersive environments and advanced interactive technologies supporting eHealth and Smart Society topics, motivation, behavioural change, patients’ empowerment and awareness building as well as training and learning. Imaginary has always been a pioneering and innovative company playing a key role in European Research: the company worked on more than 25 EU research projects as well as on many industrial commercial projects covering the whole process from user-centred design, to design and development of game-based and immersive solutions to evaluation phases. Imaginary also won several awards for their serious games in different application areas. Imaginary is continuously involved in the organization of several international events about their topics of expertise; many publications have already been produced and are regularly submitted to international conferences and magazines. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Virtual reality applications • Other

Marketplace Opportunities PRODUCT

353 / 880 REHABILITY REHABILITY is the game-based neuro-rehabilitation system designed with specialists and patients which allows rehab also from remote under medical supervision. REHABILITY has won several awards. For info, video and scientific bibliography see www.rehability.me

354 / 880 Inalways Corporation, Taiwan

Organisation

Country Taiwan City New Taipei City Street Web http://www.inalways.com.tw

Person

Name P. C. Hung R&D Director

Organisation A Taiwan-based company specializing in the marketing & sales and development of generic drugs, health foods, and medical devices. Areas of Activity

• Biomaterials • Project proposals support services • Biosensors • Medical devices • Biotechnologies (Pharma&Medical • IT Applications for Health Devices) • Pharmaceutics • Life sciences related activities

Marketplace Opportunities INVESTMENT OPPORTUNITY Investments opportunity in healthcare Inalways Corp. is a Taiex-listed company with two main business interests focusing on the consumer electronics and medical healthcare industries. In addition to its recent acquisitions of four biotech companies in 2016, Inalways has also aggressively expanded its investments on the healthcare market through granting funds to medical institutions and cooperation with private companies

355 / 880 Indaco Venture Partners SGR

Organisation

Country Italy City Milano Street Galleria San Babila 4B Web http://www.indacosgr.com/

Person

Name Davide Turco Managing Director

Organisation Founded in 2016, today Indaco Venture Partners SGR is the largest independent Italian venture capital asset management company, with a strong specialization in companies that innovate in digital media, electronics and robotics, MedTech, and new materials. Indaco manages over 250 million across its five funds. Investments in Indaco Ventures Fund I are focused on growth-stage companies whose competitive advantage stem from cutting-edge proprietary technologies and innovations. In terms of teams and technologies, the focus is on Italian enterprises, although investments are made throughout Europe, USA and Israel. Anchor institutional investors in Indaco Ventures Fund I include Intesa Sanpaolo, Fondazione Cariplo and Fondo Italiano d’Investimento. In the digital sector, Indaco has an advisory partnership with growITup. The investment team managers have more than 10 years of experience in venture investing in Italy and abroad and have executed a high number of successful exits, including IPOs and transactions with corporate partners Areas of Activity

• Investments

356 / 880 Indivenire srl

Organisation

Country Italy City Trento Street via Alla Cascata 56/C Web http://www.indiveni.re

Person

Name Laura Pasquardini CEO & Cofounder

Organisation Indivenire provides an efficient outsourced Biotech R & D department to companies that can not afford the costs of space, equipment and personnel. Areas of Activity

• Analytical and characterization services • Life sciences related activities • Biomaterials • Medical devices • Biosensors • Biotechnologies (Pharma&Medical Devices) • Consulting services

Marketplace Opportunities SERVICE Outsourced R&D services We offer highly qualified staff with a solid scientific background, with access to sample preparation laboratories, micro-analysis and micro-processing facilities and the possibility to solve various problems. PARTNERSHIP Cooperation We are looking for new partners working in different fields in order to create a wide network of R&D services with complementary skills.

357 / 880 Industrio

Organisation

Country Italy City Rovereto Street Web http://industrio.co/

Person

Name gabriele catania PR Industrio

Organisation Industrio Venture, an accelerator of "concrete startups" based in Rovereto (Trentino-Sudtirol). At Industrio we are committed to funding and building great products. But we do more than investing. We provide to you and your team a seed fund, professional prototyping development resources and strong manufacturing support. Areas of Activity

• 3D Printing/addictive manufacturing for biomedical applications • Investments • Manufacturing & process engineering

Marketplace Opportunities SERVICE Funds, manufacturing and business services to support startups growth We are committed to funding and building great products. But we do more than investing. We provide to you and your team a seed fund, professional prototyping development resources and strong manufacturing support. Industrio is focused on support pre-revenue hardware startups that are looking to grow and bring amazing products to market from Italy. Twice a year (in spring and autumn) we run a 6 months prototype-to-product program where we drive selected teams to achieve the most important things a hardware startup need to accomplish in the shorter time: business model, prototype, DFM, certification, go to market, fund raising. Also every week you will meet with our 40+ advisor network and partners that will give you feedback on your product concepts, prototypes and product development. Industrio invests in only hardware startups made by a team of entrepreneurs that want to build a real product like: consumer device, B2B devices, automation and mechatronics, robotics, biohacking, energy and environment, smart home appliances, Internet of things.

358 / 880 InfiniteVision Optics

Organisation

Country France City Strasbourg Street 4 rue Boussingault Web https://www.infinitevisionoptics.com/

Person

Name Carsten Laue CEO

Organisation It is IVO's purpose to provide the best possible vision to patients after cataract surgery. We do this thanks to the Areas of Activity

• Electromedical and medical equipment (non diag) • Medical devices

Marketplace Opportunities PRODUCT Precisight® adjustable intraocular lens system Cataract treatment is the most frequent surgical intervention in the world with approximately 80'000 operations per day. With the surgery it is possible to correct the patient far- or nearsightedness providing sharp vision at one or several distances. Unfortunately, patients who had corneal vision correction in the past often suffer from visual problems after cataract surgery. Phenomena such as halos and glares prevent them from night driving which leaves them very disappointed. The Precisight® lens allows for easy adjustment of the visual outcome for such patients. With the Precisight® lens surgeons know that they don't need to leave refractive cornea patients with a sub optimal outcome. Precisight® was CE marked in 2017 and the first commercialized lenses are introduced since July, 2018.

359 / 880 INFN - Technology Transfer Office

Organisation

Country Italy City Frascati Street Web https://web.infn.it/TechTransfer/index.php/en/

Person

Name Cristina Placido Innovation Promoter

Organisation The National Institute of Nuclear Physics - INFN, is the Italian research agency devoted to theoretical and experimental studies in the field of subnuclear, particle, astroparticle physics and relative applications. Fundamental research in these areas requires the use of cutting-edge technology and instruments, developed by the INFN at its own laboratories and in collaboration with industries. With the mission of increasing the impact of INFN scientific results on everyday life, Technology Transfer Office’s commitment is to support researchers in intellectual property protection (patents, know-how, etc…) and to make those technologies available to companies by means of IP licensing and cooperation agreements. The development of technologies related to medical applications of physics is gaining more and more relevance at INFN, also thanks to the many collaborations both with companies and medical research centres. By attending the event, INFN TTO is looking for industrial partners interested in IP licensing and/or in cooperating to further develop technologies and bring them to the market. Areas of Activity

• 3D Printing/addictive manufacturing for • Software, ICT applications, system biomedical applications integration • Analytical and characterization services • Surgery technologies and applications • Bioinformatics, Big data analytics • Other • Consulting services • Medical devices • Diagnostics - Equipment and accessories • IT Applications for Health • Diagnostics - Imaging equipment and processing • Electromedical and medical equipment (non diag) • Pharmaceutics

Marketplace Opportunities PARTNERSHIP Available Technologies

Technologies developed for particle physics are successfully used in both medical diagnostics and 360 / 880 therapy, and for the study and manufacture of new drugs. In particular, the main activities relate on: - RADIOTHERAPY – HADRONTHERAPY: Innovative solutions for therapeutic beam diagnostics; Software for Treatment Planning Systems; Devices for real-time dose monitoring (both for patients and medical staff); Equipements for a real-time monitoring of the radiotherapy treatment; Instrumentation to improve LinAc performances. - DIAGNOSTIC IMAGING: high performance detectors and software dedicated to data acquisition and analysis of various image files, obtained with different imaging techniques (CT, SPECT, PET, NMR); A 7T NMR machine and multimodal diagnostic systems (PET/NMR/EEG) for enabling an early diagnosis of degenerative diseases. - RADIOPHARMACEUTICALS: radioisotopes production for the realization of innovative radiopharmaceuticals for diagnostic, therapeutic and theranostic purposes; technologies for an alternative production of the most common radionuclides applied in the clinical practice, focusing in particular on Tc-99m isotope production. PRODUCT Technologies and Patents

Detailed informations about INFN's technologies and patents are available and continuously updated at INFN Tech Transfer website: https://web.infn.it/TechTransfer/index.php/en/how-can-we-help-you/technology-licensing

361 / 880 INNOVATION ACTA S.R.L.

Organisation

Country Italy City Roma Street VIA D.A. AZUNI,9 Web WWW.INNOVATIONACTA.EU

Person

Name Natascia Cannella SOLE ADMINISTRATOR

Organisation Innovation Acta s.r.l. is born from the experience gained in many years of planning and realization of research projects in the field of Life Sciences. The projects are funded by consortia including public and private institutions, both national and international. In the first step the mission of our Grants Managers is to support our Clients in the preparation of project applications (research and advanced training calls). We start with the identification of an appropriate financing strategy through the establishment of a successful consortia, then we provide the organization and writing of the proposal and finally we take care of the formal submission of the project. In the second step the aim of our Staff is to support the management, the administrative issues, the communication and the dissemination of the project. Areas of Activity

• Project proposals support services

Marketplace Opportunities SERVICE Project proposal support, project management. Funding strategies, Consortia building, Legal assistance (consortium / grant agreements), Realization and submission of proposals, Management and accounting, Administrative assistance, Progress reports, Training. Innovation Acta main tasks cover: - Registration of the proposal into the PP and collection of administrative forms from all participants. - Writing the proposal following the EC instructions and template. To this purpose a “guided” template with some suggestions on how to write the several sections will be prepared. - Coordinating the project partners in preparing the “participant description” section. - Supporting the project partners in preparing the budget of the project; collecting all budget information and writing of the section on resources to be committed. 362 / 880 - Supporting the partners during the negotiation phase. - Supporting the project coordinator in the preparation of progress and administrative periodic reports. - Supporting the project coordinator in the resolution of any administrative or contractual issues within the partnership and with the Commission (administrative amendments to the Grant Agreement). - Ensure that the administrative guidelines are correctly followed by all beneficiaries - Support the administrative bodies and deliverables of the different beneficiaries’ institutions. - Monitoring and timing of technical deliverables and milestones. - Support the project coordinator for the interim administrative follow up of the project and checking the partners budget follow up. - Support the coordinator to collate periodic cost statements, helping in preparing and checking costs statements. Innovation Acta also deals with the communication and dissemination of the projects including web design (graphics and contents), social media and graphic material. In particular, Innovation Acta takes care of Creation of the project visual identity (logo, document and slide templates), realization and management of the project website, illustrative graphs, posters, brochures and newsletters of the project, organization of workshops, meetings and conferences.

363 / 880 InnoVitsLab Srl

Organisation

Country Italy City Milano Street via Durando 38/a Web http://www.innovitslab.com

Person

Name Donato Pastore CEO

Organisation InnoVitsLab helps start-ups and companies to reduce business risk inherent in projects with high technological and market uncertainty, leveraging our assessment competence, facilitating the funding process and promoting collaboration between startups and managers. The InnoVitsLab coreteam is made up of both startuppers and managers from big corporations who share a deep knowledge of both worlds.Weconnect these two cultures by bridging experienced managersinto the startups world. Here @mit, on behalf of an investor interested in life-science and health tech, we're scouting for startups looking for a seed investment of around 500/600k. Areas of Activity

• Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY We're scouting for startups that are looking for a seed investment of 500/ 600k€ Here @mit, on behalf of an investor interested in life-science and health tech, we're scouting for startups looking for a seed investment of around 500/600k.

364 / 880 Inserm

Organisation

Country France City Lille Street 1. rue du Prof Calmette, Institut Pasteur de Lille, Bâtiment IBL Web http://www.ciil.fr/research-teams/bacterial- respiratory-infection-pertussis-tuberculosis/team- projects/

Person

Name Nathalie Mielcarek Director of Research at INSERM (French National Institute for Health and Medical Research)

Organisation The Center for Infection and Immunity of Lille (CIIL, www.ciil.fr) is located on the campus of the Institut Pasteur de Lille (IPL)(https://www.pasteur-lille.fr). My laboratory is focusing on pertussis and tuberculosis and I'm particularly involved in the development of a nasal vaccine against pertussis which is currently in clinical development. Areas of Activity

• Vaccines

Marketplace Opportunities PARTNERSHIP Development of a nasal vaccine against pertussis On December 18, 2013, Iliad Biotechnologies, the French National Institute of Health and Medical Research (Inserm) subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille (IPL) signed scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1. BPZE1 is currently in a Phase 2a clinical trial sponsored by the U.S. National Institute of Health (NIH). In parallel, in our laboratory at the Center of Infection and Immunity of Lille, France, we are exploring in pre-clinical infectious and non-infectious models the anti- inflammatory properties of BPZE1. PRODUCT Innovative nasal vaccine against whooping cough BPZE1 is an innovative nasal vaccine against pertussis. BPZE1 is a live attenuated Bordetella pertussis bacteria which was constructed by the genetic removal or inactivation of 3 toxins: pertussis toxin (PT), dermonecrotic toxin, and tracheal cytotoxin. It was shown to be safe in several preclinical models, including highly immunocompromised animals, and to protect mice against B. pertussis challenge after a single nasal vaccination. It has successfully undergone human phase 1 safety trials and was shown to 365 / 880 be safe in adults, able to transiently colonize the human respiratory tract and to induce immune responses to several B. pertussis antigens in all colonized individuals. Using nonhuman primates, we showed that BPZE1 protects against both pertussis disease and B. pertussis infection. Interestingly, broad anti-inflammatory properties of the BPZE1 vaccine candidate were demonstrated and support its development as a promising agent to prevent and/or treat inflammatory pathologies including allergic diseases. INVESTMENT OPPORTUNITY Opportunity to participate in the Class C fundraising round BPZE1 is covered by 33 issued patents and 24 pending patents around the world. Patents have issued for broad composition of use and methods for preventing whooping cough, in the U.S. and Europe, as well as for other indications, such as asthma, influenza, etc. Commercialization of the initial product is planned for 2023, but by Q1 2020 Iliad expect to have completed key endpoints in the Phase 2 studies and have initiated more serious partnering discussions with large pharma. Iliad has raised $12M to date and have signed a term sheet for Class C Units to provide financing to complete Phase 2 studies. There may still be an opportunity to participate in the Class C fundraising round. Iliad is open to discussing strategic partnerships and/or strategic investments.

366 / 880 InSilicoTrials Technologies

Organisation

Country Italy City Milano Street via parini 9 Web www.insilicotrials.com

Person

Name Luca Emili CEO

Organisation InSilicoTrials is the first cloud-based platform that provides healthcare companies and researchers with easy-to-use tools to perform computational modeling and simulation in pharmaceutical and medical devices development Areas of Activity

• Analytical and characterization services • Regulatory affairs, validation • Bioinformatics, Big data analytics • Software, ICT applications, system • Biotechnologies (Pharma&Medical integration Devices) • Other • Electromedical and medical equipment • Medical devices (non diag) • Investments • Medical research • Pharmaceutics

Marketplace Opportunities PARTNERSHIP Scientific and Solver Partnerships We are always looking to expand our modeling and simulation capabilities and provide as many of them as possible on our platform. Academia specialized in healthcare computational modeling and simulation, solver software providers, research hospitals or companies that want to bring their own models and simulations onto our platform are potential partners that we invite for collaboration. Partnerships so far: Hospitals • San Raffaele Hospital (IT) • CRO Aviano Oncological Reference Center (IT) • IRCCS Galeazzi Orthopedic Institute (IT) • Erasmus Medical Center Rotterdam (NL) • Emory University (US) • University of North Carolina at Chapel Hill (US) Research centers • Université Libre de Bruxelles (BE) 367 / 880 • University of Bath (UK) • University of Pavia (IT) • Universitat de Valencia (ES) • CompBioMed (EU) • Politecnico di Milano (IT) Companies • ANSYS • Microsoft Corporation • Siemens SERVICE Democratizing modeling and simulation for R&D of healthcare products InSilicoTrials.com is a web platform that allows companies and institutions to accelerate the research and development processes specific to the medical devices and pharmaceutical sectors and reduce costs and time by using models and simulations (M&S). These M&S are developed using advanced technologies by researchers at the highest scientific level. Through M&S, InSilicoTrials.com accelerates the evolution of science by exploiting the experience and know-how of specialists in the field, by preventing the repetition of studies already performed, and by spreading the knowledge through the web. Additionally, InSilicoTrials.com provides companies with own private software environment with high security standards. In this environment, for example the performance of new prototypes can be tested, or new prosthesis designs can be investigated, or the concentration data of a new drug candidate can be explored without any security fears. The models and the data available on the platform are provided by the Scientific Partners, under a commercial contract with InSilicoTrials. Specifically, the Scientific Partners are research groups and internationally known companies, and their M&S are the results of extensive researches that have given rise to scientific publications, European or international projects, patents, etc. The strong innovative component of the project led the U.S. Food and Drug Administration (FDA) to propose a five-year collaboration agreement that was signed on the July 22nd, 2017. We have already filed the application for two patents and we are working with Jacobacci&Partners – an important patent and intellectual property firm – for the filing of two additional patents related to the blockchain platform. INVESTMENT OPPORTUNITY Series A We are looking for €3,5 million to support platform and business development. We've already received €630.000 of investment from Angel Investor and CrowdFunding, and we are generating revenue with significant customers in EU and ASIA. We are also working with FDA and EMA.

368 / 880 Institute for Anthropological Research

Organisation

Country Croatia City Zagreb Street Ljudevita Gaja 32 Web http://www.inantro.hr/en/home-3/

Person

Name Saša Missoni Director, Scientific Associate

Organisation Public research institute based in Zagreb, Croatia. Research activity of IAR encompasses various scientific disciplines (such as molecular anthropology, bioarchaeology, population genetics, cultural anthropology, biomedical anthropology, public health etc.). It is an unique research organization in the country that implements interdisciplinary research and fosters holistic approach. Areas of Activity

• CRO (Contract Research Organisation) • Other • Genetics & Genomics • Project proposals support services • Medical research • Proteomics, metabolomics, nutrigenomics • Life sciences related activities

Marketplace Opportunities PROJECT COOPERATION Biomedical research and health studies IAR is interested in participating in projects that deal with child and maternal health (birth cohorts studies, early growth and development, predisposing factors for complex disease development, genetic and epigenetic analyses), personalised medicine (drug resistance, genetic predisposition to diseases), impact of environment on health (plasticity of epigenome, toxicology, transgenerational exposome). IAR is leader of "Croatian Islands’ Birth cohort Study" (CRIBS). CRIBS is a pilot birth cohort study encompassing 500 mother-child pairs, with the aim of assessing environmental and biological risk factor for development of MetS and similar complex diseases. Future research on biological sample of mother-child pairs would include genetic and epigenetic analyses. IAR participated in NIH funded projects "Integrated GWAS and EWAS of Cardiometabolic Traits in an Island Population" and "Genetics of Metabolic Syndrome in an Island Population" with the aim to determine genetic and environmental factors underlying the development of metabolic syndrome in an adult Croatian subpopulation. The collected samples were analysed for epigenetic modifications (epigenome-wide methylation analysis – EWAS) and obtained results were integrated with the results of earlier genome-wide association study (GWAS), to detect a correlation of genetic and epigenetic 369 / 880 factors that contribute to development of cardiometabolic disorders. IAR was just granted a project entitled "Centre for Applied Bioanthropology" (European fund for Regional Development), for establishment of four laboratories which will start working in second half of 2019: Laboratory for Molecular Anthropology; Laboratory for Analytical Chemistry, Laboratory for Evolutionary Anthropology and Bioarchaeology and Laboratory for Microbial Ecology. The Centre will enable implementation of various analyses (molecular anthropology and molecular genetics studies, including NGS population analyses, prevalence and development of diseases; multielemental analyses, including biological and environmental samples; microbiota analyses etc.) and research such as development of diagnostic and intervention program for tackling obesity (identification of risk factors and biomarkers for obesity development, development of individualized dietary and physical activity programs), development of healthy ageing models etc.

370 / 880 Intelligenza Trasparente Srl

Organisation

Country Italy City Milan Street via Vittor Pisani 28 Web http://brain-intra.com

Person

Name Alessandro Rotilio CEO

Organisation New method for drug development and delivery. www.brain-intra.com Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Pharmaceutics

Marketplace Opportunities PARTNERSHIP Drug development An innovative protocol for drug testing and development. INVESTMENT OPPORTUNITY Theragnostic in brain cancer An innovative medical device for brain diagnosis and treatment. REQUEST Ultrasound testing Methods for ultrasound testing

371 / 880 Interceptin

Organisation

Country Italy City Verona Street Stradone San Fermo 14 Web Interceptin.com

Person

Name Michele Marzola CEO

Organisation Interceptin proposes a therapeutic treatment for tumors expressing PSMA and/or PSCA in their vasculature (prostate, pancreas, bladder, stomach, colon). Our solution is based on the combination of two recombinant single chain antibody fragments, which are capable of addressing at the same time both the main tumoral mass and even the smallest metastases. When associated with a non- immunogenic toxin, Interceptin is a powerful ADC capable of reducing tumor masses by 75% in one month with just four injections, leading to healing without side effects, avoiding invasive procedures and debilitating effects, typical of traditional treatments. Furthermore, our antibody fragments are able to carry multiple payloads, hence toxins can be combined with I-131 or advanced chemo for a more effective and complete treatment. The theranostic features of Interceptin permit to tailor frequency and intensity of injections to the characteristic of each patient, arriving at fully tailored therapies. Our pharmacoeconomics are very favorable, with a lower cost per patient than current Gold Standard. We will address a $ 150 BN market with > 3M patients p.a. directly addressable by our ADC. We expect to be able to generate more than > € 5 BN revenues for our future acquirer Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Pharmaceutics

372 / 880 interlanguage s.r.l.

Organisation

Country Italy City Modena Street Strada Scaglia Est 134 Web https://interlanguage.it

Person

Name Paola Modica Sales Manager

Organisation Delivering professional translations into all languages to Life Science companies since 1986: IFUs, SDS, clinical studies, package leaflets, software, informed consents, DMFs, scientific articles and all kinds of documents for your internal and external communications. ISO-certified service. Let's meet to discover how we can be of service to you! Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Regulatory affairs, validation • Chemicals & APIs • Life sciences related activities • Consulting services • EPR, Clinical/healthcare management • CRO (Contract Research Organisation) software • Diagnostics - Equipment and accessories • Project proposals support services • Electromedical and medical equipment • Medical devices (non diag) • IT Applications for Health • Manufacturing & process engineering • Medical research • Medical facilities furnishings, equipment, goods • Packaging & labelling

Marketplace Opportunities SERVICE Translation Services to Life Science Industry interlanguage s.r.l. provides translation, proofreading and project management for a variety of language services: translations, conference interpreting, voice-over, subtitling. Quality certifications: ISO 9001:2015 (Quality System), ISO 17100:2015 (Translation Service), UNI 10574:2007 (Interpreting Service). Providing translation services to companies in the medical, biomedical and pharmaceutical industry since 1986.

373 / 880 INTERNATIONAL CHECKS GROUP

Organisation

Country Ireland City DUBLIN Street Web http://www.internationalchecksgroup.com

Person

Name Mattia Nuti C.E.O.

Organisation International Checks Group is an associations of companies created byMattia Nuti since 2012 located in Ireland, Italy, Switzerland,United Kingdom. Inspections and consulting on Safety and Quality of Medical Devices are the strong points of the companies, based on experienced and qualified staff working beside medtech industries and medics. Areas of Activity

• 3D Printing/addictive manufacturing for • Nutraceutics, probiotics, functional food, biomedical applications cosmeceutics • Analytical and characterization services • Packaging & labelling • Bioinformatics, Big data analytics • Peptides, proteins & antibodies • Biomaterials preparation • Biosensors • Pharmaceutics • Biotechnologies (Pharma&Medical • Physiotherapy, Orthopaedic technology Devices) • Proteomics, metabolomics, nutrigenomics • Chemicals & APIs • Regulatory affairs, validation • CMO (Contract Manufacturing • Life sciences related activities Organisation) • Software, ICT applications, system • Consulting services integration • CRO (Contract Research Organisation) • EPR, Clinical/healthcare management • Diagnostics IVD software • Diagnostics - Equipment and accessories • Surgery technologies and applications • Diagnostics - Imaging equipment and • Vaccines processing • Virtual reality applications • Drug screening & delivery • Other • eHealth, mHealth, telemedicine • Laboratory equipment, reagents, software • Electromedical and medical equipment • Project proposals support services (non diag) • Medical devices • Genetics & Genomics • IT Applications for Health • Investments

374 / 880 • Manufacturing & process engineering • Medical research • Medical facilities furnishings, equipment, goods

Marketplace Opportunities SERVICE A NEW WAY OF THINKING FOR SAFETY AND QUALITY OF MEDICAL DEVICES Services: Market research - Design market oriented -Market research - Benchmarking - Trend and scenario Analysis - Ergonomic and usability Industrial design -Concept design (scketches, rendering) - Product design and refinement (3D video) - Graphic User Interface - Web design CAD CAM Engineering -CAD 3D Engineering - Software Parametric Pro-E, Creo, Solidworks, Catia - Innovation for Materials - Innovation for Technologies - Cost saving Prototyping & Production - Tooling and production - PUR, Injection moulding, Thermoforming, Composites materials. Certifications -ISO 13485 Medical Devices - Quality Management System -ISO 9001 Quality Management System -ISO 14971 Risk Management for Medical Devices -ISO 31000 Risk Management -ISO 19011 Internal Audit -FDA -GMP -EC Marking -Revision or Creation of Technical Files -Test and recurrent test IEC 62353 -Consultancies IEC 60601 -Qualified Expert in Radiation Safety -Safety, heath and welfare at work -Training Courses on Safety and Quality -Expanding business in Europe, USA, China -Clinics Engineering -Distributions and Development -Notified Body for regulatory and quality affairs

375 / 880 INVENTION S.R.L.

Organisation

Country Italy City BOLOGNA Street VIA DELLE ARMI 1 Web http://invention.it

Person

Name ANNA MARIA FORNACIARI European Patent Attorney

Organisation The company, founded in July 1983 by Ing. Giancarlo Dall'Olio, has actively taken the first steps in Osteria Grande (BO), where the headquarters were located, starting a fruitful promotional activity in the Marche and Abruzzo. After a few years the continuous growth of the company and the need for careful customer assistance required the relocation of the headquarters in the heart of Bologna and the opening of a branch located in Fermo (AP). Today our company offers an accurate and prompt advice covering the Emilia Romagna, Marche and Abruzzo territory in a capillary way thanks to the "historical" offices of Bologna and Fermo (AP) and to the recent decentralized offices of Modena (MO) and Città di Castello (PG). We have been operating for over 30 years, in Italy and abroad, in the Industrial and Intellectual Property sector, availing of consultants registered in the Order of Italian Consultants in Industrial Property, in the Register of Consultants accredited to the European Patent Office (EPO) and at the Office for the Harmonization of the Internal Market (OHIM) in Alicante, Spain. We provide advice and assist our clients regarding the filing, in Italy and abroad, of patents, trademarks and ornamental models, availing of correspondents with proven experience, and with regard to the realization of prior art searches, in national and international scope, including patents, trademarks and ornamental models. We also provide technical opinions supported by prior art searches regarding any counterfeiting, in Italy and abroad, of Third Party property rights. We are also able to provide precise and careful technical-legal assistance regarding counterfeiting actions, precautionary measures, merit causes, etc. Areas of Activity

• Consulting services

376 / 880 Inventya Ventures (EU) Ltd.

Organisation

Country Ireland City Dublin Street Dublin Enterprise & Technology Centre Limited, t/ a Guinness Enterprise Centre, Taylor’s Lane, Dublin 8 Web www.inventya.com

Person

Name Aušra Lingytė European Project Mananger

Organisation Inventyais a leading innovation consultancy specialising in support organisations inall stages of the innovation and IP commercialisation process. We work with businesses, academic, public research organisations, and investors providing market and customer insight which adds significant value to new product development and marketing strategies. We partner with SMEs, large organisations and research institutesthroughout the innovation process acting as a trusted advisor and provider of tailored solutions helping them tobring their idea to market. Inventyais anactive delivery partenr ofkey European innovation and technology transfer programmessuch asEnterprise Europe Networkand theCentre for Global Eco Innovation- http://www.cgeinnovation.org/ Overview An International Science, Engineering and Technology Commercialisation Consultancy Founded in 2010 25 staff with different technical backgrounds Presence through the EU - UK, Italy, France, Belgium, Ireland Key strengths Research Excellence Funding Know-how Global Outlook Experience in working in various Geographical Markets & across different industries Experience in EU programmes Areas of Activity

• Life sciences related activities • Project proposals support services • Software, ICT applications, system integration • Surgery technologies and applications • Virtual reality applications

377 / 880 Marketplace Opportunities SERVICE Exploitation, dissemination and commercialization partner in H2020 projects Inventya has a long association with complex multiple-partner and consortia R&D programmes. We work with a wide range of academic, commercial and public sector partners across the EU create, deliver, evaluate and (most importantly) commercialize ground breaking developments with scientific and technological R&D. As a partner in H2020 project Inventya proactively leads on the management of the IP generated by the project, on the development of the commercial proposition and on its implementation by managing the product entry in the market after the end of the project funding. European Programmes - Delivered on 7 ERDF projects, 2 INTERREG, 1 FP7 , 1 H2020 and various Framework projects - Currently a partner in the Centre for Global Eco-innovation – a £9.8 million ERDF project with Lancaster and Liverpool Universities designed to support 285 SMEs - Track record of achieving or over-achieving targets Inventya's expertise lies in: PRE-PROPOSAL SUPPORT Leading project consortia with partnering searches, contract negotiation, project management and reporting Impact assessment and structuring the project deliverables to maximize potential for commercialization Writing consortia proposals, schedule work packages and cost-out partner contributions EXPLOITATION Market Research and Market Intelligence Yearly Exploitation Plan and Business Models IP MANAGEMENT Lead on the development of the IPR Standard and IPR Working Group Lead on the consortia preferred model for IPR exploitation COMMERCIALISATION Activities dependant on the preferred IPR exploitation model. Support with raising the necessary debt/equity finance DISSEMINATION Project marketing information (web portal, flyers) and other PR (social media, newsletter, exhibitions) Lead on project dissemination, events calendar and manage project publications. Experience in working in international markets - Innovation panel and contacts with 25,000 “business managers” - International Technology transfer experience - In-house capabilities in 9 of the main languages - 27 associates covering 10 countries and with synergic skills and expertise

378 / 880 Investment and Development Agency of Latvia (LIAA)

Organisation

Country Latvia City Riga Street Perses iela 2 Web http://www.liaa.gov.lv/lv

Person

Name Andra Minkevica Head of Representative Office in Italy, Investment and Development Agency of Latvia (LIAA)

Organisation Investment and Development Agency of Latvia (LIAA) provides tailor-made services accordingly to the customer needs – linking foreign and local companies as well as providing start-up companies with access to the knowledge and investment, in order to boost development of innovation, technology transfer and international competitiveness. We are providing information about Life Sciences sector in Latvia and cooperation opportunities with the major players (research, education and business), as well as favourable environment for start-ups (such as special tax regime, venture capital, accelerators, business incubators, support for innovation development and other). Areas of Activity

• Analytical and characterization services • Nutraceutics, probiotics, functional food, • Biotechnologies (Pharma&Medical cosmeceutics Devices) • Pharmaceutics • CMO (Contract Manufacturing • Software, ICT applications, system Organisation) integration • Consulting services • Laboratory equipment, reagents, software • Diagnostics - Equipment and accessories • Medical devices • Genetics & Genomics • IT Applications for Health • Manufacturing & process engineering • Medical research

379 / 880 Invitalia - Invest in Italy

Organisation

Country Italy City rome Street via Calabria 46 Web http://investinitaly.com/en

Person

Name antonella keller Engineer\

Organisation In collaboration with Italian Trade Agency - ITA we facilitate the establishment and the development of foreign companies in Italy, promoting business opportunities, helping foreign investors to establish or expand their operations, supporting investors throughout the investment life cycle. Areas of Activity

• Investments • Other • Project proposals support services

Marketplace Opportunities PARTNERSHIP Inward Investment In collaboration with Italian Trade Agency we facilitate the establishment and the development of foreign companies in Italy, promoting business opportunities and supporting investors throughout the investment life cycle SERVICE Foreign Investor Support In collaboration with ITA we facilitate the establishment and the development of foreign companies in Italy, promoting business opportunities and supporting investors throughout the investment life cycle

380 / 880 InVivo BioTech Services GmbH

Organisation

Country Germany City Hennigsdorf Street Neuendorfstr. 24a, 16761 Hennigsdorf Web www.invivo.de

Person

Name Anke Holzinger Marketing & Customer Services GmbH

Organisation InVivo is a contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins for research, diagnostic and pre- clinical use. InVivo is an ISO 9001 certified company with over 19 years’ experience. As a trusted provider of cost-effective outsourcing solutions, InVivo has worked with a large number of satisfied clients. Companies of all sizes, including small university spin-offs, major research institutes, and biopharmaceutical companies, have taken advantage of InVivo‘s expertise as an independent contract manufacturer. Invivo also offers the expression of recombinant proteins and antibodies in HEK cells via transient transfection. With this method we can produce your recombinant antibody within 4 weeks in g scale. Please visit our website: transient-transfection.com for more technical details. Areas of Activity

• CMO (Contract Manufacturing • Peptides, proteins & antibodies Organisation) preparation • Diagnostics IVD • Manufacturing & process engineering

Marketplace Opportunities SERVICE Monoclonal Antibody Production As a CMO Invivo is able to produce antibodies up to 1 kg. Our experience is based on the manufacture of more than 3000 different antibodies. Our own serum-free media and a sophisticated perfusion cultivation enable us to offer competitive prices. SERVICE InVEST- Invivo's Expression System for transient Transfection InVEST is a high yielding process to produce recombinant proteins/antibodies in mammalian cells within weeks. Invivo established on DoE-based optimization of all relevant parameters, which results in about 80‑fold 381 / 880 production increase in comparison to a commercially available transient gene expression system. INNOVATIVE ASPECTS AND MAIN ADVANTAGES During recent years, InVivo has addressed several issues to optimized the process: 1.Optimized host cell line 2.Customized CD-ACF media platform 3.Large scale plasmid preparation 4.Vector design 5.Novel polycationic transfection reagent With this efficient method, it is now possible to obtain mammalian derived proteins within weeks. Stable cell line development, which is always related to hard and time-consuming lab work, is no longer needed. MARKET APPLICATION Whilst commercial production of tons of biopharmaceuticals uses consistently productive stable cell lines (which take many months to develop), the production of milligram to gram amounts of high- grade material for early pre-clinical and biochemical characterization studies can be performed by transient gene expression systems within the drug development pipeline. TYPE OF PARTNER SOUGHT We are looking for pharmaceutical or other companies who are in the need to produce many candidates of recombinant antibodies / proteins in parallel.

382 / 880 IRBM SpA

Organisation

Country Italy City Pomezia Street Via Pontina Km 30,600 Web http://www.irbm.it

Person

Name Pier Giorgio Pacifici Business Development Manager

Organisation At IRBM, we are committed to accelerating drug discovery and preclinical development. When it comes to supporting you, we strongly believe in the value of assigning highly experienced scientists to your research projects, and thanks to the proven track record of our team, we have built highly successful collaborations with global industry leaders, NPO’s, biotech and academia. Initially a Merck Research Laboratories site, we reorganized into an independent company in 2009, retaining the core scientific leadership and team that developed 4 drugs now on the market. We have facilities in Milan and Rome and our capabilities include HTS, strong medicinal chemistry and peptide chemistry, CADD, in vitro biology, DMPK, biologics capabilities including a proprietary phage library and an in-house cGMP CMO facility currently focused on experimental adenoviral vaccine production. Integrated drug discovery projects are carried out entirely at our facility near Rome where we can act as an auxiliary R&D hub for our partners’ research. In addition to integrated work, we also conduct Fee for Service and Full Time Equivalent based projects to support our partner's research efforts. Our team’s expertise in drug discovery is applicable to any therapeutic area, and we provide additional scientific support and know-how for the development of compounds in highly competitive fields such as infectious diseases, neurodegeneration and oncology. Working with us means choosing a team with a passion for drug discovery and one that values both you as a client and your project. Our scientists have the creativity and skill to advance projects in a timely, focused manner, applying IRBM’s integrated capabilities toward understanding and addressing the key challenges upfront. Our results in delivering 4 marketed drugs and more than 25 preclinical candidates are supported by more than 800 published papers and more than 100 patents. Our aim, at IRBM, is to be as flexible and collaborative as possible with our partners and to that end we are prepared in certain cases to offer a variety of business models. Areas of Activity

• Analytical and characterization services • Vaccines • CRO (Contract Research Organisation) • Pharmaceutics • Life sciences related activities

Marketplace Opportunities

384 / 880 SERVICE Lead Optimization At this stage, our chemists and biologists focus on improving the profile of the selected leads until it matches the target candidate profile agreed upon with our partners. The seamless integration between our departments drives the generation of appropriate in vitro and in vivo data and results are immediately fed back to our chemists to inform the next round of modifications. Fast turnaround times ensure the most efficient progression of your project to proof-of-concept and preclinical studies. Benefiting from our state-of-the-art facilities, our researchers can deploy both in vitro and in vivo resources in order to ensure the highest quality of data, while mitigating risk and improving the safety and efficacy profile of your drug candidate. Our Offering: - Standard and parallel synthesis approaches and automated purification/analytical capabilities; - NMR support (e.g. structural characterization, aggregation state, target/ligand interactions); - Multiple relevant in vitro biochemical and cell biology assays; - Highly sensitive in vitro assays (e.g. CYP450 inhibition, hERG binding, etc.) - Strong expertise in blood-brain barrier penetration studies and proprietary in vitro model, predictive of in vivo properties; - PK and metabolite ID studies in rodents or lagomorphs, for small molecules and peptides, even after microdosing; - Expertise in xenograft/PDX studies; - Metabolomics and biomarker ID in animal and human biofluids; - Formulation support. - Scale-up synthesis of lead compound (up to Kg. scale); SERVICE Hit to lead Once our team has identified promising hits through a comprehensive screening campaign, we assess the hit series to evaluate their potential and select the most attractive for optimization. The series undergo comprehensive profiling and preliminary structure-activity relationships (SAR) are investigated. Each series’s physicochemical properties, potency,selectivity and chemical tractability is evaluated to select only the most promising leads for further development. We design a strong validation funnel in order to prioritize compounds with bona fide activity and confirm this using orthogonal techniques such as biophysics for target based projects, and/or functional/disease relevant cell models. The decades-long experience of our team enables us to select the best candidates to move forward into lead optimization, and to identify any potential challenges to address during the lead optimization phase. This includes evaluation of chemical alternatives to hits with low metabolic stability, patent space assessments to ensure patentability of a novel chemical entity, and initial DMPK studies to identify areas of improvement. Our Offering: - High-throughput screening follow-up and clustering; - Multi-dimensional optimization of drug-like properties; - Drug feasibility assessment based on patent space, SAR and DMPK criteria; - Improvement of ADME properties; - Scaffold hopping; - Pharmacophore modelling; - Evaluation of chemical alternatives. SERVICE Hit identification We recognize the challenges inherent in identifying the most promising hit for your target and we tackle them by developing and validating meaningful primary assays and robust confirmation/

385 / 880 validation tools. Our team can deploy robust screening tools, including high-throughput screening technology on a 350,000-compound library, to ensure your project advances quickly. Our experience also enables us to tackle hit identification in particularly challenging targets, where our competitors may have been unsuccessful. Our Offering: - Pilot screening to validate output of full high-throughput screening campaign; - Virtual screening; - High-throughput screening (HTS) campaigns; - Proprietary, curated compound library with 350,000 compounds; - Compound library hosting and screening through a fully automated system; - Screening platform with multiple detection technologies; - Proprietary phage display libraries for peptide and biologics discovery; - Protein and peptide production; - Knowledge-based design; - NMR-driven fragment-based approaches; - Preliminary structure-activity relationship (SAR) acquisition; - Protein-ligand interaction studies by NMR; - Kinetic/thermodynamic binding studies. SERVICE Target validation At IRBM, our experience in the development of custom assays is leveraged into a robust, efficient and multi-parameter validation platform to confirm the biological and pathological role of your novel target. The data package generated by our team can then be transferred seamlessly forward for Hit Identification. Our Offering: - In vitro and In vivo gene knock-out and over-expression studies; - Expression profiling in relevant proprietary or commercially available cell lines; - Development and deployment of bioassays to measure biological activity and characterize the pharmacology of the target; - Target deconvolution. SERVICE Integrated Drug Discovery Your Partner Research Organization We are your one-stop shop for preclinical drug discovery and development services, either in an integrated fashion, or through individual capabilities ranging from target validation, assay development, high-throughput screening to lead optimization, pharmacology, and preclinical ADME. Our team of over 150 experienced researchers has delivered over 25 preclinical candidates and developed 5 drugs currently on the market, benefiting from our site’s resources including an in-house NMR facility, a LAR unit, an experienced Peptide Therapeutics group, a phage display library, a proprietary compound collection and automated screening facility, and much more. Your R&D Accelerator At IRBM, we can accelerate your drug discovery and development projects through a combination of state-of-the-art facilities and scientific excellency. This combination has been in our DNA since we were part of Merck Research Laboratories, and our team stands ready to offer not just practical skill, but scientific insights and expertise to help navigate any scientific challenge. We can expand the bandwidth of your R&D efforts, working on integrated drug discovery projects and we can even function as an additional R&D site for your research. Alternately, we are happy to consider standalone services and smaller-scale projects. Either way, we employ a flexible business model that ensures your needs are met and your project progresses swiftly and efficiently through the stages of development. In the case of integrated projects, the right Team Leader is selected based on the project’s specifics,

386 / 880 and a team of drug hunters is assembled from all applicable units, to carry the project from HTS to a preclinical candidate. Frequent communication between us and our partners ensures a smooth progression of the project, which is typically structured on a FTE-based model. Alternately, for standalone services, Team Leader and team members are selected from the units involved in the service, and the partner’s project is completed on a fee-for-service basis. Whatever your needs may be, we can support your research and accelerate your R&D. At IRBM, science comes first.

387 / 880 IRST IRCCS

Organisation

Country Italy City Meldola Street Via Piero Maroncelli, 40 Web http://www.irst.emr.it/AssistenzaeRicerca/ BiosciencesLaboratory/tabid/3942/Default.aspx

Person

Name Valentina Bugani Research and Technology Transfer Office

Organisation Istituto Scientifico per lo Studio e la Cura dei Tumori (IRST) IRCCS promotes and manages cancer research with the aim of gaining knowledge and furthering excellence, innovation and progress in the areas of diagnosis/healthcare, prevention and organizational pathways. Areas of Activity

• Biotechnologies (Pharma&Medical • EPR, Clinical/healthcare management Devices) software • Medical research • Medical devices • Pharmaceutics • Life sciences related activities

Marketplace Opportunities PRODUCT Scientific research at all levels in the areas of clinical care, organizational healthcare and biomedical-translational research Specific areas of interest Epidemiology: data obtained on incidence/prevalence/survival enable surveillance and prevention activities to be performed. Palliative care: essential for the maintenance of high-level care in far advanced stages of cancer Basic research: aimed at increasing our knowledge of molecular processes at the basis of biological phenomena, this type of research is the starling point fix all subsequent investigations and Is conducted mainly at a theoretical and practical (laboratory) level. Preclinical research: the research phase in which researchers, before evaluating the effects of a new treatment in a clinical setting, verify its efficacy and, in particular, its safety for the patent. This type of research is key to the development of new drugs, equipment or therapeutic approaches. It involves in experimental in vitro and in vivo (based on the use of cells grown in the laboratory or using animal models) projects carried out under strict supervision and according to well-der-mad national and international regulations. Biomolecular research: identification of biological and predictive markers that can be used for early

389 / 880 diagnosis, risk classification, prognosis of solid tumors, treatment personalization and development of new drugs. Translational research: direct transfer of the results of laboratory research to clinical practice (from bench to beside). Clinical research: execution of clinical studies on cancer in full compliance with national and international norms.

390 / 880 Istituti Clinici Scientifici Maugeri SpA SB - IRCCS

Organisation

Country Italy City Pavia Street ICS Maugeri SpA SB, Via Maugeri 10 Web https://www.icsmaugeri.it/

Person

Name Daniela Rossi Laboratory Head

Organisation The Laboratory for Research on Neurodegenerative Disorders is part of the Centre for Molecular Medicine of the Istituti Clinici Scientifici Maugeri SpA SB, a clinical institution located in Pavia that receives each year several patients affected by neurological, heart and oncologic disorders. This Centre, which includes also the laboratories of Molecular Cardiology, Epigenetics, Nanomedicine and Molecular Imaging and Bioinformatics, promotes and conducts multidisciplinary basic and translational research aimed at increasing our understanding of the causes and mechanisms leading to the major neurological, heart and oncologic disorders. The Istituti Clinici Scientifici Maugeri SpA SB are involved in the development of novel therapeutic approaches as well as in various clinical trials. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Life sciences related activities • Drug screening & delivery • Medical research • Peptides, proteins & antibodies preparation

Marketplace Opportunities PRODUCT Novel peptide therapeutics for the treatment of neurological disorders Delivering therapeutic agents to the central nervous system (CNS) represents a major challenge to the treatment of most neurodegenerative disorders, due to the presence of the blood-brain barrier (BBB), a complex biological interface that prevents transport of most drugs from the vasculature into the parenchyma of CNS after systemic administration. An additional problem of most therapeutics that target intracellular molecules is the low biomembrane permeability, which makes these agents of limited therapeutic value. To address these issues, we have developed novel peptide therapeutics that are constituted by 391 / 880 biologically active peptidic moieties fused to a carrier peptide. In addition to delivering its bioactive conjugates across the BBB into the CNS, the carrier improves their passage through the biological membranes, enabling their penetration and efficient transduction into different cell types, so that they can exert their activity intracellularly. We have currently designed different bioactive domains suitable to target specific signaling pathways that are dysregulated in various neurological diseases and we have conjugated them to a carrier system. A pipeline of peptide therapeutics are available and some of them have been patented. INVESTMENT OPPORTUNITY Looking for investors for business development We look for investors (venture capitalists, seed financing) interested in: 1) Developing a start-up company based on our peptide technology 2) Establishing sponsored research agreements to develop our pipeline of new peptide therapeutics PARTNERSHIP Seeking partners aiming to advance therapy development in their disease of interest We look for strategic partners interested in: 1) Developing our pipeline of new peptide therapeutics (cell protective, anti-inflammatory, kinase inhibitors) in their disease of interest 2) Licensing opportunities (we seek partners to license our development stage product candidates) 3) Developing our patented drug condidates from advanced preclinical to clinical stage (e.g. Pharma companies)

392 / 880 Istituto Auxologico Italiano

Organisation

Country Italy City Piancavallo (VB) Street Web https://www.auxologico.it/sedi/auxologico- piancavallo

Person

Name Nicola Cau Scientific and Technical Movement Lab Supervisor

Organisation With several decades of expertise in the specific and comprehensive treatment of obesity, severe obesity and its complications, Auxologico has developed scientific knowledge and advanced diagnostic and therapeutic protocols considered a model for Italy and Europe. With headquarters in Lombardy and in Piedmont, the Obesity Center of Auxologico carries out a highly specialized clinical activity for the treatment of severe obesity and its complications. Areas of Activity

• eHealth, mHealth, telemedicine • Life sciences related activities • Medical research • Physiotherapy, Orthopaedic technology

Marketplace Opportunities PARTNERSHIP Collaboration - Obeses and Neurological Patients Rehab We are looking for collaborations with companies, research centers or other institutions interested in creating and developing research protocols or developing and testing innovative products in the field of rehabilitation both of subjects with obesity and of subjects with neurological deseases. We are also open to promote networkring in telemedicine, VR/AR and app development projects.

393 / 880 Istituto Zooprofilattico Sperimentale PLVA

Organisation

Country Italy City Torino Street via Bologna 48 Web http://www.izsto.it/

Person

Name Angelo Romano Research fellow

Organisation The Istituto Zooprofilattico Sperimentale del Piemonte , Liguria e Valle d’Aosta (IZSPLV) is an health governmental body founded in 1912. The Institute tasks are to guarantee consumer’s health by protecting animal population health and welfare and by improving and controlling food and feed production, thus enhancing the safety levels for food and feed: it supports local and national veterinary services in epidemiological analysis, food hygiene and environmental control activity and research activity. National and local veterinary services, and professional veterinarian, breeders, food manufacturers and consumers too, can address to our Institute for scientific and technical advices, controls and animal health diagnostics. Moreover, the Institute carries out research in neuroscience, in particular sets up, coordinates, and conducts studies in cellular and molecular neurobiology and neuropathology. IZSPLVA performs annually more than one million and a half analyses according to ISO 17025. Institute headquarters and central laboratories are placed in Torino, but there are also peripheral laboratories inAlessandria, Asti, Cuneo, Novara, Vercelli (Piemonte), Genova, Imperia, La Spezia, Savona (Liguria) and Aosta(Valle D’Aosta). Some 400 people work in IZPLVA, including veterinarians, chemists, biologists, statisticians, laboratory technicians, IT support and administrative staff. Areas of Activity

• Analytical and characterization services • Life sciences related activities • Bioinformatics, Big data analytics • Other • Diagnostics IVD • IT Applications for Health • Genetics & Genomics • Medical research

Marketplace Opportunities SERVICE

394 / 880 Food Microbiology, Safety and Challenge The Food Control Laboratory carries out microbiological and molecular analyses in the field of food safety. The lab has advanced equipment (PCR, PFGE, WGS) and high qualified staff to research pathogens, indicator bacteria and normal microbiota in foods performing traditional coltural methods and genomic approaches. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The Lab has pilot plants for the production of experimental batches of cheeses, sausages and preserves. The contamination of batches with pathogens bacteria and toxins are useful to study how food bacteria populations may behave in vivo. In the lab the New Generation Sequencing (NGS) is also available. This technique let us carry out metagenomics studies and identify the whole bacterial flora of food. Moreover, NGS may be a useful tool to characterize the Italian traditional productions. MARKET APPLICATION Food market. All types of foodstuff: fresh and preserved food, perishable and stable food. TYPE OF PARTNER SOUGHT We are looking for food business operators interested in new food producing experiences: new products, new food preservation methodologies, new formulations.

395 / 880 Istituto Zooprofilattico Sperimentale del Piemonte Liguria e Valle d'Aosta

Organisation

Country Italy City Torino Street Via Bologna 148 Web http://www.izsto.it/

Person

Name Elena Berrone Research fellow

Organisation The Istituto Zooprofilattico Sperimentale del Piemonte , Liguria e Valle d’Aosta (IZSPLV) is an health governmental body founded in 1912. The Institute tasks are to guarantee consumer’s health by protecting animal population health and welfare and by improving and controlling food and feed production, thus enhancing the safety levels for food and feed: it supports local and national veterinary services in epidemiological analysis, food hygiene and environmental control activity and research activity. National and local veterinary services, and professional veterinarian, breeders, food manufacturers and consumers too, can address to our Institute for scientific and technical advices, controls and animal health diagnostics. Moreover, the Institute carries out research in neuroscience, in particular sets up, coordinates, and conducts studies in cellular and molecular neurobiology and neuropathology.IZSPLVA performs annually more than one million and a half analyses according to ISO 17025.Institute headquarters and central laboratories are placed in Torino, but there are also peripheral laboratories in Alessandria, Asti, Cuneo, Novara, Vercelli (Piemonte), Genova, Imperia, La Spezia, Savona (Liguria) and Aosta (Valle D’Aosta).Some 400 people work in IZPLVA, including veterinarians, chemists, biologists, statisticians, laboratory technicians, IT support and administrative staff.The Institute coordinates six National References Centers which are laboratories designated by the Italian Ministry of Health to provide scientific advice and technical support for ministerial or regional bodies on the main issues relating of feed and food law and animal health where there is a need for precise analytical results: National Reference Centre for Animal Encephalopathies (CEA), National Reference Centre for Surveillance and Monitoring of Animal Feed (CREAA), National Reference Centre for Veterinarian Comparative Oncology (CEROVEC), National Reference Centre for Wild Animal Diseases (CERMAS), national Reference Cenetre for Biological Methods applied to anabolic treatment in food producing animals (CIBA.), Recently CEA is, also, OIE (World Organisation for Animal Health) Reference Center for BSE and Scrapie. Areas of Activity

• Analytical and characterization services • Life sciences related activities

396 / 880 • Diagnostics - Imaging equipment and • Other processing • Laboratory equipment, reagents, software • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics • Proteomics, metabolomics, nutrigenomics

Marketplace Opportunities PARTNERSHIP NOVEL MODEL FOR MOLECULAR, BIOLOGICAL, PATHOLOGICAL AND CLINICAL STUDIES OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease; a cure/treatment is still lacking since most drugs effective in mouse model have failed in clinical trials. The Neuroscience Dept of IZSTO developed the first transgenic swine that reproduces clinical and pathobiological aspects of ALS. This novel animal model is a useful alternative, because it is more closely related to human species, and has a longer preclinical and clinical phase than rodents. The main objective of our research project is to: provide animals for in vivo test; Create a bio-bank (tissue samples and cultured cells) for ex vivo/in vitro tests; Clarify ALS pathogenesis; Identify biomarkers in order to support diagnosis, to provide information on prognosis and progression of ALS disease and to find effective drugs. INNOVATIVE ASPECTS AND MAIN ADVANTAGES: To date, most studies on ALS are based mainly on experimental rodents models such as transgenic mice and rats over-expressing the mutated human SOD1 gene. However, doubts have been raised about the suitability of rodents to faithfully reproduce the human disease. Many of the drugs, which were able to prolong SOD1 mice lifespan, did not demonstrate any efficacy in ALS patients. This would seem to be attributable to a number of limitations that rodents have as models, such as their small size, the difference in Central Nervous System (CNS) anatomy and the several physiological and metabolic differences due to phylogenetic distance with the humans. On the contrary, the swine, with the exclusion of non-human primates, presents anatomical, physiological and protein features more similar to those of humans, in particular the anatomy and physiology of the CNS. Furthermore, both gene content and sequence are highly conserved between pig and human. MARKET APPLICATION: Identification and validation of new biomarkers; Discovery new cell signaling and/or molecule; Tissue and cell line for screening test; Development of new medical/surgical device; Innovative solutions in diagnostic imaging; Development of new treatments. TYPE OF PARTNER SOUGHT: We would like to undertake new national and international scientific relationships with profit or academic/no-profit partner in order to develop new sectors of research; in particular, we need experts on: 1. Full device (system) development and tests application. 2. Genomics and proteomics studies. 3. Reagents configuration and evaluation. 4. Market analysis, for a correct product definition. 5. Evaluation studies, for diagnostic purposes. PARTNERSHIP AN.AGEING: ANIMALS FOR BRAIN AGEING Significant improvements in lifestyle and in medicine led in recent decades to a significant increase in the elderly population in most developed countries. It has been estimated that the number of people over 65 years old will double until 2030 and that the elderly population will represent for about one- fifth of the world's population over the next two decades. In parallel, scientific studies have shown that also the expectation of life of the animals that share environment and habits with humans is 397 / 880 increasing. Since several aspects complicate the human study (limited availability of material, ethical and social factors) and cellular models are not able to reproduce the complexity of the nervous system, animals can be used as a useful alternative. For these reasons, this project aims to utilize animals as a tool to investigate the underlying mechanisms of human brain aging. To date, we have more than 150 brains, belonging to elderly animals including dogs, cats, cows, donkeys, dolphins and some exotic species. The characterization of neuropathological lesions, the research for biomarkers and the study of potential new pathways in different animal species will help to identify similarities and differences with humans. The study of animals that share the same environment and habits with humans may also be useful to clarify which genetic, environmental and nutritional factors can influence behaviour and brain biology in the course of aging. INNOVATIVE ASPECTS AND MAIN ADVANTAGES: The project is based on the idea that some categories of animals (pets and livestock) sharing the same environment and habits with humans, can represent a good model for the study of the processes associated to brain aging. In particular, to understand why different animal species showing different ways of aging, can provide useful information about the underlying physiological and pathological mechanisms. In addition, it is important to emphasize that we will not do animal testing. Aims of the project are: - to study processes related to brain aging in different animal species in order to identify similarities and differences with humans. - to study genetic, environmental and nutritional factors about mechanisms associated with animals brain aging - to share a wide collection of tissues from elderly animals with different research groups interested in comparative pathology studies between humans and animals. MARKET APPLICATION: Investigators at academic (University) and non profit research institutions. TYPE OF PARTNER SOUGHT: Tissues from our bank are available to all the investigators at academic and non profit research institutions who are engaged in research on animal and human aging. Useful the collaboration with research groups with expertise in different -omics techniques. SERVICE FIGHTING FOOD FRAUDS: SAFETY OF MEAT AND RESIDUE MONITORING We offer our experience in the field of food frauds and authenticity. We have validated an enzymatic method (based on HADH activity) to differentiate fresh from frozen-thawed poultrymeat and we are working on: detection of undeclared soy proteins and caseins in meat by immunohistochemistry, histological method to distinguish between swine and bovine fresh and frozen/thawed meat, standardized microscopical protocol to differentiate between mechanically separated meat (MSM) and non-MSM and between high and low- pressure-MSM. We have already validated and accredited an histological method to differentiate between fresh and frozen-thawed fish. Furthermore our expertise in the field of residue monitoring is based on a 10 years experience: through several animal experiments we validated and accredited the histopathological method for the detection of the effects of anabolic substances on target tissues. The National Reference Centre (CIBA – National reference centre for biological screening of anabolic substances on producing animal) is dedicated to set up and develop biologically-based methods for the disclosure of anabolic practices in bovine husbandry: bioassays and –omics-based analytical methods have been developed. INNOVATIVE ASPECTS AND MAIN ADVANTAGES: In the field of meat frauds and authenticity, there are still many remaining challenges: we are working on some of these important issues. The main goals of our research activity is to develop and validate analytical methods for detecting sanitary (and/or commercial) frauds in order to strengthen consumers health protection. It will be possible to translate the results of the research into operational tools which can be successfully used to improve the efficiency of the Official Control system. Furthermore stakeholders can benefit from the development of methods that can be applied to meat and meat products with the aim of detecting frauds (self-monitoring activities and plans). In the field of residue monitoring we are expanding our research field through the implementation of

398 / 880 an EU network, involving the most important reference laboratories and research companies. Following the EFSA recommendations to improve the effectiveness of the screening phase of residue control, we are setting up several research project in cooperation with other EU partners, developing new biologically-based techniques (i.e. –omics sciences) for the disclosure of illicit practices in cattle breeding. MARKET APPLICATION: Which market is most relevant for your product/service. The most relevant market for our services is represented by the laboratories working for the official control authorities or in self-monitoring for food producing companies. SERVICE SURVEILLANCE OF VECTOR BORNE DISEASE We offer: design of entomological active surveillance plan, according to risk factors that affect mosquitoes abundance in order to identify the presence of mosquitoes potential pathogen vectors or exotic invasive mosquitoes; design of virological/serological risk-based surveillance on sentinel animals, in order to early detect mosquito borne diseases introduction or circulation; design of data collection protocols, in order to establish guidelines that facilitates standardized methods; risk communication related to mosquitoes and mosquito borne diseases to stakeholders and citizens. INNOVATIVE ASPECTS AND MAIN ADVANTAGES: Entomological surveillance and diagnostic investigations on vectors allow identifying early viral circulation in the area in order to set up preventive measures for public health purposes TYPE OF PARTNER SOUGHT: Health organizations

399 / 880 It-med srl

Organisation

Country Italy City Torino Street strada del lionetto 6 Web www.it-med.it

Person

Name Franco Cornagliotto Director

Organisation IT-MeD is an innovative start-up in the medical devices sector. IT-MeD concept and realize innovative medical devices. Our products are: . Re-Motus, is the only device in the market able to register the peristalsis of the stomach and colon . Re-Cordis (heart failure) is a new product that will be ready for the market on december 2019. Areas of Activity

• Bioinformatics, Big data analytics • Medical devices • eHealth, mHealth, telemedicine • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT Re-Motus Re-Motus is a device, produced by IT-MeD, capable of diagnosing the type and magnitude of the alterations of the autonomic nervous system of the gastrointestinal tract (ElastroGastroColongrafia). Possible gastroparesis or colon paresis, hypo and hyperfunction of gastric or colic emptying are recorded with a totally noninvasive approach due to the external recording of peristaltic movements of the stomach and intestines. Re-Motus is a device useful for the diabetic, functional gastroenterologic, neurological,endocrinological and pediatric patients. Re-Cordis (heart failure) is a new product that will be ready for the market on december 2019.

400 / 880 Italian Angels for Growth

Organisation

Country Italy City Milano Street Web https://www.italianangels.net/en/home/

Person

Name Leonardo Giagnoni Senior analyst

Organisation Business angels network Italian Angels for Growth (IAG) is Italy's largest angel investors' network. Over the years it has deployed more than Eur 20 million in 40 startups. IAG's 150 members are committed to support brilliant entrepreneurs willing the make their mark in a variety of high tech sectors such as Internet, health care, clean tech and high tech at large, and, by so doing, give a little contribution to make Italy a prosperous and genuinely entrepreneurial economy again. Areas of Activity

• Consulting services • Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Business Angels Investments Italian Angels for Growth, or IAG, is where business angels meet the most tenacious and prepared entrepreneurs. Our members typically invest 200K € – 1M € by participating in early stage financing rounds in companies in the fintech, industrial & energy, internet & tech and life science sectors. Italian Angels for Growth gives a guide and a methodology to its members that, independently, constitute a consortium for each investment operation, collaborating on a daily basis with the professional staff of the association Each consortium is led by a “voluntary” partner, who invests a significant amount and acts as the leader of the investment: the Champion The Champions follow the investment by making themselves available to the founder, but they also supervise the protection of the interests of the business angels and the quality of the transaction.

401 / 880 Italtel

Organisation

Country Italy City Settimo Milanese Street Via Reiss Romoli Web www.italtel.com

Person

Name Paolo Comi Research and Innovation Manager

Organisation Italtel provides its customers with powerful products for the efficient delivery of innovative, multimedia, interactive services, allowing the mixing of information and data retrieved from different networks and from any user device. Italtel offers also remarkable expertise in IT solutions, network integration and security aspects. Italtel’s competence in Contextual Communication includes advanced IoT products and solutions in sectors like eHealth, mHealth, Smart Energy, Smart Cities. All the solutions are deployable over both legacy HW and virtualized platforms. In its offer are proprietary products, engineering and network consultancy services, managed services and solutions such as VoIP, unified communications and collaboration, HD video, interconnection and interoperability, Next Generation Data Center and Mobile Broadband solutions. SDN, NFV, WebRTC, IoT, Big Data Analytics that are focus areas of current RD activities. Italtel has extensive experience in collaborative research projects with the primary objective of exploring and experimenting with new technologies and new solutions that can be quickly adopted in products under development, according to the indications from customers and market. Areas of Activity

• Analytical and characterization services • Virtual reality applications • Bioinformatics, Big data analytics • Project proposals support services • eHealth, mHealth, telemedicine • IT Applications for Health • Software, ICT applications, system integration • EPR, Clinical/healthcare management software

Marketplace Opportunities PARTNERSHIP Better Health and Care Research Collaboration We are looking for industrial and academic partners with the aim to participate in H2020/national calls for project proposals. 402 / 880 Providing better health and care is a key objective of the European Commission for their citizens. Nonetheless, it is a complex challenge requiring multi-disciplinary and well orchestrated skills. Italtel has strong competences in ICT, networks, IoT, security, for creating reliable solutions with guaranteed quality of experience (QoE). We are able to design, develop, deploy and operate complex multi-vendor, multi-technology solutions. We are willing to collaborate with enthusiast and motivated partners in European research projects for providing our contribution to better health and care in Europe. PROJECT COOPERATION Collaborative research in eHealth/mHealth, Wellbeing, Ageing and Social Challenges We are willing to provide our contribution to better health and care in Europe. We know that this is a complex challenge requiring multi-disciplinary and well orchestrated skills. With our experience in collaborative research and industrial level system desing and integration skills we are willing to collaborate with industrial, SME and academic partners for the forthcoming calls under the different frameworks and programmes funded by the European Commission.

403 / 880 Ivtech srl

Organisation

Country Italy City Massarosa Street via di Bagnaia 414 Web www.ivtech.it

Person

Name Tommaso Sbrana CEO

Organisation IVTech srl is an Italian SME, founded in 2014 and focused on the Life Sciences field. It was born as a spin-off of the University of Pisa and now it is a company which works in parallel with the University. IVTech provides technology and services to customers who need to refine their in-vitro models. The company goal is to become a key partner for any researcher in order to develop in-vitro models more correlated with human reality. IVTech philosophy is that in order to obtain a more predictive in-vitro test, it is required a technology which allows for a better mimicking of the real human environment. In particular if tissues are expose to a stimulus similar to the pato-physiological one (i.e. 3D topology, dynamicity and cross modulation) also their in-vitro response will be closed to the real one. Therefore the R&D activities of the Italian company are focused on the design and production of new chambers to implement the pato- physiological stimuli of different tissues. IVTech produces advanced cell culture chambers that can be used to test relevant portions of tissues (i.e. biopsy), 3D scaffold colonized by cells, floating spheroids and 2D/3D models developed with cell lines. Currently IVTech has 3 products on the market: •LiveBox1, a single flow bioreactor for 2D and 3D in-vitro models in attached cell culture conditions, •LiveBox 2, a double flow bioreactor for physiological barrier simulation and the use of floating biological material •LiveFlow, a compact and low weight peristaltic pump, compatible with the incubator environment. It is equipped with a drawer to house the bioreactors connected to the pump. The main characteristics of the IVTech chambers are: •the modularity, that is the possibility to interconnect in series several chambers in a fluidic circuit, in order to design as in a Lego strategy approach a multi-organ in-vitro model •the compatibility with standard cell culture protocols developed for static plate, due to the cell seeding surface and the chambers volume compatible with that ones of a standard well of a 24 well plate •the possibility to monitor the tissues in real time, using an inverted microscope, due to the transparency of chambers •the possibility to collect all the attached biological material at the end of an experiment, removing the glass discs used as support (i.e. LiveBox1) or the membranes (i.e. LiveBox 2) where cells adhere. The mix between the advantages linked with the upgrade in the technology and the importability of 404 / 880 standard cell culture protocols and analysis represents one of the key aspect in the competition with products provided by competitors. Areas of Activity

• Biomaterials • Life sciences related activities • Biotechnologies (Pharma&Medical • Vaccines Devices) • Laboratory equipment, reagents, software • CRO (Contract Research Organisation) • Medical devices • Drug screening & delivery • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PRODUCT LiveBox1 LiveBox1 is a transparent chamber designed for inter-connected dynamic cell cultures. LiveBox1 is featured with a flow inlet and outlet for the perfusion of cell culture media. The clamp system provided with the LiveBox1 assures the watertight closure of the system in both static and dynamic conditions (up to 1 mL/min). Features: •The system is designed to reproduce the typical volume of the single well of a 24-well plate •The removable transparent glass bottom allows for: - Live imaging during static/dynamic culture, i.e. in situ imaging of the three-dimensional culture environment using microscopy techniques. - Post culture imaging including staining procedures or any other sample processing. After disassembling the LiveBox1, the glass slide supporting the cell monolayer or 3D construct can be easily removed from its bottom part and used for further investigations and analysis. •Modularity: LiveBox1 can be inter-connected with other cell culture chambers in order to mimic cross talk between tissues (multi-organ simulation). PRODUCT LiveBox2 LiveBox2 is a transparent chamber, developed for in-vitro models of physiological barriers (e.g. lung and intestinal epithelium). LiveBox2 is designed for inter-connected dynamic cell cultures and it is equipped with two flow inlets and outlets, and a holder to house a porous membrane. The clamp system provided with the LiveBox2 assures the watertight closure of the system in both static and dynamic conditions (up to 0.5 mL/min in apical or basal compartments) Features: •The system is designed to reproduce the typical surface of a transwell insert for a 12-well plate •The removable transparent glass bottom allows for: - Live imaging during static/dynamic culture, i.e. in situ imaging of the three-dimensional culture environment using optical microscopy. •The removable holder allows for: - Housing of different commercial porous membranes, according with the specific cell type or tissue. - Easy and safe handling of the membrane where cells are seeded - Post culture imaging, including staining procedures or any other sample processing. After disassembling the LiveBox2, the holder system supporting the cell monolayer or 3D construct can be easily removed from the bottom part and used for further investigations and analysis. •Modularity: LiveBox2 can be connected with other cell culture systems in order to mimic cross talk between tissues (multi-organ simulation).

405 / 880 PRODUCT LiveFlow LiveFlow is a compact and low weight peristaltic pump, compatible with the incubator environment. Two removable heads drives up to two independent circuits/head. LiveFlow is equipped with a drawer able to house up to four bioreactors. Therefore you can perform up to four independent experiments in parallel. The intuitive and user-friendly interface permits a quick and easy set-up of the system, with two independent heads able to apply a flow rate between 50-500 µL/min. Features: •LiveFlow is compatible with the incubator environment •Its small weight allows an easy transfer of the LiveFlow pump from the laminar hood to the incubator/ microscope •LiveFlow is equipped with two pumping heads, each one driving two independent circuits •Each pumping head is removable, sterilisable and reusable •LiveFlow is equipped with a drawer that houses up to four LiveBox. The design allows chambers monitoring using an inverted microscope •The interface is intuitive and user friendly: - A couple of buttons allows an easy setting of flow rates - A display shows the flow rate selected for each head - Flow direction can be reverted through a dedicated button SERVICE Services for advanced in-vitro models Engineering services for advanced in-vitro models design: - starting from our commercial devices, development of fluid dynamic simulations (CFD models) to estimate the effect of a certain parameter (i.e. flow rate). Standard applications: chemical compounds delivery or cells viability - mathematical models to downscale the physiological ration between tissues from the in-vivo reality to the in-vitro model, in order to maintain a high correlation degree. Biological service: - thanks to our partners network, development of the whole biological advanced in-vitro model. PARTNERSHIP Distribution agreement We are looking for partners in the distribution of our products outside the Italian borders.

406 / 880 IXTAL srl

Organisation

Country Italy City Novara Street Via Bovio 6 Web www.ixtal.it

Person

Name Davide Ferraris Managing Director

Organisation IXTAL is a research-driven company that provides solutions in the field of protein science, structural biology and drug design. IXTAL offers a wide range of research services and solutions for the biotech and pharma industry, wherever protein technology and expertise are needed. IXTAL's clients include small and major pharmaceutical and biotech companies that want access to cutting-edge protein technologies and drug discovery services. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Life sciences related activities • CRO (Contract Research Organisation) • Drug screening & delivery • Medical research • Peptides, proteins & antibodies preparation

Marketplace Opportunities SERVICE Protein science and technology, engineering and production of proteins for custom applications, structure-based drug design, small molecule XRD IXTAL offers a wide range of research services and solutions for the biotech and pharma industry, wherever protein technology and expertise are needed. IXTAL services include: - Production of target proteins - Engineering and design of tailored enzymes and proteins for custom applications - Proteins biochemical and biophysical profiling - Protein structure analysis - Drug discovery services (protein-drug structure solution and interaction profiling, structure-based in silico drug design) - Small molecule structure solution 407 / 880 IXTAL is looking for cooperation with Pharma companies interested in the effective, rational, structure- based drug discovery and development. IXTAL is interested in exploring protein enabling technologies for the development of biosensor, lab- on-chips, diagnostics and point-of-care testing devices.

408 / 880 Jefferson

Organisation

Country United States City Philadelphia Street 1020 Walnut Street Philadelphia, PA 19107 Web https://www.jefferson.edu/

Person

Name Claudia Cirillo Consultant - Assistant to SVP for Strategic Affairs (Europe)

Organisation Jefferson (Philadelphia University + Thomas Jefferson University) is a comprehensive university with preeminence in transdisciplinary, experiential professional education, research and discovery, delivering exceptional value for the 21st century students with excellence in architecture, business, design, fashion, engineering, health, medicine, science and textiles - infused with the liberal arts. In the medical field, Jefferson hosts one of the oldest institutions of higher education in the United States, the Sidney Kimmel Medical College (SKMC), which has awarded more than 31,000 medical degrees and has more living graduates than any other medical school in the nation. Jefferson can boast: - 9 colleges and 4 schools spanning medicine, science, but also architecture, design, fashion, textiles, business, engineering and more - 160 undergraduate/graduate programs, - 7,800 students, - 1,070 medical student rotations, - 1,300 residents and fellows Jefferson and Jefferson Health were ranked by U.S. News & World Report as the nation’s 16th Best Hospital. Among the top clinical specialties nationally high-ranked: Ear, Nose & Throat, Ophthalmology (Wills Eye Hospital); Orthopedics (Rothman Institute, Philadelphia Hand to Shoulder Center); Cancer (Sidney Kimmel Cancer Center); Cardiology & Heart Surgery; Diabetes & Endocrinology; Gastroenterology & GI Surgery; Geriatric; Nephrology; Neurology & Neurosurgery, Vickie & Jack Farber Institute for Neuroscience. It counts 13 hospitals, 2,824 licensed beds, 6,000 physicians and practitioners, 7,200 nurses, 50+ outpatient and urgent care locations and 3 million outpatient visits; - Sidney Kimmel Cancer Center (NCI-designated); - over 110 million USD in public/private research funding.

409 / 880 Areas of Activity

• 3D Printing/addictive manufacturing for • Vaccines biomedical applications • Other • Biotechnologies (Pharma&Medical • Project proposals support services Devices) • IT Applications for Health • Consulting services • eHealth, mHealth, telemedicine • Medical research • Life sciences related activities

Marketplace Opportunities SERVICE Internationalization Interested in expanding international partnerships also through joint access to resources administered by the European Commission (via grant applications involving international consortia). Willing to consider new international collaborations also in the field of medical travel and tourism PARTNERSHIP Expanding international collaborations on academic programs and clinical research Several long-standing partnerships with distinguished academic institutions already ongoing. Willing to expand pool of international partners to promote new academic programs and clinical trial research projects (academic exchanges, joint applications for EU grants, etc.). PROJECT COOPERATION Horizon 2020 Looking for international partners to evaluate joint application for European grant resources in several areas of clinical research. Several applications already made or about to be made and awaiting feedback from the European Commission. A dedicated legal entity for participation in international research (including European programs) has been created. REQUEST Participation in International Projects Jefferson would consider partnership requests for upcoming Horizon 2020 SC1 calls, as well as affiliations to consortia aimed at promoting international cooperation, research and student and faculty mobility (Erasmus, Fulbright, etc.).

410 / 880 JM Consulting Srl - Adiuto

Organisation

Country Italy City Gossolengo Street Via Donatori di Sangue, 3 Web www.adipharma.eu

Person

Name Davide Rossetti Business Development

Organisation Jm Consulting develops software solutions for the management of Quality Systems in regulated companies. Its solution named AdiPharma allows to improve efficiency through digitalization of document and quality processes, information concerning Training of Human Resources. All this conforming to Data Integrity and in compliance with FDA Cfr21 and EU-GMP. Areas of Activity

• Consulting services • Software, ICT applications, system integration • IT Applications for Health

Marketplace Opportunities PRODUCT Solution for simple management of QA processes Our solution named AdiPharma allows to simply manage processes of Quality Assurance in Regulated environments. AdiPharma is a unique solution which allows the management of document workflows (i.e. SOPs, Modules, Master Batch Record, Protocols, ...... ), quality processes (i.e. CAPA, Change Control, Claims, Deviations, Audit Reports, Non Conformities, .....) and Training data of HR. AdiPharma is user friendly, web-based, usability is granted also on Tablets or Smartphones, times to go-live are reduced. Its scalability make it suitable both for SME and for big Corporations.

411 / 880 Johnson & Johnson Innovation

Organisation

Country Italy City Cologno Monzese Street Via buonarroti 23 Web https://www.jnjinnovation.com/

Person

Name Marcella Origgi New Scientific Venture Lead Italy

Organisation The London innovation centre is part of Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Corporation, Ltd. Johnson & Johnson Innovation focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies focused on early-stage opportunities a one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of those innovations to solve unmet needs in patients. More information can be found here:www.jnjinnovation.com. Areas of Activity

• Biomaterials • Medical devices • Pharmaceutics • IT Applications for Health • Vaccines • Virtual reality applications

Marketplace Opportunities PARTNERSHIP Partnership to accelerate NME offered by third parties We are looking for really breakthrough new treatments, drugs

412 / 880 Jozef Stefan Institute, Ljubljana, Slovenia

Organisation

Country Slovenia City Ljubljana Street Jamova 39

Person

Name Miha Butinar Postdoctoral Assistant

Organisation Department of Biochemistry, Molecular and Structural Biology, "Jozef Stefan" Institute: The major goals of our research are to characterize the individual proteases (primarily from the cathepsin family) and their inhibitors (stefins, cystatins and related proteins) and to unravel the molecular mechanisms of processes leading to programmed cell death or regulating the immune response of the organism. In addition, our research is focused towards understanding the roles of proteases in various pathological processes, such as cancer, rheumatoid arthritis and osteoarthritis, while also developing molecular delivery systems for diagnostics and therapeutics by providing specific target delivery. We also participate in the development of activity-based probes for proteases suitable for work in cellular and in vivo models, and for testing pharmacologically-relevant compounds. In addition, we have a key role in establishing a center for proteomic research, which would cover the needs of whole Slovenia. Areas of Activity

• Diagnostics - Imaging equipment and • Proteomics, metabolomics, nutrigenomics processing • Life sciences related activities • Drug screening & delivery • Medical research • Pharmaceutics

Marketplace Opportunities INVESTMENT OPPORTUNITY Novel molecular delivery system for diagnostics or therapeutics A molecular delivery system for diagnostics and therapeutics has been developed, by providing targeted delivery of markers or drugs to targeted cell types. Markers or drugs are specifically delivered to targeted site in liposomes, using cathepsin inhibitors as guides towards cathepsins released by inflammatory and tumor cells. The system prevents toxic side effects, reduces the dosage, and treatment costs, while increasing the signal intensity of markers. Problem:

413 / 880 Despite the progress of modern medicine, inflammatory diseases and cancer still represents a major problem of the developed world. In cancer, early detection is crucial for patient survival, as well as detection of metastasis in later stages. There is need for more efficient markers in diagnostics that would enable that. In treatment a number of drugs exhibit major harmful side effects or are inefficient because of low bioavailability. There is a need for development of novel, more efficient drugs and novel targeted drug delivery systems. Current delivery systems are often based on nanoparticles or conjugation with antibodies; however, nanoparticle systems are often nonspecific and require high doses of drugs to be effective, and antibody-based systems are costly. Solution: The invention solves this problem by safely and accurately delivering the markers or drug to its target site. Inflammatory and tumor cells characteristically secrete enzymes cathepsins that the delivery system is targeting. A specific cathepsin inhibitor is linked to a liposome via a lipid tail, and the liposome encloses the drug, offering protection from the environmental factors, preventing marker or drug degradation as well as nonspecific delivery. The system is used for specifically targeting cathepsins in the inflammatory and tumor microenvironment, and therefore bringing the liposome containing the markers or drug (eg. doxorubicin), to the target site. Application: The technology is applicable for detection purposes with specific delivery of markers to the targeted site. Apart from diagnostic purposes it is also applicable for targeted delivery of both anti-tumor and anti-inflammatory drugs. PROJECT COOPERATION In vivo Imaging Core Facility In vivo imaging facility has major experience in imaging small laboratory animals that are used in cancer or inflammatory related studies, using state of the art in vivo imaging systems for bioluminescence/fluorescence imaging (IVIS Spectrum, PerkinElmer) and complementary microCT imaging system (Quantum FX µCT, PerkinElmer). The focus of our research is involved in cancer development and progression, and inflammatory diseases, as well as drug delivery systems for diagnostic and therapeutic purposes. FUNDING PROGRAMME AND REFERENCE H2020 TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE The In vivo imaging facility seeks technical cooperation or offering our services in joint projects demanding advanced imaging expertise. PROJECT COOPERATION Proteomic Core Facility Proteomic lab has major expertise in dealing with a broad spectrum of samples that are analysed using state-of-the-art MS-instruments (Orbitrap Velos LTQ (Thermo Scientific), MALDI-TOF (Bruker Daltonics). The focus of our research is on proteases and their substrates and their role in disease development and progression (cancer, inflammation …). We have developed different proteomic approaches that enabled us to provide the first unbiased evidence for sheddase activity of cysteine cathepsins in context of cancer. We also developed a simple and straightforward technology for profiling specificity of proteases that can be adapted to a wide range of proteolytic enzymes. Our methods enable in- depth profiling of proteomic samples aiming to increase the analysis efficiency without increasing the costs. FUNDING PROGRAMME AND REFERENCE H2020 TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE The proteomic facility seeks technical cooperation or offering our services in joint projects demanding advanced proteomic expertise.

414 / 880 JSB Solutions

Organisation

Country Italy City Sesto Fiorentino (FI) Street Via di Calenzano, 62 Web www.jsb-solutions.com

Person

Name Jacopo Montigiani General Manager

Organisation JSB Solutions is a consulting company born in 2009 to meet the advanced needs of the pharmaceutical, biotechnology and industrial world. Our crew is specialized in three main areas: - Pharma Consulting - CRO (Contract Research Organization) - Software Solutions. OUR VISION Let's clients focus on core activities OUR MISSION Facilitates clients’ work Areas of Activity

• CRO (Contract Research Organisation) • Life sciences related activities • Manufacturing & process engineering • IT Applications for Health • Pharmaceutics • Regulatory affairs, validation

Marketplace Opportunities SERVICE Software Solutions Our Software Solutions are reliable and efficient systems designed to assist companies in the management of the most important processes and procedures. We help in safety optimization of the workplace, in the clinical trial management, and in the GMP compliance of business procedures, giving the best performance in terms of speed and flexibility. We also develop internal and external projects based on the application of Blockchain technology. Our Products: - Contrappunto Software for eCRF management in Clinical Trials - Safety Suite for safety optimization in the workplace - GMP Booster for business procedures management

415 / 880 MARKET APPLICATION Pharma, medical devices SERVICE Pharma Consulting We support life science companies during the whole drug development life cycle. We assist pharma industries in order to work in compliance with GMP regulations and standards, to comply with all the regulatory procedures and to optimize validation strategies. Our wide range of services also includes training & recruiting. MARKET APPLICATION Pharma, medical devices SERVICE CRO (Contract Research Organization) Our CRO is composed by multidisciplinary professionals with different backgrounds and experiences. With a focus on advanced therapies we give support at all stages of clinical study: from regulatory, application and documents approval to project management including clinical monitoring, medical and safety control and data management and statistic. SERVICE Blockchain Open Lab Blockchain Open Lab is the place where professionals share ideas, expertise and promote contamination between different sectors. Workshop, events, meetings: the Open Lab is constantly moving ahead, engaging the members that are already part of it and new members, answering the questions of those who still have not a clear idea of what blockchain is and what it could become for their business.

416 / 880 K-Tree Srl

Organisation

Country Italy City Pont-Saint-Martin Street Via Carlo Viola n. 78 Web www.k-tree.it

Person

Name Paolo Vismara Consulente Direzionale

Organisation K-Tree is an innovative start-up specialized in the field of data mining, IoT and Artificial Intelligence. In particular K-Tree want to apply these technologies in the fields of telemedicine and agrifood. We have already developed a tool for monitoring the real-time positioning of patients in a clinic that generates alarm messages for the doctor. K-Tree started a collaboration with other companies with the aim of improving its skills in telemedicine and now it is developing an IoT system for the detection of patient's vital parameters. The NewCo's name will be NEXT STEP. This system is designed for the telemonitoring of patients with chronic diseases. The target is to allow the patient to undergo a professional visit while remaining at home. The system, although it is easy to use, it has a very high technological value and can detect up to 12 parameters with a great accuracy. The data collected are processed by an artificial intelligence platform that creates predictive algorithms that support the doctor in his diagnosis for example. The same mechanism is applied to the plants going to detect biometric data and processing them with an artificial intelligence. In this regard, an adaptive greenhouse has been created. This greenhouse is able to manage autonomously the plants inside it thanks to sensors and actuators. Areas of Activity

• Bioinformatics, Big data analytics • Life sciences related activities • Biosensors • Software, ICT applications, system • Biotechnologies (Pharma&Medical integration Devices) • Other • Diagnostics - Equipment and accessories • IT Applications for Health • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine

417 / 880 • Electromedical and medical equipment (non diag)

Marketplace Opportunities INVESTMENT OPPORTUNITY CyberDoc: IoT Sensors for monitoring position and vital parameters in both closed and open environments + Machine Learning algorithm to help doctors' diagnosis Problem: In the last few years there has been a significant increase in healthcare costs. Hospitals are increasingly crowded and this leads to a worsening in the quality of care. Solution: We’re developing an innovative device to overcome this problem. The device is able to detect up to 12 vital parameters such as ECG signal, heart rate, blood pressure etc. with a great accuracy and with the use of low power sensors in order to reduce the costs and consumes. Moreover the device is portable so that it can be used outside protected environments (hospitals) and user friendly so that it can be used by anyone without the need of a doctor. Our goal is to provide a complete system made up of 3 components: •The device that detect vital parameters •A monitoring centre where data collected by device are sent and then processed by an Artificial Intelligence. The monitoring centre will be the interface between patients’ home and the hospitals •The hospitals where the doctors receive processed data in order to have support in diagnosis. So the target is the relocation of the hospital to the patient’s home in order to allow doctors to carry out a professional visit remotly. We are also able to provide the CRM software in order to manage all the activities. Innovation: The vital parameters collected by the device are processed by an appropriately trained Artificial Intelligence in a way that the doctors don’t receive raw data but an elaboration of the data for example alarm messages if the patient has problems and an urgent transport to the hospital is needed. So the Artificial Intelligence platform supports doctor diagnosis using predictive algorithms. Furthermore the GPS module integrated in the device allow to know where the patient is in every moment. Market: We expect that, after an initial step of testing, our solution will have a strong impact in digital medicine that is a very broad field intended to grow in the coming years. Competition: We have already tested the device to monitor the surgeon’s stress during a surgery detecting vital parameters and processing them with an Artificial Intelligence. The device is able to detect all the parameters needed for a diagnosis without being cumbersome while other devices can detect only 3 parameters. The platform can also be used via CLOUD: CLOUD platforms, which can be sold as Services (Opex) instead of purchasing licenses (Capex). Team: Our team consists of doctors, engineers and IT specialists in order to be able to have a state of the art product. In fact the skills of each element of the team are essential. The doctors have the knowledge of which parameters are important for a good diagnosis and how to interpret the output of the predictive algorithm. The engineer and IT specialists are involved in the research and development of the device (hardware) and in the implementation of machine learning algorithm (software). PARTNERSHIP IoT Sensors for monitoring position and vital parameters in both closed and open environments Technology: K-Tree srl within SMART HEALTH, uses an IoT system, based on the Wireless Body Area Network (WBAN) both for the positioning of people and for the transmission of vital parameters. In general, with the platform and its sensors, an inventory management system is created, capable of locating both indoors and outdoors. The sensors, designed entirely by K-Tree srl, is open to the use of different communication protocols, which, together with low power consumption, make it able to easily adapt to various needs and environments: 418 / 880 Innovation: Possibility of use for monitoring people inside buildings and/or outside, for example in hospital environments or in patient’s home. We are developing the system for the telemonitoring of patients with chronic diseases, to allow patients undergoing professional visits remaining at home. The system can detect up to 12 parameters with a great accuracy, and the data are processed by an Artificial Intelligence platform supporting doctor diagnosis using predictive algorithms. Technical Specifications: Low power consumption thanks to IoT sensors. Customization possibilities with the integration of different technologies, WiFi, GPRS, GPS and other protocols such as: Bluetooth, ZigBee, and MQTT; we can detect several vital parameters such as ECG signal, heart rate, blood pressure, temperature etc. Stage of development: we are currently testing our prototype in a hospital under the supervision of a doctor. Our goal is to engineer the device in order to improve performance and the portability.

419 / 880 Karabuk UNIVERSITY

Organisation

Country Turkey City Karabuk Street

Person

Name Batuhan Özusta Student

Organisation I want to learn information about the company. I who learn new technology improve new biomaterials and I want to make new biomaterials. Therefore I want to see new technology. Why do I want to come to this organization? Because I want to learn new technology about biotechnology I learn new information about Biomaterials. I want to do production Biomaterials and I will speak with a company with this project. If the I will find the company for my project I will do my project with the company. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical research biomedical applications • Medical devices • Biomaterials • Biosensors • Chemicals & APIs • Manufacturing & process engineering

Marketplace Opportunities

PRODUCT Biomaterials I want to make biomaterials. My Biomaterial has used the implant. I will work with Co-Cr Biomaterial and I want to take information about it. PROJECT COOPERATION Scientific and Technological Research Council of Turkey I will want to make research project with scientific and technological research council of turkey. This project will be with industry. PROJECT COOPERATION Project of Science I have accepted two projects about Biomaterials. This project accepted by scientific and technological research council of turkey.

420 / 880 Katalyxer srl

Organisation

Country Italy City Cavaion V.se Street Strada Preela Zanoni 11 Web http://www.katalyxer.com

Person

Name Andrea Benoni CEO

Organisation Our focus is R&D and patenting in the domains: - "Security and Privacy by design" cloud services with pervasive cryptography. - Predictive system for diabetes and other chronical diseases using an innovative mathematical model in combination with IA - Advanced knowledge base system to manage information and support interactive IA (Intelligence augmentation) systems Areas of Activity

• Bioinformatics, Big data analytics • Software, ICT applications, system • eHealth, mHealth, telemedicine integration • Nutraceutics, probiotics, functional food, • IT Applications for Health cosmeceutics • Life sciences related activities

Marketplace Opportunities PARTNERSHIP Assess our Privacy-by-design patented cloud technology in GDPR domain Our US-European patented technology is a Privacy-by-design infrastructure permitting the user to maintain complete control of his information. Thanks to pervasive cryptography, anonymization, role/domain segregation and smart-contract, our technology permit to overcome the limitations of traditional approaches. We are looking for partners to study the use of our patented technology in the GDPR regulation domain, how anonymization permit to overcome the limits imposed, and how the advanced control/ cryptography allows the Privacy-by-design required by the ruler PRODUCT Katalyxer DEI Privacy-by-design cloud service for user-centric data interchange Our US-European patented technology is a Privacy-by-design infrastructure permitting the user to 422 / 880 maintain complete control of his information. Thanks to pervasive cryptography, anonymization, role/domain segregation and smart-contract, our technology permit to overcome the limitations of traditional approaches. SERVICE Katalyxer DEI Privacy-by-design cloud service for user-centric data interchange Our US-European patented technology is a Privacy-by-design infrastructure permitting the user to maintain complete control of his information. Thanks to pervasive cryptography, anonymization, role/domain segregation and smart-contract, our technology permit to overcome the limitations of traditional approaches.

423 / 880 KB Investment

Organisation

Country Korea, Republic Of City Seoul Street Web http://www.kbic.co.kr

Person

Name Min Shin Manager

Organisation KB Investment is a 100% subsidiary company of KB Financial Group, the biggest financial group in Korea, with its active fund size over $1B USD. For more than 25 years, companies and executives have chosen to partner with KB Investment because of the deep industry experience, strong network of business relationships, and track record of success. KB Investment have invested more than 700 companies since the establishment, and more than 100 companies have listed in stock market globally. KB investment Bio team is one of the biggest team among local venture capital corporate with its special expertise in various fields with bio sector. KB investment aims at enlarging the investment size, expanding the areas of investment, and strengthening its professional expertise to contribute value to growth of the companies, and by extension, to growth of the whole industries. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Life sciences related activities • Diagnostics IVD • Vaccines • Diagnostics - Equipment and accessories • Laboratory equipment, reagents, software • Diagnostics - Imaging equipment and • Medical devices processing • IT Applications for Health • Drug screening & delivery • Genetics & Genomics • Investments • Peptides, proteins & antibodies preparation

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity Bio/healthcare is a relevant field for KB investments. KB invests approximately 30-50 M USD annually in such area. Bio team of the KB investment is one of the biggest team among local venture capital corporates with its special expertise in various fields within bio sector. 424 / 880 KBIC invests across the various stages of a company’s life: - Early to late stage of venture capital: proven entrepreneurs with deep domain experience or innovative business model - Growth and Buyouts as private equity investment: proven, scalable business model

425 / 880 Kerline Srl

Organisation

Country Italy City Bologna Street Via Gobetti 101 Web www.kerline.com

Person

Name Alberto Del Rio CEO

Organisation Kerline® is specialized in the production and engineering of natural biomaterials deriving from protein revalorization. Fullker® is the first biomaterial product line based on keratin proteins. Fullker is a natural and multifunctional biomaterial suitable for production of SkinKer dressings (nanofibrous, self- absorbable transdermal dressings for skin reconstruction and wound healing applications) or cutting- edge and multifunctional dermocosmetic or trichological products. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical research biomedical applications • Nutraceutics, probiotics, functional food, • Biomaterials cosmeceutics • Biosensors • Pharmaceutics • Biotechnologies (Pharma&Medical • Medical devices Devices) • Chemicals & APIs • Manufacturing & process engineering

Marketplace Opportunities PRODUCT Manufacturing of keratin based biomaterials and advanced keratin based products We manufacture pure keratin (FullKer®) from keratin-rich materials. FullKer® preserves chemical and biological properties of native protein and is natural, biocompatible and with biological effectiveness. INVESTMENT OPPORTUNITY Seeking investments in the area of life sciences, health & wellbeing We seek investments for Kerline's products (FullKer® and other biomaterials) Area of interest: Cosmetics | Trichological products | Advanced medications | Biomedical devices | Pharmaceuticals.

426 / 880 SERVICE Circular economy of keratin-rich by-products of agro-food industries Keratin is available from many different keratin-rich sources as major component of several by- products of agro-food industries including human and animals hair, bristles, wool and feathers. We offer individual consulting aimed to: analyse the regulatory framework | increase the commitment to circular economy | reduce waste disposal costs | increase the value of the biomass | create alternative solutions to recover protein from biomasses

427 / 880 Kerline Srl

Organisation

Country Italy City Bologna Street Via P. Gobetti 101 Web http://www.kerline.com

Person

Name Greta Varchi Researcher

Organisation Kerline® is specialized in the production and engineering of natural biomaterials deriving from protein revalorization. Fullker® is the first biomaterial product line based on keratin proteins. Fullker is a natural and multifunctional biomaterial suitable for production of SkinKer dressings (nanofibrous, self- absorbable transdermal dressings for skin reconstruction and wound healing applications) or cutting- edge and multifunctional dermocosmetic or trichological products. Areas of Activity

• Biomaterials • Medical devices • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities SERVICE Circular economy of keratin-rich by-products of agro-food industries Keratin is available from many different keratin-rich sources as major component of several by- products of agro-food industries including human and animals hair, bristles, wool and feathers. We offer individual consulting aimed to: analyse the regulatory framework | increase the commitment to circular economy | reduce waste disposal costs | increase the value of the biomass | create alternative solutions to recover protein from biomasses INVESTMENT OPPORTUNITY Seeking investments in the area of life sciences, health & wellbeing We seek investments for Kerline's products (FullKer® and other biomaterials) Area of interest: Cosmetics | Trichological products | Advanced medications | Biomedical devices | Pharmaceuticals. PRODUCT Manufacturing of keratin based biomaterials and advanced keratin based

428 / 880 products We manufacture pure keratin (FullKer®) from keratin-rich materials. FullKer® preserves chemical and biological properties of native protein and is natural, biocompatible and with biological effectiveness.

429 / 880 Kingo Investment Partners

Organisation

Country Korea, Republic Of City Seoul Street

Person

Name Seung Ryul Lee general manager

Organisation Kingo Investment Partners is a newborn Venture Capital firm which is financially backed by proven leaders of Korea’s healthcare industry. With an exceptional team of shareholders and field experts, we pursue active investments in bio sector and assist our portfolio companies with a full range of support. We offer long-term investment horizon beyond typical investment cycles; The world-class SMC (Samsung Medical Center), a strong alliance owned by our key shareholder SSK University, serves as a potential client as well as an excellent testbed. Other major shareholders such as KyungDong Pharma and Daehwa Pharmaceutical provide insights on product development based on the 40-years of success as a mid-sized pharmaceutical company. Our Bio team is specialized for assisting our portfolio companies to leverage these unique opportunities throughout the product/commercial development and to achieve high-growth transformation. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Medical devices • Diagnostics IVD • Genetics & Genomics • Peptides, proteins & antibodies preparation

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity pharma, diagnostics, drug delivery, biosensors Kingo Investment Partners is a newborn Venture Capital firm which is financially backed by proven leaders of Korea’s healthcare industry. With an exceptional team of shareholders and field experts, we pursue active investments in bio sector and assist our portfolio companies with a full range of support. We offer long-term investment horizon beyond typical investment cycles Areas of interest for investment: - Pharma/Diagnostics/Drug delivery/Biosensors Types of investment - Equity investment up to 2M USD

430 / 880 Kitos Biotech s.r.l.s.

Organisation

Country Italy City ALGHERO Street Porto Conte Ricerche S.P. 55 Porto Conte - Capo Caccia km 8,400 Loc. Tramariglio Web http://www.kitosbiotech.org

Person

Name Francesco Paolo Fiorentino Chief Scientific Officer

Organisation We support research centers, biotechs and pharmas in the field of medicinal chemistry and oncology to develop their products at preclinical stage. We help in the development of a scientifically sound and cost-effective experimental plan to evaluate the in vitro drug efficacy and the mechanism of action of their products, taking advantage of automation systems, live-cell imaging and more than 100 in-house cell lines. We perform experiments and analyze data in our laboratory, providing ready-to-use results for customer's pipelines. Areas of Activity

• Analytical and characterization services • Life sciences related activities • CRO (Contract Research Organisation) • Drug screening & delivery • Medical research

Marketplace Opportunities SERVICE In Vitro Cell-Based Assays for Cancer Research We provide a range of in vitro cell-based assays and molecular assays to the academic and commercial anticancer drug discovery market in the form of contract research. REQUEST Distributors We are looking for distributors of our cell-based assay services in Italy and abroad.

431 / 880 KNOW-CENTER GmbH

Organisation

Country Austria City Graz Street Inffeldgasse 13/6 Web http://www.know-center.tugraz.at/

Person

Name Enrico Andriolo International Cooperations

Organisation KNOW-CENTER (www.know-center.tugraz.at) is Austria’s leading research center for data-driven business and big data analytics. Founded in 2001, the center is located at the Graz University of Technology campus, counts more than 110 researchers and operates as a private body. Over the past years has conducted more than 30 international EU projects and over 600 industry projects, covering the following business areas: Industrial Data Analytics, Data-Driven Markets, Strategic Intelligence, Data-Driven Process and Decision Support, Learning 4.0 and Digital Life Science. In close cooperation with companies and within numerous research projects, KNOW-CENTER turns large amounts of data into useable information and develops intelligent applications and systems in order to help users identify, visualize, structure and transfer knowledge in social networks and mobile working situations or personalized according to the specific requirements of individual users. With more than 50 business and science partners as a business oriented and applied research entity KNOW-CENTER contributes to the continuous development and implementation of scientific findings in the area of data-driven business. As a competence center it has the objective and task to promote and further extend applied research for its business partners and customers. KNOW-CENTER founded the Big Data Network Europe and lead it together with the Big Data Center Berlin and is member of Big Data Value Association. Areas of Activity

• Analytical and characterization services • Medical facilities furnishings, equipment, • Bioinformatics, Big data analytics goods • Biosensors • Nutraceutics, probiotics, functional food, • Biotechnologies (Pharma&Medical cosmeceutics Devices) • Pharmaceutics • Consulting services • Life sciences related activities • Diagnostics - Equipment and accessories • Software, ICT applications, system • Diagnostics - Imaging equipment and integration processing • EPR, Clinical/healthcare management

432 / 880 • eHealth, mHealth, telemedicine software • Genetics & Genomics • Medical devices • Manufacturing & process engineering • IT Applications for Health • Medical research

Marketplace Opportunities SERVICE DATA ANALYTICS

RESEARCH AND DEVELOPMENT Predictive modelling of biological processing and drugs Analysing new candidates submitting to patents and scientific publications Pharmacophorical profiling Monitoring and analyzing patents and other IP rights CLINICAL TRAILS Optimize design by targeting specific patient groups Medical records analysis (causality analysis) Dynamic sampling and streaming data analysis Genotype analysis OPERATIONS AND SUPPLY CHAIN Demand forecasting Inventory management Processes optimization Quality control Safety and workforce sentiment analysis COMMERCIAL Pricing optimization Market access Identification of treatable patient Sentiment analysis on drugs/company (forums, social networks) Support implementation of cutting-edge technologies EVIDENCE BASED MEDICINE Identification of best/most promising treatment Pharmacovigilance Analysis of data from bio-sensors Pharmacogenetic testing (right dosages) RISK AND COMPLIANCE Enable quality and compliance to monitor risk in real-time, identify outliers PRODUCT MED360 - www.med360.at

Increase efficiency to find relevant medical publications Easy-to-use tool, collects automatically new publication matching the interests of medical researchers Researchers can read articles, mark favourites for later use, discard junk or forward interesting stuff to friends and peers SERVICE DECISION SUPPORT TOOLS

Design and develop human-centered decision support systems used whenever possible to allow rapid 433 / 880 and effective decision making Use of visual-knowledge interfaces to foster the collaborative analysis and exploration of data Use of data management methods and technologies for real time processing and analytics Development of digital applications to empower patients to make decisions about their health SERVICE BIOSENSORS

DATA MANAGEMENT Collect real-time biosensors data (e.g. EEG, EMG, EYE, BIO) ADVANCED ANALYTICS Categorize human performance of activities and use of statistical modelling and machine learning techniques

434 / 880 Korian

Organisation

Country Italy City Milan Street Web http://www.korian.it/

Person

Name Francesca Brescia Open Innovation Manager

Organisation Korian, with 780 facilities, operates Europe’s largest network of long-term care nursing homes, specialised clinics, assisted-living facilities, home care and hospital home care services. Korian Group operates in four countries : France, Germany, Belgium and Italy. Korian is the only provider of healthcare services in Italy that is present in all sectors: long-term care nursing homes, specialised clinics, assisted living facilities and home care networks. Korian is known as a benchmark care provider and offers a full range of services for patients and residents based on the continuity of care. Areas of Activity

• Other

Marketplace Opportunities PARTNERSHIP New techlogies for elderly We are seeking new start up or new products/services in assistive/healthcare technologies that help elderly Seniors REQUEST Smart home and Ambient Assisted Living technologies for seniors We are seeking collaboration for smart home devices and AAL technologies for ageing people

435 / 880 L3-Lab Shanghai Ltd

Organisation

Country China City Shanghai Street Jing An District, Jiaozhou road 322, building 8, floor 2 Web www.l3-lab.com

Person

Name Lapo Tanzj CEO

Organisation L3 is a consulting Lab committed to providing analysis, strategies, management and sales services. Our added value is the integration in the Chinese local business market and the strong partnership with Chinese andinternational companies. L3 enhances managed projects with innovation, technology and the integration between on-line and off-line business. L3 is part of LAMA Group, with 25 international experts in Shanghai, Beijing, Milan and Florence. L3 founders have more than 15 years of experience in international business development. Areas of Activity

• Consulting services • Project proposals support services • Life sciences related activities • Other

Marketplace Opportunities SERVICE Chinese market access support Thanks to its network and partnership, L3-Lab can help Italian life sciences companies and organisations in the access and integration in the Chinese local business market, providing analysis, strategies, management and sales services support

436 / 880 L4T-Light4tech

Organisation

Country Italy City Firenze Street Via della Cernaia 5 Web www.l4t.it

Person

Name Lorenzo Targetti CEO

Organisation The company founded in Florence in 2014acts as a platform to transform optic, photonic and spectroscopic research carried by CNR and LENS research centres into marketable products in the field of biomedical devices, microscopy imaging and sensing technology. Our most recent projects include: EmoLED, a medical device using light to heal difficult and chronic wounds (www.emoled.com) launched in the market in spring this year. Areas of Activity

• Diagnostics - Imaging equipment and processing • Life sciences related activities • Medical devices

Marketplace Opportunities INVESTMENT OPPORTUNITY RAPTOR MICROSCOPY LAB It is a fully integrated modular laboratory for extracting 3D high resolution microscopy images. Thanks to an unique combination of different microscopes: Light sheet, 2 photons and Galvo micrscopes managed through a proprietory AI software system, it is possible to obtain very high definition large volume images (up to 1 cubic centimetre) and super fast biological activities such as action potential. Particularly suitable for Brain research and organoids analysis and diagnostic. PARTNERSHIP EMOLED-innovative MD for Phototherapy EMOLED is an innovative Medical Device, CE approved, that uses LED light to facilitate the healing of ulcers (more info at www.emoled.com). The product has been successfully introduced in the Italian market in the spring 2018 and now we are seeking for international distributors. PRODUCT

437 / 880 EMOLED-innovative MD for Phototherapy An innovative class IIA medical device that uses LED light to accelerate wound healing of ulcers such as CVI leg ulcers and Diabetic Foot Ulcers.

438 / 880 Laboratorios Rubio, S. A.

Organisation

Country Spain City Castellbisbal Street Industria, 29 - P.I. Comte de Sert Web www.laboratoriosrubio.com

Person

Name Carlos Rubio Executive President

Organisation Laboratorios Rubio is a family - owned company founded in 1968, thus celebrating its 50th aniversary this year. The strategic objective for the key therapeutic areas of the company is to provide a “global therapy to the patient" providing a wide range of products, including drugs, medical devices, in vitro diagnostic tests, pharmacogenetic analysis and food supplements. Rubió is pioneer in offering products to specialists for low incidence/prevalence diseases. Main areas: CardioVascular, Rheumatology, Nephrology / Urology and Central Nervous System. PRESENTING LIPOSCALE, AN ADVANCED LIPOPROTEIN PROFILING TEST BASED IN 2D NMR CE MARKED. Secondary Areas: Oncology / Radiotherapy. Depending on the market approach, Laboratorios Rubio has 2 different Business Units. Rx Business Unit Responsible of promote and selling the prescription drugs portfolio of products. This is the oldest unit and includes drugs produced internally as well as licensing-in products: drugs and medical devices. Our specialization in low incidence/prevalence diseases, make us to have a very close relationship with physicians and scientific societies, allowing us to introduce new products in the market or, even, develop new markets for mature products. We visit them directly with our own sales team, which covers all the Spanish territory. Additionally, in this area of activity, Rubió has developed its export business since 1982. Currently the international business represents the third part of the company total turnover, and invest in expansion projects in existing and new markets, with a particular focus on EU and emerging countries. We have presence in more than 50 countries, through partners. Diagnostic and MD Business Unit The Diagnostic Business Unit Presently has 7 people and based on the Liposcale IVD and some new OTX additions which will require promotion to physicians. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Medical devices

439 / 880 • Diagnostics IVD • Drug screening & delivery • Investments

Marketplace Opportunities PARTNERSHIP Late stage developers of IVD (test kits, instrumentation, software and services) and other medical devices for specific therapeutic areas Rubio is seeking middle or late stage developers of innovative IVD or other kind of medical devices in cardiovascular risk management, nephrology/urology, rheumatology, CNS and ICU in the EU markets and abroad. SOLUTION OR EXPERTISE SOUGHT We are looking mostly for incremental innovation or "first in kind" IVD or other medical devices. Our offer: launching and development of innovative MD or diagnostic lines, participate in the latter stages (final clinical trials, regulatory, market access when appropriate) economically and with our expertise. This would help to share investment and risks, and possibly facilitate access to public grants. As specified above we are looking mostly for innovation, but ideally it would help if the IP can be protected by patent or secret know-how. TYPE OF PARTNER SOUGHT Private companies or public research groups developer of innovative IVD or other kind of medical devices that can offer a solid product or project that can lead to an agreement with long-term territorial exclusivity for differentiated and innovative products. PARTNERSHIP In licensing opportunities for Spain. Medical devises, prescription drugs or any other product that needs the physician prescription or recommendation, for the patients of our Therapeutical areas (Cardiovascular, Rheumatology, Nephrology, Urology/Andrology and Central Nervous System, also Oncology / Radiotherapy ) SOLUTION OR EXPERTISE SOUGHT Partners with R & D or technical expertise able to develop the kind of products we seek and lacking their own commercial solution in Spain or looking for a better one. Laboratorios Rubio is specifically seeking for innovative medical devices or prescription drugs that are not present in Spain, or are not being promoted and that we could commercially boost with our experienced activity TYPE OF PARTNER SOUGHT Companies interested in the Spanish market with differentiated and innovative products that fit in our therapeutical areas of expertise. Partners that are not only looking for a distributor, but are looking for a close partnership to work with Laboratorios Rubió team. PRODUCT LIPOSCALE® TEST The Liposcale® test is an advanced lipoprotein test based on 2D Nuclear Magnetic Resonance (NMR 2D). The test determines the size and number of lipoprotein particles for the main types (i.e., VLDL, LDL and HDL) as well as each subtype size and concentration. Nine categories could be established according to size (large, medium and small particles) of each main type. Thanks to 2D based Nuclear Magnetic Resonance spectroscopy, Liposcale® test provides much more accurate and precise analytical results than alternative currently used methods. This test is also technologically innovative because it directly measures the physical size of the particles under a non- destructive sample method. All values and measurements are highly reproducible. The use of lipoprotein particles to identify and control lipid disease evolution show more accuracy in 440 / 880 Cardiovascular Risk (CVR) evaluation than the measurement of LDL cholesterol levels according to the guidelines and consensus of several medical societies. The Liposcale® medical software algorithm has been developed at the University Rovira i Virgili (Tarragona, Spain) and is patented and CE marked. LIPOSCALE® REPORT The LIPOSCALE® Report, elaborated with the lipoproteins measurement results, provides the common lipid profile values (i.e., Total cholesterol, c-LDL, c-HDL and Triglycerides) and several more risk specific parameters on: -- The size and quantification number of each main lipoprotein subclasses related to cardiovascular disease risk as well as its deviation from normal values. -- A specific lipid map for patient atherogenic risk, including an illustration called Lipidic Contour, with all integrated atherogenic parameters for clear disease classification. --The particle values, in digital format, for customized reports, patient’s clinical assessment and follow- up. -- Patient’s results assessment and its correlation with normal or abnormal population data values. This test can be used for both, clinical and research purposes, and is available in Spain since January 2017. The process operates under a central lab model that can potentially be implemented worldwide. The platform located at http://www.report.liposcale.com allows sample traceability and provide access to the individual LIPOSCALE® reports in a secured and protected data environment. INNOVATIVE VALUE OF LIPOSCALE® Liposcale® provides innovation in terms of in vitro lipid diagnostic processes and has become an essential tool for performing a more in-depth study of residual CV risk. Residual risk is currently unacceptably high and accounts for 70% of CV risk once the classic risk factors are controlled. 18 Liposcale® is a tool that enables making personalized decisions about prevention and treatment based on the estimate and handling of CV risk in the following situations: •ATHEROGENIC DYSLIPIDEMIA (AD) AD is a disorder of lipoprotein metabolism characterized by slightly low HDL levels, slightly high TG levels, normal LDL-C levels (or slightly high) and clearly increased LDL-P levels due to the presence of smaller LDL-P which are capable of crossing the arterial walls more easily. AD is associated with CVD high risk and is the main cause of residual CV risk. 1. According to the ICARIA study, there is a high prevalence of AD in Spain. It is estimated that 1,400,000 people in working age are experiencing this situation (6% of the working population) 12. 2. It is the main cause of residual CV risk after LDL-C targets are achieved 13. 3. Generally undetected by conventional tests. •DISCORDANT PATIENT There are patients in whom there is a physiological imbalance of LDL-C and LDL-P levels (lack of homeostasis) in the sense of having normal or slight deviation of LDL-C values while the LDL-P values are elevated until a high risk level. Discordance is defined as LDL-C greater than or equal to median while the alternative measure to compare, like LDL-P, is less than the median (or vice versa )20. For individuals with discordant LDL-C and LDL-P levels, the attributable atherosclerotic risk for LDL fraction is better indicated by LDL-P. 14. •PREDIABETES SIGNS Liposcale® can detect lipoprotein profiles that are associated with pro-atherogenic stages developed in prediabetes and insulin resistance status. The early detection of these characteristic profiles can help to prevent the future development of chronic hyperglycemia 15-16. •SELECTIVE TREATMENT, RESIDUAL RISK AND PATIENT FOLLOW-UP The treatment selection per each lipoprotein profile, the therapeutic objective to achieve and the treatment control and its accomplishment, could be determined by the Liposcale® test more accurately than conventional methods. Several medical treatments and life-style changes are the base for different therapeutic objectives to achieve initially and/or as a follow-up. In several of them the quantification of LDL-P could determine the different drugs, CV risks and objectives to achieve, particularly to evaluate carefully the Residual Risk of patients with previous CV events and CVD. 17

441 / 880 PROJECT COOPERATION Cooperation in generating new claims for Liposcale or new products based on the same NMR technology or others Laboratorios Rubio is interested in cooperating with other private companies, universities and research centers to develop new claims for the existing product Liposcale (see Liposcale description). Also, in developing new products using the same or different technology in lipidomics and related metabolomics.

442 / 880 Laboratory of Biology of Synapses- CIBIO

Organisation

Country Italy City Trento Street

Person

Name Giovanni Piccoli assistant professor

Organisation The Laboratory of Biology of Synapses investigates the molecular bases underlying the physiology and the pathology of the central nervous system. The team encompasses Dr. Giovanni Piccoli and Dr. Francesca Pischedda, experienced neurobiologists a with proven track record in the field. Neurobiology rises a number of scientific and technical needs. Our team is characterizing and further optimizing natural occurring molecules to develop new solutions in the life science field. Areas of Activity

• Peptides, proteins & antibodies preparation • Life sciences related activities

Marketplace Opportunities PRODUCT Neurostore The ability to produce in vitro neuronal cultures has been fundamental to advance our understanding of the nervous system: about 2.5k publications/year deal with primary neurons. However, primary culture require special expertise, extensive animal handling and have a short shelf-life. Neurostore cryo-preserved neurons are a valuable alternative to acutely dissociated primary cultures. Upon thawing, cryo-preserved cultures require minimal handling and fully develop in vitro. Therefore cryo- preserved neurons represent a useful tool for academia or SMEs lacking capabilities and logistic infrastructure to prepare primary culture.

443 / 880 Labospace Srl

Organisation

Country Italy City Milano Street Via Apella 41 Web http://www.labospace.com/

Person

Name Paolo Cappella Life Sciences Consulting, Ph.D

Organisation LaboSpace Srl is a ISO-9001 certificated laboratory service provider with branches in UK and Italy operating in the area of Immunology, cancer research, neuroscience, cardiovascular disease, endocrinology and target therapy application. LaboSpace services for the research market cover immunohistochemistry multiplex IHC , Luminex, ELISA and Meso Scale assays platform and Flow Cytometry. In May 2011 LaboSpace was granted by the Local Government of the accreditation as Diagnostic laboratory as SMeL for human genetics and pathological anatomy. Areas of Activity

• Analytical and characterization services • Medical research • Biotechnologies (Pharma&Medical • Laboratory equipment, reagents, software Devices) • Consulting services • CRO (Contract Research Organisation) • Diagnostics - Equipment and accessories

Marketplace Opportunities SERVICE QC Cell Lines Authentication Service Inadvertent cell line contamination has been a major problem for biomedical researchers with estimates that 18-36% of all cell lines are either misidentified or cross-contaminated with another cell line. Cell line integrity is of almost importance since the validity of the data obtained often depends on the identity of the cell line or stem cells used. Standardization and validation needs in biosciences researches help curb the inadvertent use of cross-contaminated or otherwise misidentified cell lines, supporting academia and biotech during submission of research publications or cell lines bio-banking process. Nowadays, higher Impact Factor Journals as “Nature” or “Cell” reserve the right to demand to scientists that the data be removed from the paper up to paper reject if cell line authentication is deemed unsatisfactory. Labospace scientists provides reliable, fast and affordable authentication of human cancer cell lines, 444 / 880 stem cell lines, xenografts, and more utilizing STR DNA technology, according to ATCC guidelines. Moreover mycoplasma status can be evaluated by high efficiency PCR assays. Functional assays by polychromatic flow cytometer could be request and can include cell viability, immunephenotype profile, DNA content and cytokines secrations. Marketplace is Academia, Biotech, Pharma are interested in CQ Cell Line Authentication. Moreover any entities or consortium applying to European project in Life Sciences, involving cell based applications. SERVICE Flow cytometry Outsourcing Services Flow cytometry is a laser-based technology that analyzes multiple characteristics of a single particle. It allows multiparametric analysis of thousands of particles or cells per second and helps to adequately identify or functionally characterize complex cell populations of interest. Flow cytometry is a versatile technology for developing drug-specific assays. It is often used in basic research, discovery, preclinical and clinical trials by multicolor immunophenotyping. Moreover additional fields involved in flow cytometry includes plant, veterinary and nutraceutical applications. The expert scientific staff at Labospace can provide service for project management, flow cytometry method transfer, method development, method validation, high quality sample analysis and results interpretation. Our experiences includes evaluation of various test items including but limited to monoclonal antibodies, small molecules, proteins and peptides. Labospace can develop novel flow cytometry assays as needed if appropriated reagents are available. Flow Cytometry Services at Labospace offers a competitive advantages realized through outsourcing from customer to high quality and reliable results, carry out experiments according client specifications and needs, meeting expectations and timelines for a single experiment or a clinical trials. Flow Cytometry Outsourcing Services at Labospace srl are dedicated to Academia, Biotech, Nutraceutical and Pharmaceutical companies. SERVICE Multiplex Testing Services of Multi-Analyte Profiling Labospace offers Multiplex Biomarker Custom Development and Testing Services based on our Cytokine expertise on Luminex and Meso Scale Technology. Both platforms technology allows simultaneous quantification of MultiAnalyte Profiling including cytokines / chemokines / biomarkers in serum, plasma, sputum and other biological samples Labospace is offering tailor-made assay development of Multi Arrays usually based on already available commercial assays as well as additional of new innovative biological markers. Moreover it will develop the assay and will evaluate, verify and optimize the dynamic range, signal linearity, assay specificity and will ensure Multiplex compatibility, providing also to customer sample testing services. Labospace clients portfolio include academia, biotech and pharma companies. Since beads based Assays are relevant for measuring any soluble biological analytes in mouse and rat fluids where sample limitation is an often an issue for any other bioanalytical tecniques, this service can be useful for CRO and pharma entities. Cytokine Multiplex monitoring is relevant in advanced cancer treatments using monoclonal antibodies and engineering therapeutic CAR-T cells. Biologics can trigger severe cytokine release syndrome (CRS) and some deaths have been reported, causing life-threatening pulmonary edema, if the patients were not appropriately treated. In this case, entities involved in patient treatments and clinical trials as well as clinic, CRO and pharma companies can benefit to Luminex and Meso Scale in Labospace service.

445 / 880 LABOZETA SPA

Organisation

Country Italy City ROME Street VIA TIBURTINA, 1166 Web HTTPS://LABOZETA.IT

Person

Name RICCARDO VILLA AREA MANAGER

Organisation OUR COMPANY IS SPECIALIZED IN DESIGN AND FURNITURE OF SCIENTIFIC LABORATORIES. IN PARTICULAR : CONSTRUCTION AND MAINTENANCE OF ASSOCIATED SYSTEM OF HEATING, PLUMBING, TECHNICAL GASES, ELECTRICAL, SAFETY, INCLUDING THE NECESSARY ACTIVITIES OF CONSTRUCTION AND INSTALLATION.MANAGEMENT OF CONSTRUCTION AND MAINTENANCE ACTIVITIES FOR CONDITIONING AND VENTILATION SYSTEM. MARKETING, INSTALLATION AND TECHNICAL SUPPORT SERVICE FOR MAINTENANCE OF FURNISHINGS (LAB FURNITURE), AND SCIENTIFIC EQUIPMENT Areas of Activity

• Laboratory equipment, reagents, software

Marketplace Opportunities PRODUCT LABORATORY SYSTEM LABORATORY FURNITURE OF : WORK BENCHES, FUME CUPBOARDS, BIOHAZARD CABINET, SAFETY CABINET, BALANCE TABLES, PHARMA AND OFFICE PARTITION WALLS, ETC

447 / 880 Laerbium Pharma srl

Organisation

Country Italy City Corciano Street Via Togliatti 73/a Web www.laerbium.com

Person

Name Alessandro Sorelli Marketing

Organisation LAERBIUM Pharma Ltd. is a company engaged in studies and research on cellular nutrition and herbal medicine. It 'was founded in 1999 by the passion of a group of university researchers (doctors, biologists, nutritionists and pharmaceutical chemicals) that have transferred their knowledge and academic skills. It is based in Umbria (Perugia), a district called "the green heart of Italy" because of its geographical location, rich vegetation and land conservation (environmental and historical). LAERBIUM Pharma designs and markets a series of dietary supplements (herbal remedies and nutraceuticals) and functional cosmetics (cosmeceuticals), adapted to the needs of major physiological balance, health and wellness. The rational formula shall comply with the most current and qualified scientific literature (evidence- based), thus being able to provide some references. Particular attention is paid in the supply of herbal extracts, requiring suppliers to the analytical and technical documentation complies with all European standards and thus being able to provide the consumer with the highest quality standards. Even the factories with we work in partnership, are able to provide the highest quality standards through continuous technological and human resources updating and quality procedures adopted. In addition, our home company is associated with FEDERSALUS, the main professional association of Italian companies in food supplements, regarded as the main interlocutor of the Ministry of Health. All our products are meeting the regulations and updated in real time to all requests sent by the competent offices of the Ministry of Health. All products are characterized by high efficiency, quality and safety. We are looking for innovative raw materials and high quality profile, requiring suppliers to analytical and technical documentation complies with all European standards. Market their products through the pharmaceutical network and hospital supplies, in accordance with the provisions of the Italian regulations. Our proven formulas are valid complementary remedies suitable for doctors' work; are distribuited into thematic areas corresponding to the physio-pathological problems most frequently. Intense scientific update is integrated by the activity of nutrition and health promotion, through conferences, seminars 448 / 880 and refresher courses for doctors and health workers, on issues of cellular nutrition and herbal medicine. Areas of Activity

• CMO (Contract Manufacturing • Regulatory affairs, validation Organisation) • Consulting services • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PRODUCT Food / dietary supplements, Nutraceuticals We produce food supplements, nutraceuticlas products and comsetics and have been in business since by 1999. Since 2011 Laerbium produce a wide range of product based on functional chocolate such as: sugar free choccolate; raw chocolate, chocolate bars added with mediterranean herbal extracts; chocolate bar added with probiotics. All products are made in Italy with innovative raw materials and high quality profile. We assure the hightest efficiency, quality and safety for everyone. Laerbium Pharma is associated with FEDERSALUS, the main professional association of Italian companies in food supplements, regarded as the main interlocutor of the Ministry of Health. We are also member of "Polo GGB | Genomics, Genetics and Biology". We carry out research projects in collaboration with the University of Perugia and the University of Camerino. INNOVATIVE ASPECTS AND MAIN ADVANTAGES All our products are formulated and produced in Italy. Well-documented raw materials. Natural extracts with reduced risk of side effects. Health claims and technical documentation complies all the European standards and laws. We provide taylor-made and market-specific products for our commercial partners. MARKET APPLICATION Healthcare and wellness: osteoarticular, lipid metabolism, vitamin supplementation, Osteoarticular/ joint, digestive system, immune system, nervous system, prostate / LUTS, probiotic, tonic, circulatory system. FINISHED PRODUCTS - Food and dietary supplements for the following health needs: probiotic, circulatory system, physical and mental fatigue, prostate / LUTS, nervous system, digestive system, vitamin supplementation, osteoarticular system / joint - Functional chocolate: raw chocolate, sugar free chocolate, choccolate with herbal extracts, choccolate with probiotics - Comsetic products: legs gel, hyaluronic acid, cocoa butter RAW MATERIALS - micro-encapsulated essential oils - raw cocoa mass SERVICES - contract manufactoring - regulatory and business consulting TYPE OF PARTNER SOUGHT We are looking for commercial partners in UE or extra-UE Countries for the pharmacy market such as traders, wholesalers, retailers. INVESTMENT OPPORTUNITY 449 / 880 Functional Chocolate Factory Since 2011 Laerbium produce a wide range of product based on functional chocolate such as: sugar free choccolate; raw chocolate, chocolate bars added with mediterranean herbal extracts; chocolate bar added with probiotics. Actually these product are sold as functional foods. We are looking for investor to improve this business and to market other product registered as chocolate-based food supplements. We are looking for investor to improve this business and to market other product registered as chocolate-based food supplements. We already have several customers waiting to buy this type of products.

450 / 880 Lamipress Srl

Organisation

Country Italy City Monte San Pietro (BO) Street via I. Bandiera 14/C Web www.lamipress.it/en

Person

Name Francesca Emili international sales & marketing

Organisation Lamipress produces stamping components (sheared and deep drawn) according to customers' drawings. We work out of all kind of sheet metal. We design and manufacture in house the progressive dies and tools, in order to offer the parts exactly as requested by our customers. Lamipress srl was founded in 1993 inBologna, Italy, by the Piccinini brothers Ermete and Mauro, who have been shareholders of Meccanica Stamper srl since 1979 (specialising in assembly and manufacture of automated machinery). The company specialises in the manufacturing of sheared components providing its customers with a finished product starting from the design phase to the manufacture of moulds and up to thermal and surface treatments on the manufactured item. The high quality of the supplies is due to thirty years of experience in the sector and an accurate control of all machining phases. The great synergies achieved by combining the knowhow of both the companies in the Group, Stamper and Lamipress, allow us to offer our customer both assembled and sub assembly pieces. Target sectors: Electrical appliances Electromechanics Automation and robotics Agriculture Automotive Building construction Hydraulics Motorcycle manufacturing Oleodynamics Biomedical Areas of Activity

• Manufacturing & process engineering

451 / 880 Marketplace Opportunities SERVICE Subcontracting of Sheared and Deep Drawn Components Lamipress produces stamping components (sheared and deep drawn) according to customers' drawings. We work out of all kind of sheet metal. We design and manufacture in house the progressive dies and tools, in order to offer the parts exactly as requested by our customers. The company specialises in the manufacturing of sheared components providing its customers with a finished product starting from the design phase to the manufacture of moulds and up to thermal and surface treatments on the manufactured item. The high quality of the supplies is due to thirty years of experience in the sector and an accurate control of all machining phases. The great synergies achieved by combining the knowhow of both the companies in the Group, Stamper and Lamipress, allow us to offer our customer both assembled and sub assembly pieces. PRODUCT Sheared and Deep Drawn Components Lamipress produces stamping components (sheared and deep drawn) according to customers' drawings. We work out of all kind of sheet metal. We design and manufacture in house the progressive dies and tools, in order to offer the parts exactly as requested by our customers. The company specialises in the manufacturing of sheared components providing its customers with a finished product starting from the design phase to the manufacture of moulds and up to thermal and surface treatments on the manufactured item. The high quality of the supplies is due to thirty years of experience in the sector and an accurate control of all machining phases. The great synergies achieved by combining the knowhow of both the companies in the Group, Stamper and Lamipress, allow us to offer our customer both assembled and sub assembly pieces. PARTNERSHIP Buyers for sheared and deep drawn components for medical equipments We look for Partnerships with Companies in the medical sector who would need our competence and experience in the production of sheared and deep drawn components for medical equipments.

452 / 880 Lead Discovery Siena

Organisation

Country Italy City Castelnuovo Berardenga Street Via Vittorio Alfieri 31 Web www.leaddiscoverysiena.it

Person

Name Laura Maccari Project Manager

Organisation LDS is a SME providing tools and expertise to develop drug discovery. LDS was founded as a spin-off of the University of Siena in 2012 by combining the scientific background and the entrepreneurship of its management to offer specific competences and solutions in drug discovery. Today, LDS offers pharmaceutical services for Industry and Academia and has a diversified pipeline of in licensed and proprietary products for oncology and infections therapeutic areas, including rare diseases. Our focus is to foster the design and development of early drug discovery campaigns up to pre-clinical phases. LDS actively participates to national and international projects, with a special attention to local synergies at industrial and academic level within the Life Sciences area. LDS has been awarded the “Tuscany StartCup”, 1st Classified, Innovation National Award, Sant’Anna School of Advanced Studies, Pisa, Italy, 2009, and “Best Presentation in Oncology” by Novartis Oncology at BioInItaly Investment Forum, Milan, Italy, 2015. LDS laboratories are located in the Toscana Life Sciences facilities (www.toscanalifesciences.org) a non-profit organization supporting research activities and promoting the creation of innovative companies in Life Sciences. Toscana Life sciences is located in the Glaxo Smith Klyne (GSK) campus in Siena where other multinational pharma companies have strategically chosen to locate their primary research and development activities. Areas of Activity

• Analytical and characterization services • Peptides, proteins & antibodies • Bioinformatics, Big data analytics preparation • Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Life sciences related activities • CRO (Contract Research Organisation) • Drug screening & delivery • Medical research

453 / 880 Marketplace Opportunities PARTNERSHIP Lead Discovery Siena- Antibacterial pipeline There is a very urgent need of novel antibiotics since a big number of resistant bacteria to current marketed drugs is emerging. LDS is actively involved in the discovery of antibacterial compounds with new chemical structures able to fight both wild type and resistant bacteria. LDS Antibacterial project has recently discovered a new class of linear guanidines active in vitro against clinically relevant pathogens. The lead compound of this class is LDS101 which proved to be very potent (MIC 0.5-8 µg/mL) against a wide range of resistant Gram-negative bacteria, including Klebsiella, Pseudomonas and Acinetobacter species which represent the most worrisome pathogens. A preliminary ADME characterization has been performed on LDS101 which proved to have good solubility and chemical stability. Currently LDS is focusing on expanding the Hit series by exploring the SAR. Very promising new derivatives have been identified with low cytotoxicity and very good activitiy against Gram negative bacteria. LDS owns the IP of the product. MARKET APPLICATION Antibacterial TYPE OF PARTNER SOUGHT Research co-operation, Technical co-operation, License agreement, Manufacturing agreement, Sales/ Distribution, Investment/Financing PARTNERSHIP Lead Discovery Siena - Glioblastoma product Glioblastoma (GBM) is the most aggressive (WHO grade IV) brain tumor in adults and the most frequent one. The majority of GBM patients do not live over a year and the average 5-year survival rate for patients is less than 3%. After standard treatment, which requires surgical resection followed by concomitant radiotherapy and temozolomide therapy, fatal relapses commonly occur, and recurrent GBM tends to be even more aggressive and resistant to medical treatment than its primary counterpart. LDS has developed a wide expertise on Src Family Kinase inhibitors as therapeutic intervention against a number of cancers. In vitro and in vivo studies have been conducted to advance most promising compounds, and a Lead product has been identified. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Current Lead compound has been widely characterized in vitro, and shows a clear efficacy in intracranial model of glioblastoma in mice after oral administration. In vivo PK studies confirmed the ability of the compound to cross the BBB. This is a clear advantage versus other kinase inhibitors proposed for GBM treatment (i.e. dasatinib) which failed to reach the target also because of poor penetration into brain. Also, no safety issues were highlighted in mice. LDS owns the IP of the product. MARKET APPLICATION Oncology, Brain Cancer, Glioblastoma TYPE OF PARTNER SOUGHT Research co-operation, Technical co-operation, License agreement, Manufacturing agreement, Sales/ Distribution, Investment/Financing SERVICE Drug Discovery Services LDS provides different services useful in the drug discovery process, such as molecular modeling, SAR and QSAR studies, custom library synthesis, in vitro ADME evaluation, in vitro biological testing, protein production and purification, assay set up and validation, in vivo pharmacokinetic studies, antibody 454 / 880 drug conjugates design and development. In details: - “HIT “package Molecular Modeling studies on molecules library using commercial database, LDS molecules database, and Mo.Li.Rom. Database; In vitro tests (on 10-30 compounds better extimated); Structure-activity relationship studies; Scale-up (50 mg) of the most active compound. - “LEAD” package Generation of a virtual library focused on an Hit previously identified; Parallel synthesis of the best predicted (from computational studies) compounds (about 20-40); In vitro tests; Scale-up (up to 50 mg) of the most active compound. - “Scaffold-base LEAD” package In silico optimization of your products; Parallel synthesis of the best predicted compounds (20-40 compounds); In vitro tests; Scale-up (up to 100 mg) of the optimized leads. - Other Services 3D receptor structure developement by means of homology modeling tchinques; Pharmacokinetic properties prediction of molecules library; Molecular dynamics studies; QSAR models developement; Ad hoc synthesis of small molecules or natural products; Combinatorial synthesis. MARKET APPLICATION Pharma, biotech

455 / 880 LEITAT

Organisation

Country Spain City Barcelona Street C/Innovació 2 Web http://www.leitat.org

Person

Name Mireia Barcons, PhD Business Development Manager

Organisation LEITAT is a technological center specialised in material, device and production technologies. LEITAT develops R&D activities in the areas of biomedicine, biotechnologies, nanotechnology, material sciences, environment, surface treatments with deep knowledge and experience in technologic transfers to several industrial sectors (chemistry & material, transport, health, packaging, energy, textile, detergency, environment, cosmetic, pharmacy, building, food, sport, maritime and security). LEITAT is recognized by the Spanish government as a CIT (Centre of Technological Innovation) and is one of the 5 Technology centres which are accredited by the Regional Government of Catalonia. Additionally, LEITAT takes part each year in many projects financed by the regional and national governments, participates in projects co-funded by the European Commission, and develops private R&D projects funded by industrial partners. LEITAT has 4 R&D divisions, and the “HEALTH AND BIOMEDICINE” division has a strong preclinical pharmaceutical background that uses cutting edge technology and infrastructure to bring projects and ideas to the next level. We have strong expertise in all steps of the pre-clinical development from in vitro to animal studies and biomarker investigation. Areas of Activity

• Analytical and characterization services • Peptides, proteins & antibodies • Biomaterials preparation • Biosensors • Proteomics, metabolomics, nutrigenomics • CRO (Contract Research Organisation) • Life sciences related activities • Medical research • Project proposals support services • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PARTNERSHIP Health and biomedicine service and partnerships At LEITAT we carry out R&D oriented to biomedicine and application of biologic processes and products. 456 / 880 Main research fields: - Cancer therapy, diagnostics, prognosis and illness monitoring. - Specialized bioservices including generation of monoclonal antibodies. - Toxicology, migration determination and development of markers. - Development of bioprocesses. - Extraction of active principles. - ADME-Tox studies on drugs - Synthesis and functionalization of nanomaterials for their later application in different families of nanocomposites. - Nanosecurity and study on the environmental impact during the life cycle of the nanomaterials. Some of the subject matters of the Projects being carried out are: - Generation of electrochemical biosensors based on hybrid biomolecule-nanoparticle to assess the immune functional response. - Development of angiogenesis peptides by zera® technology. - New strategies based on biomarkers for cancer detection, prognosis, prediction and development of new treatments. - Characterization of predictive genetic models for anticancer drugs; systematization of the personalized therapeutic intervention. - Biological active principles obtained from micro-alga innovative extraction processes. - Application of nano-particles technology based on therapy and detection of different types of cancer. - Integral challenge to breast cancer. - New methodology for the identification of natural compounds of high commercial value derived from the diverse and unexplored flora from Mediterranean countries. - Biopolymeric capsules to be applied in food safety. - Appreciation of biocide technology in its application in air and fabrics filters for the prevention of nosocomial infections. - Research on healthy ingredients and food.

457 / 880 Liaison Office - University of Calabria

Organisation

Country Italy City Rende (CS) Street Piazza Vermicelli Web http://www.unical.it/portale/ateneo/ amministrazione/aree/lio/

Person

Name Giuliana De Luca Technology Transfer Manager

Organisation The Liaison Office (LiO)is the research and technology transfer office of the University of Calabria (Unical). Mission Promote the participation of the Unical research groups to European, national and regional programmes aiming at financing research projects of excellence. Facilitate the transfer of Unical research products, technologies and innovations to the business world. Services Administrative and fundraising support; Technology transfer facilitation; Patenting and other protections; Licensing; Star-up/Spin off assistance; Networking; Communication; Research grants activation and management; Advanced R&TT training; Incubation of innovative start-up and spin-off companies. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Software, ICT applications, system • Diagnostics - Imaging equipment and integration processing • Medical devices • eHealth, mHealth, telemedicine • Nutraceutics, probiotics, functional food,

458 / 880 cosmeceutics • Peptides, proteins & antibodies preparation

Marketplace Opportunities PRODUCT PATENT: BIARYL AMIDES OR UREAS AS TRPV1 LIGANDS The invention relates to high affinity compounds, able to bind the transient receptor potential cation channel, subfamily Vanilloid type 1 (TRPV1), and to inhibit the Fatty Acid Amide Hydrolase (FAAH). Being both the receptor and the enzyme involved in pain processing and neurogenic inflammatory responses, the compounds find application in medical conditions involving the endovanilloid and endocannabinoid systems, in particular as agents for pain, anti-inflammatory, cluster headache, anti- oxidant and anti-cancer therapy. TRPV1 agonists are expected to be more powerful analgesic drugs than TRPV1 antagonists as they simultaneously block all receptors on capsaicin-sensitive nerves. Dual TRPV1 agonist/FAAH blocker compounds may offer the unusual possibility to target simultaneously two pathways relevant for the same disease, while not causing addiction and tachyphylaxis. Moreover, the chemical structure of these compounds provides the opportunity of developing new radiotracers for PET imaging. These radiotracers are of great relevance for mapping TRPV1 receptors in pathological conditions. Rif.: Patent number: IT142427. Assignee: University of Calabria; University of Siena. Inventors: Aiello Francesca; Brizzi Antonella; Corelli Federico. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Simple and fast synthesis. Generation of a library of compounds. High selectivity against TRPv1 receptor. Powerful analgesic drugs. No central drawbacks (not addictive or toxic, stable). MARKET APPLICATION Pharmacological tools for studying endovanilloid and endocannabinoid related physiopathological conditions. Radiotracers for Positron Emission Tomography (PET) imaging. TYPE OF PARTNER SOUGHT Clinical Trial; Funds. PRODUCT PATENT: PREPARATION OF 2-OXO-1H-PYRROL-1(5H)-CARBOXAMIDES AND THEIR USE AS NOVEL DERIVATIVES FOR THE TREATMENT OF HIV This invention relates to the synthesis of novel anti-HIV compounds able to associate a significant anti- HIV activity with a low degree of toxicity, and therefore suitable for a prolonged therapeutical treatment. The inventors have found that some 2-oxo-1H-pyrrol-1(5H)-carboxamides, posses a specific anti-HIV activity as potent inhibitors of inverse transcriptase, while showing a cytotoxic activity that in same cases is 10-20 times lower with respect to commercial anti-HIV drugs, such as Ripilvirine and Etravirine These new compounds have been synthesized by a novel and efficient synthetic approach, involving the catalytic carbonylation of propargyl ureas. Rif.: Priority number: 102016000022765. Assignees: University of Calabria; University of Parma; Italian National Research Council; University of Rome “Tor Vergata”; University of Messina. Inventors: Bartolo Gabriele, Raffaella Mancuso, Nicola Della Ca’, Mirco Costa, Michele Queirolo, Beatrice Macchi, Antonio Mastino, Salvatore V. Giofrè, Roberto Romeo. INNOVATIVE ASPECTS AND MAIN ADVANTAGES 459 / 880 The innovative aspects concern the novel synthetic route developed for the preparation of the new anti-HIV drugs and the favorable activity/toxicity ratio shown by the newly synthesized molecules. The main advantage of the invention consists in the efficient preparation of a new class of anti-HIV drugs, characterized by a significant activity against the virus causing AIDS associated with a very low toxicity. MARKET APPLICATION The reference industry is constituted by pharmaceutical companies. PRODUCT PATENT: AZITHROMYCIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES FOR USE AS NEUROPROTECTORS The invention concerns azithromycin, its pharmaceutically acceptable salts or solvates for use as neuroprotectors in the treatment or prevention of brain damage caused by ischemia or hemorrhage. Rif.: Patent number: IT1405314. Assignee: University of Calabria. Inventors: Amantea Diana; Bagetta Giacinto; Caltagirone Carlo; Corasaniti Maria Tiziana; Nappi Giuseppe. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The use of the azithromycin, its pharmaceutically acceptable salts or solvates for the treatment of ischemic stroke is an innovative and very clinically beneficial approach since in addition to the demonstrated efficacy, the drug is less toxic than other potential neuroprotective drugs which, when tested in the clinic, have produced unsatisfactory results. MARKET APPLICATION The invention allows the development of a new method for the treatment of pathologies associated with ischemia-reperfusion. TYPE OF PARTNER SOUGHT Clinical trial, funds. PRODUCT PATENT: NOVEL ESTROGEN RECEPTORS LIGANDS COUPLED TO PROTEIN G The invention relates to the use of nicotinic acid or nicotinamide and to compositions thereof for use in the treatment of pathological conditions that can benefit from the biological activity induced by the activation of GPR30 receptor. The invention is also related to a method for the evaluation/selection of agonist or antagonist GPR30 receptor ligands. Rif.: Patent Number: IT1421641. Assignee: University of Calabria. Inventors: Maggiolini Marcello; Santolla Maria Francesca. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Finding new compounds both of endogenous and synthetic origin capable to bind and activate the transduction pathway mediated by GPER is extremely important for setting innovative diagnostic, prognostic, and therapeutic tools in a wide range of physiopathological conditions (e.g. tumors, cardiovascular, neurodegenerative, metabolic diseases among others) wherein GPER can exert a fundamental biological role. MARKET APPLICATION Molecular biology, diagnostics, pharmaceutical industry. PRODUCT PATENT: PORTABLE MEDICAL DEVICE AND METHOD FOR QUANTITATIVE RETINAL IMAGE ANALYSIS THROUGH A SMARTPHONE The invention consists of an integrated system that allows acquisition and quantitative analysis of high-resolution images of the retina. The integrated system includes an optical device and a software app. The optical device is a smartphone-adapted lens for acquisition of high-resolution images of the 460 / 880 retina. The software is a smartphone app for quantitative analysis of the retinal images acquired through the hardware component of the device. The computation is carried out by means of cloud- based technologies. The retinal image analysis provides quantitative indices of retinal damage that are proven for being relevant for both clinical and research purposes. Rif.: Patent numbers: IT1423628/US9468377. Assignee: University of Calabria. Inventors: Stamile Claudio; Umeton Renato; Cavallari Michele; Calimeri Francesco; Orzi Francesco. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The innovation refers to the technical field of portable medical devices. Specifically, the innovation consists in a portable medical device that allows acquisition and analysis of retinal images through a smartphone. Up to now physicians need to rely on qualitative evaluation of the retinal vessels through an ophthalmoscope-based inspection of the fundus oculi. Although the ophthalmoscope is a lightweight, handy diagnostic instrument, the procedure is highly operator-dependent. In addition, the ophthalmoscope low-quality image cannot be recorded for further processing. This invention allows acquisition of a high-quality image to be immediately evaluated for quantitative changes suggestive of vessel pathology. The whole analysis is carried out by means of the portable, smartphone-based device. MARKET APPLICATION Emergency rooms Field hospital Mobile medical units PRODUCT PATENT: MONOSPECIFIC ANTIBODY AND METHOD OF PRODUCTION USING AS ANTIGEN AN ISOFORM OF THE HUMAN FAD SYNTHETASE (or SYNTHASE) The antiserum is directed against human FAD synthase or FMN:ATP adenylyl transferase, a collection of enzymatic isoforms involved in FAD biosynthesis. It specifically reacts with the isoforms in human (and rat) biopsies, cellular extracts, plasma, and blood lysates, liquor. It is able to immune-react with both domains contained in the longest isoforms. FAD synthase deficiency and/or impairment have been linked to certain human neuro-muscular diseases, such as the RR-MADD, which, if early diagnosed, can be treated with the simple ingestion of riboflavin in high doses. Early diagnosis requires measurements of the human enzyme level. Rif.: Patent number: ITEP2247621. Assignees: University of Calabria; University of Bari. Inventors: Barile Maria; Torchetti Enza Maria; Indiveri Cesare; Galluccio Michele. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The patented antibody is the best molecular test available. It is of interest for research and diagnostic purposes. It is expected that several research group and companies should purchase the antiserum. Differently from other antisera raised against the same enzyme, our antiserum recognizes each FAD synthase isoform. It has been tested in dot blot, immuno-blotting and immuno-fluorescence analysis. The antiserum also recognizes isoforms from model organisms like S. cerevisiae and C. elegans. Methods for measuring FAD synthase activity require specific competences in enzymology and spectrofluorometric assay, thus are time and money consuming. The antibody permits a rapid and simple analysis feasible by any laboratories. MARKET APPLICATION Biotechnology. Molecular diagnostics. PRODUCT PATENT: LEPTIN ANTAGONIST SYNTHETIC MOLECULE AND

461 / 880 PHARMACEUTICAL USE This invention concerns a synthetic molecule which is a leptin antagonist tetrapeptide in which the sequence of the four amino acids is characterized by the fact that the central amino acids are D and F. This invention concerns also the pharmaceutical use of these molecules as anti-cancer drugs in cells where leptin promotes tumor growth and progression and the use of the pegylated peptides as anti- cancer drugs in vivo. The tetrapeptides of this invention act as antagonists of leptin both in vitro and in vivo. The proposed peptides, after further experiments and biological and medical assessments, will provide drugs useful for the treatment of breast cancer and other leptin-related cancers. Rif.: IT1423968. Assignee: University of Calabria. Inventors: Andò Sebastiano; Barone Ines; Catalano Stefania; De Marco Rosaria; Leggio Antonella; Liguori Angelo. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The peptides tested, are simple and small molecules which inhibit the leptin receptor. Furthermore since these molecules do not act as receptor agonists in the absence of leptin they overcame the therapeutic limit of other known peptide antagonists. MARKET APPLICATION Pharmaceutical Industry for the development of antitumor drugs. PRODUCT PATENT: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PROVIDING CARDIOPROTECTION IN SUBJECTS WHO EXPERIENCED A MYOCARDIAL INFARCTION Myocardial infarction occurs when the blood supply to part of the heart is interrupted causing cells death. The immediate goal is to restore blood flow. However, this may lead to a ischemia-reperfusion (I/R) injury. Successful cardioprotection is limited by a small number of therapeutic targets. The inventors showed that a SelenoproteinT-derived peptide 43-52 is effective against I/R injury. POSSIBLE APPLICATIONS ┨Administration to a subject having one or more signs or symptoms of acute myocardial infarction injury. ┨Simultaneously or sequentially administration (i.e. before/after) with a revascularization procedure performed on the subject. ┨Administration in combination with an additional active agent. ADVANTAGES ┨PSELT peptide is synthetized by any well-known method in art. ┨PSELT peptide is the functional motif of the endogenous protein Selenoprotein T. ┨PSELT peptide determines cardioprotection at physiological doses. PATENT INFO PATENT OWNERS University of Calabria Institut National de la Santé et de la Recherche Médicale Université de Rouen Normandie INVENTORS Tommaso Angelone | Youssef Anouar | Carmine Rocca | Loubna Boukhzar PATENT STATUS Pending PRIORITY DATE 03/10/2017 LICENSE Europe COMMERCIAL RIGHTS

462 / 880 Non-exclusive AVAILABILITY Available PRODUCT PATENT: REDUCTION OF OXIDATIVE STRESS IN HEMODIALYSIS PROCESS Hemodialysis patients manifest excessive oxidative stress (OS) status, which causes an increase of cardiovascular disease. This invention relates to a process for the preparation of a functionalized dialysis cartridge with antioxidant compounds with the aim of reducing OS in hemodialysis process. Functionalization of dialysis cartridge comprising the following steps: a) washing a dialysis cartridge with a solution containing a redox pair; b) washing said dialysis cartridge with a solution containing 5 one or more antioxidant compounds. POSSIBLE APPLICATIONS ┨Functionalization of traditional dialysis cartridge before hemodialysis process with the aim of reducing OS. ADVANTAGES ┨Reduction of OS in hemodialysis patient. ┨Consequent reduction of side effects related to excessive OS level. ┨Increase patient's quality of life. ┨Consequent reduction of public health expenditure. PATENT INFO PATENT OWNER University of Calabria INVENTORS Francesco Puoci | Vincenzo Pezzi |Ortensia Ilaria Parisi | Fabio Amone | Rocco Malivindi | Luca Scrivano | Alessandro Melicchio | Anna Perri | Danilo Lofaro PATENT STATUS Pending PRIORITY DATE 20/11/2017 LICENSE International COMMERCIAL RIGHTS Exclusive AVAILABILITY Available TECHNOLOGICAL AREA Health and Biomedical

463 / 880 Life Science Investments & Solutions GmbH

Organisation

Country Austria City Voecklabruck Street Web http://www.life-science-invest.com

Person

Name Monika Rosenauer CEO

Organisation Our aim is to assist you on your way to gain a foodhold in Lifescience as well as to ensure your long term benefits by two pillars support: CAPITAL and KNOW HOW. Lifescience Investments & Solution’s mission is to transform your company to a competitive and strong market player in the biotechnology business. CAPITAL: we provide : - Start up financing - Project funding - Co- financing of product developments or manufacturing plants - Finance Takeovers We also provide support in Business process optimization, Product management and portfolio adjustment, Market entry and penetration, De-risking strategy development and implementation, Supply chain optimization. Areas of Activity

• Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Investments in Biotech/Life Science Business Life Science Investments & Solution supports: - Start up financing - Project funding - Co- financing of product developments or manufacturing plants - Finance Takeovers

464 / 880 Life Sciences Lombardy Cluster

Organisation

Country Italy City milano Street via pantano 9 Web www.lombardialifesciences.it

Person

Name Vera Codazzi Cluster Manager

Organisation Lombardy Life SciencesCluster (LLS) represents all actors working in life science sector placed in Lombardy. Until now 62 companies (large companies as well as SMEs), 14 research institutions, 9 university, 22 hospitals, 6 associations and 1 public body are involved. After 2 start up years, in July 2015 Cluster developed in an Association with growing relevance at regional level. Now it is the principal local subjectfor the Lombardy Region to consult in planning its strategy in the life sciences sector. The mission of the Cluster can be gathered in the following objectives: - Enhancing technology transfer - Fostering innovation and competitiveness in companies, particularly in SMEs - Increasing companies visibility on the market - Improving innovation and internationalization - Facilitating access to fundings opportunities The Cluster organization supports its members in developing business oriented joint business or initiative, at national and international level or facilitating to start up R&D and TT projects, or even organizing promotional and networking activities. Areas of Activity

• 3D Printing/addictive manufacturing for • Nutraceutics, probiotics, functional food, biomedical applications cosmeceutics • Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Life sciences related activities • Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • IT Applications for Health • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine • Investments • Medical research

Marketplace Opportunities

465 / 880 SERVICE Lombardy life Sciences cluster, your non stop entrance to Lombardy LS world Lombardy Life Science cluster is the gateway to all regional opportunites in the life science sector. Lombardy Region refers to the cluster to debate and define local policies. The Cluster develops specific activities/projects in support/connected to these policies.

466 / 880 LifeSeeder

Organisation

Country Italy City Roma Street Via di Castel Romano, 100 Web https://www.lifeseeder.com/

Person

Name Fabio Miraglia CEO LifeSeeder

Organisation Equity crowdfunding platform for Life Sciences. LifeSeeder represents a meeting point between companies looking for new capital and investors in the sector. Areas of Activity

• 3D Printing/addictive manufacturing for • Nutraceutics, probiotics, functional food, biomedical applications cosmeceutics • Bioinformatics, Big data analytics • Pharmaceutics • Biomaterials • Physiotherapy, Orthopaedic technology • Biosensors • Proteomics, metabolomics, nutrigenomics • Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Surgery technologies and applications • Consulting services • Virtual reality applications • Diagnostics - Equipment and accessories • Other • Diagnostics - Imaging equipment and • Project proposals support services processing • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Electromedical and medical equipment (non diag) • Genetics & Genomics • Investments • Manufacturing & process engineering • Medical facilities furnishings, equipment, goods

Marketplace Opportunities INVESTMENT OPPORTUNITY LifeSeeder - The Life Sciences Equity Crowdfunding platform LifeSeeder is an equity crowdfunding platform specific for the life sciences sector, consisting of a large network of specialized investors, multinationals and stakeholders in the sector who invest in companies with highly innovative projects. At LifeSeeder, we make it easy for SMEs and Life Science startups to meet with highly innovative 467 / 880 projects, and investors interested in making those projects big. Each application follows a path before starting to raise capital: - Scientific evaluation of the project, carried out by leading experts and academics - Economic and Legal Evaluation, carried out by the International DLA Piper Study - Pre-matching, where the application is presented in preview to Professional Investors of the LifeSeeder network The selection process follows high standards of confidentiality. LifeSeeder is also able to support companies in searching for new venture capitals

468 / 880 Linari NanoTech srl

Organisation

Country Italy City Pisa Street Via Umberto Forti 24/14 Web www.linaribiomedical.com

Person

Name Stefano Linari Founder & CEO

Organisation LinariEngineering is an high tech company active in electrospinning technologies for nanomaterial production and e-health solution for visual rehabilitation. Areas of Activity

• 3D Printing/addictive manufacturing for • Laboratory equipment, reagents, software biomedical applications • Biomaterials • CMO (Contract Manufacturing Organisation) • CRO (Contract Research Organisation)

Marketplace Opportunities PRODUCT Electrospinning Devices for nanofibers applications Electrospinning machines and accessories for lab and industrial scale production of nanomaterials. We have more than ten years experience in industrial automation and plant control systems. We can join our electrospinning devices, even in customized version with other station along manufacturing pipeline like, automatic visual inspection, 3D scanner, RFID identification, robotic handling. MARKET APPLICATION Filtration, biomedical, sensing device, renewable energy. Custom solution and integrated prodution line available SERVICE CRM Service for nanomaterial development Help companies and reseach centers to insert nanofibers and nano particles inside their process and products PARTNERSHIP

469 / 880 Distributors of scientific devices We are actively looking for new distributors and commercial partners world wide joining our selected network. PROJECT COOPERATION R&D project partnership Linari Nanotech is actively looking to be involved in nanotech related R&D project as SME

470 / 880 Link IT Srl

Organisation

Country Italy City Buguggiate Street Via Trieste, 47 Web http://www.linkgroup.it/

Person

Name Sandro Pignataro Manager

Organisation La realizzazione del software su misura è un’attività estremamente complessa e in Link IT, dal 1998, ci siamo specializzati con successo in questo campo. Non avendo sposato nessuna tecnologia, ci possiamo permettere di utilizzare gli strumenti più avanzati ed adatti al nostro cliente: Python, Django, Twisted, Javascript/Ajax, Postgresql, Angular sono solo alcuni degli strumenti che utilizziamo per i nostri progetti. La nostra curiosità e professionalità, libera da vincoli con partner esterni, ci permette da sempre di dare in estrema libertà consigli tecnici ai nostri clienti. Metteteci alla prova. Loro lo hanno fatto: IntesaSanPaolo, Missoni, LaFeltrinelli, Toro Assicurazioni, Tecniplast, Unione degli Industriali della Provincia di Varese / di Bergamo, Confindustria Lombardia e tanti altri. Areas of Activity

• Manufacturing & process engineering • Project proposals support services • Software, ICT applications, system • IT Applications for Health integration • EPR, Clinical/healthcare management software • Other

Marketplace Opportunities SERVICE IT and Consulting LinkIt is a software house with a strong partnership with a Business hub located in Switzerland. The offers an innovative model of services in IT world and a strategic view on business development service. REQUEST

471 / 880 Customers and partners for new business We are part of an international hub located in Switzerland that offers a qualified network of companies. PRODUCT Software ERP Odoo Odoo is an integrated software ERP for business and Open source.

472 / 880 Logidex Srl

Organisation

Country Italy City Turin Street Via Montemagno 39 Web www.logidex.it

Person

Name Tina Lombardi Partner

Organisation Logidex is an Italian manufacturer of nutraceutical health supplements. The company, based in the beautiful area of Piedmont, was established in 2012. Since then it has grown fast, building its reputation on the solid scientific experience and know-how of its founders. The supplements are "engineered" nutraceuticals developed under the guidance of proven clinical studies and scientific publications. Since its foundation, Logidex has gained excellent reputation in Italy. Its products are available in all leading pharmacies. Areas of Activity

• Nutraceutics, probiotics, functional food, cosmeceutics • Medical devices

Marketplace Opportunities PARTNERSHIP Nutraceuticals - looking for partners to expand We are an innovative young company in the fields of nutraceuticals. We develop products with solid scientific base that in Italy have already a strong market and support from the medical professionals. We are actively looking for opportunities to expand our sales to foreign markets and for possible investment partners in order to accelerate our growth.

473 / 880 M bioserviceS GmbH

Organisation

Country Austria City Linz Street Kapuzinerstr. 82 Web www.mbioservices.com

Person

Name Maria Seriakov Managing Director

Organisation M bioserviceS work with companies manufacturing, using and handling animal and human derived materials. We support our customers along the entire Supply Chain and offer a variety of services such as: Access to new raw materials sources worldwide Supply of rare biological products (nimal and human blood-based products such as:defibrinated blood, plasma, serum, albumin, globulin, erythrocytes, other blood fractions, enzymes, tissues and organs collected and processed according to the customer’s requirements) Entry into new markets Individually designed transport logistics concept Regulatory support in import, export and registration matters Tailored solutions for product and business development We answer questions like:- WHERE do I find biologic raw materials for my production?- WHAT do I know about the source and the manufacturer?- HOW do I recognize good quality?- WHO helps with import, export or registration?

Areas of Activity

• Biomaterials • Project proposals support services • Consulting services • Regulatory affairs, validation • Other

Marketplace Opportunities PRODUCT Act-O2-Hem Act-O2-Hem is an active hemoglobin with high ability to bind Oxygen and bring it to human and animal cells or cell cultures as needed. It is suitable to serve as a potent oxygen carrier in various in vitro and in vivo applications.

474 / 880 Act-O2-Hem is manufactured from calves red blood cells sourced in Tyrol, Austria – a region free of most notifiable bovine diseases as well as of BSE. The European Union has granted funds available under the EUROSTARS program for the further development and production upscaling of Act-O2-Hem. Act-O2-Hem has various intended applications such as: - Human Erythrocytes replacement in cell culture media used during transportation of organs for perfusion - Active ingredient in wound bandages (especially for chronic wounds) - Cell Culture additive for better oxygenating - Ingredient for biological coating of Cell Culture plastics - Veterinary applications – contributing to joints healing of pet animals - In fight against hair loss - In any other area where an improved oxygen supply is required SERVICE Overview - Products and Services: We support international customers along the entire Supply Chain and offer a variety of services such as: 1. Access to new raw materials sources worldwide 2. Supply of rare biological products 3. Entry into new markets 4. Individually designed transport logistics concepts 5. Regulatory support in import, export and registration matters 6. Tailored solutions for product and business development We help businesses connect easily, rapidly, directly. Talk to us and benefit from a network of experienced professionals in manufacturing, handling, logistics and marketing.

475 / 880 M3DATEK Srl

Organisation

Country Italy City Parma Street V.le delle Scienze 17/A Web http://www.m3datek.com

Person

Name Lisa Elviri CEO at M3datek

Organisation M3DATEK bioprinting activity center around the development of compositional materials and 3D printing systems targeting tissure repair and tissue regeneration. In the R&D area the main activity of the M3datek group is based on the development of new materials (bio-inks), like stimuli-sensitive bio compatible and bioresorbable polymers. Then these bio-ink can dispensed from a 3D printeer in a layer-by-layer approach to buid finely tuned scaffolds in a variety of advanced design, presenting significantly improved cell-compatibility. M3datek’s printer platform is continuously under development through the creation of highly reproducible, robust and flexible instruments. M3datek’s printers are developed for use in tissue repair and regeneration and in vitro and in vivo experiments are on going. Experimental model (in vivo animal experiments), performed and coordinated by experienced staff at M3datek, are used for investigating the tissue repair and tissue regeneration properties of the developed products. Areas of Activity

• 3D Printing/addictive manufacturing for • Pharmaceutics biomedical applications • Medical devices • Analytical and characterization services • Biomaterials • Biotechnologies (Pharma&Medical Devices)

Marketplace Opportunities PROJECT COOPERATION 3D printed scaffolds We are looking for partners for national and international project applications based on scaffolds for regenerative medicine and drug delivery. PRODUCT

476 / 880 3D printed medical devices We develop 3D printed medical devices based on natural polysaccharides or proteins to act as active support for tissue regeneration and localized controlled drug delivery. PARTNERSHIP In search of Partnership with start-up or medical devices companies We are looking for new national and international partnership with research centers or medical device companies for the development of innovative prototypes for tissue regeneration INVESTMENT OPPORTUNITY Investors search We are looking for investors for the development and validation of 3D printed medical devices for applications in the tissue regeneration field

477 / 880 Maggioli S.p.A.

Organisation

Country Italy City Santarcangelo di Romagna Street Via del Carpino 8 Web http://www.maggioli.it/

Person

Name Armend Duzha EU Project Manager

Organisation Maggioli S.p.A. (Società per Azioni) is the main Italian company with a guiding role for those who operate in Local Public sector, offering a broad range of specific, highly professional solutions in several domains (business areas): i) Information Technology, ii) Services & Technologies, iii) Publishing, Training and Education, iv) Document Management, and v) Museums, Art and Culture. Maggioli Informatica, the IT pole of Gruppo Maggioli, born from the integration and experience of Maggioli’s software houses and other local IT companies acquired during the recent years (e.g., CEDAF, STUDIO K, ELDASOFT, SAGA, ASITECH, TINN, A.P. Systems etc.) is the most qualified system integrator and leader in provisioning complete IT services and consultancy for the Local Public sector: more than 6,000 Municipalities out of 8,048 in Italy runs about 100.000 modules provided by Maggioli Informatica. In addition, it provides services and solutions to more than 3,800 museums and 1,200 SMEs. R&D Activities Maggioli Informatica has a successful track record of coordinating and participating in large-scale R&D projects, both at European and national level, an outstanding large-scale software and services engineering and IT integration background, and rich experience in requirements analysis, interoperability technologies, cloud and service-oriented architectures. The company has significant experience in the e-Health domain, and is supplying ICT solutions and services for the management of social and health services. Areas of Activity

• Consulting services • IT Applications for Health • eHealth, mHealth, telemedicine • Software, ICT applications, system integration • EPR, Clinical/healthcare management

478 / 880 software

Marketplace Opportunities PRODUCT ICARO ICARO is an innovative and integrated system developed by Maggioli Informatica for the management of social and health services, supporting the operators as from the issues related to the access to services up to delivery and accounting of services. In addition to the management of the different social and health services supplied by Municipalities and Local Healthcare Organizations, ICARO aims to promote a holistic approach to health, which integrates social and health services for home care. PRODUCT SOCIABLE SOCIABLE is a simple to use, highly functional solution that introduces a radical new approach for ICT assisted cognitive training and social activation for a wide range of senior citizens including cognitive intact elderly, older adults with Mild Cognitive Impairment. SOCIABLE supports personalized cognitive training interventions, designed by cognitive neuroscientists and health experts according to medically sound principles covering all cognitive skills. This approach was built on three tested technological pillars (in the scope of the SOCIABLE project), which had proven therapeutical value, namely: - INTERACTIVITY: Novel perceptive mixed reality interfaces based on multi-touch surfaces; - PERSONALIZATION: An open platform for cognitive training games development, which allows the flexible creation and customization of cognitive training games; - SOCIALIZATION: “Profiling” and social “matching” capabilities boosting social networking and interaction between aged individuals. PARTNERSHIP EU Partnership We are interested in partnerships with SMEs, research institutions, universitites, and end-user organisations for the forthcoming calls under the different frameworks and/or programmes (co-)funded by the European Commission (e.g., Horizon 2020, AAL etc.). PROJECT COOPERATION New cooperations in eHealth, Wellbeing and Inclusion domain We are interested in collaboration opportunities with SMEs, research institutions, universities, and end- user organisations for the forthcoming calls under the different frameworks and/or programmes (co- )funded by the European Commission (e.g., Horizon 2020, AAL etc.).

479 / 880 Marchionni Marco

Organisation

Country Italy City Milano Street

Person

Name Marco Marchionni Medical Doctor

Organisation I am a Medical Doctor and neurosurgeon currently working in the United Kingdom. In addition to my clinical duties together with a colleague of mine, as well as a friend, we have invented the first syringe that operators can use with only one single hand. As of today the operator must use two hands while using a traditional syringe and two hands are needed in order to remove the cap from the needle and/or to detach the needle from the syringe. Having two hands to use a syringe is often a problem for the operator and also involves the risk of accidental needle-stick injuries. The operator can use our innovative syringe with only one hand and therefore with zero risk of accidental needle-stick injuries (as the hand using the syringe is always placed behind the needle) and freedom to perform other tasks with the other free hand (such as holding/preparing a vial containing the medication to be injected).. Areas of Activity

• Medical devices

Marketplace Opportunities

PARTNERSHIP Partnership on patented first syringe that can be used with only one hand, not exposing the operator to the risk of accidental needle-stick injuries. We are looking for partners/investors or company interested in buying the patent license. INVESTMENT OPPORTUNITY Investment on patented first syringe that can be used with only one hand, not exposing the operator to the risk of accidental needle-stick injuries.

We are looking for partners/investors or company interested in buying the patent license. PRODUCT

480 / 880 The first syringe that operators can use with one hand, not exposing the operator to the risk of accidental needle-stick injuries. The new syringe has the following unique advantages 1) Use with a single hand . The operator must use only one hand to remove the cap from the needle and must use only one hand to detach the needle from the syringe. 2) No risk of accidental needle stick injury . During the removal operation of the cap and during the detached operation of the needle the operator's hand is always behind the needle . Prevention of the haematologicaly trasmissible disease such as hepatitis HIV and others. 3) No modifications of the plates / molds of the syringe body or of the already existing needle parts are necessary as far as the production process is concerned. Only a very tiny wheel need to be added during the assembly process. The usage of this new syringe is straightforward, easy, intuitive and efficient. Prototypes are already available ( see attached video). Being able to use a syringe with one single hand is a great advantage for the operator. The operator will be contemporaneously able to grasp hold and use any other devices/instruments or act on the patient or act on the injective . Up to now, on the market there is no syringe with these characteristics. The overall cost of production is minimal. The global syringe market is worth around $ 16 billion. The new syringe is patent procted. We have proceeded to extend the patent worlwide.

481 / 880 MCC Sistemi S.r.l.

Organisation

Country Italy City Cassina de' Pecchi Street Via Gramsci 5

Person

Name Maurizio Colombi CEO

Organisation MCC Sistemi S.r.l. is an Italian company founded in 2016 by a group of experienced professionals willing to share their technical, commercial and financial expertise. The company has developed an innovative method and an electromedical device (named “Phoenix”) for the therapeutic treatment of tissue injuries and faster tissue regeneration processes. Areas of Activity

• Electromedical and medical equipment (non diag) • Medical devices

Marketplace Opportunities PARTNERSHIP Looking for partners interested in further developing an innovative electromedical device (“Phoenix”)

MCC Sistemi S.r.l. is looking for partners interested in a cooperation to accelerate the market introduction of “Phoenix” electromedical device. A collaboration in the field of R&D and co- development is considered. For more details please see the product profile. INVESTMENT OPPORTUNITY Looking for investors willing to finance the final development phase of an innovative electromedical device (“Phoenix”)

The “Phoenix” electromedical apparatus is in a growth and establishment phase. Therefore MCC Sistemi S.r.l. looks for investors willing to fund the final development stage before the official registration as medical device and the start of commercialization. For more details please see the product profile. PRODUCT

482 / 880 Innovative electromedical device (“Phoenix”) for the therapeutic treatment of tissue injuries and faster tissue regeneration processes

MCC Sistemi S.r.l. has developed an innovative electromedical apparatus (named “Phoenix”) for the therapeutic treatment of tissue injuries and the speeding up of the tissue regeneration processes. According to the Technology Readiness Levels (TRL) the “Phoenix” device is at stage TRL 7 (i.e. system prototype demonstration in operational environment). The “Phoenix” apparatus comprises a control unit which is connected to an applicator, disposed close to the tissue injury to be treated. The control unit is configured to generate, through the applicator, an electric field to be applied on the tissue injury. The control unit is also configured to generate an air / oxygen stream directed towards the applicator and also to transform the air / oxygen flow into an ozone stream to be diffused and applied to the tissue injury in combination with the electric field. The “Phoenix” device has been produced in a small pre-series and distributed to laboratories in order to experiment and obtain a variety of possible effective applications. Other clinical studies and trial results are already available. So far two versions of the device have been developed: a professional one (for health facilities) and a portable one (for home health care patients).

483 / 880 MDClone

Organisation

Country Israel City Beer-Sheva Street Web http://www.mdclone.com

Person

Name Hanan Drobiner Sales Director - Europe

Organisation “MDClone is a truly transformative technology. It allows us to harness the power of big data in healthcare, so that we can learn from every patient encounter and ultimately improve the precision, quality, safety and outcomes of clinical care.”

DR. PHILIP PAYNE, DIRECTOR, INSTITUTE FOR INFORMATICS, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS Areas of Activity

• Bioinformatics, Big data analytics • IT Applications for Health • eHealth, mHealth, telemedicine • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT MDClone - Big Data Liberation & Democratization Leverage the temporal nature of healthcare - connect any data from any source and organize it in an engine designed for answering even the most complex healthcare questions by any user with no mediators and no programming skills PRODUCT MDClone - Cohort Base Data Synthetization Engine Move from risk mitigation to risk elimination - generate unidentified synthetic data and drive more insights without the privacy risk for any cohort of interest in real-time PARTNERSHIP Finding the right partner to penetrate to the Italian digital health market MDClone is looking for the right partner in Italy. A partner that could easily facilitate and coordinate meetings with Chief Information Oficers of leading Italian hospitals. 484 / 880 REQUEST Connections to CIOs of major EU hopsitals A partner that could easily facilitate and coordinate meetings with CIOs of leading EU hospitals.

485 / 880 Meba Srl

Organisation

Country Romania City Timisoara Street Web http://www.meba.ro

Person

Name Teresa Rook Consultant

Organisation Meba Srl is focused in the study and implementation of new processes in Health Services. Specifically, Meba Srl is focusing on the CBH system, the Cross Border Healthcare, deliberated by the Directive 2011/24/EU. We are helping patients to find a solution for their surgery in one of the EU countries Areas of Activity

• Consulting services • Medical devices • IT Applications for Health

Marketplace Opportunities SERVICE Cross Border Healthcare Our goal is to promote and disclose in the European Community the development of the Cross Border Healthcare, since the Directive 2011/24/EU has been implemented in all the European Union countries. Our target is also to facilitate the patients in getting information on this new opportunity they have, and also facilitate them during their therapeutic path, thanks to our network composed by private clinicis, medical manufacturing companies and the best surgeons. That's why we are continuosly searching for new clinics and new healthcare thechnologies to garantee the best options to our patients.

486 / 880 Mechatronics in Bologna 4.0

Organisation

Country Italy City Borgo Panigale Street Via Piero Jahier 2 Web https://www.mechatronicsinbo.com/it/

Person

Name Paolo Bertuzzi Business Development Assistant

Organisation MIB 4.0 is a network of Italian subcontracting companies acting as a Smart Supply Chain within CAMSER Subcontracting Division. Its main strengths are its specialisation and integration of designing and manufacturing competences, flexibility, customer-oriented and problem-solving approach as well as high technical and management skills. Co-engineering - prototyping and pre-series - industrialisation: We are a Team of Engineers, Technicians and Designers who serve as One-Stop-Shop, i.e. single point of reference: we assist our clients from the designing phase (Co-engineering), through prototyping and pre-series, to industrialization. We supply assemblies, subassemblies, components, machines or parts of systems to a wide range of industries, e.g. healthcare, electromechanics, automation and robotics. Our offering also includes high precision mechanical machining, such as stamping and shearing, assembly, wiring, functional tests and logistics management. Areas of Activity

• CMO (Contract Manufacturing • Medical devices Organisation) • eHealth, mHealth, telemedicine • Manufacturing & process engineering

Marketplace Opportunities PRODUCT Biomedical Simulator We designed and manufactured a Biomedical Simulator for mechanical tests on hip and spinal replacement implants as well as on materials. PARTNERSHIP Buyers for Biomedical Simulator We are looking for companies interested in our biomedical simulator for tests on implants and materials. PRODUCT

487 / 880 Process Automations We design Process Automations also with robots and visual systems PARTNERSHIP Buyer for Automations We are looking for companies interested in our automations

488 / 880 Medi.Alfa

Organisation

Country Italy City Alfonsine (Ravenna) Street via Antonellini, 46

Person

Name Dario Nanni owner

Organisation The Medi.Alfa company operates in the nutraceutical and nutricosmetics sector with innovative technology. I am interested to contact companies producing organic raw materials. I also look for partners for a financial cooperation to introduce the brand on the market. The knowledge of national distributors is also appreciated. Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities REQUEST organic raw materials I am looking for companies producing organic raw materials. INVESTMENT OPPORTUNITY looking for investors I am looking for partners availabe for a financial cooperation, aimed to introduce my brand into the market.

489 / 880 Medical Trials Analysis

Organisation

Country Italy City Ferrara Street Via Fossato di Mortara, 66, Web http://www.mtagroup.net/

Person

Name Raffaella Vergura Project Manager

Organisation Medical Trials Analysis (MTA) Group is a comprehensive CRO providing full-range activities in clinical trials, clinical investigations and medical education linked to clinical research. MTA's mission is to provide services aimed to FOCUS, harmonize the entire trial management process and to SPEED the INNOVATION in MEDICAL SCIENCE toward the delivery of any new therapeutic treatment and intervention that will improve patient quality of life. The key feature of MTA is the distinctly scientific matrix and its strong link with the academic and research environments. Beside feasibiltiy studies, regulatory activities, management and monitoring services for clinical research, MTA provides quality assurance services including sites auditing and methodological support to hospitals, universities and research centers for the preparation and finalization of clinical trial protocols. MTA is also actively involved in the educational field with a priprietary e-learning platform and providing continuous edcucation courses to public insitutions and private companies. MTA is a young and dynamic company strongly oriented on the innovative nature of the strategic and operational approaches applicable to the activities and the services provided. This is possible thanks to a highly qualified team with 70% of staff with a postgraduate qualification and constantly updated within their areas of activity through an annual very extended and customized training plan. During the 10 years of its activities MTA Group enrolled more than 17.000 patients in around 1.100 investigational sites across 28 countries and provided certified trainings at an average of 30 professional people per year. Areas of Activity

• Biomaterials • Pharmaceutics • Biotechnologies (Pharma&Medical • Regulatory affairs, validation Devices) • Life sciences related activities • CRO (Contract Research Organisation) • Other • Diagnostics IVD • Medical devices

490 / 880 • Diagnostics - Equipment and accessories • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE More Than A CRO services MTA offers comprehensive services for clinical development and market access of pharmaceutical products, medical devices, nutraceutics and probiotics. MTA services range from the initial study design (including proof of concept study) to the public distribution of the results. Thanks to its academic roots, MTA encompasses very highly educated staff with diversified backgrounds and experiences assuring the adequate referent for a wide variety of projects. Providing support to innovative therapeutic approaches (both pharmacological and not) is MTA's major challange. MTA strong and long-lasting collaborations with the academic enviroment assures a consolidated network of academic investigational sites in 30 countries world-wide. Over the years MTA developed solid and long lasting partnerships with regional CROs. Currently MTA can count on resident local staff for regulatory activities and study follow up in 30 countries world- wide. SERVICE MTA e-learning MTA e-Learning is an on-line platform for distance learning on clinical research. The training courses have different objectives according to the learning needs of the user The video lessons are prepared by professional university teachers with experience in the field of clinical research and can be followed whenever and wherever the student prefers. MTA e-learning is the brainchild of Medical Trials Analysis Italy Srl (MTA) to share the skills of its employees through the most innovative tools. MTA is an Italian CRO registered at AIFA since 2009 and certified ISO 9001: 2008 in 2013 for the design and delivery of training courses in the field of clinical research, and scientific, medical and pharmacological fields. SERVICE MTA web training service MTA Web training service is a comprehensive package that merges the specific know-how of MTA professional with the availability of a web-based dedicated platform to offer customized web based trainings. Based on the client’s specific needs MTA will develop the training materials in form of presentation, video-presentation or video lessons as well as the evaluation materials for the trainees. Users will have the possibility to interact with reference tutors through virtual classes. Based on assessment tests, official certificates of achievements on the training topics might be issued by MTA Italy which is certified ISO 9001: 2008 for the design and delivery of training courses in the field of clinical research, and scientific, medical and pharmacological fields.

491 / 880 MediCon Ingegneria srl

Organisation

Country Italy City Budrio Street via E.Mattei, 20 Web https://www.mediconingegneria.it/

Person

Name Giacomo Giacobbi Sales Manager

Organisation MediCon Ingegneria is a Research and Development center active in the field of embedded electronics, hardware and software. Our aim is to perform research, design and consulting with the best technologies, respecting laws and standards, making use of state-of-the-art methodologies for research and development, risk management, and documentation. Our main fields of application are: Medical Devices, Hydraulic mobile machinery, Industrial machinery. Since 20 years we have developed hundreds of innovation projects with industry, and allowed our customers to place on the market successful and reliable products. We have a strong experience in system safety and functional safety. Our activity include entire Industrial Research projects, customer R&D support, complete research and design of devices, including industrialized prototyping and certification. Our R&D is based on a team of engineers committed to use state-of-the-art thecnology for any application. Continuing training is one of the priorities of our company. Areas of Activity

• Diagnostics - Equipment and accessories • Medical devices • eHealth, mHealth, telemedicine • Electromedical and medical equipment (non diag) • Regulatory affairs, validation

Marketplace Opportunities SERVICE Certification All our designs are accompanied by a technical file in accordance with the requirements of the following directives, ready to be submitted to certification body. Moreover, we can draw up the technical file for your designs that have not been accompanied with this documentation. On behalf of our customers, we have obtained certifications from several bodies, among which TÜV, 492 / 880 CSA, FDA, IMQ, CERMET, …. and respect the following directives - 93/42/EEC “medical devices” - 2007/47/EC amending 93/42/EEC Link - 93/42/EEC consolidated version - 2006/95/EC “low voltage” - 2004/108/EC “electromagnetic compatibility” PRODUCT IOT (Internet of Thing) - IOE (Internet of Everything) solutions Goal === Provide connectivity to your product / system / plant all over the world Key Points ======- Set up a local LR-WPAN, to interconnect parts of your product / system / plant - Ability to interconnect large number of nodes (hundreds / thousands) in a defined area - Cost competitive cable replacement - Robust and reliable data connection - Low power consumption, to allow effective battery power supply - Integrate Internet communication capabilities in your product / system / plant - Provide remote access to the product / system / plant - Use the most suitable communication protocols, in order to optimize performances and reduce costs - Manage relationships with worldwide telecommunication service providers Applications ======e-health

493 / 880 Mediplasma

Organisation

Country Italy City Marigliano (NA) Street Corso VITTORIO EMANUELE III 202 Web http://www.mediplasma.it/

Person

Name Francesco Menna CEO

Organisation Founded in 2010, Mediplasma is an Italian academic spin-off that operates in the plasma-chemical technologies and biochemical industry. Mediplasma provides innovative plasma-coating treatments able to improve physical-chemical, clinical and commercial features of different devices. Depending on the experimental set up these treatments are able to improve the biocompatibility of materials with cells and biological tissues, and to impart new surface properties to biomedical devices such as antibacterial character, cell affinity, lubricity and others. Plasma technology is highly convenient for the industry in that it uses limited amount of chemicals and no solvent, thus resulting also environmental friendly. Moreover, this technology is energy saving and highly effective despite being economically feasible. This technology will be applied on medical devices already on the market without changing their massive properties and is addressed to all kind European industries.

Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Medical devices

Marketplace Opportunities SERVICE Plasma-chemical treatments Mediplasma provides innovative plasma-coating treatments able to improve physical-chemical, clinical and commercial features of different devices. Depending on the experimental set up these treatments are able to improve the biocompatibility of materials with cells and biological tissues, and to impart new surface properties to biomedical devices such as antibacterial character, cell affinity, lubricity and others. Plasma technology is highly convenient for the industry in that it uses limited 494 / 880 amount of chemicals and no solvent, thus resulting also environmental friendly. Moreover, this technology is energy saving and highly effective despite being economically feasible. This technology will be applied on medical devices already on the market without changing their massive properties and is addressed to all kind European industries. Recently, Mediplasma has started to apply plasmochemical technology in the food packaging sector because the great versatility of our surface treatments allows to confer extremely advantageous and targeted characteristics according to the various types of food to be preserved. For example, by means of PE-CVD processes it is possible to modify the surface of hydrophobic or hydrophilic polymers, by engaging specific polar chemical groups which increase or decrease the cell adhesion to the material. In contrast, the PEO-like coatings, with hydrogel characteristics similar to PEG and PEO polymers, can be deposited by plasma to obtain anti- adhesive properties (non-fouling). SERVICE Plasma treatments on medical devices

The technology offered will impact on many different markets. Our plan is to demonstrate to the major companies that our proposal will definitely solve the exposed problems in a very easy way thus giving a new great key selling point to their market. Our technology is primarily addressed to the high volume market already existing; but when required by companies, can be also addressed to niche markets with high added value. The markets we are currently focused on are producers and developers of medical devices interested in our innovative technology, such as urinary catheters, contact lenses and intra- ocular lenses (IOL), arterial and venous introducers. These markets have a size of millions of pieces and thus of billions of euros; they are mature and in continuous and steady growth. Introducing our treatment on a number of pieces so high, also our expectation of growth is extremely high. Mediplasma does not enter new devices on the market but offers a technology that makes the device itself very competitive compared to those currently on the market, as it gives them unique and innovative features. So, companies can gain market share and at the same time benefit from a significant price increase. SERVICE Plasma chemical treatments on food packaging In the current market, packaging has acquired increasing importance, particularly in the food sector. The goal is to look for original packaging solutions, studying and analyzing the properties of the materials and therefore improving their characteristics through our innovative cold plasmas surface treatment. Plasma processes are used to modify the surface properties of materials, giving them extremely advantageous and targeted characteristics according to the various types of food to be preserved.

495 / 880 Menarini Silicon Biosystems

Organisation

Country Italy City Castel Maggiore Street C/o MSB Via G.di Vittorio 21b/3 Web http://www.siliconbiosystems.com

Person

Name Massimo Scrobogna Product Manager

Organisation Menarini Silicon Biosystems develops techno¬logies and products to help researchers understand the biological complexity of disease through the study of single cells. Offering two technologies, CELLSEARCH® and DEPArray™ NxT together, the company now provides an end-to-end workflow solution for the study of CTCs in the clinical research setting. Areas of Activity

• Analytical and characterization services • Pharmaceutics • Bioinformatics, Big data analytics • Life sciences related activities • Biotechnologies (Pharma&Medical Devices) • Genetics & Genomics • Medical research

Marketplace Opportunities PRODUCT Ampli1™ LowPass Kit Ampli1™ LowPass Kit is designed to generate multiplexed, sequencing-ready libraries in a streamlined single-day protocol, to detect chromosomal aneuploidies and copy number aberrations (CNAs) by low- pass whole genome sequencing. PRODUCT Ampli1™ WGA Kit The Ampli1™ Whole Genome Amplification (WGA) kit has been developed and optimized for balanced and complete amplification of the total DNA content of a single cell. The output of the Ampli1™ WGA protocol is a well-balanced library of approximately 19 million fragments representing the entire genome. Looking for PRODUCT DEPArray NxT DEPArray NxT is a new benchtop instrument, designed with a more friendly user interface that allows

497 / 880 one to rapidly obtain 100% pure cells with reduced operator interaction. Our next-generation software permits quicker selection of cells of interest with an exceptional level of accuracy, reproducibility, and high-quality images. Looking for PRODUCT CELLSEARCH CELLSEARCH® Circulating Tumor Cell Test is the first and only clinically validated blood test cleared by the U.S. Food and Drug Administration for detecting and enumerating circulating tumor cells (CTCs) to help manage patients with metastatic breast, prostate, and colorectal cancers. The test is also approved by the China Food and Drug Administration for use in monitoring metastatic breast cancer patients. SERVICE Clinical Laboratory Services We offer RUO global clinical laboratory services for clinical trials in the evaluation of drugs and tests utilizing CELLSEARCH® and DEPArray™ platform SERVICE Fee For Services Today, through our Fee-for-Service, investigators can leverage the benefits of our technology and scientific expertise using their own samples and get back results and data generated with our workflows. Our services are all performed by expert in-house R&D scientists working in our state of the art facility at Menarini Silicon Biosystems Headquarters in Bologna, Italy and Huntingdon Valley, PA

498 / 880 MERITZ Securities Co., Ltd

Organisation

Country Korea, Republic Of City Seoul Street 15, Gukjegeunmyung-ro 6-gil, Yeongdeungpo-gu Web https://www.imeritz.com

Person

Name MUJIN LEE Deputy General Manager

Organisation Comprehensive financial investment company that is engaged in investment, trading, brokerage. Since the merger with Meritz Securities in April 2010, we have been able to make short-term financing, international financing and leasing services for deposits utilizing the license of the integrated financial business until March 2020. Areas of Activity

• Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity - biotech, medical devices, healthcare Meritz Securities seeks investments in new promising start-ups and firms in the biotech, pharmaceutical, biomedical and healthcare markets.

499 / 880 mHealth Technologies srl

Organisation

Country Italy City Bologna Street Viale Giuseppe Fanin, 48 Web http://mhealthtechnologies.it/

Person

Name Paolo Bertuzzi Vicepresident

Organisation mHealth Technologies s.r.l. is a spin-off of the University of Bologna. We were born in 2014 following successful experiences matured in national and international research activities in the field of active and healthy ageing and in the field of movement disorders such as Parkinson’s Disease. We are a team of expert researchers in the fields of movement analysis, signal processing, algorithm development, wearable sensors, and data mining. We propose wearable solutions for monitoring, assessment and rehabilitation of the motor function. We address the needs of an ageing population and of people with motor impairments. mHT solutions provide relevant outcomes to the clinician and effective feedback to the users. Users become proactive in their health management. mHT solutions are easy-to-use systems. Depending on the specific motor impairment, we use smartphones, tablet and ad hoc sensors. We can also fully customize our systems in order to answer your specific needs, and we can provide support and data analysis service. The ambitious objective of mHT is to take healthcare out of the hospital and to embed it into people’s lives. R&D activities exploit mHT expertise on embedded systems design, real-time and predictive algorithms, biomedical signal processing, biomechanical modelling, mHealth applications, wearable sensors and sensor fusion, Health applications, statistical analysis, and data mining. R&D experiences are in the fields of: Wearable systems for monitoring and conditioning human motor function Development and deployment of wireless personal-area-network for tele-medicine applications, remote monitoring and tele-rehabilitation of balance and movement in older and chronic diseased subjects in the home environment Due to its background, mHT can be an ideal partner in research projects. We are interested in collaborating in innovative and exciting projects, by providing our expertise and/or our systems. We can also collaborate in the fields of strategy development, proposal preparation, implementation, and exploitation. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Electromedical and medical equipment (non diag)

500 / 880 • Manufacturing & process engineering • Medical devices

Marketplace Opportunities PRODUCT Gait Tutor The Gait Tutor is our first solution for rehabilitation of gait; it is based on the concept that the repetition of the correct movement is the most effective gait training. Gait Tutor uses two sensors (to wear on the shoes) and a smartphone to provide ubiquitous tutoring of gait performances and to rehabilitate persons with motor disabilities to regain effective and safe gait patterns. After detecting gait characteristics such as increased (or decreased) velocity, asymmetries, festination, shuffling, or irregular steps, it can provide instructions aimed at restoring a correct gait pattern. It can also provide praise messages every time gait is accurate and effective, and can automatically regulate message intensity and verbosity. PRODUCT Smartphone-based Functional Assessment *This system it is one of the "Innovation Radar Prize 2016" finalist.* By instrumenting a functional test it is possible to provide automatic algorithms for an objective and comprehensive assessment which goes well beyond the traditional clinical measures (i.e. stopwatch) and scores. mHealth Technologies has developed novel smartphone apps for instrumenting clinical tests for functional assessment: Timed Up and Go, Posturography, Gait Analysis, Repeated Chair Standing,etc. Our apps have a user-friendly interface with a single start/stop button. At the end of the assessment a personalised report is automatically generated. Our apps automatically perform the data recording, the signal processing, and the features extraction and can provide personalised audio guidance and feedbacks. Algorithms and methods are validated against proper gold standards such as force plates and stereophotogrammetric systems.

501 / 880 mHealth Technologies srl

Organisation

Country Italy City BOLOGNA Street Via Giuseppe Fanin, 48 Web http://www.mhealthtechnologies.it

Person

Name Carlo Tacconi CEO

Organisation mHealth Technologies s.r.l. is a spin-off of the University of Bologna. We were born in 2014 following successful experiences matured in national and international research activities in the field of active and healthy ageing (http://farseeingresearch.eu/) and in the field of movement disorders such as Parkinson’s Disease (http://www.cupid-project.eu/). We are a team of expert researchers in the fields of movement analysis, signal processing, algorithm development, wearable sensors, and data mining. We propose wearable solutions for monitoring, assessment and rehabilitation of the motor function. We address the needs of an ageing population and of people with motor impairments. mHT solutions provide relevant outcomes to the clinician and effective feedback to the users. Users become proactive in their health management. mHT solutions are easy-to-use systems. Depending on the specific motor impairment, we use smartphones, tablet and ad hoc sensors. We can also fully customize our systems in order to answer your specific needs, and we can provide support and data analysis service. The ambitious objective of mHT is to take healthcare out of the hospital and to embed it into people’s lives. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Software, ICT applications, system integration • Medical devices

Marketplace Opportunities PRODUCT Smartphone-based Functional Assessment *This system it is one of the "Innovation Radar Prize 2016" finalist.* By instrumenting a functional test it is possible to provide automatic algorithms for an objective and comprehensive assessment which goes well beyond the traditional clinical measures (i.e. stopwatch) 502 / 880 and scores. mHealth Technologies has developed novel smartphone apps for instrumenting clinical tests for functional assessment: Timed Up and Go, Posturography, Gait Analysis, Repeated Chair Standing,etc. Our apps have a user-friendly interface with a single start/stop button. At the end of the assessment a personalised report is automatically generated. Our apps automatically perform the data recording, the signal processing, and the features extraction and can provide personalised audio guidance and feedbacks. Algorithms and methods are validated against proper gold standards such as force plates and stereophotogrammetric systems. PRODUCT Gait Tutor The Gait Tutor is our first solution for rehabilitation of gait; it is based on the concept that the repetition of the correct movement is the most effective gait training. Gait Tutor uses two sensors (to wear on the shoes) and a smartphone to provide ubiquitous tutoring of gait performances and to rehabilitate persons with motor disabilities to regain effective and safe gait patterns. After detecting gait characteristics such as increased (or decreased) velocity, asymmetries, festination, shuffling, or irregular steps, it can provide instructions aimed at restoring a correct gait pattern. It can also provide praise messages every time gait is accurate and effective, and can automatically regulate message intensity and verbosity.

503 / 880 Micar Innovation (Micar21)

Organisation

Country Bulgaria City Sofia Street 38A, Karamfil street Web http://micar21.com/

Person

Name DIMITAR DIMITROV CEO, Co-Founder

Organisation Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through new blockbuster drug molecules for a large class of diseases. Micar Innovation focuses on non-clinical Proof-of-Concepts (POCs) in preclinical R&D and Hit-to-Lead (H2L) achievements in areas such as neuroscience, oncology, cardio- vascularity, dermatology, rare diseases. Micar21 is our drug discovery platform for small molecule drug candidates. The business model is based on licensing our intellectual property to commercial partners and on the creation new spin out companies. Areas of Activity

• Biotechnologies (Pharma&Medical • Nutraceutics, probiotics, functional food, Devices) cosmeceutics • Consulting services • Pharmaceutics • Drug screening & delivery • Life sciences related activities • Genetics & Genomics • Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Bolka Pharmaceuticals - Invest now in Preclinical Phase in novel drug molecule for the treatment of Chronic Pain Bolka Pharmaceuticals is spin off company of Micar Innovation, registered in Sofia, Bulgaria. Under terms of the agreement, Micar Innovation grants Bolka Pharmaceuticals (Sofia - Bulgaria) an exclusive option to license and develop MIC4578 drugs targeting Chronic Pain disease. Bolka Pharmaceuticals capital is in the hands of Micar Innovation driven by impact and provide value to our future investors. Please visit: www.Bolka.Life INVESTMENT OPPORTUNITY

504 / 880 Pancreatic Pharmaceuticals - Invest now in Preclinical Phase in novel drug molecule for the treatment of Pancreatic Cancer Pancreatic Pharmaceuticals is spin off company of Micar Innovation, registered in Sofia, Bulgaria. Under terms of the agreement, Micar Innovation grants Pancreatic Pharmaceuticals (Sofia - Bulgaria) an exclusive option to license and develop MIC6479 drugs targeting Pancreatic Cancer disease. Pancreatic Pharmaceuticals capital is in the hands of Micar Innovation driven by impact and provide value to our future investors. Please visit: www.Pancreatic.Life SERVICE DRUG DISCOVERY SERVICES. Your Drug Discovery factory of novel biologically active compounds for the treatment of diversity diseases Micar Innovation provide innovative most fast & accurate structure based in silico drug design and Artificial Intelligence (AI). Micar Innovation provide in silico screening for the detection of biologically active compounds / discovers new small molecule drugs through power of Artificial intelligence (AI), we offer a combination of the most advanced approaches currently used. Micar Innovation is a small molecule pharmaceutical incubator. Our focus is creating high-value therapies with transformative potential to address diseases and disorders with significant unmet need. Translating breakthrough scientific insights into novel therapies. Do not hesitate to contact us: micar21.com

505 / 880 Microlab

Organisation

Country Italy City Roma Street Via Castiglione d'Orcia, 28 Web www.microlabprogetti.com

Person

Name Giulio Sfoglietti Project Manager

Organisation Microlab, established in 1981, is involved in Design/Consultancy/Manufacturing in Electronics market, in Defence/Aerospace, Telecommunications, ICT, ElectroMedicals and Alternative Energies sectors.We have designed hundreds of Products for our Customers, much of them being now our close partners. Moreover, starting involving our historical partners but successively widening the horizon, we started even a business activity dealing with internazionalization. We operate searching for business opportunities in Turkey and bordering countries, Central and South America, Sub-Saharian Africa, Eastern Europe, China and Iran. Due to partnership with local Companies we can: - Find local partner as Distributors, Sales Representatives, and for Maintenance and Installation services; - Support establishing Business Alliances and Joint-Ventures; - Support Companies to partecipate to Governative Tenders; - Support to open Liason Offices, Branches or Factories; Last but not least, we support companies to Subscription, Monitoring and Participation to UN and World Bank Contracts. Areas of Activity

• Biosensors • Virtual reality applications • Consulting services • Project proposals support services • eHealth, mHealth, telemedicine • Medical devices • Electromedical and medical equipment • IT Applications for Health (non diag) • Nutraceutics, probiotics, functional food, cosmeceutics • Software, ICT applications, system integration

Marketplace Opportunities SERVICE

506 / 880 Business Opportunities in Central/South America, Sub-Saharian Africa, Eastern Europe, Turkey, China, Iran Due to the partnerships with various local professionals we propose high grade services. The mix of technical know-how corporate advisory allow us to support our Clients in deployment of their internationalization actions. The Countries we mainly are involved in are China, Taiwan, Turkey and bordering countries, Iran, Middle/Far East, Central/South America, Nigeria, Kenya, and Eastern Europe. Main Services are aimed to: - Find local partner as Distributors, Sales Representatives, and for Maintenance and Installation services; - Support establishing Business Alliances and Joint-Ventures; - Support Companies to partecipate to Government Tenders; - Find Investors; - Support to establish Liason Offices, Branches or Factories. Moreover we support companies to Subscription, Monitoring and Participation to UN and World Bank Tenders. MAIN ADVANTAGES Strong presence on territory with reliable local partners. MARKET APPLICATION Pharmaceutical, Medical Devices, IT/Smart Applications for Health TYPE OF PARTNER SOUGHT Companies/Research Institutes wishing to explore new markets and searching for new business opportunities. SERVICE Design, Consulting and Manufacturing Services Due to our broad spectrum of know-how, Microlab can approach many areas of the Electronics Design. Whether the Customer needs just a consultancy or a complete design support or manufacturing services, Microlab can accomplish that thanks to more than 30 years spent to solve and support Customer requests. INNOVATIVE ASPECTS AND MAIN ADVANTAGES 35-year expertise. Flexible handling of projects. MARKET APPLICATION Medical Devices, IT/Smart Applications for Health. TYPE OF PARTNER SOUGHT Profiles we think could need our Expertise/Know-how are: - Companies looking for hardware/software design support in an extensive manner or even for specific areas, i.e. the like of GUI or connectivity, nowadays requested in almost every product. - Companies requesting for manufacturing services - Research Centers/Universities requesting for support in developing their Projects both during the design and test phases. In fact, other than giving support for the design, we can even manufacture the prototypes or the small lots requested for the evaluation/test phase.

507 / 880 Mikroliz Biotechnology

Organisation

Country Turkey City Ankara Street METU Technopolis OSTIM Web http://www.mikroliz.com

Person

Name Medine COTAK Founder

Organisation Mikroliz is a young SME working on bacteriophage and its enzymes, seeking solutions for nosocomial multidrug resistant pathogens. Mikroliz conducted a number of R&D projects and has highly skilled researchers. Currently focusing on ESKAPE pathogens, we are in development phase of a potential new drug. Areas of Activity

• Biosensors • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation Devices) • Proteomics, metabolomics, nutrigenomics • Diagnostics IVD • Life sciences related activities • Drug screening & delivery • Genetics & Genomics • Medical research

Marketplace Opportunities PROJECT COOPERATION New R&D Project Cooperation We are open to new cross-border R&D projects on bacterial pathogens, pharmaceutical proteins and antibodies, recombinant pharmaceutical proteins, antimicrobial resistance, infectious diseases, biosensors and related fields. We can be a technical partner responsible of conducting research, laboratory experiments, recombinant enzyme production and routine laboratory tests. PRODUCT Bacteriophages against ESKAPE Pathogens We are currently developing bacteriophage and its endolysin that kills pandrug resistant ESKAPE pathogens. We completed in vitro experiments, and now we are starting in vivo animal experiments. PARTNERSHIP

508 / 880 H2020 Partnership Mikroliz is a highly skilled start-up formed by PhD level researchers with international project experience. We are open to new Horizon 2020 project ideas as a partner.

509 / 880 Milltech Srl

Organisation

Country Italy City Zola Predosa (BO) Street via J.F. Kennedy, 12 Web www.milltech.it/en

Person

Name Francesca Emili International Sales & Marketing

Organisation Milltech produces high-precision Milled and Turned components according to customers' drawing. Dimensions for Milling: min 1mm x 1mm, max 10,000mm x 2,500mm x 1,250mmDimensions for Turning: min ø1 mm, maximum: ø300mm L= 600 mm We work on all materials: e.g. aluminium and all its alloys, steel in general, stainless steel, titanium, copper, brass, bronze and plastics in general. Most competitive in production batches from 10 to 1000 pieces. Thanks to our several partners, we can also deliver the parts with superficial treatment. ABOUT US: Milltech was created by a group of technicians who shared decades of professional experience, different and supplementary to each other, in the production and prototyping of high precision mechanical components. Milltech is able to perform the entire cycle: from technical design to the requested mechanical parts, through prototyping and manufacturing to the finished product. Milltech meets the customer's need for flexibility due to the agility of its production structure, which can quickly shift from small to medium batch production. Milltech ensure the maximum level of environmental sustainability of its processes, and ensures that its products are COMPLETELY MADE IN ITALY in compliance with qualitative standards that are among the best in the market. The Product Development Department offers best-in-class expertise. Main sectors which we supply are: - Electronics - Electromechanics - Hydraulics - Optik - Opto-Mechatronik - Biomedical: we produce components for ophtalmogicmachines and for gait equipments for Italian and Foreigner Companies Areas of Activity

510 / 880 • Manufacturing & process engineering

Marketplace Opportunities PRODUCT Milled Components Milltech produces high-precision Milled components according to customers' drawing. Dimensions: min 1mm x 1mm, max 10,000mm x 2,500mm x 1,250mm We work on all materials: e.g. aluminium and all its alloys, steel in general, stainless steel, titanium, copper, brass, bronze and plastics in general. Most competitive in production batches from 10 to 1000 pieces. Thanks to our several partners, we can also deliver the parts with superficial treatment. PRODUCT Turned Components Milltech produces high-precision Turned components according to customers' drawing. Dimensions: min ø1 mm, maximum: ø300mm L= 600 mm We work on all materials: e.g. aluminium and all its alloys, steel in general, stainless steel, titanium, copper, brass, bronze and plastics in general. Most competitive in production batches from 10 to 1000 pieces. Thanks to our several partners, we can also deliver the parts with superficial treatment. SERVICE Suppliyng of Milled and Tuned Components according to Drawing Milltech produces high-precision Milled and Turned components according to customers' drawing. Dimensions for Milling: min 1mm x 1mm, max 10,000mm x 2,500mm x 1,250mm Dimensions for Turning: min ø1 mm, maximum: ø300mm L= 600 mm We work on all materials: e.g. aluminium and all its alloys, steel in general, stainless steel, titanium, copper, brass, bronze and plastics in general. Most competitive in production batches from 10 to 1000 pieces. Thanks to our several partners, we can also deliver the parts with superficial treatment. PARTNERSHIP Partnerships with Companies in need of milled and turned components for medical equipments We look for Partnerships with Companies in the medical sector who would need our competence and experience in the production of milled and turned components for medical equipments.

511 / 880 Miltenyi Biotec Srlu

Organisation

Country Italy City Bologna Street Via Paolo Nanni Costa 30 Web https://www.miltenyibiotec.com/DE-en/about-us/ about-miltenyi-biotec.html

Person

Name claudia maldini Marketing Manager

Organisation Miltenyi Biotec’s global team of over 2,000 employees design, develop, manufacture, and market products that help advance biomedical research and enable cell and gene therapy programs. With headquarters in Bergisch Gladbach, Germany and dedicated manufacturing facilities in Germany and the US, we supply the world with flow cytometry analyzers and sorters, instrumentation for clinical applications, cell culture devices, reagents, and cell separation technologies. GMP-grade suites for in-house and contracted manufacturing of cell products and lentiviral vectors are integral parts of our European and North American sites. Miltenyi Biotec’s engineers, scientists, clinicians, and support teams are all dedicated to helping improve human lives. It is their know-how that is at the root of our product innovation, long-term growth, and worldwide success. Areas of Activity

• Biotechnologies (Pharma&Medical • Laboratory equipment, reagents, software Devices) • Medical devices • Drug screening & delivery • Manufacturing & process engineering • Medical research

Marketplace Opportunities PRODUCT Cell Therapy manufacturing At the forefront of pioneering clinical research: we change the way of generating gene-engineered T cells. We offer clinical-scale cell selection and GMP-compliant cell manufacturing, from immuno-oncology, regenerative medicine, to graft engineering. PRODUCT

512 / 880 IPC and QC by Flow Cytometry Innovation is at the core of each MACSQuant® Instrument, offering that application which is most relevant for you: automation, CFR21 compliance, high-throughput, multiparameter, or even sorting. Get superior reproducibility with REAfinity™ Recombinant Antibodies, optimized for flow cytometry at every step of your cell manufacturing process. PRODUCT Immuno-Oncology supported by Miltenyi Biotec MACS Technology From parallel cell isolation to fully automated multisample cell separations, we offer flexible workflow solutions for automating MACS® Technology. Interested in higher throughput cell separation and processing? We also offer integration into liquid handling platforms with comprehensive solutions: -Optimized workflows for innovative research in immuno-oncology -Products ranging from research to clinical grade to allow for smooth translation towards innovative cell and gene therapy concepts -Products and solutions for drug screening processes

513 / 880 Mirnagreen srl

Organisation

Country Italy City BOLZANO Street VIA VOLTA 13/A Web http://www.mirnagreen.com

Person

Name Roberto Viola President

Organisation Mirnagreen is the world first supplier of plant microRNA extracts with revolutionary health-giving properties. Areas of Activity

• Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PRODUCT Plant microRNA extracts New revolutionary ingredients for the nutraceuticals, cosmeceuticals and functional food markets. Extracted from natural plant sources through a proprietary food-grade technology. Can be used for the development of unique new products and solutions with immuno-modulant and anti-inflammatory properties. PARTNERSHIP Product development and commercialization We are seeking business partners for the development and commercialization of natural plant microRNA-based products for the nutraceutical, cosmeceutical, functional foods/feed and beverage markets. INVESTMENT OPPORTUNITY First round investment open We are seeking €1-2M capital investment to realize the first global plant microRNA extraction plant using proprietary technology and help bring the products to the international markets.

514 / 880 MTTlab Srl

Organisation

Country Italy City Trieste Street via Gallina 5 Web www.mttlab.eu

Person

Name Cristina Degrassi CEO

Organisation MTTlab is a preclinical CRO (Contract Research Organization) providing biomedical, biotechnological and pharmaceutical testing services for biotech industry. MTTlab delivers both in vitro and in vivo data sets for the preclinical evaluation of investigational compounds which can be used for regulatory submissions, project evaluation, scientific publications and fund raising. MTTlab provides support for client studies or projects from the earliest research stages and assists with both scientific and regulatory challenges to obtain valid results within requested deadlines. MTTlab offers small/medium size (up to 500 mice in a single experiment) in vivo studies (toxicology, efficacy, behavioral, disease models) and relevant in vitro studies to private companies, universities, academic institutions and government research centers worldwide. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • CRO (Contract Research Organisation) • Drug screening & delivery • Medical research

Marketplace Opportunities SERVICE Medical Devices Testing (both in vivo and in vitro) MTTlab is a preclinical CRO (Contract Research Organization) providing medical devices testing for biotech industry. The services are tailored, within the legislative framework (ISO10993 etc), according to the client request. MTTlab team recognizes the clients need for timely delivery of accurate and accessible data in order to support critical decisions affecting the progress of your research/technology. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Main advantages: flexibility, short lead time, extensive expertise, reproducibility, tight working relationship with clients (prompt feedback, weekly updates) 515 / 880 MARKET APPLICATION Pharma, Biotech, Academic etc. in need of biological testing of medical devices according to ISO 10993, TYPE OF PARTNER SOUGHT MTTlab offers medical devices testing to private companies and government research centers both in Italy and EU. SERVICE In vivo Studies on rodent models MTTlab offers variety of biomedical, biotechnological and toxicology testing services as well as providing assistance with early research and proof-of-principle pharmacology studies in rodent models. MTTlab performs small/medium scale in vivo studies, including toxicology, efficacy, behavioral, disease models. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Main advantages: flexibility, short lead time, extensive expertise, reproducibility, tight working relationship with clients (prompt feedback, weekly updates) MARKET APPLICATION MTTlab services are available worldwide for private companies, academic institutions and government research centers. TYPE OF PARTNER SOUGHT MTTlab is looking for clients who need of a quick proof-of-idea or proof-of-concept in vivo/ex vivo experiment and relevant/related in vitro experiment.

516 / 880 MultiGel srl

Organisation

Country Italy City Tavarnelle Val di Pesa Street Via Cimabue 4/6 Web http://multigel.it

Person

Name Alberto Baldini Director

Organisation The company MultiGel srl, established in May 2014, is continuing the tradition of a family-owned company founded in Firenze, Italy, almost 80 years ago, producing manual, semiautomatic and automatic machinery and lines for the filling and packaging of pharmaceutical, herbal and cosmetic products. The machines produced by MultiGel are designed for the pharmaceutical industry, laboratories, R&D and galenic pharmacies. Multigel offers a vast range of equipment designed to meet the requirements of all its customers, from small manual machines for the production of capsules to the most complete automatic lines for filling, counting and capping any type of container for any kind of product, like powders, liquids, creams and solid forms. Areas of Activity

• Electromedical and medical equipment • Laboratory equipment, reagents, software (non diag) • Medical devices • Manufacturing & process engineering • Nutraceutics, probiotics, functional food, cosmeceutics • Packaging & labelling • Pharmaceutics

Marketplace Opportunities PRODUCT Machines for pharma, nutraceuticals MultiGel srl offers a wide set of machines for the pharma and cosmetics industry, laboratories, galenic pharmacies and R&D facilities . Multigel produces customized manual, semiautomatic and automatic machinery and lines for the filling and packaging of pharmaceutical, herbal and cosmetic products, with high quality standards to give the best product possible to our clients. Scale is not a problem, from small manual machines for the production of capsules to the most complete automatic lines for filling, counting and capping any type of container for any kind of product, like powders, liquids, creams and solid forms. Great experience (the team worked many years in this business area) and high level expertises ensures 517 / 880 the satisfaction of our clients

518 / 880 Musculoskeletal Tissue Bank - Rizzoli Orthopaedic Institute

Organisation

Country Italy City BOLOGNA Street via G. C. Pupilli 1 Web http://www.ior.it/btm

Person

Name Leonardo Vivarelli Researcher

Organisation The Musculoskeletal Tissue Bank of the Rizzoli Orthopedic Institute (Bologna, Italy) has been active since 1962 and is a reference center for the Emilia-Romagna Italian Region. It provides 50% of all the musculoskeletal tissue used in Italy, allowing over 5,000 surgical interventions per year for oncological or trauma patients in the orthopedic, maxillofacial, neurosurgery and odonto-stomatology fields. BTM ensures the quality and safety of distributed tissues, helps to establish and disseminate standards and guidelines, and participates in innovative technological projects in the fields of tissue engineering and regenerative medicine. Tissues and biomaterials processed by the qualified personnel of BTM are essential for reconstruction procedures in orthopoedic surgery, such as prosthetic reimplants, spine surgery, fracture synthesis and ligament reconstructions. Moreover, BTM aims to achieve an optimal balance between basic and applied research in order to emphasize the technology development and product development and their interplay. Areas of Activity

• 3D Printing/addictive manufacturing for • Surgery technologies and applications biomedical applications • Other • Biomaterials • Medical devices • Biotechnologies (Pharma&Medical Devices) • Manufacturing & process engineering • Medical research

Marketplace Opportunities PRODUCT Custom Human Bone Grafts - Manual and computerized processing The Musculoskeletal Tissue Bank of Bologna distributes human tissues processed in a Class A Clean Room, and ahas specialized in grafts customization. 519 / 880 There are two methodologies to obtain custom grafts, the manual processing (performed thanks tho the skills of our laboratory technicians) and CNC machining (with a higher precision and standardization). Regarding manual processing, custom tissues are processed on a specific request; starting from femur, tibia, hemipelvis or other tissues technicians can obtain custom shafts, corticocancellous blocks, etc. Regardin computerized processing, since 2010 we have specialized in customizing grafts thanks to a numerical control mill suitable for clean rooms, capable to reproduce CAD-CAM models from corticocancellous bones, with high precision. After a CT segmentation we can perform a CAD modeling of required graft, then we perform a CAM programming of the milling machine, as final step we perform the processing in Clean Room. We offer custom grafts for different surgical specialties, such as: corrective, prosthetic, traumatological and oncological orthopedic surgery; hand surgery; dentistry; maxillofacial and plastic surgery; neurosurgery. PARTNERSHIP Allograft Spacers - Human cortical bone spinal cages Spinal fusion has been used for decades to manage a variety of spinal disorders. The earliest implants were highly invasive procedures such that spinal instrumentation was introduced to increase the rate of successful fusion, decrease the period of patient recovery, and allow surgeons to restore physiologic curvature of the spine segments affected. The objective is to take to the European market a new intervertebral cage, which allows to obtain a fast and robust physiological spinal fusion; moreover this innovative cage will be made of human cortical bone, a natural and resorbable material. Thanks to our Clean Room Milling Machine, cortical bone intervertebral cages of different shapes and sizes can be produced in series, with greater osteoconductive and osteoinductive properties and lower costs compared to synthetic substitutes currently on the market. We are looking for medical devices producers, to develop a specific instrumentation for cortical bone cages implantation. PARTNERSHIP Allograft sterilization by supercritical carbon dioxide Sterilization of allografts is an important issue since those tissues are sensitive to high temperatures. Low temperature sterilization methods like gamma irradiation, as well as ethylene oxide gas (EO) and low-temperature formaldehyde/steam exposure have been shown to alter morphology, structure, and surface properties of different biological tissues. An alternative method for the inactivation of microorganisms is the application of dense phase and supercritical carbon dioxide (scCO2) that offers many advantages as a sterilization agent, since it is non-toxic, non-reactive and has high penetration ability. Thus, we are interested to explore and study this innovative sterilization method by the collaboration with facilities and/or experts in the field of supercritical fluids.

520 / 880 MyAir llc

Organisation

Country Italy City Milano Street Web www.myairgo.com

Person

Name david kuller ceo

Organisation Producer of AirGo Respiratory Holter, the patented ergonomic 24/7 respiratory monitor providing realtime actionable data streams for a variety of clinically proven diagnostic applications including Automated Sleep disorder classification, COPD patient management, ICU Sleep quality assessment, opiate dosage titration and others. Areas of Activity

• Biosensors • Life sciences related activities • Diagnostics - Equipment and accessories • Medical devices • eHealth, mHealth, telemedicine • Medical research • Physiotherapy, Orthopaedic technology

Marketplace Opportunities INVESTMENT OPPORTUNITY Series A investment We are currently seeking $2m to build our European sales network. Our patented ergonomic 24/7 Respiratory Holter "AirGo" has been clinically proven to be equivalent with spirometry yet useable unobtrusively during normal daily life and show significant promise for remote respiratory patient management (COPD, ALS, MS, etc). Other clinical trials have validated our fully automated sleep disordered screening capabilities. Our 5th generation platform is currently being field tested with Class IIa certification scheduled for Q4'18 and sales in early '19. PRODUCT AirGo Respiratory Holter AirGo is a patented ergonomic 24/7 respiratory monitor providing realtime actionable data streams for a variety of clinically proven diagnostic applications including Automated Sleep disorder classification, COPD patient management, ICU Sleep quality assessment, opiate dosage titration and others.

521 / 880 N. T. Laboratory srl

Organisation

Country Italy City Calenzano Street via Baldanzese 35 Web http://www.ntlaboratory.com

Person

Name Matteo Fallani R&I Project Manager

Organisation N.T. LABORATORY is an international engineering, manufacturing and trading company based in Italy since 1999. As a supplier of advanced, reliable and affordable IVD diagnostic equipment, it has gained global recognition for its high quality laboratory solutions including instruments, reagents and consumables, suitable for human and veterinary medicine. A team of quality control managers monitor every step of the production process, ensuring accurate development and realization of the final product. Our company standards allow us to fulfill customer requirements by offering innovative technology, convenience, cost effectiveness and flexibility. Mission and Strategy Our mission is to make diagnostics instruments that help to detect diseases. Our strategy is to create value for all our stakeholders by accelerating the flow of innovative, new cutting-edge equipments and testing kits that provide improved outcomes for laboratories throughout the world. Most of the products we sell today were discovered or developed by our own scientists and our success depends to great extent on our ability to continue to discover, develop and bring to market innovative new diagnostic equipments. We manufacture and distribute our products through facilities in Italy and our products are sold in approximately 40 countries List of countries where the company or products are currently registered Egypt, Kuwait, Iran, Korea, Vietnam, Philippines, Mongolia, China, Indonesia, Russia, Uzbekistan, Ukraina and Georgia. Products N.T. LABORATORY develops and manufactures a largerangeof highly competitive IVD equipment, accessories, consumables and reagents for medical laboratories (various types of automatic and semi- automatic analyzers) IPR There are currrently under patent important technologies in the field of robotics, fluidics, mechanical and optical solutions applied to diagnostics. N.T. Laboratory is costantly cooperating with several universities and research centers. R&D is the central focus of our company. R&D is ultimately driven by market demand. Since 2003, N.T. spent approximately 20% of its sales on R&D. This figure is quite high in our industry; 522 / 880 8% is the industry average and almost all of our competitors spend under 12%. N.T. focuses on R&D because we view R&D as our biggest competitive advantage against our competitors. R&D reinforces our core mission; bringing to market the latest, most cost-effective diagnostic equipments. Two of the best examples of our R&D activities are two EU projects in which we have been recently involved: FP7 RESPOC project (www.respoc.eu) and H2020 DMC-MALVEC project (www.dmc- malvec.eu) still ongoing. Areas of Activity

• Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • Manufacturing & process engineering • Laboratory equipment, reagents, software

Marketplace Opportunities PARTNERSHIP Looking for collaboration in EU project partnerships We are interested in any collaboration in the context of EU projects in the Health and ICT areas. We offer our deep expertise in dthe engineering, development and prototyping of medical devices for the IVD and diagnostics sectors SERVICE Engineering and automation for IVD processes Almost 20 years experience in developing and manufacturing medical devices for the IVD market. Several R&D collaborative projects, also in the EU context. Two of the best examples of our R&D activities are two EU projects in which we have been recently involved: FP7 RESPOC project (www.respoc.eu) and H2020 DMC-MALVEC project (www.dmc-malvec.eu) still ongoing. We look for private companies and research centers needing expertise in the development and manufacturing of medical devices, as well as prototyping activities. Collaboration in EU projects partnerships. PRODUCT IVD Diagnostic systems for clinical chemistry and andrology N.T. LABORATORY develops and manufactures a large range of equipment, accessories, consumables and reagents for medical laboratories. Various types of automatic and semi-automatic analyzers are available to fulfill the daily needs of every diagnostic lab, from rural hospitals to reference diagnostic centres, and they are continuously monitored by our specialists for their accurate performances. Our range of photometers and cell counters, along with accessories, solutions and consumables, meets the small and medium laboratory needs. Most of our products are open systems. Our diagnostics products compete with products manufactured by many other companies in highly competitive markets throughout the world. Important competitive factors include safety, effectiveness and ease of use; price and demonstrated cost-effectiveness; marketing effectiveness; and research and development of new products and processes. Most new products that we introduce must compete with other products already on the market or products that are later developed by competitors. Manufacturers of counterfeit, non- proprietary diagnostics equipment makers invest far less than we do in R&D and therefore can price their products much lower than our branded products. We believe our long-term competitive success depends upon discovering and developing either alone or in collaboration with others or acquiring innovative cost-effective diagnostic technologies that provide improved outcomes to users.

523 / 880 NANOFABER srl

Organisation

Country Italy City ROMA Street VIA G. A. BADOERO, 82 Web www.nanofaber.com

Person

Name antonio rinaldi R&D director

Organisation NANOFABER is a spin-off company dealing with innovative nanoparticales technology and nanobiomaterial made by electrospinning. The company headquarter is in Rome and is also an official ENEA SPIN-OFF , with the main operation site at ENEA Casaccia (National Institute of New Technology, Innovation, Sustainable Development). While based in Italy, the Company was co-funded also by Spanish researchers, leading scientists in responsive nanoparticles technology, mainly plasmonic and magnetic responsive. The Rome site focuses on state of the art Electrospinning of biopolymers for tissue engineering, drug delivery, and biosening. The scope of the Company is diverse . The main item for the event are proprietory (patented in Italy and abroad) microsponges with high residence time for drug delivery and cosmetics.Though, a catalogueof available products for purchase is available in the online store at Company's website www.nanofaber.com. Areas of Activity

• Analytical and characterization services • Nutraceutics, probiotics, functional food, • Biomaterials cosmeceutics • Biosensors • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation Devices) • Pharmaceutics • CMO (Contract Manufacturing • Regulatory affairs, validation Organisation) • Project proposals support services • Drug screening & delivery • Medical devices • Investments • Medical research

Marketplace Opportunities PRODUCT

524 / 880 Nanoporous microsponges of hyaluronic acid with high residency time for drug delivery Technology patented internationally for new injectable crosslinked hyaluronic acid to be used for viscoinduction (medical device) , drug delivery (excipient) , or cosmetics (filler). These particles can stay for more than 8 weeks in the site of intra-articular injection . In addition can be loaded with nearly any protein or drug for a controlled release. Released for R&D usage as exploitation package only INVESTMENT OPPORTUNITY Patented microsponges of hyaluronic acid Investment opportunity to support IP and global licensing operation worldwide. Technolgy already patented in Italy , as well as Japan, the latter being strategic market. Italy and EU are part of this expansion/licensing endeavors.

525 / 880 Nanomnia srl

Organisation

Country Italy City Verona Street Via di Mezzo 46, Perzacco di Zevio, VR Web www.nanomia.eu

Person

Name Michele Bovi CTO

Organisation Nanomnia designs and synthesizes biodegradable and biocompatible organic nanoparticles, in which active principles are encapsulated for the targeted delivery to a specific biological tissue, being it animal, plant or human. Nanomnia’s current encapsulation products has a wide variety of applications and provides them with many opportunities for future growth. The main areas of application will focus on pharmaceuticals, cosmetics, nutraceutics and agritech applications. Due to their extremely small size, nanoparticles can cross cell membranes and target a specific cell population. Due to these factors the amount of active ingredients in a compound to be reduced between 10-100 times when encapsulated. The targeting result enhances biological response to the active compound and restricts its effects to the targeted cells reducing waste, toxicity, and costs. Innnovation is achieved through biotechnology, on these sides: - Biodegradability and biocompatibility of the encapsulating “shell” polymer in the target tissue, human, animal or plant; - Stability of encapsulated compound in the target tissue; - Optimized size; - Modification of nanoparticle for specific targeting; - Optimized release profile in the target biological tissue. This way, Nanomnia may create tailor-made nanoparticles with peculiar unique properties. Areas of Activity

• Biomaterials • Pharmaceutics • Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Other • Consulting services • Medical devices

526 / 880 • CRO (Contract Research Organisation) • Drug screening & delivery • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Spray Drying Expertise Nanomnia Srl currently uses a Mini Spray Dryer Buchi B-290 for encapsulation experiments, obtaining and high reproducible microparticles products. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Spray drying is one of the most common approach of producing dry powder from complex solutions by an efficient sprayzation of the liquid and its rapid drying with a hot gas. This technology is the preferred method of drying many thermally-sensitive materials such as foods and pharmaceuticals. Nanomnia Srl provides an R&D service for companies or laboratories to improve the features of an active principle by the nano or micro encapsulation using spray drying technology. PARTNERSHIP Biomaterials development for tissue engineering Nanomnia activities are aimed to the development of organic biocompatible and biodegradable nanotools, namely nanoparticles, nanofibers, nanointermediates and nanoporous materials. Nanomnia focuses on biomaterial sciences for nanotech based applications, ranging from cosmetics, pharmacological, nutraceutical, environmental and medical technology. It has a recent university background, and experience gained in organic nanoencapsulation of molecules and complexes for research purposes. We look for partners as research groups, companies or academic, in order to develop innovative and disruptive systems for applications in human tissue technology. SERVICE Organic nano- and microencapsulation of active ingredients Nanomnia designs and synthesizes biodegradable and biocompatible organic nanoparticles, in which active principles are encapsulated for the delivery to a biological organism. Provided small sized, nanoparticles can cross cell membranes and capillaries. Moreover, exploiting the binding of a peptide onto nanoparticles surface, they can be specifically addressed to a target cell population (skin, brain, muscle, plant...). On these bases, the amount of encapsulated compound can be reduced about 10-100 folds compared to non-encapsulated one. Nanoparticles allow specific targeting, enhancing the biological response to the active principle and restricting its effects only on the interested cells. This way, reduction of dispersion, toxicity and any collateral effects will be achieved, as well as costs. With the same principle, but different approach, we are developing inorganic self-folding nanostructures encapsulating pollution agents for bioremediation of polluted waters, as well as nanointermediates as scaffolds for tissue engineering and regenerative medicine. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Our nanoparticle-producing method is based on organic material to encapsulate any kind of compound in a specific way, according to the chemical-physical properties of the compound itself. Such a taylor-made method allows us to satisfy the request for higher specificity in terms of the body tissue to be reached, and also to reduce dispersion and costs. We guarantee biocompatibility, biodegradation and enhanced biodisponibility. 527 / 880 Given the youth of nanotechnology as a science, our competitors are startups or companies raising from academia of as branches of bigger companies. The number is less then ten in Italy, but increasing in Europe. Most of them work with inorganic starting material, easier to manipulate comapred to the organic. MARKET APPLICATION Environmental, pharmaceutical, cosmetics and agro-zoo-technical companies, research groups, which would integrate nanotechnological innovation into their network development and to whom we offer skills, in term of cellular models, biotechnological approaches, evaluation of applicability and industrial nanotechnologies. Nanotechnology involves a wide range of innovative industrial applications, and in the last decade became one of the key enabling technologies (KETs ) when propelled by funding for R&D, both public and private. On a research-based knowlegde, TYPE OF PARTNER SOUGHT We are looking for partners as companies already present in he marketplace, in the field of cosmetics, nutraceutical, pharma, bioemediation, tissue engineering field. The partner can also be a research universitary group, or the R&D branch of a company. The partner ideally has a product, being it an active compound, an ingredient as food supplement or a drug, whose effects are boosted by encapsulation, allowing the compound to be delivered more efficiently and with higher specificity, to the interested biological site or tissue.

528 / 880 Nanomnia srl

Organisation

Country Italy City Verona Street Via di mezzo 46 - Zevio Web http://www.nanomnia.eu

Person

Name Marta Bonaconsa CEO

Organisation Nanomnia designs and synthesizes biodegradable and biocompatible organic nanoparticles, in which active principles are encapsulated for the targeted delivery to a specific biological tissue, being it animal, plant or human. Nanomnia’s current encapsulation products has a wide variety of applications and provides them with many opportunities for future growth. The main areas of application will focus on pharmaceuticals, cosmetics, nutraceutics and agritech applications. Due to their extremely small size, nanoparticles can cross cell membranes and target a specific cell population. Due to these factors the amount of active ingredients in a compound to be reduced between 10-100 times when encapsulated. The targeting result enhances biological response to the active compound and restricts its effects to the targeted cells reducing waste, toxicity, and costs. Innnovation is achieved through biotechnology, on these sides: - Biodegradability and biocompatibility of the encapsulating “shell” polymer in the target tissue, human, animal or plant; - Stability of encapsulated compound in the target tissue; - Optimized size; - Modification of nanoparticle for specific targeting; - Optimized release profile in the target biological tissue. This way, Nanomnia may create tailor-made nanoparticles with peculiar unique properties. Areas of Activity

• Biomaterials • Pharmaceutics • Biotechnologies (Pharma&Medical • Medical devices Devices) • Drug screening & delivery

529 / 880 • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Spray Drying Expertise Nanomnia Srl currently uses a Mini Spray Dryer Buchi B-290 for encapsulation experiments, obtaining and high reproducible microparticles products. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Spray drying is one of the most common approach of producing dry powder from complex solutions by an efficient sprayzation of the liquid and its rapid drying with a hot gas. This technology is the preferred method of drying many thermally-sensitive materials such as foods and pharmaceuticals. Nanomnia Srl provides an R&D service for companies or laboratories to improve the features of an active principle by the nano or micro encapsulation using spray drying technology. SERVICE Organic nano- and microencapsulation of active ingredients Nanomnia designs and synthesizes biodegradable and biocompatible organic nanoparticles, in which active principles are encapsulated for the delivery to a biological organism. Provided small sized, nanoparticles can cross cell membranes and capillaries. Moreover, exploiting the binding of a peptide onto nanoparticles surface, they can be specifically addressed to a target cell population (skin, brain, muscle, plant...). On these bases, the amount of encapsulated compound can be reduced about 10-100 folds compared to non-encapsulated one. Nanoparticles allow specific targeting, enhancing the biological response to the active principle and restricting its effects only on the interested cells. This way, reduction of dispersion, toxicity and any collateral effects will be achieved, as well as costs. With the same principle, but different approach, we are developing inorganic self-folding nanostructures encapsulating pollution agents for bioremediation of polluted waters, as well as nanointermediates as scaffolds for tissue engineering and regenerative medicine. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Our nanoparticle-producing method is based on organic material to encapsulate any kind of compound in a specific way, according to the chemical-physical properties of the compound itself. Such a taylor-made method allows us to satisfy the request for higher specificity in terms of the body tissue to be reached, and also to reduce dispersion and costs. We guarantee biocompatibility, biodegradation and enhanced biodisponibility. Given the youth of nanotechnology as a science, our competitors are startups or companies raising from academia of as branches of bigger companies. The number is less then ten in Italy, but increasing in Europe. Most of them work with inorganic starting material, easier to manipulate comapred to the organic. MARKET APPLICATION Environmental, pharmaceutical, cosmetics and agro-zoo-technical companies, research groups, which would integrate nanotechnological innovation into their network development and to whom we offer skills, in term of cellular models, biotechnological approaches, evaluation of applicability and industrial nanotechnologies. Nanotechnology involves a wide range of innovative industrial applications, and in the last decade became one of the key enabling technologies (KETs ) when propelled by funding for R&D, both public and private. On a research-based knowlegde, TYPE OF PARTNER SOUGHT 530 / 880 We are looking for partners as companies already present in he marketplace, in the field of cosmetics, nutraceutical, pharma, bioemediation, tissue engineering field. The partner can also be a research universitary group, or the R&D branch of a company. The partner ideally has a product, being it an active compound, an ingredient as food supplement or a drug, whose effects are boosted by encapsulation, allowing the compound to be delivered more efficiently and with higher specificity, to the interested biological site or tissue. PARTNERSHIP Biomaterials development for tissue engineering Nanomnia activities are aimed to the development of organic biocompatible and biodegradable nanotools, namely nanoparticles, nanofibers, nanointermediates and nanoporous materials. Nanomnia focuses on biomaterial sciences for nanotech based applications, ranging from cosmetics, pharmacological, nutraceutical, environmental and medical technology. It has a recent university background, and experience gained in organic nanoencapsulation of molecules and complexes for research purposes. We look for partners as research groups, companies or academic, in order to develop innovative and disruptive systems for applications in human tissue technology.

531 / 880 National Pirogov Memorial Medical University, Vinnytsya

Organisation

Country Ukraine City Vinnytsya Street Pirogov str., 56 Web https://www.vnmu.edu.ua/

Person

Name Olga Drachuk Associate Professor, Department of Pharmacology, Ph.D.

Organisation National Pirogov Memorial Medical University, Vinnytsya (VNMU) has been training competent doctors and creating scientific research for more than 90 years. For this period about 44 thousands of specialists have been trained, who works in Ukraine and in many countries of the world. The Medical University has traditions in educational and research activities. The areas of our research interests are: -Research of antihypoxyc, nootropic and actoprotective actions of the natural metabolites; -To develop the mHealth App for allergy suffers, which includes exact data on environmental allergy sources (different pollen, molds) and time of their flowering or spores spread, so there the risk of pollen exposure can be assessed and prevented; -Aspects in tactics of maintaining patients with diabetes mellitus and prevention of its complications; -HCC predictors in patients with HBV and HCV. Early diagnostic and timely treatment; -Acute and Chronic Pain in children with oncology: improve diagnostic, treatment; -Improving the management of MDR-TB patients with lung/gut microbiota monitoring and manipulation; -The research of the biological properties of microorganisms classified by the World Health Organization to the list of "priority pathogens" that are the most threatening human health and the development of means of combating them; -Forensic diagnosis of mechanical trauma using technology systems to process digital images; -Spatio-temporal organization of walking in men under performance of motor and cognitive tasks in Normal and Pathological states; -Mini-invasion methods of diagnostics and correction of innate treatises for children; -The role of the hydrogen sulfide system in the pathway mechanisms of metabolic and functional disorders in various organs and systems; perspective of correction; -Genetic factors in the development and treatment efficacy of asthma and comorbid pathology; -Genetic factors in the development and treatment efficacy of COPD and comorbid pathologies; 532 / 880 -Microbiome and antibiotic resistance in patients of different COPD groups during and between exacerbations; -Role of genetic factors on the level of proinflammatory cytokines in healthy smokers. Role of the smoking cessation protocols on the level of smoking cessation and blood levels of proinflammatory cytokines; -Study of genetic, clinical, psychological, pharmacological, correlative associations in pathogenesis of development of comorbidity of obstructive pulmonary diseases (asthma, COPD) with cardiovascular diseases; -Personalization of treatment of the patients with obstructive pulmonary diseases (asthma, COPD) and cardiovascular pathology with genetic, clinical, psychological, correlative associations and drug-drug interactions; -Aspects of quality of life monitoring, physical and psychological health and rehabilitation program at chronic obstructive pulmonary disease (COPD) and asthma patients; -Efficacy of implementation of quality of life monitoring, physical and psychological health and rehabilitation program at the patients with coronary artery diseases after revascularization; -Creation of wide sustainable clinical research network for monitoring regional antimicrobial resistance; -Micronutrient, metabolic and genetic determinants of sarcopenia in patients with liver cirrhosis; -Physiological and hygienic assessment of the peculiarities of the adaptation of children, adolescents and youth to the conditions of education in modern educational institutions and the scientific basis of university hygiene: psychophysiological and psychohygienic support for mental health and well-being promotion among pupils and students; -Oncopathology in women of reproductive age, thе diagnosis and prevention; -Metabolic syndrome in women with endocrine pathology, thе diagnosis and prevention; -The modern features of prevention of the great obstetric syndromes; -Search and study of new drugs with anti-inflammatory and anti-inflammatory activity; -4-D simulation of the maxillofacial components interaction. Areas of Activity

• Biomaterials • Proteomics, metabolomics, nutrigenomics • Diagnostics - Equipment and accessories • Life sciences related activities • Drug screening & delivery • Medical devices • Medical research • Pharmaceutics

Marketplace Opportunities REQUEST Looking for partners for R&D collaboration We are looking for partners for R&D collaboration. We are looking for potential investors interested in the cooperation for research new drugs, products and medical technologies. PROJECT COOPERATION Looking for partners for cooperation in EU projects We are highly interested in collaborating and partnering with researchers, universities, laboratories, pharmaceutical and other companies interested in the same fields of investigations. We have expertise working in preclinical, laboratory and clinical research, and in international collaborations. PRODUCT The natural metabolites derivatives - new antihypoxyc and actoprotective compounds with wide spectrum of actions and low toxicity Many challenges for the modern person (increasing number of disasters and stressful situations, the 533 / 880 deterioration of the environmental situation due to pollution of the environment with industrial and radiation waste, need to maintain efficiency and fulfill the goal in all conditions, professional activity in any climatic zone) also the process of rehabilitation after suffering severe diseases, professional activity in any climatic zone , ability to sport higher achievements stimulate to research active substances for improvement of physical and mental efficiency. New compounds - natural organism metabolites and benzimidazole derivatives showed actoprotective (improvement of physical and mental efficiency), nootropic, neuroprotective, antihypoxic effects in previous experiments. Actoprotectors are metabolitotropic drugs with wide list of indicatios: in sport medicine , in complicated conditions (different temperatures); in general medical practice - in the treatment of internal, surgical, infectious, skin, in neurology, psychiatry, gynecology, dentistry, with acute poisoning; in military medicine (in hot climates, highlands, radioactive radiation); in medicine of extreme conditions; at asthenic states of different nature (with neurasthenia, somatic diseases, in the pre- and postoperative period), fatigue . The new compounds are interested because of wide spectrum of potential clinical usage and low toxicity.

534 / 880 NeroFermento srl

Organisation

Country Italy City Ravenna Street Via Romea Nord, 246 Web http://www.nerofermento.it/

Person

Name Stefano Silvi Partner

Organisation Nero Fermento is an innovative company born from the love for the land that meets technology. It stems from the collaboration between two well-established companies in the agro-food industry: a farm dedicated to the production of garlic of Voghiera PDO, and a company engaged in the field of renewable energy and environmental solutions for the development of technologies aimed at ensuring the sustainability of production processes. Nero Fermento expresses the ideal synergy between quality farming and technological research, to enhance the excellence products of our country, 100% made in Italy. NeroFermento produces black garlic thruough the natural fermentation of Voghiera Garlic PDO under closely monitored conditions, without additives, preservatives or yeasts, in controlled humidity and temperature for at least 60 days. Our "Nero di Voghiera" black garlic it's not only sapid and tasty, with umami notes, balsamic, acid and sweet but also easier to digest, rich in amino acids. It has almost seventeen times the amount of antioxidants when compared to our White Garlic. Several studies have shown that black garlic can improve cholesterol levels, reduce inflammation and may prevent colon cancer. That's why NeroFermento is collaborating with the University of Ferrara to develop and produce nutraceutical products, from the powder as well as pills. We are developing black shallots and black onions as well. Areas of Activity

• Manufacturing & process engineering • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PRODUCT

535 / 880 Nero di Voghiera - Italian black garlic products We are developing powders and pills as nutraceutical products PROJECT COOPERATION Nero di Voghiera - Italian black garlic products Looking for partners to develop super foods based on black garlic as well as nutraceutical products

536 / 880 Netminds

Organisation

Country Italy City Arzano Street Via Atellana 25 Web www.netminds.it

Person

Name Leonardo Lettieri Ceo

Organisation Webagency founded by a young and innovative team in 2000 with the aim of offering unique solutions with great added value for customers. In 2016 it founded Meangrip, a spin off dedicated to the development of videogames. To become a leader in research and development in the field of IT products such as web applications, applications for mobile devices (iOS, Android, Windows Phone), videogames, virtual audio-guide systems, virtual, augmented and mixed reality with Microsoft Hololens. Areas of Activity

• Consulting services • Virtual reality applications • Packaging & labelling • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT HOLONET by Microsoft HOLOLENS HoloNet is an application for Microsoft HoloLens©, developed for museums to enrich the emotional experience and the perception of visitors through the “Mixed Reality”. This technology allows you to visualize real objects as 3D holograms, giving the possibility to interact with them in the surrounding environment through specific commands (gesture tracking, eye tracking and voice commands). The goal is to enhance the edutainment, which is a form of entertainment that aims both to educate and to entertain, as playful learning becomes essential to the pleasure of learning.

537 / 880 Neuraxpharm Italy

Organisation

Country Italy City Ascoli Piceno Street Via Piceno Aprutina 47 Web www.fb-health.com

Person

Name Francesca Marchetti Business Development Manager

Organisation Neuraxpharm Italy, formerly known as FB Health, is a pharmaceutical company based in Ascoli Piceno, Italy, part of a multinational group of companies focused in CNS. Such Group is a strategic combination of leading and experienced European pharmaceutical companies with outstanding development, manufacturing and sales capabilities focused on CNS. The product portfolio includes branded CNS products, INN generics and nutraceuticals. Additionally, the Group also manufactures finished dosage forms (FDFs) and niche active pharmaceutical ingredients (APIs) in the CNS and the respiratory areas. Areas of Activity

• Chemicals & APIs • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PRODUCT Nutraceuticals in CNS addressing unmet medical needs Neuraxpharm Italy has developed a broad range of nutraceuticals for the prevention and treatment of pathologies affecting the CNS. The nutraceutical pipeline, derived from food sources but with health benefits that go beyond nutritional value, positions itself as adjuvant for cognitive and vascular disorders, anxiety, insomnia, depression and pain. PRODUCT Gx, Gx+, Biosimilars, Innovative products in the CNS Neuraxpharm Group is looking for innovative products, generics, super-generics and/or biosimilars to add to its product portfolio both for the Italian market and for other EU market.

538 / 880 Nextage S.r.l

Organisation

Country Italy City Genoa Street Web https://nextage-on.com/

Person

Name Lorenzo Ottonello Business Development Manager

Organisation Nextage provides its expertise in designing effective and efficient tools, especially in the field of: •Hospital resource allocation, planning & optimization •Smartphone based solution •Web applications •Computational and data intensive applications (Cloud and Big Data) Nextage research activities in healthcare systems are headed towards two main objectives: •the perspective of the personalized medicine concept. The company envisions a new concept of medicine, designed and developed around the individual; •the supporting technologies, for huge data acquisition, storage and analysis. VISION We believe in innovation, communication and efficient processes. We realize smart solutions in complex environments to make relations easier. MISSION To offer added value services in the Information and Communication Technology market, with a particular focus on solutions for health care. Our values are well summarized by the claim "innovation made easy". Areas of Activity

• Bioinformatics, Big data analytics • EPR, Clinical/healthcare management • Consulting services software • eHealth, mHealth, telemedicine • Project proposals support services • Life sciences related activities • IT Applications for Health • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT Colibri Colibri is a cloud-based platform for management of chronic patients comprising of a mobile 539 / 880 application for patients and a web application for healthcare professionals. It is focused on creating and strenghtening the relationship between the patient and his doctor. The Web Application is designed for healthcare professionals to set the personalized therapy and monitor the patient. It uses a logic of alert and limits aimed to give clear indications to the patient and receive immediate feedback on the trend of the pharmacological therapy. The mobile application is conceived to enhance the adherence of the therapy by using the following features: •physical therapy management (drugs, reminder) •controls (physiological parameters, visits) •diet&food (calories, diet) •physical activity In addition, alert, reminder, limits and goals help the adherence to a "tasks" established by the healthcare professional. The product also entails advanced functions, as image processing, predictive analytic and automatic document translation PARTNERSHIP Strategic consulting for new product development We intend Software development as a fullstack development focused on web and mobile applications using innovative technologies. We provide services for analysis, design, development and deployment/management of the infrastructure. Our staff is selected with the following skills: functional analysts; backend/ frontend developers; ux/ui designers experts in cloud solutions / aws; experts in big data solutions and technologies; Linux system engineers; Sql and no sql db. We are currently involved in the development of a Software Analytics platform in cooperation with 3M Italia and following this successfull engagement we are keen to find any other potential opportunities. SERVICE IT Governance IT Governance means maintaining high levels of performance of IT processes and systems in relation to business priorities, managing risks that threaten information flows to support operations and protect company know-how. We have a dedicated business unit (senior security consultants, junior security consultants, senior legal consultants) that can support you throughout the entire IT governance improvement path (business decision, preparation, audit, maintenance) with the following consulting services: Lead Auditor ISO/IEC 9001 Lead Auditor ISO/IEC 27001 Lead Auditor ISO/IEC 20000 Lead Auditor ISO/IEC 22301 CBAP – Business Analyst Certifications ITIL v3 Foundation ECDL – IT Security Certification COBIT Data Protection Management System 44001 Auditor

INVESTMENT OPPORTUNITY SurgiQ Among the innovative projects Nextage holds shares in, SurgiQ is the most ready for investment and currently setting up a seed round. SurgiQ is a web platform that uses Artificial Intelligence to revolutionise the way healthcare is planned 540 / 880 and delivered. It brings a positive impact on patient outcome and waiting time, healthcare provider operations and its costs. Among the values the users appreciate the most there are its unique and comprehensive approach to data collection and auditing, its ease of use and effectiveness in supporting day by day activities. The startup is in its scale up phase. It managed about 40,000 patients in 2017 in Italy and demonstrated 12-15% savings in a pilot in a large hospital in London. SurgiQ raised a € 300k pre-seed in 2017 and it is now looking for a € 500-600k seed round (of which 100-200k is committed) at a pre-money of € 2.5M. Money will be used mostly to support operations & expand in the UK market, where the 20+ ongoing negotiations will be converted in at least 3-4 projects in the next 9 months. The company already incorporated SurgiQ Ltd, which is now an approved vendor for the UK government on the G-Cloud 10 digital procurement framework, dramatically lowering barriers to market entry. Key investments will be in establishing a UK team and in developing integrations with key UK vendors to enable integration, speeding up market uptake. SurgiQ already started discussions with UK VC funds to sustain global scale-up with a large series A once traction in UK is demonstrated. Market presence in Italy has been consolidated through a distribution agreement signed with one of the Top 3 health IT vendors, leading to a number of ongoing joint bids and tenders. SurgiQ is a R&D intensive company and is currently going to boost its AI engine with a € 100k research grant obtained trough a regional research fund in Italy. Further investments will speed up research and help foster partnerships which are currently seeing SurgiQ involved in regional and national program for health startups. The company have been also selected as one of the 4 scale-up fostered by the BioUpper program, and thanks to this it is now building up its AI offering together with IBM. For further information please liaise with SurgiQ CEO: [email protected] SERVICE Research Program Definition and Management Nextage is an innovative SME that to date obtained and managed public grants on collaborative research projects ranging from 30k€ up to about 2M€. Our expertise includes grants funded by pharma companies, local and regional government, national government and the EU. We also developed a strong expertise in Pre-Commercial Procurement tenders (PCP). On most of such projects, Nextage also delivered all or part of the technical activities. We can support companies of any size to identify new research opportunities (public funded grants) and fulfill applications, both from a fundraising and a technical perspective. Nextage helps its clients identifying the content and ideas which are ready and appropriate for funding, scouting on both regional, national and EU research grants. Then it can prepare the grant proposal and support the client in the submission process and if required manage it once granted.

PARTNERSHIP Research projects to develop scalable applications for health Nextage proposes its expertise and is searching for partners in Italy and abroad to carry our research and development projects in the field of life science. The end-user applications we are targeting are in the domain of healthcare data exchange and business intelligence. Technology we’re interested and expert in are mobile health, big data & analytics. We also look for partners to develop blockchain projects

541 / 880 NIB Biotec srl

Organisation

Country Italy City Turin Street

Person

Name Sergio Occhipinti CEO

Organisation The founders of NIB biotec srl are authors of a patent concerning the use of urinary molecules as biomarkers for prostate cancer. The main activity of NIB biotec srl is focused on the development of a low cost device to detect these molecules. This device would represent a new screening test for prostate cancer. In general, the company will work on research, analysis, validation of molecules for medical use. Moreover, the activities will be focused on research, development, validation, production and distribution of medical devices for in vitro diagnostic. Areas of Activity

• Biosensors • Medical devices • Biotechnologies (Pharma&Medical Devices) • Diagnostics IVD • Medical research

Marketplace Opportunities PRODUCT Innovative device to detect urinary molecules as for the screening of prostate cancer NIB biotec srl will provide an innovative device, based on scientific evidences, to detect urinary molecules as for the screening of prostate cancer. Applications: The company offers products and services in the field of in vitro diagnostic. Reference market: Products are referred to public and private healthcare facilities and medical offices.

542 / 880 NIS Materials srl

Organisation

Country Italy City Bologna Street

Person

Name Marco Marchetti CEO

Organisation NIS Materials is a company that deals with research, development, production and marketing of active ingredients for the industry based on biomaterials, photocatalytic materials, nanotechnologies and advanced biomaterials obtained with innovative bioinspired derivation process system set by NIS. NIS Materials is divided into 2 divisions: NIS PRODUCTION, is the division that deals with the development, production and sales of NIS products, while NIS LAB is the R & D division of NIS Materials and deals with scientific research in the field of advanced materials and nanotechnologies, studying and putting in place, in addition to the synthesis process, also potential applications and their implementation in production processes in order to transfer their properties and functionalities in products and end products or to find new properties due to synergistic effect . Areas of Activity

• Biomaterials • Other

Marketplace Opportunities

SERVICE NIS LAB: Research, development, prototyping and scale-up of new materials and processes NIS Materials offers prototyping and development services for new products and production processes on customer request, designed and developed according to their needs. Through the NIS LAB division, a laboratory entirely dedicated to the design and development of new materials and processes with appropriate equipment and expertise, NIS Materials independently performs research activities developing new materials or technologies that can be introduced or integrated into production processes and in new products / applications to offer to companies in specific sectors, in particular for the development of biomaterials, inorganic materials, bio-composites and biohybrids, biocompatible coatings and drug delivery systems and antibacterial active ingredients. The services offered are as follows: - Chemical research applied on behalf of third parties with search for solutions designed for customer

543 / 880 needs - Development of new products, new technologies developed by themselves and offered to customers - Study of alternative solutions to improve products and especially production processes by studying ad hoc integration in the production process of a customer product in order to improve the properties of the product itself -Industrial scalability of products / processes developed and full support for the technological transfer of the customer PRODUCT NACTIVE - Nis antimicrobial action inorganic oxidative system NIS Materials has developed a proprietary technology for bacterial abatement called NACTIVE (Nis Antimicrobial aCTion Inorvanic oxidatiVE system) that has labeled a series of materials that NIS Materials produces and sells, used as antibacterial active ingredients that can be included in a wide range of applications and matrices for use as a coating or in bulk for the self-sanitizing treatment of surfaces and artefacts that require this feature over time NIS materials are innovative both for their process of obtaining and for their structure and type of material from which they derive the characteristics of greater efficiency compared to competitors. First of all, the materials developed by NIS Materials are obtained through a specific process put in place by NIS of Bioinspired derivation which allows to obtain products through processes that only use water and pressure temperature without resorting to toxic and dangerous solvents. The innovation lies in the fact that through this process it is possible to obtain materials that are unique in terms of features and functionality. Moreover, all the materials obtained are of micrometric dimensions and despite this, they are able to have higher efficiencies compared to nanometric materials. This also determines an absence of real or potential toxicity to the environment and to humans both by product and by process.

544 / 880 Nordtext

Organisation

Country Latvia City Riga Street Brivibas iela 40-19 Web http://www.nordtext.com

Person

Name Katrīna Šole Head of Life Sciences

Organisation Nordtext is a specialist language services provider for life sciences industries. Our commitment to quality, use of cutting-edge technologies and a network of linguistic experts covering 34 therapeutic areas, has earned Nordtext a strong reputation among CROs, medical device manufacturers and pharmaceutical companies worldwide. Areas of Activity

• Life sciences related activities

Marketplace Opportunities SERVICE Language solutions for Life Sciences companies Document translation Editing/ proofreading/ verification Interpreting Terminology management Desktop Publishing Website translation Software localisation E-learning and Training translation services

545 / 880 Norwegian University of Science and Technology, Faculty of Medicine and Health Sciences

Organisation

Country Norway City Trondheim Street Olay Kyrres gate 9 Web https://www.ntnu.edu/

Person

Name Mara Diaconu EU Project Developer

Organisation Norwegian University of Science and Technology (NTNU) is Norway’s largest university with almost 40 000 students, 6700 employees where 4000 hold teaching and research positions. With a strong merit within the Horizon 2020 programme NTNU is a significant participant with several coordinated projects. NTNU hosts the Kavli Institute for Systems Neuroscience, four national centres of excellence and elite, seven centres for research-based innovation, as well as a wide range of research schools. The Research Group on Geriatrics (GeMS), Movement and Stroke is part of the Faculty of Medicine and Health Sciences and it runs cross-disciplinary research and clinical trials as well as mechanism studies for movement control, falls prevention studies, method studies and epidemiological studies. The group is responsible for well-equipped movement laboratories, has access to a usability laboratory, and has highly competent staff with extensive research and clinical competence regarding age-related decline in function, physical activity and activity monitoring, and assessment of balance and gait in different populations. The main researchers of the group are: Jorunn Helbostad, Torunn Askim, Beatrix Vereijken and Artur Serrano. The Cardiac Exercise Research Group (CERG) is part of the Faculty of Medicine and Health Sciences and aims to define optimal exercise programs for everyday people in order to increase the likelihood of development and preservation of good health throughout life. The Faculty of Medicine and Health Sciences is located in the fully integrated St. Olav University Hospital and has an integrated practice, which provides convenient access to patients and locations for running clinical research studies. Areas of Activity

• Bioinformatics, Big data analytics • Surgery technologies and applications • eHealth, mHealth, telemedicine • Virtual reality applications • Genetics & Genomics • Project proposals support services • Medical research • IT Applications for Health

546 / 880 • Physiotherapy, Orthopaedic technology • Life sciences related activities • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT Personal Activity Intelligence (PAI) tracker for health (healthy and active people, heat and stroke patients, dementia patients, fraile population) PAI is short for Personal Activity Intelligence. You earn PAI points every time your heart rate increases: The higher heart rate, the faster you earn PAI. Our research shows that persons who achieve 100 PAI or more every week live for an average of almost five years longer than others. PAI is based on the only thing that reflects the intensity of your activity, namely your heart rate. Everything you need to do in order to use PAI is to measure your heart rate continuously. PAI is integrated in the Apple Watch and other activity tracker devices. If the score on your wrist reads 100 or more, you are probably physically active enough. If it reads less than 100, you could reduce your own health risk by exercising more. Better than today's recommendations PAI considers your age, your gender, your resting heart rate and your maximum heart rate. In other words, PAI is not based on the number of steps you walk or how many minutes of physical activity you perform each day. Those measurements do not consider the intensity of the activity, which could make PAI a more accurate and attractive activity standard to decide if you exercise enough. More about it here: https://www.ntnu.edu/cerg/personal-activity-intelligence PROJECT COOPERATION Healthy ageing and rehabilitation Research and scientific cross cutting expertise in cross-disciplinary research and clinical trials as well as mechanism studies for movement control, falls prevention studies, method studies and epidemiological studies. Focus and expertise: - particular focus on use of technology to monitor and enhance movements and the use of welfare technologies for people with dementia. - Motor control, development, and learning - Movement problems in children and older adults - Developing exergames for active, healthy ageing and rehabilitation - Development of health technology solutions to promote active ageing - Movement disorders and falls at old age - Measurement and interventions related to balance, gait and physical activity Development of mobile health technology solutions for promotion of movement Prof. Beatrix Vereijken and Prof.Jorunn Helbostad, Department of Neuromedicine and Movement Science: - partners in the EU Project Farseeing http://farseeingresearch.eu/ - FARSEEING aimed to promote better prediction, identification and prevention of falls with a focus on ICT devices and the unique proactive opportunities they can provide to older adults to support them in their own environment. FARSEEING has been recently selected by the European Commission as one of the top 3 most influential and high-impact projects of the last 11 years in the field of ICT for Active and Healthy Ageing, and the most successful consortium leading to groundbreaking results to improve the understanding and management of falls (see the report available here, p.101). Moreover, two of the project results, have been recognized as 'key innovations' by the Innovation Radar of the European Commission (http://publications.jrc.ec.europa.eu/repository/bitstream/JRC96339/jrc96339.pdf). - Coordinators for the H2020 PreventIT project http://www.preventit.eu/ - Help young seniors to stay 547 / 880 active and healthy with the use of mobile technology. Mobile technology can be used to activate and motivate people, and is especially powerful when tailored to an individual’s needs, challenges, and barriers. The project will finish this year in December. - National funding - Exergaming for active healthy ageing and rehabilitation https://www.ntnu.edu/ health/exergaming PARTNERSHIP Dementia patients - welfare and new technologies Virtual reality and Augmented reality are becoming affordable and technically sound options for large scale implementations. A field of interesting application is dementia care. Our welfare technology, neurology and ageing group at NTNU is interested in pursuing and shaping an H2020 proposal in this area. Interest and expertise - Immersive virtual reality environments for dementia patients - Serious games integrating advanced therapies for Alzheimer's Projects in implementation: - Coordinator: SENSE-GARDEN - Virtual and memory adaptable spaces creating stimuli for the senses in ageing people with dementia (AAL Programme 2016) - Partner: eWARE - Early Warning Accompanies Robotics Excellence (AAL Programme 2016) Expert in the field: Artur Serrano, Professor in Welfare Technology, Department of Neuroscience and Movement Science, Faculty of Medicine and Health Sciences, NTNU; Adjunct Professor at the Norwegian Centre for eHealth Research, University Hospital of North Norway PARTNERSHIP Social robots for healthcare In our previous work we have identified how different perceptions of care robots varies depending on the inter-personal connection a human has with the humans of whom she/he takes care. From the caregiver side, it has been raised questions of what will happen to the “warm hands” of care, when cold, mechanical – but precise – robot hands “replace” human care workers. Or as we define it, supplementing human practices. Building on results of the EU-funded project VictoryaHome (www.victoryahome.eu) which received the prize for best Active and Assisted Living project AAL Award 2015, and connecting to the ongoing project SENSE-GARDEN (www.sense-garden.eu), both with Prof. Serrano as PI, this WP will investigate the human nature of the work being “replaced/supplemented,” by participating in planned case studies with welfare robots, especially targeting care-workers and their perceptions of the nature of human work vs. the nature of robot work. Priority will be a hot topic in the care sector as the valuation processes associated with automation by introducing technology/robots, probing the question of how does the "hierarchy" of values change when technology, people, priorities and tasks are reversed? There is capacity pressure in all areas of the healthcare sector. Hospitals are struggling with max capacities. The risk of deaths and complications rises rapidly when the occupancy passes roughly ninety percent. It sucks a lot of resources and hospitals are materially not equipped with the "fire wave." They have dared to start talking about prioritization, but have not come to prevention even in relation to demographic developments. The municipal services want even more advocates to talk about prioritization. Projects in implementation -COORDINATOR - Horizon 2020 MSCA RISE 2018 - LIBEFOTS Exchange - LIFEBOTS Exchange - creating a new reality of care and welfare through the inclusion of social robots. Previous participation in FP and H2020 TEAM-HOS (Coordinator) Methodology and Tools for World-best Teamwork in Hospitals Project ID: IST-1999-11567 Funded under: FP5-IST

548 / 880 Funding scheme: CSC - Cost-sharing contracts PERSONA (Activity line coordinator) Perceptive spaces promoting independent aging Project ID: 045459 Funded under: FP6-IST Topic(s): IST-2005-2.6.2 - Ambient Assisted Living (AAL) in the Ageing Society Funding scheme: IP - Integrated Project PARTNERSHIP Cardiovascular diseases and physical activity The Cardiac Exercise Research Group (CERG) aims to define optimal exercise programs for everyday people in order to increase the likelihood of development and preservation of good health throughout life. The group consists of eminent scientists, technicians, medical doctors and promising research talent from all over the world who are studying the effect of exercise as a medicine in order to treat heart and lifestyle related diseases. In 2011 CERG achieved the prestigious honour of becoming a K.G. Jebsen Center for Medical Research. CERG is localised in the fully integrated St. Olav University Hospital and has an integrated practice, which provides convenient access to patients and locations for running clinical research studies. Professor Ulrik Wisløff leads the group. https://www.ntnu.edu/employees/ulrik.wisloff Dr. Wisløff is the inventor of the Personalized Activity Intelligence (PAI), a simple metric, which calculates how much weekly physical activity one needs to prevent disease and early death. The PAI app is free and available in all app stores.

549 / 880 Novassay SA

Organisation

Country Switzerland City Lausanne Street BIOPOLE Route de la Corniche,4 CH-1066 EPALINGES Web http://www.novassay.com

Person

Name Deepak Kotak Chief Business Officer

Organisation Novassay is a privately owned, Swiss-based Biotechnology company established in 2013. Novassay is pursuing drug development programs of small molecules in Neuropathic Pain and antibodies in Oncology where calcium ion channels are playing a pivotal role. Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Peptides, proteins & antibodies preparation • Pharmaceutics

Marketplace Opportunities PARTNERSHIP Novassay SA Neuropathic Pain Opportunity Novassay is seeking a pharma/biotech partner for the development of a novel gabapentinoid for neuropathic pain that has demonstrated analgesia and a lack of brain penetration avoiding brain mediated adverse effects in the gold standard neuropathic pain animal model demonstrating pre- clinical proof of concept. Novassay now seeks a partner to advance the lead compound through GLP/ Tox and Phase I studies. PRODUCT Small molecules and antibodies in pain and oncology Novassay is developing small molecules acting on the calcium voltage-gated ion channel for neuropathic pain and ion channel antibodies in oncology. The lead product is a gabapentinoid acting on the α2δ-1 subunit of the calcium channel that is upregulated in the spinal cord in chronic neuropathic pain. Unlike the present incumbents, this molecule is peripherally restricted and does not penetrate the brain and therefore avoids brain related adverse effects of dizziness, falls, somnolence, nausea, weight gain, concentration and memory 550 / 880 difficulties, the risk of abuse, suicide risk and dependence. NVA1309 addresses key areas of unmet need for safer and better-tolerated analgesics. Ion channels are increasingly becoming recognised as new therapeutic targets in oncology. The α2δ-1 subunit has been shown to be overexpressed in a number of cancers and Novassay holds IP for both calcium and sodium channel antibodies in oncology INVESTMENT OPPORTUNITY Novassay Series A Novassay is seeking a €5m Series A round to advance its lead small molecule in neuropathic pain through GLP/Toxicology and Phase I development. There is strong pharma interest after phase I and attractive exit metrics in a short timeline. -NVA1309 potential to be BEST IN CLASS in the $5Bn neuropathic pain drug market -Only non-brain penetrating analgesic -Low developmental risk compared to drugs for new molecular pain targets -Positive pre-clinical proof of concept in best animal model highly predictive of success -NVA1309 is highly specific and more potent in binding than Pregabalin the market leader -No competition for the same molecular target -Novassay owns 100% of the Intellectual Property and the patents run to 2035-7 -Management has deep industry drug development experience -Scientific Advisory Board are world leaders in pain research and clinical studies -Well defined low cost of advancing NVA1309 into the clinic -EXIT 3/4 YEARS -Venture capital returns for lower than normal drug development risks

551 / 880 NuMat Medtech

Organisation

Country Spain City Palma Street Europa Building 2nd floor - Parc Bit Web http://www.numat.es

Person

Name Antonio Caldentey CEO

Organisation Biomed company engaged in the development of coatings based on natural molecules for medical applications, like dental and orthopaedic implants Areas of Activity

• Biomaterials • Biotechnologies (Pharma&Medical Devices) • Medical devices

Marketplace Opportunities INVESTMENT OPPORTUNITY Fundraising of €1.1M to support Co-development projects with two global implant manufacturers NuMat is looking for a €1.1M to carry out preclinical biocompatibility studies of two of our coatings addressed to orthopedic and dental implants. We are working with two industrial partners based on an MTA agreement to apply our coatings on their implant technologies. We closed a financing round on Q3 2018 of €530K and we are looking for additional funds of €1.1.M for the Q3-Q4 of 2019. PRODUCT Multifunctional coatings for dental and orthopedic implants NuMat Medtech is developing medical coatings with the aim of achieving better features for implants such as the reduction of infections and inflammation, tissue regeneration around the implant, modulation of the osseointegrative properties and reduction of risk rejection. Above-mentioned characteristics make the biocoatings potentially appropriate for titanium implants and other metal alloys. These technologies can be used in patients with poor bone quality (diabetes, osteoporosis) and are using natural biomolecules that are stable, cheap and easy to obtain. All that features give NuMat's technology a clear competitive advantage and open a window of opportunity to develop an outstanding product to solve unmet needs and to be addressed for the segment of premium implants. 552 / 880 PARTNERSHIP Multifunctional coatings for dental and orthopedic implants NuMat Medtech is developing medical coatings with the aim of achieving better features for implants such as the reduction of infections and inflammation, tissue regeneration around the implant, modulation of the osseointegrative properties and reduction of risk rejection. Above-mentioned characteristics make the biocoatings potentially appropriate for titanium implants and other metal alloys. These technologies can be used in patients with poor bone quality (diabetes, osteoporosis) and are using natural biomolecules that are stable, cheap and easy to obtain. All that features give NuMat's technology a clear competitive advantage and open a window of opportunity to develop an outstanding product to solve unmet needs and to be addressed for the segment of premium implants.

553 / 880 Nuovaray s.r.l.

Organisation

Country Italy City Bologna Street via Battindarno 147 Web http://www.nuovaray.it/

Person

Name Prince Amewoyi Technical Assistance

Organisation The Nuova Ray s.r.l. Was founded in 1993 by the association of a group of companies with 20 years of experience in the electronics and electro-medical industry. The knowledge and the spirit of innovation have enabled us to be the leader in the electronic semi-finished products for medical and aesthetic use, delivering to our customers with reliable quality products and comprehensive support services, just to ensure the final result and consolidate the partnership. The project start from 1Mhz to 5Mhz autotuning module. Which solves the problem of head-change in case of problems with one normally used (it can be replaced without having to tune in frequency) Our main production of semi-finished products consists of tuned power modules and oscillating module for ultrasonic equipment, power modules for radio frequency devices, ultrasonic processing heads (frequencies between 1Mhz, 1.5Mhz, 2Mhz, 3Mhz, 5Mhz) and accessory electronic cards such as Sequencer (for multi-head machines), interface card (for connectivity and panel piloting), demo display card (to simulate the machine's functionality at design time) and the software supplied in case of Supplying power modules with interface board. Our electro-medicals are the result of specific research by our engineers who have been following the market for several years with the aim of developing ever more secure, efficient and functional innovative products. Areas of Activity

• Electromedical and medical equipment (non diag)

Marketplace Opportunities SERVICE Customer service Customer support during design, prototype realization, industrialization. Customization of all product components, including packaging and container. PARTNERSHIP REQUIRED PARTNER/S Manufacturers of Ultrasound and Radio Frequency 554 / 880 PRODUCT MARCHIO E PRODOTTI The brand New Ray distinguishes the products developed by the company and designed by its technical team. REQUEST Manufacturers of Ultrasound and Radio Frequency Contact manufacturing companies in the electromedical and aesthetic (ultrasound and radiofrequency) sectors to present our products and the potential of our company

555 / 880 Nuvyta

Organisation

Country Italy City Cologno Monzese Street viale Emilia 83 Web www.nuvyta.com

Person

Name Alice Magni ceo

Organisation We are a startup the does IT applications for the Healthcare. We have a strong knowledge in the Healthcare Clinic and Administrative domain and we are building a new software based on the latest technologies available on the market, having as objective the simplification of clinitians work letting them focus on what really matters: the patient. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Software, ICT applications, system integration • EPR, Clinical/healthcare management software • Medical devices

Marketplace Opportunities PARTNERSHIP SW SYSTEM INTEGRATION Our aim is to become a solid Healthcare Software Vendor. Our System is highly scalable, configurable and integrable by third parties, therefor we are searching for System Integrators who want to partner with us to develop our platform on Hospitals and other Healthcare Providers. Thanks above all to the possibility to customize the software independent of the use of the source code, Nuvyta's strategy is based on the assumption that the offer is conveyed by several partners resulting in a clear division of roles. • The Vendor, Nuvyta, is responsible for developing the product and delivering the software via the client-based cloud platform and selling subscriptions and maintenance • The Partner, on the other hand, takes care of any support for the on-premises installation of the platform's customers and of the personalization services for the final customer, the delivery and the 1st and 2nd level Help Desk PRODUCT

556 / 880 Nuvyta Clinical Platform Nuvyta is an interoperability platform for managing clinical content. • It is Cloud Based, therefore highly scalable, Cross-platform and Multi-Databese • It is based on a standard data model FHIR (Fast Healthcare Interoperability Resources) expandable and persistent on secure and performing storage in database NoSQL document viewer and patient events • Has a workflow Configuration Environment for customizing the platform's behavior in managing patient care pathways • It has a web development environment including monitoring dashboards for development, test and production environments, which allow a strong personalization of the tool without the need to write code.

557 / 880 OACP

Organisation

Country Italy City Bologna Street Viale Fanin 48 Web www.oacp.it

Person

Name Enrico Di Oto CEO

Organisation We produce and sell chemicals to reduce the time and costs of the genetic diagnostics test for cancer. Areas of Activity

• Biotechnologies (Pharma&Medical • Laboratory equipment, reagents, software Devices) • Diagnostics IVD • Diagnostics - Equipment and accessories • Genetics & Genomics

Marketplace Opportunities

PARTNERSHIP Market penetration and expansion We are looking for selling partners in the EU, South America and Russia INVESTMENT OPPORTUNITY Opportunity We are looking for a qualified investment to expand our activities and to scale faster.

558 / 880 Oaklins Arietti S.r.l.

Organisation

Country Italy City Bologna Street Via Marsala, 9 Web https://www.oaklins.com/it/en/

Person

Name Marco Mobrici Director

Organisation Oaklins Arietti has been doing deals differently, successfully advising strategic and financial investors on the origination, structuring and financing of cross-border deals. By merging into Oaklins, the world’s most experienced mid-market M&A advisor, our esteemed local professionals now have access to 700 global professionals, actively cooperating in dedicated industry teams in 40 countries worldwide. Oaklins’ trusted senior advisors have the skills and experience to ensure the best results for our clients, whether at home or abroad. Oaklins always involves industry specialists, takes a global view and leverages our deep local connections. With specialists in M&A advisory, ECMs and strategic finance teams, the Oaklins way is to make a difference for every client on every deal. Areas of Activity

• Consulting services • Project proposals support services • Investments • Other

Marketplace Opportunities SERVICE M&A Advisory > Mergers We work alongside the ownership of companies by prioritising and providing accurate evaluations. Our international reach allows us to identify potential foreign buyers allowing sellers to avoid disclosure of sensitive data to local competition. We manage the transaction from the initial moment to the closing. > Acquisitions Thanks to our global presence, we are able to identify the appropriate targets by approaching them locally. We specialise in midmarket acquisitions, providing advice to customers in all phases of the transaction, from its strategic definition to closure. SERVICE

559 / 880 Grants Advisory > Financing from International Financial Institutions We assist our clients in accessing financing from International Financial Institutions, such as the European Investment Bank and the World Bank System, which provide debt and grants for R&D, international expansion and restructuring. > Concessional Finance We support our clients in accessing grants from Governments and Public Institutions for specific projects, such as innovation and internationalization. In particular, we support clients in accessing grants from Horizon 2020, the framework program of European Commission for R&D, as alternative way of fundraising. > Restructuring and Business Planning We provide significant value in analyzing and executing complex projects, devoting attention to industrial dynamics. PROJECT COOPERATION European Funds & Grants - Horizon 2020 Participation to selected calls, in particular by supporting all type of companies in: - proposal writing - partners search - negotiation with programme bodies - project management and coordination - dissemination and communication - financial and administrative reporting - all the aspects needed for the project implementation Ref.: SME Instrument, Fast Track to Innovation (FTI), European Investment Bank (EIB), European Investment Fund (EIF), COSME, LIFE, CIP Ecoinnovation, Intelligent Energy Europe (IEE), Regional Operation Programmes (ROP), National Funds.

560 / 880 Oli-fit Ltd

Organisation

Country Malta City Qawra Street Web http:/olifit-naturalremedies.com

Person

Name Manuele Biazzo Director Oli-fit Limited

Organisation Oli-fit is producing natural cosmetic remedies starting from a green manufacturing process that is not involving the use of any chemical solvents. Moreover the active ingredients are extracted materials classified as '' waste'' . The company is perfectly inserted in the green economy and bio-economy sector. Areas of Activity

• Biomaterials • Nutraceutics, probiotics, functional food, cosmeceutics • Life sciences related activities

Marketplace Opportunities PRODUCT Natural remedies for skin diseases My idea was based on producing cosmetic products without the addition of any chemical additives. Basically my cosmetics are based only on active ingredients and also during the manufacturing process no chemicals have been used. This process obviously is protected by a patent. However I would like to extend the patent and to include different findings. Thanks to this green technique the final customer will have a product that for sure is safe and it is very effective as the concentration of active ingredients is well balanced. In the cosmetic sector there is a strong tendency into diversification of a product, so mainly with one ingredient (having 1 activity) is it possible to formulate several products. My approach is different also in this case. In fact the molecular mechanism behind different skin problems like: ‘’aging’’, psoriasis complications, eczema complications, burns, sun irritation….is always 561 / 880 the same. My targets is a class of proteins called ''heat shock proteins'' that are involved in all these processes and also the inflammation and oxidation pathways. For this reason I decided to produce 1 natural cream that is acting on a molecular base that is common in different pathologies. Moreover the stability of the product is very high and the risk of microbial contamination is null (as there is no water). This product is 100% made in Italy and all the raw material are processed in a way of ‘’ kilometre zero’’ meaning that everything has been collected and processed in the same place. For the moment I placed on the market only 1 product (however I have other 3 ready to be launched following the same manufacturing technique): CLO’’’. This product is made only by olive oil, beeswax, nettle leaves liphophilic extract, lavender essential oil and zinc oxide. As you can easily understand by the ingredient list the anti-oxidant and anti-inflammatory activity of the product is very high. Moreover this formulation showed a tremendous increase of the proteins involved in the stress response (and in the aging process) HSPs . This family of proteins is lost during aging process and with the cream you are able to restore the normal rate of expression of these proteins. INVESTMENT OPPORTUNITY Seeking for Investment into a green extraction process that will provide a 100% natural products and also a 100% natural manufacturing process We are looking for investors in the development of our concept and our technique. We think that a natural product should be produced also by a natural technique. In particular we do not use any chemical solvent to extract our active molecules and we use also materials classified as '' waste''. This technique has a great potential of diversification and up to know without a small investment we were able to place on the market already 1 product that it starts to show its potential and the satisfaction of clients for the technique behind it. PARTNERSHIP Partnership in distribution of a real natural product, with no additives The '' green'' cosmetic sector is growing and to find a real natural product is always more difficult. What Oli-fit is offering is a range of products produced by a natural extraction process that is not generating any waste and it is not using any solvent. Moreover the final INCI will be based only on active ingredients and no more that 5 ingredients in total. We would like to implement a strong distribution channel and we are open to any interesting partnership. Moreover we would like to renew our patent including in it new discoveries. Our products are producing incredible results that we monitor through clinical observations but we would like to have some real clinical trial now that we accumulate all the observation needed to have a clear idea on the final effect.

562 / 880 Omini Pharma srls

Organisation

Country Italy City Vigante - Milan Street Monzese 6 Web www.ominipharma.it

Person

Name Gabriele Omini CEO

Organisation Omini Pharma srls is a new start-up innovative company, based near Milan, Italy, specialized in the complete service for the pharmaceutical company and our specialization is on the developing new Medical Devices according to Directive 93/42 CEE and Food Supplements (2002/46/CEE). Our CRO is specialized in the clinical studies for Medical Device according to ISO 14155 and MEDDEV 2.7.1. With same attention and quality standards we also turn clinical trials for Dietary Supplements of high clinical impact. As CRO we can help you on developing the opportune protocol design and we can accompany you in the total development of your clinical trials. All members are habilitated to conduct monitoring visits for Pharmaceutical products. To help you, please find the list of Our Principal Services: - Developing new formulations for Medical Devices and Food Supplements - Advices for preparing Technical Files - Regulatory support and industrialization advices - CRO for pre-clinical and clinical trials - Post market vigilance and surveillance - Market placement and research of partners Areas of Activity

• Consulting services • Medical devices • CRO (Contract Research Organisation) • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PRODUCT Fillergyn MD Menopause and the correlated hormone unbalance, markedly modify the physiology of vaginal ecosystem. The early hallmark sign of hormone insufficiency is atrophic vaginitis, resulting in thinning and inflammation of vaginal walls with vaginal dryness and burning, vulvar pruritus, watery vaginal discharge, urgency and urinary incontinence, discomfort during intercourse, etc. Because vaginal 563 / 880 atrophy is attributable to estrogens deficiency, it may occur most often after menopause but it can also develop in premenopausal women who take antiestrogenic medications or who have medical or surgical conditions which may decrease levels of estrogens. Up to 40 % of postmenopausal women may experience symptoms of vaginal atrophy however, despite the prevalence of symptoms of vaginal atrophy, only 20-25 % of symptomatic women seek medical attention, therefore it is important to underline that atrophic vaginitis may be considered an overlooked and under diagnosed condition. Moreover the treatment of vaginal atrophy will not only alleviate the symptoms but also the possible vaginal infection. Indeed, the thinning of endometrium and the increased vaginal pH, induced by estrogens decline, may result in vaginal and urinary tract infections and mechanical weakness. Adequate estrogens replacement by pharmacological therapy may alleviate existing symptoms and therefore it has been considered the gold standard therapy for long time. However, more recently, a large clinical trial (The women’s health initiative) comparing the efficacy of estrogens plus progestin treatment versus placebo in 16608 menopausal women, “was stopped early, after a mean 5.6 years of follow-up, because the overall health risks of hormone therapy exceeded its benefits.” Taking into account all the above mentioned facts, it is self-evident that a non-pharmacological treatment may have an important impact in the therapy of atrophic vaginitis. Omini Pharma developed a CE mark medical device based on a vaginal gel containing hyaluronic acid (HA), methyl sufonyl methane (MSM) and tea three oil (TTO); this composition is also patented by EU patent N° 1444984. HYALURONIC ACID is a well known poly-saccharide which is present in most body tissues and particularly in loose connective tissue, urogenital organs including. In the female and male urogenital organs HA is distributed in a selective way, in particular in female urogenital organs, HA content is high in the vagina and urinary bladder. At the present, HA has reached predominance in aesthetic medicine where it is now the injectable dermal filler of choice for most cosmetic physician. The rational behind HA for skin rejuvenation is to fill the interstitial space and, with his highly hydrophilic structure and his rheological property, HA retains water and therefore more volume. The undoubted HA capacity to increase tissue volume and tissue hydration associated with its adhesion capacity to vaginal mucosa are the bases for restructuration and filling of vaginal tissues. The safety of HA administration is largely known both from its extensive use as injectable filler in aesthetic medicine, and also from a large use in viscosupplementation therapy, resulting one of the most common used intra-articular injected compound in osteoarthritis. MSM is a natural compound involved in the sulphur cycle in the nature and represents, with other MSM-like compounds, almost the 85% of the body sulphur. MSM is largely used in several nutrition supplements, but in this medical device MSM plays a double role. In one hand, the well known potent radical scavenging activity of MSM may help in destroying free radicals released during inflammation. On the other hand, we have demonstrated a potent antagonistic effect in vitro against hyaluronidases, the enzymes involved in the catabolism of HA, and therefore the combination of HA and MSM will potentiate the efficacy of HA. TTO is a natural and highly purified extract of Melaleuca alternifolia oil which is probably the most natural antibacterial and antimycotic product used. Within the antibacterial spectrum of TTO, its activity has been demonstrated also against the vaginal anaerobic bacteria and Candida albicans. As for MSM, TTO shows a double effect, the antibacterial and antimycotic activity will be useful against vaginal pathogens whose infection, as already stated, is favoured in atrophic vaginitis. Moreover the antibacterial activity will again prevent HA degradation by bacterial hyaluronidases. The Medical Device has been tested in a clinical trial at the University of Trieste (IRCS Burlo Garofolo, Trieste, Italy, in press) showing an excellent efficacy and tolerability. The results obtained in this double-blind placebo controlled trial clearly showed the efficacy and the very good tolerability of the 4 weeks vaginal treatment with this new medical device containing HA, TTO and MSM on a total of 36 post-menopausal patients. REQUEST MD distributor we are looking for a distributor for our MD already CE marked in IIA class

564 / 880 PRODUCT food supplements for women - Fillergyn Bone is a new generation food supplement which is using natural highly purified active compounds with, hormone modulating activity and supporting the anti-osteoporosis action. - Fillergyn Silver Lady is a new generation food supplement which is using natural highly purified active compounds with, hormone modulating activity and estrogenic stimulator action. - Fillergyn Lady Mind is a new generation food supplement which is using natural natural highly purified active compounds stimulating the CNS helping the cognitively ability, concentrate capacity and memory. - Fillergyn Night Lady is a new generation food supplement which is using natural highly purified active compounds with, hormone modulating activity and supporting the restore a good sleeping and consequently to reduce the anxiety. - Fillergyn Relief is a new generation food supplement which is using natural highly purified active compounds with anti-inflammatory, hormone modulating activity and CNS activities. - Fillergyn La vie en Rose is a new generation food supplement which is using natural highly purified active compounds supporting anti-inflammatory, anti-bacterial actions and pain modulating. - Fillergyn No Dol is a new generation food supplement which is using natural highly purified active compounds supporting anti-inflammatory, anti-bacterial actions and pain modulating action. - Fillergyn Vagicream is a new generation of cosmetic cream which is using natural highly purified active compounds that lead on supporting anti-inflammatory, anti-bacterial actions and pain modulating action. PRODUCT Food Supplement lines: Silver Age Office Worker Relief Hard Worker Relief Women Sport Athletes Ophthalmic Orthopedic Dysmetabolism Protein Bars and Special Food PARTNERSHIP MD distribuor we are looking for distributor for our MD (fillergyn)

565 / 880 Omnes

Organisation

Country France City Paris Street 37-41 rue du Rocher Web https://www.omnescapital.com/en/our-business/ venture-capital/ntic-and-biotech-venture- capital.html

Person

Name Claire Poulard Associate

Organisation With over € 700 million under management, Omnes is helping innovative, up-and-coming start-ups to create the leaders of tomorrow INVESTMENT STRATEGY: Establish minority shareholdings in innovative up-and-coming businesses with tremendous growth potential In EU-based countries Two target sectors: tech and health sectors (Biotech and Medtech) Different investment stages: Series A rounds, Series B rounds Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Investments • Pharmaceutics

Marketplace Opportunities INVESTMENT OPPORTUNITY Venture Capital With over € 700 million under management, Omnes is helping innovative, up-and-coming start-ups to create the leaders of tomorrow. We invest both in Biotech and Medtech startups based in EU countries.

566 / 880 OPHERA srl

Organisation

Country Italy City CAMPOGALLIANO Street via Ronzoni n°7 Web http://www.ophera.it/

Person

Name Luisa Pecorari R&D Director

Organisation OPHERA s.r.l is a company with a cutting-edge scientific profile which researches and develops top- quality formulas and natural active ingredients for personal care and other industrial applications. The company operates also as a partner and/or consultant for companies seeking innovative biological, biomedical and biotechnological solutions. Areas of Activity

• 3D Printing/addictive manufacturing for • Project proposals support services biomedical applications • Medical devices • Biotechnologies (Pharma&Medical Devices) • Diagnostics - Equipment and accessories • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PROJECT COOPERATION PATENT: NEW BIOMARKERS PANEL FOR EARLY AND NON INVASIVE DIAGNOSIS (NEW APPROACH)

In the last few years, my company has supported a multidisciplinary team of researchers that has focused on an innovative diagnostic approach and we just tabled a patent application. Our idea is based on an applicative concept that can be very useful in the early diagnosis of sub- clinical situations (both pathological and stress-related). By combining this specific biological language with advanced molecular biology techniques and innovative technologies, it would be possible to realize new devices able to promote a more early interpretation of health status (and, in the case of application in zootechnic, improve animal performance). Our approach is not invasive, extemporaneous, painless and it doesn’t interfere with the spontaneous 567 / 880 status of the subject: just passively detects signals and transfer a specific signal alert. To get to this achievement, we have invested several years and resources and today we can offer a very promising and innovative opportunity to a qualified company interested in co-investments new approaches for early diagnosis. (Further details are available under the signature of a secrecy agreement). PROJECT COOPERATION new approach for early diagnosis and optimization of the management practices for well-being In the last few years, my company has supported a multidisciplinary team of researchers that has focused on an innovative diagnostic approach and we just tabled a patent application (Biomarkers for early and not invasive diagnosis of infectious disease). We are looking for a partnership with a specialized company in the field of diagnosis to strength the R&D process of this concept and to more effectively explore the possibility to develop a new device. Our approach could lead to a to facilitate the early diagnosis of few diseases and optimize management practices for well-being.

568 / 880 OPIS Srl

Organisation

Country Italy City Desio, MB Street Via Matteotti 10 Web http://opis-europe.com/

Person

Name Anita Ghirardi Marketing Manager

Organisation OPIS is a European clinical CRO providing premium support for the management of global clinical trials from phase I to IV as well as pre- and post-marketing medical device investigations. Founded in 1998, the company has 20 years of extensive experience in a wide range of therapeutic areas. Its recent oncology/immuno-oncology portfolio amounts to over 400 trials. OPIS’s strength lies in its people and its specialized teams who assist clients from A-Z with medical writing, scientific and statistical consultancy for trial design and skilled teams of operational staff across Europe that ensure high quality project execution. The OPIS e-clinical suite is developed to streamline digitalization of clinical data. Fully FDA 21 CRF Part 11 compliant and developed in close collaboration with the OPIS biometry and clinical operations units it offers: •CLINICAL.NET, a modular and extremely user-friendly platform to handle all clinical trial data •A consolidated platform to handle named-patient programmes digitally •An investigator toolkit to facilitate and coordinate patient and clinician participation in clinical trials. With flexible business models, OPIS clients come first and offers are truly shaped around individual Sponsor needs. The OPIS teams are passionate about what they do and OPIS wants its name to stand for excellence. Areas of Activity

• CRO (Contract Research Organisation) • Medical research • Life sciences related activities

Marketplace Opportunities SERVICE Clinical trail support Tailored clinical trial services for phase I-IV trials in a wide range of therapeutic areas including oncology and rare disease indications. Specialized in trial start-up, data management and e-clinical solutions

569 / 880 PARTNERSHIP Clinical trial management Partnerships with Pharma, Biotech, Medtech or Nutraceutic companies for drug, device or product development in clinical stage.

570 / 880 Optimad Engineering srl

Organisation

Country Italy City Torino Street Via Giacinto Collegno 18 - Optimad Engineering Web www.optimad.it

Person

Name Marco Cisternino Product Developer

Organisation OPTIMADEngineering srl develops software for fluid dynamicsanalysis, design and optimization. The company has been founded in 2006 by a group of researchers in fluid mechanics and design optimisation, enjoying since then the status of being a Spin-Off of the Department of Mechanical and Aerospace Engineering of the Politecnico di Torino. OPTIMAD can offer expertise and solutions for Life Sciences in: Computational Fluid Dynamics (CFD) (simulation of biological fluids) Fluid-Structure Interaction (biological fluids and soft tissues, air and lung, ...) Rarified gases (vacuum technolgies,...) Geometrical Morphing (support to the design of prosthesis, identification of sugical surfaces,...) Optimal Control and Shape Optimization (vascular prosthesis design support,....) Growth Models in Complex Geometries (tumor growth simulations in real geometries) Turbomachinery (pumps, compressors,aspirators, central vacuum systems, dialysis machines,,...) Design of experimental test benchfor in vitro simulation of vascular flud dynamics (silicone vessels models design, flow measurement systems,...) Areas of Activity

• Consulting services • IT Applications for Health • Diagnostics - Imaging equipment and processing • Software, ICT applications, system integration • Surgery technologies and applications

Marketplace Opportunities PROJECT COOPERATION CFD Shape Optimization Under Uncertainty for Medical Devices ABSTRACT: Computational Fluid Dynamics (CFD) is an attractive tool in the development process of any device subject to a fluid flow. CFD allows to test design candidates numerically, reducing prototyping costs and development time. Furthermore, CFD can be used within an automated design process in order to find a (set of) optimal design(s) compliant with the project specifications. However, realising and testing many designs can be an unaffordable task. 571 / 880 OPTIMAD offers to vascular prosthesis and medical devices (pumps, compressors, aspirators, vacuum technologies) designers and manufacturers a complete, user-friendly and integrated work-flow targeting shape optimization and parameter space exploration through CFD simulations. TECHNICAL SPECS: By integrating multi-fidelity CFD solvers, shape parametrisation techniques and optimisation algorithms with uncertainty propagation in a High-Performance Computing framework, our work-flow ensures time-efficient execution of the task, with considerable cost reduction of the entire design process. Within the open architecture of this work-flow, application-specific tools can be easily integrated in order to address multi-disciplinary design optimisation. CURRENT STAGE OF DEVELOPMENT: This work-flow is already on the market and can be customised according to user-specify needs. OWN CONTRIBUTION: OPTIMAD developed not only the whole tools integration, but implemented an original geometry parameterisation tool and uncertainty propagation methods. INNOVATIVE ASPECTS AND MAIN ADVANTAGES * a highly automated CFD shape optimization under uncertainty work-flow * minimal and intuitive set of information provided by the end-user * budget-constraints customized optimization runs TYPE OF PARTNER SOUGHT * vascular prosthesis designers and manufacturers * medical devices designers and manufacturers * medical devices research institutions PRODUCT Morphing technologies for prosthesis With advances in both medical imaging and computer programming, it becomes easier and easier to get three-dimensional (3D) virtual models that represent a patients’ own anatomy. As a consequence, digital modelling patient compliant prosthesis is an attractive tool for surgeon and prosthesis manufacturers. OPTIMAD has developed a suite of numerical tools for manipulating and morphing of geometrical models. Geometrical constraints can be easily introduced by the user during the workflow. The tools are entirely developed by OPTIMAD and they can be customized or extended for application-specific purposes. Natural applications of the suite is: * personalized prosthesis design on scanned data * shape optimization under constraint of aesthetic/medical prosthesis * physical based deformation of bio-prosthesis during simulations The know-how, the experience and the software are at “on the market” stage of development, thus OPTIMAD is looking for * technical partners interested in the introduction of the morphing tools during their design/analysis workflow * research teams involved in biomedical projects * biotech companies developing numerical applications

572 / 880 Panakes Partners SGRSpa

Organisation

Country Italy City Milano Street Via Ruggero Boscovich 31 Web www.panakes.it

Person

Name Alessio Beverina Partners

Organisation Panakes Partners is a Venture Capital investor that finances medical companies, early stage startup and SMEs, with extremely promising products and great ambition, in Europe and Israel. Thanks to its strong entrepreneurial and financial experience the team provides more than capital,and aims at working together with entrepreneurs to develop successful businesses as an active and well-connected investor. Panakes also has strong relationships with selected industrial partners to help companies to accelerate their development. Areas of Activity

• Medical devices • IT Applications for Health

Marketplace Opportunities INVESTMENT OPPORTUNITY Venture capital Panakes Partners is Venture Capital firm dedicated to early stage investments in healthcare in Europe and Israel

573 / 880 PANTECNICA SpA

Organisation

Country Italy City Rho Street Via Magenta 77/14A Web www.pantecnica.it

Person

Name Sergio Comino Key Account Medical Technology

Organisation Technical and application consultancy, development and supply of anti-vibration systems and engineered sealing systems for any kind of fluids with certified manufacturing processes and compounds. Areas of Activity

• Biotechnologies (Pharma&Medical • Laboratory equipment, reagents, software Devices) • Medical devices • Diagnostics - Equipment and accessories • IT Applications for Health • Electromedical and medical equipment (non diag) • Manufacturing & process engineering • Pharmaceutics • Other

Marketplace Opportunities PRODUCT Pantecnica Medical Technology Engineered sealing systems in thermoplastic compounds for any kind of fluids (for medical devices and internal medicine), with certified manufacturing processes and materials. INNOVATIVE ASPECTS AND MAIN ADVANTAGES High-performance plastics (such as: PTFE, PTFE compounds, PEEK, PPS, PEI, PE, Moldflon®) in medical engineering. Engineered solutions fit for the most demanding conditions in numerous applications that guarantee medical progress and optimal treatment results while maintaining cost effectiveness. MARKET APPLICATION Medical devices and internal medicine special devices ; such as color-coded PTFE tubings, Tube modules, Trocar tube, seals for piston pumps, ventilation tubes, friction bearings, diaphragms, porous PTFE. PRODUCT

574 / 880 Sealing Systems Sealing Systems & Components in thermoplastic compounds & elastomers for any kind of fluids (medical devices and internal medicine), with certified manufacturing processes and materials. SERVICE Technical and application engineering consultancy Technical and application engineering consultancy for the design, development, production and supply of systems and components for fluid sealing systems and components with certification of materials and process systems.

575 / 880 PCI Pharma services

Organisation

Country United Kingdom City Bridgend Street Web https://pciservices.com/

Person

Name Anne Bouchet Business Development Clinical services

Organisation PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market. With facilities in North America and Europe, PCI supports pharmaceutical and biotech companies with products destined for more than 100 countries around the world. PCI provides services for each stage of the product lifecycle – from early Phase I through commercial launch and long-term supply – and partners with customers to provide key insight and expertise in enabling successful commercialization and bringing lifesaving medications to patients Areas of Activity

• Biotechnologies (Pharma&Medical • Packaging & labelling Devices) • Pharmaceutics • CMO (Contract Manufacturing • Medical devices Organisation) • CRO (Contract Research Organisation) • Manufacturing & process engineering • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE clinical manufacturing and packaging solutions, Storage & Worldwide Distribution Our global Clinical Trial Services include: •Pharmaceutical Development Including Highly Potent Molecules •Clinical Trial Manufacture Including Highly Potent Molecules •Phase I aseptic processing •Schedule 8 & 9 Phase I drug manufacturing •Clinical Packaging and Packaging Design •Primary Packaging •Secondary Packaging 576 / 880 •Specialty Product Packaging •Clinical Supplies Management •Clinical Planning and Support •Project Management •IVRS-IWRS •Qualified Persons (QPs) •Support Services •Data Access

577 / 880 PHARM - PHARMACEUTICAL RESEARCH MANAGEMENT SRL

Organisation

Country Italy City Lodi Street Via Einstein, SNC - Loc. Cascina Codazza c/o Parco Tecnologico Padano Web https://pharmsrlcom.wordpress.com/

Person

Name Mariapaola Felisi Trial Administration

Organisation PHArmaceutical Research Management (PHARM) SRL is a private enterprise established in 2011 with the mission of stimulating and facilitating Pharmaceutical Companies to invest in neglected therapeutic areas (i.e. paediatrics, rare disorders, advanced therapies). PHARM SRL acts as an interface between public and private sector offering experience and support in all management, organizational, strategic, regulatory, biostatistics, methodological aspects of drug research development, in compliance with applicable regulations and GXPs. PHARM SRL is registered as SPONSOR and Contract Research Organization (CRO) for clinical trials of medicinal products; Areas of Activity

• Consulting services • Regulatory affairs, validation • CRO (Contract Research Organisation) • Life sciences related activities • Medical research • Pharmaceutics

Marketplace Opportunities SERVICE Regulatory applications Translational services for Pharma Industries willing to introduce regulatory and technological innovations (advanced therapies, biologics, orphan drugs and paediatric drugs); Preparation of dossier for Orphan Designation; Preparation of the Paediatric Investigation Plan (PIP); Support the request for “Scientific Advice” and “Protocol Assistance“ SERVICE Planning and coordination of GCP clinical trials Design and draft of the clinical protocol; Developing informed consent/assent forms 578 / 880 Design of Case Report Form; Data management; Development of monitoring plans Administrative and budgetary management; Clinical Trial Applications for all phases of the clinical research of a product; Preparation/review of Standard Operating Procedures

579 / 880 Pharma & Biotech Advisors srl

Organisation

Country Italy City Milano Street Via Placido Riccardi 19

Person

Name Paolo Barbanti CEO

Organisation We are a management consulting firm that helps clients to solve their toughest problems in strategy, operations, organization and change. Our work is helping life sciences and med-tech companies drive an industry evolution through improved R&D productivity and drug safety, sales and marketing excellence, and growth in increasingly complex organizations.We help technology companies to transform into sharper, better versions of themselves, delivering better value for patients, fueling innovation and reducing the cost and complexity of health systems in today's evolving market. We invest significant resources in building knowledge, accumulating experience in technology assessment and transfer, in product management and launch of new products on the marketplace and establishing partnerships between companies. We see it as our mission to bring this knowledge to our clients.We do this to help build internal support and get to real issues advising firms on opportunities in licensing, alliances, portfolio management, and emerging therapeutic areas and technologies. Because R&D pipelines and the search for the next blockbuster are essential to continued strong performance, we help clients develop sound R&D strategies.What we do:Identification of new business opportunities, new products / technologies / services in the life sciences and med-tech sector, their evaluation and their transferCorporate and growth strategyMarket researchNew product definition, design and implementationScouting of new products, licensing and integration in the marketplaceMarket strategy implementationAlliances and Joint VenturesTechnology and commercial transfer from universities and International centres of excellence Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Medical devices • Consulting services • eHealth, mHealth, telemedicine • Investments • Medical research

Marketplace Opportunities SERVICE

580 / 880 Managing consulting for life sciences and med tech companies We help technology companies to transform into sharper, better versions of themselves, delivering better value for patients, fueling innovation and reducing the cost and complexity of health systems in today's evolving market. We invest significant resources in building knowledge, accumulating experience in technology assessment and transfer, in product management and launch of new products on the marketplace and establishing partnerships between companies. We see it as our mission to bring this knowledge to our clients. What we do: Identification of new business opportunities, new products / technologies / services in the life sciences and med-tech sector, their evaluation and their transfer Corporate and growth strategy Market research New product definition, design and implementation Scouting of new products, licensing and integration in the marketplace Market strategy implementation Alliances and Joint Ventures Technology and commercial transfer from universities and International centres of excellence

581 / 880 Pharmacell

Organisation

Country Turkey City Ankara Street Camlica Mahallesi 149. Sokak Regnum Ticaret Merkezi 16/B-2 06200 Yenimahalle, Ankara, Türkiye Web http://www.pharmacell.com.tr/

Person

Name Ali Uyar Business Development Manager

Organisation Pharmacell is a Turkish medical company founded in 2010 The company is interested in importing cutting-edge medical devices, innovative medicine and cosmetics and exporting medicine, cosmetics and medical devices. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Vaccines • Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • Electromedical and medical equipment (non diag) • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PRODUCT Nasal Aspirators for Babies The aspirators used to easen the respiration of the baby, so that the baby can sleep without any unnatural interruptions and can breathe easier in daily activities. The nasal aspirator prevent babies to have dermatological problems emerged because of harsh use of ordinary aspirators. Also, it contributes decreasing the effects of the ear infection, sinus infections or coughing. -Provides quick solutions to respiration problems of babies -Can be bought by the clients easily since they do not have the requirement of prescription. -Went through numerous lab tests, there is no side-effects -The lab tests highlighted the effectiveness of the product. -Does not include cortisone or steroids, perfectly healthy -Softer product surface 582 / 880 -Changeable leads, increased hygiene -Highly hygienic packaging PARTNERSHIP Partnership for Distribution Our firm has a wide business network and years of experience in marketing and sales of products within the health industry. Also, our firm has different references from other companies on marketing their products. If any partnership is planned, the references will be provided. REQUEST Innovative Medicines, Medical Devices, etc. We are looking for innovative products for Turkish market.

583 / 880 PharmaPrime

Organisation

Country Italy City Rome Street Via flaminia 71 Web https://www.pharmaprime.it

Person

Name Luca Buscioni CEO & CO FOUNDER

Organisation PharmaPrime is the first European on-demand platform that enables customers to receive pharmaceutical, para-pharmaceutical, cosmetic and veterinary goods, at the lowest prices, from top- rated local pharmacies in 40 minutes. We are partnered with the biggest pharmaceutical companies and insurance companies.

PharmaPrime allows pharmacies to acquire new customers without cost in logistics, marketing or technology infrastructures. Pharmacies directly receive the customer order and payment from PharmaPrime. They gain the opportunity to learn about para-pharmaceutical and cosmetic products consumer preferences through reports generated by PharmaPrime platform. Customers can choose any in-stock product with discretion and ease. For medicines that need a doctor’s prescription, The Pharma Man (messenger) will pick up the prescription either by the customer or by the doctor and deliver it to the pharmacy to withdraw the products. He then delivers them to the customer, according to the selected time and address indicated on the website. Throughout the process, customers can track their purchased products in real time through the PharmaPrime platform.

We take into account the multiple issues that surround pharmaceutical companies, in regards to the final step between a business and consumer transaction. We provide innovative marketing and selling channels, using our web platform, our dedicated call center, and our delivery service. Customers will never go without a question unanswered.

Our medication/refill reminder is supported by a dedicated customer care staff. We give companies the possibility to follow and support patients during their health journey. Areas of Activity

• Analytical and characterization services • Life sciences related activities • Bioinformatics, Big data analytics • Software, ICT applications, system • Biotechnologies (Pharma&Medical integration Devices) • EPR, Clinical/healthcare management • Drug screening & delivery software

584 / 880 • eHealth, mHealth, telemedicine • Other • Investments • Medical devices • Pharmaceutics • IT Applications for Health • Regulatory affairs, validation

Marketplace Opportunities SERVICE Medicine delivered in 40 minutes PharmaPrime delivers medicine to your home or office within 40 minutes from the online purchase order or at the time of your convenience. It is online in Rome, Milan, Turin, Genoa and Bologna, 365 days a year from 8 am to 12 pm. On an online platform it is possible to order medicines, para pharmaceutical and cosmetic products choosing from a 2 million products catalog, instead of the 5000 products that are normally available in a single pharmacy.. Communicate with your pharmacist online, so no questions go unanswered. PharmaPrime brings the pharmacy to your doorstep with comfort, convenience and care. INVESTMENT OPPORTUNITY PharmaPrime: a great reason to invest It is an opportunity for investors to expand an innovative company with the potential to grow into a global market. We have netted 110,000 euros in 2018 alone. We have already developed trusted partnerships with some of the biggest and most desired pharmaceutical companies in the world such as Bayer, Angelini, Danone, and UCB. We have also secured a partnership with Walgreens to expand our business in Spain and France. We are interested in expanding our company in Tel-Aviv. The most important and respected companies have noticed and want to be a part of our business, allowing us to form a clear and concise exit strategy.

585 / 880 PI and BI Srl

Organisation

Country Italy City Empoli Street Via Fidippide 20 Web https://www.piandbi.com

Person

Name Matteo Piccini CEO

Organisation PI and BI provides complete and integrated Smart Sensing Solutions for multiple, temporary or permanent, needs about monitoring and real-time detection, from the most basic and widespread (Smart Air, Soil, Water and Weather) to the most advanced and pervasive (Smart Energy, Lighting and Parking) up to larger and more complex scenarios (Smart Agriculture, City and Industry). Areas of Activity

• Manufacturing & process engineering • Software, ICT applications, system integration • IT Applications for Health

Marketplace Opportunities PRODUCT Smart Air Smart Air is the full-integrated Smart Sensing Solution for real-time Air Quality Indicative Parameters (shown in the table below) monitoring, according EU Directive 2008/50/EC and WHO Air Quality Guidelines. Temperature (-40 ~ +85 °C / ±1 °C) Humidity (0 ~ 100% RH / ±3% RH) Pressure (30 ~ 110 kPa / ±0.1 kPa) Illuminance (0 ~ 400.000 Lux / ±1 Lux) Ultraviolet Radiation (0 ~ 15 UVI / ±1 UVI) CO (0 ~ 500 ppm / ±1 ppm) CO2 (0 ~ 5000 ppm / ±50 ppm) O2 (0 ~ 30% / ±0.1%) 586 / 880 O3 (0 ~ 20 ppm / ±0.015 ppm) NO (0 ~ 250 ppm / ±0.5 ppm) NO2 (0 ~ 20 ppm / ±0.1 ppm) SO2 (0 ~ 20 ppm / ±0.1 ppm) NH3 (0 ~ 100 ppm / ±0.5 ppm) CH4 (0 ~ 100% LEL / ±0.15% LEL) H2 (0 ~ 1000 ppm / ±10 ppm) H2S (0 ~ 100 ppm / ±0.1 ppm) HCI (0 ~ 50 ppm / ±1 ppm) HCN (0 ~ 50 ppm / ±0.2 ppm) PH3 (0 ~ 20 ppm / ±0.1 ppm) C2H4O (0 ~ 100 ppm/ ±1 ppm) Cl2 (0 ~ 50 ppm / ±0.1 ppm) C4H10 (50 ~ 5000 ppm) C6H5CH3 (1 ~ 30 ppm) CH3CH2OH (1 ~ 5000 ppm) V.O.C. (30 ~ 400 ppm) PM 1, PM2.5, PM10 (0.4 ~ 17 μm) Smart Air, such as all our Smart Sensing Solutions, is supplied by an all-inclusive (hw/sw) monthly-fee formula and can be widely customized, to meet the specific monitoring or detection needs of each specific scenario (both indoor and outdoor), as well as easily integrated with other infrastructures or automation systems (PAC/PLC) already present or later installed.

587 / 880 Plusimple srl - App that simplify your Health -

Organisation

Country Italy City BARI Street Viale Beata Elia 204 Web http://www.plusimple.com

Person

Name Claudio Piccarreta CEO

Organisation Plusimple is an innovative, with social vocation startup that provides simple, secure and organized health communication. Nowadays more and more users are looking for direct contact with professionals and healthcare facilities before and after a medical examination. Current statistics show that: 51% of citizens have used at least one online healthcare service (Healthcare Innovation Observatory 2016, School of Management of the Politecnico di Milano), 52% of patients communicate online with their doctor; 72% of patients prefer to receive online feedback (Philips Future Health Study 2016) Patients often use WhatsApp, Facebook, and online forums to resolve their doubts or update their doctor about exams and treatments, risk losing important information, obtaining incomplete responses and disseminating personal data without any protection. Professionals find themselves having to collect disordered information from different sources and try to avoid requests invading their privacy by reaching them at any time and across any communication channel. Plusimple is the online platform designed to meet the specific needs of the world of health. Always accessible from any device through web browser or mobile app, it offers physicians, medical professionals and healthcare providers an effective solution to increase their visibility on internet and interact with patients, associations and colleagues in an organized and secure manner. All information and messages exchanged with patients and colleagues come from a single channel of communication, Plusimple platform, reduce information and time leakage. The professional-patient relationship is mediated by Plusimple, by shifting communication on a single source, invading privacy on private channels and relieving pressure on the professional. All nursing care professionals automatically access the same information shared by the patient, shortening the evaluation timing, and being able to face directly through internal messaging with colleagues. Plusimple is always with the patient before the visit, with the possibility to request and exchange 588 / 880 documents and information useful to the preparation. During the visit with communications and summaries on prescribed prescriptions and therapies, shared with all the CareTeam. After visiting with updating on patient evolutions and planning for subsequent care activities. Plusimple allows you to communicate with colleagues and patients via computers or apps, by utilizing a web tool specifically designed for healthcare. Areas of Activity

• Analytical and characterization services • Software, ICT applications, system • Bioinformatics, Big data analytics integration • Diagnostics - Imaging equipment and • EPR, Clinical/healthcare management processing software • eHealth, mHealth, telemedicine • Other • Medical facilities furnishings, equipment, • Medical devices goods • IT Applications for Health • Pharmaceutics • Life sciences related activities

Marketplace Opportunities PRODUCT Digital Health Communication Platform for health/commercial/marketing/ technological purposes. Plusimple is a web and mobile app aimed to support communication in healthcare. We're searching for partners to exploit this solution and add more improvements as to reach new benefits and metrics. Plusimple can helps Patients Associations, Health Departments, Hospitals and professionals to improve communication and engagement with the health stakeholders. Plusimple is an innovative platform that actually yet connects public and private health facilities, patients associations and patient in the same virtual place. Imagine to have on your pocket a complete platform to communicate with health professionals, community on your health needs, communicate with facilities and patients associations. We actually work with National Patients Associations such as Fedemo (hemophiliac patients) and their 34 associations, AICCA (national Heart disease patients association), and other patients associations. Plusimple is used actually by health professionals, Private Health centers and Public Health Departments. Partners purposes: -Use: exploit Plusimple as stable solution with patients and health professionals to improve their activities; -Commercial: sell in bundle or alone a new digital solution that help to earn new competitive advantages; -Technological: integrate and work a platform with available API and with general purposes to facilitate communication in healthcare with all the health related stakeholder; -Investments: invest in a native and fully global scalable solution that will lead to globalize healthcare relation. We can receive and give advantages working with: -Health departments such as public and private Hospitals and Health Center; (for clinical and marketing purposes); -National and Local Patients Associations; (for engagement and patients advocacy purposes); -Pharma and health companies ( for marketing and commercial purposes); -National Health Institutions to improve national health delivering and relationship; -Health tech companies (for technological integration and commercial purposes); -Health R&D Center (for clinical and data purposes);

589 / 880 We can work with italian and foreign partners thanks to scalable architecture of Plusimple, for a wider and international network. PRODUCT Plusimple - A new tool that simplify all the healthcare scenario Plusimple improves medical communication . All the information and messages shared with patients and collaborators arrive from only one channel, which is the Plusimple platform, riducing the risk of losing information and time. Each professional that is part of the care team has automatically access to the same information shared by the patient, riducing time of evaluation and improving direct communication thanks to the instant messaging system. The relation between doctors and patients is mediated by Plusimple that, keeping the communication on one source only, avoids any privacy invasion and ease the pressure over health professionals. Plusimple is a web based platform built to meet the specific needs of the healthcare’s world. It is always reachable by web browser and mobile app and it offers to health professionals and medical facilities a smart solution to increase their online visibility and get in touch with patients, associations and collaborators in an organized and safe way. INVESTMENT OPPORTUNITY Plusimple - App that simplify your Health - Plusimple is an innovative, with social vocation startup that provides simple, secure and organized health communication. Nowadays more and more users are looking for direct contact with professionals and healthcare facilities before and after a medical examination. Current statistics show that: 51% of citizens have used at least one online healthcare service (Healthcare Innovation Observatory 2016, School of Management of the Politecnico di Milano), 52% of patients communicate online with their doctor; 72% of patients prefer to receive online feedback (Philips Future Health Study 2016) Patients often use WhatsApp, Facebook, and online forums to resolve their doubts or update their doctor about exams and treatments, risk losing important information, obtaining incomplete responses and disseminating personal data without any protection. Professionals find themselves having to collect disordered information from different sources and try to avoid requests invading their privacy by reaching them at any time and across any communication channel. Plusimple is the online platform designed to meet the specific needs of the world of health. Always accessible from any device through web browser or mobile app, it offers physicians, medical professionals and healthcare providers an effective solution to increase their visibility on internet and interact with patients, associations and colleagues in an organized and secure manner. All information and messages exchanged with patients and colleagues come from a single channel of communication, Plusimple platform, reduce information and time leakage. The professional-patient relationship is mediated by Plusimple, by shifting communication on a single source, invading privacy on private channels and relieving pressure on the professional. All nursing care professionals automatically access the same information shared by the patient, shortening the evaluation timing, and being able to face directly through internal messaging with colleagues. Plusimple is always with the patient before the visit, with the possibility to request and exchange documents and information useful to the preparation. During the visit with communications and summaries on prescribed prescriptions and therapies, shared with all the CareTeam. After visiting with updating on patient evolutions and planning for subsequent care activities. Plusimple allows you to communicate with colleagues and patients via computers or apps, by utilizing a web tool specifically designed for healthcare. PROJECT COOPERATION Plusimple srl - App that improve relationship with your patients and health

590 / 880 professionals. Plusimple is an innovative, with social vocation startup that provides simple, secure and organized health communication. Nowadays more and more users are looking for direct contact with professionals and healthcare facilities before and after a medical examination. Current statistics show that: 51% of citizens have used at least one online healthcare service (Healthcare Innovation Observatory 2016, School of Management of the Politecnico di Milano), 52% of patients communicate online with their doctor; 72% of patients prefer to receive online feedback (Philips Future Health Study 2016) Patients often use WhatsApp, Facebook, and online forums to resolve their doubts or update their doctor about exams and treatments, risk losing important information, obtaining incomplete responses and disseminating personal data without any protection. Professionals find themselves having to collect disordered information from different sources and try to avoid requests invading their privacy by reaching them at any time and across any communication channel. Plusimple is the online platform designed to meet the specific needs of the world of health. Always accessible from any device through web browser or mobile app, it offers physicians, medical professionals and healthcare providers an effective solution to increase their visibility on internet and interact with patients, associations and colleagues in an organized and secure manner. All information and messages exchanged with patients and colleagues come from a single channel of communication, Plusimple platform, reduce information and time leakage. The professional-patient relationship is mediated by Plusimple, by shifting communication on a single source, invading privacy on private channels and relieving pressure on the professional. All nursing care professionals automatically access the same information shared by the patient, shortening the evaluation timing, and being able to face directly through internal messaging with colleagues. Plusimple is always with the patient before the visit, with the possibility to request and exchange documents and information useful to the preparation. During the visit with communications and summaries on prescribed prescriptions and therapies, shared with all the CareTeam. After visiting with updating on patient evolutions and planning for subsequent care activities. Plusimple allows you to communicate with colleagues and patients via computers or apps, by utilizing a web tool specifically designed for healthcare.

591 / 880 PODOACTIVA Italia srl

Organisation

Country Italy City Milano Street Via Cesare da Sesto 11 Web www.podoactiva.com

Person

Name Marta Serrano Valenzuela Head of Development and Marketing Strategy

Organisation We are a biotechnology Company specialized in podiatry and biomechanics, which strives to improve people’s quality of life by improving their gait, applying the knowledge and experience of our multidisciplinary team and technological innovation for the diagnosis, design and manufacture of personalized treatments. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Medical devices • Consulting services • Diagnostics - Equipment and accessories • Physiotherapy, Orthopaedic technology

Marketplace Opportunities PRODUCT Customised insoles for health improvement Podoactiva Italia srl offers the most advanced customised insoles on the market based on one’s biomechanical and anatomical parameters. At present they are used by 250,000 patients and over 2,000 elite athletes. They are designed using proprietary and patented technology employing Artificial Intelligence systems. They are highly effective for prevention and treatment of injuries, sport injuries, for children, senior citizens and everyday life. PARTNERSHIP Healthcare improvement of the population through partnership agreements using advanced insoles for prevention Podoactiva staff are experts in solving pathologies related to the feet or problems resulting from these, such as sports injuries, ailments due to improper foot strike, time-related problems, biomechanical issues of the back or kees or lower limbs, or child podiatry cases. Podoactiva Italia srl looks for medical centres, single professionists, associations of people or 592 / 880 organisations of any kind, insurance companies, willing to sign joint agreements for the promotion of such an added value prevention practice. The company offers a good percentage on collaboration deals. SERVICE Health prevention service for target groups of any age by using customised insoles Podoactiva Italia srl offers the most advanced customised insoles on the market based on one’s biomechanical and anatomical parameters. At present they are used by 250,000 patients and over 2,000 elite athletes. They are designed using proprietary and patented technology employing Artificial Intelligence systems. They are highly effective for prevention and treatment of injuries, sport injuries, for children, senior citizens and everyday life.

593 / 880 Politecnico di Milano - Technology Transfer Office (Profile 1)

Organisation

Country Italy City Milan Street piazza Leonardo da Vinci 32 Web https://www.polimi.it/it/ricerca-scientifica/la- ricerca-al-politecnico/trasferimento-tecnologico/

Person

Name Paola Bagnoli Technology Transfer Manager

Organisation The Technology Transfer Office (TTO) of Politecnico di Milano supports the faculty members, researchers and students in the intellectual property (IP) protection, development and technology transfer of their innovative projects. More specifically, TTO assists anyone at Politecnico who wants to develop and transfer IP (i.e. know-how, patents, designs) or launch a start-up or a spin-off in innovative fields, based on the results obtained from research and teaching activities. TTO proposes several projects developed at Politecnico di Milano in the Life Science area, mainly in the field of cell culture (e.g. bioreactor for mechanical stimulation and stem cells culture, microfluidic devices for drug screening, etc.) and biomedical devices (e.g. drug delivery pumps, devices for assisted surgery and cardiac surgery, etc.). We search for partners interested in patent licensing or research cooperation with the aim of transferring the new technologies to the industrial market. Our Researchers will be available for presenting their projects to companies and funds during B2B and pitches at the Meet in Italy for Life Science. List of Projects (see cooperation profiles for details): Cross-linked gelatin hydrogels Hydrogel capable of containing and conveying cells Electrostatic Micro-pump Lipomodelling Device Eye Tracker Portable electrocardiographic apparatus: ECG pocket Aortic Cannula Apparatus for navigation and fusion of echographic and volumetric images of a patient Miniaturized endoscopic camera. Areas of Activity

• 3D Printing/addictive manufacturing for • Investments

594 / 880 biomedical applications • Manufacturing & process engineering • Bioinformatics, Big data analytics • Medical research • Biomaterials • Life sciences related activities • Biosensors • Software, ICT applications, system • Biotechnologies (Pharma&Medical integration Devices) • Surgery technologies and applications • Diagnostics IVD • Virtual reality applications • Diagnostics - Equipment and accessories • Medical devices • Diagnostics - Imaging equipment and • IT Applications for Health processing • Drug screening & delivery • eHealth, mHealth, telemedicine • Electromedical and medical equipment (non diag)

Marketplace Opportunities SERVICE IP rights We assists anyone at Politecnico who wants to develop and transfer IP (i.e. know-how, patents, designs) or launch a start-up or a spin-off in innovative fields, based on the results obtained from research and teaching activities. PROJECT COOPERATION Various projects Cross-linked gelatin hydrogels Hydrogel capable of containing and conveying cells Electrostatic Micro-pump Lipomodelling Device Eye Tracker Portable electrocardiographic apparatus: ECG pocket Aortic Cannula Apparatus for navigation and fusion of echographic and volumetric images of a patient Miniaturized endoscopic camera.

595 / 880 Politecnico di Torino

Organisation

Country Italy City Torino Street Corso Duca degli Abruzzi 24 Web https://www.polito.it/

Person

Name Ilaria Allora Research programme officer

Organisation Politecnico di Torino was founded in 1906 and has its roots in the Technical School for Engineers created in 1859. It is internationally ranked among the most important universities in Europe for engineering and architecture studies, with 33,000 students (out of which 15% are international students coming from over 100 different countries). Politecnico is a center of excellence for education and research in engineering, architecture, design and planning and it works in close cooperation with the socio-economic system. It is a comprehensive Research University where education and research complement each other and create synergies in order to address the needs of the economic system, of the local community and, above all, of its students. Politecnico is committed to a strong internationalization process of its teaching, research and technology transfer activities: not only does it work in cooperation with the best universities and research centers in world, but it has also been signing agreements and contracts with important international corporations, as well as local businesses, meaning to be for the latter a focal point for innovation. The participation to many international projects allows Politecnico to count on a great experience: in the FP7 Politecnico has more than 230 approved projects with a total EU contribution of 66 million Euro, ranking among the top 200 entities participating in Framework Program. In H2020 Politecnico has already 144 approved projects with a total EU contribution of 50 million Euro. It has a strong experience in project coordination too: the Research Support Department has been involved in the management of EU RTD projects since 1995. Areas of Activity

• 3D Printing/addictive manufacturing for • Electromedical and medical equipment biomedical applications (non diag) • Biomaterials • Other • Biosensors • Medical devices • Biotechnologies (Pharma&Medical Devices)

596 / 880 • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing

Marketplace Opportunities PARTNERSHIP A NANOCONSTRUCT FOR ANTITUMOR THERAPY A novel multifuncitonal nanoconstruct is proposed, constituted by a biomimetic and non-immunogenic shell derived from tumor cells, and a therapeutically-active core, able to generate toxic species against cancer cells. The nanoconstruct is also able to perform diagnostic imaging of the tumor region. The nanoconstruct has high selectivity to target cells, reducing side effects on healthy cells. It provides for the absence of chemotherapeutic drugs no side effects associated with their somministration. It has high biocompatibility, immunotransparency and non-toxicity. The dimensions are nanometric (less than 150-200 nm) and has therapeutic efficacy developed by the nanocrystalline heart that is capable of releasing toxic species only on target cells. Diagnostic imaging occurs thanks to the nanoscale contrast agent property when energized by a suitable UV light source. The nanoconstruct is biodegradable, therefore it shows final dissolution at the end of therapeutic and diagnostic activity. POSSIBLE APPLICATIONS: - Anticancer therapy - Diagnostic imaging of target cancer cells - Possibility to apply it as a antibacterial coating or somministration ADVANTAGES: - Selective - Multifuncitonal offering therapy and diagnosis at the same time - Biodegradable - Biocompatible at the end of its work - Efficaceous - Immunotransparent - Not a drug carrier SERVICE BIOREACTORS & TRANSPORT PHENOMENA The Bioreactors & transport phenomena Unit of the Industrial Bioengineering Group is focused on the development of advanced bioreactors for cell/tissue research, drug discovery, disease modelling, and cell-based regenerative medicine. The research activity combines computer-aided design, fluid dynamics modelling, and biomechanics for the development of easy-to-use bioreactors. The proposed bioreactors are devices designed to provide a cell/tissue-specific in vitro native-like culture environment (perfusion, mechanical and electrical stimuli), online monitoring and automation (Arduino microprocessors), with the final aim to maximize bioprocess efficiency and standardization. POSSIBLE APPLICATIONS: Basic cell/tissue regenerative medicine research Drug discovery Disease modelling Cell-based regenerative medicine ADVANTAGES: Native-like, 3D, dynamic in vitro culture conditions Monitored and controlled culture environment Smart and cost-effective technological solutions Bioprocess reproducibility, scalability, and standardization KEYWORDS: Dynamic cell/tissue culture, fluid and transport phenomena computational modeling, computer-aided 597 / 880 design, tissue engineering, regenerative medicine Services: Customized bioreactor design and development, Customized easy-to-use monitoring and control systems Looking also for Partnership for R&D collaboration in Regenerative Medicine and Microfluidics PARTNERSHIP ROLE OF BLOOD FLUID DYNAMICS IN CARDIOVASCULAR DISEASE, CLINICAL DECISION MAKING, AND CARDIOVASCULAR DEVICE PERFORMANCE The Cardiovascular Bioflows Unit of the Industrial Bioengineering Group is focused on the integration of medical imaging and computational modelling for the study of cardiovascular disease development, diagnosis and treatment. In particular, starting from medical images the blood fluid dynamics is reconstructed using computer-assisted image processing and computational fluid dynamic modeling techniques. Computational tools allow the investigation of challenging and clinically relevant problems and harness the power of biofluid mechanics analysis to solve problems at the clinical forefront. In this sense, computational blood fluid dynamics has the capacity to enhance clinical diagnosis, prognosis and treatment. Specifically, it contributes to: (1) Enriching the knowledge of basic relationships between local blood fluid dynamics and focal disease, testing quantitative hypotheses in controlled conditions; (2) Supporting decisions in the clinical practice, improving therapeutic treatments and surgical strategies; (3) Designing, optimizing and evaluating the performance of implants and devices. POSSIBLE APPLICATIONS: Risk stratification and risk prediction for vascular diseases Biofluid transport modelling Surgical planning for cardiovascular devices Design and optimization of cardiovascular devices. KEYWORDS: Hemodynamics, atherosclerosis, aneurysm, fluid and transport phenomena computational modeling, computer-aided design, cardiovascular disease, personalized medicine, diagnosis SERVICE FLUID DYNAMICS EXPERIMENTAL AND COMPUTATIONAL ANALYSIS FOR THE DESIGN, OPTIMIZATION AND EVALUATION OF CARDIOVASCULAR DEVICES The Cardiovascular Bioflows Unit of the Industrial Bioengineering Group is focused on the analysis of blood fluid dynamics with experimental and computational tools. In particular, the extensive experience (>10 years) in the research of the relationships between local blood fluid dynamics and focal disease, the Unit has experience in (1) simulation of therapeutic treatments and surgical strategies in both physical and computational models; (2) Design, optimization and evaluation of the performances of implants and devices. POSSIBLE APPLICATIONS: Surgical planning for cardiovascular devices Design, optimization and evaluation of coronary stents Design, optimization and evaluation of stent graft for aortic aneurysms Design, optimization and evaluation of artificial heart valves ADVANTAGES Test of quantitative hypotheses in controlled conditions Parametric analyses to explore the space of solutions Relatively low investment and rapid calculation time for most applications. KEYWORDS: Aneurysm, stent, artificial valve, fluid and transport phenomena computational modeling, computer- aided design, computational fluid dynamics, cardiovascular disease, personalized medicine, FFR SERVICE

598 / 880 BIOMECHANICS The Biomechanics Unit of the Industrial Bioengineering Group has a long experience of experimental and numerical research in the structural analysis of biomechanical systems. It have been working together with clinicians and companies involved in medical device manufacturing, assisting them in the design and the assessment of surgical techniques and medical products, and in the certification process. Biomechanical issues are regularly faced exploiting both computational and experimental competences, also capitalised on the design of proper testing setups when international standard requirements are not available. To date, many collaborations and partnerships have been already established with companies acting, among others, in the fields of orthopaedics and traumatology, orthotics, cardiovascular, dental, biomaterials and sport equipment. POSSIBLE APPLICATIONS Device design and testing Numerical modelling and FEA services Multibody assessment of surgical techniques Experimental assessments in a regulatory perspective Risk prediction for diseases of the skeletal system

599 / 880 Politecnico di Torino

Organisation

Country Italy City Torino Street Web http://polito.it

Person

Name Chiara Tonda-Turo Researcher

Organisation The group of Bionanotechnologies at Politecnico di Torino is active in biomedical research, with particular emphasis on engineering in surgery, biomolecular, cellular and tissue engineering; controlled drug delivery; bioartificial systems and materials. The group is highly multidisciplinary with competences ranging from chemistry to materials science and biomedical engineering, and combines expertise in polymer synthesis, biomedicine, engineering and bionanotechnologies to design novel bioinspired constructs able to guide and induce specific biological responses. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical devices biomedical applications • Biomaterials • Biotechnologies (Pharma&Medical Devices) • Drug screening & delivery

Marketplace Opportunities PRODUCT Biomedical materials Novel polymeric systems for drug and cell delivery REQUEST Partnership development of novel solution to solve chalelnging diseases

600 / 880 PORTOLANO CAVALLO

Organisation

Country Italy City Milan Street Piazza Borromeo, 12 Web http://www.portolano.it/

Person

Name Luca Gambini Partner

Organisation Portolano Cavallo provides legal advice to companies operating in complex and evolving sectors: we are leader in the Digital, Media and Technology sectors, in addition to being recognized in the Life Sciences and Fashion/Luxury fields. The firm’s practice areas range from litigation to M&A and venture capital, from emerging companies to the exploitation and protection of intellectual property, from employment to data protection, privacy and cyber-security issues. In all these areaswe are recognized by multiple legal Italian and international rankings and awards. LIFE SCIENCES We are one of the few law firms in Italy able to provide a full-service assistance to clients from the Life Sciences industry. Our experience in the Life Sciences sector encompasses all contractual, contentious, and regulatory aspects of pharmaceuticals, medical devices, health and healthcare services (both digital and traditional), as well as cosmetics and food supplements. The majority of our work is cross- border for domestic and foreign clients (multinationals as well as startups and also technology companies expanding into the Life Sciences sector). We cooperate with universities and polytechnics, healthcare institutions, contract research organizations (CROs), as well as clusters and technology parks, incubators and accelerators. We are one of the members of Biolegis, a pan-European network of independent law firms with in- depth expertise in life sciences.We are members of several Life Sciences-focused associations and initiatives: Antonia Verna has been selected as mentor for the Life Sciences committee of the “Unicredit Startlab” and is member of the Advisory Board of Fondazione Centro San Raffaele; we are members of the Assolombarda Life Sciences Group and an Italian association of pharmaceutical industries (AFI – Associazione Farmaceutici Industria). We have an unmatched competitive advantage compared to the other firms in this industry due to our Digital, Media & Technology leadership in Italy. Digitalization is universally recognized as the new frontier of all Life Sciences: use of big data to develop and deploy pharmaceutical products, exponential growth of “medical devices”, etc. We increasingly often advise on complex legal issues arising through technological developments applied to Life Sciences. We provide legal assistance to clients operating in the Life Sciences industry in the following matters: • during start-up phases • drafting and negotiation of commercial agreements, such as supply, distribution and co-marketing of 601 / 880 pharmaceutical products, “toll manufacturing arrangements” drafting and negotiation of joint venture agreements and technology transfers, development, exploitation, valuation, concession and intellectual property acquisition rights agreements, etc. • in various stages of research and product development, from the drafting of contracts relating to clinical trials, including contracts with CROs and investigators, to the resolution of issues that may arise during a trial in the regulatory, compliance and best-practices environments, with regard to the release to the market of medicinal products and medical devices, including advice for the launch of wearables devices and for matters relating to the price and reimbursement of medicines, market access, and the interfacing with public authorities and with other sector operators, as well as for measures restricting the marketing of medicinal products, referral procedures, inspections by regulatory authorities, etc. • in the protection of intellectual and industrial property, both in adversary and out-of-court legal proceedings • in the marketing and advertising of medicines and medical devices or, in general, of products and services in the health and pharmaceutical sector • in matter of antitrust, both in the context of extraordinary transactions and of exploitation of intellectual property rights, with particular focus on all major antitrust and regulatory issues that have become particularly relevant in recent years • in M&A transactions, Private Equity and Venture Capital, both to investors and target businesses • in all matters relating to privacy, cybersecurity and use of big data • in adversary legal proceedingsand for assistance in the performance of internal audit procedures in major Italian and foreign companies OFFICES • In Milan, we are in Piazza Borromeo, 12. • In Rome, we are in Via Rasella, 155. • In New York, we are in Midtown Manhattan at 261 Madison avenue. OUR CLIENTS • more than 50 Fortune Global 500 companies (ranking of the top 500 corporations worldwide as measured by revenue, published annually by Fortune magazine). • one out of two is a US multinational company • eight out of ten are large companies (more than 500 employees) • many companies belonging to healthcare and life sciences industry • a good number of startups and venture capital funds Areas of Activity

• Life sciences related activities

Marketplace Opportunities

SERVICE Legal advice for Intellectual Property issues We are legal experts in all areas related to Intellectual Property Law, including trademarks, patents, copyrights, know-how and domain names. We assist our clients in assessing their IP rights and in using the right tools to obtain the best protection, from the IP prosecution process to its enforcement, both on a national and international level. We also assist our clients in negotiating and drafting licensing agreements, as well as agreements relating to the transfer of knowhow and development of software and digital products. Our renowned expertise in the technology sector makes us the best partner for companies and start- ups that are investing in research and developments. One of our main goal is to provide our clients with a clear understanding of their IP portfolios, in order to create an added value to their business. SERVICE

602 / 880 Legal advice for life sciences industry Portolano Cavallo keeps being engaged for advice on proposed new business models and delivery systems in the Life Sciences sector including in particular where there is no existing case-law/ precedent upon which to rely and or cutting edge expertise and innovative thinking bring particular added value. The life sciences and health care industry is strongly modifying its business models and healthcare delivery systems by implementing new technologies and making an increased use of internet, cloud computing, mobile applications, etc. The main operators of the industry deem that such new models and systems would represent the main trends and opportunities for this industry in the next years and would consequently generate the main future legal challenges, especially in the data protection, IT, IP and advertising legal sectors. Based on the above, Portolano Cavallo has been able to leverage its existing TMT leadership with international clients on all the main legal matters arising from the life sciences and health care industry, especially in the use of new technologies and platforms, new media and in the increasing digitalization of the industry. SERVICE Legal advice for innovative statups We assist startups in creating and developing new business opportunities. Our legal services to startups include advising on the feasibility and implementation of their business and negotiating with venture capital funds, banks, companies and private investors. In particular, we help entrepreneurs to choose the most convenient and suitable legal structure for their project in order to attract investors. We provide legal support in relation to the negotiation and drafting of contractual and corporate joint venture, as well as of financing and investment agreements. SERVICE Legal advice on privacy and cyber security Our firm’s assistance concerns any aspects connected with data protection laws, including: • data protection compliance • data security and data breach • data transfers • cookies • employees’ control • cloud computing • mobile apps • payment systems • clinical trials • wearable technologies • big data • privacy of employees • information governance • retention policy • etc. In particular, some of the activities carried out by the firm in these fields are: • assistance relating to the implementation of clinical trials in Europe; • assistance in relation to multi-jurisdictions CRM compliance projects; • assistance in relation to privacy issues connected with the launch of an e-commerce activity in Europe; • strategic consultancy is relation to transfers of personal data abroad; • compliance with data protection laws and cookies requirements; • assistance in relation to the processing of data within social networks; • assistance in relation to proceedings before the Italian Data Protection Authority (Garante per la Protezione dei Dati Personali);

603 / 880 • assistance in connection with independent agencies’ requests to access personal data; • drafting of policies for internet security and business’ email address use; • etc. Personal data and information is a fundamental asset for any kind of business nowadays. Information and data need to be managed efficiently, adequately protected and exploited. At the same time, risks connected with the use of information (cyber risks, data breaches, etc.) may cause not only economic damages but also affect significantly a company’s reliability and reputation. The development of new technologies and the diffusion of cloud infrastructures need to be carefully approached on a national level, but also considered under a global perspective, bearing in mind implications concerning jurisdiction, competent authorities and applicable laws. SERVICE Legal advice on commercial, corporate and M&A matters In the Private Equity and Venture Capital sector, the firm has gained significant experience in investment operations, mainly regarding companies in the media, life sciences, new technologies and Internet sector thanks to the firm’s focus that combine unique technical expertise and knowledge of these industries. The private equity and venture capital team is composed of professionals specialized in contractual, corporate, financial and fiscal aspects, all noted by several rankings as industry experts. Our firm has significant experience in Private Equity and Venture Capital, having assisted investment funds, target companies, founders and management operations in start-ups, early stage investment, development and follow-on capital, leveraged buy-out (LBO), secondary purchase and management buy-outs (MBOs) in their various forms and exit. SERVICE Labor and employment legal advice We assist our clients from an employer’s standpoint on numerous aspects of the relationship between employer and employee. These include disputes before the labor courts and conciliation procedures before worksite committees and with trade unions. The members of our employment law department regularly advise on: • employment contracts for managers and employees • restrictive agreements, including non-compete agreements and minimum duration agreements • company policies, disciplinary codes, and internet and email use policies • company transfers and outsourcing • incentive plans, including stock option plans • various aspects of managing the employment relationship, including disciplinary measures and transfers • individual and collective dismissal • employee privacy issues • legal proceedings • negotiations and settlement agreements SERVICE Legal advice on dispute resolution We assist national and international companies in disputes involving commercial law, intellectual property and radio and television rights, as well as in Internet, e-commerce and IT matters. Our experience in the field of corporate disputes includes cases arising from mergers, acquisitions and bankruptcy proceedings. We are experts in the following areas: • protection of television formats • assistance in proceedings before the Television and Minors Committee relating to the violation of regulations for the protection of young viewers • representation in court cases and in proceedings before the Italian Communications Authority 604 / 880 (AGCOM) and the Italian Antitrust Authority (AGCM) relating to carriage of television channels, government authorizations, use of terrestrial frequencies and transmission systems • proceedings before the AGCM relating to improper commercial practices • proceedings before AGCOM relating to television advertising • litigation relating to trademarks in the television sector • disputes relating to the position of television channels in the Logical Channel Numbering system • arbitration proceedings involving complex industrial property issues • litigation involving copyright in software • disputes over directors’ liability and their implications in insurance law (i.e., directors’ and officers’ liability insurance) • bankruptcy proceedings, including bankruptcy, extraordinary administration, arrangements with creditors and restructuring agreements • public auctions pursuant to court orders and the bankruptcy of cinematography libraries

605 / 880 Portolano Cavallo Studio Legale

Organisation

Country Italy City Milano Street Piazza Borromeo, 12 Web http://www.portolano.it/

Person

Name Antonia Verna Partner

Organisation Portolano Cavallo provides legal advice to companies operating in complex and evolving sectors: we are leader in the Digital, Media and Technology sectors, in addition to being recognized in the Life Sciences and Fashion/Luxury fields. The firm’s practice areas range from litigation to M&A and venture capital, from emerging companies to the exploitation and protection of intellectual property, from employment to data protection, privacy and cyber-security issues. In all these areaswe are recognized by multiple legal Italian and international rankings and awards. LIFE SCIENCES We are one of the few law firms in Italy able to provide a full-service assistance to clients from the Life Sciences industry. Our experience in the Life Sciences sector encompasses all contractual, contentious, and regulatory aspects of pharmaceuticals, medical devices, health and healthcare services (both digital and traditional), as well as cosmetics and food supplements. The majority of our work is cross- border for domestic and foreign clients (multinationals as well as startups and also technology companies expanding into the Life Sciences sector). We cooperate with universities and polytechnics, healthcare institutions, contract research organizations (CROs), as well as clusters and technology parks, incubators and accelerators. We are one of the members of Biolegis, a pan-European network of independent law firms with in- depth expertise in life sciences.We are members of several Life Sciences-focused associations and initiatives: Antonia Verna has been selected as mentor for the Life Sciences committee of the “Unicredit Startlab” and is member of the Advisory Board of Fondazione Centro San Raffaele; we are members of the Assolombarda Life Sciences Group and an Italian association of pharmaceutical industries (AFI – Associazione Farmaceutici Industria). We have an unmatched competitive advantage compared to the other firms in this industry due to our Digital, Media & Technology leadership in Italy. Digitalization is universally recognized as the new frontier of all Life Sciences: use of big data to develop and deploy pharmaceutical products, exponential growth of “medical devices”, etc. We increasingly often advise on complex legal issues arising through technological developments applied to Life Sciences. We provide legal assistance to clients operating in the Life Sciences industry in the following matters: • during start-up phases • drafting and negotiation of commercial agreements, such as supply, distribution and co-marketing of 606 / 880 pharmaceutical products, “toll manufacturing arrangements” drafting and negotiation of joint venture agreements and technology transfers, development, exploitation, valuation, concession and intellectual property acquisition rights agreements, etc. • in various stages of research and product development, from the drafting of contracts relating to clinical trials, including contracts with CROs and investigators, to the resolution of issues that may arise during a trial in the regulatory, compliance and best-practices environments, with regard to the release to the market of medicinal products and medical devices, including advice for the launch of wearables devices and for matters relating to the price and reimbursement of medicines, market access, and the interfacing with public authorities and with other sector operators, as well as for measures restricting the marketing of medicinal products, referral procedures, inspections by regulatory authorities, etc. • in the protection of intellectual and industrial property, both in adversary and out-of-court legal proceedings • in the marketing and advertising of medicines and medical devices or, in general, of products and services in the health and pharmaceutical sector • in matter of antitrust, both in the context of extraordinary transactions and of exploitation of intellectual property rights, with particular focus on all major antitrust and regulatory issues that have become particularly relevant in recent years • in M&A transactions, Private Equity and Venture Capital, both to investors and target businesses • in all matters relating to privacy, cybersecurity and use of big data • in adversary legal proceedingsand for assistance in the performance of internal audit procedures in major Italian and foreign companies OFFICES • In Milan, we are in Piazza Borromeo, 12. • In Rome, we are in Via Rasella, 155. • In New York, we are in Midtown Manhattan at 261 Madison avenue. OUR CLIENTS • more than 50 Fortune Global 500 companies (ranking of the top 500 corporations worldwide as measured by revenue, published annually by Fortune magazine). • one out of two is a US multinational company • eight out of ten are large companies (more than 500 employees) • many companies belonging to healthcare and life sciences industry • a good number of startups and venture capital funds Areas of Activity

• Life sciences related activities • Other

Marketplace Opportunities SERVICE Legal advice for Intellectual Property issues We are legal experts in all areas related to Intellectual Property Law, including trademarks, patents, copyrights, know-how and domain names. We assist our clients in assessing their IP rights and in using the right tools to obtain the best protection, from the IP prosecution process to its enforcement, both on a national and international level. We also assist our clients in negotiating and drafting licensing agreements, as well as agreements relating to the transfer of knowhow and development of software and digital products. Our renowned expertise in the technology sector makes us the best partner for companies and start- ups that are investing in research and developments. One of our main goal is to provide our clients with a clear understanding of their IP portfolios, in order to create an added value to their business. SERVICE

607 / 880 Legal advice for innovative statups We assist startups in creating and developing new business opportunities. Our legal services to startups include advising on the feasibility and implementation of their business and negotiating with venture capital funds, banks, companies and private investors. In particular, we help entrepreneurs to choose the most convenient and suitable legal structure for their project in order to attract investors. We provide legal support in relation to the negotiation and drafting of contractual and corporate joint venture, as well as of financing and investment agreements. Our “startup team” attorneys have expertise in a range of practice areas including corporate, tax and litigation and knowledge of the digital, technology sectors. Our main goal is to assist startups in creating and developing new business opportunities. We promote networking activities with venture capital funds/investors to offer this international network to entrepreneurs; we organize workshops on legal topics for startups and investors; and we support several domestic and international startup events. SERVICE Legal advice for life sciences industry Portolano Cavallo keeps being engaged for advice on proposed new business models and delivery systems in the Life Sciences sector including in particular where there is no existing case-law/ precedent upon which to rely and or cutting edge expertise and innovative thinking bring particular added value. The life sciences and health care industry is strongly modifying its business models and healthcare delivery systems by implementing new technologies and making an increased use of internet, cloud computing, mobile applications, etc. The main operators of the industry deem that such new models and systems would represent the main trends and opportunities for this industry in the next years and would consequently generate the main future legal challenges, especially in the data protection, IT, IP and advertising legal sectors. Based on the above, Portolano Cavallo has been able to leverage its existing TMT leadership with international clients on all the main legal matters arising from the life sciences and health care industry, especially in the use of new technologies and platforms, new media and in the increasing digitalization of the industry. SERVICE Legal advice on privacy and cyber security Our firm’s assistance concerns any aspects connected with data protection laws, including: • data protection compliance • data security and data breach • data transfers • cookies • employees’ control • cloud computing • mobile apps • payment systems • clinical trials • wearable technologies • big data • privacy of employees • information governance • retention policy • etc. In particular, some of the activities carried out by the firm in these fields are: • assistance relating to the implementation of clinical trials in Europe; • assistance in relation to multi-jurisdictions CRM compliance projects; • assistance in relation to privacy issues connected with the launch of an e-commerce activity in

608 / 880 Europe; • strategic consultancy is relation to transfers of personal data abroad; • compliance with data protection laws and cookies requirements; • assistance in relation to the processing of data within social networks; • assistance in relation to proceedings before the Italian Data Protection Authority (Garante per la Protezione dei Dati Personali); • assistance in connection with independent agencies’ requests to access personal data; • drafting of policies for internet security and business’ email address use; • etc. Personal data and information is a fundamental asset for any kind of business nowadays. Information and data need to be managed efficiently, adequately protected and exploited. At the same time, risks connected with the use of information (cyber risks, data breaches, etc.) may cause not only economic damages but also affect significantly a company’s reliability and reputation. The development of new technologies and the diffusion of cloud infrastructures need to be carefully approached on a national level, but also considered under a global perspective, bearing in mind implications concerning jurisdiction, competent authorities and applicable laws. SERVICE Legal advice on commercial, corporate and M&A matters In the Private Equity and Venture Capital sector, the firm has gained significant experience in investment operations, mainly regarding companies in the media, life sciences, new technologies and Internet sector thanks to the firm’s focus that combine unique technical expertise and knowledge of these industries. The private equity and venture capital team is composed of professionals specialized in contractual, corporate, financial and fiscal aspects, all noted by several rankings as industry experts. Our firm has significant experience in Private Equity and Venture Capital, having assisted investment funds, target companies, founders and management operations in start-ups, early stage investment, development and follow-on capital, leveraged buy-out (LBO), secondary purchase and management buy-outs (MBOs) in their various forms and exit. SERVICE Labor and employment legal advice We assist our clients from an employer’s standpoint on numerous aspects of the relationship between employer and employee. These include disputes before the labor courts and conciliation procedures before worksite committees and with trade unions. The members of our employment law department regularly advise on: • employment contracts for managers and employees • restrictive agreements, including non-compete agreements and minimum duration agreements • company policies, disciplinary codes, and internet and email use policies • company transfers and outsourcing • incentive plans, including stock option plans • various aspects of managing the employment relationship, including disciplinary measures and transfers • individual and collective dismissal • employee privacy issues • legal proceedings • negotiations and settlement agreements SERVICE Legal advice on dispute resolution We assist national and international companies in disputes involving commercial law, intellectual property and radio and television rights, as well as in Internet, e-commerce and IT matters. Our experience in the field of corporate disputes includes cases arising from mergers, acquisitions and 609 / 880 bankruptcy proceedings. We are experts in the following areas: • protection of television formats • assistance in proceedings before the Television and Minors Committee relating to the violation of regulations for the protection of young viewers • representation in court cases and in proceedings before the Italian Communications Authority (AGCOM) and the Italian Antitrust Authority (AGCM) relating to carriage of television channels, government authorizations, use of terrestrial frequencies and transmission systems • proceedings before the AGCM relating to improper commercial practices • proceedings before AGCOM relating to television advertising • litigation relating to trademarks in the television sector • disputes relating to the position of television channels in the Logical Channel Numbering system • arbitration proceedings involving complex industrial property issues • litigation involving copyright in software • disputes over directors’ liability and their implications in insurance law (i.e., directors’ and officers’ liability insurance) • bankruptcy proceedings, including bankruptcy, extraordinary administration, arrangements with creditors and restructuring agreements • public auctions pursuant to court orders and the bankruptcy of cinematography libraries

610 / 880 Postbiotica

Organisation

Country Italy City Milan Street Piazza PIO XI Web https://postbiotica.com

Person

Name Umberto Salvatore Project Manager

Organisation Postbiotica is an innovative Biopharmaceutical Company born to develop a new therapeutic treatments based on new molecules with a high biological impact called Postbiotics. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PRODUCT POSTBIOTICS Postbiotics are molecules with immunomodulatory properties product by bacteria and naturally released during food fermentation in human gut. We hold a new fermentative process "pbtech" in which we design and modulate the Postbiotics productions selecting the best bacterial strains from the human gut. Moreover we can produce different Postbiotics starting from the same bacterial strain we can modulate the fermentation process to produce multiple Postbiotics applicable to different therapeutic areas. Postbiotics are safer because they lack living bacteria and bacterial components which can enhance an occuring inflammation. it’s important to infant use. Higher concentration of active components are immediately available because they don’t need bacterial growth or colonization postbiotics are thermo-resistant and highly stable for months the fermentation process is highly controlled in order to produce Postbiotics with reproducible chemical and functional activities the applications are multiple: from medical devices to food supplements useful both for humans and petcare. The Postbiotics represent a really innovative way in the approach and care of immunological disorders. PARTNERSHIP

611 / 880 Co-partnership Looking for a partners which are interested to develop a new products with Postbiotics

612 / 880 PRAXI Intellectual Property S.p.A.

Organisation

Country Italy City Milano Street Via Mario Pagano, 69/A Web www.praxi-ip.praxi

Person

Name Maria Gabriella Tana Patent attorney

Organisation PRAXI Intellectual Property is a company specialized in Industrial and Intellectual Property and is controlled by PRAXI S.pA, a primary management Italian consulting company. PRAXI Intellectual Property provides services related to patent protection, trademarks, utility models, designs and copyrights. These services include the analysis, filing, prosecution and management of IP rights applications, anti-infringement actions and economic-financial valuations of intangible assets. PRAXI IP is accessible to Clients through its network of national Offices (Genova, Milano, Padova, Roma, Torino, Trento, Verona) and offers a consistent service across the globe through its well-established international partners. PRAXI IP provides assistance to clients operating in the Life Science industry with dedicated professionals with a doctorate degree and a strong background in electronic end IT bioengineering. Our team includes also professionals specialized in biochemistry and biomaterials. Areas of Activity

• 3D Printing/addictive manufacturing for • Electromedical and medical equipment biomedical applications (non diag) • Analytical and characterization services • Manufacturing & process engineering • Bioinformatics, Big data analytics • Software, ICT applications, system • Biomaterials integration • Biosensors • EPR, Clinical/healthcare management • Biotechnologies (Pharma&Medical software Devices) • Surgery technologies and applications • Consulting services • Virtual reality applications • Diagnostics - Equipment and accessories • Laboratory equipment, reagents, software • Diagnostics - Imaging equipment and • Medical devices processing • IT Applications for Health • Drug screening & delivery • eHealth, mHealth, telemedicine

Marketplace Opportunities

613 / 880 SERVICE IP training Our services include the organisation of IP training courses suited to your specific needs. They can be in-house or at our offices, whichever suits you best. The courses are held by our most experienced professionals who are members of Italian and International intellectual property-related associations, authors of articles and publications, speakers at conferences and seminars organized by economic institutions and universities. SERVICE IP contracts Threats to a company’s IP assets often derive from information leaks, corporate espionage, theft of know-how, or the non-respect of internal company rules. The stipulation of contracts with agents, suppliers, collaborators and clients allows proper management of Intellectual Property. Likewise, internal procedures necessary to comply with law requirements in connection with, for example, personal data or risk management, may be used to maximise the protection of IP. Our expert team can provide you with an assessment of the risks arising from interaction with your clients, suppliers, employees and collaborators, an evaluation of existing contractual and internal procedures for the management of confidential information, we draw up new procedures and contractual models that can be managed autonomously; and provide in-house training for the proper management of your company’s Intellectual Property. SERVICE Software protection Software can be protected: - by authors’ rights when it meets the relevant creativity and originality requirements - as a patent when it contains one or more technically innovative algorithms. In the first case, you can also register software at the Special Public Registry held by the S.I.A.E. (the Italian body where authors’ rights are registered). Any software that meets the requirements for creativity and a minimum degree of originality with respect to pre-existing software, including elaborations of and variations on previous software, can be registered. Our team can assist you in this matter. SERVICE Drafting and filing of Italian, European and International patent applications Patents protect the technical and technological aspects of a product or a process that possesses novelty, inventiveness, and industrial applicability. A patent is therefore an exclusive right granted to an inventor or inventors who have filed a patent application to exploit their innovation, in the specific territory where it is protected. A first meeting with you allows us to acquire the necessary technical information and fully understand both the invention and your needs, and to establish the most cost- effective and strongest protection strategy.

614 / 880 Probiomedica srl

Organisation

Country Italy City Firenze Street via di Santo Spirito 14, Firenze

Person

Name Giovanni Romano Enterpreneur

Organisation Probiomedica combines photonics and robotics, engineering and biology, and aims to develop innovative devices applied to health and personal care. Probiomedica has its own experts dedicated to the study of technological innovations, to improve our products and create new ones. The first product to valorize is Capsulight. CapsuLight is an ingestible LED capsule for the treatment of the bacterium Helicobacter pylori. CapsuLight is a light-emitting capsule, as small as an antibiotic pill but without its side effects as it is not a drug, and it isdisposable. CapsuLight is safe, because it relies on the technological experience about ingestible devices, developedsince about 15 years. In two words, CapsuLight is a "LED antibiotic"! CapsuLight emits light frequencies studied to obtain the besteffectiveness for the killing of Helicobacter pylori, thanks to its emission in the red and blue wavelengths. Areas of Activity

• Electromedical and medical equipment (non diag) • Medical devices

Marketplace Opportunities PARTNERSHIP Medical or robotic devices for phototherapy As an Italian SME, we are available for R&D collaborations and participation in European projects (Photonics call, FET call, robotics call.) in the field of phototherapy We could provide our experience in the design of medical devices, mechanical and electronic design, assembly, together with connections with Universities such as Scuola Superiore Sant'Anna (The BioRobotics Institute) and University of Florence. INVESTMENT OPPORTUNITY Investment for CapsuLight development We are looking for investment for speeding up CapsuLight valorization, testing, validation and

615 / 880 commercial distribution. CapsuLight is an ingestible LED capsule for the treatment of the bacterium Helicobacter pylori. CapsuLight is a light-emitting capsule, as small as an antibiotic pill but without its side effects as it is not a drug, and it is disposable. TYPE OF PARTNER SOUGHT Business angels or VC looking for an innovative and breaktrough idea!

616 / 880 Progenus

Organisation

Country Belgium City Gembloux Street Rue Camille Hubert 7a Web http://www.progenus.be

Person

Name Benedicte Renaville COO

Organisation Coming from academic research, Progenus has three departments: R&D, kits and laboratory services. At Progenus, we believe in innovation and are highly oriented towards high-level research for our customers. Therefore, we offer a full range of services to our partners for DNA research, from the development of a simple test to a complete research project. Based on its R&D department, Progenus also develops and sells its own DNA analysis kits for the detection of animals, plants and microorganisms. Finally, Progenus also makes available its expertise through its laboratory services for genetic and genomic testing. Areas of Activity

• Analytical and characterization services • Genetics & Genomics • Bioinformatics, Big data analytics • CRO (Contract Research Organisation) • Diagnostics IVD

Marketplace Opportunities SERVICE Real-Time PCR development Progenus develops and validate your PCR test according to your specifications and needs. PARTNERSHIP DNA research Progenus is specialised in DNA analysis from the design of primers and probes to the bio informatics analysis of big data, pipeline development, laboratory validations, ... Progenus has a long experience in the management and coordination of research project. We will be happy to discuss new project opportunities SERVICE Pig DNA analysis for halal certification of products Progenus can test your products to certify the absence of residual pig DNA for further certifications (halal, ...)

617 / 880 PROLABIN & TEFARM

Organisation

Country Italy City Perugia Street Via dell'Acciaio 9 Web www.prolabintefarm.com

Person

Name Michele Sisani R&D Director

Organisation Prolabin&Tefarm s.r.l.(P&T) is expert in the production of biocompatible inorgano-organic layered compounds belonging to the class of hydrotalcites and zirconium phosphates/phosphonates. These lamellar solids are innovative products used asnanostructurantpolymer additives,active ingredientsforcosmetic,pharmaceuticalandhealth care applicationsandheterogeneous catalysts. P&T researchers gained their experience and know how from research carried out over more than 30 years in the Dep. of Chemistry at the university of Perugia, enabling them to transfer their knowledge and technology to industry. All the products are composed of lamellar solids, or synthetic clays, produced with ecofriendly procedures using only water as a solvent, therefore suitable for companies that seek innovative and green products. P&T benefits from EU and national calls to enable the research, development and dissemination of new products for strategic market sectors. P&T proposes itself as a partner in networks whose aim is to carry out innovative projects in order to obtain high quality products. Areas of Activity

• 3D Printing/addictive manufacturing for • Packaging & labelling biomedical applications • Peptides, proteins & antibodies • Analytical and characterization services preparation • Biomaterials • Pharmaceutics • Biotechnologies (Pharma&Medical • Regulatory affairs, validation Devices) • Life sciences related activities • Chemicals & APIs • Other • CMO (Contract Manufacturing • Laboratory equipment, reagents, software Organisation) • Project proposals support services • Diagnostics - Equipment and accessories • Medical devices • Diagnostics - Imaging equipment and processing • Drug screening & delivery

618 / 880 • Manufacturing & process engineering • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Development of new active ingredients for cosmetic, nutraceutic and pharmaceutical applications P&T offers innovative solutions for the vehiculation of active ingredient of health care interest. P&T possess knowledge and expertise in the field of intercalation of active molecules in layered biocompatible materials in order to develop new hybrid systems able to protect the ingredient against oxidation and photodegradation, to modified the release with a controlled mechanism and to increase the bioavailability. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Biocompatible layered inorganic compounds are a class of special materials that can be used for the intercalation/encapsulation of active ingredients with very high loading (up to 50 wt%) compared with the conventional techniques. The layered hosting shell is able to protect the active molecules against oxidation and photodegradation because it absorbs and reflects UV rays often responsible for photodecomposition of certain ingredient and prevents or limits the oxygen penetration inside the layers. The release of the active ingredient depends on a mechanism that is regulated by the ionic exchange and it can be tuned using a suitable formulation able to exhibit a controlled release profile in each specific medium (drug delivery systems). For topical application this strategy represents a good solution even for very aggressive actives because the ingredient can be gradually released avoiding the direct contact of the whole concentration with the skin. The intercalation of the actives also allows the increment of the ingredient bioavailability because molecules are stored ionic form and once released they are immediately soluble and ready to be absorbed. This advantage allows the reduction of the active ingredient concentration in the formulation maintaining the same degree of efficacy. Intercalation technology could be employed to mask the bad taste of some active ingredients improving the organoleptic properties of the formulations and the compliance. Moreover the layered structure of the ingredient confers better rheological properties to semisolid formulation (creams, emulsions, pastes and suspensions) in terms of spreadability and extrudability. MARKET APPLICATION This technology is useful to produce new active ingredients for cosmetic, nutraceutic and pharmaceutical formulations. Using these new raw materials is possible to develop special formulations with modified and optimized release (also drug delivery systems). The intercalation technology allows the improvement of the stability of labile active ingredients increasing the efficacy and the safety of the final formulations. TYPE OF PARTNER SOUGHT Producers or formulators in the field of cosmetic, nutraceutic and/or pharmaceutical products. Italy and EU. Development of new active ingredients for special health care formulation. The partner should be involved in the selection of the active ingredient of interest and in the formulation development study. At the end of the cooperation the partner will be the end user of the new ingredients and it will commercialize its products based on this new technology. PARTNERSHIP Consortium creation in the field of innovative health care product P&T has a consolidated expertise and knowledge in the field of production of new active ingredient with: - modified and controlled release - better photostability and stability against oxidation 619 / 880 - increased bioavailability P&T is lokking for partners interested in the use of these new active ingredient for the development of: - new drug delivery systems - new formulations with better efficacy and safety - new medical devices - polymeric nanocomposite systems for biomedical applications FUNDING PROGRAMME AND REFERENCE Horizon 2020 and following EU programme. National funding. TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE RTDs involved in the filed of cosmetic, nutraceutic and pharmaceutical applications. SEMs with special expertise in the field of vehiculation and formulation of cosmetic, nutraceutic and pharmaceutical ingredients. Companies that produce cosmetic, nutraceutic and pharamceutical formulations, medical devices.

620 / 880 Prometheus Bio-Medical, Inc.

Organisation

Country United States City NEW YORK Street 40 E 9TH STREET, SUITE 3K, NEW YORK, NY 10003, USA. Web https://www.prometheus.world

Person

Name PrometheusBioMedical Gabriel Veridze Founder and Chairperson

Organisation Multinational Full Service CRO. Areas of Activity

• CRO (Contract Research Organisation) • Medical research

621 / 880 Prometheus Srl

Organisation

Country Italy City Parma Street Via Trento, 30 Web http://prometheus3d.com

Person

Name Alice Michelangeli CSO

Organisation Prometheus is a biotech startup that developes 3d human and animals tissues for pharmaceutical research and wounds care. Areas of Activity

• 3D Printing/addictive manufacturing for • Surgery technologies and applications biomedical applications • Medical devices • Biomaterials • Biotechnologies (Pharma&Medical Devices) • Manufacturing & process engineering

Marketplace Opportunities REQUEST Medical devices regulatory - clinical trials We are looking for a consultant to better understand the regulatory procedures to reach the human market.

622 / 880 PSO Group

Organisation

Country Hungary City Budapest Street Tanuló str 1-3.

Person

Name Peter Hadi CEO

Organisation PSO- Pharma Support Organization PSO offers complex medical, marketing, sales, distribution and IT solutions to clients within the healthcare and pharmaceutical sector. Legal entities within PSO represent high quality standards in their own field of competence while being part of PSO, optimal resource allocation and project management is guaranteed to each project. PSO also incubates promising start-up companies in healthcare data-mining, telemedicine,medical applicationsand innovative marketing/promotion services. Areas of Activity

• Analytical and characterization services • Nutraceutics, probiotics, functional food, • Bioinformatics, Big data analytics cosmeceutics • CMO (Contract Manufacturing • Pharmaceutics Organisation) • Regulatory affairs, validation • Consulting services • Project proposals support services • CRO (Contract Research Organisation) • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Genetics & Genomics • Medical research

Marketplace Opportunities PARTNERSHIP Searching for licence-in, sales, distribution opportunities; project partnership and consulting Mission & Value: 1. Distribution of top quality products / supplying top quality services 2. Development of a systematic portfolio respecting social utilities 3. Providing value added solutions responding to local needs & expectations SERVICE

623 / 880 Complex medical, marketing, sales, distribution and IT solutions to clients within the healthcare and pharmaceutical sector PSO service portfolio: 1. Healthcare / Pharmaceuticals strategy & portfolio management 2. Sales & Marketing & Distribution: full scale business management, 360° marketing solutions, widespread competences - innovative marketing tools 3. Regulatory & Quality Assurance: Complete registration process management of various international companies’ medicinal & food products in Hungary; extensive network & cooperation with all local Authorities; multiple years of experience in timely regulatory process management ; CTA preparation & submission, Amendements and Notification ; MAA preparation & submission for medicinal & food products ; reimbursement strategy management, processes ; full scale of quality assurance services in the areas of clinical, medical, production, distribution and organization 4. Complete medical support of all PSO Group activites include: medical advice and monitoring; medical content development & writing; pharmacovigilance. 5. Clinical Affairs:Phase I-IV Clinical & NITs & IIR studies covering all therapeutic areas: >100 trials, >170 sites in itiated & managed, >1200 subjects enrolled ; full scale operations & project management ;1st SIV within 1 week of CA/EC approvals ; 1st subject in within 1 week of SIV 6. Human Resource Services: 20 years of HR experience and extensive network of candidates, high- quality, industry-specific services - unique hiring, selection & training methods

624 / 880 QUAD Investment Management

Organisation

Country Korea, Republic Of City Seoul Street 10F Block A, The K Twin Towers, 50 Jongno 1-gil, Jongno-gu Web http://www.quadim.com

Person

Name Youngtae HONG Managing Director

Organisation QUAD has a strong interest in the start-ups and small companies incorporated based on the innovative and cutting-edge sciences developed in Universities and research institutes. As an equity investment firm, QUAD has invested in the companies across a variety of business areas regardless of territories. Talented and experienced investment professionals from diverse backgrounds at QUAD could provide in-depth investment analysis and the networks required across different fields of interest. Especially, QUAD has plentiful resources in the area of BIO/healthcare, which becomes the important industry with the increasing investment from the private as well as the public. Based on QUAD’s own investment process and the proficiencies in understanding the core value of companies, we are seeking for the right and good biotech and healthcare companies with the potential to be key players in the global market.

Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Genetics & Genomics • Investments • Pharmaceutics

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity in biotech, medical devices, healthcare QUAD has plentiful resources in the area of BIO/healthcare, which becomes the important industry with the increasing investment from the private as well as the public. Based on QUAD’s own investment process and the proficiencies in understanding the core value of 625 / 880 companies, we are seeking for the right and good biotech and healthcare companies with the potential to be key players in the global market. Sectors of interest for investment: New drugs (small molecules and Biologics) for any diseases with unmet medical needs Medical and/or research devices with breakthrough technologies Gene therapies and related technologies and findings Types of investment: Equity investment Setting up a JV with Korean collaborators

626 / 880 Quipu srl

Organisation

Country Italy City Pisa Street Via Moruzzi 1 Web www.quipu.eu

Person

Name Vincenzo Gemignani CEO

Organisation Quipu is a company founded in 2011 as a spin-off of the Italian National Research Council and the University of Pisa, Italy. The team includes engineers and doctors who share 20years work experience in the field of medical ultrasound. The mission of Quipu is to create a new generation of diagnostic ultrasound systems based on software applications. Quipu developed a software platform that contains innovative applications (software programs that performs specific ultrasonic examinations) for medical ultrasound. The platform runs on a standard personal computer based on Microsoft Windows, Mac OS X or Linux. Today, the platform works in connection with any existing ultrasound scanner and adds advanced functions to standard ultrasound devices. In a second development step, a new-generation ultrasound scanner will be introduced that will complete a new medical ultrasound architecture based on software applications. Quipu has completed and is selling its first two applications in the field of the cardiovascular disease prevention: (i) FMD Studio for the assessment of the endothelial function by the Flow Mediated Dilation test; (ii) Carotid Studio for the assessment of the carotid thickness and stiffness in early assessment of atherosclerosis. The software product is a CE medical device (93/42/EEC) and is obtaining FDA clearance. Areas of Activity

• Software, ICT applications, system integration • Medical devices • IT Applications for Health

Marketplace Opportunities PRODUCT

627 / 880 Software Platform for Medical Image Processing Quipu developed a new software application platform for medical ultrasound image processing. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The platform runs on a standard computer and can work in conjunction with ultrasound devices currently available in hospitals. The applications process the ultrasound video images and provide advanced functions for standard (and also low-end) devices. MARKET APPLICATION The software product is a CE medical device (93/42/EEC) and is going to obtain the FDA clearance. Current product market is the global market for medical ultrasound devices. INVESTMENT OPPORTUNITY Investment opportunity for Quipu business scale-up Quipu is looking for an investment to scale-up its business in the next three years

628 / 880 Qwyddy Technologies OÜ

Organisation

Country Estonia City Tallinn Street Parda 8 Web http://www.qwyddy-tech.com

Person

Name Fabio Ferrari CEO

Organisation Qwyddy Technologies helps companies innovating their products and infrastructure thanks to the IoT, data analysis and Industry 4.0 technologies. Our hardware is industrial grade and certified for use in medical devices. Our lightweight software and firmware make use of last generation technologies and fits perfectly in medical and safety devices. Areas of Activity

• Bioinformatics, Big data analytics • IT Applications for Health • Software, ICT applications, system integration • Other

Marketplace Opportunities PRODUCT Eywa - Modular IoT Platform Eywa is an hardware and software platform aimed at monitoring, controlling and analyzing data about any kind of connected product, machinery or environment. Built with the newest technologies, it allows companies, distributors and users to get connected to their device and gathering from them any kind of information. SERVICE Product and infrastructure enhancement, get knowledge from data Our goal is to improve people's live through technology. We make use of connected last generation microcontrollers to connect products, machineries and devices. All our microcontrollers are industrial grade and certified for mission critical fields, such as medical, automotive and space use. Our Mission is supporting companies to be at the leading edge of technology, creating digital projects capable of engaging people through experiences, products and services. By way of Technology, we are determined to make our World a better place, making it more connected, cleaner and more hospitable. 629 / 880 RAUMEDIC

Organisation

Country Germany City Norimberga Street Hermann-Staudinger- Helmbrechts Web www.raumedic.com

Person

Name alessandro menini Marketing Manager

Organisation Innovative Manufacturer of single use polymer devices for the MED-TECH & PHARMA Industry. Headquarter in Germany. Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Medical devices

Marketplace Opportunities PRODUCT Intelligent Catheters with microchips Development of tailor made single use catheters with integrated electronical components (cameras, sensors) mainly for diagnostic purpose. PRODUCT Putch Pumps & Drug Delivery Devices Development and production of complex devices for subcutaneous administration of liquid drugs (Patch Pumps) and Dry Powder Inhalers for the treatment of respiratory diseases. PRODUCT Single use OEM polymer solutions Raumedic (www.raumedic.com), is a Multinational Company developing and manufacturing in OEM precision tubings, components and finished devices for the Medical Device and Pharmaceutical sectors. The Company process all known of thermoplastic polymers in medical grade and silicone, as well as materials included in the implantable category, class III of the 93/42 / CEE Regulation. With over 50 years of industrial know-how in the field of complex extrusion, precision molding and assembling, Raumedic is able to give shape to customer ideas by developing high single use polymer products with raw materials specially formulated for the required characteristics. This is also possible thanks to the high integration between Research & Development, Prototyping & Validation, Production 630 / 880 & final sterilization, all internal resources within the Company. PARTNERSHIP Complex med-tech devices for diagnostic and drug deliveries Focus on development of customized intelligent catheters (with microchips) and complex drug delivery devices for MED-TECH and Pharma Industries. PARTNERSHIP Reliable partners with clean room production Looking for sub-suppliers in automation assembly as well as flexible providers of injection silicone parts.

631 / 880 React4life

Organisation

Country Italy City Genova Street Via D. Fiasella 1 Web www.react4life.com

Person

Name Maurizio Aiello Business developer

Organisation React4life has developed Multi In Vitro Organ (MIVO), an innovative fluidic bioreactors emulating portions of the human body, to improve the effectiveness of pharmaceutical tests, discover innovative therapeutic approaches, and reduce animal testing. MIVO allows to host and cultivate epithelial tissues with the function of interface membranes to artificially recreate cell migration phenomena (for the study of tumor metastasis onset and new anticancer therapies validation), diffusion of molecules (for the study of the absorption of cosmetic products on the dermis), diffusion of nutrients (for the study of nutrient absorption in the intestinal wall). Beyond that, the React4life portfolio currently includes two in vitro 3D tumor models (i.e. breast cancer model, neuroblastoma model), whose validation is underway. The business model is dual: the sale of MIVO for research use and the offering of a kit composed of MIVO and artificial tissues as a model of disease for in vitro testing. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Medical devices • Drug screening & delivery • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PRODUCT MIVO - Multi In Vitro Organ bioreactor The lack of suitable accredited organ models makes it impossible to perform scientifically reliable, controlled and reproducible tests on molecules and compounds generally that interact with the human 632 / 880 body. This problem is felt in various life sciences sectors (pharma, cosmetics, primary care, agro-food, pollution). The most widely used approaches for in vitro testing include the use of 2D systems, Petri dishes or slides, and animal models. The first method is unreliable mainly because the 2D conditions do not correspond to the tridimensionality of the human body. The second presents other disadvantages, among the best known, the differences between man and animal, high experimental costs and ethical issues. For molecular or drug diffusion studies, Transwell are commonly used; Transwell have predetermined size, non-replaceable membranes and, in general, are far from a physiological 3D context, being mostly represented by a monolayer of cells. Multi In Vitro Organ (MIVO) patented technology, developed by React4life to model physiological barriers in vitro, wants to fill these gaps, finally conducting to more realistic and reliable tests. MIVO consists in a fluid-dynamic, multi-chamber culture system where it is possible to test, just by varying the interfacing membrane and the parameters of the system: – drug efficacy – cosmetics absorption and transdermal diffusion – nutrient digestibility – in general, all those processes taking place at interfaces. MIVO allows observing the tissues and cells cultured within, under a traditional inverted microscope. It can accommodate commercial 3D equivalent tissues, biopsies of different shape and thickness or artificial membranes moving towards the concept of personalized medicine. Among these, React4life can provide a broad range of membrane models including polymeric electrospun membranes and 3D printed membranes. MIVO applications: - Pharmaceutical & Cancer Pharma research is an area in which many animal experiments are conducted. In vitro methods need to be considered in terms of the 3Rs (Replacement, Reduction and Refinement) concept of alternatives, which regulate animal experimentation. The MIVO by React4life allows to test in vitro new drug formulations on 2D and 3D engineered disease models, through a technological, reproducible and cruelty-free approach. The fluid-dynamic system allows a controlled drug release to the engineered disease model, representing a unique approach in the field of in vitro tests. Feel free to design, control, enhance your drug with no more concern about testing. MIVO technologies allow growing 3D cancer models, advanced and living, for immediate, easy to perform and affordable drug testing. Two in vitro 3D tumor models (breast cancer model, neuroblastoma model) validation is currently underway by React4life. - Cosmetics In Europe, animal models have been definitely banned as concerns cosmetics applications. However, alternative models are taking hold to conduce cheaper, quicker and more effective cosmetics tests. Within React4life MIVO technology, it is possible to conduce a series of tests on advanced 3D models of Human Skin Equivalent developed in our laboratories. MIVO technology allows growing 3D living advanced models for skin on air-liquid interface, within a fluid-dynamic environment, thus achieving an unprecedented level in terms of test reliability. Examples of provided tests: – dermal drug delivery & transdermal diffusion – skin elasticity (anti-aging) – skin hydration - Agri-food and pollution Agri-food: in vitro digestion models are essential to study the structural changes, digestibility and release of food components under simulated gastrointestinal conditions. MIVO technology allows to test in vitro the digestibility of food compounds through a technological, reproducible and cruelty-free approach. Our system of membranes, combined with a fluid-dynamic system, allows to functionally simulate the absorption of compounds at the stomach and intestinal

633 / 880 levels. Discover a bunch of new opportunities for your business in the agri-food sector with our bioreactor offerings. Pollution: air is essential for living, and a good quality of air reflects a good quality of life. MIVO technology, allows to test in vitro the diffusion of nano/micro-particles through customized membranes functionally mimicking the pulmonary barrier. Easy to use, cheap and reliable solutions for all your needs in the field of air pollution testing. SERVICE Transdermal tests in vitro of cosmetic/dermatological formulations and medical devices Bu using React4life MIVO technology, we conduce a series of tests on Skin Tissue models which may be developed in our laboratories or commercially available, human tissues of animal biopsies. MIVO technology allows growing 3D living skin tissues on air-liquid interface, within a fluid-dynamic environment, thus achieving an unprecedented level in terms of test reliability. Examples of provided tests: – dermal drug delivery & transdermal diffusion - medical device diffusion – antipollution tests – SPF skin protection SERVICE Intestinal permeation of food compounds in vitro In vitro digestion models are essential to study the structural changes, digestibility and release of food components under simulated gastrointestinal conditions. MIVO technology allows to test in vitro the digestibility of food compounds through a technological, reproducible and cruelty-free approach. Our system of membranes, combined with a fluid-dynamic system, allows to functionally simulate the absorption of compounds at the stomach and intestinal levels. Discover a bunch of new opportunities for your business in the agri-food sector with our bioreactor offerings. PARTNERSHIP Commercial distribution React4life is seeking for partners to distribute our product and services in Italy and Europe.

634 / 880 Red River Hills

Organisation

Country Serbia City Nis Street Crvena reka

Person

Name Milica Stankovic Director

Organisation The "Red River Hills" complex consists of plantations "Lavandula" and "Siempreviva", located at the foot of mountain “Suva”, in the eastern part of Republic of Serbia. Organic herbs are grown on rocky and mountainous country, on the left bank of river Nishava, between three mountain massifs. This conditions creates almost Mediterranean climate, which favors lavender and immortelle. Plantation "Lavandula" engaged in the production of essential oils of lavender, honey production of lavender, and dry leaf of melissa. Plantation "Siempreviva" produces essential oils of immortelle, dried flower of immortelle, dried leaf of melissa. Products: essential oil of immortele, sage, carrot, yarrow, heather, angelica, mint, lavender. Areas of Activity

• Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

635 / 880 Remorides

Organisation

Country Italy City Motteggiana Street Via Alessandro Volta 4/a Web https://www.remorides.com

Person

Name Marco Begotti R&D Manager

Organisation REMORIDES is an innovative Italian firm founded in 2013. Central Core of the company revolves around providing advanced tools for Mission-Critical Fields. The company includes an Engineering division (centred on Industrial Automation, Facilities, Testing...) as well as software development of "Opera", the company's flagship product. In the last years, the company mainly focused on creating advanced solutions designed specifically for Data Integrity and Auditing Controls. Areas of Activity

• Life sciences related activities • Software, ICT applications, system integration • IT Applications for Health

Marketplace Opportunities PRODUCT Opera Integrity The wide range of products developed internally by Remorides includes OPERA Integrity. This product has been designed to meet the needs of customers in terms of DATA integrity. Today, DATA integrity is a central aspect in areas defined as "critical field" such as biomedical / pharmaceutical which is subject to stringent regulatory obligations. Thanks to OPERA Integrity software, it is easy to maintain DATA integrity; among the services that the system offers for biomedical/pharmaceutical companies we find: - The acquisition, through tools, of data from medical devices - Processing of the data collected - Interfacing with management information systems - User profile management - Traceability of operations carried out - Electronic compilation of acquisition reports The advantage of OPERA integrity is to have two application platforms: Opera Web Application and 638 / 880 Opera Android Application that contribute by bringing an assured quality.

639 / 880 Renovo SPA

Organisation

Country Italy City Mantova Street Via Pietro Verri 1 Web https://www.renovospa.it

Person

Name Giorgio Casoni Business Developer

Organisation Renovo BioChemicals srl is the division of Renovo SpA specialized in the research, extraction and marketing of active ingredients (nutraceuticals and cosmeceuticals) obtained from agricultural and forestry by-products. A first activity already started concerns the extraction and marketing of polyphenols from the vegetation waters of olives. This product is covered by 23 international patents and clinical trials that demonstrate its effectiveness as a powerful antioxidant. The R&D activity of Renovo SpA is carrying out researches aimed at extracting natural extracts from agricultural and agro-industrial waste. These extracts are used in the nutraceutical sector for the care of humans and animals. Areas of Activity

• Biomaterials • Medical devices • Biotechnologies (Pharma&Medical Devices) • Investments • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PRODUCT Hidrox dietary supplement HIDROX® is the first food supplement in the world to contain olive polyphenols, in particular hydroxytyrosol, obtained from the juice of fresh, organically grown olives. HIDROX® contains antioxidant polyphenols, especially hydroxytyrosol, obtained from the juice of fresh olives (Olea europaea). Scientific research of the past 15 years indicates that olive polyphenols help promote joint health and cardiovascular wellness, and are being studied for their ability to support healthy colon, brain, skin and immune functions. Olive polyphenols are believed to fight the toxic effects of cell damaging free radicals.

640 / 880 Repado Ltd

Organisation

Country Greece City Athens Street V. Georgiou 11 & Souri Str Web www.repado.com

Person

Name Vivian Sophou Business Development Manager

Organisation Repado is an ISO 13485:2012 certified Software Development House that specializes exclusively in the Medical Sector. Lab Automation, Liquid handling & Molecular IVD are some of the fields for which we develop/ implement complete software solutions. Repado owns a worldwide network of partners and collaborates closely with some of the most prestige houses in the field. Based on the company's extensive experience in high-end Lab robotics, our service portfolio includes innovative products for OEM’s as well as ODM products (owned by its customers), which extend from "low level driver interfaces" to "controlling software" and "dedicated solutions" such as external genomic applications like PCR Setup, DNA Extraction, Sample Prep etc. independent of instrument manufacturer. Repado presents LTM: its Medical Device Management Suite, for interacting with any type of medical device installed in the field (https://ltm-suite.com). In addition, Repado develops powerful modules for Lab Automation devices that can run individually or in-sync (http://repado.com/solar.php), multi-level architecture platforms (www.repado.com/lirix.php), external applications for creating pipetting sequences (www.repado.com/autrax.php) & more. For a detailed presentation of the Repado products and services, you are welcome to visit our website (www.repado.com). Areas of Activity

• Biotechnologies (Pharma&Medical • Laboratory equipment, reagents, software Devices) • Medical devices • Consulting services • IT Applications for Health • eHealth, mHealth, telemedicine • Software, ICT applications, system integration • EPR, Clinical/healthcare management software

Marketplace Opportunities PRODUCT LTM - the Medical Device Management Suite LTM is our Medical Device Management Suite, a plug 'n play solution that can be instantly integrated on any medical device. 641 / 880 Its advanced features allow user to: • Connect, Monitor & Manage multiple medical devices in the field • Create his own Network & be linked with his customers & providers in Real-time • Provide & Receive Premium Support Services on device failure & • LTM allows forward & backward device traceability as imposed by the latest EU Directive. It is an IVDR/ HIPAA Complaint Solution. LTM's advanced features & functionality are tailored to the needs of all the different medical business profiles. On the link below you can find more on its functionality and networking benefits: https://repado.com/index.php

642 / 880 Research Consortium Hypatia

Organisation

Country Italy City Rome Street

Person

Name Lorenzo Scatena General Manager

Organisation Hypatia is a research consortium and non-profit organization established in 2008 by the encounter between universities, research institutes and enterprises with the aim to promote, develop and enhance scientific, technological and human resources of the territory. Research activities are mainly focused on materials science, environmental sustainability, renewable energy technologies, and biomedical devices. The Consortium also addresses technology transfer issues and provides business services, offering assistance and advice to those who want to take full advantage of the growth opportunities in the area of R&D, through participation in co-financing EU, national and regional projects. The Research Consortium Hypatia is based at the Italian Space Agency headquarter (Rome, Italy) and characterized by a multidisciplinary scientific expertise, including chemistry, materials science, physics, bioengineering, mechanical engineering and electronic engineering. Moreover, within the Consortium it is also operative a legal department to supervise technology transfer processes, intellectual property and patent management. Areas of Activity

• 3D Printing/addictive manufacturing for • Manufacturing & process engineering biomedical applications • Medical research • Analytical and characterization services • Project proposals support services • Biomaterials • Biosensors • Consulting services

Marketplace Opportunities SERVICE Advisory The Research Consortium Hypatia can support an effective and tailored technology transfer process, thanks to the multidisciplinary approach in different fields: - Bioengineering - Additive Manufacturing - Satellite Application and Service commercialisation - Financial and funding opportunities

643 / 880 Research Unit for Dietary Studies at The Parker Institute

Organisation

Country Denmark City Frederiksberg Street Nordre Fasanvej 57, vej 8 entrance 8 Web http://www.parkerinst.dk/units/research-unit- dietary-studies

Person

Name Berit Heitmann Professor

Organisation At The Parker Institute - Copenhagen University Hospital, Bispebjerg og Frederiksberg, the Research Unit for Dietary Studies (EEK) conducts research on diet disease relationships in populations. The aim is to initiate and carry out research in the field of nutritional epidemiology on an international level, focusing on the importance of diet for the development of lifestyle related disease and death. Furthermore, the aim is to encourage and stimulate other researchers, including the training of younger researchers, to con-duct research within the field of nutritional epidemiology. Finally, EEK hosts of a network of nutritional epide-miology aiming at gathering the experts of this field, to ensure the opportunity of exchanging and sharing knowledge, e.g. arranging symposia and workshops on nutritional research Areas of Activity

• eHealth, mHealth, telemedicine • Other • Medical research • IT Applications for Health • Nutraceutics, probiotics, functional food, cosmeceutics • Life sciences related activities

Marketplace Opportunities PARTNERSHIP NoHoW - an evidence based ICT tool for weight loss maintenance (Horizon2020) The NoHoW consortium is looking for investment or partners to develop a commercial version of the TK that would be appealing for end users, with the development of further content for the TK to be conducted by the consortium. INVESTMENT OPPORTUNITY

644 / 880 NoHoW - an evidence based ICT tool for weight loss maintenance (Horizon2020) The NoHoW consortium is looking for investment or partners to develop a commercial version of the TK that would be appealing for end users, with the development of further content for the TK to be conducted by the consortium. PRODUCT NoHoW - an evidence based ICT tool for weight loss maintenance (Horizon2020) Most adults who try to lose weight fail to maintain it. Effective interventions and commercial programmes for weight loss are widely available, but most people re-gain their lost weight. Currently few comprehensive solutions exist to help Europeans manage weight loss maintenance (WLM). Current research suggests the most promising evidence-based behaviour change techniques for WLM are self-monitoring, goal setting, action control, building self-efficacy and intrinsic motivation. Recent research also suggests that stress management and emotion regulation skills are key enablers of relapse prevention and weight regain. Information technology offers attractive tools for teaching and supporting these techniques, some of which are currently delivered through resource-intensive face-to-face therapies. IT-based delivery includes networked-wireless tracking technologies, weighing-scales and activity sensors, online tools and smart-phone apps, multi-media resources and internet-based support. NoHoW has developed an online Toolkit (TK) for weight loss maintenance based on this evidence. The TK includes content to teach users how to best self-monitor their weight and manage stress and emotion to maintain their weight loss in the long term. Users can also use the TK to self-monitor their own weight, physical activity and sleep with data collected through wireless scales and activity trackers. Versions of the TK are available in English, Danish and Portuguese. The TK is currently being tested in a randomised control trial with over 1,600 users in the UK, Denmark and Portugal, which will finish 1-year data collection in March 2019. Our go-to-market strategy is to license the NoHoW TK, or elements of the NoHoW TK, to companies that wish to add evidence-based weight loss management technologies, tools, behaviour change approaches and personalized navigation tools to their existing service/product portfolio or to provide weight loss management services/products as a new offering to their customers. This could include weight loss companies, pharma, food, technology companies (e.g. fitbit, Garmin), health insurance companies or public health bodies.

645 / 880 RetiNEXT

Organisation

Country Italy City Savona Street Via Alla Marina 2

Person

Name Marco Feligioni Project Leader

Organisation RetiNEXT is pharmaceutical project aiming to develop a new treatment for Excitotoxic pathologies in the eye. We discovered a new mechanism that regulates glutamate release and we designed a new drug that we want to develop as potential treatment. The organization is proprietary of an international patent already extended in 6 countries (USA, EUROPE, JAPAN, CINA, South Corea, INDIA). We are looking for investments to continue the preclinical phases for the treatment of glaucoma. WE ARE LOOKING FOR INVESTORS OR CO-DEVELOPMENT OR LICENSING PARTNERS Areas of Activity

• Investments • Peptides, proteins & antibodies preparation • Pharmaceutics

Marketplace Opportunities

PRODUCT A new molecule to contrast retinal cell death in glaucoma. Glaucoma is widely recognized as a multifactorial, progressive and neurodegenerative disorder that affects retinal cells viability leading patients to a progressive visual field loss and ultimately to blindness. Being characterized by several features, up to date, we can’t consider glaucoma as an unique disease but clinical evidences have described a list of several glaucomas that can be grouped in two main types called Open-angle glaucoma (OAG) and Angle-closure Glaucoma (ACG) (4). Nowadays, it has been estimated that more than 60 million people worldwide are affected by glaucoma and they will rise up to 80 million, those of which 47% will be Asians, in 2020. Overall, there will be around 5.9 million of bilateral blind patients affected by OAG while 5.3 million people will be the ACG patients in 2020. Taking in account the numbers of patients involved and the financial and social effects arising from blindness, glaucoma deserves efforts in several fields of the research, especially medical, to find new molecular targets followed by new cures. Glutamate

646 / 880 Glutamate is the major excitotatory neurotrasmitter in the brain which has an important role in the synaptic transmission. For this reason defects on the normal physiology of the glutamate modulation can cause synaptic dysfunction. The over-release of glutamate, in fact, can lead to the cell death. This can be caused by many conditions including the over-stimulation of presynaptic NMDA receptors. Retina. Retina has a large content of glutamate transmission and also NMDA receptors are present at this level and they control glutamate release. In presence of intraocular pressure increase, which is the condition of glaucoma, the retinal cells undergo to death due to over stimulation included glutamate activity. NMDA is still an important receptor at retinal level too. Our Molecule The molecule we developed is able to reduce glutamate release by blocking specifically NMDA presynaptic receptor. Our molecule is able to block a protein/protein interaction which is at the base of the molecular mechanism that we discovered that controls NMDA-evoked release of glutamate. PARTNERSHIP Investors, co-development or licensing partners The project is so far at preclinical phase and we need to compleate glaucoma models, toxicology and GMP production. In 1,5 year time the project will be finished to enter in clinical phase I We need a partner to develop the product with. Can be investor pool, co-development partner or licensing. We don't need consultants. We have already business plan and we know where to do all the studies. INVESTMENT OPPORTUNITY Investors needed The project is so far at preclinical phase and we need to compleate glaucoma models, toxicology and GMP production. We have the financial support from istitutional grant to finish the glaucoma model experiements. In vivo experiment on glaucoma model will be compleated in 6 months. Then we will go for the toxicology and GMP molecule production. In 1,5 year time the project will be finished to enter in clinical phase I We need a Venture Capital or Pharma partner to sign a commitment for supporting the studies after in vivo model studies. Can be investor pool, co-development or licensing partners.

In case investors wants to be part of the project i will be more than happy to discuss. We have all the necessary documents.

647 / 880 RH Bophelo

Organisation

Country South Africa City Johannesburg Street 18 Melrose Boulvard, Melrose Web http://www.rhbophelo.co.za

Person

Name Quinton Zunga Chief Executive Officer

Organisation Medical Infrastructure Company listed on the Johannesburg Stock Exchange. RH currently manages the R1.6bn Razorite Healthcare Fund (the “RHF”).The RHF focuses on investing in healthcare infrastructure, providing accessible and affordable quality healthcare to the greater population of South Africa. Areas of Activity

• eHealth, mHealth, telemedicine • EPR, Clinical/healthcare management • Electromedical and medical equipment software (non diag) • Medical devices • Investments • IT Applications for Health • Medical facilities furnishings, equipment, goods • Software, ICT applications, system integration

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment in healthcare We are a healthcare investment company investing in medical infrastructure and technology. Our Investment Philosophy: RH Managers (Pty) Ltd seeks to create value for the Fund through the following investment approach: - Identify healthcare and rehabilitation opportunities from as early as pre-feasibility stage; - Access under-funded companies or opportunities with rapid growth potential or a proven ability to capitalize on immediate and long-term growth opportunities without taking significant risks. - Actively manage portfolio companies through hands-on partnerships to improve corporate, financial, operational and strategic management. - Position portfolio companies for exit by collaborating with management to build companies with strong operations, good growth prospects and international governance and management practices, to create appealing acquisition targets for both strategic and financial investors. 649 / 880 Rīga Stradiņš University

Organisation

Country Latvia City Riga Street Dzirciema iela Web www.rsu.lv

Person

Name Julija Voicehovska Principal researcher, associate professor

Organisation Rīga Stradiņš University, RSU, is a leading academic research institution in the fields of medicine, pharmacy, dentistry, rehabilitation and nursing sciences. Research in social sciences, humanities and law, for which RSU has a significant intellectual and theoretical base, is becoming increasingly important. An ever-increasing attention is paid to the transfer of knowledge and technologies by integrating knowledge in the basic functions of the University, and also transforming knowledge in to products and services that are useful to the society. Since 2008, Rīga Stradiņš University research activities have been organized within the following RSU priority research directions: Ageing: biological ageing factors and quality of life in Latvian population Structural biology, functional and biomechanical studies for new diagnostic tools and new therapeutic interventions Endogenous and exogenous risk factors in Latvia, comprehensive analysis of public health determinants Modern approaches to infection agents, their role in infections relevant for Latvia Mortality and disability factors during childhood Cancer: research on clinical and molecular characteristics and their advancement for prevention, early diagnosis and improvement of treatment strategies Immunochemical, radiological and clinical methods in research on dentofacial and maxillofacial deformities and anomalies Clinical epidemiology of functional limitations caused by health disturbances Social dimension of medicine, effects of globalisation Areas of Activity

• Medical research

Marketplace Opportunities PRODUCT Epidermal lipid barrier restoring cream (ideal for metabolic syndrome

650 / 880 patients) Novelty cream composition represents a mixture of water and fats, fat-like and other compounds. High percentual fat and fat-like substance content is crucial in achieving epidermal bilipid layer restoration and its water-lipid mantle. Cream enhances both skin’s elasticity, hydration and restorability. The stand-out feature is a prominent and stable effect of complex cream composition due to emulsifiers INNOVATIVE ASPECTS AND MAIN ADVANTAGES Composition and technology developed: Industrial applicability: EC regulation No 1223/2009 on cosmetic products (30.10.2009), article 11 Observational study for cream done (8 weeks, 83 pacients, control group) Studies have confirmed that the cream restores epidermal lipid barrier of the skin and skin barrier function in patients with the metabolic syndrome improves turgor and hydration of the skin, restores elasticity and smooth skin relief, reduces the phenomenon of pigmentation Customers surveys done IP protection: LVL patent granted PCT application submitted MARKET APPLICATION Beach-head market: Metabolic Syndrome (MetS) patients Skin damage is associated with MetS Approximately 360 million people had MetS in 2011; MetS incidence worldwide ranges from 15% to 20% MetS is associated with premature ageing of the skin due to impaired barrier function of the skin. TYPE OF PARTNER SOUGHT Path to market, further studies/development/collaboration would be appreciated: License partner (manufacturer, distributer) Investor (further studies)

651 / 880 Rizzoli Orthopedic Institute

Organisation

Country Italy City Bologna Street via di Barbiano, 1/10 Web http://www.ior.it/en/ricerca-e-innovazione

Person

Name Davide Golinelli MD Public Health

Organisation Rizzoli Orthopaedic Institute is the main Italian institute of orthopedics and traumatology. In 1981 the Italian Health Ministry gave Rizzoli the status of a 'Scientific research hospital' due to its high level of healthcare in orthopedics and traumatology.In fact, the institute's strength lies in the close integration between healthcare (about 150,000 patients examined and over 20,000 orthopedic operations every year) and scientific research, which is carried out in fifteen laboratories at the institute employing a staff of 300 including doctors, biologists and technicians. Furthermore, it is a place of university teaching, due to its association with Bologna University. Areas of Activity

• 3D Printing/addictive manufacturing for • Nutraceutics, probiotics, functional food, biomedical applications cosmeceutics • Analytical and characterization services • Pharmaceutics • Bioinformatics, Big data analytics • Software, ICT applications, system • Biomaterials integration • Biosensors • EPR, Clinical/healthcare management • Biotechnologies (Pharma&Medical software Devices) • Surgery technologies and applications • CRO (Contract Research Organisation) • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Investments • Medical research

Marketplace Opportunities PARTNERSHIP A professional connection with the technological/research/clinical activities of Rizzoli Orthopedic Institute Technopole Contact Dr. Davide Golinelli for a free consulence in the following fields: - finding an internal contact able to explain the most important ongoing muscloskeletal regenerative clinical activities of Rizzoli Orthopedic Institute excellence innovation centre; 652 / 880 - beginning R&D collaborations with the Rizzoli RIT Department; - scouting for funding opportunities and developing new R&D networks; - applying to National and European Projects; - technology and knowledge transfer. MAIN ADVANTAGES The main advantages in collaborating with the Rizzoli Orthopedic Institute is the opportunity to participate in R&D activities with an excellent Italian hospital and a leader in Orthopedics and Regenerative Medicine solutions and innovations. The Rizzoli Orthopedic Insitute and all its branches are proud to join the Clust-ER associations, the new Emilia Romagna Region High Technologies Network

653 / 880 Rizzoli Orthopedic Institute - Istituto Ortopedico Rizzoli

Organisation

Country Italy City Bologna Street Via di Barbiano, 26 Web https://www.linkedin.com/in/nicola- fazio-6b675913

Person

Name Nicola Fazio Industrial Researcher

Organisation The Rizzoli RIT - Research, Innovation & Technology Department is the Industrial Research Technopole of excellence of The Rizzoli Orthopedic Institute. Such branch of the Rizzoli IRCSS Hospital manages its participation into the Regional, National and European High Technology Networks. Activities of research laboratories, which constitute the RIT Department, are characterized by their relations with industrial partners, operating in the following research fields: regenerative medicine; biomedicine; pharmaceutics; biomechanics; clinical translations. Technology transfer and Industrial research are the leading principles of RIT Laboratories.

Areas of Activity

• 3D Printing/addictive manufacturing for • Medical devices biomedical applications • IT Applications for Health • Biomaterials • Biotechnologies (Pharma&Medical Devices) • Medical research • Pharmaceutics

Marketplace Opportunities SERVICE

654 / 880 A professional connection with the technological/research/clinical activities of Rizzoli Orthopedic Institute Technopole With 7 years of experience in the fields of industrial research, technology transfer, fund raising and regenerative medicine products development, Dr. Nicola Fazio, Ph.D., offers his complete and kind avalaibility for a professional interaction with the complex acitivities of the Rizzoli Technopole, the Research, Innovation and Technology (RIT) Department. Contact Dr. Nicola Fazio for a free consulence in the following fields: - developing regenerative medicine solutions in Orthopedy; - finding an internal contact able to explain the most important ongoing muscloskeletal regenerative clinical activities of Rizzoli Orthopedic Institute excellence innovation centre; - beginning R&D collaborations with the Rizzoli RIT Department; - scouting for funding opportunities and developing new R&D networks; - applying to European Projects; - technology transfer. MAIN ADVANTAGES The main advantages in collaborating with the Rizzoli Orthopedic Institute is the opportunity to participate in R&D activities with an excellent Italian hospital and a leader in Orthopedics and Regenerative Medicine solutions and innovations. The Rizzoli Orthopedic Insitute and all its branches are proud to join the Clust-ER associations, the new Emilia Romagna Region High Technologies Network PROJECT COOPERATION Patents and Technology Transfer Rizzoli Orthopedic Institute has a long established experience in patent innovative device and methods in the orthopedic field. To date, several recently patented ideas and devices are still available for licensing. Contact Dr. Nicola Fazio to begin a new industrial partnership or for asking more information about the following inventions: - fast and unexpensive test for osteoporosis diagnosis; - wear-resistant implants; - new method to produce Demineralized Bone Matrix; - Ewing Sarcoma nanovescicle-based treatment. INVESTMENT OPPORTUNITY Patents and Technology Transfer Rizzoli Orthopedic Institute has a long established experience in patent innovative device and methods in the orthopedic field. To date, several recently patented ideas and devices are still available for licensing. Contact Dr. Nicola Fazio to begin a new industrial partnership or for asking more information about the following inventions: - fast and unexpensive test for osteoporosis diagnosis; - wear-resistant implants; - new method to produce Demineralized Bone Matrix; - Ewing Sarcoma nanovescicle-based treatment.

655 / 880 Rödl & Partner - Attorneys-at-Law, Tax Consultants, Certified Public Accountants and Labour Consultancy

Organisation

Country Italy City Milan Street Largo Donegani 2 Web http://www.roedl.net/it/it/

Person

Name Rosa Mosca Law Firm

Organisation Rödl & Partner is a multi-disciplinary professional services firm. We provide audit, accounting, tax, legal and labour consulting services for international businesses. In particular we are specialized in Intellectual Property and Data Protection matters: Registration of Italian, European and International trademarks: preliminary filing’s strategies, filing procedures, territorial extensions, prosecution, renewal; opposition procedures for Italian, European and International trademarks; coexistence agreements. Researches and opinions on the registrable trademarks; Surveillance at local and international level on trademarks, social and commercial names, designs and models, domain names; Web Watch Surveillance: service which identifies cases of potential abuse of the brand and its identity, of derogatory comments, and of unauthorized use. Drafting, filing, management of National, European and International design; Counterfeiting, unfair competition and anti-cybersquatting: opinions and legal advice; drafting and negotiating contracts for the transfer and / or licensing of industrial and intellectual property rights, rights on invention; trademarks and patents regulations; Customs measures; Protection of copyrights, software, know-how; Domain names and e-commerce, registration’s procedure and appeals for reassignment; Technical consultancy; Due diligence and evaluation of intellectual assets; I.P. Finance: intangible assets used as guarantees for loans, obtaining financing through the granting of i.p. rights, leasing contracts. Areas of Activity

• Bioinformatics, Big data analytics • Regulatory affairs, validation • Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Software, ICT applications, system • Consulting services integration

656 / 880 • eHealth, mHealth, telemedicine • Other • Manufacturing & process engineering • Laboratory equipment, reagents, software • Medical facilities furnishings, equipment, • Medical devices goods • IT Applications for Health • Nutraceutics, probiotics, functional food, cosmeceutics • Packaging & labelling • Pharmaceutics

Marketplace Opportunities SERVICE Intelelctual Property and Data Protection consultance Rödl & Partner is a multi-disciplinary professional services firm. We provide audit, accounting, tax, legal and labour consulting services for international businesses. In particular we are specialized in Intellectual Property and Data Protection matters.

657 / 880 RTC S.p.A.

Organisation

Country Italy City Pomezia Street Via Tito Speri, 12 Web http://www.rtc.it

Person

Name Morena Cascone Senior Business Development Manager

Organisation RTC leading CRO in Europewith more 45years of experience providing high quality in nonclinical research to national and international chemical and pharmaceutical companies. RTC is accredited by AAALAC and offers a full range of toxicological studies and consultancy services for the following sectors: Chemicals, Agrochemicals, Pharmaceuticals, Biocides. RTC high standard quality is guaranteed through European, American and Japanese authorities’ approval. Areas of Activity

• Analytical and characterization services • Nutraceutics, probiotics, functional food, • Biotechnologies (Pharma&Medical cosmeceutics Devices) • Pharmaceutics • CRO (Contract Research Organisation) • Vaccines • Drug screening & delivery • Medical research

Marketplace Opportunities SERVICE RTC - High Competence in non-clinical development RTC leading CRO in Europe with 45 years of experience providing high quality in nonclinical research to national and international chemical and pharmaceutical companies. RTC is accredited by AAALAC and offers a full range of toxicological studies and consultancy services for the following sectors: Chemicals, Agrochemicals, Pharmaceuticals, Biocides. RTC high standard quality is guaranteed through European, American and Japanese authorities’ approval

658 / 880 RUBERTI srl

Organisation

Country Italy City QUISTELLO Street via Basaglie, 1/c Web https://www.ruberti.it

Person

Name EMANUELE ZONTA EXPORT SALES MGR.

Organisation Engineering and Manufacturing of complete and/or part of machines and taylor made PU/ABS bodies suitable for biomedical equipments such as dialysis machines, MRI scanners, CT scanners, air-cleaners; neurostimultaion/rehabilitation systems etc.. Ruberti is a leader in the design and manufacture of plastic products, as a partner in the global management of " states of supply ", composed of polyurethane parts, thermoforming, sheet metal, profiles, electric and electronic components . The flexibility of the service offered , the widespread know-how and rooted in the company have allowed us to face any target market , pointing to technological innovation as a distinguishing factor in the identity of Ruberti Areas of Activity

• Manufacturing & process engineering • Medical devices

Marketplace Opportunities PRODUCT Hi-tech material combination for better helthcare design. Latest design and cutting-edge Engineering and Manufacturing of complete and/or part of machines and taylor made PU/ABS bodies, covers and housing suitable for medical equipments such as dialysis machine, ultrasound, mammography, CT scans, MRI machine, PET scan and PET-CT scan, neurostimulation/rehabilitation systems, air-purifier, radiant heater for neonatal incubator, etc..) etc.. Ruberti is a leader in the design and manufacture of special plastic products, as a partner in the global management of the " states of supply ", composed of polyurethane parts, thermoformings, sheet metals, profiles, electric and electronic components . The flexibility of the service offered , the widespread know-how and rooted in the company have allowed us to face any target market , pointing to technological innovation as a distinguishing factor in the identity of Ruberti . SERVICE

659 / 880 DESIGN,ENGINEERING,PRODUCTION OF SPECIAL PLASTIC PARTS FOR MEDICAL DEVICES We offer design taylor-made engineering and manufacturing of body parts, housings and covers made of dedicated plastic materials (Structure Polyurethane, Integral Polyurethane, ABS Thermoplastic) suitable to biomedical devices and complying with the latest regulations.

660 / 880 S.A.F.AN. BIOINFORMATICS s.a.s

Organisation

Country Italy City Torino Street via Fulvio Croce 23/B Web http://safan-bioinformatics.it

Person

Name Luisa Pugliese Ceo

Organisation S.A.F.AN. BIOINFORMATICS is a small bioinformatic/chemoinformatic company based in Torino, Italy. It was born in 2004 after a business plan competition organized by the Politecnico of Turin.Our know how both in basic and applied research in the field bioinformatics, chemoinformatics and structural biology allow us to collaborate with Italian and European companies. S.A.F.AN. BIOINFORMATICS was a partener in the protein engineering fp7 project "NewProt" (http://swift.cmbi.ru.nl/gv/newprot/) and is now partner of the CaSR Biomedicine H2020 project (https://casr.meduniwien.ac.at/) Our know how let us develop new technologies for in silico profiling of small molecules and peptides, SAFAN-ISPSM and SAFAN-ISPPEPTIDE, with the goal of decrease the costs and increase the speed of the drug development process. Indeed drug discovery is a high-risk crucial process in pharmaceutical industry, as it can result, after many years and big investments, in a successful marketed drug or in total failure. To limit risks in “vitro” pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs. However costs for in vitro test limit the number of experiments that can be planned and even after the profiling is performed, the picture in uncomplete and not always the right decision are taken. We propose the use of a new technology for in “silico” profiling having the output and reliability of in “vitro” hit validation methods but with in “silico” times and costs. Areas of Activity

• Bioinformatics, Big data analytics • Laboratory equipment, reagents, software • Consulting services • Drug screening & delivery • Life sciences related activities

Marketplace Opportunities SERVICE

661 / 880 SAFAN-ISPSM SAFAN-ISPSM forecasts the binding of a small molecule against a library of 4500 proteins. The technology gives results comparable to the experimental profiling but has in silico time and costs and can be run without the need of synthesizing the molecule. SERVICE SAFAN-ISPPEPTIDE for peptide profiling SAFAN-ISPPEPTIDE forecast the binding energy of a peptide to 4500 proteins. It has in-silico times and costs but its reliability is comparable to an experiment. It could be very helpful to forecast the interaction between peptides and immunological proteins. PARTNERSHIP Eu project cooperation We are looking for EU project cooperation. We can offer a very wide know how in bioinformatics, chemoinformatics and structural bioinformatics INVESTMENT OPPORTUNITY SAFAN-ISP: the new standard for binding energy evaluation The interactions between small molecules and proteins constitute one of the most important parts of interconnected biological networks and are of vital importance for characterizing the expression and function of proteins related to discovering drug candidates for clinical diagnosis. Our new technology SAFAN-ISP, working on small molecules and peptides, has in silico times and costs but its reliability is very close to an experiment, giving it a very high value.

662 / 880 S&P Brain

Organisation

Country Italy City Orbassano (TO) Street Regione Gonzole 10 Web https://www.spbrain.com/

Person

Name Marina Boido Researcher

Organisation S&P BRAIN provides complete in vivo proof-of-concept research to meet the needs of pharmaceuticals, biotechnology and medical devices companies or research centers. S&P Brain offers preclinical studies in small animals spanning from a wide range of behavioral tests to models of neurological injuries to cardiovascular, endocrine and metabolic measures, leading to reliable results required for the preclinical phase. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Drug screening & delivery • Medical research

Marketplace Opportunities SERVICE S&P Brain service S&P BRAIN provides to pharmaceutical, biotechnology and medical device Companies and to Research Centers high quality research and on-time results that are tailored to our clientʼs need to prove in vivo the efficacy of new drugs for the treatment of neurological or psychiatric disorders or biocompatibility of biomedical devices. S&P BRAIN’ staff has extensive experiences in designing specialized in vivo studies or identifying new and robust models for the preclinical proof of concepts and to adapt them to customer's project needs. REQUEST Looking for new business contacts We would like to establish contacts with pharmaceutical, biotechnology and medical device companies and research centers, to perform proof-of-efficacy of new drugs or pilot in vivo studies

663 / 880 S4BT - Solution for Business and Technologies

Organisation

Country Italy City Latina Street V.le PL Nervi, Latinafiori Torre 4 Web http://www.s4bt.it/

Person

Name Domenico Salzano General Manager

Organisation We are an ISO 9001:2015 certified organization made up of 80 specialists. We are also outstanding AFI - (Association of Italian Pharmaceutical Industries) shareholders. S4BT is specialized in: - Software solutions - Consulting Service But what really makes us different is our unique approach. This is why major national and international companies have been working with us for years. Our extensive knowledge of the industry allows us to offer concrete, practical solutions and for over 20 years our R&D group has been designing and developing some of the most innovative software around. Our specific consulting services include Validation, Computer System Validation, Project Management, Data Integrity, Manufacturing and Process Engineering, Equipment, Systems and Utilities Qualification. Areas of Activity

• Biotechnologies (Pharma&Medical • Other Devices) • Laboratory equipment, reagents, software • Chemicals & APIs • Project proposals support services • Consulting services • Medical devices • Manufacturing & process engineering • IT Applications for Health • Packaging & labelling • Pharmaceutics • Regulatory affairs, validation • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT

664 / 880 PRAGMA - Workflow Manager PRAGMA is a Workflow Management System that assures you the perfect compliance with the industry’s standards and rules. PRAGMA manages processes of: - Quality Assurance - Maintenance - Quality Control - Environmental Health and Safety - Project Management - Production - Maintenance - IT - Logistics and Wharehouse. The platform is scalable, web-based, flexible and completely customizable. A solution CFR21 Compliant that stores every detailed piece of information, accessible only to authorized departments and resources. Working with the right tools makes the job easier and flowing. Whenever. SERVICE S4BT Consulting Whatever your specific field is, choosing the most suitable People, Competencies and Technologies will always be the most crucial decision. We have been offering our specialized services to small, medium and large Chemical, Pharmaceutical, Medical, and Cosmetical companies for more than 25 years. S4BT Consulting is made up of more than 50 consultants operating in the following Macro Areas: •IT & CSV •Engineering & Qualification •QA & Compliance •Quality Control •Validation •Tech Transfer •New Product Introduction •Project Management SERVICE Equipment, Systems and Utilities Qualification In accordo alle cGMP gli equipment, i sistemi e le utilities di produzione che hanno impatto diretto sulla qualità di un prodotto, devono essere sottoposti ad una convalida che attesti la riproducibilità e la ripetibilità nella manifattura di un prodotto per ottenere la conformità alle sue specifiche di riferimento. REQUEST New business opportunities We research new potential customers and new business opportunities.

665 / 880 S4BT Consulting

Organisation

Country Italy City Latina Street V.le PL Nervi, Latinafiori Torre 4 Web http://www.s4bt.it/

Person

Name Gianpiero Calabrò Project Manager

Organisation We have been offering our specialized services to small, medium and large Chemical, Pharmaceutical, Medical and Cosmetical companies for more than 25 years. Our organization is made up of more than 50 specialists operating in the following Macro Areas: •IT & CSV •Engineering & Qualification •QA & Compliance •Quality Control •Validation •Tech Transfer •New Product Introduction •Project Management We are UNI EN ISO 9001:2015 certified organization, and we operate in a specific Quality System. Our purpose is to achieve all the objectives within time and cost predictions. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Software, ICT applications, system • Chemicals & APIs integration • Consulting services • Other • Nutraceutics, probiotics, functional food, • IT Applications for Health cosmeceutics • Packaging & labelling • Pharmaceutics • Regulatory affairs, validation

Marketplace Opportunities SERVICE

666 / 880 S4BT Consulting We have been offering our specialized services to small, medium and large Chemical, Pharmaceutical, Medical, and Cosmetical companies for more than 25 years. S4BT Consulting is made up of more than 50 consultants operating in the following Macro Areas: •IT & CSV •Engineering & Qualification •QA & Compliance •Quality Control •Validation •Tech Transfer •New Product Introduction •Project Management

667 / 880 S4mdc Medical Device Consultants Italy

Organisation

Country Italy City Medolla (Modena) Street Via Sant Antonio 15 Web www.s4mdc.com

Person

Name Scott Roberts Consultant

Organisation S4MDC Medical Device Consultants, is an Italian based association of management professionalssupporting MED DEV companies with numerous key services We provide SMEs with assistance in developing and expanding their businesses internationally, understanding of regulatory affairs in various countries, product development and prototyping, developing systems to provide management change and provide interim HR management. Strategic and Financial planning to assist management in defining business strategy, monitoring financial performance and obtaining funding. Market and business plans operative forward pathways and market access. Identification of potential investors including specialist venture capitalists and preparation of information to present to such organisations. Internationalisation projects from distribution networks setup and on going management, to OEM and OBL agreements. Finding and managing distributors worldwide with one of the largest databases of distributors available. Regulatory Affairs consultancy to comply with EU Directives and assistance with European Authorised representative services. QA management system development for ISO, GMP and validation processes. New product development engineering and prototyping. Corporate image. Our team is comprised of experienced multilingual senior managers with proven success records in the above areas. Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Surgery technologies and applications • Consulting services • Medical devices • Electromedical and medical equipment

668 / 880 (non diag) • Investments • Physiotherapy, Orthopaedic technology • Regulatory affairs, validation

Marketplace Opportunities SERVICE Consultancy for SME Medical Device Companies S4MDC is an association of management professionals with extensive experience in the medical device sector. We provide SMEs with assistance in developing and expanding their businesses, understanding of regulatory affairs in various countries, product development and prototyping, developing systems to provide management change and provide interim HR management. In details: - Strategic Company Business and Marketing and Sales planning with qualified Management Accountants and Marketing and Sales professionals with extensive experience in the medical device sector. - Regulatory Affairs and QA management systems development for ISO, GMP and validation processes, to comply with EU Directives and assistance with European Authorised representative services. - Internationalization projects from distribution networks setup and on going management, to OEM and OBL agreements. - Key management and executive personnel, including interim management services for key positions. - New product development engineering and prototyping. - Advertising and promotion - Intellectual Property services. - Industrial Design.

669 / 880 Sapienza - Università di Roma

Organisation

Country Italy City Roma Street Via Eudossiana 18

Person

Name Antonio Zuorro Associate Professor

Organisation The Department of Chemical Engineering Materials & Environment of the University La Sapienza of Rome gives particular importance to research in the field of Biotechnology and Biochemical Engineering. Within the joint lab, called “iBeta”, we study advanced processes for the recovery of high value-added compounds from plant tissues (mainly agro-industrial wastes) or microbial biomass (principally microalgae). Agro-industrial residues represent a real problem for food companies because of their high cost of treatment, which is mainly due to the huge amounts generated and the fact that they are produced in a short period of time. Despite of that, fruit and vegetable wastes are very rich in antioxidants with beneficial effects on human health. According to many studies, these compounds possess interesting antimicrobial properties as well as the ability to provide protection against lipoprotein oxidation, cardiovascular and senescence diseases and some types of cancer. Microalgae are considered one of the most promising alternative sources of lipids for biodiesel production and antioxidants for human health. One of the major bottlenecks in the overall process is represented by the high energy consumption associated with the extraction of targeted molecules from the algal cells, mainly due to the thickness and highly resistance of cell walls. Common treatments (mechanical, ultrasound-assisted, …) allow good recoveries but are energy intensive and potentially capable of damaging valuable components. For these reasons, we develop new processes to disrupt the cell wall by economic enzymatic pretreatments and consequently increase the extraction yields. Our research therefore includes an experimental phase, aim to study the influence of the operating parameters on the extraction yields of these bioactive compounds from various matrices (e.g. lycopene from tomato peels, melanoidins from coffee wastes, polyphenols from blueberries residues, artichoke wastes and olive pomace, lipids and antioxidants from microalgae) and the characteristics of solvent mixtures and / or low-cost commercial enzyme preparations, specifically developed and tailored on the basis of the vegetable structure or microalgal cell wall composition. Areas of Activity

• Biomaterials • Laboratory equipment, reagents, software • Chemicals & APIs • Project proposals support services • Manufacturing & process engineering • Nutraceutics, probiotics, functional food,

674 / 880 cosmeceutics

Marketplace Opportunities PRODUCT Value added compounds from microalgae or agro industrial wastes Polyphenols are a class of plant secondary metabolites exhibiting high antioxidant activity and other important properties such as induction of apoptosis, inhibition of DNA synthesis and modulation of signal transduction pathways. The antioxidant activity of these compounds is related to their ability to quench reactive oxygen species (ROS) and to stimulate the endogenous defense system. For these reasons, polyphenols are recognized as important phytonutrients capable of protecting cellular components from oxidative damage and contributing to the prevention of oxidative stress-related degenerative diseases. During the industrial processing of fruits and vegetables, a large amount of wastes, such as stems, peels, leaves, is discarded. These are often unsuitable for human consumption and is usually disposed of as a solid waste. However, they are a very rich source of bioactive compounds, such as polyphenols. The reason is to be found in the fact that, during plant development, phenolic compounds tend to accumulate in the peripheral parts of the plant, where they perform their biological functions. Our study is aimed at assessing the suitability of phenolic extracts obtained from agroindustrial residues as an ingredient for the production of new functional foods. TYPE OF PARTNER SOUGHT: Companies interested in new processes for the extraction of value added compounds from agro industrial wastes or from microalgae. PRODUCT Greener and cost-effective routes for the biogenic synthesis of metal nanoparticles from agro-industrial wastes for biomedical application The goal of the project is the development of an environment-friendly method for the production of nanoparticles (NPs). Current protocols include the use of couples of costly and non-sustainable chemicals. Food wastes containing phenolic compounds have shown bioactive and anti-oxidant properties. In this contribution we investigate the feasibility of using commonly-found agro-industrial wastes as a flexible raw material in order to obtain NPs. The concept contributes significantly to the investigation of innovative nano-production of metal particles. It contributes to valorization of waste as bioactive resources being employed in green chemical reactions. According to NPs production, these new approaches are addressed at reducing environmental impact by giving safe products. Regarding the latter ones, the development of this technology seems to be highly suitable even for biomedicine and electronics engineering research.

675 / 880 Sardegna Ricerche

Organisation

Country Italy City Cagliari Street Web http://www.sardegnaricerche.it

Person

Name Caterina Carboni Biomed District

Organisation Sardegna Ricerche is a regional Agency that: 1. supports innovation of the production system, favouring technology transfer from universities and research centres to industry 2. fosters the set up of innovative enterprises and attracts high-tech companies to Sardinia 3. promotes, manages and develops the Science and Technology Park of Sardinia 4. enhances human capital through advanced training and work placement programmes 5. delivers services to Sardinian SMEs aimed at the introduction of new technologies and products and modernisation of corporate organisation. Within its activities, Sardegna Ricerche promotes activities of the Cluster for Biomedicine and Health Technologies. One activity is represented by the Biomedical Platform The Platform consists of the Biomedical Research Support Unit and the Technological Laboratories , serving the entire regional territory. The Biomedical Research Support Unit serves as a reference point for pre-clinical and clinical research and experimental activities carried out in the regional territory and carries out technical-scientific assistance, monitoring, dissemination and exploitation of results, information and training. Areas of Activity

• Bioinformatics, Big data analytics • Software, ICT applications, system • eHealth, mHealth, telemedicine integration • Pharmaceutics • Other • Proteomics, metabolomics, nutrigenomics • Laboratory equipment, reagents, software • Regulatory affairs, validation • Project proposals support services • Life sciences related activities

Marketplace Opportunities SERVICE Laboratory of Bioanalytical Technologies (TBA) The laboratory is equipped with analytical and research instrumentation for chromatographic and mass spectroscopy, and also provides the basic instrumentation of an analytical chemistry laboratory. An HPLC-DAD with UV-Vis detector of diodes (Agilent ChemStation Series 1100) allows the quantification of analytes in complex samples and the collection of chromatographic fractions. The 676 / 880 HPLC-DAD analysis provides a detailed molecular profile of the organic compounds, which can be identified by comparison with standard compounds. Using a triple quadrupole mass spectrometer (Four micro API interfaced with a Waters TM 2690 HPLC Separation Module with Auto Sampler and Alliance Waters columns and Mass Lynx software), LC / MS / MS analysis can be performed. The instrument is equipped with an atmospheric pressure ionisation interface (API Z-Spray). In addition to routine analyzes, it is possible to perform qualitative screenings and quantitative analyzes, with extreme precision and accuracy, of trace elements. The combination of liquid phase chromatography with this mass detector allows the analysis of a wide range of molecules, including thermolable substances, non-volatile substances and high molecular weight compounds. Technological equipment - HPLC with Diode-1100 series detector (Agilent) - LC / MS / MS Waters - Other equipment SERVICE Next Generation Sequencing Laboratory (NGS) The Next Generation Sequencing Platform has a production capacity in 2016 of 10 TBase / month. Runs large-scale sequencing projects from data output to analysis. The facility has been used for large-scale projects in various areas, including complete sequencing of human genes, transcripts, metagenomics, identification of DNA binding sites of chromatinic and regulatory proteins, sequencing of the exon and target regions. Complete these experimental infrastructures of high-process data analysis pipelines specializing in combined analysis of the entire genome, esom and transcript. The New Generation Sequencing Services facility is certified, starting in 2016, by the Illuminated Propel Program. Technological equipment - High throughput sequencing technology for large and complex studies, including sequencing of the routine human genome - HiSeq 2000 (Maximum Output 150-200 Gb) - Illumina HiSeq 2500 (Maximum Output 350 Gb) - Illumina HiSeq 3000 (Maximum Output 750 Gb) - End-to-end sequencing, integrating cluster generation, amplification, sequencing, and data analysis: Illumina MiSeq SERVICE Microlab - Optical and Electronic Microscopy Laboratory The CRS4 electronic microscopy laboratory has a decade of optical and electronic microscopy experience. Thanks to the important skills gained, combined with a unique instrumental offering in Sardinia, and among the few present on the national territory, the Laboratory provides research services to businesses, universities and public and private research organizations. The services are mainly aimed at the nanotechnology industry applied to the biomedical field, pharmaceuticals, characterization of new materials and new production processes, environmental analyzes, cultural goods, alternative energies, advanced mechanics and electronics. Laboratory equipment is connected to a system of storage, sharing and image management that can provide a unique service of its own, guaranteeing its users the direct usability of images generated through a cloud based system. The system is also evolving with the addition of industry-leading service capabilities such as remote viewing in real time during data analysis and acquisition. Technological equipment - Aperio Scan scope XT - Dual Beam FEI NovaNanolab 600 - Leica Mz 7.5 - Olympus BX61 Metallographic Optical Microscope

677 / 880 Savvy Venture Partners

Organisation

Country South Africa City Johannesburg Street 82 Maude Street, Sandton, 2196 Web http://www.savvyvp.com

Person

Name Thabo Ncalo Managing Partner

Organisation Savvy Venture Partners is a niche investment management firm focusing on business support and venture capital investing in Africa - with a particular focus on South Africa. It focuses on supporting and investing in early stage and emerging businesses operating in the consumer, innovation and technology sectors. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical research biomedical applications • Medical facilities furnishings, equipment, • Biotechnologies (Pharma&Medical goods Devices) • IT Applications for Health • Consulting services • Diagnostics - Imaging equipment and processing • Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment opportunity in healthcare We invest in emerging start-ups in health-tech, edu-tech, fin-tech, agri-tech and broader innovation driven sectors.

678 / 880 SCENT S.r.l.

Organisation

Country Italy City Ferrara Street Web https://www.scent-srl.it/#loaded

Person

Name Nicolò Landini Sole Administrator

Organisation SCENT (SemiConductor-based Electronic Network for Tumors) is a startup founded on April 1st, 2015, which aims to develop chemoresistive sensor technologies in order to refine oncological and medical screening. Areas of Activity

• Biosensors • Medical devices • Biotechnologies (Pharma&Medical • IT Applications for Health Devices) • Diagnostics IVD • Diagnostics - Equipment and accessories • Medical research

Marketplace Opportunities PRODUCT SCENT A1 Patented device aimed to be combined with FOBT test, in order to improve the reliability of colorectal cancer pre-screening. INVESTMENT OPPORTUNITY SCENT fund raising for certifications. The two devices patented from SCENT (SCENT A1 and SCENT B1) are now requiring certifications to be ready for the market. We started the medical trial, to collect the technical file, with astonishing results given from the prototypes, and while gathering data we are looking for the investments needed to obtain the ISO and the quality certifications for the final product. PRODUCT SCENT B1 Patented device, aimed to the oncological post-screening, and to the biological markers research on 679 / 880 blood, tissues and cell & bacteria samples. PROJECT COOPERATION H2020 calls on medical, nanostructures and biological research SCENT S.r.l. combines experts in physics (physics of matter, nanostructured sensors, semiconductors), biology, and oncology. The wide pool of competences guaranteed from the team allows a great variety in the fields of application, and together with two patented devices (one already in Europe), shows great chances to compete successfully through european- and international- wide projects and calls. We are actually looking for early stages proposals, project plannings and execution of calls, as partners to bigger project managers. REQUEST Certifications for screening devices / nanostructured multifunctional sensors What SCENT S.r.l. lacks mostly by now are the certifications for the two devices developed by now. We are looking for experts which may help us in the software, firmware and hardware certification processes.

680 / 880 Scuola Superiore Sant'Anna

Organisation

Country Italy City Pisa Street Piazza Martiri della Libertà, 33 Web http://santannapisa.it

Person

Name Elisa Grassi Innovation Promoter

Organisation The Scuola Superiore Sant'Anna is a public university institute - with special autonomy - working in the field of applied sciences: Economics and Management, Law Sciences, Political Sciences, Agricultural Sciences and Biotechnology, Medical Sciences, and Industrial and Information Engineering. The Scuola Superiore Sant'Anna is ranked as the 1st best University in Italy by theTimes Higher Education World University Rankings 2018.The Scuola Superiore Sant'Anna aims at experimenting innovative paths in research and education. Professors and researchers live and interact with the students, day after day, enjoying a continuous cultural and intellectual exchange.Innovative ideas, which are then developed in collaboration with foreign universities, organizations, companies and research institutes, are generated here. Due to its international nature, education of excellence and scientific community, the Scuola Superiore Sant'Anna established itself as a reference both in Italy and abroad. Areas of Activity

• 3D Printing/addictive manufacturing for • Software, ICT applications, system biomedical applications integration • Biosensors • EPR, Clinical/healthcare management • Biotechnologies (Pharma&Medical software Devices) • Surgery technologies and applications • eHealth, mHealth, telemedicine • Virtual reality applications • Electromedical and medical equipment • Other (non diag) • Medical devices • Medical research • IT Applications for Health • Nutraceutics, probiotics, functional food, cosmeceutics • Physiotherapy, Orthopaedic technology • Life sciences related activities

Marketplace Opportunities PRODUCT A modular smart system for infants’ rehabilitation at home based on

681 / 880 mechatronic toys A telemonitored smart system will be presented, designed to augment the clinical effectiveness of the therapy while reducing costs. The CareToy system appears as an ecological playground for babies, providing a wide selection of audiovisual stimuli, while accurately recording the infant's motor activity by means of a variety of sensors distributed around the environment. Patented system PRODUCT Patent: Stimulation and ultrasound system of an in vitro sample Besides the well-known use of ultrasound in diagnostic, ultrasound as therapeutic tool emerged more recently. Thanks to its intrinsic non-invasiveness (no incisions and no ionizing radiation) and the possibility to localize the treatment with extreme precision (use of a focused beam), therapeutic ultrasound is rapidly gaining clinical acceptance for a wide range of pathologies. Indeed, ultrasound- based technologies are nowadays a hot topic in medicine- and surgery-oriented research, with several applications currently under exploration. However, a deep knowledge about specific mechanisms connected to ultrasound stimulation are missing. This invention enables to study in deep ultrasound stimulation-related phenomena occurring to materials and living cells, lately enabling an optimization of the stimulation process, in several domains.

682 / 880 Scuola Superiore Sant'Anna

Organisation

Country Italy City PISA Street Piazza Martiri della Libertà , 33 Web http://www.santannapisa.it/it

Person

Name Marco Casarosa knowledge transfer manager

Organisation The Scuola Superiore Sant'Anna is a public university institute - with special autonomy - working in the field of applied sciences: Economics and Management, Law Sciences, Political Sciences, Agricultural Sciences and Biotechnology, Medical Sciences, and Industrial and Information Engineering. The Scuola Superiore Sant'Anna is ranked as the 2nd best University in Italy by theTimes Higher EducationWorld University Rankings 2015-2016.The Scuola Superiore Sant'Anna aims at experimenting innovative paths in research and education. Professors and researchers live and interact with the students, day after day, enjoying a continuouscultural and intellectual exchange.Innovative ideas, which are then developed in collaboration with foreign universities, organizations, companies and research institutes, are generated here. Due to its international nature, education of excellence and scientific community, the Scuola Superiore Sant'Anna established itself as a reference both in Italy and abroad. Areas of Activity

• Biotechnologies (Pharma&Medical • EPR, Clinical/healthcare management Devices) software • eHealth, mHealth, telemedicine • Surgery technologies and applications • Electromedical and medical equipment • Virtual reality applications (non diag) • Project proposals support services • Medical research • Medical devices • Nutraceutics, probiotics, functional food, • IT Applications for Health cosmeceutics • Regulatory affairs, validation • Life sciences related activities • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT Miniaturized microrobotic device for locomotion in liquids Magnetic actuation device for locomotion in fluid environment for biomedical and environmental 683 / 880 monitoring applications. INNOVATIVE ASPECTS AND MAIN ADVANTAGES This device allows to monitor organs and body environment from distance. The system avoid the insertion of cables, resulting extremely sensitive and reducing impedence. MARKET APPLICATION Biomedical monitoring applications. VARIOUS GRANTED PATENT AND PENDING PATENT PRODUCT Robotic apparatus for minimally invasive surgery The Single-Port lapaRoscopy bImaNual roboT (SPRINT) is an highly dexterous tool for SINGLE PORT SURGERY, comprising: • An umbilical access port that allows smooth insertion of the robot in the abdomen, panoramic vision system and gas insulation, the port is made up in such a way to allow the operator to insert an additional instrument to the abdomen while surgery is underway • Internal robotic platform with a bimanual 14 degrees of freedom (DOF) robot for performing surgery with embedded 3D stereoscopic vision system • External robotic manipulator: a 4 DOF parallel robot for handling the SPRINT robot (alternatively an industrial robot can be used) • The operating console incorporating the image of the operative field has intelligent features bridging the perceptual link between the surgeon and the microrobotic end effectors. In addition, haptic interfaces and augmented reality solutions are incorporated in the surgical console, thus enabling an effective and friendly interaction between the operator and the platforms/tools/tissue. Finally, advanced computer software enables the surgeon to execute the intended procedure ‘virtually’ (when needed in problematic cases) before actual performance. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Dexterity, speed of operation and strength on the end-effector, while reducing the invasiveness of the procedure due to the approach to single access port. THE PRESENCE OF AN INNER LUMEN, ONCE THE ROBOTIC PLATFORM IS READY FOR SURGERY, ALLOWS THE PASSAGE OF ADDITIONAL INSTRUMENTS AVOIDING AN ADDITIONAL HOLE IN THE BODY THE PATIENT. Arm actuation by electromagnetic motors implemented by a feedback force input through the reading of the current absorbed by the motors. A size of the arm that can ensure an insertion through a single hole, while ensuring the desired performance specifications. The hybrid parallel/serial arm is able to guarantee a greater rigidity, a higher precision and fluidity of movement; moreover cables actuation of this kinematic architecture is simpler to implement than the serial architecture. The proposed latching mechanism ensures a rigid support for the arms, which can be introduced in a sequential manner exploiting the entire inner lumen. Moreover the latching mechanism allows to fix more than two arms at a time, to replace surgical instrument if necessary and to choose the most favorable spatial arrangements to complete the specific surgery. MARKET APPLICATION The proposed system would cover all possible procedures of abdominal surgery District. Particularly, a possible application could be bariatric surgical procedures to treat morbid obesity. Robotic manufacturing revenue represents an annual increase of 14.9%. According to the opinion of leading surgeons in the field of robotic surgery a plausible estimation of surgical procedures (cholecystectomy, anti-reflux surgery, urologic and gynaecologic surgery) account for a global market of about 1.8M interventions a year in the US in 2013 and approximately 4.8 million procedures a year worldwide, particularly it was estimated 120.000 procedures with SPRINT. By 2020 Single Port Laparoscopy account US$9.5 bilion. GRANTED PATENT IN US, GB, FR, DE, IT PRODUCT 684 / 880 Bi-directional pneumatic braided muscle actuator The device offered is a pneumatic braided muscle actuator, able to produce bi-directional force and motion, and variable stiffness. Pneumatic muscles are generally preferred thanks to their high power to weight ratio, light weight, easy to install, hazard-free use and inherent compliance. The existing/ traditional pneumatic muscle actuator has a fixed braid fiber angle and is usually able to produce a pulling uni-directional force when actuated. Conversely this actuator is able to achieve variable stiffness depending on the braid angle. PATENT PENDING US, CN, EP PRODUCT Smart Artificial Pancreas Refilled by Mechatronic Pills The device is an artificial organ for the delivery of a proper amount of insulin in response to particular parameters, registered by a glycemia sensor. The device is refillable with ingestible capsules, containing insulin. One of the major issue in DT1 is patient’s therapy adherence because of the frequency of required monitoring and related action to be undertaken (pill ingestion, injection, precise amount of insulin). The device can autonomously and jointly monitor and release pill. Respect to other solutions it is entirely implanted in the body. The docking/refilling mechatronic station, surgically interfaced with the stomach/duodenum wall that do not required a daily or hourly action by the patient, nor a periodic substitution or modifications. The first factor largely limits patient daily life an obliged it to pay much attention; the second requires periodic surgery for battery recharge, which is avoided thanks to wireless recharge and refill of the insulin through the pill. Smart sensorized ingestible capsules act as insulin cargos along the gastrointestinal tract, allowing the patient an autonomous management of the device and possibly to forget to have such a debilitating disease. Furthermore the release in the peritoneal cavity drives much greater absorption respect to subcutaneous injections, since it quickly reach the portal vein allowing to stop the hepatic glucose production. The patent also claim the controlled administration of a substance in a human-body through the implanted infusion device, where insulin can be substituted with a different substance. GRANTED PATENT US, GB, FR, DE PRODUCT LIQUID MULTIPLEXING IN BIOSENSOR MICROCHAMBERS Devices for simultaneous multiple-analytes analyses by a plurality of bioSensors. PATENT PENDING PRODUCT Robotic Finger for thermal and tactile feedback THIS PATENT MIGHT BE INTEGRATED WITH THE WEARABLE DEVICE WITH INTEGRATED RECEPTORS SENSORIAL STIMULS FEEDBACK Wearable device for the finger, or integrated in a glove, that allows the simultaneus perception of tactile and thermal feedback in a AUGMENTED REALITY or VIRTUAL REALITY context. PATENT PENDING PRODUCT WEARABLE DEVICE WITH INTEGRATED RECEPTORS SENSORIAL STIMULS FEEDBACK THIS PATENT MIGHT BE INTEGRATED WITH THE Robotic Finger for thermal and tactile feedback. Software and device allowing the perception of space stimolus according to the specific positioning iof receptors in the space. PATENT PENDING

685 / 880 Secure Network

Organisation

Country Italy City Milan Street Web www.securenetwork.it

Person

Name Francesco Carbone Sales Manager

Organisation Secure Network performs comprehensive security assessments, securing applications and infrastructures thoroughly and extensively. Our range of services covers different types of activities, including penetration tests, vulnerability assessment, digital forensic, cybersecurity training and awareness. We have a strong focus on healthcare. Areas of Activity

• Consulting services • Software, ICT applications, system integration • Other

Marketplace Opportunities SERVICE Cybersecurity Consulting Service We offer a wide range of consulting services to make applications, networks, IoT devices secure from external attackers.

PARTNERSHIP Tech Partnership We are open to partnerships with other companies, system integrators or consultancy companies that may require to provide security assessment to their customers.

686 / 880 SensArs Neuroprosthetics

Organisation

Country Switzerland City Lausanne Street av sevelin 13b Web http://www.sensars.com/

Person

Name Francesco Maria Petrini CEO

Organisation SensArs is an EPFL (Switzerland) spin-off that has raised more than 800’000 CHF in grants, used to develop SENSY, unique worldwide device to restore sensory feedback to lower limb amputees from their prosthesis (2 pending patents). SENSY was tested with three amputees, proving that SENSY reduces the risk of falls, prosthesis device fatigue, phantom limb pain. Leg amputees are 4 million in USA and Europe. SensArs is organizing a series A fund raising of 6 million, needed to develop the final version of SENSY, and to run a trial with 50 patients for CE mark Areas of Activity

• Medical devices

Marketplace Opportunities

PRODUCT SENSY We developed SENSY which, restoring sensory feedback from the missing leg of amputees through their prosthesis, solves the problems connected with its lack: it boosts mobility, avoids falls, reduces fatigue, perceives the prosthesis as part of the body, and treats phantom limb pain. The device is composed of intraneural electrodes and neurostimulator, an external controller and a sensorized insole. The neurostimulator is implanted in the limb and is wired to intraneural electrodes that are inserted transversally into the sciatic nerve. Stimulation is driven wirelessly by an external controller, which transforms the readouts from the insole into stimulation parameters. The insole is adaptable to the prostheses currently available in the market. SENSY has been tested in 3 lower limb amputees. INVESTMENT OPPORTUNITY

687 / 880 Series A: product completion and clinical trials 2 financing rounds will be needed to make the business viable. In particular, the first round of 6 Million EUR will finance the development of the first prototype of SENSY, will support the pilot series manufacture, the clinical trials and the expenses for requiring CE approval. The second one of 8 Million EUR will allow the implementation of the marketing strategy, the serial production of SENSY and its sale. Now, we are looking for VC, CVC, BA for series A.

688 / 880 SenTech S.r.l

Organisation

Country Italy City Rome Street Via di Quarto Peperino, 35 Web www.sentech.it

Person

Name Michele Russo Chief Engineer

Organisation SenTech is a Small Italian Enterprise devoted to: - System analysis and design - Control systems development - Software implementation - Direction Finder Technologies - Medical Imaging Processing The company's purpose is the study, analysis, simulation, production, maintenance and installation of systems or electronic components, electro-optical, RF, antennas, electrical, laser, their hardware and software aspects for use in both civil and military systems. Areas of Activity

• 3D Printing/addictive manufacturing for • Software, ICT applications, system biomedical applications integration • Diagnostics - Imaging equipment and • IT Applications for Health processing • eHealth, mHealth, telemedicine • Electromedical and medical equipment (non diag)

Marketplace Opportunities SERVICE Medical Image Processing SenTech is active in medical image processing SW development, in particular for neurosurgery and it cooperates with Università La Sapienza and with Azienda Ospedaliera San Camillo - Forlanini. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Main activites are: Registration; Segmentation; Data Fusion; Rendering 3D; Data Conversion. Registration of TOF, functional MRI, tractography on TAC and MRI. Segmentation of vascular apparatus, neoplacy, tissues and their 3D rendering for neuronavigator use during neurosurgery MARKET APPLICATION Hospital; University

690 / 880 SeqOne

Organisation

Country France City Montpellier Street Web https://seq.one

Person

Name Jean-Marc Holder COO

Organisation SeqOne makes it possible to efficiently analyze "high resolution" NGS data efficiently in clinical routine applications. The system is built around three key technology pillars: 1) a proprietary machine-learning- based variant prioritization engine that is designed to identify variants that are medically relevant to each specific patient. In field tests, SeqOne has been able to reduce the hundreds of thousands of candidate variables to a shortlist of less than 20 alternatives that are relatively straightforward for the genomic expert to analyze. This dramatically reduces the time and cost of genomic interpretation making the use of NGS data in clinical routine a realistic and cost-effective option. 2) An app-store-like catalog of genomic interpretation tools, each optimized for a specific medical problem. By offering specific solutions to address each medical problem, SeqOne can optimize each aspect of the process, from error checking to the machine learning models used, thus ensuring the most accurate identification of causal variants. SeqOne includes applications from external developers which allows it to leverage the expertise of leading bioinformatics experts in the community to provide even better solutions. 3)The platform also addresses the operational challenges of performing NGS analysis at scale including, secure data storage, management of process quality and traceability needed for certification. The platform dramatically reduces time, cost and resources needed to interpret NGS data in clinical routine. Its high-performance architecture coupled with the app-store approach also makes it possible to do sophisticated cohort analysis to identify patterns that may reveal new biomarkers. Areas of Activity

• Diagnostics IVD • IT Applications for Health • Genetics & Genomics • Medical devices

Marketplace Opportunities PRODUCT Genomic analysis solution for precision medicine in rare diseases SeqOne makes it possible to efficiently analyze "high resolution" NGS data efficiently in clinical routine applications with specific emphasis on NGS - grade data such as Exome, RNA-Seq or Whole Genome data. 691 / 880 The system is built around three key technology pillars: 1) a proprietary machine-learning-based variant prioritization engine, 2) An app-store-like catalog of genomic interpretation tools, each optimized for a specific medical problem. 3)The platform also addresses the operational challenges of performing NGS analysis at scale including, secure data storage, management of process quality and traceability needed for certification. We have developed a high-performancee variant priortisation engine that is optimised for diagnositcs in rare diseases. REQUEST Genomic analysis platform international distributors We are looking for distributors for our SeqOne genomics analysis platform internationally. PARTNERSHIP Bioinformatic application developers wanted SeqOne is an innovative genomic analysis platform for clinical routine. Our platform is built around an application catalogue that is co-developed with an ecosystem of expert developers and which provides specific, optimised solutions for each unique genomic analysis needs. If you have a bioinformatic application you are interested in developing, we would love to speak with you.

692 / 880 seQure Life Sciences

Organisation

Country Italy City Rome Street Via Squarcina, 13 Web http://sequrelifesciences.com/

Person

Name Daniela Marcozzi VP, Strategic Account Management & Scientific Director

Organisation seQure Life Sciences is a niche services provider operating in the Life Sciences sector. We provide services and consultancy in four core areas: - Pharmaco/Device-Vigilance; - Quality Assurance and Compliance; - Regulatory Affairs; Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Medical devices • Consulting services • CRO (Contract Research Organisation) • Medical research • Pharmaceutics

Marketplace Opportunities SERVICE Pharmacovigilance Our Pharmacovigilance services include: - Case Processing and Reporting; - Safety System & Database Implementation; - QPPV & Deputy. SERVICE Quality Management We offer advanced solutions for Quality Management area: - Quality & Compliance for GxP; - QA & Compliance for Safety/Pharmacovigilance; SERVICE

693 / 880 Regulatory Affairs Our Regulatory Affairs experts can provide support through all stages of drug development: - Regulatory Consultancy; - Marketing Authorization Application; - Preparation and Management of Applications; - Product Characteristics; - Regulatory Medical Writing; - Orphan Drug Designations; PARTNERSHIP Cooperation in Quality Management&Pharmacovigilance Partnership with service providers in Europe for Quality Management&Pharmacovigilance activities.

694 / 880 Setlance

Organisation

Country Italy City Siena Street Via Fiorentina 1 Web https://www.setlance.com

Person

Name Chiara Falciani Head of R&D

Organisation SetLance is a biotech company focusing its activity on the development of peptide-based drugs. It was founded in 2009 by Luisa Bracci, Chiara Falciani and Alessandro Pini, professors at the University of Siena, Italy. Setlance strictly collaborates with the Department of Medical Biotechnologies with which it share rooms and facilities, with a fruitful reciprocal contamination. The company aims at the development of novel peptide-based drug candidates for the treatment of severe human diseases – with a special focus on bacterial infections and cancer. Areas of Activity

• Biotechnologies (Pharma&Medical • Peptides, proteins & antibodies Devices) preparation • Diagnostics - Imaging equipment and processing • Drug screening & delivery • Medical research

Marketplace Opportunities PRODUCT Cancer-specific peptides No new drug or diagnostic is redundant to fight cancer. We develop cancer-specific peptides, stable to degradation due to a innovative branching structure, to be used in addressing cancer cells. These new peptides can selectively recognize cancer cells in mice, and by means of their payload, either a tracer or a chemotherapeutic can act as diagnostics or therapeutics, respectively. These promising results have been published in different international journals. Setlance branched peptides offer a new opportunity to address cancer cells with a biotecnological product which combines the advantage of high specificity to that of being a synthetic molecule with a semplified industrial manufacturing development. PARTNERSHIP

695 / 880 Tumor targeting peptides exploitation The branched cancer specific peptides intellectual property is protected with a patent for their use. Setlance is seeking for a partner for the development of the peptides as diagnostics or therapeutics or both.

696 / 880 SHAPEME

Organisation

Country Italy City Bologna Street via federigo Enriques 9 Web www.shapeme.it

Person

Name Matteo Bonicelli della Vite CEO

Organisation CORPORATE WELLNESS SERVICES Areas of Activity

• Software, ICT applications, system integration

Marketplace Opportunities PRODUCT Corporate Wellness Programs We help companies to improve their performances taking care of their workforce wellness. We design customized programs that enables companies to have more loyal, motivated, and productive workers. INVESTMENT OPPORTUNITY Investment Throug Equity Crowdfunding Our equity crowdfunding campaign is open. People can invest in our company a minimum amount of 500€. Here are all the informations: https://bit.ly/2uQq5HV

697 / 880 SIA Health Lab (CheeksUp)

Organisation

Country Latvia City Riga Street Eizensteina iela 57-79 Web http://www.facebook.com/cheeksup

Person

Name Ilze Zaharane Founder,CEO

Organisation We provide IT solutions for speech therapy (early interventions and rehabilitation) what are designed to increase the quality outcomes of therapy. Our product is engaging small patients in the orofacial exercises and speech training (sounds, syllables, words). For professionals we have web based tools, and for patients desctop aplication for use at home. Homework exercise plans can me managed remoteley. Our solutions are good support tool for telepractice ore patients who come from rural areas, and can't attent therapy sessions in the needed intensity. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Virtual reality applications • Other

Marketplace Opportunities

PRODUCT CheeksUp home windows application for use at home after speech therapist reccomendation. This tool is providing interesting visual enviroment to motivate patients starting from 2 years. Besides that, it is a greate suppor tool for parents to do doable homework, because training through game it is interesting for children, and the necessary content is individually prepared by patients speech therapist. Homework system works together with CHeeksUp web Pro application, where therapists create individually tailored speech training plans for use at home to strenghten and automate child skills on specific sound target. PRODUCT CheeksUp Web Pro This online application is a tool for speech therapists. It allows to create individual exercise plans with instant bunny voice recording just using smartphone connected to internet. Words, syllable and sounds 698 / 880 what are said by bunny makes the learning process much more engaging and interesting. With this tool speech therapists reassign the repetitive tasks to application and with proper usage, it brings therapy outcomes much faster.

699 / 880 Siad S.p.a.

Organisation

Country Italy City Rome Street Via Vitorchiano, 99 Web www.siad.com

Person

Name Elisabetta Quacquarini Sales department

Organisation SIAD is one of the most important chemical groups in Italy and supplies afullrange of industrial, specialty, food and medical gases, in addition to operating in the following sectors connected with the world of gases: engineering, healthcare, industrial goods and services. Founded in Bergamo in 1927, SIAD boasts a solid tradition and has acquired consolidated experience over its 85 year existence.Over time, it has succeeded in entering new geographic markets and sectors, whilst growing as a flexible and dynamic organisation and guaranteeing the utmost quality, reliability and professionalism.

The SIAD Group operates in the healthcare sector at a hospital level and in homecare. Thanks to the offer of medical and surgical specialty gases and systems for cryobiology and life sciences, SIAD Healthcare is considered one of the most accredited suppliers to the Italian public and private health service. Areas of Activity

• 3D Printing/addictive manufacturing for • Laboratory equipment, reagents, software biomedical applications • Analytical and characterization services • Chemicals & APIs • Pharmaceutics

Marketplace Opportunities PRODUCT Technical gases and application, Services Analytical Assistance, Technical Assistance Products and Services, Packaged gases, Gases for food use, Gases for welding and cutting, Pure and very pure gases, Gas mixtures, LAT calibration mixtures and Distribution plants and equipment MARKET APPLICATION Food and Beverage, Automotive, Chemical and Pharmaceutical, Electronics assembly, Environmental, Healthcare, Research and analysis laboratories, Oil and gas, Metal Production, Welding and cutting, 700 / 880 Semiconductor

701 / 880 Sidam Srl

Organisation

Country Italy City Mirandola Street Via Statale Sud, 169 Web http://www.sidamgroup.com

Person

Name Piero Camurati CMO

Organisation «We research , directly on the market, for latent needs and requirements, in order to design, develop and manufature increasingly innovative devices. We can do this thanks to our flexible structure, through which we are able to realise and give shape to that innovation that translates into projects requested directly by the market.» Results prove it: SIDAM’s constant growth in terms of employees and turnover, the patents obtained throughout the world, the top results during quality checks are evidence of constant commitment and passion. Throughout the years, we have identified many Hospital Wards for which to develop new products. Our highly specialised innovations quickly confirmed themselves to be a huge success in the biotech sector, and are used by the world’s most important hospitals in their Radiology, Intensive Care and Subcutaneous Infusion wards. SIDAM is able to cover all company areas, from marketing activities to R&D, from production up to sales and post-sales activities, for the purpose of ensuring utmost control over the quality of all its products, keep a clear view of the market needs, offering its customers innovation and an increasingly accurate service. INTENSIVE CARE For intensive care units, we make both medical devices, including the Nutrivent, and electro-medical equipment, such as the Optivent. MEDICAL IMAGING For Medical Imaging, SIDAM makes disposable medical devices (for the transfer of means of contrast for CT, MR, ultrasound scans and angiographies), electro-medical equipment, in other words Thermostatic Cells (Warm-MB - multi bottle, Warm-SB - single bottle and Warm - SP - single bag), as well as injectors for means of contrast during ultrasound scans.For interventional radiology, we deal with Vertebroplasty. We are also working on a number of research areas where we see an opportunity to bring our competence and skills to solve everydays challenges of hospitals and physicians. Areas of Activity

• Medical devices

703 / 880 Marketplace Opportunities PRODUCT MEDICAL IMAGING For Medical Imaging, SIDAM makes disposable medical devices for: - Radioline products, for the transfer of means of contrast for CT, MR, ultrasound scans and angiographies, hemodynamics - male uretrography, fistulography contrast examination systems - Warm line, electro-medical equipment, in other words Thermostatic Cells (Warm-MB - multi bottle, Warm-SB - single bottle and Warm - SP - single bag) - injectors for means of contrast during ultrasound scans (i.e. ECHOSID 2008 infusion system). - interventional radiology, we deal with Vertebroplasty. PRODUCT INTENSIVE CARE For intensive care units, we make both medical devices, including the Nutrivent, and electro-medical equipment, such as the Optivent. Nutrivent: an innovative system for respiratory monitoring. The NutriVent™ nasogastric catheter is indicated whenever gastric drainage and enteral nutrition have to be combined with abdominal pressure measurements (i.e., peritonitis, obesity, multiple blood transfusions, polytrauma) or pleural pressure measurements (patients undergoing invasive or noninvasive mechanical ventilation). Measurements obtained from the NutriVent™ cathether allow to accurately calculate both lung and thoracic compliance/elastance. These data are essential to estimate work of breathing and lung stress. Due to the wide range of indications and their clinical relevance, the NutriVent™ catheter can be considered as an alternative to conventional nasogastric tubes in any critical patient. Optivent OptiVent™ is an electro-medical device for the completely automated management of the multi- functional Nutrivent™ nasogastric probe. Among these operations are included: • system calibration; • setting of the pressure zero; • support to the positioning of the nasogastric probe; • periodic and automatic inflation and deflation of the balloons on the nasogastric probe, • registration in continuous mode of the pressures supplied, data graphic and numeric display; • storage of patient data; • transfer of the data registered on the computer. The equipment is provided with a practical touch screen interface for an immediate input of the requested data and for a simple interaction with the system. OptiVent™ allows to register and monitor, in continuous mode, basic parameters in the management of the critical patient: transpulmonary pressure (Ptp), Elastance (E), Compliance (C), inspiratory effort, endoabdominal pressure Pga (with NutriVent™ provided with two balloons), transdiaphragmatic pressure (with Nutrivent™ provided with two balloons). The registration of the esophageal pressure allows to split Elastance and Compliance into their components: of the whole respiratory system, of the lung, of the chest.

704 / 880 Sigma Consulting - SIGMA Integrated Systems

Organisation

Country Italy City Rome Street Via Adriano Olivetti 24/26 Web http://www.sigmaconsulting.it

Person

Name Simone Cirocchi International Market Manager

Organisation Established in 1998, Sigma Consulting S.r.l. is an Systems Integrator Company specialized in the design and manufacturing of Electronic and ICT Systems for avionic, naval and ground platforms. Main fields of application are: Defence and Intelligence, Homeland Security, Command & Control, Flight & Radar simulators, Systems Engineering. Sigma also develops IoT platforms for smart farming, smart city and telemedicine applications. Sigma is the leader company of the ATEN IS Group Areas of Activity

• eHealth, mHealth, telemedicine • Project proposals support services • Genetics & Genomics • IT Applications for Health • Software, ICT applications, system integration • Laboratory equipment, reagents, software

Marketplace Opportunities PRODUCT FATA (Far Assistance Telemedicine Analyzer) Telemedicine Platform FATA is Modular software platform which interfaces with both the instruments and the other actors of the service: doctors, listening center operators, patients, care giver; It receveis biomedical data from mobile devices (certified devices, smartphone); It allows various medical and remote services and mobility: telerefert, telediagnosis, teleconsultation .... As well as intuitive but complete functions of electronic and mobile health diary

705 / 880 PRODUCT SELF-ADHESIVE SECURITY STICKER® FOR DNA AND FINGERPRINT CAPTURE BRIEF DESCRIPTION OF THE INVENTION The self-adhesive security sticker® for DNA and fingerprint capture is a product that could be used for security and genetic purposes. TECHNICAL FIELD OF THE INVENTION The present invention is a safety seal to stamp, to register or to adhere the fingerprints of the persons, but being the main purpose the collection of particles from the remains of the dead epithelial cells (moisture of the finger, greasiness, etc) that remain adhered and allow with certain reagents to determine in the laboratories the DNA or the genetic fingerprint of a person SERVICE International Market Opportunities SIGMA Integrated Systems is the division of SIGMA Consulting, which deals with foreign market opportunities. SIGMA is the leader company of the ATEN IS Group and has the scope to act as system integrator, marketing organization creator, product seller of the ATEN IS Network which includes 32 Hi Tech companies and four primary research institutes. ATEN IS has already established international partnerships with local companies in the following countries: •Europe: France, Spain, Bulgaria •Asia: Turkey, China, India •Africa: Marocco, Tunisia •America: Brazil, Ecuador, Peru’, Chile, Colombia. Based on the support of our worldwide partners, we can offer our services for sell or develop new product in each of these countries.

706 / 880 Sinan Compass Ltd.

Organisation

Country United Kingdom City Liverpool Street Innovation Centre 1, Liverpool Science Park, 131 Mount Pleasant Web www.sinancompass.co.uk

Person

Name Dr Jameel Zayed Managing Director

Organisation We are a China-focussed M&A / licensing healthcare advisory services firm for young & emerging healthcare SME leaders seeking to localise in China. Our business development / export services support market entry toChina via partnering with domestic leaders. Areas we specialise in are: pharma drug licensing transactions, medtech/IVD market entry, life sciencesinstrumentation investment, and exports. We're located in UK, Netherlands, and China. We work selectively with industry-leading SMEs, corporations, & PE fund groups. www.sinancompass.co.uk Areas of Activity

• Analytical and characterization services • Investments • Biomaterials • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation Devices) • Pharmaceutics • Chemicals & APIs • Life sciences related activities • Consulting services • Surgery technologies and applications • Diagnostics IVD • Vaccines • Diagnostics - Equipment and accessories • Medical devices • Diagnostics - Imaging equipment and • IT Applications for Health processing • Drug screening & delivery • Genetics & Genomics

Marketplace Opportunities REQUEST

708 / 880 China deals - investment / licensing / distribution (China) Sectors: - Pharmaceuticals (biologics, drug discovery platforms, biomanufacturing, consumables, approvals), - Medical devices (IVD, instrumentation, implants, materials, equipment, IT). Deals: - In/Out-licensing of early & mature pharma assets across a range of areas. - Companies seeking investment to scale growth of in-market products and/or pre-clinical-Phase III pharmaceutical assets. - Distribution of in-market healthcare products (post-CE/FDA for medical products). SERVICE China market entry - investment / licensing / distribution / exports deals We support SMEs entering China to achieve: i) product exports ii) asset licensing iii) investment (strategic & M&A). SOLUTION OR EXPERTISE SOUGHT Pharmaceuticals across any of the following areas for co-development / licensing with Chinese partner: - Early-stage, late-stage, clinical, commercial therapeutic pipeline assets for licensing, - Cardiovascular, respiratory, oncology, paediatric, gynaecology, CNS, gastrointestinal, ophthalmic, psychiatric, infectious disease, viral, antibiotic, diabetes, cancer, phage display, platforms, assays, - FDA approved, orphan, market authorised, Pre-clinical, Phase I-III TYPE OF PARTNER SOUGHT Medtech across any of the following areas for market entry with Chinese partner: - Class II-III devices, - CE or FDA approved in EU home country or US - consumables, in vitro diagnostics (IVD), instrumentation, reagents, POCT (point of care testing), software, equipment, implants, wearables, catheters,

709 / 880 SIVECO Romania

Organisation

Country Romania City Bucharest Street Bucuresti-Ploiesti Web http://www.siveco.ro/en

Person

Name Monica Florea Head of Unit EU Projects

Organisation SIVECO Romania SA (www.siveco.ro, http://rd.siveco.ro) is a private shareholder company, established in 1992, located in Bucharest, Romania. Since then, SIVECO has become the largest Romanian software development company and provider of software solutions like ERML& M (Enterprise Resource Management License and Maintenance), eGovernment, eLearning, eHealth, eAgriculture, eCustoms solutions and turnkey projects acting both on the internal and international markets, and one of the most successful software integrators from Central and Eastern Europe. SIVECO has significant experience and an exceptional track record in R&D and R&I projects, having been involved as technological provider and as coordinator in many European and national research projects. In particular, SIVECO has established considerable experience and expertise in the implementation of large-scale user-centred systems at national level. SIVECO staff consists of IT specialists covering all stages of projects development: analysts, business consultants, system architects, programmers for different platforms, implementers, testers, DBAs, data analysts, accredited trainers. SIVECO Romania SA is/has been involved in seveeral European projects as technological partner (see the marketplace profile for details).

Relevant skills/experience/technologies on eHealth sector: SIVECO has developed and implemented solutions for improving the management of the health insurance funds and for increasing the quality of medical and pharmaceutical services: PIAS - Integrated Health Insurance Platform SIUI - Integrated Information System (developed by Hewlett Packard Romania and SIVECO Romania SA); SIPE – Information System for the Electronic Prescription CEAS - Health Insurance National Card DES - Electronic Health Record System SIVECO Romania SA developed the specific software applications of all the PIAS systems. Here are some references regarding the implementation of our eHealth solutions: - The National Health Insurance House (CNAS) in Romania - Unique Integrated Information System for managing the activities within CNAS. - The Ministry of Health in Bulgaria - the implementation of an integrated information system for the 710 / 880 National Health Insurance Fund in Bulgaria (NHIF); - Nepenthes Group France (Concentrateur Global Nepenthes) - a system for managing the invoices flow between the French Health Ministry and the health insurance houses; - The Ministry of Health in Croatia (HZZO) - a pilot information system for centralizing of data supplied by all the doctor’s cabinets in Croatia. Areas of Activity

• Analytical and characterization services • Virtual reality applications • Bioinformatics, Big data analytics • Project proposals support services • eHealth, mHealth, telemedicine • IT Applications for Health • Software, ICT applications, system integration • EPR, Clinical/healthcare management software

Marketplace Opportunities PARTNERSHIP SIVECO as project partner As a technological partner for software development, SIVECO can participate in the following stages of a project: • System designing • Prototype development and setup • Data collection and analysis • piloting, prototype validation, feedback, fine tune and completion • AR/VR technologies • eTraining for patients, carers and medical staff. SIVECO Romania SA is/has been involved as technological partner in the following European Projects: FLOOD-serv - Public FLOOD Emergency and Awareness SERVice (HORIZON 2020); NEWTON - Networked Labs for Training in Sciences and Technologies for Information and Communication (HORIZON 2020); BEACONING - Breaking Educational Barriers with Contextualised, Pervasive and Gameful Learning (HORIZON 2020); SpeechXRays – Multi-channel biometrics combining acoustic and machine vision analysis of speech, lip movement and face (HORIZON 2020); FLEXMETER – Flexible smart metering for multiple energy vectors with active prosumers (HORIZON 2020); COncORDE – Development of Coordination Mechanisms During Different Kinds of Emergencies (FP7 Security); Linked2Safety - A Next-Generation, Secure Linked Data Medical Information Space For Semantically- Interconnecting Electronic Health Records and Clinical Trials Systems Advancing Patients Safety In Clinical Research (FP7); Eurocancercoms - Establishing an efficient network for cancer communication in Europe (FP7); P.CEZANNE - Integration of Nano- Biology and ICT to Provide a Continuous Care and Implantable Monitoring System for Diabetic patients; LifeWear - Mobilized Lifestyle with Wearables (ITEA 2); SEAS - Smart Energy Aware Systems (ITEA 2); Brain@home - Moving and enhancing brain training for an active life (AAL - Ambient Assisted Living JP); PALETTEV2 - PervAsive Learning Environment for Training and moTivation of Elderly (AAL - Ambient Assisted Living JP); FollowMe (AAL - Ambient Assisted Living JP); STAGE - Streaming of Theatre and Arts for old aGe Entertainment (AAL - Ambient Assisted Living JP);

711 / 880 ProMe - PROfessional InterGenerational Cooperation and Mentoring (AAL - Ambient Assisted Living JP); LetItFLOW - Active Distributed Workflow System for elderly (AAL - Ambient Assisted Living JP); TOI4Food - Transfer of knowledge and training for European traditional food producers related to innovative quality control methodologies (LLP - Lifelong Learning Programme); HEALTH EVERYDAY - Mobile environment for healthcare services and health education for a better life of NMD'patients (EUREKA);

712 / 880 Smartex s.r.l.

Organisation

Country Italy City Pisa Street inside the Polo Tecnologico di Navacchio Web http://www.smartex.it

Person

Name Rita Paradiso CEO

Organisation Smartex is an SME that works in the development and production of wearable devices for monitoring of physiological signals and movement of human beings and animals and in the analysis of collected data. We have a long experience due to the participation to many research projects funded at European, national and regional level, and we have provided so far R&D activities to third parties, too; in this event we are looking for the key partner(s), product(s) and/or service(s) to finally become a strong actor in this sector. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Electromedical and medical equipment (non diag) • Physiotherapy, Orthopaedic technology • Medical devices

Marketplace Opportunities PRODUCT Sensorised knee support Smartex have developed a knee support that allow recording of knee movement. Those data are (in the current version) transmitted in real time to a Smart Phone (android and iOS) and saved there, then, after the recording session is over, data cna be delivered to an email address or on a cloud service. PRODUCT WWS - Wearable Wellness System WWS is a wearable system composed by a sensorised vest with 2 fabric electrodes and a fabric piezoresistive sensor to monitor ECG and espiration, an electronic device with an integrated IMU to monitor posture and activity and analise data from the vest and a software for data visulisation. It has been used in several projects to monitor life condition and stress sportmen/women, older adults, patients, firefighters, etc.

713 / 880 Smartex s.r.l.

Organisation

Country Italy City Pisa Street inside the Polo Tecnologico di Navacchio Web http://www.smartex.it

Person

Name Roberto Orselli Business development

Organisation Smartex is an SME that works in the development and production of wearable devices for monitoring of physiological signals and movement of human beings and animals and in the analysis of collected data. We have a long experience due to the participation to many research projects funded at European, national and regional level, and we have provided so far R&D activities to third parties, too; in this event we are looking for the key partner(s), product(s) and/or service(s) to finally become a strong actor in this sector. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Electromedical and medical equipment (non diag) • Physiotherapy, Orthopaedic technology • Medical devices

Marketplace Opportunities PRODUCT WWS - Wearable Wellness System WWS is a wearable system composed by a sensorised vest with 2 fabric electrodes and a fabric piezoresistive sensor to monitor ECG and espiration, an electronic device with an integrated IMU to monitor posture and activity and analise data from the vest and a software for data visulisation. It has been used in several projects to monitor life condition and stress sportmen/women, older adults, patients, firefighters, etc. PRODUCT Sensorised knee support Smartex have developed a knee support that allow recording of knee movement. Those data are (in the current version) transmitted in real time to a Smart Phone (android and iOS) and saved there, then, after the recording session is over, data cna be delivered to an email address or on a cloud service.

714 / 880 SMS-oncology

Organisation

Country Netherlands City Amsterdam Street Web https://sms-oncology.com/

Person

Name Yuva Oz Business Developer

Organisation SMS-oncology is specialized in early phase oncology trials as well as providing expert advice and strategic consulting in oncology drug development. Areas of Activity

• Consulting services • Life sciences related activities • CRO (Contract Research Organisation) • Other • Medical research • Pharmaceutics • Regulatory affairs, validation

Marketplace Opportunities SERVICE CRO (Contract Research Organization) At SMS-oncology we believe that true passion and devotion are key to be able to exceed in what you do. Being committed and dedicated to oncology, we support our clients with our knowledgeable experts and devoted clinical project teams in a joint effort to reaching your goals and milestones. We take pride in contributing to the successful oncology drug development of our sponsors. MARKET APPLICATION SMS-oncology is a full-service oncology CRO that adds an extra dimension in clinical cancer research by providing direction to our sponsors. The majority of our clients comprises of small to mid-size biotech companies. TYPE OF PARTNER SOUGHT Our full range of services: - Consultancy - Medical writing - Expert protocol advice (free) - Project management - Regulatory affairs - Site and investigator selection 715 / 880 - Site management and monitoring - Medical affairs - Pharmacovigilance - Data management - Insights & analytics reports

716 / 880 Società Italiana Brevetti S.p.A.

Organisation

Country Italy City Roma Street Piazza di Pietra 39 Web www.sib.com

Person

Name Paolo di Giovine Patent attorney

Organisation We are an internationally recognised intellectual property firm specialising in the protection and enforcement of patents, trademarks, models, designs and copyrights. Our services cover all areas of intellectual property, both technical and legal. We file applicationsworld wide for patents, trademarks, designs,utility models and plant breeders’ rights. We devise strategies to manage and exploit intellectual property rights and offer a wide range of related services. We manageportfoliosand searches, license agreements, patent and trademark valuations, freedom to operate and due diligence analyses as well as value-enhancing strategies and assistance in intellectual property-related financial and tax issues. We enforceintellectual property rights world wide. We offer legal advice and assistanceon counterfeiting, usurpation, unfair competition and on any issue involving intellectual property rights. Our clients include enterprises of all sizes, fromstart-uptocorporate, as well asuniversities/research centresandforeign associates. Areas of Activity

• Other

Marketplace Opportunities SERVICE Intellectual Property Protection Consultancy Protection and enforcement of patents, trademarks, models and designs

719 / 880 SOCOREX Isba SA

Organisation

Country Switzerland City Ecublens, Lausanne Street Ch. Champ-Colomb 7A Web http://socorex.com

Person

Name Giulia Faè Area Manager Italy and Ticino

Organisation ABOUT US Socorex Isba SA is a Swiss manufacturer of high precision laboratory instruments used for measuring, dosing, transferring, dispensing and injecting liquids in a large number of applications. Socorex liquid handling products have been appreciated on the worldwide market for more than 50 years. SOCOREX PRODUCTS AND THEIR APPLICATIONS Manual and electronic micropipettes, single and multichannel pipettors, repeater pipettes, dispensers, pipette controllers and re-usable syringes, together with pipette tips, consumables and accessories, constitute the heart of today’s programme and are used by scientists, researchers and teachers in private, industrial, academic and government laboratories all over the world, every day. All users know Socorex is their quality partner, not a mere supplier, in precision liquid handling, offering durable solutions to all their needs. QUALITY MANAGEMENT “A to Z” Quality Management includes stringent component selection, quality check at every production stage and individual instrument performance control in the metrology laboratory, attested by an individual ISO 8655 certificate. Socorex QC laboratory, which is accredited by the Swiss Accreditation Services (SAS) of the Federal Office of Metrology can also offer calibrations in full compliance with ISO 17025 on new instruments. Each instrument bears its own serial number. Warranty coverage is 3 years on all manual pipettors, 3 years on electronic pipettes, dispensers and repeaters. ISO 9001 and ISO 13485 Quality Management System certifications are the formalization of Socorex’s traditional commitment to precision and quality. The product lines which are used in the In Vitro Diagnostics fields conform to the IVD 98/79 EEC directive for medical devices and are CE certified accordingly. DISTRIBUTION Scientists are served efficiently by the dedicated network of Socorex distributors. Distributors are selected amongst the best laboratory equipment suppliers. Areas of Activity

• Laboratory equipment, reagents, software • Medical devices

720 / 880 Marketplace Opportunities PRODUCT Your quality partner worldwide for precision liquid handling I am offering you to meet you and, after a short presentation, let you go with the brand new Italian edition of our "Precision Liquid Volumetry" general catalogue (2019 edition). My presence as Socorex Area Manager (Italy and Ticino), based in Milan and working all over the country signals our new approach on the Italian Market, which I shall be happy to introduce to you on this occasion. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The few minutes invested may help you save thousands of euros from your liquid handling instrument and consumable budgets. In other words, I shall discuss how your organization can get more for less money, with no quality compromise whatsoever. Socorex wide range of products is there to meet and exceed your expectations: all the technical features, such as accuracy, ease of use, comfort, reliability and durability, which any user wants, are combined to offer the best instruments at fair prices. MARKET APPLICATION Micropipettes and dispensers remain basic tools in any laboratory handling liquids. Our experience enables us to supply you with the right instruments for any application. Even viscous liquids, foaming solutions, strong acids and hazardous fluids can be handled safely and effectively by using the Socorex product we shall be glad to select with you. TYPE OF PARTNER SOUGHT I would like to meet demanding scientists, from any lab in Italy, involved in routine, research and educational activities in any Life Science field - such as biotechnology and molecular biology, just to name a few. Awaiting your meeting proposal, I am looking forward to the pleasure of seeing you soon.

721 / 880 Softcare Studios

Organisation

Country Italy City Roma Street Via Franco Sacchetti 52 Web http://www.tommigame.com/

Person

Name Valentino Megale CEO

Organisation Softcare Studios is a digital health startup working to improve patients therapy experience and therapy efficiency using virtual reality (VR) and artificial intelligence (AI). Our first project is TOMMI, a VR game developed to help children better cope with stressful and painful medical treatments and improve therapy adherence, aiming to reduce patients’ sedation rate and providing them stress, clinical anxiety and pain relief. At the same time, TOMMI also uses AI to collect data about patients wellbeing conditions and stress levels, supporting doctors for smarter decisions during therapy. TOMMI is designed with a special focus on pediatric oncology, but it also applies to pediatric dentistry and orthopedics, and it involves children parents too during the gaming sessions. Areas of Activity

• eHealth, mHealth, telemedicine • Virtual reality applications • IT Applications for Health

Marketplace Opportunities PRODUCT TOMMI TOMMI is a Virtual Reality experience developed to help children better cope with stressful and painful medical treatments, aiming to reduce patients’ sedation rate and providing them stress, clinical anxiety and pain relief. TOMMI is designed in collaboration with doctors and provided in form of a VR game, applying evidence based approaches to engage children senses and focus their attention out of therapy negative feelings. Game design has a special focus on pediatric oncology, but it also applies to pediatric dentistry and orthopedics, and it involves children parents too during the gaming sessions. 722 / 880 At the same time, game levels are developed to test children therapy related psychomotor skills and the project uses proprietary AI to measure stress related biometrics through innovative data collection and analysis methods. This way, TOMMI provides objective metrics about patients wellbeing conditions and stress levels, aiming to support children tracking during therapy and support the medical staff work routine. TOMMI team was selected to join 3 International accelerator programs, Merck Accelerator Program in Germany (2017), TMCx at Texas Medical Center in US (2018), Accelerace in Denmark (2018) and it’s now part of Silicon Valley’s Y Combinator Startup School 2018. TOMMI has been also awarded with several prizes supporting its innovative approach: Pfizer Healthcare Challenge (2017), Premio Nidi by Innovami (2017), Web Marketing Festival prize (2017), Italian Startup Europe Awards (2017), Boost Your Idea (2018), Premio Marzotto (2017). TOMMI is now ready to be tested in hospitals and first clinical collaborations are raising in Italy, Houston’s Texas Medical Center and Denmark. TOMMI is the first product of Softcare Studios, a digital health startup founded in 2017 in Rome by a team of professional, passionated and visionary entrepreneurs committed to improve patients therapy experience using virtual reality and artificial intelligence.

723 / 880 Softech srl

Organisation

Country Italy City Castel Maggiore Street Via Di Vittorio 21/B2 Web http://www.softech-engineering.it

Person

Name Massimo Galletto CEO

Organisation SofTech is an italian company founded in 1997 and focused on the development on software solution for Care Management and integrated care delivery with an holistic approach for a person-centred vision. With over 20 years of experience in socialcare and 10 years in healtcare we are able to propose integrated and disruptive solution. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health • Software, ICT applications, system integration • EPR, Clinical/healthcare management software

Marketplace Opportunities PRODUCT Care Management platform for integrated care delivery Garsia® is a holistic care management platform for integrated care delivery through a personalized interdisciplinary approach, where clinicians, coordinators, social workers, patients and family members can share a systemthat supports joint ownership of care.

724 / 880 Soladis Group

Organisation

Country France City Biot Street 2000 route des Lucioles - Les Algorithmes Aristote A Web www.soladis.com

Person

Name Diana Ferranti Data Scientist

Organisation Soladis is a service provider dedicated to the acquisition, analysis, valorization of data. Providing its services through 4 business units : SOLADIS Statistics : dedicated to statistics, biostatistics, data science. On methodologies, protocols, data management, analysis and reporting SOLADIS Clinical studies : dedicated to clinical studies and medical expertise SOLADIS Digital : dedicated to the exploitation of data with advanced IT tools (smart data, big data, ad hoc data…) SOLADIS Connect : dedicated to sensors, connected devices and IoT Thanks to our highly-qualified team and to the synergies of our business units, we are able to support our partners on various projects, from early phase R&D to Marketing, through industrial projects. Areas of Activity

• Analytical and characterization services • Proteomics, metabolomics, nutrigenomics • Bioinformatics, Big data analytics • Regulatory affairs, validation • Biosensors • Life sciences related activities • Biotechnologies (Pharma&Medical • Software, ICT applications, system Devices) integration • Consulting services • EPR, Clinical/healthcare management • CRO (Contract Research Organisation) software • Diagnostics - Equipment and accessories • Surgery technologies and applications • eHealth, mHealth, telemedicine • Vaccines • Electromedical and medical equipment • Virtual reality applications (non diag) • Other • Genetics & Genomics • Project proposals support services • Investments • Medical devices • Manufacturing & process engineering • IT Applications for Health • Medical research • Nutraceutics, probiotics, functional food,

725 / 880 cosmeceutics • Pharmaceutics

Marketplace Opportunities SERVICE Acquisition, Analysis, Valorization of data Soladis is a service provider dedicated to the acquisition, analysis, valorization of data. Providing its services through 4 business units, we have a large experience in data exploitation, clinical studies in EU, protocols, analysis and reporting and predictive maintenance. With our higly skilled teams we can support you through a very personalized offer according to your necessities.

726 / 880 Sonnomedica

Organisation

Country Italy City Milano Street Via Cerva 25 Web www.sonnomedica.it

Person

Name Marco Caglieris CEO

Organisation Sonnomedica is a fully operational Sleep Medical Center in Milan (Italy) and we deliver medical care for sleep disorders, sell equipment and devices for the treatments, offer eHealth / eCommerce services nationwide. Our innovation for the snoring and sleep apnea problems: 62% of European people suffer from SNORING SLEEP APNEA: million people worldwide live attached to a respirator (CPAP) and this market worth more than $ 15 billion in 2014 before our new minimally invasive surgery there was no viable simple mininvasive permanent solution now the new Barbed Snore Surgery is ready and we want to scale up the market Areas of Activity

• Consulting services • Life sciences related activities • Medical devices

Marketplace Opportunities PARTNERSHIP New breakthrough Snore/Sleep Apnea Surgery A new revolutionary surgical technique to treat Snoring and Sleep apnea problems (OSAS), called BSS – Barbed Snore Surgery, has been recently developed in Italy. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The new technique has been conceived by Prof. Dr. Mario Mantovani introducing for the first time the use of an absolute revolutionary material, the barbed suture, in the surgery of the oral and pharyngeal district of the human body. The basic innovative principle of the B.S.S. – Barbed Snore Surgery consists of reducing the 727 / 880 collapsibility of the retro palatal tract, responsible for vibrations (snoring) or obstructions (apneas), by means of threads anchoring the inner layer of the upper airway, made of soft tissues like muscles and mucosae, to the natural and solid anatomic grips that surround them, namely the posterior nasal spine, the two pterygo mandibular rafes and pterygoid hamuli. Main advantages are: - effective - minimally invasive (no cuts) - low side effects - reversible surgery - validated / published technique - more than 300 patients treated MARKET APPLICATION We focus on B2C market in Italy and in main european countries. We consider also worlwide development opportunities. Regarding sleep apnea in Europe alone there are millions of people being treated with continuous ventilation equipment (CPAP) and who would like to have a permanent solution to their problem. And in EU a new directive (UE -2014/85/UE) require sleep tests for all drivers (pro, no-pro drivers): only in Italy the specialists expect more than 1 million new patient for sleep apnea problems. Today also the issue of simple snoring does not have a proper solution that instead Barbed Snore Surgery can offer. TYPE OF PARTNER SOUGHT We look for: - a partnership with private hospitals / health provider networks in principal european countries and non-EU countries - B2C healthcare marketing specialists INVESTMENT OPPORTUNITY Investors for Snore/Sleep Apnea Surgery market development The global market for sleep aids was worth US $ 58.080 million in 2014 and rising incidence of sleep apnea in developed countries is the primary reason for the booming growth of the global market sleep aids (11% CAGR in the period 2014-2019, see Persistence Market Research Report). The innovations introduced recently by the EU regarding driving licenses and the need of compulsory medical checks to prevent "falling asleep" while driving will result in an important market growth. In Italy the market is largely underdeveloped and expected very significant growth that will be necessary for new medical service providers (centers of sleep medicine). SOLUTION OR EXPERTISE SOUGHT Sonnomedica defined a business plan for 2016-2020 fully develop the market thanks to product and service innovation introduced and search new financial partners to implement it. TYPE OF PARTNER SOUGHT We are looking for new investors (Investors (VCs, Family offices, Business Angels or Corporate partners) for the development of the Italian market (for sleep medicine in general) and the worlwide market (for new snore surgery developed in Milan, Italy).

728 / 880 SPECIPIG S.L.

Organisation

Country Spain City El Prat del Llobregat Street Autovia de Castelldefels C-31. Km. 190,5 Web www.specipig.com

Person

Name Assela Bosch Business Development Manager

Organisation SPECIPIG, is a pioneer Breeding and Biomedical Research Centre focused on the pig model.We breed miniature pigs and run in-vivo pig model studies for: - Medical device, tissue regeneration and new materials development: to test prototypes, to establish efficacy, to determine biocompatibility, to improve product knowledge, to minimize risk in the development, to convince the market with scientific evidence, and to attract investment to further develop the project. - Pharma preclinical development: to run efficacy, toxicology, pharmacokinetic, tolerance and proof of concept studies. We are GLP certified and have fully equipped surgery rooms and housing facilities to be able to fully cover the needs of any trial. We are experts on the pig model, training the pigs to cope with the trial requirements with the least stress and securing the best welfare. Areas of Activity

• Biomaterials • Medical devices • Biotechnologies (Pharma&Medical Devices) • CRO (Contract Research Organisation) • Pharmaceutics

Marketplace Opportunities SERVICE In vivo trials based on the pig model We offer our expertise and facilities to run in-vivo trials based on the pig model. Medical device, tissue regeneration, new biomaterials or pharma trials to assess on the proof of concept, to run efficacy, biocompatibility or any other trial (pK, toxicity,..). All under GLP certification and with a fully equipped surgery room and facilities to do the implantation or initial treatment and do the clinical follow-up all along the trial. INNOVATIVE ASPECTS AND MAIN ADVANTAGES We are experts on the pig model, training the pigs to cope with the trial requirements with the least 729 / 880 stress and securing the best welfare. Innovative aspects: - Expertise on the animal model. - Fully equipped surgery room. - Housing facilities that enable clinical follow-up for as long as necessary. MARKET APPLICATION Medical device Pharmaceutics Biopharma Biotechnology TYPE OF PARTNER SOUGHT Start-up, push-off, SME or any company with a new device, material, tissue that need to run in-vivo trials to determine proof of concept, to certify efficacy, biocompatibility, toxicity, in a model that is the most similar for many systems (cardiovascular, digestive, dental, skin, urinary,...) to the human model.

730 / 880 Speedinvest

Organisation

Country Austria City Vienna Street Web https://speedinvest.com/

Person

Name Max Germann Analyst

Organisation Speedinvest invests capital in world class talent (200M € assets under management). We provide entrepreneurial know-how and operational experience that is essential to building excellent companies. WeWe work hands-on. Our partners work, hands-on, together with our founders as part of our own Growth Partner Program. We provide our founders with the experience, network and operational support to help them address their challenges. The high ratio of partners within the fund enables us to engage with every single one of our portfolio companies. We provide the network. Over 100 investors behind Speedinvest actively help our portfolio companies grow. These are companies such as RedBull and Funke-Group and a network of some of the most successful business angels and entrepreneurs in Europe. Our strong connections with other venture capital funds such as NEA facilitate follow-on funding. We are entrepreneurs. Our partners are all experienced practitioners, most of them multi-exit founders, who can leverage years of operational experience and vast networks within their areas of expertise. We are not bankers or consultants; we are entrepreneurs for entrepreneurs. Connect to the US. Our bridge to the US via our office in the Silicon Valley as well as our partnership with NEA, the world’s biggest VC fund, offers founders invaluable access to the US market. Our portfolio companies can therefore benefit from connections to US tech companies, a wider range of exit channels and better valuations. Areas of Activity

• Investments

Marketplace Opportunities INVESTMENT OPPORTUNITY

731 / 880 Investment opportunity We invest in the following sectors, including life sciences related high-potential startups: Fintech/Insurtech, Industry, Deeptech, Consumertech, and Network Effects. We are inspired by innovative ideas that bear the potential to transform the future, and are eager to drive forward founder-investor success stories. We manage pre-seed, seed, series A, series B investments depending on the startup stage of development and sector

732 / 880 Spirohome

Organisation

Country Turkey City Ankara Street ODTU Teknokent Silikon Blok 15A, Çankaya/ Ankara ODTÜ kampüsü - TURKE Web http://spirohome.io/

Person

Name Kerem Yaşar Co-founder and CTO

Organisation Spirohome is an e-health platform developed to help patients manage chronic respiratory conditions such as Asthma and COPD. With its smart inhalers, the Spirohome spirometer and mobile applications, the Spirohome platform tracks a patient’s respiratory values and adherence with clinical accuracy, all through a personalised experienced. The Spirohome platform is designed to reduce costs for pharma, research organizations, and insurance companies. Areas of Activity

• CRO (Contract Research Organisation) • Regulatory affairs, validation • Diagnostics - Equipment and accessories • EPR, Clinical/healthcare management • eHealth, mHealth, telemedicine software • Investments • Medical devices • Medical research

Marketplace Opportunities PRODUCT Spirohome Inhaler Smart inhaler attachment that tracks adherence and improves inhaler technique. Build up adherence and technique Non-adherence and poor inhalation technique in asthma treatment leads to increased asthma symptoms, hospitalizations and healthcare costs. Spirohome Inhaler is a smart attachment that encourages adherence while enhancing patient's inhalation technique. Sensors help eliminate misuse Flow sensor senses inhalation flow to guide user to achieve better flow technique. One sensor fits all Spirohome Inhaler fits to most MDIs. Patients can easily calibrate the attachment with the mobile 733 / 880 application's help to use the inhaler with maximum accuracy. Track your adherence Spirohome Inhaler works with the Spirohome app. Patients can easily track their adherence and get feedback on their inhalation technique. PRODUCT Spirohome Clinic Pulmonary function testing device for clinical use Digitalize your clinic Spirohome Clinic is a spirometer designed for clinical use and could be used in hospitals, health clinics and as part of clinical studies. Prevent cross-contamination Spirohome Clinic works with disposable bacterial filters to prevent cross contamination. Spirometer itself can be easily cleaned after each use. Intuitive user experience Spirohome Clinic provides intuitive test experience on tablet while offering fresh user experience for storing and sorting patients info. Track your patients easily Desktop app helps physicians to easily track their patients' spirometry and adherence data while enables them to schedule new visits. It also provides secure web based data visualisation for clinical studies. PRODUCT Spirohome Personal pulmonary function testing device. Track your lungs, any time. Spirohome is a personal spirometer designed for asthma, COPD and cystic fibrosis patients along with health enthusiasts who want to be aware of their lung condition. Spirohome enables patients to monitor their disease and prevents attacks while avoiding unnecessary hospital visits. Cutting edge technology Patent pending technology behind the personal spirometer uses ultrasonic flow sensing which is the most advanced technology for spirometer devices available in the market. Spirohome works as accurate as a spirometer you would see in a hospital. INVESTMENT OPPORTUNITY Series A Investment Spirohome is looking forward to having Series A round in the 2nd quarter of 2019 in order to support growth, enlarge business on different market segments and to add more team members behind product and service.

734 / 880 Sportello Matematico per l'Industria Italiana

Organisation

Country Italy City Rome Street via dei Taurini 19 Web https://www.sportellomatematico.it/SMII/

Person

Name Maurizio Ceseri Research Fellow

Organisation Sportello Matematico per l'Industria Italiana is a project of the Istituto per le Applicazioni del Calcolo (IAC) of the National Research Council of Italy (CNR) started in december 2012. Sportello Matematico offers a brokerage services in the field of Mathematical Technologies, that is Modelling, Simulation and Optimization (MSO), Bioinformatics, Statistics. Very often, the enterprises that want to cooperate with Academia do not know how to find the research partner that suits their needs. A skilled team will offer you free support in creating cooperation agreements with a network of more than 40 research institutions expert in the field of Mathematical Technologies. Our research partners have expertise in mathematical methods applied to several fields of life sciences: modeling of diseases such as tumour, HIV and diabetes; protein-protein interaction; DNA- protein interactions; fluid dynamics of the blood system; algorithms for non-invasive diagnostics; microarrays analysis; DNA sequencing; (Big) Data analysis; medical imaging; 3D modeling and simulation; Design Of Experiment (DOE). We offer a unified structure to which an enterprise can address its business issues; we support the firm to find the suitable research group in our network to deal with the proposed problem; we facilitate the communications among all the actors. Finally, the company will have a solution tailored to its needs. Areas of Activity

• Bioinformatics, Big data analytics • Other • Consulting services • IT Applications for Health • Diagnostics - Imaging equipment and processing • Manufacturing & process engineering • Software, ICT applications, system integration

Marketplace Opportunities

735 / 880 SERVICE Networking service in the field of Industrial Mathematics Sportello Matematico is a new Italian project that build a network of relationships between Academia and Industry in the field of Applied and Industrial Mathematics. Very often, the enterprises that want to cooperate with Academia do not know how to find the research partner that suits their needs. Thus, we offer a structure to which an enterprise can address its business issues; we support the firm to find the suitable research group in our network to deal with the proposed problem; we facilitate the communications among all the actors. Finally, the company will have a solution tailored to its needs. SERVICE Mathematical Technologies for Innovation Mathematical Technologies are fundamental to increase innovativeness and competitiveness of enterprises and with their help, Enterprises can obtain substantial results in their business. Here is a list of examples of possible cooperation between Enterprises in the Life Science sectors and Research groups in Mathematical Technologies. Design of Experiment. Development of new methods for the optimal design of experiments and quantitative simulations of chemical processes. Mathematical Technologies can help Enterprises to reduce experimental costs of up to 80%. Simulation of chemical processes. Development of mathematical models of the chemical processes involved in drug production and both pharmacokinetics and pharmacodynamics. These tools have a real predictive capacity able to reduce drug’s development time.

Medical Imaging. Development of high-tech innovative solutions in medical imaging to create new and more powerful investigative and diagnostic instruments. Virtual Prototyping. Mathematical methods than can simulate the structural strain and stress distribution in a bone-prosthesis system thus helping the development of new prosthesis. Optimization of work shift of hospital staff. Software tools to better plan the work shift of physicians in a hospital taking into account the huge number of constraints. The software can calculate the optimal distribution of work shift over a period of 8 weeks in 6 hours. Emergency department workflow optimization. Development of decision support system to improve an ED’s timeliness of care, quality of care, and operational efficiency while reducing avoidable readmissions.

736 / 880 Sportello Matematico per l'Industria Italiana

Organisation

Country Italy City Roma Street via dei liburni, 2 Web http://www.sportellomatematico.it/SMII/

Person

Name Silvia Vermicelli Senior Technology Transfer Officer

Organisation Sportello Matematico per l'Industria Italiana is a project of the Istituto per le Applicazioni del Calcolo (IAC) of the National Research Council of Italy (CNR) started in december 2012. Sportello Matematico offers a brokerage services in the field of Mathematical Technologies, that is Modelling, Simulation and Optimization (MSO), Bioinformatics, Statistics. Very often, the enterprises that want to cooperate with Academia do not know how to find the research partner that suits their needs. A skilled team will offer you free support in creating cooperation agreements with a network of more than 40 research institutions expert in the field of Mathematical Technologies. Our research partners have expertise in mathematical methods applied to several fields of life sciences: modeling of diseases such as tumour, HIV and diabetes; protein-protein interaction; DNA- protein interactions; fluid dynamics of the blood system; algorithms for non-invasive diagnostics; microarrays analysis; DNA sequencing; (Big) Data analysis; medical imaging; 3D modeling and simulation; Design Of Experiment (DOE). We offer a unified structure to which an enterprise can address its business issues; we support the firm to find the suitable research group in our network to deal with the proposed problem; we facilitate the communications among all the actors. Finally, the company will have a solution tailored to its needs. Areas of Activity

• Bioinformatics, Big data analytics • Other • Consulting services • IT Applications for Health • Manufacturing & process engineering • Software, ICT applications, system integration

Marketplace Opportunities SERVICE

737 / 880 Mathematical Technologies for Innovation Mathematical Technologies are fundamental to increase innovativeness and competitiveness of enterprises and with their help, Enterprises can obtain substantial results in their business. Here is a list of examples of possible cooperation between Enterprises in the Life Science sectors and Research groups in Mathematical Technologies. Design of Experiment. Development of new methods for the optimal design of experiments and quantitative simulations of chemical processes. Mathematical Technologies can help Enterprises to reduce experimental costs of up to 80%. Simulation of chemical processes. Development of mathematical models of the chemical processes involved in drug production and both pharmacokinetics and pharmacodynamics. These tools have a real predictive capacity able to reduce drug’s development time.

Medical Imaging. Development of high-tech innovative solutions in medical imaging to create new and more powerful investigative and diagnostic instruments. Virtual Prototyping. Mathematical methods than can simulate the structural strain and stress distribution in a bone-prosthesis system thus helping the development of new prosthesis. Optimization of work shift of hospital staff. Software tools to better plan the work shift of physicians in a hospital taking into account the huge number of constraints. The software can calculate the optimal distribution of work shift over a period of 8 weeks in 6 hours. Emergency department workflow optimization. Development of decision support system to improve an ED’s timeliness of care, quality of care, and operational efficiency while reducing avoidable readmissions. SERVICE Networking service in the field of Industrial Mathematics Sportello Matematico is a new Italian project that build a network of relationships between Academia and Industry in the field of Applied and Industrial Mathematics. Very often, the enterprises that want to cooperate with Academia do not know how to find the research partner that suits their needs. Thus, we offer a structure to which an enterprise can address its business issues; we support the firm to find the suitable research group in our network to deal with the proposed problem; we facilitate the communications among all the actors. Finally, the company will have a solution tailored to its needs.

738 / 880 Stem Sel

Organisation

Country Italy City Bologna Street Web http://www.stemsel.it/

Person

Name Pierluigi Reschiglian CEO

Organisation Stem Sel is a technology-based company founded in November 2013 for the commercial exploitation of the cell separation technology developed by the company founders working at the University of Bologna, Italy. The core business is the development and commercialization of this technology that highly select cells from complex and heterogeneous populations for research and clinical applications. The first product is a device registered under the name of Celector®. Celector® implements an innovative and patented method for the separation and selection of stem cells from different tissues (both “discarded” tissues such as placenta and umbilical cord, and “adult” tissues as bone marrow and lipoaspirate). Areas of Activity

• Analytical and characterization services • Laboratory equipment, reagents, software • Biotechnologies (Pharma&Medical • Medical devices Devices) • Drug screening & delivery • Medical research • Life sciences related activities

Marketplace Opportunities PRODUCT Celector - Cell separation technology Celector® is a patented instrument for live cell imaging, separation and collection of living cells. The basic principles of chromatography are applied to Celector® technology. Celector® provides a label-free separation of cells based only on their native physical properties. Absence of immuno- labelling is its unique feature: it avoids signalling cascade activation, maintains the native cell

739 / 880 physiology and stem cells full regenerative potential. During the separation process, a high-resolution camera allows the visualization and recording of the eluting cells like the frames of a movie and as an additional feature, you can capture single frames that are stored in a customized library for post processing analysis of your cell samples. The advantages of Stem Sel® Srl relay on the competitiveness of Celector®, which allows: •Cheaper and shorter time of analysis •Real-time quality control (QC) of the sample and microscopic images of the separated cells in suspension •Maintenance of the cell viability •Full preservation of cell functionality for further characterization/amplification •High purity of the isolated cell population. Celector® will be ready for the market in the early 2019 with a wide array of applications, making it ideal for a range of discovery and translational research applications, from Cell Therapy to in-vitro cell tests for drug discovery. SERVICE R&D: characterization and isolation of pure stem cell populations from complex samples Stem Sel Srl (Ltd.) has developed a novel, proprietary technology for cell quality control and cell selection, which is implemented in a new instrument: Celector®. It offers new insights in cell characterization, quality control and separation of different cell populations from complex samples. It is an ideal device for R&D and clinical labs. Moreover, Stem Sel offers the development of protocols tailored to customer’s needs. With our expertise in biological and analytical sciences, we can develop specific protocols to isolate your dream cell populations from several organ origin (adipose tissue, bone marrow, foetal annex,…). The service is addressed to research lab and clinical lab who works with cell samples from basic research to in vivo models. REQUEST Looking for distributors and commercial partners Stem Sel is already developing the industrialised prototype of Celector®. In order to complete our ready-to-market phase, we need 1) a marketing campaign to reach our target clients and 2) to identify a reliable supplier or sale person with a background in science lab equipment/reagents. We are looking for candidates with a consolidated knowledge in the life science industry. INVESTMENT OPPORTUNITY Looking for investors for our breaking-through technology We are seeking potential investors (Venture Capital, Business Angels, and Companies) which are interested in supporting the development of our product Celector(R): the "chromatograph" for cells. PROJECT COOPERATION Synergistic partnership: Commercial partner Celector® is a patented instrument for live cell imaging, separation and collection of living cells. A concept of “chromatography-like” separation can be applied to Celector® since it provides a flow- assisted, time-resolved, and label-free separation of cells based only on their native physical properties. We are looking for a commercial partner to work in synergy. The partner should be acquainted to the life science industry and especially with lab equipments for cell analysis/sorting such as Flow cytomety, FACS and MACS products. Those instruments are not direct competitors of Celector® but they draft the buyers’ market area. INVESTMENT OPPORTUNITY Seeking for a bridge round to co-finance the ready-to-market phase and

740 / 880 support 2019 market entry and development We are pleased to inform that with Celector, Stem Sel has entered the top-20 companies that will present their pitch at the Italian Healthcare Venture Forum, Oct. 11, which is part of MeetInItaly.

741 / 880 STEP RI Science and Technology Park of University of Rijeka ltd.

Organisation

Country Croatia City Rijeka Street R. Matejcic 10 Web www.step.uniri.hr

Person

Name Neven Tamarut Business Development Manager

Organisation STEP RI - Science and Technology Park of the University of Rijekahas been established by the University of Rijeka in order to become premier science and technology hub, facilitating the commercialization of R&D created within scientific community, foster cooperation between university and business sector. STEP RI offers the perfect environment for emergent companies, combining superb accommodation with integrated business support services. Park offers off-site and on-site incubation services, education, R&D and innovation management consulting as well as growth and go-to-market support. Areas of Activity

• 3D Printing/addictive manufacturing for • Life sciences related activities biomedical applications • Other • Consulting services • Project proposals support services • Diagnostics - Equipment and accessories • Medical devices • Diagnostics - Imaging equipment and • IT Applications for Health processing • eHealth, mHealth, telemedicine • Electromedical and medical equipment (non diag) • Medical research

Marketplace Opportunities PRODUCT Teaching model for anatomy structures of sinuses and sinuses surgery practice A Croatian university has developed a training model for Functional Endoscopic Sinus Surgery (FESS). Precise design of the model that contains 15 coronary slices allows teaching of anatomy in schools and training of detailed surgical procedure that leads to improvement of surgeons practice. The model has 742 / 880 strong educational potential, where precise anatomy of human head is needed. Currently the training model has been developed as a product and protected as a registered design and trademark in EU and USA. The IPR are licensed to company TABLETOP ltd. PRODUCT Curved dilator for targeted thoracic drainage Subject of this offer is medical device (curved dilator) that is used for treatment of patients in intensive care who need drain of fluids from the pleural space between the lung and chest wall. The present invention provides accurate and easily set up for wire-guide to drain from the desired quadrant of the patient’s chest. Thoracic drainage in medicine has so far proved to be very invasive procedure with limited success which can only work well with educated medical staff, while used exclusively straight dilators that have no ability to change the direction of the guide-wire inside the chest. The use of invention gives more precise and simple positioning of the guide wire for the drain in the intended quadrant of the patient's chest. Technical problem being solved by the present invention refers to the improvement (i.e. shortening) of the thoracic drainage procedure.

743 / 880 Sterilizasyon Medical

Organisation

Country Turkey City Istanbul Street

Person

Name Erhan Alsancak Managing director

Organisation Sterilizasyon medical is main distrubutor of many multinational companies and manufacturer of sterilization products. Areas of Activity

• 3D Printing/addictive manufacturing for • Physiotherapy, Orthopaedic technology biomedical applications • Proteomics, metabolomics, nutrigenomics • Biomaterials • Life sciences related activities • Biosensors • EPR, Clinical/healthcare management • Biotechnologies (Pharma&Medical software Devices) • Surgery technologies and applications • Diagnostics - Imaging equipment and • Medical devices processing • eHealth, mHealth, telemedicine • Electromedical and medical equipment (non diag) • Genetics & Genomics • Nutraceutics, probiotics, functional food, cosmeceutics

744 / 880 Strategic Innovative Initiatives

Organisation

Country Turkey City Istanbul Street Teknopark Istanbul, Kuluçka, Sanayi Mahallesi Teknopark Bulvarı No:1 Blok:4 Pendik Web http://stratejikgirisimler.com/

Person

Name Tarik Ozkul General Manager

Organisation We are an innovative small SME with a concentration on medical devices. We have medical doctors on board the company so we only produce solutions for genuine medical problems. We have a patented new device for diagnosing Eustachian Tube problems. This is a problem suffered by more than 300 million people in the world. Our diagnostic device identifies the problem with the patient and guides the ENT specialist for the best course of action\ Areas of Activity

• Diagnostics - Equipment and accessories • Medical devices

Marketplace Opportunities PRODUCT 'EAR' Eustachian Assessment Rehabilitation Eustachian Tube Dysfunction (ETD) is a problem suffered by 5% of the world population. ETD patients suffer from hearing loss but also feel excruciating pain when pressure around them changes. There are several traditional methods used for solving the ETD patients but none of them addresses the root cause. Because of this the problem keeps repeating. We discovered the root cause of ETD and it turned out to be muscular confusion. With our new diagnostic device EAR, it will be possible to identify the condition of the Eustachian Tube in a short session. It is very valuable as a unique device identifiying source of problems. The device comes with consumable electrodes and several pipers. The electrodes and pipes are placed inside the month of the patient and measurement is done automatically. The session last 15-20 minutes, after that the results are obtained. Based on the report results, different course of action can be taken to solve the problem. We believe that our 'EAR' diagnostic device will find a place in every ENT specialists room. We expect EAR device assesment to be a standard procedure for measuring the capacity of Eustachian tube of all ENT patients. We expect this to be a lucrative business since sale of the EAR device and the sale of EAR consumables 745 / 880 form continuous revenue stream for the company. Being patented, it becomes a unique device offering this test. Having more than 5% of whole world population suffer some problem related to Eustachian Tube there are plenty of patients. We expect ech EAR device to serve 1000 patients on the average annually. Plese contact us if you need more information. PARTNERSHIP Partners sought for joint manufacturing and distribution Our diagnostic device is a 'first in the world' and backed up by a medical discovery. It can be used to diagnose Eustachian Tube related problems like ETD (Eustachian Tube Dysfunction) as well as reporting the health state of Eustachian Tube of regular patients. It may be the ideal instrument to diagnose potential patients for Myringotomy or Balloon dilation procedure. It has the potential to diagnose many strange ENT problems like Tinnitus as well. The device is patented and needs to be used with consumables. Sale of device and consumables may be a lucrative business considering that there are more than 300 million patients gloabally. 5% of the world population has ETD problems and these patients are ideal candidates for our diagnostic device. Once the root cause is identified using our diagnostic device, the problem may be cured using muscular stimulation or by classical surgical techniques. The device is minimally invasive and can be used in the office. It requires consumables and sale of consumables for 300 million patients is a lucrative business. We estimate each device sold will be serving potentially 1000 patients every year each requiring the consumable probes for the device. We are looking for partners who can help development/manufacturing as well as the distribution of the device. Experienced manufacturers with proven track records will be preferred. We are open to provide equity for the partnership services. We would like to work with the best manufacturers and distributers to make this device a golabal success. INVESTMENT OPPORTUNITY Seeking Series A Funding; Capital Seeking: € 3 M Almost 70% of all ear problems can be traced to the inadequate operation of Eustachian tube. Current diagnostic devices are not effective in measuring operational capacity of the eustachian tube. Our diagnostic device is a 'first in the world' which is backed up by a medical discovery. Our study has proven that Eustachian tube opens regularly like a heartbeat every 20 seconds. The two muscles that control the Eustachian Tube work synchronously and synergistically to open the tube. As the phase difference between the signals disturbed by some external reasons, the synchronicity of the muscle activity gets disturbed and Eustachian dysfunction starts. The severity of the dysfunction is directly related to how disturbed the synchronicity of the muscle activity. This discovery is the key to understanding the reason behind many Ear related problems. Our discovery is likely to explain the reasons (and possibly cure) behind those ENT problems. Once the reason is identified properly, the solution is likely to be selected properly. We have designed and patented a new diagnostic device based on this concept. The new device which we call "EAR" (Eustachian Assesment Rehabilitation) measures the capacity of the Eustachian tube based on the facts stated above.

746 / 880 Studio tau s.r.l.

Organisation

Country Italy City Milano Street Studio tau srl Web www.studiotau.it

Person

Name Sergio Ghersini General manager

Organisation Studio tau is a small company specialised in regulatory affairs consultancy for medical devices, including IVDs. We work on an international basis, providing consultancy services on: - managerial issues: regulatory affairs, business process re-engineering - product issues: technical file preparation, EU Directives and CE marking, FDA clearance - management systems: according to international standards ISO 9001, ISO 13485 and regulations like current GMPs - risk analisys and management: according to international standardsISO 14971, ISO 60601, ISO 62304 and technical reportsISO_TR_80002-2 We also carry out: - audits to assess conformity to regulations and standards and to identify gaps - courses on the above topics. Areas of Activity

• Diagnostics IVD • Laboratory equipment, reagents, software • Diagnostics - Equipment and accessories • Medical devices • Diagnostics - Imaging equipment and processing • Electromedical and medical equipment (non diag)

Marketplace Opportunities SERVICE Regulatory affairs consultancy Our company provides custom tailored consultancy services in regulatory affairs. We take care of medical devices (Directive 93/42 to be replaced by Regulation 2017/745 DM) and In Vitro Diagnostics (Directive 98/79 to be replaced by Regulation 2017/746 DM), We take care of both system and product aspects and - through our partners - we can offer an integrated service. 748 / 880 Our activity is extended also to non European markets, such as USA, Russia etc. Customer enjoys: - a unique interface for all different aspects of product and system approval - a responsive and effective system, thanks to our simple structure - good services at affordable conditions. MARKET APPLICATION Medical devices (MD) In-vitro diagnostic devices (IVDs) Laboratory equipment We provide consultancy services and support for product approval, in Europe and other areas (USA,Russia, etc.), taking care of: - technical file preparation and validation - relationships with testing laboratories and medical staff - quality management system development and implementation - relationships with Notified Bodies - Authorized Representative activities

749 / 880 SunRegen Healthcare AG

Organisation

Country Switzerland City Reinach Street Robinienweg 51 Web http://www.sunregen.ch

Person

Name David Guan Managing Director

Organisation SunRegen Healthcare AG is a pioneering biopharmaceutical company based in Basel Area of Switzerland. Our mission is to develop novel drugs for the unmet medical needs, especially for neurological diseases including Optic Atrophy and the neurodegenerative diseases. The co-founder team of SunRegen has solid business and management experience in multinational companies and very strong drug development background. SAB members are from big pharma, and each with over 30 years drug research experience. SunRegen is well recognized by the biotech industry and supported by Innosuisse, BaseLaunch, H202 SME Instrument programs. Areas of Activity

• Biotechnologies (Pharma&Medical Devices)

Marketplace Opportunities INVESTMENT OPPORTUNITY New drug development project is open for fundraising SunRegen is developing a small molecule drug for the treatment of neurological diseases including Optic Atrophy, Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease (HD). Warmly welcome early stage funding joining the journey to develop a breakthrough therapy for these diseases. Now we are opening pre-A round financing to support our preclinical studies. Our drug has incredible potential because its remarkable neuroprotective, neurorescuing, neurotrophic, and axon-outgrowth effects which were proven by 4 species, 10 neurotoxins, in more than 20 different models. Our test results have amazed every scientist who has seen them. PROJECT COOPERATION Collaborations with academia research groups or CRO SunRegen is looking forward to collaborating with academia research groups or CRO who has strong research capacity on Optic Atrophy, Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS) or Huntington’s disease (HD). The collaboration may cover the whole drug 750 / 880 research area across drug discovery, preclinical and clinical studies.

751 / 880 Swiss Business Hub Italia - Consolato generale di Svizzera

Organisation

Country Italy City Milano Street Web https://www.s-ge.com/it/company/swiss- business-hub-italy

Person

Name Stefan Zwicky Swiss Business Hub / Consolato Svizzero

Organisation Part of the Swiss Consulate General in Milan, the Swiss Business Hub Italy is a reference point for internationalization projects between Switzerland and Italy. Swiss Business Hub promotes Switzerland as business platform for international growth and is the official contact point of the 26 Cantons. Areas of Activity

• Consulting services • Investments • Project proposals support services

Marketplace Opportunities INVESTMENT OPPORTUNITY Develop your business abroad - Switzerland as a business location for your global expansion

The Swiss Business Hub promotes Switzerland as business platform for international growth. Innovative Italian companies in the Life-Science sectors throught the Swiss Business Hub Italy could send their internationalisation programme to all the 26 Cantons. This is a interesting opportunity in order to verify the possibilities in each Canton and to find the perfect business location. The support the Italian companies could receive depends from Canton to Canton.

752 / 880 Swiss Business Hub Italia - Switzerland Global Enterprise - Consolato generale di Svizzera

Organisation

Country Switzerland City Zurigo Street Web http://www.s-ge.com/

Person

Name Annalisa Ziliani Investment Promotion Officer

Organisation Part of the Swiss Consulate General in Milan, the Swiss Business Hub Italy is a reference point for internationalization projects between Switzerland and Italy. In the export perspective, SBH supports Swiss entrepreneurs to access the Italian market. Furthermore the Swiss Business Hub promotes Switzerland as business platform for international growth. Areas of Activity

• Other

Marketplace Opportunities

INVESTMENT OPPORTUNITY Develop your business abroad - Switzerland as a business location for your global expansion The Swiss Business Hub promotes Switzerland as business platform for international growth. Innovative Italian companies in the Life-Science sectors throught the Swiss Business Hub Italy could send their internationalisation programme to all the 26 Cantons. This is a interesting opportunity in order to verify the possibilities in each Canton and to find the perfect business location. The support the Italian companies could receive depends from Canton to Canton.

753 / 880 Swiss Medendi SA

Organisation

Country Switzerland City Lugano Street Via Carlo Maderno 24 Web www.swissmedendi.com

Person

Name Shahar Tsabari CEO

Organisation Swiss Medendi SA is a Switzerland based start-up company offering a CE mark disposable intravenous (IV) infusion device to avoid chemical phlebitis for a safe administration of vesicant and irritant drugs such as chemotherapeutics preventing patients from serious complications and injuries. Management of such complications has a relevant impact on hospital costs.The product is a medical device in class IIa/UE and class II/USA. It avoids blood vessels saturation by only drug resulting in a safer infusion, maintaining a sterile and closed-system environment.The device has CE mark and already registered within the "Repertorio dei dispositivi medici" in Italy and it is available for all UE countries. The device has demonstrated superior performance.SwissMedendi can leverage on a highly qualified team of experts and successful entrepreneurs supported by a strong Advisory Board. Areas of Activity

• Drug screening & delivery • Medical devices

Marketplace Opportunities PRODUCT Safe Chemotherapy Infusion (CE marking) About 250 drugs when in contact with blood vessels injure their inner wall over a longer distance from the catheter tip, causing sever or permanent injuries. Drugs such as chemotherapeutics damage patients’ blood vessels severely and irreversibly during the intravenous administration. To try to avoid such complications, these drugs are often administered through central venous catheters (CVCs). Nevertheless, CVCs administration while requiring a surgical placement and a closed patient follow up, have added other complications like occlusions, extravasation, phlebitis, thrombosis and CRBI potentially lethal. CVC procedure, whose cost is in the range of 2’000-4’500 CHF, and the overall management of the related complications has a relevant impact on hospitals budget. The potential market for a new cost-efficient device for a safe infusion of irritant and vesicant drugs, is vast. More than 5bn intravenous drug therapies are provided to patients worldwide every year, out of which about 250M are infusions of chemotherapy agents. A market growth (CAGR) of 2.3% - 5.4% p.a 754 / 880 is forecasted. SOLUTION OR EXPERTISE SOUGHT Swiss Medendi device is a class IIa/UE (class II USA) which allows a safe infusion of irritant drugs smartly putting the drug(s) in contact with a small quantity of patient’s blood prior to the administration into the patient’s blood vessels. The device is disposable, easy-to-use without moving parts which replaces the drip chamber in a standard infusion system. The usage of HC100 can avoid both chemical phlebitis damages as well as of central catheter-related complications, while improving significantly physical comfort of the patient. It is compatible with all common devices / systems while maintaining common chemotherapy protocols, procedures and settings, and it is extremely easy to use by, e.g., nursing personnel. It is a fully reimbursed device. It has been calculated that the adoption of Swiss Medendi device shall account for an overall hospital cost reduction of more than 75% (considering CVC’s implanting and removal procedures only). It is covered by already granted patents in most countries. TYPE OF PARTNER SOUGHT We are looking for distributors. INVESTMENT OPPORTUNITY Safe Chemotherapy Infusion device We are looking for investors for our Safe Chemotherapy Infusion device: Context: About 250 drugs when in contact with blood vessels injure their inner wall over a longer distance from the catheter tip, causing sever or permanent injuries. Drugs such as chemotherapeutics damage patients’ blood vessels severely and irreversibly during the intravenous administration. To try to avoid such complications, these drugs are often administered through central venous catheters (CVCs). Nevertheless, CVCs administration while requiring a surgical placement and a closed patient follow up, have added other complications like occlusions, extravasation, phlebitis, thrombosis and CRBI potentially lethal. CVC procedure, whose cost is in the range of 2’000-4’500 CHF, and the overall management of the related complications has a relevant impact on hospitals budget. MARKET The potential market for a new cost-efficient device for a safe infusion of irritant and vesicant drugs, is vast. More than 5bn intravenous drug therapies are provided to patients worldwide every year, out of which about 250M are infusions of chemotherapy agents. A market growth (CAGR) of 2.3% - 5.4% p.a is forecasted. SOLUTION Swiss Medendi device is a class IIa/UE (class II USA) which allows a safe infusion of irritant drugs smartly putting the drug(s) in contact with a small quantity of patient’s blood prior to the administration into the patient’s blood vessels. The device is disposable, easy-to-use without moving parts which replaces the drip chamber in a standard infusion system. The usage of HC100 can avoid both chemical phlebitis damages as well as of central catheter-related complications, while improving significantly physical comfort of the patient. It is compatible with all common devices / systems while maintaining common chemotherapy protocols, procedures and settings, and it is extremely easy to use by, e.g., nursing personnel. It is a fully reimbursed device. It has been calculated that the adoption of Swiss Medendi device shall account for an overall hospital cost reduction of more than 75% (considering CVC’s implanting and removal procedures only). It is covered by already granted patents in most countries.

755 / 880 SynAbs

Organisation

Country Belgium City Gosselies Street 48, Rue Auguste Piccard, ITech Incubator 2, Aile Piccard +1 Web http://www.synabs.be

Person

Name cedric volanti Strategic Marketing Advisor

Organisation SynAbs SA, « Singular Antibodies » , is a Belgium CRO providing custom antibody services as well as a catalogue of 1000+ references, mainly control, secondary & anti-species monoclonal antibodies, to the Biopharma R&D and In Vitro Diagnostic markets. Its unique triple immunisation platform – Mouse, Rat and Guinea Pig - enables SynAbs to increase the probability getting the unique monoclonal our clients are looking for, with outstanding results for eg infectious diseases, small molecules and epigenetic modifications. From complete CAR-T design to anti-CAR-T monoclonal antibodies: A one-stop-shop toolbox for cancer treatment CAR-T adoptive cell therapy has been described as the "miracle cure" of cancer. The association RD-Biotech/SynAbs/Diaclone has recently entered the field by providing a unique one- stop-shop solution for biotech players developing CAR-T adoptive cell therapies. RD-Biotech starts with the cloning and expression of the recombinant cancer antigen in order to generate the highly specific mouse monoclonal antibody against it. Thanks to our molecular platform, the sequencing of VH and VL antibody regions allows us to create an extracellular single-chain variable fragment (scFv), the first component of Chimeric antigen receptors, or CARs. RD-Biotech will then construct the complete pattern of CAR : scFv derived from an antibody, joined to a spacer peptide and a transmembrane domain, which is further linked to the intracellular T cell signaling domains of the T cell receptor. Following the collection of a patient's T cells by leukapheresis, the cells are genetically engineered by RD-Biotech through inactivated lentivirus particles containing the coding sequence for the CAR: The CAR-T cells are born! To ensure that the CAR-T cells are active, Diaclone then utilises its specific interferon gamma ELISpot assay confirming that the CAR-T combines the specificity of an antibody for CD proteins, with the cytotoxic and memory functions of T cells. The above steps are based on the development of a mouse ScFv, the use of the rat as a host animal can provide an improved immunization and thereby greater diversity of monoclonal antibodies against regions that would not be immunogenic if the mouse was used. Drawing on its expertise in secondary monoclonal antibodies, SynAbs is now part of cell therapy game by generating rat monoclonal antibodies against mouse CAR-T. Thanks to this new available tool, our partners are now able to select specific transfected CAR-T populations by flow cytometry! 756 / 880 For therapeutic applications, RD-Biotech will then close the loop, by offering to its worldwide customers its expertise to chimerize or humanize the generated ScFv, providing a better tolerance of the CAR-T to the human body while maintaining the high functionality provided by the rat immune repertoire! The best of both worlds for better antibody tools in cell therapy! Areas of Activity

• Analytical and characterization services • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation Devices) • Life sciences related activities • Diagnostics IVD • Other • Diagnostics - Equipment and accessories • Medical research

757 / 880 SynDiag

Organisation

Country Italy City Torino Street Web www.syndiag.com

Person

Name Daniele Conti Founder

Organisation SynDiag - Artificial Intelligence for Augmented Ultrasounds. SynDiag is an innovative project for the automated analysis of ultrasound images, for early detection of pathologies. Ultrasound is the golden standard for diagnosis of several pathologies. It is non-expensive and fast, thus it is the first examination performed in many cases. However, the analysis of the images requires high expertise, and sometimes important features may go unnoticed. Ovarian cancer, for example, is asymptomatic in the early stages and diagnosis is obtained mainly through ultrasound imaging. Early diagnosis is crucial, leading to 85% survival rate after 5 years, but rate drops to 25% in case of late diagnosis (source: AIRC). SynDiag goal is to fill the gap between the possibilities offered by technology and the complex task of medical diagnosis. SynDiag is mainly designed for non experts and non oncologists, to help them find early tumor indicators or to support doubtful diagnosis during their daily practice. Its current scope is obstetrics and gynecology, especially early diagnosis of ovarian cancer. SynDiag is a cloud-based software that uses state of the art artificial intelligence algorithms. It receives ultrasound clips and enriches them providing useful information. The approach is strongly data driven and supports objective diagnosis, and examination standardization. Areas of Activity

• Analytical and characterization services • Software, ICT applications, system • Bioinformatics, Big data analytics integration • Diagnostics - Imaging equipment and • Medical devices processing • IT Applications for Health • eHealth, mHealth, telemedicine • Medical research

Marketplace Opportunities

758 / 880 PRODUCT Artificial Intelligence for Augmented Ultrasounds of Ovarian Cancer SynDiag develops algorithms and software technology for automated analysis of ultrasound scans, putting in evidence signs of ovarian cancer at early stage of development. PROJECT COOPERATION Artificial Intelligence for Augmented Ultrasounds of Ovarian Cancer SynDiag cooperates with Italian Healthcare Institutions in order to develop accurate and easy-to-use software for augmented ultrasounds. Collaborations are inteded to share ultrasound scans data, perform analysis of pathological features, design and perform clinical validation tests for artificial intelligence solutions within joint research projects and asses time-shortage and economic benefits on diagnosis process. INVESTMENT OPPORTUNITY Artificial Intelligence for Augmented Ultrasounds of Ovarian Cancer SynDiag seeks seed investments for certification, IP protection and commercialization of its cloud- based product on multiple markets.

759 / 880 Syneos Health

Organisation

Country Italy City Milan Street Via Gonzaga Web https://www.syneoshealth.com/

Person

Name Vincenzo Lopreiato Director

Organisation Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 23,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Areas of Activity

• Biotechnologies (Pharma&Medical • Regulatory affairs, validation Devices) • Life sciences related activities • Consulting services • Vaccines • CRO (Contract Research Organisation) • Other • Genetics & Genomics • Project proposals support services • Investments • Medical devices • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PROJECT COOPERATION Horizon 2020 Cooperation We are interested in partnership with European SME, Research institutes and Universities for H2020 future calls across the entire drug and medical device development full cycle. PARTNERSHIP Horizon 2020 - Horizon Europe We are interested in partnership with European SME, Research institutes and Universities for H2020 future calls across the entire drug and medical device development full cycle. 760 / 880 SERVICE Real World, Late Phase & Post-Marketing services Within biopharmaceutical development, creating a strong value story is the key to market success. Real World Evidence (RWE) lays the foundation of that story with payers, physicians, patients and, increasingly, regulators, as they recognize the value of the data available through RWE. RWE generation acts as the critical bridge from clinical effectiveness to a commercially viable brand. At Syneos Health™, clinical and commercial disciplines work together, sharing insights and knowledge. It is never too early to consider commercialization in the drug development process. That’s why we are committed to working with you to design, develop and deliver fully integrated Real World Evidence ready for the peri-approval setting that collects the right data to ensure launch success. Meeting the needs of the key stakeholders through Real World Evidence generation ensures you deliver: The supportive data needed for regulators to approve and license The evidence of value needed by payers to authorize and pay for drugs The evidence physicians need to prescribe a drug with confidence And, ultimately, the right information for patients to adhere to a drug and experience the outcomes they are hoping for With your needs in mind, Syneos Health offers what no other company can: a comprehensive solution spanning from concept to commercialization, powered by the breadth and depth of Real World Evidence that Syneos Health brings to our industry. SERVICE First in Man Analysis Phase I research involves constantly moving elements, including toxicology results, regulatory requirements, program optimization, study design strategy and drug readiness. Initial human data are a critical development milestone. Our multidisciplinary Phase I PRO team of top experts can work as an extension of your team, to provide tactical options tailored to your asset’s early development, guiding you to proof-of-concept swiftly, with a meaningful exit. >500 Phase I professionals 376 beds in North America >150 beds (access to) in Asia Pacific >150 Phase I clinical trials conducted annually >23 years of reliable Phase I operations 3 distinct regulatory environments 0 483's issued in our clinics SERVICE Bioanalytical solutions Because your satisfaction is our top priority, we’ll assign you a single point of contact whose job it is to communicate on a timely basis and make sure your requirements are met throughout the entire life of your project. To support this, all of our teams that carry out bioanalysis comply with the current standards for Good Clinical Practices (GCP) and Good Laboratory Practices (GLP). SERVICE Commercial Consulting (commercial strategy and planning, pricing and market access, medical affairs, and risk and program management) We offer advisory services that can address commercial strategy and planning, pricing and market access, medical affairs, and risk and program management. Syneos HealthTM consulting practitioners span the entire product development and delivery continuum, adding high-value counsel and recommendations that make for more successful clinical development and brand launch success. SERVICE

761 / 880 Contract Commercial Organization At Syneos Health™, we are able to improve brand performance by leveraging data and insights, accumulated best practices and deep access to therapeutic expertise. Serving customers of all sizes, our CCO (Contract Commercial Organization) capabilities are the broadest and most robust in the industry delivering flexible, targeted, multi-channel programs designed to produce a higher likelihood of launch success. At the same time, our commercial and market insights along with proprietary data access can improve clinical trial design and accelerate patient recruitment. It's a powerful platform for the modern biopharmaceutical world. SERVICE Contract Research Organization Our fit-for-purpose CRO solutions are tailored to your product and requirements. Whatever your needs, we can adopt new processes and technologies, diverse therapeutic expertise and access to commercial insights that can facilitate shorter and more efficient trials designed to improve the likelihood of regulatory and commercial success. Our strong site relationship work has been recognized industry-wide, being voted “Top CRO to Work With” among top 10 global CROs in 2013, 2015 and 2017 through the CenterWatch Global Investigative Site Survey and winner of the 2017 Society for Clinical Research Sites Eagle award is something we’re extremely proud of.

762 / 880 Takis

Organisation

Country Italy City Rome Street via Castel Romano 100 Web www.takisbiotech.it

Person

Name Luigi Aurisicchio CEO/CSO

Organisation Takis is a Biotechnology Company created In November 2009 as a spin off from IRBM (Istituto di Ricerche di Biologia Molecolare P. Angeletti), a Research Center in Italy near Rome, formerly part of the global network of Merck Research Laboratories (MRL). The group has more than 15 years experience and an established track record in drug discovery, having contributed to the development of new drugs for the treatment of viral diseases and cancer and to a number of IND/CSA filings in the areas of virology and oncology. The team is also recognized for the conception and implementation of a number of innovative technologies. Takis as a Biotech pursues the discovery and development of innovative Therapeutic Cancer Vaccines based on a proprietary Adeno vector-prime DNA-boost platform technology, leveraging on its strong track record in drug discovery. Takis’ frontline candidates are two therapeutic cancer vaccines targeting distinct tumor antigens. The vaccine candidates have completed pre-clinical development and are ready for translation to the clinic. One of the main assets of Takis is the expertise in in vivo electro-gene-transfer, which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy. Takis is actively involved in the generation of humanized monoclonal antibodies for use in Oncology and Infectious Diseases. Evvivax is a newborn Takis spin-off dedicated to veterinary cancer vaccines. Tel-eVax and Erb-eVax are predicted to go on market by end 2019. Areas of Activity

• CRO (Contract Research Organisation) • Vaccines • Drug screening & delivery • Peptides, proteins & antibodies preparation • Life sciences related activities

Marketplace Opportunities INVESTMENT OPPORTUNITY

763 / 880 Therapeutic Cancer Vaccines Takis business strategy for the next 5 years is to develop its therapeutic cancer vaccines from advanced regulatory pre-clinical Phase to the achievement of clinical Proof-of-Concept and then to license out to pharma/large biotech companies in exchange for upfront, success-based milestones and royalty fees. Other R&D projects are under advanced pre-clinical development. Takis is looking for partners for co-development of products/services. INVESTMENT OPPORTUNITY TK-Neo: a new strategy to develop personalized Cancer Vaccines TK-NEO is a DNA-based Neoantigen Cancer Vaccine (NCV), for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours. NCVs are a new form of precision medicine and are a perfect clinical approach for highly heterogeneous tumors in patients with metastatic disease. Takis has developed and patented a unique method for production of patient-specific NCVs based on a 6-week process, from sequencing the specific tumour DNA, synthesis of the right DNA sequence for the specific tumour, delivery through a specific Electroporation (EP) technology used under exclusive license. The solution was proven at pre- clinical stage to increase the efficacy several fold with respect to alternative RNA and DNA based NCVs in protecting relapse and boosting immune responses as required for the maintenance of long- term anti-tumor immunity. The strategy to reach the market for TK-NEO is to sell or license the IP of TK-NEO to a large pharma company, (value estimated >100M€ or 5% of sales), after completion of clinical validation to demonstrate the applicability and safety of the approach: phase I clinical trials in melanoma are targeted during SME Instrument project, while phase II clinical trials will require 10M investment. The market value estimated for the products after 3 years from approval is 300 M€/year, with an EBIT of 60%. INVESTMENT OPPORTUNITY Tel-eVax: a Genetic Vaccine for Veterinary Cancer Immunotherapy EVVIVAX (a Takis spin-off) has developed a proprietary Veterinary Cancer Immunotherapy based on an innovative genetic vaccine called Tel-eVax, stimulating anti-tumor immunity. The treatment is based on the combination of: a) modified, genetically engineered Adenovirus targeting Telomerase Reverse Transcriptase (TERT); b) delivery of naked plasmid DNA through Electro-Gene-Transfer methodology using a tailored device, called Vet-ePoratorTM. Tel-eVax has shown efficacy for canine B-cell Lymphoma in three clinical trials in Italy and in USA, demonstrating a 3 times higher Patient Survival Time with respect to chemo treatment (96 weeks vs. 32 weeks), along with a sustainable price (treatment price/dog < 1.440 €) and no side effects. EVVIVAX needs to focus on the standardization and industrialization of the vaccine production process, definition and validation of the production process, EMA and USDA approvals for the commercialization of the solution in Europe and USA, larger scale clinical trials to verify specificity of the patients. After validation, Evvivax will implement a GMP production plant for 12.000 vaccines per year, with an investment required estimated of about 3MEuro, targeting investment from a VC. The feasibility study will focus on definition of production facilities for the industrial production, validating investment, costs and pricing, business model and go-to-market strategy. The Business Model envisaged consists in a strategic partnership with Pharma company specialized in Veterinary drugs for distribution while keeping internal production for canine lymphoma treatment. The extension of the vaccine to other pathologies, with related clinical trials and authorization, and the expansion in other countries with increased production capacity, will be targeted through Licensing or Joint Venture with pharma companies.

764 / 880 Tecnalia

Organisation

Country Spain City Donostia - San Sebastian Street Parque Tecnológico de Miramón - Paseo Mikeletegi 2 Web http://www.tecnalia.com

Person

Name Luca Odetti Italian Branch Director

Organisation TECNALIA RESEARCH & INNOVATION (www.tecnalia.com) is a private, independent, non profit applied research centre of international excellence. Legally a Foundation, Tecnalia is the leading private and independent research and technology organisation in Spain and one of the largest in Europe, employing 1,400 people (214 PhDs) and with income of 102 Million € in 2015. The whole team at TECNALIA has one GOAL: to transform knowledge into GDP, meaning wealth to improve people’s quality of life by generating business opportunities for industry. TECNALIA is committed to generate major impacts in economic terms, by means of innovation and technological development, addressed by 6 fully interconnected Business Divisions: Sustainable Construction, Energy and Environment, ICT-European Software Institute, Industry and Transport, Health, Technological Services. TECNALIA has been granted over 280 patents and promoted more than 30 spin-off companies. TECNALIA is a key agent in the ERA - European Research Area, holding position 12th among RECs and 26th overall in EC’s 6th FP7 Monitoring Report 2012. TECNALIA actively participates in the governing bodies of several European Technology Platforms and partners in 136 H2020 projects (coordinating 20% of them). TECNALIA is a member of EARTO and of EUROTECH, linking together the most important research centres in Europe. TECNALIA in Life Scences TECNALIA develops innovative solutions that help Life Sciences companies to improve their competitiveness and market positioning using creativity, technology, experience and sector problems’ knowledge TECNALIA’s offer ranges from applied R&D to technological lab services, targeting the following market segments: Food preservation, nutraceutics, bioprocesses Rehabilitation E/m-Health and Assistive Technologies Biomaterials Pharmaceutical Development Molecular Biology Areas of Activity

767 / 880 • Analytical and characterization services • Nutraceutics, probiotics, functional food, • Bioinformatics, Big data analytics cosmeceutics • Biomaterials • Pharmaceutics • Biosensors • Physiotherapy, Orthopaedic technology • Biotechnologies (Pharma&Medical • Surgery technologies and applications Devices) • Virtual reality applications • CMO (Contract Manufacturing • Medical devices Organisation) • IT Applications for Health • Diagnostics IVD • Electromedical and medical equipment (non diag) • Genetics & Genomics

Marketplace Opportunities PRODUCT FOOD&INGREDIENTS - High value-added ingredient for healthy ageing Functional food ingredient made from an extract rich in glucosinolates, mainly the precursor to sulforaphane, that has an immunostimulating activity, and the catalytic enzyme. Both components are protected by a double-layer encapsulation system that keeps them isolated from the environment and from each other. This way, the stability of both components is guaranteed until they reach the colon and are assimilated by the body. Its formulation can be used in a broad variety of foods and dietary supplements. INNOVATIVE ASPECTS AND MAIN ADVANTAGES • Purified extract of glucosinolates from broccoli by-products. • Stable encapsulated ingredient including the precursors of the active component and the enzyme needed for its activation. • Stability and activity endorsed by in vitro studies. ADVANTAGES • Natural origin: obtained from broccoli by-products. • Effect on the immune system and the reduction of incidence of prostate cancer, according to bibliographic references related to the functionality of sulforaphane. • Stable format of the ingredient that is applicable in a broad variety of food matrices and dietary supplements. • It improves the activity and bioavailability thanks to the double-layer encapsulation that allows for the stabilisation and protection of the active ingredients (glucosinolates and enzyme), separated, until they reach the intestines. • Dosage is simple thanks to the double-layer encapsulation including the enzymes needed for the activation of the active component and its conversion into sulforaphane in just one capsule. • Production costs and processes appropriate for the industry of food and food supplements. MARKET APPLICATION Functional food, Dietary supplements Within its applications as a food ingredient, it may be included in several different matrices including: • Processed fruit products. • Processed fruit products with cereals and yoghurt. • Processed vegetable products. • Dairy products. TYPE OF PARTNER SOUGHT Companies interested in including the ingredient in their products SERVICE

768 / 880 HEALTH/Biomaterials services Services regarding health related biomaterials Devices and materials for in vivo use - Biodegradable matrices for tissue regeneration. - Non-degradable materials for bone implants with controlled porosity. - Surface functionalization of devices by click chemistry, carbodiimide chemistry, etc. - Biodegradable materials for advanced therapies (polymeric coatings and nanoparticles for drug delivery, injectable hydrogels for cell therapy, etc.) Biological assessment - CE marking, issuance of certificate of compliance to ISO 10993 standards. - Characterization of the biological impact of new materials and products. - Nano-safety: assessment of the biological impact of nanomaterials (cell uptake, mutagenicity, pro- inflammatory activity, etc.) In vitro diagnostic devices and cell-based assays - Materials and enabling technologies for in vitro 3D cell cultures. - Custom design of polystyrene-based consumables. - Biosensors integrating carbon nanotubes. PRODUCT ELCODE, Smart Active Transdermal Patches for DRUG ADMINISTRATION What is it? ELCODE is a system for ionthophoretic transdermal delivery of active substances. ELCODE is a disposable patch comprising programable discharge element, ionthoporetic electrodes and active substance loaded reservoir. ELCODE can be used for delivery of various active substances in health care and cosmetic applications. How does it work? Electrical stimuli and hydrogel technology are combined in order to achieve the local and systemic delivery of drugs with restricted administration routs. INNOVATIVE ASPECTS AND MAIN ADVANTAGES The transdermal patch prototype is fully developed and the active transport of drugs has been confirmed, with four proof-of-concepts including: an anti-inflammatory, an analgesic, an anxiolytic and an antiviral. A porcine skin model has been developed (in vitro test) to test the aforementioned drugs. A patent has been registered to protect different applications and electrode models. EP14382362.3 A Murine model in vivo, expected to verify a more controlled transport and increased bioavailability of the model drug selected, will be conducted throughout 2016. Product Differentiation ELCODE has significant advantages over current systems: ELCODE device is scalable in size. Non- invasive. Easy placement and handling. Flexible and light to adapt to the human body. Low-cost system. Minimises the appearance of erythema due to the electric current. Controlled drug release. Measured dosage. May be systemic or local depending on the programming conditions of the system. For domestic or hospital use. Includes preview software aimed at predicting drug administration in the right place and time. Its advanced platform, designed to generate iontophoretic stimuli in DC or in pulse mode, uses voltage as well as power control. MARKET APPLICATION Application Diagnosis of allergies: to increase accuracy, sensitivity and patient comfort while reducing the assessment. Immunisation and vaccination: avoiding the need for hypodermic needles, administration of the vaccine could improve immune response due to the orientation of the immunogenic cells in the skin.

769 / 880 Treatment of perimenopausal symptoms and osteoporosis: some therapeutic agents show metabolising problems in the gastrointestinal tract and liver due to the use of injections. Delivery and release of hyaluronic acid. TYPE OF PARTNER SOUGHT Companies interested in developing their products based on ELCODE technology SERVICE Pharmaceutical Development Laboratory TECNALIA has the experience and necessary infrastructure to carry out the development of the formulation of a wide range of products. With over 15 years of experience, the work philosophy of the Pharmaceutical Development Laboratory is based on concern and awareness of R&D problems in the pharmaceutical sector in accordance with our clients' needs. We have a young yet qualified team to face any innovative challenge that may arise in the pharmaceutical field and respond with timely solutions; as well as high performance equipment and a strict quality system. TECNALIA´s Pharmaceutical Development Laboratory is accredited by the Spanish Medicines Agency (AEMPS) in Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). We offer solutions in several dosage forms formulation: Solids (tablets, capsules, sachets, etc.), Liquids (suspensions, solutions, syrups, etc.) and Semi-solids (gels, creams, ointments, etc.). GALENIC DEVELOPMENT Preformulation studies. Design and galenic development of innovative, generic and advertising (OTC) medicines. Design and galenic development of new dosage forms. Compatibility studies of active ingredients and excipients. Design of manufacturing processes. Transfer of manufacturing technology and "in situ" support. Reporting Expert. Patents study. ANALYTICAL DEVELOPMENT Monitoring of the first industrial manufacturing batches. Characterization of raw materials according to Pharmacopoeia. Development and validation of analytical techniques. Metal Impurities Analysis by ICP-OES. Quantification of active ingredients, impurities and degradation products in raw materials and medicines. Transfer of analytical techniques. In vitro dissolution profiles STABILITY STUDIES in short and long term, according to ICH standards. Batchs of Registration. Industrial batches of finished product (Release, changes, etc.). Ongoing. Bulk product. External management of stabilities EQUIPMENT Electronic scales. Differential Scanning Calorimetry (DSC). Volumenmeter. V Mixer. Eccentric press machine and rotary press machine. Automatic encapsulating. Fluid bed. Paila coating. Rotolab.

770 / 880 Lyophilizer. Spray-Dryer. Blistering machine. Extruder-spheroniser. Oven muffle. Climatic chambers. Chromatographs for UHPLC, HPLC (UV / VIS and fluorescence) and for HPLC -MS. Dissolution tester and fraction collector. Spectrophotometers. Durometers. Friability tester. Solid forms disintegration tester. Electronic Moisture Analyzer. Rheometer. Viscometer. Laser Diffraction Particle size Analyser and coulter. Karl-Fischer. ACCREDITATIONS AND RECOGNITIONS ISO 9001 Good Manufacturing Practices (GMP) - Pharmaceutical development and manufacturing. Good Laboratory Practices (GLP) - Pharmaceutical development. Spanish Medicines Agency (AEMPS) inspection with positive result - Clinical trials and Bioanalysis. We work under Good Clinical Practices (GCP) - Clinical Trials Unit. LINES OF INNOVATION / AREAS: New pharmaceutical release forms. Reformulation of active ingredients. "Reprofiling" of brand drugs. Clinical trials of inhaled medications. Development and clinical validation of food supplements. Monitoring of allergenic extracts. Diagnostic, prognosis and response to drug tests. Companion Diagnostics. SERVICE Pharmaceutical Laboratory – Laboratorium SANITATIS Laboratorium Sanitatis SL is authorised by AEMPS as a manufacturer and importer of pharmaceuticals and medicines under research with Registry Number 4163E and GMP Certificate. TECNALIA has a unique facility (Pilot Plant / Pharmaceutical Laboratory) to provide ample opportunities for scaling and manufacturing of medicines, medical devices, cosmetics and food suplements, always in the most stricter compliance of GMP certification. Our facilities and machinery are located at premises occupying a surface area of 1470 m2 with potential to manufacture new pharmaceuticals, new presentations and new release systems in different pharmaceutical forms: solid, semi-solid and liquid. This is a unique differentiating factor with respect to other pharmaceutical development firms. PRODUCTS Human medicines. Medical devices. Food supplements. Cosmetics. Veterinary medicines Manufacturing of Batches for Clinical Trials Importation of active substances and medicines. Manufacturing of placebos, medicines, food supplements.

771 / 880 Design of blinding strategy. Labelling for primary and secondary packaging. Storage Good Manufaturing Practices (GMP) conditions. Shipping management to the different centers. Return, reconciliation and destruction of medicines. Pilot Batches and Registration Batches Manufacture in compliance with the principles and guidelines of GMP for medicinal products. Transfer of analytical techniques Contract Manufacturing of Industrial Batches for Third Parties Quality control and certification of active substances, excipients and finished products. Manufacturing in GMP conditions. Validation of cleaning processes. Analysis and batch release. Storage in GMP conditions. Industrial Scale Scaling up from laboratory batches to industrial batches. Validation of new manufacturing and packaging processes. AUTHORIZED DOSAGE FORMS Solids (tablets, coated tablets, capsules, etc.). Liquids (solutions, syrups, drops...). Semi-solids (creams, emulsions, gels, etc.). EQUIPMENT Mixing: Rulon, V, Vima Cyclops. Granulation: High Speed, Oscillating. Drying: Static, Fluid Bed. Capsules filling: Manual, Macofar CD-40. Tabletting machine: Kilian. Tablet coating: IMA-70 drum coating. Liquids: 100L, 2.400L reactors. Semisolids: 10L, 300L, Mixer. 1st Packaging: Tube: Alu, PE. Bottles: glass, PET. Blister packing machine ALU/ALU PVC/ALU. 2nd Packaging: Cartoner. Labeling. ACREDITATIONS AND RECOGNITIONS ISO 9001 Good Manufacturing Practices (GMP) - Pharmaceutical development and manufacturing. Good Laboratory Practices (GLP) - Pharmaceutical development. Spanish Medicines Agency (AEMPS) inspection with positive result - Clinical trials and Bioanalysis. We work under Good Clinical Practices (GCP) - Clinical Trials Unit. LINES OF INNOVATION / AREAS New pharmaceutical release forms. Reformulation of active ingredients. "Reprofiling" of brand drugs. Clinical trials of inhaled medications. Development and clinical validation of food supplements. Monitoring of allergenic extracts. Diagnostic, prognosis and response to drug tests. Companion Diagnostics. SERVICE 772 / 880 Clinical Trials Unit TECNALIA's Clinical Trials Unit offers a comprehensive, reliable and efficient service in most of the clinical stages in the development of drugs and products requiring clinical validation. The extensive experience, the quality, and the response capacity and the great potential for recruitment are the uniqueness of the Clinical Trials Unit at TECNALIA, the only one in the Basque Country. TECNALIA is part of unique Clinical Trials Unit of the Basque Country. It is located at the Araba University Hospital (HUA). TECNALIA participates in the Research Commission of the HUA BIOEQUIVALENCE STUDIES Extensive experience in bioequivalence developing of all kinds of drugs administered by different routes and experimental designs, including studies with large numbers of volunteers - executed in one or more stages: Inhalers. Orals. Sublingual. Parenteral. Hormones. … CLINICAL TRIALS IN PHASE I First in human (FIH). Pharmacokinetics / Pharmacodynamics. Interactions (Drug / Food / Alcohol). Drug tolerability and safety CLINICAL TRIALS IN PHASE II, III & IV TECNALIA disposes central services from the Araba University Hospital (HUA), necessaries for the selection and follow up of participants in the trials within the medical specialities that comprise the HUA. CLINICAL NUTRITION Clinical trials designed to demonstrate the safety and efficacy of active ingredients, food supplements and functional foods. TECNALIA is specialised in the design, implementation, coordination, monitoring and analysis of clinical trials of of high quality nutritional clinical trials. The Clinical Trials Unit has experience in developing clinical trials with nutritional supplements for top companies in the national and international market. CLINICAL VALIDATION Biomarkers, prognosis/diagnostics systems and medical devices. TURNKEY PROJECTS Design and / or evaluation of the study documentation. Managing regulatory authorities and IRB/IEC submissions and approvals. Database design, data entry and queries management. Pharmacokinetics (PK) analysis, pharmacodynamic (PD) analysis and PK / PD relationship. Analysis and statistical reports. Writing and / or review of final reports MANAGEMENT OF EXTERNAL STUDIES Collaboration in the design of the study documentation and management of authorizations and contracts. Monitoring. Management of the Trial Master File (TMF). Data management. Review of the Clinical Study Report (CSR). ACREDITATIONS AND RECOGNITIONS

773 / 880 ISO 9001 Good Manufacturing Practices (GMP) - Pharmaceutical development and manufacturing. Good Laboratory Practices (GLP) - Pharmaceutical development. Spanish Medicines Agency (AEMPS) inspection with positive result - Clinical trials and Bioanalysis. We work under Good Clinical Practices (GCP) - Clinical Trials Unit. LINES OF INNOVATION / AREAS New pharmaceutical release forms. Reformulation of active ingredients. "Reprofiling" of brand drugs. Clinical trials of inhaled medications. Development and clinical validation of food supplements. Monitoring of allergenic extracts. Diagnostic, prognosis and response to drug tests. Companion Diagnostics. SERVICE Genetic Laboratory The activities and services carried out by the TECNALIA Molecular Biology Laboratory essentially fall within the framework of the biosanitary sector, specifically the field of genetics and functional genomics, through the use of new high performance technologies such as DNA micro arrays, genetic sequencing and protein and cellular analysis. In line with this profile, this area provides technological services and works on research projects within diverse knowledge areas. WORKING LINES Our activities focus on the following working lines:: Pathogenomics: Study of pathogen infection and host defence mechanisms to improve the effectiveness of infectious disease treatment. Oncogenomics and Oncogenetics: Application of high performance technologies to the study of tumours to improve the diagnosis, treatment and prognosis of the disease: study of genetic expression alterations (DNA Micro Arrays) as well as imbalances in genomic DNA (CGH arrays) and sequencing of candidate genes. Pharmacogenomics and Pharmacogenetics: Identification of an individual's susceptibility to pharmacological compounds, as well as the possibility of developing adverse side effects (toxicity). Toxicogenomics: Identification of the potential toxicity of a specific compound by characterising expression patterns induced in an experimental model and comparison of these patterns with those created by substances of known toxicity. Clinical Genetics: Use of molecular techniques (sequencing, PCR, micro satellite analysis, LOH) to identify specific genetic disorders, which are not only able to offer concrete diagnosis, but also to identify carriers of the alteration who might develop the disease. Nutritional Genomics: Application of molecular biology and high-performance genomic technologies, such as genotyping or DNA Micro arrays, to the study of obesity and related diseases. Identification of personalised hygiene/diet habits. Functional foods and food supplements: Identification of molecular action mechanisms of nutrients and/or specific food supplements. In addition to these work areas, the Genomics unit offers the possibility of designing new developments, working methodologies and protocols within the field of genomics and molecular and cellular biology, which adapt to the needs and requirements of the client or partner. Laboratory and Equipment The laboratory (220m2) has three perfectly differentiated areas, two of which are designed for preparing PCR reactions (27m2) and handling and analysing RNA within a controlled atmosphere. The laboratory's main equipment includes: NanoDrop 2000c. 2720 Thermal cycler. Verity.

774 / 880 Digi Genius gel documentation system. Power Pac Basic Power Supply electrophoresis system. Applied Biosystems 3130XL Genetic analyser. Biocap DNA/RNA biosafety cabinet. 2100 Bioanalyser. ABI 7300 Real-time thermal cycler. AC Extractor 6100 Nucleic Acid Prep Station for DNA extraction. Eppendorf vacuum concentrator 5301. GenePix 4100A microarray scanner. CHEMI-DOC XRS+ (BIO RAD) image analysis system. PROTEAN IEF SYSTEM (BIO RAD) protein first dimension system. FC500 MPL WITH UPS (BECKMAN COULTER) cytometer. SYNERGY HT (BIOTEK) microplate reader.

775 / 880 TEMAS AG

Organisation

Country Switzerland City Zurich Street Hermetschloostrasse 77 (2. Stock) Web www.temas.ch

Person

Name Christian Micheletti Project manager

Organisation TEMAS AG is a small company based in Zürich, which is engaged in supporting researchers, Start-up, and SME in innovation through our Safe-by-Design web-based platform and our consultancy. We can cover topics from regulatory affairs to toxicology and testing strategy. Our core business is in Medical Device, Cosmetics, and Nutraceuticals, and we are specialized in nanotechnology applications. The Safe-by-Design approach for nanomaterials was developed by TEMAS with the support of RIVM in FP7 and H2020 European Research Projects, and we aim at developing the concept and its application in future project proposal. Areas of Activity

• Consulting services • Software, ICT applications, system • Nutraceutics, probiotics, functional food, integration cosmeceutics • Project proposals support services • Packaging & labelling • Medical devices • Pharmaceutics • Regulatory affairs, validation

Marketplace Opportunities PRODUCT Safe-by-Design platform - Innovation management of nanotechnology (and novel substances) Managing innovation for nanomaterials is complicated due to changing regulation (or lack of specific ones), lack of standardized testing for functionality and safety, and perception by the public. The Safe by Design Platform is a web-based tool (https://temas.taglab.ch/SbDimplementation/) that can be used by innovators to design and manage innovation projects (both on products and processes) following regulations (both hard and soft), and finding the best teting methods. The platform can be tailored to the needs of the customer, and it is available to all users for free. PROJECT COOPERATION

776 / 880 Nanosafety implementation at industrial scale We are looking for partners in projects (H2020, national, PPP schemes) to apply and develop nanosafety methods, approaches and tools, working on actual case studies to bring innovative products on the market. SERVICE Consultancy on Regulatory implementation on Medical Devices for substances and nanomaterials We offer consultancy on functionality and safety of substances used in MD: - regulatory feasibility study (regulatory constrains) - update of technical documentation in light of new regulation - formulation of tiered testing strategy (in vitro and in vivo) - compilation of technical documentation - assessment of overall MD performance - contact with regulatory authorities SERVICE Testing and placing on the market innovative cosmetic products (including nanomaterials) We offer consultancy on functionality and safety of substances used in cosmetics: - formulation of tiered testing strategy (in vitro and clinical) - compilation of the technical dossier for nanomaterials - management of CNP data input - assessment of cosmetics claims - contact with regulatory authorities SERVICE Novel food assessment and authorization process We offer consultancy on claims and safety of substances used in food supplements and novel foods: - regulatory feasibility study (regulatory constrains) - following authorization process of novel foods according to regulation - formulation of tiered testing strategy for safety and claims (in vitro, in vivo, and clinical) - compilation of technical documentation - assessment of ingredients and foods claims - claims authorization procedure - contact with regulatory authorities

777 / 880 TGR srl

Organisation

Country Italy City OZZANO EMILIA Street via Lombardia 12 Web http://www.tgr.it

Person

Name Patrizia Toselli OWNER

Organisation Manufacturer of stairlifts for the disabled. Product without the need for a fixed structure. 40 years experience. Ongoing new project with Horizon 2020 participation. Areas of Activity

• Other • IT Applications for Health

Marketplace Opportunities PRODUCT STAIRS CLIMBING - JOLLY We are looking for distributors for: France, Sagna, Turkey, Iran PRODUCT EMERGY STAIRS CLIBING We are looking for a manufacturer to distribute products in Italy

778 / 880 Think4Future Srl

Organisation

Country Italy City Milano Street Via dei Cignoli 1 Web http://lifecharger.eu/

Person

Name Andrea Migliavacca CEO

Organisation Think4Future is a SME that has gathered a team of professionals endowed with a relevant know-how in developing projects of technological innovation in several fields and supporting large and medium companies in internal process reengineering. Managing innovation and changes for Think4Future means helping customers to anticipate, understand, guess and appreciate technological and market changes which are now taking in place. Think4Future has been created around a group pf professionals with extended and varied skills and experience managing innovation and change both in national and international contexts. Moreover this group has gained significant experience in research projects, co-financed by the European Commission. Think4Future has several on-going collaborations with Universities, Research Centers as well as Non-governmental organizations both in Italy and abroad. Think4Future, founded in 2015, has developed specific methodology, tools and approaches for managing the impact of innovation on organizations as well as for data analysis and impact evaluation. One of the focus is on therapies tracking analysis based on patient self-reported data. LifeCharger is the tool and the framework used to involve patients, acquire structured data reported by the patients, analyze the therapies impact on both patients’ life and patient life style. The specific approach is based on a large experience matured in many projects with a specific attention on the human capital development. Areas of Activity

• eHealth, mHealth, telemedicine • EPR, Clinical/healthcare management software • IT Applications for Health

Marketplace Opportunities PRODUCT LifeCharger LifeCharger (www.lifecharger.eu) is a comprehensive system developed to increase the quality of the 779 / 880 care by empowering the patient in the daily therapy management process. It is a platform that allows chronic patients to participate daily in gathering useful data to improve their care. LifeCharger is a tool to understand, know and cover the “Last mile of therapy”. It is an innovative ICT solution to gather patients’ data in their daily life, empowering them on one side through an intelligent and user-friendly app that help them managing their therapy and, in general, their lifestyles, and from another side, providing to the caregivers all those information that cannot be acquired with traditional methods. LifeCharger is a comprehensive system developed to increase the quality of the care by empowering the patient in the daily therapy management process. LifeCharger allows the patient to create a structured diary, day by day and share this diary with caregivers, physicians, healthcare providers. PROJECT COOPERATION LifeCharger LifeCharger (www.lifecharger.eu) is a comprehensive system developed to increase the quality of the care by empowering the patient in the daily therapy management process. It is a platform that allows chronic patients to participate daily in gathering useful data to improve their care. LifeCharger is a tool to understand, know and cover the “Last mile of therapy”. It is an innovative ICT solution to gather patients’ data in their daily life, empowering them on one side through an intelligent and user-friendly app that help them managing their therapy and, in general, their lifestyles, and from another side, providing to the caregivers all those information that cannot be acquired with traditional methods. LifeCharger is a comprehensive system developed to increase the quality of the care by empowering the patient in the daily therapy management process. LifeCharger allows the patient to create a structured diary, day by day and share this diary with caregivers, physicians, healthcare providers. We are looking for nay opportunity to cooperate with health care providers and clinicians to enforce our approach and experiment it on the field. PARTNERSHIP LifeCharger LifeCharger (www.lifecharger.eu) is a comprehensive system developed to increase the quality of the care by empowering the patient in the daily therapy management process. It is a platform that allows chronic patients to participate daily in gathering useful data to improve their care. LifeCharger is a tool to understand, know and cover the “Last mile of therapy”. It is an innovative ICT solution to gather patients’ data in their daily life, empowering them on one side through an intelligent and user-friendly app that help them managing their therapy and, in general, their lifestyles, and from another side, providing to the caregivers all those information that cannot be acquired with traditional methods. LifeCharger is a comprehensive system developed to increase the quality of the care by empowering the patient in the daily therapy management process. LifeCharger allows the patient to create a structured diary, day by day and share this diary with caregivers, physicians, healthcare providers. We are looking for any opportunity to expand and extend our service out site of Italy. INVESTMENT OPPORTUNITY LifeCharger LifeCharger (www.lifecharger.eu) is a comprehensive system developed to increase the quality of the care by empowering the patient in the daily therapy management process. It is a platform that allows chronic patients to participate daily in gathering useful data to improve their care. LifeCharger is a tool to understand, know and cover the “Last mile of therapy”. It is an innovative ICT solution to gather patients’ data in their daily life, empowering them on one side through an intelligent and user-friendly app that help them managing their therapy and, in general, their lifestyles, and from another side, providing to the caregivers all those information that cannot be acquired with traditional methods. LifeCharger is a comprehensive system developed to increase the quality of the care by empowering the patient in the daily therapy management process. 780 / 880 LifeCharger allows the patient to create a structured diary, day by day and share this diary with caregivers, physicians, healthcare providers. We want to expand our activity and we are looking for a partner who permit us to arrive to an European dimension.

781 / 880 Toscana Life Sciences Foundation

Organisation

Country Italy City Siena Street Via Fiorentina 1 Web https://www.toscanalifesciences.org

Person

Name Francesco Senatore Business Development

Organisation Toscana Life Sciences is a non-profit organization active throughout the region in supporting research activities and promoting the creation of innovative companies in the Life Sciences field. Founded at the instigation of Tuscany’s principal university, clinical, industrial and financial institutions, the Foundation is based in Siena, in the historical “Torre Fiorentina” area, where Achille Sclavo founded the eponymous Tuscan Sierotherapeutic and Vaccinogenic Institute in 1904, and where important multinational vaccine companies now strategically choose to locate their primary research and development activities. An environment of excellence that is part of a regional panorama in which the Life Sciences play a strategic role. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • IT Applications for Health • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics • Life sciences related activities • Vaccines

Marketplace Opportunities SERVICE Incubation and Technology Transfer services Unique offer of space, facilities (PCL3 laboratories and an animal facility), equipment and technological platform rental plus specialized consultancy: Facilities & Services: Animal facility, Biobanking (in progress), BSL3 lab, Business development, Research, Intellectual property management, International networking, Fundraising Technology platforms: Analytical instruments (biological and chemical analysis), Microscopy, NMR, Imaging, Cell sorting, Cellular biology assays, Next Generation Sequencing

782 / 880 TPM "Mario Veronesi"

Organisation

Country Italy City Mirandola Street via 29 Maggio, 6 Web http://tpm.bio/

Person

Name Laura Aldrovandi Project Manager

Organisation The Technopole of Mirandola (TPM) is located in the Mirandola biomedical district (Modena, Italy) which comprises more than 90 enterprises specifically focused on the development and production of active and non active medical devices for Apheresis and Plasmapheresis, Haemodialysis, Heart surgery, Anesthesia, Gynaecology, Infusion, Transfusion, Autotransfusion, Continuous Renal Replacement Therapies, Enteral and Parenteral Nutrition. TPM, inaugurated in January 2015, is meant to be a place where both business and technological expertise can co-work and grow together; TPM helps leverage research and development for a strong biomedical presence in the region in collaboration with a network of acclaimed regional High Technology Centres. TPM is certified quality system ISO 9001 e ISO 13485. TPM houses three laboratories, all organized and managed in partnership with the University of Modena and Reggio Emilia: TOXICOLOGY AND PROTEOMICS (TOP), APPLIED MICROSCOPY AND CELLULAR BIOLOGY (MAB), MATERIALS, SENSORS AND SYSTEMS (MS2) Areas of Activity

• 3D Printing/addictive manufacturing for • Medical devices biomedical applications • IT Applications for Health • Biomaterials • Biosensors • Biotechnologies (Pharma&Medical Devices) • Medical research

Marketplace Opportunities PROJECT COOPERATION Cooperation for international project We are looking for a partner in order to start a new cooperation for national and international project (H2020, Marie Curie) SERVICE

783 / 880 MS2 Laboratory The MS2 lab supports companies in the design, development, characterization and validation of new materials, products, measuring system and equipment. It brings together multiple engineering skills ranging from ICT to mechanics, electronics, chemistry and physics. - Design, feasibility studies and functional prototyping of medical devices, ranging from disposable components up to automatic mechanical tools, measuring systems and medical equipments. - Design, feasibility studies of new materials for medical applications. - Chemical/Mechanical analysis of materials and medical device components. - Development of micro and nano sensors. - Development of micro fluidic systems. - Bioprinting and biofabrication with 3D Bioplotter® - Together with MAB, MS2 lab develops new methods for 3D coprinted models of cell culture on scaffold. SERVICE MAB Laboratory - Biocompatibility tests ISO10993- sect 2-3-4-5. - Novel biocompatibility test ISO10993- sect 6-10-11 by the development of alternative cell culture strategies avoiding animal testing based also on 3D cultures. - Alternatives approaches for biocompatibility by: 1) label free assays on bi-dimensional cell cultures. 2) testing biomaterial (plastic/ceramic/biologic-skill) performance and biocompatibility with human cells for regenerative medicine, cell-based therapies and toxicology. - Microscopy, image analysis, and histology: 1) histopathology on human or animal tissues (light and in fluorescence); 2) Stereomicroscopy for material surfaces Hi-res scan and 3D reconstruction. - Medical device performance tests: efficacy of filtrating systems, in lab device simulation, development of new related technologies. - In vivo pre-clinical testing in immunocompetent and immunodeficient models supported by advanced bioimaging X-ray system (IVIS LUMINA XR III). - Microbiological testing (in collaboration with University of Modena and Reggio Emilia). SERVICE TOP Laboratory TOXICOLOGY: - Extractable and Leachables (E&L) analysis for medical devices to identify and quantify chemical compounds released (ISO 10993-18). Equipment: UPLC/APGC-QTOF and ICP-OES. - Toxicological risk assessment (ISO 10993-Part17) & Overall Biological Assessment. - Development and validation of methods for the determination and quantification of compounds of interest UPLC/APCG- QTOF. PROTEOMICS: - In vitro customized test to evaluate removal/adsorption capacity of materials. HEMO-BIOCOMPATIBILITY: - In vitro hemo-compatibility testing of biomaterials ISO 10993-Part 4. - New assay: in-vitro Human Monocyte test to evaluate cytotoxicity and inflammation response. - Equipment: Cytoflex Beckman Coulter flow cytometer. Enspire multiplate reader alpha technologies. SERVICE FOI - Funding Opportunities for Innovation Thanks to our experts network we identify the best R&D partner and support international networking creation for projects and fund raising facilitating enterprises' access to public funding opportunities at a regional, national and international level.

784 / 880 Transmed Research

Organisation

Country Italy City Ozzano dell'Emilia Street Via Tolara di Sopra, 41/E Web https://transmed-research.com/

Person

Name Micaela Pannella Researcher

Organisation Transmed Research has been set up to join excellence in research with a market-oriented approach. Our purpose is to shorten the translational process and the timing for the design and development of new products offering innovative, flexible and efficient methodologies and services based on high- throughput analysis for animal behavior, cell-based assays, clinical biomarkers. TransMed Research supports all types of in vitro and in vivo studies, through preliminary non-GLP toxicology and efficacy studies to formal GLP studies. TransMed Research supplies studies and tests ready to be included in the applications to regulatory agencies like AIFA (Italian Pharma Agency), EMA (European Medicine Agency), FDA (Food and Drug Administration) to be authorized to market pharmaceutical products. TransMed Research is a partner for public health authorities, private health care and insurance companies, to study risk factors related to the life style and co-morbilities, and proposes best practices and guidelines. TransMed Research is also an experienced partner for grant applications at national and international level. Areas of Activity

• 3D Printing/addictive manufacturing for • Pharmaceutics biomedical applications • Proteomics, metabolomics, nutrigenomics • Biotechnologies (Pharma&Medical • Medical devices Devices) • CRO (Contract Research Organisation) • Drug screening & delivery • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Toxicology TMR can help you with your drug safety and toxicology testing needs by offering a full range of 785 / 880 toxicology studies, both in vitro or in vivo, with a wide variety of compounds from small molecules, antibodies, peptides, industrial and agro-chemicals, food additives. Our in vitro toxicology platform can be customized to meet your specific necessities selecting the appropriate cell system among cell lines, primary cultures (human or animal) or stem cells.Our services include: • General toxicology • Reproductive toxicology • Histopathology • Biocompatibility SERVICE Neurobehavior Regardless of the therapeutic target, any chemical entity that penetrates the central nervous system (CNS) requires preclinical analysis of its effects. Specialized neurobehavioral testing strategies help avoid false positives or underestimated risks that may manifest later in clinical trials or during the first few years of clinical use. TMR has a long lasting expertise with design, analysis, and interpretation of neurobehavioral studies in mice and rats. Through a wide range of behavioral tests that use independent digital and video animal tracking systems, we can characterize genetically-, surgically- or pharmacologically-derived mouse models in order to obtain a complete picture of learning and memory, motor activity, coordination and gait and sensory abilities. We can assist in developing new mouse neurobehavioral paradigms and protocols, new surgical and chemical mouse and rat models, in characterizing ontogeny and neurobehavior of new transgenic models. SERVICE In Vivo TMR develops disease animal models, utilizes transgenic animals, analyzes learning and memory, motor behavior, sensory motor integration, gain, pain threshold in freely moving animals, anxiety and depression behavior in laboratory animals. Animal facility is GLP accredited and validations are performed in accordance with OECD and FDA guidelines. Animal models, microsurgery and stereotaxic surgery • neuroinflammation (experimental allergic encephalomyelitis; LPS acute and chronic administration) • acute somatic pain (intraplantar CFA and carrageenin injection) • chronic somatic and neuropathic pain (chronic CFA arthritis; axotomy, chronic contrcition injury) • visceral pain (cystitis by cyclophosphamide) • traumatic spinal cord injury (by Impactor) • intracerebroventricular acute and chronic delivery (also using chronic minipump implant and saporin- conjugated neurotoxines) Behaviour • learning and memory by computerized videotracking (Y-Maze, Morris Water Maze, Novel Object Recognition, Contextual fear conditioning) • sensory performance • motor behavior by computerized technologies (activity cage, spontaneous locomotion, footfalls and gait analysis) • microdialysis and neurotransmitters dosage (HPLC) in freely moving animals SERVICE In Vitro TMR utilizes a large number of cell lines and primary cultures and employs a wide variety of approaches ranging from immunocytochemistry, biochemistry and molecular biology using disease- specific readouts. The in vitro facility is GLP accredited and validations are performed in accordance 786 / 880 with OECD and FDA guidelines.Cell systems • cell lines (including SH-SY5Y, NT2D1, PC12, Murine Embryonic Fibroblasts) • primary cultures (inlcuding rat/mouse primary cortical neurons) • stem cells (rat embryonic stem cells, rat/mouse embryonic/adult neural stem cells, animal and human mesenchymal stem cells) Cell assays • viability (MTT, Neutral Red, pycnotic nuclei analysis, mithocondrial integrity) • neuronal profiling (neurites maturation and elongation) • stem cell lineage (immunocytochemistry/molecular biology) Imaging • conventional microscopy and fluorescence microscopy • confocal time lapse microscopy • high content analysis and screening • 2D, 3D, 4D-computeized image analysis SERVICE High Content Screening TransMed Research offers drug-screening assay with the newest high throughput technology (HCS, High Content Screening) in cellular models. Analyzing millions of cells, treated with different compounds or chemical entities simultaneously and rapidly, HCS enables maximize information in terms of predicting the activity and the safety of a drug candidate. To this end, we generate in vitro models in 96- to 384-well format for screening primary cell cultures or cell lines on a panel of dozens of morphological and molecular readouts such as cytotoxicity, cell cycle analysis, neuronal differentiation, cell morphology features and more. SERVICE Biomarker Service The identification of predictive biomarkers is a critical step in drug discovery. Biomarkers are indispensable to assess efficacy of candidate therapeutics, to further validate drug targets and to alert for potential toxicity. Also, biomarker analysis might serve phase I, II and III clinical trials. Our capabilities span a range of diseases and Methods are compliant with GLP and EMA recommendations for fluid analysis in CGP clinical studies. TMR applies a wide variety of analytic techniques at mRNA and protein level to cell lysates, cell culture media, tissues, biological fluids also in the frame of clinical studies. Immunoassays are GLP accredited and validations are performed in accordance with OECD and FDA guidelines. • ELISA for human, rat, mouse, cat, dog, and other animal species • multiparametric assay based on Luminex technology for human, rat, mouse, cat, dog, and other animal species (cytokines, Alzheimer disease biomarkers, cardiovascular biomarkers, inflammation biomarkers, endocrine biomarkers, kidney toxicity biomarkers, and others according to request) • PCR for mRNA and genotyping (standard, RT-PCR, multiplex RT-PCR)Examples: • Alzheimer disease. We test a number of analytes in cerebrospinal fluid and plasma, including the standard biomarkers (Ab40/42, tau/Ptau) and neuroinflammation markers (TNFalfa, sCD40L). We constantly up-date assays availability according to the literature and the specific needs of the projects. • Neuroinflammation. We test a number of analytes in cerebrospinal fluid and plasma, including TNFalfa, sCD40L. We constantly up-date assays availability according to the literature and the specific needs of the projects. • Shock and multi-organ failure. We test a number of analytes in cerebrospinal fluid and plasma, including human, rat and mouse targets (see pdf ). We constantly up-date assays availability according to the literature and the specific needs of the projects. PARTNERSHIP

787 / 880 Development of innovative drugs and medical devices Transmed Research is looking for companies involved in biotechnologies, pharmaceutics and biomaterials to asses efficacy and pre-clinical safety (according to EMA regulatory requirements) of their products.

788 / 880 Trustech

Organisation

Country Italy City Chivasso Street Web www.trustech.it

Person

Name Niccolò Ciprianetti Business development

Organisation Trustech is a company specialized in Micro and Nanotechnologies. A private lab (400 m2 cleanrooms class 1000 and 100) where engineers, physicists, chemists and biotechnologists are able to design, realize and industrialize Micro / Nano devices. Trustech works also within a wide network of international research centers and in close relationship with industries. Areas of Activity

• Biomaterials • Diagnostics - Equipment and accessories • Biosensors • eHealth, mHealth, telemedicine • Biotechnologies (Pharma&Medical Devices) • Diagnostics IVD

Marketplace Opportunities SERVICE Custom LOC (Lab on Chip), MEMS (Micro Electro Mechanical Systems) and thin film coatings Design, prototyping and industrialization of MEMS (Micro Electro Mechanical Systems), LOC ( Lab on Chip), microfluidic platform, micro/nano devices and thin film coatings. Trustech is a private laboratory with multidisciplinary competences in engineering, chemistry, biology and physics. We are able to provide customized solution (single step processes or whole micro/nano fabrication processes) fabricate prototypes. We can share our facility (cleanroom class 1000 and 100) with customer researchers and engineers. We would like to help company to realize innovative idea, from the proof- of-concept to the industrialization. We look for partners need prototype manufacturing and industrialization consulting. We collaborate with several university in Italy and we partecipate to funded research project. MARKET APPLICATION: Biotech, microelectronic, sensor, biosensor, food quality control, human and veterinary diagnostic. SERVICE

789 / 880 Open Innovation & Technology transfer Trustech shares its network, expertises and experiences to bring innovative solutions to customers

790 / 880 TURINGSENSE EU LAB S.R.L.

Organisation

Country Italy City Forlí Street +39 0543725074 Web http://www.turingsense.eu

Person

Name PIETRO GAROFALO Technical Director

Organisation Turingsense EU Lab aims to innovate the biomechanical / engineering field by offering services for the development of integrated systems for the monitoring of human movement, through the design of methods and algorithms and the implementation of hardware and software that are able to describe in a manner rapid and at the same time objective the kinematics and dynamics of the movement, the degrees of articulation of the upper and lower limbs, in scenarios of field monitoring (gyms, hospitals, playgrounds). Areas of Activity

• Bioinformatics, Big data analytics • Life sciences related activities • Biosensors • Software, ICT applications, system • Biotechnologies (Pharma&Medical integration Devices) • Laboratory equipment, reagents, software • Consulting services • Medical devices • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine • Medical research

Marketplace Opportunities INVESTMENT OPPORTUNITY Virtual rehab coaching at home The product we have in mind operates in home environment, by continuously interacting with the elderly patients and collect information on their muscolo-skeletal system in order to assist the patient towards his well-being. The patient is wearing a sensorized common clothing and his interaction is carried out via specific motions to reach predefined target. Later, healthcare suggestions are given to the user, based on previously collected data and knowledge obtained from other people affected by similar pathology. For example, if the patient is not able to perform the suggested motion,he/she is

791 / 880 asked to execute a different type of task to explore the root cause of the problem and report this to care-givers accordingly. PARTNERSHIP Customised monitoring of patients at home The ambition is to expand our pilot system based on wearable technology, so that a new solution concept for a “virtual coach” is created for elderly persons at home. This “V-COACH” will provide customized alerts and personal advices related at day-life issues that influence the capacity to remain active and independent. The developed tools/services will be based on integrated technology (sensors + cloud) with high levels of flexibility and adaptability to the local rehabilitative context. A gamification approach will be pursued for the realization of the virtual coach in order to assure patient motivation and to make less tedious, for example, rehabilitative exercises. Moreover in order to make sure that therapeutic interventions are effective, identification of high level 3D biofeedback methods based on 3D graphics and augmented reality will be pursued to calibrate audio and visual biofeedback and Virtual Coach intervention in order to involve and motivate the patient into the process. PRODUCT Wearable devices and smart clothing platform for mainstream market products Turingsense EU LAB, by allowing cost-effective technology and gamification methods, has introduced new concepts where even a non technical user can be guided and suggested throughout the daily experience with wearable technology. This can be applied for home monitoring and injury-prevention in sports and workplaces. - make the technology behind invisible to the user, allowing the user to deal only with clothing and smartphone and typical items used nowadays, reducing to the minimum all technical worries due to a new technology entering their home SERVICE R&D customised services for B2C products based on wearable technology R&D team of Turingsense EU Lab can provide new methodology to overcome the current limitations of wearable devices in the market by means of: - increasing the easiness of setup of the system such that not only it can be used everywhere but also with very simple steps with no learning curve needed by the end user - reducing the cost and size of the technology behind - enable a continuous improvement of the system from a R&D perspective in order to be able to respond to specific requests from the mainstream market - customisation of Turingsense platform from hardware to end user app

792 / 880 TUV Italia

Organisation

Country Italy City Casalecchio di Reno Street Via Isonzo 61 Web https://www.tuv.it/it-it

Person

Name Stefano Bolletta Sales Area Manager Italy & Spain Medical & Health Services

Organisation TUV Italy Medical Devices & Healthcare Sector MHS Ensure quality at the heart of your operations For over 15 years, TÜV Italy has provided market access solutions and expert partnership for medical device manufacturers and suppliers. We know your challenges and concerns. Our dedicated team of medical experts, engineers, provide assessments that cover the full life cycle of your medical device. Key services for the Healthcare and Medical Device industries: Clinical services Market approval and certification Quality management auditing and certification Testing and assessment Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Regulatory affairs, validation • Medical devices

Marketplace Opportunities SERVICE Our services for the Medical Device and Healthcare Industry Clinical Services. Market approval e Certification. Quality management auditing and Certification. Assessment and Technical meeting. Testing. Training.

793 / 880 SERVICE Assuring safe and effective medical devices TÜV SÜD provides services for all categories of Medical Devices including: Active medical devices Non-active medical devices Implantable medical devices Rehabilitative medical devices In-vitro diagnostics High-risk devices Drug/Device combination products Devices incorporating materials of animal origin Medical device software and applications Innovative technologies SERVICE Supporting market access TÜV SÜD’s Foreign Affairs department offers services that enable manufacturers to achieve fast market access: Providing guidance on how to enter the maximum amount of global markets with your TÜV SÜD certification. Continuously scanning the international regulatory environment to keep you up to date with the latest regulatory changes. Assisting manufacturers to develop a clear, comprehensive and efficient path for achieving regulatory approval through our regulatory strategy service.

794 / 880 UBT srl

Organisation

Country Italy City Rivotorto di Assisi Street Via Santa Maria della Spina, 25 Web http://www.ubt-tech.com/en/

Person

Name Gianluigi Tiberi Founder

Organisation X-rays free mammogramfor early breast cancer detection (cutting-edge patented technology , no ionizing radiation, no breast crushing, easy to use, competitive price ) UBT SRL (http://www.ubt-tech.com/en/ ) constructed a novel X-rays free mammogram, whose clinical validation is currently in progress.The X-rays free mammogram does not use ionizing radiation but safe microwave to perfom imaging; thus, it is safe for both patients and operators. Moreover, it does not require any breast crushing. The groundbreaking nature of the apparatus is that imaging is obtained by only processing microwave signals without the use of dangerous X-ray; thus, examinationcan be repeated any time, at any age and in any condition (pregnancy, specific illness, etc). UBT SRL activity is focused on microwave and interaction between electromagnetic fields and matter. UBT SRL (Umbria Bioengineering Technologies) is an innovative startup company and academic spin- off of the Department of Physics and Geology ( FISGEO ) of the University of Perugia, Italy. UBT has been awardedby EU H2020under scheme SMEINST Phase I (2017) and by EU H2020 under scheme SMEINST Phase II (2018). The outcome of Phase I has been published by Research-Eu magazine: https://cordis.europa.eu/research-eu/home_it.html Areas of Activity

• Biotechnologies (Pharma&Medical Devices) • Diagnostics - Imaging equipment and processing • Medical devices

Marketplace Opportunities PRODUCT X-rays free mammogram - looking for partners/distributors UBT SRL technology uses microwave to reconstruct the image of an object, highlighting possible

795 / 880 inclusions. Specifically, UBT SRL constructed and patented MammoWave, a novel X-rays free mammogram for breast cancer detection. Clinical validation of MammoWave is currently in progress at Perugia Hospital, Italy, and Foligno Hospital, Italy, after obtaining the approval of the Ministry of Health and of the Ethical Committee of Regione Umbria, Italy. The easy-to-read output and its lower price (with respect to conventional mammography) give the apparatus the potential for widespread distribution. Thus, we are looking for Partners/Distributors with a very good introduction in the Medical Device Mark ( EU and outside EU). REQUEST X-rays free mammogram - new clinical trials For the X-ray free mammogram we are looking for hospitals for performing new clinical trials. In addition, we are looking for Partnership to explore the application of Machine Learning to our microwave data PARTNERSHIP Application of Machine Learning to microwave data We are looking for Partnership to explore the application of Machine Learning to our microwave data

796 / 880 UKRAS

Organisation

Country Serbia City Vranje Street Partizanski put 8

Person

Name Igor Mladenović Director

Organisation The company for production, wholesale and retail of goods "Ukras" d.o.o Vranje was established on Sept 1st 1993 in Vranje (Serbia). "Ukras" d.o.o. Vranje is engaged in production of high quality protective gloves "BEST" and in knitted, cotton gloves that are widely used in construction, metal processing and wood processing industry. The advantage of the products on the market is that they are certified with “CE” sign and brought into line with: -New Approach Directive: Directive 93/68/EEC Personal Protective Equipment – PPE - EU standards relevant to the products. - Standards for making a producer’s declaration of compliance ISO/IEC 17050-1: 2005 The company is also certified with ISO 9001:2008 I ISO 14001:2004 "Ukras" d.o.o Vranje has complete production process. The company is also engaged in wholesale of complete protective equipment. Areas of Activity

• Medical facilities furnishings, equipment, goods

Marketplace Opportunities

PARTNERSHIP Commercial cooperation The company wishes to achieve business cooperation with companies dealing in food and medicals processing.

799 / 880 Umut Biotechnology

Organisation

Country Turkey City Ankara Street Bilkent Cyberpark, C Blok, Zemin Kat, no:6-7, Çankaya/Ankara Web http://umutbiotech.com/tr/

Person

Name umut agyuz Founder/General Manager

Organisation Umut Biotechnology was founded in 2017, yet its history dates back to an enterprise I had founded in METU Technocity by earning a Techno-venture grant from the Ministry of Industry in 2015. We are currently carrying out our activities in Bilkent Cyberpark. Umut Biotechnology consists of 2 main teams; “Biotechnology” and “Bioinformatics”. Biotechnology team is responsible for gathering biological data, providing genomic information from the blood samples and designing products (DNA detection kits) for customer use. Bioinformatics team is responsible for raw data filtering, quality check, statistical analysis, developing prediction models, big data analysis, parallel processing, data mining and developing “in house data base” for customer use. Currently, we are developing population specific genomic marker detection kits for Breast Cancer. Umut Biotech is selected as one of the best 3 companies between 830 projects in StartupBootcamp Program last year and attended International Convention BIO Entrepreneurship Bootcamp 2017 in San Diego. Umut Biotech, as vision and mission of the company, aims to create a realization for the rising threat of breast cancer risk between women around the world. The most important thing is the early detection of this disease and we designed a detection kit for this problem. The diagnosis of both breast cancer and metastasis can be done quite easily. Very sophisticated imaging techniques are used for this. We are trying to do “reverse engineering” to get to the bottom of the subject matter. If we can figure this out, we can understand why and how it started, and we can stop it when we conduct a tailor-made scan. Currently, it is started to be carried out at a specific center at Bilkent Cyberpark, yet it will soon transform into a center-free and technology-free state. We would like to collaborate with possible partner organizations from Europe and widen our business day by day. Areas of Activity

• Bioinformatics, Big data analytics • Life sciences related activities • Diagnostics IVD • Genetics & Genomics

800 / 880 • Proteomics, metabolomics, nutrigenomics

Marketplace Opportunities PRODUCT GENZ-B/45 and GENZ-T/456 detection kits The most known genes which are responsible for breast cancer can be detected by our kits. For more information, please, contact us. PARTNERSHIP We are open for collaborations from Europe We are looking for international marketing, online platform and collaboration opportunities.

801 / 880 Università degli studi di Ferrara

Organisation

Country Italy City Occhiobello Street via della Pace 5A Web http://www.unife.it/international

Person

Name Marta Bonatti Communication Manager Ferrara Technopole

Organisation The University of Ferrara offers a unique historical environment. Far from being shrouded in the past, Ferrara is a cyclist- and pedestrian-friendly sustainable town where young people can experience a high quality of life. Fostering innovative views of the future supported by deeply rooted cultural traditions is a primary goal of the University of Ferrara. Areas of Activity

• CRO (Contract Research Organisation) • Project proposals support services

802 / 880 Università degli Studi di Milano

Organisation

Country Italy City Milano Street Via Venezian 21

Person

Name Alessandro Contini Associate Professor

Organisation High quality research in pharmaceutical sciencies Areas of Activity

• Bioinformatics, Big data analytics • Software, ICT applications, system • Biomaterials integration • Consulting services • Peptides, proteins & antibodies preparation

Marketplace Opportunities SERVICE Computational design/discovery of bioactive molecules We offer cooperation on: - computational design of bioactive peptides - computational design of protein-protein interaction inhibitors - virtual screening of molecular databases SERVICE Consultancy on molecular modeling We offer consultancy to setup, manage or upgrade your molecular modelling facility as well as specific training for your internal scientists.

803 / 880 Università di Bologna

Organisation

Country Italy City Bologna Street Via Zamboni 33 Web www.unibo.it

Person

Name Alessia Di Sandro Reserach Manager

Organisation University of Bologna

UNIBO is the second largest university in Italy and one of the most important institutions of higher education across Europe. Research and Innovation are a priority of UNIBO which is very active both at the national and the European level in all the research areas. Activities related to competitive funding programs are supported by the Research Division, with more than 10 year experience in assisting research groups in the whole project lifecycle. The Research Development team deals with the UNIBO strategic positioning at local, national and international level through integrated networking and lobbying activities in each specific research area. The Research Development Team supports the development of University research and infrastructures including University Hospital to access to funding opportunities in the Area of Life Sciences (including agri-food, biotechnology, health and e- health themes), through the integrated facilitation of positioning University research in the local, national and European / international funding ranking and the promotion of access to strategic partnerships and networks. UNIBO encompasses Bologna University Hospital Authority St. Orsola Polyclinic, which is home to the School of Medicine and Surgery. The University Hospital is an internationally acclaimed institution for the study and treatment of diseases, and each year organizes medical conferences and conventions attended by professionals of international fame. UNIBO has gained a considerable experience in international and European research projects in FP7: with 274 projects funded in 2007-2013; (58 of them as coordinator) and 87,8 M€ of funding, UNIBO is the second Italian university for the attractiveness of European funding for research. Recently, the FP7-founded project FARESEEING, has been selected by the European Commission as one of the top 3 most influential and high-impact projects of the last 11 years in the field of ICT for Active and Healthy Ageing. In Horizon 2020, UNIBO is so far involved in 118 funded projects (26 as coordinator) with more than 40 M€ of funding. UNIBO is also part of the Scientific Advisory Board of the Joint Programming Initiative “Healthy Diet for a Healthy Life”. UNIBO has also developed a number of strategic partnerships, among which the ELIXIR-IIB, the Italian node of the EU infrastructure ELIXIR. UNIBO is institutionally connected to three research hospitals: 1) The St. Orsola-Malpighi University Hospital is the first General Hospital in Bologna, with more than 400 years of history, and today is the

804 / 880 official venue of the School of Medicine and Surgery. The Polyclinic is an internationally acclaimed institution equipped with 1,758 beds and staffed by 5,355 employees including university researchers and physicians. Every year handle approximately 72,000 admitted cases and an estimated 4,000,000 outpatient visits by medical specialists. 2)The Istituto Ortopedico Rizzoli (IOR) is a dedicated institution for the study and care of musculoskeletal conditions. Since its foundation in 1896, it has consolidated its fame as a leading centre for orthopaedic science and practice within and beyond the European continent. The mission of IOR is to increase knowledge on bone and joint diseases, to provide optimal care, and to develop innovative solutions to decrease the burden of musculoskeletal conditions. 3)The Istituto delle Scienze Neurologiche (ISNB) is a 120-bed medical Institution dedicated to neurological sciences, recognized in 2011 by the Italian Minister of Health as “Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)”, a medical institution of excellence, devoted to biomedical and health system research. The ISNB represents the neurological hospital of reference for the Bologna Province (population: about 950.000) for both adult and pediatric patients, but for some areas of excellence it attracts patients at a Regional and National level. Overall, it assists each year about 6.500 inpatients and delivers more than 120.000 medical examination or diagnostic procedures. The main research areas include neurodegenerative pathologies, with special reference to prion and rare mitochondrial diseases, movement disorders, neuromuscular pathologies, pathologies of the autonomic nervous system, headaches, sleep disorders with particular focus on narcolepsy, epilepsies, epidemiology of neurological diseases and innovative aspects of neurosurgical and neuroimaging procedures. Areas of Activity

• Biosensors • Peptides, proteins & antibodies • Biotechnologies (Pharma&Medical preparation Devices) • Pharmaceutics • Diagnostics IVD • Physiotherapy, Orthopaedic technology • Diagnostics - Equipment and accessories • Proteomics, metabolomics, nutrigenomics • Diagnostics - Imaging equipment and • Life sciences related activities processing • EPR, Clinical/healthcare management • Drug screening & delivery software • eHealth, mHealth, telemedicine • Surgery technologies and applications • Electromedical and medical equipment • Vaccines (non diag) • Medical devices • Genetics & Genomics • IT Applications for Health • Medical research • Medical facilities furnishings, equipment, goods • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PARTNERSHIP SC1-BHC-22-2019: Mental health in the workplace The research group of Prof. Cicchella work on biomechanics, testing and rehabilitation, strength evaluation and ergonomics, producing the first Italian version of the NIOSH guidelines for manual handling tasks and of the SF36 questionnaire. The group participated in Eureka and FP4 projects for motion analysis of neuro-muscular disease and orthopedics injuries, and cooperate with relevant research institutions, universities, companies and healthcare providers at EU and international level. The main expertise area are: Workplace assessment and wellbeing, Psycho-physical assessment of workplace, Back pain and symptoms magnification analysis, Optimization of work tasks, Implementation of large-scale physical fitness intervention (including nutrition, smoke cessation

805 / 880 programs, blood pressure control, cardiac arrhythmia assessment). The research group of Prof. Gremigni includes an associate professor, a post-doc fellow and several graduated trainees. We run research projects with a focus on methodology and statistics, and activities such as clinical assessment and psychotherapy, consultation for job-related stress and workplace bullying, continuing education for health professionals working in the public sector of safety in the workplace. The main expertise of the group are related to the development and validation of measurement instruments; large database management; complex and multivariate statistical analyses (e.g. Structural Equation Modeling). Possible task that can be developed within the topic are related to the development of surveys, database management, statistical analyses, and methodological supervision. The group of Prof. Matteucci research interests include teacher attitudes and behavior, with specific interest in teachers' sense of personal responsibility for educational outcomes, and health-related quality of life in children and adults. Prof. Matteucci coordinated the European Socrates-Minerva Project “Social networks and knowledge construction promotion in e-learning contexts “. The research group has a specific expertise on both contextual and person-specific factors that can contribute to teachers’ wellbeing, and possible task that can be developed within the topic are related to questionnaires design and selection of scale instruments, enrolment, dissemination and exploitation of the results including the creation of educational material, policy recommendations and stakeholders’ engagement. The research group of Prof. Serretti has large experience in the study of genetic risk factors involved in mental disorders and in the response to the treatments for mental diseases, including major depression, bipolar, anxiety disorders and stress-related disorders. Genetic testing is combined with diagnostic assessment, clinical phenotyping and assessment of adequacy and efficacy of the treatment, with solid experience in the study of individual risk factors and gene x environmental interactions as well. The group was involved in two EU-funded projects, the ERA-NET Neuron project “PADRE” and the IMI project “PRISM”. A possible contribution of the group falls is the study of genetic factors involved in mental health in the workplace and in the genetically-based prediction of the individual response to the treatments/interventions. The research group of Prof. Tessari has a background in cognitive psychology, neuropsychology and cognitive neuroscience, carrying out several research projects in different fields of cognition and applied psychology. The main expertise relevant for the topic revolves around the cognitive and psycho-social factors related to human social behaviour, with a strong knowledge on the psychobiological aspects related to stress. The group can offer an active role in collecting, interpreting and analysing psychobiological, cognitive and personality aspects related to stress sensibility, in order to identify the stressors of the beneficial effects of any intervention. In this context, the group can perform an assessment of the impact of changes in the working condition by quantitative and qualitative data analysis, defining psychobiological profiles of risk. The Occupational Medicine Clinic at St. Orsola-Malpighi University Hospital of Bologna directed by Prof. Violante, is actively working on environmental and occupational epidemiology, exposure assessment and toxicological analysis. The group has ongoing collaboration with Global and Italian Burden of Disease study and with the international network arising from the ISCH COST Action IS1002 “Modernet”, aimed at monitoring and tracing occupational diseases. Prof. Violante is also the Chairmanship of the Italian Society of Occupational Medicine and the group can actively collaborate in task related to: Involvement of Italian stakeholders, assessment of the burden of environmental/ occupational diseases in Italy, conduction of systematic reviews on specific topics.

806 / 880 Università di Bologna

Organisation

Country Italy City Bologna Street

Person

Name Rossella Breveglieri associate professor

Organisation Founded in 1088, the Alma Mater Studiorum – Università di Bologna (UNIBO) is known as the oldest University of the western world. Nowadays, UNIBO still remains one of the most important institutions of higher education across Europe and the second largest university in Italy. Research and Innovation are a priority of the University mission. With regards to Innovation, UNIBO filed 37 new patent applications in 2015, of which 19 are new registrations, thereby giving rise to an active patent portfolio of over 200 patents related to more than 100 inventions. With regard to the capability of attracting funding for research and innovation, UNIBO is very active both at National and European level in all the research areas. Activities related to competitive funding programs are supported by the Research and Third Mission Division. A Research Development Office deals with the UNIBO strategic positioning at local, national and international level, through integrated networking and lobby activities in each specific research area. While the Programs&Projects Office supports the UNIBO researchers from the proposal submission to the implementation phase of the projects with technical, legal, financial and administrative expertise. Thanks to its scientific excellence and a central Project Management support working closely, UNIBO has gained a considerable experience in International and European research projects, successfully participated in FP7: with 274 projects funded in 2007-2013; (58 of them as coordinator) and 87,8ML Euros of funding, UNIBO is the second Italian university for the attractiveness of European funding for research, 37st in the European ranking of institutions of higher education. In Horizon 2020, UNIBO is so far involved in 113 funded projects (26 as coordinator) with more than 40ML Euros of funding. UNIBO is also partner of the EIT Knowledge & Innovation Communities (“EIT DIGITAL”, “Climate KIC”, “EIT Raw Materials”) and many of the most important EU initiatives related to the Horizon 2020 framework program (ie. ETPs, EIPs, JPIs, etc). The Department of Biomedical and NeuroMotor Sciences (DIBINEM) aims to integrate the main biomedical disciplines with the clinical ones in the fields of Neuroscience, Orthopedics, Dentistry/ Maxillofacial Surgery. On October, 2017 The Department of Biomedical and Neuromotor Sciences has been selected by the Executive Committee of the University of Bologna as Local Champion for the National competition for Italian Departments of excellence. On January, 2018 the Ministry of Research and University has declared the DIBINEM one of the top 20 Italian Medical Departments of excellence granting more than 9.000.000,00 euro/5 years. Areas of Activity

• Medical research • Other

807 / 880 • IT Applications for Health

Marketplace Opportunities PROJECT COOPERATION Electrophysiological recordings We perform electrophysiological recordings of neural signals (single cells, multiunit) from the primate cortex. We test neurons for visuomotor tasks. We are planning to implant electrode arrays in the cortex to enable wide recordings and use these signals to decode actions. possible future applications for brain-machine interfaces. We're looking for parnerships for european projects and SME for ICT projects.

808 / 880 Università di Bologna

Organisation

Country Italy City Bologna Street Via Zamboni 33 Web https://www.unibo.it/it/ateneo/organizzazione/ amministrazione-generale/10010/3279/index.html

Person

Name Roberta Mazza Research Developer

Organisation University of Bologna - ARIC, Life Sciences and Bioeconomy Unit: Support the development of University research and access to funding in the thematic area of life sciences and bio-economics (including biotechnology, health and e-health), through the integrated support of positioning University research in the local, national and European / international strategic networks, the promotion of access to strategic partnerships and networks, the monitoring of policies, support, integration and enhancement of excellence skills and infrastructures, the development of new projects. Areas of Activity

• eHealth, mHealth, telemedicine • Project proposals support services • Genetics & Genomics • Medical research • Life sciences related activities

Marketplace Opportunities PARTNERSHIP SC1-BHC-19-2019: Implementation research for maternal and child health A) The group led by Prof. Corvaglia, is experienced in the neonatal nutrition and gastroenterology management, with specific attention to the study of Human Milk functional profile, including the development of gut microbiota. The group, in collaboration with Cambridge University, is developing an integrated device for cardiac, cerebral and intestinal function monitoring, for the routine management of very preterm infants, and is in charge of the Bologna HM Bank activities in collaboration with Granarolo S.p.A. The group can recruit preterm infants, potentially involving several national and international units, up to the first-years of follow-up, conduct evaluation of HM and gut microbiota functional profile. B) The group led by Prof. Lanari has strong interests in the evaluation of children in physical and social discomfort, with consolidated experience in the study of psychomotor development in fragile

809 / 880 populations (eg migratory processes, victims of abuse, severe poverty, inadequate parental care etc.). The group is experienced in the analysis of the family context, parenting skills, management of children with physical or psychological discomfort, clinical and instrumental screening, tools for the evaluation of the child physical and psychological development and is working within the Rights, Equality and Citizenship Programme by integrating expertise of psychologists, pediatricians and bioengineers. C) The group led by Prof. De Ponti, is experienced on evaluation of drugs safety, through prospective surveys on adverse events, PROMS, drug utilization habits, analysis of big data and systematic reviews/ meta-analysis. The group is collaborating with the Emilia-Romagna Group on Pregnancy and Exposure to Antiepileptic drugs, and co-authored the 2018 Position statement of the Italian Ministry of Health on drugs and breastfeeding. The group has several ongoing collaboration with pediatricians and nephrologists of the University Hospital on appropriateness of drug use and safety in Neonatal Intensive Care Units and for monitoring drug use and adverse drug reactions in breastfeeding. D) The group led by Prof. Sansavini has a consolidated experience on development of mother-infant interaction, communication, language, cognitive, motor and learning skills of preterm children, with language or cognitive delays, from early infancy to school age. The group carried out cross-sectional and longitudinal studies in collaboration with the University Hospital and several national and international institutions. Impact of biological and environmental factors on development has been studied. Follow-ups of preterm developing children have been implemented, early predictors of linguistic, cognitive and learning delays have been identified, and effective interventions have been developed. E) The group led by Prof. Seri focus on the molecular causes leading to human diseases, through genes mapping and identification of gene mutations in patients with different disorders, intellectual disability, epilepsy, congenital malformation and rare cancers, using high throughput next-generation sequencing technologies. The group analyzed 698 exomes, identified novel/causative genes for different disorders, and has established an available pipeline for NGS data analysis and functional studies, including protein analysis and transcriptome studies. The group can also cooperate in improving the diagnosis and management of diseases related to parental consanguinity in highly consanguineous communities across EU. F) The group led by Prof. Stagni focus on motion analysis, biomechanics and control of the musculoskeletal system in healthy and pathological conditions, addressing technological design, modelling, and data analysis for functional evaluation for clinical assessment. The group developed a novel quantitative tool for the ambulatory assessment and monitoring of motor development in children, from birth to adult age. The group also can characterize the motor control development in specific populations and/or subjects as related to relevant maternal, environmental, social and clinical factors, with respect to available typical developmental path and/or other reference populations. G) The group led by Prof. Tinuper, include neurologists, surgeons, psychologists, radiologists, geneticists and pediatric psychologists, working on electro-clinical assessment and advanced neuroimaging study of drug resistant focal epilepsies, differential diagnosis, genetics, vagus nerve stimulation and ketogenic diet in drug-resistant epilepsy, pre-conceptional counselling and clinical management of epilepsy during pregnancy. The group can develop large population-based studies on the antiepileptic drugs exposure in pregnancy, pooling data from different countries, design a dedicated database that could be permanently fed with new data, perform the therapeutic drug monitoring of antiepileptic drugs, including new molecules, during pregnancy.

810 / 880 Università di Ferrara - Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA)

Organisation

Country Italy City Ferrara Street Via Fossato di Mortara 70 Web http://www.unife.it/tecnopolo/ltta

Person

Name Paola Rizzo Associate Professor of Applied BIology

Organisation Industrial Research and Technology Transfer Laboratory accredited by Emilia Romagna Region Areas of Research and Technology Transfer Use of primary human cells to study mechanisms of differentiation and regeneration of tissues for research purposes Genomic and post-genomic researches in pathologies with high welfare impact (neoplastic, cardiovascular and neurodegenerative diseases) Preclinical testing using in vitro and in vivo (animal models) systems Areas of Activity

• Drug screening & delivery • Nutraceutics, probiotics, functional food, • Genetics & Genomics cosmeceutics • Medical research

Marketplace Opportunities SERVICE Assessment of endothelial dysfunction We can determine the effect of a treatment (drug, nutraceutical compound, physical stimulus) on endothelial cells function.

811 / 880 Università di Ferrara – Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA) – Laboratory for Preclinical Research (LARP)

Organisation

Country Italy City Ferrara Street Web https://unife.it

Person

Name Michelina Lauriola Project Manager

Organisation To promote and ensure quality in non-clinical toxicology studies designed to evaluate the effects of test substances contained in pharmaceutical, pesticides, food additives, detergents, etc. Studies have to be conducted following Good Laboratory Practices (GLP) principles to ensure quality, safety and reliability to meet the standards required for official approval as a new product, and adhering the laws and regulations common to all states belonging to OCSE (Organization for Economic Cooperation and Development). Areas of Activity

• Biomaterials • Pharmaceutics • Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Project proposals support services • Consulting services • Medical devices • Drug screening & delivery • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Toxicokinetic, sub-chronic, chronic and carcinogenicity studie 1.Toxicokinetic studies yield information on how a test substance is absorbed, distributed around the tissues, metabolized and finally excreted. They also shed light on any metabolites, toxicity mechanism

812 / 880 and target organs. Such studies are useful to assess the safety of the substance and the possible toxicity mechanisms in relation to dosage and chosen administration pathways. 2.Non clinical sub-chronic toxicity studies on rodents via the main administering pathway, which include ingestion, gastric intubation, injection (intrapleural, intraperitoneal, subcutaneous, endovenous) and dermal treatment. Personalized assessments to find the pathway best suited for the specific requirements. These studies are needed to determine the degree of safety and toxicity of the test substance via repeated administration over a relatively short period. They serve towards broader evaluations, including identification of potential target organs, toxic dose, optimal dosages to use, and evaluation of other parameters. Duration: 14, 28 or 90 days. 3.Chronic toxicity/carcinogenicity studies on rodents are needed to gauge the degree of safety and toxicity of the test substance via repeated administration over a long period covering most of the animal’s life. These studies yield a broad spectrum of information on the physiological, pathological and behavioral processes, revealing any carcinogenic effect and identifying any metabolites or biological markers of the test substance. Duration: 24, 30 months. PARTNERSHIP Expanding international innovative partneship 1.Innovative partnership with laboratories, universities and manufacturers, to ensure that new products launched on the market are increasingly risk free for public health; 2.Expanding international partnership to evaluate joint application for European grants; 3.Implement industrial strategies supported by our scientific know-how at every stage of the production cycle to enhance product safety, productivity and competitiveness; 4.To perform toxicity studies on new products and acquire health-effects results before they are marketed, considering that costs of incomplete planning and subsequent crisis management on a product already launched on the market are often very high and could be avoided by proper prior planning. PRODUCT Preclinical toxicological studies To evaluate toxicological effect of new product

813 / 880 University of Bologna

Organisation

Country Italy City Bologna Street Via Zamboni 33 Web http://www.unibo.it/brevetti

Person

Name Alla Kudryashova Innovation Promoter

Organisation Founded in 1088, Alma Mater is a great community steeped in history that nevertheless looks to the future, to growth and experimentation. Today, joining the Multicampus (Bologna, Cesena, Forli, Ravenna and Rimini), you will find a rich and innovative teaching programme, cutting-edge research and an international outlook that is constantly expanding, with students from 140 countries around the world. Our programme catalogue includes numerous, diverse courses of study, from first-cycle degrees to graduate programmes and specialisation courses, which guarantee your personal growth and training as future professionals. Areas of Activity

• Analytical and characterization services • Surgery technologies and applications • Biotechnologies (Pharma&Medical • Virtual reality applications Devices) • Other • Drug screening & delivery • Laboratory equipment, reagents, software • eHealth, mHealth, telemedicine • Medical devices • Medical research • Peptides, proteins & antibodies preparation • Pharmaceutics • Physiotherapy, Orthopaedic technology

Marketplace Opportunities PRODUCT PATENT: MULTISCALE SCAFFOLD FOR TENDON AND LIGAMENT TISSUE REGENERATION AND REPLACEMENT The present invention is referred to a scaffold able to reconstruct/replace the tendon/ligament tissue, and to the processes to obtain the scaffold. The innovative element of this device resides in its inherent ability to mimic accurately the complex multiscale aggregation of these kind of tissues.

815 / 880 More info at: https://www.unibo.it/it/ricerca/imprese-e-ricerca/brevetti/2017/supporto-per-la- rigenerazione-di-tessuti-tendinei-e-legamentosi

816 / 880 University of Bologna - Nanobiotechnology lab

Organisation

Country Italy City Bologna Street via San Giacomo, 11

Person

Name Giampaolo Zuccheri Assistant professor

Organisation Nanobiotechnology lab at the Department of Pharmacy and Biotechnology, University of Bologna, Italy. We have expertise in nucleic acid characterization, chemistry, molecular behaviour, in particular in: - DNA-based nanotechnologies - Atomic force microscopy and related techniques - Biosensors Areas of Activity

• Analytical and characterization services • Life sciences related activities • Biomaterials • Biosensors

Marketplace Opportunities SERVICE Surface and nanostructure characterization Atomic Force Microscopy is one of the main group expertises. We can offer customized structural and nanomechanical characterizations for materials and nanomaterials, surfaces, nanostructures, biological macromolecules and structures. The analysis could be performed in liquid environments and at controlled temperature. We can pair the Atomic Force Microscopy analysis with electrochemical surface characterization and fluorescence microscopy. PARTNERSHIP Development of (bio)molecular monolayers on surfaces for biosensing applications We have experience in the design, preparation and characterization of surface tethered monolayers that can be used for surface derivatization and in the preparation of specific sensitive monolayers for

817 / 880 biosensing applications. We have experience in the preparation of organic, nucleic acids, peptidic, lipidic monolayers supported on surfaces (metals, silicates, glass). We can characterize the layers with a number of techniques (in-house and through established collaborations). Through our partners, polymeric micro- oro nanoparticles and thin layers (homogeneous, nanopatterned, orderd) can be prepared and characterized.

818 / 880 University of Ferrara

Organisation

Country Italy City Ferrara Street Via Ariosto 35 Web http://www.unife.it/

Person

Name Fabiana Raco Technology Transfer Manager

Organisation Scientific research is one of the essential functions of our University as well as the basis of teaching itself. It is the engine of critical knowledge, creativity, innovation, competitiveness, and quality of education. Besides governmental funding, our University finances its own research by external fund raising, boosting the participation in national and international projects of its researchers, supported by the internal Research Service; in the 2007-2013 period, about 60 research projects were funded to UniFe, for an overall EU contribution of over 11 million Euro. Researchers may rely upon university libraries, museums, and other important facilities, such as the Scientific and Technological Center, which combines and rationalizes teaching and research in Engineering, Physics, ICT, Geology; and IUSS Ferrara 1391, which combines PhD schools, advanced study courses and routes of excellence. In all recent Italian public rankings UniFe is always among the first 10 Italian Universities. Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Medical research • Pharmaceutics • Life sciences related activities

Marketplace Opportunities PARTNERSHIP Patent portfolio in the fields of: acute and chronic pain, SMA, anti- inflammatory and antioxidant compositions The technology transfer department is looking for both national and international industrial partners for collaboration and/or licensing opportunities as well as for universities and research centres in order to scale up research results.

819 / 880 University of Ferrara

Organisation

Country Italy City Ferrara Street Dipartimento di Fisica e Scienze della Terra - via Saragat 1 Web http://www.fe.infn.it/ orientamento_fisica/?page_id=1508

Person

Name Angelo Taibi Associate Professor

Organisation The expertise of the medical physics group covers various aspects of the physics of diagnostic radiology, nuclear medicine and biophysics of blood circulation. Areas of Activity

• Biosensors • Other • Diagnostics - Equipment and accessories • Medical devices • Diagnostics - Imaging equipment and processing • Medical research

Marketplace Opportunities PARTNERSHIP Optimization of diagnostic equipment We are interested in setting up partnerships for the technology transfer in the field of medical imaging (both hardware and software).

820 / 880 University of Modena and Reggio Emilia, Center for Genome Research (CGR-UNIMORE)

Organisation

Country Italy City Modena Street Via Campi 287

Person

Name Enrico Tagliafico Associate Professor

Organisation The Center for Genome Research was instituted in 2008 with the aim of promoting basic and applied research and the spreading of the results between academic contexts and both public and private research corporations. The centre alsocontribute to train researchers in the use of peculiar scientific instrumentation and in the application of new technologies. It is also involved in promoting the integration among different research activities, in particular focusing on collaboration among the various scientific structures of the same university or belonging to other universities, research corporations or the entrepreneurial world. In paricular the centre is involved in: Promoting highly specialized studies in genomics, transcriptomics, and epigenetics. Applying innovative technologies to the study of structural and functional genomics for the purposes of biology, biotechnology, medicine, pharmacology, microbiology and agricultural science. Promoting and coordinate activity of bioinformatics applied to massive genomes studies. Developing both applied and basic research projects, in order to further acquire funds for the centre. Coordinating the synergic initiatives within the centre and among the main didactic, organizational and research structures of the university. Increase the diffusion and a national and international discussion on the obtained results. Offering technological consultations and services in genomics Developing partnership and start-up initiatives to achieve application and technological transfer of the centre researches. Promoting academic and post-academic multidisciplinary formation on genome in biotechnology, medicine, biology, microbiology, agricultural science and pharmaceutics. Areas of Activity

• Bioinformatics, Big data analytics • Proteomics, metabolomics, nutrigenomics • Biotechnologies (Pharma&Medical Devices) • Genetics & Genomics • Medical research

Marketplace Opportunities 821 / 880 SERVICE Sviluppo di analisi molecolari e genetiche a servizio della medicina personalizzata Il Centro è inoltre in grado di fornire servizi personalizzati nell’ambito della trascrittomica (Gene Expression profiling) per determinare “signature molecolari” capaci di predire la risposta a un trattamento farmacologico. Ciò risulta estremamente utile nel corso di trial clinici per endpoint secondari dello studio per determinare se esista la possibilità di predire una maggiore o minore sensibilità/resistenza ala terapia TYPE OF PARTNER SOUGHT Il Centro di Ricerche Genomiche dell’Università di Modena, diretto dal Prof. Enrico Tagliafico si occupa da molti anni di medicina personalizzata e studio dei meccanismi molecolari alla base di numerose patologie, sia genetiche che oncologiche; in particolare ha realizzato studi altamente specializzati di genomica, trascrittomica ed epigenetica. L’utilizzo di tecnologie innovative ha consentito la realizzazione di numerosi progetti di genomica strutturale e funzionale. La competenza sviluppata in questo campo e le avanzate tecnologie in possesso del Centro consentono quindi di sviluppare pannelli personalizzati per studi di farmacogenetica, per determinare cioè quanto il profilo genetico di ogni individuo modifichi la sua capacità di metabolizzare i farmaci, presentando maggiori rischi di reazioni avverse o di interazioni con altri farmaci ovvero una parziale inefficacia degli stessi. Il Centro di Ricerche Genomiche è in grado di fornire tali servizi grazie alla competenza sviluppata nell’utilizzo di metodologie molecolari e genomiche avanzate tra cui analisi di Real Time PCR, Sequenziamento Sanger, Next Generation Sequencing e Microarray. SERVICE Sviluppo di analisi genomiche a supporto della relazione tra alimentazione, malattie e corredo genetico e per lo sviluppo di cosmetologia personalizzata INNOVATIVE ASPECTS AND MAIN ADVANTAGES Il Centro è inoltre in grado di fornire servizi personalizzati nell’ambito della nutrigenomica che consente, analizzando una serie di varianti del DNA correlate ad importanti processi metabolici, di impostare un programma nutrizionale, nutraceutico e di correzione dello stile di vita personalizzato in base alle caratteristiche genetiche individuali. Gli stessi servizi potranno essere applicabili campo alla cosmetologia per lo studio dei processi biochimici fisiologici o patologici dell'organismo in relazione al profilo genetico dell’individuo TYPE OF PARTNER SOUGHT Il Centro di Ricerche Genomiche dell’Università di Modena, diretto dal Prof. Tagliafico si occupa da molti anni di medicina personalizzata e studio dei meccanismi molecolari alla base di numerose patologie, sia genetiche che oncologiche; in particolare ha realizzato studi altamente specializzati di genomica, trascrittomica ed epigenetica. L’utilizzo di tecnologie innovative ha consentito la realizzazione di numerosi progetti di genomica strutturale e funzionale. La competenza sviluppata in questo campo e le avanzate tecnologie in possesso del Centro consentono quindi di sviluppare pannelli personalizzati per studi di farmacogenetica, per determiare cioè quanto il profilo genetico di ogni individuo modifichi la sua capacità di metabolizzare i farmaci, presentando maggiori rischi di reazioni avverse o di interazioni con altri farmaci ovvero una parziale inefficacia degli stessi. Il Centro di Ricerche Genomiche è in grado di fornire tali servizi grazie alla competenza sviluppata nell’utilizzo di metodologie molecolari e genomiche avanzate tra cui analisi di Real Time PCR, Sequenziamento Sanger, Next Generation Sequencing e Microarray. PARTNERSHIP

822 / 880 Computational approaches for the identification of druggable genetic and epigenetics mechanisms in cancer Development and application of computational approaches for the identification of cancer-associated genetic, epigenetic, and transcriptional dysregulations in cacner cell lines, primary patient-derived tumor organoids, and primary tumors FUNDING PROGRAMME AND REFERENCE HORIZON 2020 Health and ICT programs TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE The activity of the Bioinformatics Core of the Center for Genome Research, headed by Silvio Bicciato, focuses on the design and application of computational and bioinformatics tools for the analysis of genomic data coming from high-throughput technologies. These methods found applications in the molecular analysis of angiogenesis, head-and-neck tumors, leukemias, multiple myeloma, melanoma, and breast cancer. Furthermore, we created tools that allow comparing genomic data from a new experiment with those present in public repositories drastically reducing the experimental costs while significantly increasing the significance of the data. For instance, we designed, deployed, and analyzed an in-silico database of high throughput experimental data and clinical information for more than 6800 breast cancer samples, obtained from whole genome sequencing and microarray assays (Cordenonsi et al, Cell 2011). To support the translation of in-silico findings toward prospective, pre- surgical clinical trials, we designed procedures to derive predictive gene signatures and to screen and re-position FDA-approved drugs as potential candidate for cancer treatment. Moreover, we developed MDP (www.mdp.unimore.it), a web-tool linking genomic profiles and pharmacological vulnerabilities of cancer cell lines from CCLE and NCI60 collections (Taccioli et al., Onncotarget 2015). Recently, to further support investigations on aberration in signaling pathways as hallmarks of malignancy, we invested in computational methods for the integrative analysis of transcriptional, epigenomics, and chromatin-conformation signals (Zanconato et al., Nat Cell Biol 2015). Finally, we created a benchmarking framework to compare the performances of algorithms in the identification of chromatin interactions and Topologically Associating Domains from Hi-C data (Forcato et al., Nat Methods 2017). PARTNERSHIP Molecular Characterization of Cancer Several studies aimed at biomarker development for guiding clinical decision-making failed to achieve a clinical applicability due in part to confounding issues such as insufficient study design with inappropriate biological questions, poorly selected clinical cohorts, technically inadequate genomic technology aimed at investigating at sequence or at transcript level only or aimed at studying a limited number of potential biomarkers. Therefore, wide-ranging molecular-based biomarkers, biology driven, are required to stratify patients for biology-informed treatment.We aim to define the different aspects of the neoplastic process in order explore the tumor heterogeneity and to improve its treatment. FUNDING PROGRAMME AND REFERENCE European Community - Cancer related calls TYPE AND ROLE OF PARTNER SOUGHT, EXISTING PARTNERS/EXPERTISE Type of partner: Academic, Genome Research. Expertise areas: Gene expression and miRNA profiling (Affymetrix Platform) Quantitative Real Time on both QuantStudio 5 and OpenArray (QuantStudio 12K) NGS DNA mutation study from various type of sample including FFPE, FNA, etc.) mutations, In particular for cancer samples CNVs, and fusion drivers simultaneously for nearly 200 genetically relevant and actionable genes. Mutational allelic burden study in Digital PCR (QuantStudio 3D platform) Identification of Gene expression signature for treatment response in clinical trials. Study of clonal evolution of the neoplastic population both between diagnosis and metastasis but also

823 / 880 at CTC and cfDNA level in case of resistance to therapy. Characterization of immune response biomarkers (RNAs) also by FFPE (NGS IonTorrent platform) Recent bibliography: Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.220. [Epub ahead of print] Oncotarget. 2017 Jul 25;8(30):49451-49469. doi: 10.18632/oncotarget.17706. Oncotarget. 2017 Mar 28;8(13):21380-21397. doi: 10.18632/oncotarget.15226. Int J Mol Sci. 2017 Jan 13;18(1). pii: E145. doi: 10.3390/ijms18010145. Ann Oncol. 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2. Int J Cancer. 2016 Apr 1;138(7):1657-69. doi: 10.1002/ijc.29920. Epub 2015 Nov 25. Oncologist. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5. Blood. 2014 Sep 25;124(13):e21-32. doi: 10.1182/blood-2013-12-544197. Epub 2014 Aug 5. Leukemia. 2014 May;28(5):1052-9. doi: 10.1038/leu.2013.302. Epub 2013 Oct 22.

824 / 880 University of Rijeka, Technology Transfer Office

Organisation

Country Croatia City Rijeka Street Radmile Matejcic 10

Person

Name Sofija Tomić expert assisstant

Organisation University of Rijeka (UNIRI) was founded in 1973 following a long-standing tradition of higher education institutions and activities.UNIRI has 14 constituents: one Academy of Applied Arts, nine faculties and four university departments, with over 48 study programmes. UoR constituents are: Academy of Applied Arts; Faculty of Economics; Faculty of Tourism and Hospitality Management; Faculty of Philosophy; Faculty of Civil Engineering; School of Medicine; Faculty of Maritime Studies; Faculty of Law; Faculty of Engineering, Faculty of Teacher Education and Faculty of Health Studies. UNIRI departments are: University Department of Biotechnology; University Department of Physics; University Department of Informatics; University Department of Mathematics.UNIRI has over 1.600 employees, more than 900 researchers and over 18.000 students. University of Rijeka Technology Transfer Office (UNIRI TTO) was established in 2009 within Science and Technology Project (STP I) financed by the World Bank and with following objectives: to enable research and development (R&D) institutions to commercialize research outputs and to increase the ability of enterprises, particularly small and medium sized companies, to invest in R&D activities. Today it is an organizational unit of the University of Rijeka Rectorate and presents an important link between academia and industry, acting in synergy with University of Rijeka Science and Technology Park (Step Ri). UNIRI TTO mission is to extract the fair market value of the University intellectual property and to stimulate creation of future viable IP by using best business practices for the benefit of the University, its components (faculties and departments), staff and community. UNIRI TTO goals are: to create the university environment that encourages generation of new knowledge; to motivate development and dissemination of intellectual property created at UoR through IP management and administrative assistance; to provide an organizational structure and procedures through which research results may be prepared for protection and commercialization; to determine the rights and obligations of the University and creators of intellectual property (researchers); to ensure that the financial returns from IP commercialization do not distort decisions 825 / 880 and operations at the University in a manner contrary to the University mission Areas of Activity

• Biotechnologies (Pharma&Medical • Medical devices Devices) • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing

Marketplace Opportunities PRODUCT B-lines; NEW feature for enhancing the level of objectivity in specific field using ultrasound diagnostics Ultrasound technology is increasingly used in different areas as a tool for diagnosis. Usage in the diagnosis of lung disease due to the specific organ structure is limited comparing to the examination of other organs. B – lines are a diagnostic indicator for the condition of lung tissue in patients . They appear on the monitor of the ultrasound device, varying in appearance, intensity and number. Due to this variability and slow movement of the human eye, it is difficult to count B-lines. Developed solution can determine objectively number of B-lines during examination of patient in real time. INNOVATIVE ASPECTS AND MAIN ADVANTAGES With this technology, a non-invasive diagnostic tool can be applied on lungs more often sparing patients from exposing to more invasive controls. It also offers opportunity to measure the effectiveness of medical treatment while solving problems of "wet lungs" (diagnosis of water in lungs) . CURRENT STAGE OF DEVELOPMENT: Functional prototype INTELLECTUAL PROPERTY RIGHTS (IPR): Applied for PCT patent rights but not yet granted, registered trademark, Copyright

826 / 880 University of Rijeka, Technology Transfer Office

Organisation

Country Croatia City Rijeka Street Radmile Matejcic 10 Web www.uniri.hr

Person

Name Petra Karanikic Head of Technology Transfer Office

Organisation University of Rijeka (UNIRI) was founded in 1973 following a long-standing tradition of higher education institutions and activities. UNIRI has 14 constituents: one Academy of Applied Arts, nine faculties and four university departments, with over 48 study programmes. UoR constituents are: Academy of Applied Arts; Faculty of Economics; Faculty of Tourism and Hospitality Management; Faculty of Philosophy; Faculty of Civil Engineering; School of Medicine; Faculty of Maritime Studies; Faculty of Law; Faculty of Engineering, Faculty of Teacher Education and Faculty of Health Studies. UNIRI departments are: University Department of Biotechnology; University Department of Physics; University Department of Informatics; University Department of Mathematics. UNIRI has over 1.600 employees, more than 900 researchers and over 18.000 students. University of Rijeka Technology Transfer Office (UNIRI TTO) was established in 2009 within Science and Technology Project (STP I) financed by the World Bank and with following objectives: to enable research and development (R&D) institutions to commercialize research outputs and to increase the ability of enterprises, particularly small and medium sized companies, to invest in R&D activities. Today it is an organizational unit of the University of Rijeka Rectorate and presents an important link between academia and industry, acting in synergy with University of Rijeka Science and Technology Park (Step Ri). UNIRI TTO mission is to extract the fair market value of the University intellectual property and to stimulate creation of future viable IP by using best business practices for the benefit of the University, its components (faculties and departments), staff and community. UNIRI TTO goals are: to create the university environment that encourages generation of new knowledge; to motivate development and dissemination of intellectual property created at UoR through IP management and administrative assistance; to provide an organizational structure and procedures through which research results may be prepared for protection and commercialization; to determine the rights and obligations of the University and creators of intellectual property (researchers); to ensure that the financial returns from IP commercialization do not distort decisions and operations at the University in a manner contrary to the University mission

827 / 880 Areas of Activity

• Medical research

Marketplace Opportunities PRODUCT Immunotoxin for the treatment of glioblastoma multiforme - ATTRI The ATTRI project is focused on glioblastoma multiforme (GBM), which represents the most malignant form of brain tumor. The overall survival prognosis is extremely short and life expectancy with standard treatment is about 14-16 months. Complete surgical excision is made impossible by the tumor’s ability to disseminate outside its visible borders. The results of preliminary experiments have shown that the focus of ATTRI on CD155 selectively kills the tumor and prevents its expansion. Thus, ATTRI has been designed to specifically remove tumor cells without affecting the healthy brain cells, which should decrease the probability of permanent neurological damage of the treated patients. The use of the smart drug specific for tumor cells can significantly prolong the lifetime of GBM patients and increase their quality of life. The results of preliminary experiments show that the same principle could also be used for the treatment of other malignant diseases. The product is still in the developing phase (testing of the prototype in the laboratory conditions).

828 / 880 University of Siena - Liaison Office

Organisation

Country Italy City Siena Street Via Valdimontone 1 Web www.unisi.it/ricerca/imprese-e-trasferimento- tecnologico/brevetti

Person

Name Pamela Federighi Innovation Promoter

Organisation The University of Siena, through its Liaison Office, offers a service for the promotion of research results and the development of research and laboratories activities such as facilitating new partnerships between researchers and companies, Intellectual Property, licensing activities and the creation of spin- offs. The Liaison Office is the reference point of University regarding: - Patents - Spin-off companies - Technology Transfer. Both a source of information and a sorting house, Liaison Office matches the specific scientific and technological competences that the University can supply to the demands of businesses, and vice versa. It also facilitates the creation of common projects involving the University’s research centres and businesses. The Liaison Office proposes projects developed at the University of Siena and its spin-offs in the area of Life Sciences, mainly in the field of Biotechnology (vaccines, applied immunology, pharmacology, oncology, development of diagnostic tests, genomics), of Medical Devices (rehabilitation and assistive technologies, haptic systems), and Agrifood (environmentally-friendly territory management, sustainable development, traceability, nutraceuticals, cosmeceuticals). We are looking for companies interested to stipulate licensing agreements of our Intellectual Property Rights. We are also interested to industrial partners for collaboration and co-development, in order to transfer new technologies to the market. Areas of Activity

• 3D Printing/addictive manufacturing for • Peptides, proteins & antibodies biomedical applications preparation • Bioinformatics, Big data analytics • Pharmaceutics • Biomaterials • Software, ICT applications, system

829 / 880 • Biosensors integration • Biotechnologies (Pharma&Medical • EPR, Clinical/healthcare management Devices) software • Diagnostics - Equipment and accessories • Surgery technologies and applications • Diagnostics - Imaging equipment and • Vaccines processing • Virtual reality applications • Drug screening & delivery • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Genetics & Genomics • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities PARTNERSHIP RESEARCH COLLABORATION IN ROBOTICS, WEARABLE SYSTEMS, HAPTIC INTERACTION, BIOMEDICAL DEVICES, REHABILITATIVE AND ASSISTIVE TECHNOLOGY Intellectual Properties, knowledge and know-how in the Research fields of Robotics, Wearable Systems, Systems for Haptic Interaction, Biomedical devices, Rehabilitative and Assistive technology. The systems are related to wearable devices and haptic devices providing both kinesthetic and cutaneous stimuli. The devices can be used in a rehabilitative scenario, gaming, and remote control. Applications: Medical sector: - Rehabilitative technology - Assistive technology - Medical devices - Robotic prosthesis - Telesurgery Exoskeletons Robotic control Remote working Computer and video game sector: - Gaming - Virtual reality and augmented reality We have various international patents pending. TYPE OF PARTNER SOUGHT We are looking for companies interested in developing the industrial prototypes of our technologies and interested to stipulate licensing agreements of our Intellectual Property Rights. We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP PHARMACEUTICAL COMPOSITION COMPRISING RESVERATROL AND POLYMYXINS FOR USE AS ANTIBACTERIAL AGENT Pharmaceutical composition of polymyxin, preferably colistin, and resveratrol, for use as a medicament as antibacterial therapy. The synergistic activity of resveratrol and colistin resulted in a restoration of sensitivity in colistin -resistant Gram-negative pathogens. Another object of the technology is the use of the aforementioned pharmaceutical composition supplemented with pharmaceutically acceptable additives and excipients for the treatment of urinary tract infections, bacterial intestinal infectious disease, intestinal decontamination and lower respiratory tract infections, the latter also in association with cystic fibrosis, bronchiectasis and chronic obstructive 830 / 880 pulmonary disease. Patent pending Priority number: 102017000025738 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP ANTI TNF-ALPHA COMPOUNDS AND USES THEREOF The invention consists in an anti-TNF-a peptide selected from a phage library, for use in the treatment and prevention of an acute or chronic inflammatory pathology selected from the group consisting of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis and psoriatic arthritis, atopic dermatitis, lupus, juvenile idiopathic arthritis, cystic fibrosis. The peptide has been shown to inhibit the binding of TNF-a and the human lymphotoxin (LT), to TNF-a receptors, thereby preventing the onset of inflammatory processes triggered by the binding. The peptide can be synthesized as a tetra-branched molecule for increased stability, or more preferably as a Multiple Antigenic Peptide. The invention further describes a pharmaceutical composition comprising the peptide described and pharmaceutically acceptable excipients, defined for systemic, oral or topical administrations, as well as preparation for inhalation. Granted patent Publication number: IT1420917 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP ODONTOIATRIC VIDEO-ENDOSCOPE DEVICE The invention relates to a system enables to perform video assisted odontology. The system comprises intraoral video-cameras, anti-fog systems, micro-illuminator devices, computers and multi-monitor workstations. The video-endoscope device allows you to perform visual odontoiatric examinations and formulate comprehensive diagnosis within a conventional dental studio. The benefits of the device are the ability to access hard-to-reach parts, view photographs, radiographs and renderings, and expose to the patient their specific case, using images and movies. In addition, the device has the advantage of ensuring less operator fatigue, because operator can be free by eyepiece magnifiers, and can keep a proper posture. Patent pending Priority number: 102016000039503 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP PROCESS FOR MANUFACTURING CUSTOMIZED FACEMASKS FOR THE TREATMENT OF MALOCCLUSION The invention relates to a process for additive manufacturing of customized facemasks for maxillary protraction, in particular for the treatment of Class III malocclusion in children. The facemask provides better comfort compared to off the shelf products, enabling sufficient wearing time and better therapeutic results. In detail, the process is based on the acquisition and processing of a 3D digital image of the patient's forehead and chin, by the use of a 3D digital camera or anatomical impressions of the body parts and a 3D digital modelling software. Consequently, a 3D printing of the corresponding forehead and chin pads is obtained. 831 / 880 The forehead and chin pads can also contain sensors of pressure and temperature in order to monitor the wearing time and for gaming purposes. Patent pending Priority number: 102018000002713 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP BRANCHED MULTIMERIC PEPTIDES FOR TUMOR DIAGNOSIS AND THERAPY The invention refers to in vivo stable branched peptides, in particular derived from the sequence of Neurotensin (NT) conjugated to functional units for specific targeting of cancer cells, either for diagnosis or therapy of tumors. Synthesis of peptides in branched tetrameric form results in molecules retaining peptide biological activity and are very resistant to the proteolytic activity of biological fluids, thus having a markedly higher half-life in respect of correspondent monomeric peptides. The inventors designed and synthesized different peptide-based branched molecules, where four copies of peptides reproducing the same sequence (NT4) were linked together by a core of three lysine residues and coupled during the solid-phase synthesis to different functional units allowing to either trace cancer cells in vivo or ex vivo or to deliver cytotoxic moieties to tumor cells. Granted patent Publication number: EP 1991561 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP ANTIVIRAL COMPOUNDS AND USES THEREOF The invention relates to compounds with antiviral properties against enveloped viruses (e.g. Zika, HIV, HSV-1, HSV-2 Influenza and the like). These compounds act as oxidants of membranes’ lipid component. While the host cells possess specific membrane repair mechanisms, enveloped viruses do not. Consequently, the compounds enact their antiviral effects through destabilization of the viral envelope alone. Used alone as single therapy or in combination with at least one approved antiviral agent, these compounds, and one of them in particular, therefore represent a tool to fight emerging enveloped viruses, for which specific antiviral molecules or vaccines are currently lacking. Patent pending Priority number: 102018000003680 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP NOVEL THERAPY IN THE TREATMENT OF ALKAPTONURIA The invention discloses the use of methotrexate, a compound used in the treatment of some neoplasms and autoimmune diseases, in the short and long-term treatment of alkaptonuria and of its complications. In detail, the invention concerns pharmaceutical compositions comprising a pharmaceutically active amount of methotrexate or acceptable salts thereof, in combination with pharmaceutically acceptable excipients and diluents, that are able to inhibit ochronosis, a major complication of alkaptonuria characterized by the accumulation of oxidized homogentisic acid in the blood and cartilages. The oral compositions or injectable solutions of the methotrexate-based pharmaceutical composition can be prepared in accordance to the administration route, although injectable solutions are preferred. 832 / 880 Granted patent Publication number: IT 1413247 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP SYSTEM FOR MONITORING ELECTRO-MEDICAL EQUIPMENT INSTALLED AT A PATIENT'S HOME The invention relates to a system for monitoring electro-medical equipment installed at a patient's home, that permits to detect operating parameters of equipment (such as detecting over the time a supply energy supplied to the equipment, recording variations in the absorption of electrical power by the equipment and identifying the operating status of the equipment); communicate information to the patient; receive commands from the patient. Patent pending Priority number: 102018000005591 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development. PARTNERSHIP A METHOD FOR BLOOD OXIDATIVE STRESS ASSESSMENT AND RELATED DEVICE The invention is in the field of biomedical analyzes and, in particular, refers to a method for assessing the oxidative stress in a biological sample of a patient. The invention relates also to a device for carrying out this method. Patent pending Priority number: 102018000006166 TYPE OF PARTNER SOUGHT We are willing to stipulate licensing agreements of our Intellectual Property Rights; We are also interested to industrial partners for collaboration and co-development.

833 / 880 UT Austin - Dell Medical School

Organisation

Country United States City AUSTIN Street 1701 Trinity Street Web https://dellmed.utexas.edu/

Person

Name Verena Kallhoff, Ph.D., MBA Manager, WorkSpaces @ Texas Health CoLab

Organisation Dell Medical School works to make health care better and more accessible. We aim to build a better system to support innovation, health, economic development and opportunity for all. Areas of Activity

• 3D Printing/addictive manufacturing for • EPR, Clinical/healthcare management biomedical applications software • Bioinformatics, Big data analytics • Surgery technologies and applications • Biotechnologies (Pharma&Medical • Medical devices Devices) • IT Applications for Health • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine • Pharmaceutics • Life sciences related activities

Marketplace Opportunities SERVICE Mentoring for Healthcare startups entering the US I am looking for healthcare companies interested in entering the US market. PARTNERSHIP Explore partnerships with healthcare incubators/accelerators Looking for partners who work with healthcare startups in Italy/Europe interested in collaborating with the US

835 / 880 VAXXIT SRL

Organisation

Country Italy City Roma Street Via dei Valeri 1 Web http://www.vaxxit.com

Person

Name Giovanni Cozzone Co-founder and CEO

Organisation Vaxxit S.r.l. (Rome, Italy) is an early-stage biopharmaceuticals company developing vaccines against HIV, Herpes Simplex Virus (HSV) and M. Tuberculosis (TB), all WHO global health priorities. The lead product, TatImmune®, has been developed with Africa in mind. TatImmune is a novel therapeutic vaccine for people with HIV on antiretroviral therapy (ART). Successfully tested in Italy and South Africa in 314 volunteers of different race, sex, ART regimen and virus type. Proven in Phase II studies showing strong humoral and cellular responses against HIV and steep reduction of the virus reservoirs. Vaxxit seeks investors and commercial companies as partners and mentors for building a strong management team for the way forward to phase III studies and commercialization. Enquiries are welcomed. Founded in July 2012, Vaxxit operates primarily in outsourcing and through research and commercial collaborations. Co-founder and CEO, Dr Giovanni Cozzone has led operations in close collaboration with senior scientists and industry professionals having more than 200 years of aggregate experience in vaccine development. Areas of Activity

• Biotechnologies (Pharma&Medical • Vaccines Devices) • Medical research • Peptides, proteins & antibodies preparation • Pharmaceutics

Marketplace Opportunities PRODUCT TatImmune®, a novel therapeutic vaccine for people with HIV on antiretroviral therapy (ART) Nearly 40 million people in the world live with HIV (PH+), of which 27 million in Sub-Saharan Africa where, in spite of ART) the infection is increasing especially among women and young people, the most 836 / 880 exposed to the virus. Women are hardest hit accounting for the majority of people infected. South Africa has the world’s largest epidemic, 7.1 million PH+, 20% of the population. New infections (>300.000/year) continue in spite of massive ART programs (2017: 4 million PH+, US$ 2 billion spent for ART) that are being jeopardized by serious therapeutic shortfalls of ART: no effect on virus reservoirs, widespread non-adherence and no-response to therapy, no effect on chronic immune activation and immunodeficiency. TatImmune represents a promising solution to ART shortfalls, compensating where ART fails by targeting HIV-1 Tat, a key virulence factor essential for virus survival and infectivity that ART does not affect. TatImmune is given only once in a lifetime: 3 doses, one month apart. Clinically tested in 3 phase I studies (Italy), and 2 phase II studies in Italy and RSA, with 314 volunteers of different race, sex, ART regimen and HIV virus subtype. Results show strong durable boost of immune defences (CD4/CD8 T cells, B and NK cells) and drastic durable reduction of virus reservoirs against which ART has no effect (-70% after 8 years). Efficacy demonstrated with major types of ART regimens and HIV subtypes.Funding for clinical trials (about EUR 30 Million over 15 years) was provided by Italian and European research grants. The results are published and have been independently assessed by the South Africa National Department of Health and by UNIDO, the United Nations Industrial Development Organization, both advocating registration and use in South Africa. Phase III licensure studies in RSA will enrol recently diagnosed PH+ and PH+ on ART for many years, aiming to improve response to ART in the former, and enhancing/intensifying ART efficacy in the latter. Trial protocols have already been discussed (Sept. 2017) with SAHPRA, the regulatory body of South Africa, and will be discussed with the US Food and Drug Administration. The South African trials will be used to support licensure in the USA and Europe. PRODUCT HIVaxTat®, novel pre-clinical vaccines against HSV and TB Herpes simplex viruses (HSV-1 and HSV-2) are causes of disease worldwide: recurrent symptomatic and asymptomatic infections, cause diseases varying from cold scores to blindness, meningitis or encephalitis, particularly severe and potentially lethal in infants and immunocompromised people. HSV infection is one of the worldwide leading causes of encephalitis, with hospitalization and mortality rates relatively high if compared with other etiological causes, especially in the immunosuppressed and the elderly. Several studies have suggested that HSV1 and 2 infections are also involved in the onset of other diseases, among which, Alzheimer’s disease, atherosclerosis, increased risk of horizontal and vertical HIV acquisition and transmission and of bacterial vaginosis. M. Tuberculosis (TB) is one of the leading causes of death, worldwide and the top killer of people with HIV. In 2016, there were more than 10 million new infections, 1.7 million deaths of which 400 thousand among people co-infected with HIV (40% of total HIV deaths). Unmet needs for HSV: revention of HSV acquisition and strategies to ensure control of HSV reactivation are essential to reduce the burden of HSV on global health. Unmet needs for TB: strategies to ensure maintenance of TB latency and control reactivation are essential to reduce the TB burden on global health. Vaxxit's collaborating scientists are pursuing a pathogenesis-driven strategy aiming to achieve broad and long-lasting CD8 T cell responses which, as recent clinical observations indicate, play a key role in controlling HSV. Memory CD8 T cells displaying high cytotoxic potential against HSV and other intracellular pathogens are considered particularly efficacious to this end. HSVaxTat®, is a novel vaccine platform that boosts simultaneously CD8 T cell (cellular) and humoral responses against intracellular pathogens like TB. HSVaxTat exploits and combines the Th-1 immunomodulatory properties of the HIV-1 Tat protein expressed in vivo with the safety of attenuated and replication-defective HSV-1 vector-based vaccines which, without HIV-1 Tat, would not elicit protective CD8 T cell responses or achieve total protection. HSVaxTat candidate vaccines retain the immunogenic potential of live vaccines while having the safety features of attenuated and replication- defective vaccines. The HSVaxTat vaccine platform may succeed where other strategies have failed, and has potential also

837 / 880 to improve response to other vaccinations requiring or benefiting from Th1 responses. PARTNERSHIP Global/regional/national clinical development, distribution and sales partnership(s) TatImmune, Vaxxit's lead product, is phase III-ready in South Africa and can be phase III-ready within 6 months in USA and Europe. These markets are patent protected. Vaxxit is seeking industry partners for clinical development, distribution and sales in each of these markets and in the rest of the world. PARTNERSHIP Co-development partners for HSVaxTat®, novel pre-clinican vaccines against HSV and TB and vaccine platform for other vaccines aiming to elicit a Th1 response. Vaxxit is seeking co-development partners for the HSVaxTat® vaccine candidates and other vaccines. Stage of development of HSV and TB candidates: efficacy in mice; efficacy and safety in 2nd animal species is needed for IND submission for phase i/II studies in humans. INVESTMENT OPPORTUNITY Series A Round Vaxxit Srl (Rome, Italy) offers investors/partners Series A preferred stock for a EUR 10 million investment Use of Funds: a) phase III trials for licensure in South Africa of TatImmune®, a therapeutic vaccine for people with HIV on antiretroviral therapy(ART); b) hire 2 senior directors (clinical and BD) REQUEST Would like to meet with prospective investors and commercial partners Would like to meet with prospective investors and commercial partners to present the Series A Round and discuss distribution and sales.

838 / 880 Vera Salus Ricerca srl

Organisation

Country Italy City Augusta Street Via Francesco Caracciolo 9/a Web http://www.verasalusricerca.it

Person

Name Giovanni Pitari Co-founder, R&D Director

Organisation Vera Salus Ricerca Srl (VSR) is a biotech target discovery company, which is specialized in basic and translational research for the development of innovative technologies and drugs to be applied for the cure of patients. VSR is developing a pipeline of highly innovative products and also works as a Contract Service Provider, with flexible business models. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Life sciences related activities • CRO (Contract Research Organisation) • Drug screening & delivery • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE BIOMEDICAL RESEARCH SERVICES We perform translational research directed at obtaining innovative biomedical products (drugs, nutraceuticals, medical devices) that can be applied to prevent, delay or treat pathological conditions. INNOVATIVE ASPECTS AND MAIN ADVANTAGES We have developed an array of innovative methodologies and protocols to support basic and clinical research that we would like to offer according to the well established Fee-for-Service model. Among others, biomedical services available in our Core Laboratory include functional assays in real-time on cells from patients (proliferation, differentiation, adhesion, migration, invasion, epithelial barrier function), molecular biology strategies (gene editing, silencing and overexpression, gene therapy, immunoprecipitation, immunodetection), analyses of receptor signaling and signal transduction, drug screening, citotoxicity assesment, and biomarker validation. In addition, we made available our in-

839 / 880 house expertise and specialized know-how to assist with all phases of research planning and execution, including experimental design, data analysis and interpretation, presentation and publication of results. MARKET APPLICATION Red, Green and Yellow Biotechs, clinical research institutions, small and medium-size pharmaceutical companies and Big Pharma TYPE OF PARTNER SOUGHT Small, medium and large Biomedical Enterprises and Public or Private Clinical Research Institutions from European or other International Countries. INVESTMENT OPPORTUNITY INNOVATIVE DRUG DEVELOPMENT We seek early stage financing for distinct translational medical projects in therapeutics. We developed a proprietary chemical-factory technology poised to be exploited for innovative drug development. New drugs will stem directly from our patent-protected compound platform, derived from natural chemicals with embedded disease-selectivity and collateral tissue-protective effects. Developing drugs can be envisioned in different fields of medicine, from oncology to neurology, from degenerative disorders to inflammation and infections. We are open to flexible terms of investments, including licencing or financing, co-development or acquisition. INVESTMENT OPPORTUNITY NUTRACEUTICS DEVELOPMENT We seek financing for specific problem-solving nutraceutical projects. We have screened hundreds of mediterranean natural compounds and characterized chemical properties and biological actions. We want to make available to investors or interested organizations our chemical library, biological findings and investigational know-how for the development of novel nutraceutics to be applied to protect, improve or restore human and/or animal health. New nutraceutics will exploit our optimized screening protocols and research methodologies employing diverse specialties of science (biochemistry, biology, immunology, pharmacology, genetic, proteomic, medicinal chemistry, etc.). We are open to flexible terms of investments, including licencing, service-agreements or co- development. INVESTMENT OPPORTUNITY A NEW SMALL MOLECULE TO TREAT MELANOMA We succesfully performed discovery, lead identification and optimization, and proof-of-concept of a new molecular entity (NME) to be exploited for melanoma treatment. The new drug is of natural origin and comprises characterized scaffolds and pharmacophores with antiproliferative, tumor-selective actions. The technology has the potential to be extended to other epithelial cancers for broader commercialization strategies. We seek financing for further drug development and are open to flexible terms of business and investment.

840 / 880 Vetspin Srl

Organisation

Country Italy City Castenaso Street via Toscanini, 9 Web http://www.vetspin.com

Person

Name Matteo Ligabue co-CEO

Organisation VETSPIN is a Contract Research Organization founded in 2004 as a spinoff of the University of Bologna. VETSPIN performs Pre-Clinical and Clinical trials for regulatory purposes in farm animals. The research team supplies the highest level of scientific knowledge, quality standards and regulatory competence to their customer's requests, whether for routine studies or specific complex and innovative projects. VETSPIN works in compliance with GLP guidelines and the facilities are subjected to regular GLP inspections by Italian authorities. Areas of Activity

• Analytical and characterization services • Regulatory affairs, validation • Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Vaccines • Consulting services • Laboratory equipment, reagents, software • CRO (Contract Research Organisation) • Medical devices • Investments • IT Applications for Health • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities SERVICE Contract Research Organization Our core service include all types of preclinical and clinical studies required for the registration of a pharmaceutical product veterinarian. We are also able to conduct proof of concept studies for the development and testing of new compounds. All regulatory studies are conducted in the Good Laboratory Practices (GLP) context. 841 / 880 Our Laboratories are able to setting up extra-GLP activities for diagnostic analytical chemistry, biochemistry and histopathology. INVESTMENT OPPORTUNITY Investment for a global perspective We strongly believe in our skills and competences which have been consolidated over 14 years of continuous activity. We started as a spin-off of the faculty of veterinary medicine and, although relying exclusively on our resources, we managed to implement an independent research center. Now we are focusing on the possibility of expansion on new markets. We are aware that a contribution of investment resources could have a considerable leverage effect on our chances of success. PARTNERSHIP Synergy & Opportunities We have always been open to innovation and new opportunities. This is why we are a company willing to evaluate synergistic strategies with companies, public institutions or stakeholders who intend to make use of our expertise in the field of drug research, in the European regulatory framework and in analytical chemistry. REQUEST Pharma, Regulatory, Quality and Analytical Expertise Our expertise in the field of drug research, the regulatory environment, the application of quality systems and the ability to develop chemical analytical methods has transformed our know-how into efficient and transferable competences in many sectors, even those that are not strictly related at our current market.

842 / 880 VIROSTATICS srl

Organisation

Country Italy City Sassari Street ViroStatics srl Viale Umberto I 46 Web http://www.virostatics.com/

Person

Name Franco Lori Founder - CEO

Organisation ViroStatics is a privately held small pharmaceutical company dedicated to the discovery and the development of novel compounds for a multifaceted treatment of cancers and viral diseases, focusing on novel, selective, host cell kinase targeted inhibitors. The Company has developed a robust pipeline of proprietary compounds to distinguish themselves from the competition through their unique kinaseselectivity, efficacy and safety profiles. Consistent with its well defined mechanism of action, ViroStatics’ lead compound has a good toxicity profile while exerting potent activityin preclinicalmodelsagainst most aggressive cancers with high unmet need such as lung cancer, pancreatic cancer, highly malignant lymphoma and acute leukemia. The Team and Advisors combines scientific, business, legal, and technology expertise, spanning the entire process of drug development fromtranslationalsciencethrough preclinicalandclinicaldrugdevelopment. http://www.virostatics.com/ Areas of Activity

• Analytical and characterization services • Pharmaceutics • Diagnostics IVD • Medical research

Marketplace Opportunities PRODUCT VS2-370, a novel CDK4/6/9 inhibitor against cancers and chronic infections VS2-370, a powerful and innovative cyclin-dependent kinase inhibitor, and a potential candidate for the treatment of aggressive tumors such as lung cancer, pancreatic cancer, lymphomas and leukemia, and for the treatment / eradication of human immunodeficiency, as well as tumors associated with the virus itself. SERVICE

843 / 880 Services Platform in Immunology, Drug Discovery & Research Program including clinical trials Discovering and developing drug hits and leads requires a high level of specialized support and expertise. At ViroStatics our scientists help you do more by providing services that enable predictive answers for drug discovery research. With dedicated specialists and a team of experts in screening, profiling and custom assay development, ViroStatics can support your research team before, during, and after your process of drug research and development. Our custom SPIDERGRAM biology service program can provide specialized and reliable solutions to develop the most appropriate assay for your research or discovery on target of interest. Dedicated project managers will support you along the process with frequent progress updates. PARTNERSHIP Partnering for further development of lead preclinical candidate VS2-370 ViroStatics is looking for a partner and/or investor to complete pre-clinical development and move to clinical studies. PROJECT COOPERATION Project cooperation for further development of lead preclinical candidate VS2-370 ViroStatics is looking for a project cooperator to complete pre-clinical development and move to clinical studies.

844 / 880 Virtualmind s.r.l.

Organisation

Country Italy City Roma Street VIA ERMINIO MACARIO 45 Web http://www.virtualmind.it

Person

Name Davide Angelelli CEO

Organisation Design and Engineering company Areas of Activity

• 3D Printing/addictive manufacturing for • Virtual reality applications biomedical applications • Medical devices • Biomaterials • IT Applications for Health • Biosensors • Diagnostics - Imaging equipment and processing • Medical research

Marketplace Opportunities PRODUCT Endoscopic 360° pillcam Miniaturization 360° device

845 / 880 Virtualware

Organisation

Country Spain City Basauri Street C\Usausuaga 7 Web www.virtualwaregroup.com

Person

Name Jon Arambarri R&D Manager

Organisation Virtualware is an innovative and technological company that specialize in the development of Hardware and Software solutions based on Immersive and Interactive technologies. We offer high-tech value-added solutions, products and services through our offices in the United Kingdom, Spain and Latin America as well as through our partners around the world. Virtualware is made up of a multidisciplinary team of highly qualified professionals working together to create truly interactive experiences. www.virtualwaregroup.com is an strategic focus on R&D about the use of Graphical&Interactive Technologies facing Socital challenges such as eHealth . A succesful product already in the market is www.virtualrehab.info Through the application of technology to the Health sector, we can develop products based on serious games that help Healthcare professionals manage diseases and disorders in fields such as Physiotherapy, Neurology and Psychology. Our solutions are directed to hospitals, clinics and social and health institutions for the treatment of disabling illnesses and conditions. Further information about our R&D experience: http://virtualwaregroup.com/group/labs Areas of Activity

• eHealth, mHealth, telemedicine • Virtual reality applications • IT Applications for Health

Marketplace Opportunities PARTNERSHIP Experience in AR and HMI interfaces for eHealth www.virtualwaregroup.com is an Spanish Creative SME involved in spreading the use of Graphical& Interactive Technologies facing Societal challenges such as eHealth. Through the application of technology to the Health sector, we can develop products that help Healthcare professionals manage diseases and disorders in fields such as Physiotherapy, Neurology and Psychology. 846 / 880 Our solutions are directed to hospitals, clinics and social and health institutions for the treatment of disabling illnesses and conditions. Further information about our R&D Experience: http://virtualwaregroup.com/group/labs PARTNERSHIP looking for medical partners for R&D cooperation looking for medical partners for R&D cooperation in H2020 projects in the field of serious games for physical & cognitive rehabilitation of the elderly PARTNERSHIP looking for medical expertise partners lloking for medical expertise partners interested in research about games aplication in the rehabilitation SERVICE Virtualware Health Through the application of technology to the Health sector, we can develop products that help Healthcare professionals manage diseases and disorders in fields such as Physiotherapy, Neurology and Psychology. Our solutions are directed to hospitals, clinics and social and health institutions for the treatment of disabling illnesses and conditions. http://virtualwaregroup.com/en/group/health PROJECT COOPERATION Looking for Medical partners interested in developing games for physical and cognitive rehabilitaion of the elderly

Marketexpectations-At present, the global Physiotherapy equipment market is valued at over 14.2B and is expected to grow to over €20.8B by 2022, while the global market for Virtual Reality (VR) in healthcare is projected to reach €3.6B by 2020. Our vision is to develope low-cost solution for physical and Cognitive rehabilitation of Elder People We put our experience in gaming sector for developing innovatives theraphies based on games. We aslk for collaboration of healthcare professionals and/or IT providers (AI, platform providers) to develop a global solution adapted to real-users needs . Our Capabilities: Smart interfaces VR/AR Capabilities searched: - Medical expertise: -Hw: Low cost accurate sensors for tracking human movements -Software: Big data processing REQUEST Medical partners for R&D projects in Serious Games

We are looking mainly for medical partners interested in developing R&D projects based on Gaming for physical & cognitive rehabilitation of the elderly

847 / 880 Vitalis Komerc doo

Organisation

Country Serbia City Nis Street Anastasa Jovanovica 17 Web www.venovin.com

Person

Name Ivan Stanojevic CEO / Development sector

Organisation Vitalis Komerc doo was established in 1993. and through its long-term healthcare business, has always had the mission of improving the quality of all aspects of life through human health. Vitalis Komerc has been successfully implementing its mission for 20 years in the country and abroad, with full responsibility both for its customers and their employees, as well as for society globally. We are a full member of the Serbian Chamber of Commerce and the Regional Chamber of Commerce of Niš. The mission of our company is not only to respond to the needs of its consumers, but also to constantly strive for higher and better quality. www.venovin.com Areas of Activity

• Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics

Marketplace Opportunities PRODUCT Venovin - support blood system and circulation VENOVIN® is a natural product that helps with the illness caused by poor circulation and the resulting complications. NO ALCOHOL! (Alcohol free). It is intended as a support to the bloodstream and circulatory system. Venovin contains a mixture of medicinal herbs with red wine (0% alcohol). Only red wine has more than 600 ingredients extracted from a mixture of herbs to increase blood vessel elasticity, act antithrombotic and anti-inflammatory (preventing the formation of thrombus and inflammation). Venovin is rich in polyphenolic compounds that act vasoprotective (reduce permeability and increase elasticity of the blood vessels walls), antioxidative, antiinflammatory, antithyrobic and potentially anticancerogenic. In addition to red wine, the following vegetable herbs were used in the production of Venovin preparations: dry leaf and root of nettle, duck wavy bark, dry matrix leaf, petro-herb herb, duck breast herb and dry herb herb. For Venovin, we can say he is an elixir for debt. It prevents the formation of malignant cells, rejuvenates 848 / 880 blood, regulates sugar, increases immunity and retains age. Red wine is considered to be a drink and a food and a lot due to a large number of nutrients that are considered precious to the human body. Literature data indicate that plant species that come into the composition of the preparation are chemically and clinically tested and contain essential oil, phenols, tannins, flavonoids, catechins, phytosterols, vitamins and other chemical compounds. Venus achieves exceptional results and when used without baseline therapy, there is no contraindication and because of its strength and multi-efficacy it belongs to the group of the best elixirs to preserve vitality and health. Symptoms of reduced circulation: neuropathy, cold extremities, tingling and cramps, short - to - thin breathing, low calorie fatigue - obesity, arrhythmia, weak memory, chronic fatigue. THE POSSIBLE EFFECTS OF THE SPECTACLE WILL BE PROVIDED: - Quality pure red wine - in the mysterious formula of combining medicinal herbs - in the quality of Suvoplanin and Whitish Medicinal Herbs VENOVIN RECOMMENDS FOR ANY PERSONS SPECIAL AND SPECIAL: - People with pronounced peripheral circulation disorders (cold hands and feet) - People with swings of blood vessels (arteriosclerosis) - people with deep vein thrombosis - People with increased blood pressure - persons suffering from seasonal disease - people with gangrene - persons with open sores (ulcus cruris) www.venovin.com

849 / 880 VivacSo Srl

Organisation

Country Italy City Torino Street Corso Castelfidardo 30/A Web www.vivacso.com

Person

Name Diego Dolcetta Neurologist, entrepreneur

Organisation One of the three founders of VivacSo Srl, Diego Dolcetta, CEO. He is Neurologist, PhD AND hemiparetic after a car accident: that's likely why he looks at his medical needs with kind of a special gaze. He found quite a number of problems that were neglected by the Medicine. The lack of logical and simple solutions durinfg the past century left room to complex, unsatisfactory, invasive solutions. A suited ankle-foot orthosis (AFO) to the spastic foot (which rotates inward) is currently completely missing, and we decided to start our activity from here: helping the safety and speed of the gait, the main problem of a vast series of different patients. Areas of Activity

• Medical devices

Marketplace Opportunities PRODUCT Ópponent, the First Frontal Ankle-Foot Orthosis (www.vivacso.com/prodotti) The hemiparetic patients in EU are currently roughly 4,8 millions (see Truelsen et al, 2006), with 800,000 new cases/year, and their main problem is obviously the safety and speed of the gait. The AFOs on the market are all adaptations to the presently prevalent disability of old solutions, ideated in the early '900 for the foot drop (common in the past, not now), and are poorly efficacious: the foot drops on the longitudinal plane and its weight is light, and there is no way to adapt them to the counteraction of a torsional reflex, strongly acting on the frontal plane. This is why the tendon transfer, a branch of the orthopedic surgery, is now a frequently proposed solution, as well as the botulinum toxin infiltrations: both of them are as invasive as poorly effective. This is basically why these AFOs, surgeries and treatments are applied in a narrow minority of cases. Our EU patented AFO, called Ópponent, opposes efficacious constraints to the torsional reflex, on the frontal plane, making the unwanted movement impossible, but supporting the foot at the same time. The same torsional movement is cause of ankle sprain (roughly 14 millions/year in EU, see Janssen 2014), frequently recurrent (weak ankles) and leading to a disability worsening over time. 850 / 880 The recurrence is due to the lack of an AFO making the ankle sprain impossible, like Ópponent. These two basic versions, for neurological (ready to the launch to market) and for orthopaedic patients (close to it), both superior to competitors for handiness, beauty and efficacy (see www.vivacso.com/ product), would be distributed as first, also exploiting a new web-based marketing strategy (B2C, engaging the patient, while currently the patient's opinion is completely neglected and the mediation of the prescribed AFO is a business between the physiatrist physician and the orthopedic workshop), attracting the customer with web-based techniques. The generated income would allow important R&D investments: they would allow the development of an electromechanical Ópponent version for neurological patients and an Ópponent version perfectly suited to sporting activity of people with weak ankles. PARTNERSHIP Marketing Manager/distributor As told above, a Marketing Manager is the Key-Figure that VivacSo needs. He should be able to lead the Company to success in the National and then International market. He should be able of selling Ópponent through the traditional flow chart (contacting and convincing physiatrists and orthopaedic workshops) and at the same time exploiting new, web-based strategies: attracting patients to the interactive website, convincing them to buy there and join the VivacSo Community etc etc, with the help of web specialists. The Marketing Manager could be a partner. An already established distributor could also be a perfect partner. INVESTMENT OPPORTUNITY Investment needed to hire missing competences A) VivacSo possesses a product needed by the market, with high aesthetic value, high competitive advantages, EU patented, already tested, ready to launch in its first version: the product is called Ópponent. Other versions will rapidly follow. VivacSo Srl lacks of a Marketing Manager. Actual partners do not have the professional features requested to afford the Italian and International Market. First of all, the investment would be needed to pay in the very first phase a Marketing Manager. B) Investor is needed to better develop some competences: - Marketing manager - a web-based marketing strategy C) At the same (or in a following) time, the investment will help the company to perform a further clinical validation for which we already have collaborations with University of Padua (Bioengineering Dep) and Vicenza Hospital (Rehab Dep). To have the project timely done, at least a dedicated student/ young physiatrist for one year should be hired. The investment should also cover the related Research costs, if investor shares its necessity.

PROJECT COOPERATION A University/Distributor cooperating with VivacSo The Clinical Validation is a task that could be easily taken into consideration by a well-equipped Rehab Dep of an Italian or foreign University.

851 / 880 Vivomicx

Organisation

Country Netherlands City Groningen Street H.W. Mesdagstraat 53 Web www.vivomicx.eu

Person

Name Jan Zuidema CBO & co-founder

Organisation Vivomicx analyses subsets of cells in tissue, thus giving insight in the expression profiles of the various subsets providing clues for drug development. Areas of Activity

• Analytical and characterization services • Pharmaceutics • CRO (Contract Research Organisation) • Diagnostics IVD • Drug screening & delivery

Marketplace Opportunities SERVICE Our expertise in analysing subsets of cells in tissue could complement your service package This is a call out to other CRO's that offer services to which the services of Vivomicx of analysing subsets of cells in tissue could be an addition. We are looking for co-marketing opportunities so we can market your CRO services and you can market our services in your market and with your clients. INNOVATIVE ASPECTS AND MAIN ADVANTAGES Create a much bigger network of companies that will help each other in finding customers, lowering costs of market access. MARKET APPLICATION Preclinical and clinical services. Product validation (efficacy of drug or efficacu of drug targeting). TYPE OF PARTNER SOUGHT Preclinical, clinical services CRO's. Analytical services companies etc. SERVICE Validation of the delivery of your therapy to the target cells We would like to get in touch with targeted delivery companies that want to ensure in preclinical or clinical phase that their compound actually reaches the target tissue and the effects thereof. INNOVATIVE ASPECTS AND MAIN ADVANTAGES 852 / 880 You will learn in an early stage wheather your new product has a chance of making it through the drug development pipeline. MARKET APPLICATION Drug targeting TYPE OF PARTNER SOUGHT Innovative biotech or pharma companies SERVICE applying multi-omicx analysis on subsets of cells in tissue We are specialized in using Laser Micro dissection to select specific subsets of cells from tissue. The more targeted your therapy the more relevant information is available in the cells of interest. Vivomicx unlocks this information through the selection of the cells and our collaboration with SME's that have different omicxs services like QTPCR, miRNA analysis, Next Generation Sequencing and Kinome profiling. Our analysis provides relevant information for drug discovery & drug development.

853 / 880 Vrije Universiteit Brussel

Organisation

Country Belgium City Brussels Street B-PHOT, Pleinlaan 2, (tva BE0449012406) Web http://www.actphast.eu/

Person

Name Hugo Thienpont Actphast Coordinator and Director of Brussels Photonics

Organisation Brussels Photonics is coordinator of the EU programme ACTPHAST4.0. ACTPHAST 4.0 (ACceleraTing PHotonics innovAtion for SMEs: a one STop-shop-incubator) is a unique photonics innovation incubator for Europe which is perfectly aligned with the needs of SMEs in overcoming the challenges and seizing the opportunities afforded by the new digital revolution of Industry 4.0 in which photonics technologies are a key enabler. ACTPHAST 4.0 will directly support the broader and faster take-up of photonics by a critical mass of SMEs by providing action-oriented solutions on two complementary levels, driven by the business needs of the companies: (i) ready-made access to rapid prototyping services using the top photonics technologies and expert know-how of Europe’s leading photonics competence centers covering the entire integrated supply chain of photonics technology platform capabilities to make deep interventions in the SMEs’ new product development through focused short-duration co-innovation projects; (ii) professional coaching on the technical, business and financial aspects of the innovation process, from concept feasibility through to a mass-manufacturable marketable product. ACTPHAST 4.0 is designed to ensure that all of Europe’s SMEs, in particular first users and early adopters across a wide range of end user industries, have open access to the incubator for timely, efficient and cost-effective photonics innovation support. Areas of Activity

• Other

Marketplace Opportunities SERVICE Actphast 4.0 for the Life Sciences & Health domain A relevant application domain in Actphast 4.0 is the life sciences & health sector. With predictions of double-digit growth into the future, biophotonics is one of the most vibrant and promising of global markets. Increasingly component manufacturers are addressing this market and aligning their products with the requirements of systems and whole solution providers, thus generating additional synergies. 854 / 880 Breakthrough advances in photonic methods and techniques for health and life sciences will contribute to solving several grand challenges for Europe and the rest of the world. Due to demographic changes and more particularly the ageing of the population, new and efficient methods and devices need to be developed that allow maintenance of a quality life with affordable healthcare, and the introduction of new cost-effective photonics-enabled solutions to the healthcare market will play a major role in meeting this challenge. It is also anticipated that there will be a huge demand for photonics solutions in the quality control/ assurance of production processes related to the healthcare market, especially in food and pharmaceutical production environments where high quality standards with zero defects must be met. Examples of where photonics is applied in Life Sciences & Health include: Biomedicine: Photonic enabled microfluidics, Imaging guides, Sensor catheters, RI sensors, Opto- fluidics, Minimal invasive diagnostics,Treatment monitoring by imaging, Retinal implants, Microinstruments for early diagnostics of cancer, Endomicroscopes for colonoscopy, gastroscopy, bronchoscopy, Miniature OCT systems, Biotechnology, Opto-fluidics, Bio-chips, Lab-on-chip system, Point-of-care diagnostics, Microcytometers, μTAS devices How it works in 8 simple steps: 1 - Registration of interest: a company must make a formal initial request for support using the online registration form on the ACTPHAST 4.0 website. 2 - Central Contact Point & Business Coach: all registrations of interest come through to the ACTPHAST 4.0 Central Contact Point (CCP) and are assigned to a Central Business Coach for rapid follow-up driven by the company's business need. 3 - Technical Coordination Team: once qualified as a “potential” innovation project, the details of the request are passed to the ACTPHAST 4.0 Technical Coordination Team (TCT) in order to identify and appoint the most suitable technical expert from the pool of up to 200 top photonics experts amongst the ACTPHAST 4.0 Partners, who offers the best match with the requirements of the company. 4 - Scouting Engagement: once a suitable expert is appointed to a project, the next step is for that person plus the Business Coach to arrange for an in-depth discussion with the company about the potential project under NDA and to jointly submit a scouting report. 5 - Innovation Project Proposal: if the scouting report provides a positive recommendation to proceed with a full project proposal, and this recommendation is accepted by the TCT, then a suitable person from the ACTPHAST 4.0 Partners is selected and appointed to act as Project Leader to write the detailed proposal together with the Business Coach and the company. 6 - Evaluation Meeting: the ACTPHAST 4.0 TCT members meet once every two months to evaluate submitted Innovation Project Proposals and decide which proposals should be approved for support. 7 - Contract:m where an innovation project is approved for support, the next step is the process of preparing and signing the contract document between all of the relevant parties to the project. 8 - Project Execution & Follow-Up: 0nce the contract is signed, the project commences with a formal kick-off meeting between all of the parties and project team members. The Business Coach stays in continuous contact for post-project follow-up on impact and to make connections with the Photonics Pilot Lines and Venture Forum where appropriate for full commercial exploitation of the innovation.

855 / 880 VSY Biotechnology

Organisation

Country Turkey City ISTANBUL Street Tuzla Organize Sanayi Bölgesi 3.Cadde No:3 Tepeören, Tuzla, İstanbul Web http://www.vsybiotechnology.com/

Person

Name Ercan Varlıbaş Chairman

Organisation VSY Biotechnology is a progressive and innovative company that focuses on consumer satisfaction by creating superior state-of-the-art ophthalmology and orthopedics products designed and manufactured to greatly enhance and improve vision and comfort for a wide range of patients around the globe. Starting from foundation to today, quality and safety standards are the source of our success. To meet the needs of patients and healthcare professionals around the globe, VSY Biotechnology serves to more than 60 countries around the globe from our headquarter in Amsterdam, The Netherlands. With our know-how in biotechnology, we will continue to enlighten the World by combining these disciplines for the patients. Areas of Activity

• Biomaterials • Life sciences related activities • Biotechnologies (Pharma&Medical • Surgery technologies and applications Devices) • Chemicals & APIs • Nutraceutics, probiotics, functional food, cosmeceutics

856 / 880 W Life Sciences

Organisation

Country Switzerland City Nyon Street Clémenty 62 Web http://www.wlifesciences.com

Person

Name Wilma Lukas Managing Director

Organisation W Life Sciences is an independent consulting firm based in Switzerland W Life Sciences facilitates strategic relationships, provides advisory services in business development, licensing activities and evaluation of opportunities Acting as Expert for different organizations: Innosuisse (Swiss Innovation Agency), crowdfunding company, start-up accelerator, expert for grant applications at a foundation Areas of Activity

• Biotechnologies (Pharma&Medical • Life sciences related activities Devices) • Consulting services • Pharmaceutics

Marketplace Opportunities SERVICE Business development services Support biotechs, start-ups, TTO, Innovation centers in their business development activities: - Search and identify innovative opportunities for Pharma companies - Evaluations of opportunities for investors - Interim management INVESTMENT OPPORTUNITY Looking for:

- One investor is looking for therapeutics involved in aging - Pharma company is looking to acquire late-stage or on the market products in a broad range of therapeutic areas (but NO nutraceutical, natural product, veterinary or OTC) - Medium pharma company is looking for clinical products (niche, orphan) with rights for Europe PARTNERSHIP

857 / 880 Opportunities Biotech companies looking for investment or partnerships: 1) Immuno-oncology, phase I, small molecule, oral 2) Oncology, pre-clinical, targeting KRAS-driven cancers 3) Drug-resistant hypertension, small molecule, preclinical, 4) Rare and Ultrarare diseases, small molecule, early pre-clinical INVESTMENT OPPORTUNITY Looking for investment Biotech company is looking for investment: Neurodegenerative product, pre-clinical, new mechanism of action REQUEST CFO needed (Switzerland) A biotech in the French part of Switzerland is looking for a CFO with a scientific experience.

858 / 880 Walden International

Organisation

Country Taiwan City Taipei Street Web http://www.waldenintl.com

Person

Name Samantha Lee Investment Director

Organisation Over 30 years ago, Walden International pioneered the concept of cross-border venture investments. We seek the best entrepreneurs who look to build great companies through leverage of talent and markets independent of geography. Walden International is the leading venture capital firm focused on cross-border investments – our integrated team is dedicated to helping you build the next industry leading companies. The firm's funds total US$2.6 billion in committed capital. Walden International has invested in over 500 companies in 12 countries, with in excess of 100 IPOs on 15 Stock Exchanges and more than 70 M&A exits. Areas of Activity

• CRO (Contract Research Organisation) • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Investments • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities INVESTMENT OPPORTUNITY Investments in life sciences We make stage independent venture capital investments. Our investments go from opportunities in early stage (seed or startup) to expansion stage (growth) for companies that can benefit from the capital and value-add experience we can use to help accelerate your growth. Our areas of investments are: Life Sciences, Communications, Electronics, Digital Consumer, Enterprise Software, Internet, IT Services, Semiconductors, Clean Tech. Consider the following points in mind: - We invest in companies with a clear solution to a well defined problem. This means having a qualified base that you can identify, size and define a sales channel through which you can reach your target customers. - Be able to simply, explain why your product or service is compelling. 859 / 880 - We back a team that is either well proven in the past or have unique and relevant experience that can make a difference in achieving success. We look for a balance of the skills needed to successfully build a company including team building, marketing/positioning, fund raising and frugality. PARTNERSHIP Business developments in Taiwan Seeking companies that are looking for investment partners in Taiwan for developing the market opportunities in Asia countries.

860 / 880 Warrant Group, Gruppo Tecnoinvestimenti, European Funding Division

Organisation

Country Italy City Casalecchio (BO) Street Via Bazzanese, 32/7 Web http://www.warrantgroup.it/

Person

Name Lisa Bregoli Senior Project Manager

Organisation Warrant Group S.r.L, gruppo Tecnoinvestimenti, provides full-spectrum consulting in business finance. We are organized in several divisions working in synergy to deliver our clients the best support tools for the success of business initiatives and to assist in the preparation and management of strategic projects. Areas of Activity

• 3D Printing/addictive manufacturing for • Medical research biomedical applications • Peptides, proteins & antibodies • Bioinformatics, Big data analytics preparation • Biomaterials • Pharmaceutics • Biosensors • Proteomics, metabolomics, nutrigenomics • Biotechnologies (Pharma&Medical • Regulatory affairs, validation Devices) • Life sciences related activities • Chemicals & APIs • Software, ICT applications, system • Consulting services integration • CRO (Contract Research Organisation) • EPR, Clinical/healthcare management • Diagnostics - Equipment and accessories software • Diagnostics - Imaging equipment and • Vaccines processing • Project proposals support services • Drug screening & delivery • Medical devices • eHealth, mHealth, telemedicine • IT Applications for Health • Genetics & Genomics • Manufacturing & process engineering

Marketplace Opportunities

861 / 880 PARTNERSHIP H2020 partner search in different calls of the SC1 workprogramme The European Funding Division supports entreprises, private and public bodies at national and international level in participating to and managing Research and Innovation European projects: Horizon 2020 and other programmes. We offer a complete support for the participation in H2020 project with exclusive information service and assistance from the design and planning stage to the management of the projects and results.

862 / 880 Wellcare

Organisation

Country Italy City Milano Street via Lodovico il Moro 17 Web wellcare.it

Person

Name Carla Serra PR director

Organisation Wellcare is an italian marketing & Communication agency focus on the health&care market. Wellcare monitors and supports eHealth innovation of young companies improving the quality of life and fostering relations with consumers. Since 2015, Wellcare organizes the Cosmofarma StartUp Village inside the main european pharmaceutical exhibition, Cosmofarma Exhibition. During the 3 days event, each year in April, the startups selected show their projects to national and international pharma companies and stakeholders (32,000 visitors). Since 2017, Wellcare is a member of Italia Startup, the non-profit association representing the Italian startu-ups ecosystem. Wellcare has created PharmacyHub.it, the first European platform of interactive 3D virtual reality open 365 days a year h24 dedicated to the pharmacist. PharmacyHub.it uses the innovative technological platform developed in San Francisco by an Italian startup. Areas of Activity

• Consulting services

Marketplace Opportunities PROJECT COOPERATION Call for Ideas: free participation to COSMOFARMA 2019 for 20 start-ups Wellcare is selecting start-ups for the Cosmofarma Startup Village at the next Cosmofarma Exhibition, in Bologna, April 2019. The Startup Village is a huge area where startup can show their projects and meet pharma companies, stakeholders, media and pharmacists. The Adoption Program create a bridge between startups and pharma industry in an open innovation perspective. The participation is free for the start-ups selected.

863 / 880 WELLMICRO SRL

Organisation

Country Italy City Bologna Street Viale Fanin 48 Web https://wellmicro.com/

Person

Name Andrea Castagnetti CEO

Organisation Simultaneously with the launch in 2007 of the Human Microbiome Project in the United States and in 2008 the European equivalent MetaHIT Consortium, there has been an acknowledgment via gradually increasing the essential role that intestinal microorganisms have on the human and animal health. Wellmicro Srl aims to offer a monitoring service and characterization of microbial ecosystem composition (microbiota) of human and/or animal gut. The Microbiopassport® proposed by Wellmicro Srl is the most important innovative element, serving as a unique and patentedway to represent the intestinal microbial ecology was a subject in an easily interpretable way both the patient and the personal physician/nutritionist who proposes the analysis. In the absence of this effort of "translation", the output data from deep sequencing of the sample would be difficult to understand outside of a small circle of experts in the field, and unusable by the end user with a view to assessing the health status of ' gastrointestinal system and propose strategies for its food recovery/maintenance. In order to restore an image of the individual's intestinal ecosystem state, thespecific potential in terms of protection of health or the involvement in diseases, Wellmicro Srl has chosen to be represented in Microbiopassport® key parameters, to identify the state of health. Areas of Activity

• Analytical and characterization services • Life sciences related activities • Consulting services • Genetics & Genomics • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE MICROBIOPASSPORT® Applying our patented method, the Microbiopassport® of Wellmicro Srl returns an image of the individual's intestinal ecosystem state, the specific potential in terms of protection of health or the involvement in diseases. The Microbiopassport® is integrated with suggestions for the professional (doctor and/or nutrition professional) with a nutritional or therapeutic approach, favoring the 864 / 880 maintenance or recovery of a "healthy" configuration. The service includes delivery of equipment for the collection and storage of the sample, the extraction and purification of bacterial DNA from the sample, all phases of the sequencing, bioinformatic analysis and the production of the report. SERVICE MICROBIOME R&D CONSULTING Applying techniques developed within the research group that led to the idea of Wellmicro (molecular genetic characterization techniques, adhesive test to intestinal epithelial cells, in vitro tests for assessment of anti-inflammatory potential of bacterial strains), is possible to characterize probiotic microorganisms for human or animal use, assessing their competition performance against pathogenic microorganisms and immunomodulatory properties. Furthermore, with the recent development of a system for reproducing in vitro the interaction process microbiota-human intestinal mucosa is possible to monitor the state of health of the intestinal ecosystem in subjects suffering from inflammatory bowel disease, and/or evaluate the impact of probiotic microorganisms on the ecosystem dysbiosis associated with mucosa, responding to the growing needs of gastroenterologists, nutritionists and manufacturers of probiotic microorganisms. The expertise of the members of Wellmicro Srl in the study of the human intestinal microbiota is a valuable counseling service for all the companies involved in the identification, development and production of prebiotic and/or probiotic. PARTNERSHIP MICROBIOPASSPORT® DISTRIBUTION We are looking for commercial partnerships for the distribution and development of our individual microbial ecosystem characterization service, both in Italy and abroad. INVESTMENT OPPORTUNITY SCALE-UP We are looking for investments aimed to strengthen the commercial network and open new markets.

865 / 880 Wellness & Wireless Srl

Organisation

Country Italy City Reggio Emilia Street Via F.lli Cervi 80 Web http://www.super-op.com

Person

Name Paolo Gambini CEO

Organisation Wellness & Wireless develops and sell digital consumer services for health, wellness and sport, including: - Yukendu: a wellness mobile coaching service for an healthier lifestyle - SuperOp - Training Optimizer: measuring daily BP and HR values to assess the readiness of the body to handle a new training load. Areas of Activity

• eHealth, mHealth, telemedicine • IT Applications for Health

Marketplace Opportunities INVESTMENT OPPORTUNITY Looking for investments from either financial or industrial partner Wellness & Wilreless has developed and is currently selling an innovative product, SuperOp - Training Optimizer, that helps improving sport performance and protecting health. SuperOp has already been adopted by throusands of sport enthusiasts and by many italian and international top athletes and teams, from Vncenzo Nibali in cycling to the Italian Athletics Federation, from the Dutch Rowing National team to the Chinese Race Walking Team. We are currently looking for the financial resources to scale up SuperOp sales in Europe, USA and China.

866 / 880 www.protesiinsilicone.it

Organisation

Country Italy City Bologna Street Via Osoppo 6, Bologna, Emilia-Romagna, 40139, Italy Web Http://www.protesiinsilicone.it

Person

Name Erica Buzzi Silicone prostesis Technician & digital advanced manufactoring

Organisation Italian sculptor and prosthetics maker Erica Buzzi has been working for several years, in collaboration with orthopedic technicians and a group of other artisans interested in this area, to create high definition silicone prosthetics. Rather than approaching the creation of these prosthetics as an opportunity only available to those with significant amounts of money to throw at it, Buzzi is hoping to continue to refine the process in such a way that the costs will be lowered and the pieces will be much more widely available. She has been working for the last 5 years on 3D digital technology applied on biomedical products and developed a new process in order to realize silicone gloves, fingers and partialfeet prosthesis. In June 2018 was born a new aesthetic device in medical silicone for toes that have suffered serious infections, trauma or malformations such as total and partial loss of the nail of the big toe, brachymetatarsia, diabetes. This is a new product not yet on the market but tested on different people: they come as high-definition silicone caps that recreate shapes and colors mimetic compared to the original fingers and adaptable to the specific needs of the wearer. The cost is that of a standard but the definition and quality is that of a personalized device. The product, thus conceived, responds to a specific market request in the medical and podiatric aesthetic sector with which She has come into contact during these years of research and work in collaboration with technicians and professionals in the sector. The project is in the phase of closing the research & application / test. Areas of Activity

• 3D Printing/addictive manufacturing for • Software, ICT applications, system biomedical applications integration • Biomaterials • Virtual reality applications • Consulting services • Other • eHealth, mHealth, telemedicine • Medical devices • Investments • IT Applications for Health • Manufacturing & process engineering • Physiotherapy, Orthopaedic technology • Life sciences related activities

Marketplace Opportunities

867 / 880 PRODUCT Beauty Sil Cap Beauty Sil Cap is an aesthetic medical device for those who no longer have a toenail or have a defect in their toes due to different causes. Many women (but also men) ask for a solution for this type of problem to be able to go back to wearing open shoes even in summer, going to the beach or swimming pool without hiding their feet. The mimetic silicone cap is designed to allow a wider number of people access to treatments and therapies that otherwise would be too expensive or not accessible in places far from the metropolis. Beauty Sil Cap is the result of research and application in the field, given the constant demand, which closes to June 2018. It is therefore planned to build a start up to start production and distribution at pharmacies, specialized centers, technicians in the field podiatry. INVESTMENT OPPORTUNITY Venture Capitalists and Financial Investors I am searching for Venture Capitalists or Business Angels to invest in my next steps towards new projects. PRODUCT Silicone Designer & Prosthesis Digital Advance Manufacturing I am a specialist in orthopedic silicone implants, coatings and applications of 3D technology in orthoprdic field. I combine a passion for this profession, the world of 3D technologies and polymer materials in research and development of new solutions in the field of high-tech prosthetic using 3D scanners and 3D printers joined to the Italian manufacturing tradition of high quality. The goal is to increase accessibility to treatment and orthopedic devices , increase the degree of customization and quality at a sustainable business model and more socially equitable. Last R&D : - Beauty Silicon Cap for toes without nails or Brachymetatarsia/Diabetes problems - silicone glove for hand prosthesis, - new 3D digital workflow for silicone prosthetic finger/toes . www.protesiinsilicone.it PARTNERSHIP partners virtual environments and augmented reality for immersive training and distance learning SERVICE Digital strategist for silicone prosthesis production

With the diffusion of digital technologies in the medical field and their applications in the prosthetic segment of the mimetic reconstruction of the limbs, new skills indispensable to the technicians have emerged for the realization of high quality silicone devices. Our research provides strategies and support for the digitalisation of production processes to improve the sustainability and quality of tailor- made medical products with a view to containment and gradual investment.

868 / 880 Yellowstone Holding AG

Organisation

Country Switzerland City Versoix Street Route de Suisse 160 Web http://www.yellowstoneholding.ch/

Person

Name CHAN-YUAN LU Investment Manager

Organisation We aim to promote new innovative products or technologies from Switzerland to the Asia market via our strong connections. Areas of Activity

• Bioinformatics, Big data analytics • Genetics & Genomics • Biomaterials • Investments • Biosensors • Life sciences related activities • Biotechnologies (Pharma&Medical • Surgery technologies and applications Devices) • Virtual reality applications • Diagnostics IVD • Medical devices • Diagnostics - Equipment and accessories • Diagnostics - Imaging equipment and processing • eHealth, mHealth, telemedicine • Electromedical and medical equipment (non diag)

Marketplace Opportunities INVESTMENT OPPORTUNITY Investment in innovative medtech technologies Yellowstone Holding aims to promote new innovative products or technologies via its strong connections. Investment Criteria: - MedTech related - Products / Technologies ready for commercialization - Investment volume between CHF 1 to 3 million

870 / 880 Yghea CRO Division of Bioikos Ambiente Srl

Organisation

Country Italy City Bologna Street Via Rivani 99 Web http://www.yghea.it/

Person

Name Eleonora Romagnoli Scientific Director

Organisation Yghea is a Clinical Research Organization placed in Bologna. Our main strengths: 20 years experience, extensive knowledge of the national context, best fitting solutions to Sponsor's needs, hight quality standard and promotion of continuous training. Beyond the clinical research support services, we offer training services on topics related to clinical trial conduction (e.g. GCP, quality, pharmacovigilance) to candidate monitors and Institutions/ Investigational sites. Areas of Activity

• CRO (Contract Research Organisation)

Marketplace Opportunities SERVICE Interventional and non interventional clinical trials management (medicinal products and medical devices) Medical Writing, Regulatory services (Clinical Trial Application to Competent Authorities - Central and Local /Contract Negotiation with sites), Data Management including CRF design and e-CRF deployment, Monitoring (from Feasibility to Close-out), Statistics, TMF Management, Project Management, Budgeting.

871 / 880 ZCube - Zambon

Organisation

Country Italy City Bresso Street Via Lillo del Duca 10

Person

Name Federica Destro Program and community specialist

Organisation Zcube, Zambon Reasearch Venture, is the division that actively deals with innovation, scouting for modern health solutions in the field of Life Sciences, supporting the validation of drug delivery systems, medical devices, biomarkers, diagnostic, digital health and big data solutions. Thanks to an expert team and a network of entrepreneurs, business angels and venture capitalists, Zcube invests and supports innovative ideas from their early development phases right through to the market launch. It is made of three units: Zcare, Open Accelerator and OpenZone. ZCare develops HI-tech & HI-touch integrated solutions to transform disease management into a caring experience. Open Accelerator is the international fast track acceleration program dedicated to projects in life sciences, with a specific focus on Central Nervous System (CNS) and Respiratory diseases. OpenZone is the Life Sciences campus on the outskirts of Milan created by Zambon as a fundamental part of its Open Innovation philosophy. OpenZone currently is home to over 22 organizations working in the Life Sciences field, and a visionary development plan will double its spaces by 2020 Areas of Activity

• Biosensors • eHealth, mHealth, telemedicine • Medical devices

Marketplace Opportunities REQUEST Life science startups and projects Open Accelerator aims at identifying international innovative projects in Life Sciences. In line with Zambon Vision, the 2018 call focused on two therapeutics areas: CNS and Respiratory (including Rare Diseases in both areas). Specifically, we look for modern health solutions in the field of Drug Delivery Systems; Medical Devices, Biomarkers, Diagnostics; Wearables and Digital Health; Big Data.

872 / 880 ZCube - Zambon

Organisation

Country Italy City Milan Street

Person

Name Anna Giulia Sanarico Junior Project Manager

Organisation Zambon' research venture, actively exploring innovative solutions for patient health. Zcube is made of three units: Zcare, Open Accelerator and OpenZone. Open Accelerator is the “made-in-Italy” acceleration program that offers a 12-week acceleration path for financing innovative ideas in the field of life sciences. Open Accelerator is the international fast track acceleration program dedicated to projects in life sciences, with a specific focus on Central Nervous System (CNS) and Respiratory diseases. OpenZone is the Life Sciences campus on the outskirts of Milan created by Zambon as a fundamental part of its Open Innovation philosophy. OpenZone currently is home to over 22 organizations working in the Life Sciences field, and a visionary development plan will double its spaces by 2020. Areas of Activity

• Biosensors • Medical devices • Biotechnologies (Pharma&Medical Devices) • eHealth, mHealth, telemedicine • Investments

Marketplace Opportunities PROJECT COOPERATION Life science startups and projects Open Accelerator aims at identifying international innovative projects in Life Sciences. In line with Zambon Vision, the 2018 call focused on two therapeutics areas: CNS and Respiratory (including Rare Diseases in both areas). Specifically, we look for modern health solutions in the field of Drug Delivery Systems; Medical Devices, Biomarkers, Diagnostics; Wearables and Digital Health; Big Data.

873 / 880 Zefiro Srl

Organisation

Country Italy City Milan Street Via San Giovanni sul muro 18 Web www.microcore.it

Person

Name Marco Rossi Founder & CEO

Organisation Emenem Srl (the holding company) and Zefiro Srl (the operational company, a recently established start-up), has developed and registered a new technology – Micro Co.Re. spray and Micro Co.Re. film – for the topical administration of active ingredients (pharmaceutical and/or cosmetic elements). Areas of Activity

• Nutraceutics, probiotics, functional food, cosmeceutics • Pharmaceutics • Medical devices

Marketplace Opportunities PRODUCT PRODUCTS AND FORMULAS ALREADY AVAILABLE FOR COMMERCIALIZATION - Claim: Lymphatic draining effects and enhancement of local microcirculation to effectively prevent cellulitis and related skin blemishes. - Active ingredients: Dextran, Capsaicin, Ruscogenine, Caffeine. - Technology: Micro Co.Re. Spray ______-Claim: Moisturizing, elasticising and anti wrinkle action for facial masks, under eye and lips regions. - Active Ingredients: Hyaluronic Acid - Technology: Micro Co.Re. Film ______

- Claim: For prevention of poor circulation in lower limbs, local phlebopathies, "heavy legs" and varicose veins. - Active Ingredients: Antarcticine, Hyaluronic Acid, Diosmine 874 / 880 - Technology: Micro Co.Re. Spray ______- Claim: In case of sleep disorder (i.e. caused by stress) or jet - lag - Active Ingredients: Melatonine, Chamomile extract - Technology: Micro Co.Re. film (sublingual) ______- Claims: Recommended in the case of prolonged, repeated athletic activity (endurance sports, bicycling, marathons, team sports,...) - Active Ingredients: Carnosine, Antarcticine - Technology: Micro Co.Re. film ______The Micro Co.Re. platforms are also available for the creation of “ad hoc” products, developed based on specific needs and client requests. Comprehensive documentation about clinical trials, permeation,effectiveness and safety tests, user experience available upon request. PRODUCT Innovative technologies and products for local and topical administration of active ingredients Zefiro Srl, a recently established innovative start-up, has developed and registered (among other inventions) two new technologies – Micro Co.Re. spray and Micro Co.Re. film – for administering active pharmaceutical and/or cosmetic elements. Micro Co.Re. technological platforms (both Spray and Film) utilize a micro-encapsulation system in hydrogenated liposomes, as enhancer for the penetration/ absorption of active principles. The Micro Co.Re. platforms are extremely flexible and open to multiple applications. MICRO CO.RE. FILM: Polymer solutions containing phospholipids for application through multilayer film for both pharmaceutical use (medical devices, food supplement or drugs) and cosmetics.

Micro Co.Re film is a transparent polymeric eligible film for both topical and sublingual administration of active ingredients. Micro Co.Re. film active ingredients are formulated within a preparation that combines the action enhancers of phospholipids with a hydrosoluble polymer solution. Combination of these components makes it possible to improve the bioavailability and absorption of poorly water- soluble and poorly permeable ingredients. Cutaneous films can be produced in different shapes in order to better fulfill user requirements (i.e. facial masks, ankle joints, knees, skin surface,...) . In addition to film-eligibile for cutaneous applications, other pharmaceutical forms and potential applications are available for Micro Co.Re. film: • Gel or Spray-dried solutions: - This is an alternative to film-eligible solutions that makes it possible to apply the gel directly on the skin where, once it has solidified, it forms a film that permits long-term release of the active ingredient being administered. • Sub-lingual or buccal administration: - Drugs and active ingredients are absorbed directly and faster into the bloodstream without being metabolized through the digestive system and liver. - Drugs that are absorbed under the tongue or between the cheek and gum can be easier to take for people who have problems swallowing pills. – Same results and benefits can be achieved with lower doses of active principle. MICRO CO.RE. SPRAY Hydro-alcohlo based emulsion containing one or more active molecules micro- encapsulated in hydrogenated liposomes. This kind of micro-emulsion can be nebulized (aerosolized) on regular clothings or on textile fibers, in order to charge (and recharge) fabrics with cosmetic and medical active substances. Once put on, articles of clothing that have undergone this treatment permit the transdermal release of active

875 / 880 ingredients directly through the skin in a controlled manner; in other words in such a way as to guarantee a gradual, constant and continuous release over time. Comprehensive documentation about clinical trials, permeation, effectiveness and safety tests, user experience available upon request.

876 / 880 ZekaKare

Organisation

Country Turkey City Ankara Street Cepa Ofis 10.Kat 1004 Numara Mustafa Kemal Mah. 2123. Cad. No:2-D Cankaya / ANKARA Web http://www.zekakare.com/

Person

Name Mustafa Zati Chief Executive

Organisation ZekaKare is a software development company based in Ankara, TURKEY. We develop software solutions for our clients and also we sell our innovative recruitment and HR management software. Our software solutions are tailored for our clients’ needs and demands. We provide cloud based software solutions operating on Windows, IOS and Android platforms. Based on our strong programming capacity, we recently launched data analytics and visualization services. We can analyze and create meaningful insights through innovative approaches and genuine algorithms of our own. Our clientele consists of Medicine producers, Nutrition Producers, Bio-research Labs and Public institutions looking for insights. Areas of Activity

• Analytical and characterization services • IT Applications for Health • Bioinformatics, Big data analytics • Software, ICT applications, system integration

Marketplace Opportunities PRODUCT Pinxit HR Management Software Our signature cloud-based HR software is an innovative decision support system. Developed to facilitate hiring processes by identifying and measuring core abilities of candidates through a number of computer-based tests, Pinxit gives HR managers reliable quantitative data to choose between candidates. The software has machine learning capabilities to improve effectiveness as it is used continuously. Currently covering 30+ core abilities, we are able to add specific abilities for our clients with our pedological experts. Our measurement approaches are certified by METU, Turkey’s leading university. References from life sciences sector include Medicine Wholesellers, Pharmacies, Research Labs, Manufacturers and Medicine and Cosmetics Export/Importers.

877 / 880 SERVICE Software Development We develop software solutions for clients with our strong expertise and technical capabilities. We can deliver software on our technical infrastructure or we can setup them on your infrastructure. We offer 7 days support for your working hours. We can develop products on Windows, IOS and Android platforms for you. Current software products we delivered for life sciences sector include: IMS and sales data consolidation and reporting software for Medicine Distributors; Shipment quantity and frequency management software for Medicine Depots (Wholesellers); ERP and production management software for Nutrition Producers; ERP-HR Management software for managing staff and shifts for Research Companies. PROJECT COOPERATION Project Partnership – Role: Software ZekaKare had executed and completed 8 government funded grant projects in Turkey. We are currently involved as a partner in 3 EU grant project proposals. With our proven expertise in project management and software development, we can deliver software aspects of new projects. We are able to create and manage English language applications and project management procedures.

878 / 880 Zeta Research srl

Organisation

Country Italy City Trieste Street via Caccia 8 Web www.zetaresearch.eu

Person

Name Federica Zobec CEO

Organisation Zeta Research is a CRO (Contract Research Organization) recognized by AIFA (Italian Medicines Agency) for the development of clinical trials (Ministerial Decree of November 15, 2011) operating at national and international level. It offers scientific and statistical consultation in the medical, clinical and nutrition field, in the design, development, and management of clinical trials, scientific studies and research projects. Principal products/services The services range from the creation of the study design with the drafting of a protocol and CRF to document management, the selection of the Centers in the submission of the study to the Ethics Committees and notified to the Competent Authorities, the implementation of a site or portal dedicated a data collection to electronic data management, from remote monitoring or at centers for cleaning a database or recoding of the data (according to specific MedDRA - Medical Dictionary for Regulatory Activities), the statistical analysis on the data collected in the drafting of scientific material for publications. In recent years Zeta Research has focused its expertise and resources invested in the collection of online data (Electronic Data Capture - EDC) with the use of computer systems validated according to the Computer System Validation (CSV) on its own servers in Clinical Data Management (CDM) and in the statistical analysis of the data collected. The service guarantees to companies and to research centers involved in clinical trials in the quality of the data collected in the database and then validated with results that can be used for registration or markings of new products, for the post-marketing surveillance and expendable in the scientific community with publications or presentations. The data obtained by the internal procedures implemented by the Zeta Research meet the specific regulatory requirements and international guidelines (application of ICH GCP, Annex 11 CFR part 11, Statement of Privacy, and standards SCDM, GCDMP & CDISC). To offer a complete service to its customers, Zeta Research also offers IT services such as: development of software for creating, viewing and managing custom databases, web site creation and use of Cloud on own servers. At its headquarters Zeta Research has also set up 10 CATI stations for recall and phone services to patients or marketing activities. Areas of Activity

• Biotechnologies (Pharma&Medical • Pharmaceutics Devices) • Medical devices

879 / 880 • Consulting services • CRO (Contract Research Organisation) • Medical research • Nutraceutics, probiotics, functional food, cosmeceutics

Marketplace Opportunities SERVICE Clinical research for pharma, nutrition, medical devices As a CRO recognized by AIFA, Zeta Research provides the following services: - Clinical Planning & Management: research planning, methodological and normative adequacy, end-point definition, sample design and sample size, Statistical Analysis Plan (SAP), protocol design, ITC (Information and Communication Technologies) solutions for randomizing, treatment allocation, data collection, cost-efficiency and risk-benefit analysis, statistical methodology design, design and realization of paper CRF (Case Report Form) on paper / electronic support, documentation for Ethics Committees (EC). - Trial and Site Management and Monitoring: site recruitment, start-up activity , ethics committees: authorization requests and management, administrative authorizations, start-up and monitoring on-site and remote clinical experimentations, monitoring, process control and follow-up. - Clinical Data Management and Medical Writing: data collection & data entry, CRF and e-CRF processing, data validation and verification, data transfer and codification, data monitoring, statistical analysis, study reporting, scientific posters and papers.

880 / 880